_pmid,_doi,_publicationTitle,resourceName,resourceType,observationType,details,foundIn,contextSnippet,confidence
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- mice (n=33) exhibited reduced dopamine transient frequency compared to Nf1+/+ littermates (n=19) (unpaired t-test; t50=3.06, p=0.004)",Results,"Peak analysis of baseline dLight1.2 recordings revealed that Nf1+/- mice (n = 33) exhibit reduced transient frequency (unpaired t-test; t50 = 3.06, p=0.004)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- putative dopaminergic neurons (n=18) showed lower spontaneous firing rates compared to Nf1+/+ neurons (n=12) (unpaired t-test; t28=2.58, p<0.05)",Results,"Spontaneous firing rates (right) were lower (unpaired t-test; t28 = 2.58, p=0.0w) in Nf1+/- putative dopaminergic neurons (n = 18) compared to Nf1+/+ neurons (n = 12)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- neurons (n=29) had increased rheobase (171.7±7.779 pA) compared to Nf1+/+ (n=21, 124.1±8.65 pA) (unpaired t-test; t48=4.05, p<0.001)",Results,"Rheobase (right; unpaired t-test; t48 = 4.05, p<0.001) but not action potential threshold was increased in Nf1+/- (n = 29) putative dopaminergic neurons compared to Nf1+/+ (n = 21)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- putative dopaminergic neurons (n=29) had increased input resistance (235.7±16.32 MΩ) and decreased capacitance (41.27±2.026 pF) compared to Nf1+/+ neurons (n=21, 172.4±10.94 MΩ, 47.35±2.032 pF)",Results,"Nf1+/- putative dopaminergic neurons (n = 29) had increased input resistance (Rm; left; unpaired t-test; t48 = 2.97, p=0.005) and decreased capacitance (Cm; right; t48 = 2.54, p=0.01)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"VTA dopaminergic soma cross-sectional area was reduced in Nf1+/- mice (n=2586 somata) compared to Nf1+/+ (n=2344 somata) (two-sample Kolmogorov-Smirnov test; D=0.18, p<0.001)",Results,"The cumulative probability distribution of the cross sectional area of manually traced Nf1+/+ (n = 2344) and Nf1+/- (n = 2586) VTA dopaminergic neuron somata (two-sample Kolmogorov-Smirnov test; D = 0.18, p<0.001)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Biomarker,"Nf1+/- putative dopaminergic neurons displayed increased sIPSC frequency but not sIPSC amplitude, sEPSC frequency, or sEPSC amplitude compared to Nf1+/+ neurons",Results,"Nf1+/- putative dopaminergic neurons displayed increased sIPSC frequency but not sIPSC amplitude, sEPSC frequency, or sEPSC amplitude compared to Nf1+/+ neurons",0.9
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Behavioral,"Nf1+/- mice exhibited larger dLight1.2 responses to CS presentation on first day of testing compared to Nf1+/+ littermates (unpaired t-test; t20=2.34, p=0.03)",Results,"Nf1+/- mice displayed enhanced dLight1.2 responses to CS presentation on the first day of testing (Figure 4J, inset) compared to Nf1+/+ littermates",0.9
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,animal_model,Behavioral,Nf1+/- mice had greater peak responses to light (p<0.001) but not tone onset (p>0.99) compared to Nf1+/+ mice (n=10 each group),Results,"Nf1+/- mice had greater peak responses to light (p<0.001) but not tone onset (p>0.99) compared to Nf1+/+ mice (n+/+ = 10, n+/- = 10)",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,pAAV-hSyn-dLight1.2,genetic_reagent,Efficacy,"dLight1.2 allows for sub-micromolar detection of extracellular dopamine concentrations with sub-second resolution and negligible sensitivity to other monoamines, GABA, and glutamate",Results,"the genetically encoded, fluorescent dopamine sensor dLight1.2 which allows for sub-micromolar detection of extracellular dopamine concentrations with sub-second resolution and negligible sensitivity to other monoamines, GABA, and glutamate",0.9
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,pAAV-hSyn-dLight1.2,genetic_reagent,Efficacy,Robust LNAc dopamine transients were observed time-locked to reward consumption in both Nf1+/- and Nf1+/+ mice with no significant difference between genotypes,Results,"In both Nf1+/- and Nf1+/+ mice, we observed robust LNAc dopamine transients time-locked to reward consumption that were not significantly different between genotypes",0.9
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,pAAV-hSyn-dLight1.2,genetic_reagent,Efficacy,"Morphine sulfate (5 mg/kg, s.c.) increased dLight1.2 transient rate versus saline in Nf1+/- mice (paired t-test; t8=2.65, p=0.03)",Results,"Pre-treatment with 5.0 mg/kg (s.c.) morphine sulfate (MS5.0) increased dLight1.2 transient rate versus saline pre-treatment (paired t-test; t8 = 2.65, p=0.03) in Nf1+/- mice",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,pAAV-hSyn-hChR2(H134R)-EYFP,genetic_reagent,Efficacy,"Two seconds of vSC optogenetic stimulation (5 mW, 20 Hz, 5 ms pulse width) produced time-locked, short latency dopamine release in the LNAc at stimulus onset",Results,"two seconds of vSC optogenetic stimulation (5 mW, 20 Hz, 5 ms pulse width) produced time-locked, short latency dopamine release in the LNAc at stimulus onset that subsequently decayed to baseline",0.9
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,pAAV-DJ-Ef1α-DO-eNpHR3.0-eYFP-WPRE-pA,genetic_reagent,Efficacy,"Optogenetic inhibition with 532 nm light (5 mW, 30 Hz, 20 ms pulse width) decreased escape to shelter percentage in Nf1+/- mice from baseline to 33%, similar to Nf1+/+ mice (41%)",Results,"Delivery of 532 nm light (5 mW, 30 Hz, 20 ms pulse width) to the VTA during looming stimulus presentation decreased the percentage of VTA Th-Off-NpHR-eYFP Nf1+/- mice that escaped to the shelter to a level (33%) that was similar to Nf1+/+ mice (41%)",0.9
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,pAAV-DJ-Ef1α-DO-eNpHR3.0-eYFP-WPRE-pA,genetic_reagent,Efficacy,"Only 14.7±0.01% of NpHR-positive cells in the VTA expressed tyrosine hydroxylase, indicating successful targeting of VTA non-Th neurons",Results,"Post hoc analysis revealed that only 14.7 ± 0.01% of NpHR-positive cells in the VTA expressed tyrosine hydroxylase, indicating successful targeting of VTA non-Th neurons",0.95
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,pAAV-Th-tTA-WPRE,genetic_reagent,Efficacy,"Th-VAST vector specificity was 58.7±3.0% in VTA and 74.2±2.2% in SNc, lower than 81% achieved with AAV-PHP.eB-Th-GFP",Results,the specificity of Th-VAST vectors was lower in the VTA (58.7% vs 81%) and SNc (74.2% vs 81%) despite good XFP restriction to these areas,0.9
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,Anti-tyrosine hydroxylase (Rabbit polyclonal),antibody,Efficacy,"Successfully labeled dopaminergic terminals and neurons for immunofluorescence analysis, showing no difference in TH expression across striatal sub-compartments between genotypes",Results,there was no difference in dopaminergic terminal tyrosine hydroxylase expression across striatal sub-compartments,0.85
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,Anti-GFP (mouse polyclonal),antibody,Efficacy,"Successfully detected dLight1.2 expression (stained for GFP, green) in representative histological images showing fiber tip location",Results,"Representative histological image showing the fiber tip location and expression of dLight1.2 (stained for GFP, green) and dopaminergic terminal tyrosine hydroxylase",0.85
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Nf1 c.5425 C > T ; Arg1809Cys-mutant mice,animal_model,Efficacy,"Nf1 f/1809 ; hGFAP-Cre mice did not develop OPGs at 3 months of age (0/8), unlike Nf1 f/neo ; hGFAP-Cre mice which all developed OPGs (6/6)",Results,mice harboring a germline Nf1 R1809C mutation with somatic loss of Nf1 in neuroglial progenitor cells...did not develop OPGs at 3 months of age (0/8),0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Nf1 c.5425 C > T ; Arg1809Cys-mutant mice,animal_model,Biomarker,"Optic nerves from Nf1 f/1809 ; hGFAP-Cre mice had similar optic nerve volume (0.05 mm³), proliferative index (0.8% Ki67+ cells), microglia content (6.4% Iba1+ cells), and T-cell content (1.2 CD3+ cells) compared to controls",Results,optic nerves from Nf1 f/1809 ; hGFAP-Cre mice were indistinguishable from Nf1 f/f controls (CTL) with respect to optic nerve volume...proliferative index...microglia content...T-cell content,0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Nf1 c.5425 C > T ; Arg1809Cys-mutant mice,animal_model,Efficacy,"Nf1 f/1809 ; Hoxb7-Cre mice did not develop pNFs at 6 months of age (0/52), unlike Nf1 f/neo ; Hoxb7-Cre mice (11/16) and Nf1 f/f ; Hoxb7-Cre mice (7/13)",Results,Nf1 f/1809 ; Hoxb7-Cre mice did not develop pNFs at 6 months of age (0/52),0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Nf1 c.5425 C > T ; Arg1809Cys-mutant mice,animal_model,Mechanistic,"Nf1+/1809 RGC neurons did not have increased activity relative to WT RGCs, unlike Nf1+/neo neurons which had 2.5-3.9-fold increase in action potential firing rates",Results,"Nf1+/neo, but not the Nf1+/1809, neurons had increased activity relative to WT RGCs, as measured by action potential (AP) firing rates (2.5–3.9-fold increase relative to WT control)",0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Nf1 c.5425 C > T ; Arg1809Cys-mutant mice,animal_model,Biomarker,"Nf1+/1809 neurons had elevated RAS activity (2.3-2.7-fold increase) similar to Nf1+/neo neurons, but did not produce increased midkine or neuroligin-3",Results,"RAS-GTP levels were increased by 2.3–2.7-fold in Nf1+/1809 RGC and hippocampal neurons relative to WT controls, similar to Nf1+/neo neurons",0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,R681X Nf1-mutant mice,animal_model,Biomarker,"Increased midkine expression was detected in RGCs from Nf1+/R681X-mutant mice, another mouse strain that develops optic gliomas",Results,Increased midkine expression was also detected in RGCs from Nf1+/R681X-mutant mice...another mouse strain that develops optic gliomas following somatic Nf1 inactivation,0.9
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Nf1 f/neo ; hGFAP-Cre mice,animal_model,Efficacy,"All Nf1 f/neo ; hGFAP-Cre mice developed OPGs (6/6) with increased optic nerve volumes (0.079 mm³), proliferative indices (5.9% Ki67+ cells), microglia (11.8% Iba1+ cells), and T cells (7 CD3+ cells)",Results,all Nf1 f/neo ; hGFAP-Cre mice (Nf1-OPG)...developed OPGs (6/6) with increased optic nerve volumes (0.079 mm³)...proliferative indices (5.9% Ki67+ cells),0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Nf1 flox/flox ; Hoxb7-Cre mice,animal_model,Efficacy,Nf1 f/f ; Hoxb7-Cre mice developed pNFs (7/13) and exhibited enlarged DRGs,Results,"Nf1 f/neo ; Hoxb7-Cre mice (11/16), and Nf1 f/f ; Hoxb7-Cre mice (7/13), Nf1 f/1809 ; Hoxb7-Cre mice did not develop pNFs",0.9
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Ki67,antibody,Biomarker,Lamotrigine treatment resulted in reduced optic nerve proliferation (5.7-fold decrease in %Ki67+ cells) in Nf1-OPG mice compared to vehicle-treated controls,Results,lamotrigine treatment resulted in reduced optic nerve proliferation (%Ki67+ cells; 5.7-fold decrease),0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,Iba1,antibody,Biomarker,Lamotrigine treatment resulted in reduced microglia content (1.7-fold decrease in %Iba1+ cells) in Nf1-OPG mice,Results,lamotrigine treatment resulted in...microglia (%Iba1+ cells; 1.7-fold decrease),0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,SOX10,antibody,Biomarker,Nf1 f/1809 ; Hoxb7-Cre mice DRGs contained fewer SOX10+ Schwann cell precursors compared to Nf1 f/neo ; Hoxb7-Cre and Nf1 f/f ; Hoxb7-Cre mice,Results,"their DRGs contained fewer total cells, as well as fewer SOX10+ Schwann cell precursors, the cell of origin for these pNF tumors",0.9
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,AXION Biosystems 48-well MEA plates,computational_tool,Mechanistic,"Multi-electrode arrays measured 2.5-3.9-fold increase in action potential firing rates in Nf1+/neo RGC neurons compared to WT controls, while Nf1+/1809 neurons showed no increase",Results,"Nf1+/neo, but not the Nf1+/1809, neurons had increased activity relative to WT RGCs, as measured by action potential (AP) firing rates",0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,sh NF1 1–3 lentiviral particles,genetic_reagent,Mechanistic,COL1A2 treatment increased proliferation of shNF1 SCs (2.5-2.9-fold increase in Ki67+ cells) to levels similar to NF1-mutant sensory neuron conditioned media,Results,COL1A2 treatment increased the proliferation of shNF1 SCs and Nf1−/− DRG NSCs (2.5–2.9-fold increase in Ki67+ cells),0.95
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,sh COL1A2 lentiviral particles,genetic_reagent,Efficacy,COL1A2 short hairpin-mediated genetic reduction (65.1% reduction) completely abrogated the increase in proliferation conferred by NF1-mutant sensory neuron CM,Results,The increase in proliferation conferred by NF1-mutant sensory neuron CM or COL1A2 alone was completely abrogated by...genetic COL1A2 short hairpin-mediated genetic reduction,0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"NF1 patients had significantly shorter total sleep duration (7.2 ± 0.8 h) compared to controls (8.0 ± 0.6 h, p = 0.001)",Results,"NF1 patients had a significantly shorter total sleep duration (7.2 ± 0.8 h) compared to controls (8.0 ± 0.6 h, p = 0.001).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"Sleep efficiency was lower in NF1 patients (80 ± 5%) compared to controls (88 ± 4%, p = 0.008)",Results,"The sleep efficiency was lower in NF1 patients (80 ± 5%) compared to controls (88 ± 4%, p = 0.008).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"REM sleep duration was reduced in NF1 patients (80 ± 12 min) versus controls (95 ± 10 min, p = 0.022)",Results,"The REM sleep duration was reduced in NF1 patients (80 ± 12 min) versus controls (95 ± 10 min, p = 0.022).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"Deep sleep duration was shorter in NF1 patients (60 ± 10 min) compared to controls (80 ± 8 min, p = 0.015)",Results,"The deep sleep duration was also shorter in NF1 patients (60 ± 10 min) compared to controls (80 ± 8 min, p = 0.015).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"Light sleep duration showed significant reduction in NF1 patients (240 ± 20 min) compared to controls (270 ± 15 min, p = 0.027)",Results,"The light sleep duration showed a significant reduction in NF1 patients (240 ± 20 min) compared to controls (270 ± 15 min, p = 0.027).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"NF1 patients exhibited higher resting heart rate during sleep (82 ± 5 bpm) compared to controls (76 ± 4 bpm, p = 0.010)",Results,"NF1 patients exhibited a higher resting heart rate during sleep (82 ± 5 bpm) compared to controls (76 ± 4 bpm, p = 0.010).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"Heart rate variability (HRV) was significantly lower in NF1 patients (48 ± 6) compared to controls (60 ± 7, p = 0.003)",Results,"Heart rate variability (HRV) was significantly lower in NF1 patients (48 ± 6) compared to controls (60 ± 7, p = 0.003).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"Respiratory rate was elevated in NF1 patients (22 ± 2 breaths/minute) compared to controls (18 ± 1.5 breaths/minute, p = 0.004)",Results,"The respiratory rate was elevated in NF1 patients (22 ± 2 breaths/minute) compared to controls (18 ± 1.5 breaths/minute, p = 0.004).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"Blood oxygen levels (SpO2) were lower in NF1 patients (95 ± 2%) versus controls (98 ± 1%, p = 0.002)",Results,"Blood oxygen levels (SpO2) were lower in NF1 patients (95 ± 2%) versus controls (98 ± 1%, p = 0.002).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,"NF1 patients experienced higher frequency of nocturnal awakenings (2.4 ± 1.2 episodes/night) compared to controls (0.8 ± 0.6 episodes/night, p = 0.003)",Results,"NF1 patients experienced a higher frequency of nocturnal awakenings (2.4 ± 1.2 episodes/night) compared to controls (0.8 ± 0.6 episodes/night, p = 0.003).",0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Behavioral,"NF1 patients napped more frequently (2.1 ± 1.4 days/week) and for longer durations (75.4 ± 30.2 min) compared to controls (1.2 ± 0.8 days/week; 38.7 ± 15.6 min, p = 0.013)",Results,NF1 patients napped more frequently (2.1 ± 1.4 days/week) and for longer durations (75.4 ± 30.2 min) compared to controls (1.2 ± 0.8 days/week; 38.7 ± 15.6 min; p = 0.013).,0.95
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,Apple Watch Ultra model 2,clinical_assessment_tool,Biomarker,Time to sleep onset was comparable between groups (NF1: 18.2 ± 7.4 min; controls: 15.4 ± 6.1 min; p > 0.05),Results,The time to sleep onset was comparable between groups (NF1: 18.2 ± 7.4 min; controls: 15.4 ± 6.1 min; p > 0.05).,0.95
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,Krox20Cre,genetic_reagent,Efficacy,"All Scf(flox/gfp);Krox20Cre mice (n=20) displayed progressive hair graying with first round occurring homogenously during postnatal days 30-40, converting all black pigmented hairs to white within 9 months",Results,"Invariably, all Scf mice (flox/gfp;Krox20Cre n = 20) displayed progressive hair graying. The first round of hair graying occurred homogenously during postnatal days 30–40 (P30–P40).",0.95
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,Krox20Cre,genetic_reagent,Mechanistic,"Krox20 lineage cells showed dynamic localization during HF morphogenesis, detected only in infundibulum and bulge at P0, expanding to entire upper HF at P2, then colonizing matrix beginning at P6-P10",Results,"we found that LacZ+ cells were detected only as a small population of cells located at the infundibulum and bulge of the HF at P0. At P2, LacZ+ cells occupied the entire upper portion of the HF.",0.9
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,K14Cre,genetic_reagent,Efficacy,"Scf(flox/gfp);K14Cre mice displayed complete absence of hair pigmentation beginning at birth, lasting throughout their lives (n=8)",Results,"Strikingly, depletion of SCF in keratinocytes resulted in mice displaying a complete absence of hair pigmentation, beginning at birth (Fig. 2 F), and this phenotype was limited to hair pigmentation",0.95
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,DhhCre,genetic_reagent,Efficacy,"Scf(flox/gfp);DhhCre mice showed no hair color changes for up to 6 months (n=8), demonstrating hair pigmentation does not depend on SCF expression in Schwann cells",Results,"In mice lacking SCF in Schwann cells (Scf flox/gfp;DhhCre), we did not observe any hair color changes for up to 6 mo (Fig. 2 A). n = 8.",0.9
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,TyrCreERT2,genetic_reagent,Efficacy,"Scf(flox/gfp);TyrCreERT2 mice had no phenotype in hair color (n=8), ruling out melanocyte cell-autonomous SCF contributions to hair pigmentation",Results,mice with SCF depletion in melanocytes (Scf flox/gfp;TyrCreERT2) had no phenotype in hair color (Fig. 2 C) after validation of Cre expression in the hair matrix melanocytes,0.9
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,K14-Scf,genetic_reagent,Efficacy,"K14-Scf;Scf(flox/gfp);K14Cre mice displayed white hair with dark skin (n=8), unable to rescue hair depigmentation despite ectopic SCF expression under K14 promoter",Results,"Surprisingly, the K14-Scf;Scf flox/gfp;K14Cre mice displayed white hair with dark skin (Fig. 4 A,B), indicating that even though Scf is expressed under a K14 promoter, K14-Scf was unable to rescue",0.9
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,DCT antibody (PEP8h),antibody,Biomarker,DCT immunostaining revealed significant loss of DCT+ differentiated mature melanocytes in Scf(flox/gfp);Krox20Cre mouse HF at P10 (P<0.05) and P11 (P<0.0001),Results,DCT immunostaining revealed a significant loss of DCT+ differentiated mature melanocytes in the Scf flox/gfp;Krox20Cre mouse HF at P10 (P < 0.05) and P11 (P < 0.0001),0.95
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,"KIT antibody (Cell Signaling, 3074)",antibody,Biomarker,"In Scf(flox/gfp);K14Cre mice, KIT+ melanocytes were detected only in lower matrix but completely absent in upper HF matrix, demonstrating SCF loss affects only mature melanocytes",Results,"However, in the skin from Scf flox/gfp;K14Cre mice, KIT+ melanocytes were detected only in the lower matrix but were completely absent in the upper HF matrix",0.9
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,tetO-DTA,genetic_reagent,Efficacy,"Krox20Cre;R26-rtTA;tetO-DTA mice showed signs of hair loss starting at P40 and significant hair loss by P50 (n=8), with complete arrest of new hair generation within 15 days",Results,"We observed signs of hair loss (rough coat) starting at starting P40, and they had significant hair loss by P50 (Fig. 7 B). n = 8... Krox20Cre;R26-rtTA;tetO-DTA mice had a complete arrest of new hair generation",0.9
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,ImageJ,computational_tool,Biomarker,Melanin density analysis by ImageJ showed significant reduction in Scf(flox/gfp);Krox20Cre graying hair shafts (P<0.0001) from 100 randomly selected HFs in each group,Results,Quantification and statistical analysis of E showing a significant reduction of melanin density in Scf flox/gfp;Krox20Cre graying hair shafts. Melanin density was analyzed by ImageJ.,0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Efficacy,NF1-deficient MCF7 cells (NF1-45) proliferate faster in 2D culture compared to NF1-WT controls,Results,"Compared to NF1-WT controls (NF1-EV and Nf1-WT), NF1-deficient cells proliferate faster in 2D",0.85
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Efficacy,"NF1-45 MCF7 cells developed larger 3D spherical colonies compared to NF1-EV control, indicating greater tumor potential",Results,"When compared to the NF1-EV control, NF1-45 developed larger 3D spherical colonies, indicating greater tumor potential",0.85
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Biomarker,NF1 deficiency in MCF7 cells resulted in decreased expression of the neurofibromin 250 kDa isoform,Results,"In the MCF7 cells, NF1 deficiency resulted in decreased expression of the neurofibromin 250 kDa isoform",0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Biomarker,NF1-45 MCF7 cells had decreased active and total ERα activation at baseline and following estradiol stimulation,Results,we saw that NF1-45 cells had decreased active and total ERα activation at baseline and following estradiol (E2) stimulation,0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,MCF7,cell_line,Biomarker,"NF1 deficiency in MCF7 cells dramatically increased active T202/Y204-phosphorylated ERK, indicative of increased RAS-pathway signaling",Results,"we found that NF1 deficiency dramatically increased active T202/Y204-phosphorylated ERK, which is indicative of increased RAS-pathway signaling",0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,Nf1-PS rat model,animal_model,Efficacy,Nf1-PS rats have the earliest onset tumors at 8 weeks,Results,"The Nf1-PS rats have the earliest onset tumors (8 weeks), followed by Nf1-IFPS (10 weeks), followed by Nf1-IF (1 year)",0.95
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,Nf1-IFPS rat model,animal_model,Efficacy,Nf1-IFPS rats develop tumors at 10 weeks,Results,"The Nf1-PS rats have the earliest onset tumors (8 weeks), followed by Nf1-IFPS (10 weeks), followed by Nf1-IF (1 year)",0.95
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,Nf1-IF rat model,animal_model,Efficacy,Nf1-IF rats develop tumors at 1 year,Results,"The Nf1-PS rats have the earliest onset tumors (8 weeks), followed by Nf1-IFPS (10 weeks), followed by Nf1-IF (1 year)",0.95
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,IncuCyte,computational_tool,Mechanistic,Used to measure cell doublings via confluence over time for 48hr proliferation assays with 10 nM estradiol,Results,"cells were grown for 48hr with 10 nM estradiol (E2) in a Sartorius IncuCyte, and cell doublings were measured via confluence over time",0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,Agilent Seahorse XF-96,computational_tool,Biomarker,NF1 deficiency decreased basal and maximal OXPHOS across all models as measured by OCR,Results,"Across our human and rat models, NF1 deficiency decreased basal and maximal OXPHOS",0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,Agilent Seahorse XF-96,computational_tool,Biomarker,NF1 deficiency restricted energetic flexibility and all NF1-deficient lines have smaller max bioenergetic scopes,Results,we found that NF1 deficiency restricted energetic flexibility...all NF1-deficient lines have smaller max bioenergetic scopes,0.85
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,iDEP 9.1,computational_tool,Mechanistic,Used to generate PCA coordinates showing global shift in gene expression in NF1-deficient cells compared to NF1-WT controls,Results,PCA displayed the global shift in gene expression in the NF1-deficient cells compared to the NF1-WT controls. PCA coordinates were generated using iDEP 9.1,0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,SynergyFinder R package,computational_tool,Efficacy,"Showed ~4X increase in synergy between DGAT1/2i and 4OHT, ~1.5X increase with COB, and 1.5X increase with EVE in NF1-45 cells",Results,"we saw a ∼4X increase in synergy between DGAT1/2i and 4OHT, a ∼1.5X increase in synergy between DGAT1/2i and COB, and a 1.5X increase in synergy between DGAT1/2i and EVE",0.95
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,CEAS R Package,computational_tool,Biomarker,Used to calculate JATP values showing NF1 deficiency restricts joules of ATP production in MCF7 cells and rat mammary fibroblasts,Results,NF1 deficiency restricts joules of ATP (JATP) production in MCF7 cells and rat mammary fibroblasts. JATP values were calculated using CEAS (R Package),0.9
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,Matrigel spheroids,advanced_cellular_model,Efficacy,"NF1-45 cells developed larger 3D spherical colonies compared to controls, indicating greater tumor potential",Results,"When compared to the NF1-EV control, NF1-45 developed larger 3D spherical colonies, indicating greater tumor potential",0.85
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,P.L.E.A.S.E.® device,clinical_assessment_tool,Safety,Pain during microporation lasting a few seconds reported in one subject for T1 neurofibroma,Results,"During Visit 1, one subject reported pain during T1 neurofibroma microporation, lasting a few seconds",0.9
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,P.L.E.A.S.E.® device,clinical_assessment_tool,Safety,Burning sensation after microporation and saline solution application lasting 4-8 minutes reported in subjects,Results,"burning sensation after microporation and saline solution application on C1 neurofibroma, lasting 4 min...burning sensation after microporation and saline solution application on both C neurofibromas, lasting 8 min",0.9
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,P.L.E.A.S.E.® device,clinical_assessment_tool,Efficacy,All T and C neurofibromas displayed healing in the shape of the laser microporation grid on the surface at Visit 2 and Visit 3,Results,all T and C neurofibromas displayed healing in the shape of the laser microporation grid on the surface of the neurofibromas,0.9
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,Dermlite DL3,clinical_assessment_tool,Other,Used for dermoscopy observations showing hyperemia and shining dots around micropores (epithelialization) and desquamation in neurofibromas,Results,"On dermoscopy, hyperemia and shining dots around the micropores were noted (epithelialization), with some neurofibromas presenting desquamation",0.8
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,NIH Consensus Development Conference NF1 diagnostic criteria,clinical_assessment_tool,Other,"Used to confirm NF1 diagnosis in study participants, though specific diagnostic outcomes not detailed in results",Results,"six subjects were screened, enrolled, and completed the study",0.7
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,anti-HLA-DR Percp-cy5.5,antibody,Biomarker,Successfully detected marked downregulation of HLA-DR expression in CD14+ monocytes exposed to NF2-EVs for 24 h,Results,CD14+ monocytes exposed to NF2-EVs for 24 h displayed a marked downregulation of HLA-DR expression (Figure 2A),0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,anti-CD33 APC,antibody,Biomarker,Detected increased percentage of HLA-DR−CD33+CD11b+ cells after NF2-EVs treatment,Results,an increased percentage of HLA-DR−CD33+CD11b+ cells (Figure 2B),0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,anti-CD11b FITC,antibody,Biomarker,Detected increased percentage of HLA-DR−CD33+CD11b+ cells after NF2-EVs treatment,Results,an increased percentage of HLA-DR−CD33+CD11b+ cells (Figure 2B),0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,Cell Counting Kit-8,clinical_assessment_tool,Efficacy,Demonstrated that NF2-EVs significantly enhanced proliferation of NF2-associated schwannoma cells in vitro compared to control group,Results,significantly enhanced their proliferation in vitro compared to the control group without NF2-EVs (Figure 4C),0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,Orbitrap Fusion Lumos mass spectrometer,computational_tool,Biomarker,"Identified HSP90 as one of the ten most abundantly expressed proteins in NF2-EVs, including HSP90AB1 and HSP90AA1",Results,"the ten most abundantly expressed proteins in NF2-EVs include HSPA8, GAPDH, ACTG1, ACTB, HSP90AB1, HSP90AA1, PKM, CLTC, FN1, and TUBB",0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,CD9 antibody,antibody,Biomarker,Confirmed presence of CD9 in NF2-EVs via western blotting,Results,Protein analysis via western blotting confirmed the presence of CD81 and CD9 in NF2-EVs,0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,CD81 antibody,antibody,Biomarker,Confirmed presence of CD81 in NF2-EVs via western blotting,Results,Protein analysis via western blotting confirmed the presence of CD81 and CD9 in NF2-EVs,0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,TOMM20 antibody,antibody,Biomarker,Used as mitochondrial marker control in western blot analysis of NF2-EVs,Results,and the mitochondrial marker TOMM20 as control (Figure 1B),0.8
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,HSP90 antibody,antibody,Biomarker,Confirmed HSP90 was significantly highly expressed in NF2-associated schwannoma tissues via Western blot analysis,Results,Further Western blot analysis of HSP90 in NF2-associated schwannoma tissues provided further confirmation that HSP90 was significantly highly expressed,0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,AKT antibody,antibody,Mechanistic,Detected correlation between HSP90 expression and AKT activation in NF2-associated schwannoma cells,Results,Our analysis revealed a correlation between HSP90 expression and the activation of pAKT and pERK,0.8
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,p-AKT antibody,antibody,Mechanistic,"Showed NF2-EVs HSP90OE significantly enhanced AKT phosphorylation in monocytes, while NF2-EVs HSP90KD decreased AKT phosphorylation",Results,"treatment with NF2-EVs HSP90OE significantly enhanced AKT phosphorylation in monocytes. Conversely, when exposed to NF2-EVs HSP90OE, we observed a marked decrease in AKT phosphorylation",0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,ERK antibody,antibody,Mechanistic,Detected correlation between HSP90 expression and ERK activation in NF2-associated schwannoma cells,Results,Our analysis revealed a correlation between HSP90 expression and the activation of pAKT and pERK,0.8
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,STRING database,computational_tool,Biomarker,"Used to analyze protein-protein interaction network with threshold score >0.9, identifying HSP90AA1 and HSP90AB1 among top ten key hub nodes",Results,"Utilizing the STRING online database (version 11.3) alongside Cytoscape software (version 3.7.2), we meticulously analyzed and visualized the protein-protein interaction (PPI) network, setting a threshold score of >0.9",0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,Cytoscape,computational_tool,Biomarker,Used with STRING database to visualize protein-protein interaction network and identify HSP90AA1 and HSP90AB1 among top ten key hub nodes ranked by Maximum Clique Centrality method,Results,"the top ten key hub nodes—ranked by the Maximum Clique Centrality (MCC) method—were HSPA8, HSP90AA1, HSP90AB1, GAPDH, HSPA5, HSPA1A, TUBA1A, EEF1A1, ACTB, and CCT2",0.9
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,Primary Schwannoma Cells,patient_derived_model,Efficacy,Showed significantly higher proliferation ability in NF2-EVs HSP90OE group compared to NF2-EVs and NF2-EVs HSP90KD groups,Results,the proliferation ability was significantly higher in the NF2-EVs HSP90OE group compared to the other groups (NF2-EVs and NF2-EVs HSP90KD),0.9
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1(ob) (-/-) conditional mouse model,animal_model,Efficacy,29% increase in calcified tissue volume by 3D µCT at 21 days post-fracture,Results,"...the callus from mice appeared larger (Figs. 1 and 2), as quantified by a 29% increase in calcified tissue volume by 3D µCT (A Fig. 2).",0.95
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1(ob) (-/-) conditional mouse model,animal_model,Efficacy,18% decrease in both callus BV/TV and callus bridging cortices BV/TV at 21 days post-fracture,Results,"This increase in callus volume was accompanied by an 18% decrease in both callus BV/TV and callus bridging cortices BV/TV (A, C Fig. 2)...",0.95
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1(ob) (-/-) conditional mouse model,animal_model,Efficacy,27% decrease in callus bridging cortices BV/TV and 26% decrease in callus BV/TV at 28 days post-fracture,Results,"...the difference between WT and B, C calluses further amplified to reach a 27% decrease in callus bridging cortices BV/TV and a 26% decrease in callus BV/TV...",0.95
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1(ob) (-/-) conditional mouse model,animal_model,Biomarker,"Significantly decreased callus bridging cortices BMD (799.3 ± 94.4 vs 877.7 ± 69.0, p = .018) and callus BMD (1000.8 ± 56.3 vs 1052.4 ± 53.1, p = .019)",Results,"...both callus bridging cortices BMD (877.7 ± 69.0 versus 799.3 ± 94.4, p = .018) and callus BMD (1052.4 ± 53.1 versus 1000.8 ± 56.3, p = .019) were significantly decreased in mutant mice.",0.95
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1(ob) (-/-) conditional mouse model,animal_model,Mechanistic,26% reduction in maximum force endured and 16% reduction in callus stiffness at 28 days post-fracture,Results,...calluses displayed a significant 26% reduction in maximum force endured compared with WT littermate calluses and a 16% reduction in callus stiffness.,0.95
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1(ob) (-/-) conditional mouse model,animal_model,Biomarker,Significantly increased osteoclast-covered surfaces at 28 days post-fracture,Results,...we observed that osteoclast-covered surfaces were significantly increased 28 days after fracture in mutant calluses (Fig. 4)...,0.9
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1(ob) (-/-) conditional mouse model,animal_model,Biomarker,Significant increase in callus OV/TV with thick osteoid matrix accumulation,Results,"...the presence of a thick osteoid matrix, visualized by von Kossa/van Gieson staining of undecalcified sections (Fig. 4), was observed in mutant calluses. This significant increase in callus OV/TV...",0.9
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1 flox/flox calvaria osteoblasts,cell_line,Mechanistic,Increased ERK1/2 phosphorylation following cre-recombinase adenovirus infection,Results,"Following cre-recombinase adrenovirus infection, ERK1/2 phosphorylation status was increased compared with GFP mock-transfected controls, indicating effective adenovirus-mediated recombination...",0.9
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Nf1 flox/flox calvaria osteoblasts,cell_line,Efficacy,Lovastatin treatment (20 µM for 12 hours) consistently decreased ERK1/2 activation in Nf1−/− osteoblasts,Results,Lovastatin treatment (20 µM for 12 hours) consistently decreased ERK1/2 activation in Nf1−/− osteoblasts compared with vehicle-treated controls.,0.95
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,2.3-kb α1(I) collagen-cre Nf1 flox/flox mice,animal_model,Safety,No differences in body weight observed between groups at study endpoint,Results,"...animals were able to ambulate and thrive adequately, and no differences in body weight were observed between groups at the endpoint of the study...",0.9
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,Ad5-CMV-Cre,genetic_reagent,Mechanistic,Effective adenovirus-mediated recombination of Nf1 flox/flox allele and activation of ERK1/2 signaling,Results,"Following cre-recombinase adrenovirus infection, ERK1/2 phosphorylation status was increased compared with GFP mock-transfected controls, indicating effective adenovirus-mediated recombination of the Nf1 flox/flox allele...",0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,Lbx1 Cre,genetic_reagent,Safety,"Newborn Lbx1 Cre;Nf1 flox/flox mice were smaller, exhibited cyanosis and lack of feeding, and died perinatally",Results,"Newborn Lbx1 Cre ;Nf1 flox/flox  mice were smaller, exhibited cyanosis and lack of feeding, and died perinatally.",0.95
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,Lbx1 Cre,genetic_reagent,Mechanistic,"Highly specific to the myogenic lineage in limbs and did not cause reporter recombination in neural cells, connective tissue, or cartilage",Results,"In the limbs, Lbx1 Cre  and Myf5 Cre  were highly specific to the myogenic lineage and did not cause reporter recombination in, for example, neural cells, connective tissue, or cartilage.",0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,Myf5 Cre,genetic_reagent,Safety,Myf5 Cre;Nf1 flox/flox mice were born at normal Mendelian ratios at normal size and were viable for further analysis,Results,Myf5 Cre ;Nf1 flox/flox  mice were born at normal Mendelian ratios at normal size and were used for further analysis.,0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,Myf5 Cre,genetic_reagent,Mechanistic,Highly specific to the myogenic lineage in limbs with minimal off-target activity in dorsal root ganglia but no recombination in limb neurons,Results,"The Myf5 Cre  line showed minimal off‐target activity in dorsal root ganglia, as described previously,   but no recombination was detected in limb neurons",0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,Myf5 Cre,genetic_reagent,Efficacy,Efficacy of Nf1 deletion was controlled in E18 and p21 muscle tissue showing successful gene knockout,Results,Efficacy of Nf1 deletion was controlled in E18 and p21 muscle tissue ( Figure  1H  and  1I ).,0.85
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,Myf5 Cre,genetic_reagent,Safety,Lifespan for Nf1 Myf5 mice consistently was approximately 20-25 weeks,Results,which for Nf1 Myf5  mice consistently was approximately 20–25 weeks.,0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,MaxQuant (v1.5.3.30),computational_tool,Efficacy,Proteome analysis yielded 274 significantly deregulated proteins between controls and Nf1 Myf5,Results,Proteome analysis of p21 TA muscle lysates yielded 274 significantly deregulated proteins between controls and Nf1 Myf5,0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,DESeq2,computational_tool,Efficacy,Transcriptome analysis yielded 1917 differentially expressed genes; 928 genes were down-regulated and 989 genes were up-regulated in Nf1 Myf5 muscle,Results,Transcriptome analysis yielded 1917 differentially expressed genes; 928 genes were down‐regulated and 989 genes were up‐regulated in Nf1 Myf5  muscle relative to controls,0.95
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,GSEA software 4.0.1,computational_tool,Efficacy,GSEA highlighted enrichment of genes associated with 'glucose catabolic process' in control muscle and 'oxidative phosphorylation' in Nf1 Myf5 muscle,Results,GSEA of the RNA‐Seq data highlighted enrichment of genes associated with 'glucose catabolic process' in control muscle and of genes associated with 'oxidative phosphorylation' in Nf1 Myf5  muscle,0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,mouse anti-MyHC type 1 (DSHB BA-D5),antibody,Efficacy,Successfully detected type 1 fibres revealing predominant size reduction of type 2 muscle fibres in Nf1 Myf5 mice,Results,Staining for type 1 fibres (MyHC‐1 + ) revealed a predominant size reduction of type 2 muscle fibres,0.85
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,mouse anti-MyHC type 2A (DSHB SC-71),antibody,Efficacy,Successfully detected shift of type 2B/X to type 2A fibres towards the fast oxidative phenotype in Nf1 Myf5 mice,Results,"We then analysed the proportion of type 2A and type 2B fibres in adult mice, revealing a shift of type 2B/X to type 2A fibres, that is, towards the fast oxidative phenotype, in Nf1 Myf5  mice",0.85
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,mouse anti-MyHC type 2B (DSHB BF-F3),antibody,Biomarker,Protein levels of MyHC-2B were decreased in Nf1 Myf5 TA muscles,Results,"In accordance, protein levels of MyHC‐1 were increased, and levels of MyHC‐2B were decreased in Nf1 Myf5  TA muscles",0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,rabbit anti-PPARG (Cell Signaling Technology 2443),antibody,Biomarker,Specific up-regulation of PPARγ isoform 1 was confirmed on the protein level in 7-week-old and also already in 2-week-old animals,Results,specific up‐regulation of PPARγ isoform 1 was confirmed on the protein level in 7‐week‐old and also already in 2‐week‐old animals,0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,rabbit anti-phosphor (pThr172) AMPKa (Cell Signaling Technology 2535),antibody,Biomarker,Nf1 Myf5 muscle showed increased levels of phosphorylated AMP-dependent kinase (AMPK),Results,"In line, Nf1 Myf5  muscle showed increased levels of phosphorylated AMP‐dependent kinase (AMPK), the most prominent intracellular energy sensor",0.9
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,rabbit anti-phosphor (s235/236) S6 (Cell Signaling Technology 4858),antibody,Biomarker,p21 Nf1 Myf5 muscle tissue showed decreased S6 Ser235/236 phosphorylation indicating decreased mTORC1 signalling,Results,"p21 Nf1 Myf5  muscle tissue showed hallmarks of decreased mTORC1 signalling, with decreased phosphorylation of mTOR Ser2448 and decreased S6 Ser235/236 phosphorylation",0.9
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,"Colony formation suppressed by prodrug FTIs 1 and 2 at ≥0.3 μM, with effects greatly enhanced by combinational treatment with lovastatin",Results,"Both prodrugs, in the absence of lovastatin, suppressed colony formation by the NF1 MPNST cell line S462TY when used at ≥0.3 μM...the suppressive effects of the two FTIs were greatly enhanced by combinational treatment with lovastatin",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,"IG2 showed no effect on colony formation up to 7 μM alone, but potentiation observed with concentrations as low as 0.5 μM when co-treated with lovastatin",Results,"By itself, IG 2 had no effect on S462TY colony formation up to 7 μM...Co-treatment with lovastatin markedly enhanced IG 2 suppression of colony formation. This potentiation was observed with concentrations of IG 2 as low as 0.5 μM",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,Concentrations of lovastatin as low as 250 nM reproducibly enhanced IG2 suppression of colony formation,Results,Concentrations of lovastatin as low as 250 nM reproducibly enhanced IG 2 suppression of colony formation,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,"Lovastatin (0.5 μM) and IG2 (5 μM) had only minor effects on proliferation or viability individually, but co-treatment resulted in concentration-dependent decreases in cell number",Results,"Lovastatin and IG 2 at concentrations of 0.5 μM and 5 μM, respectively, had only minor effects on proliferation or viability...However, co-treatment with 0.5 μM lovastatin and varied concentrations of IG 2 resulted in concentration-dependent decreases in cell number",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Mechanistic,Combining IG2 with concentrations of lovastatin as low as 0.1 μM caused concentration-dependent activation of DEVDase (procaspase-3/7 activation),Results,"However, combining IG 2 with concentrations of lovastatin as low as 0.1 μM caused a concentration-dependent activation of DEVDase that paralleled reductions in colony formation",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Efficacy,Synergy observed at all 4 concentrations of IG2 with each of the 3 lovastatin concentrations in MTT assay,Results,Synergy was observed at all 4 concentrations of IG 2 with each of the 3 lovastatin concentrations,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Mechanistic,"5 μM IG2 accumulated non-prenylated RAB5A and RAP1A within 4 h of treatment, while 0.5 or 1.0 μM had no effect",Results,Cultures exposed to 5 μM of IG 2 (but not 0.5 or 1.0 μM) accumulated non-prenylated RAB5A...and non-prenylated RAP1A...These accumulations occurred within 4 h of treatment,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Mechanistic,"0.25 μM lovastatin caused accumulation of non-prenylated RAB5A within 4 h, with 0.5 μM accelerating accumulation and also stimulating non-prenylated RAP1A",Results,Accumulations of non-prenylated RAB5A were also observed within 4 h of treatment with 0.25 μM of lovastatin...Treatment with a higher concentration of lovastatin (0.5 μM) accelerated the accumulation...also stimulated the accumulation of non-prenylated RAP1A,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,S462TY,cell_line,Mechanistic,"Co-treatment with 0.25 μM lovastatin and 1.0 μM IG2 caused dramatic accumulations of non-prenylated N-RAS within 4 h, while neither agent alone affected N-RAS prenylation at these concentrations",Results,"when S462TY cultures were co-treated with concentrations of lovastatin (0.25 μM) and IG 2 (1.0 μM) that singularly had no effect on N-RAS prenylation, dramatic accumulations of non-prenylated RAS were observed within 4 h of co-treatment",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,ST88-14,cell_line,Efficacy,Co-treatment with concentrations of lovastatin or IG2 that had little to no effect individually resulted in cooperative inhibition of colony formation,Results,Co-treatment of ST88-14 cells with concentrations of lovastatin or IG 2 that had little to no effect individually resulted in a cooperative inhibition of colony formation,0.9
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,ST88-14,cell_line,Efficacy,"MTT assays showed cooperative inhibition of growth/viability by lovastatin plus IG2 co-treatment, with synergistic interaction confirmed by CI versus Fa plots",Results,MTT assays also show a cooperative inhibition of growth/viability by lovastatin plus IG 2 co-treatment...CI versus Fa plots of MTT-derived data indicated that lovastatin and IG 2 worked synergistically,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,iSC,cell_line,Efficacy,"Neither 0.5 μM lovastatin nor concentrations of IG2 up to 5 μM affected colony formation, and no synergistic suppression observed with co-treatment",Results,Neither 0.5 μM of lovastatin nor concentrations of IG 2 up to 5 μM affected iSC colony formation...we observed no synergistic suppression of iSC colony formation following co-treatment with lovastatin and IG 2,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,MCF10A,cell_line,Efficacy,"Concentrations of IG2 could be reached that were cytostatic/cytotoxic in MTT assay, but co-treatment with lovastatin did not enhance the effects",Results,although concentrations of IG 2 could be reached that were cytostatic/cytotoxic (as scored in an MTT assay) to cultures of normal human breast MCF10A epithelial cells...co-treatment with lovastatin did not enhance the effects of IG 2,0.9
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,Balb/c mice,animal_model,Safety,Twice daily dosing with ~100 μmole/kg IG2 or 40 mg/kg lovastatin + 20 μmole/kg IG2 was lethal or necessitated euthanasia within three days,Results,"we determined that twice daily dosing of female Balb/c mice with ~100 μmole/kg of IG 2 per injection, or 40 mg/kg of lovastatin + 20 μmole/kg of IG 2, was either lethal or necessitated euthanasia of treated mice within a three-day period",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,Balb/c mice,animal_model,Safety,"Twice daily 20 mg/kg lovastatin + 20 μmole/kg IG2 caused hind limb paralyses in 2 out of 4 mice, necessitating treatment termination",Results,"With twice daily 20 mg/kg of lovastatin + 20 μmole/kg of IG 2 treatments, two out of four mice exhibited hind limb paralyses that necessitated termination of treatment",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,Balb/c mice,animal_model,Safety,"Twice daily treatment for seven consecutive days with 10 or 20 mg/kg lovastatin, 20 μmole/kg IG2, or combinations had no adverse effects on mouse weights, general appearance, or mobility",Results,"twice daily treatment, for seven consecutive days, with 10 or 20 mg/kg of lovastatin, 20 μmole/kg of IG 2, 20 mg/kg of lovastatin + 10 μmole/kg of IG 2, or 10 mg/kg of lovastatin + 20 μmole/kg of IG 2 had no adverse effects on mouse weights, general appearance, or mobility",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,Balb/c mice,animal_model,Mechanistic,"Small percentage of lung N-Ras was non-prenylated following twice-daily treatment with 20 μmol/kg IG2, markedly increased with co-treatment of 10 mg/kg lovastatin",Results,A small percentage of lung N-Ras was non-prenylated following twice-daily treatment with 20 μmol/kg of IG 2...Co-treatment with 10 mg/kg of lovastatin markedly increased the amount of non-prenylated N-Ras,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,NOD SCID mice (NOD.CB17-Prkdc/NCrCrl),animal_model,Efficacy,"Combinational treatment significantly reduced S462TY xenograft growth over the course of treatment, with almost no tumor growth during latter half of treatment",Results,The box plots...indicate that combinational treatment significantly reduced S462TY xenograft growth over the course of treatment...the box plot...suggests almost no tumor growth during the latter half of combinational treatment,0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,NOD SCID mice (NOD.CB17-Prkdc/NCrCrl),animal_model,Efficacy,Tumors resumed growth and increased in volume by 35-80% within 6 days of cessation of combinational treatment,Results,"However, the tumors resumed growth and increased in volume by 35–80% within 6 days of cessation of treatment",0.95
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,A549,cell_line,Efficacy,"Lovastatin strongly synergized with IG2 to suppress growth of A549 cells, a non-small cell lung carcinoma cell line with mutated K-Ras",Discussion,"in a preclinical study, we found that lovastatin strongly synergized with IG 2 to suppress the growth of A549 cells, a non-small cell lung carcinoma cell line with mutated K-Ras as a driver",0.9
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,CompuSyn software Version 1.0,computational_tool,Other,"Used to assess antagonistic, additive, and synergistic outcomes in combinational treatment protocols through CI versus Fa plots",Results,"Plots of combination index (CI) versus fraction affected (Fa) can be used to assess antagonistic, additive, and synergistic outcomes in combinational treatment protocols",0.9
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,H3K27me3 antibody,antibody,Biomarker,Loss of H3K27me3 detected in 45 of 82 (55%) of MPNSTs with IHC data available,Results,We identified loss of H3K27me3 in 45 of 82 (55%) of MPNSTs with IHC data available,0.95
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,H3K27me3 antibody,antibody,Biomarker,"H3K27me3 immunoreactivity classification was associated with overall survival in individuals with NF1, but not in sporadic MPNSTs",Results,"Classification by H3K27me3 immunoreactivity was associated with overall survival in individuals with NF1, but not in sporadic MPNSTs",0.9
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,H3K27me3 antibody,antibody,Biomarker,"H3K27me3 loss was strongly associated with high tumor cellularity estimates, decreased immune cell infiltration and adaptive immune response activation",Results,"H3K27me3 loss was strongly associated with high tumor cellularity estimates, decreased immune cell infiltration and adaptive immune response activation",0.9
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,IchorCNA,computational_tool,Biomarker,"Successfully detected copy-number aberrations recurrently found in MPNSTs in cell-free DNA, including loss of chromosomes 1p, 5q, 4q, and 22, and chromosome 8 amplification",Results,"Overall, we detected copy-number aberrations recurrently found in MPNSTs, including loss of chromosomes 1p, 5q, 4q, and 22, and chromosome 8 amplification",0.9
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,FACETS,computational_tool,Biomarker,Identified whole-genome doubling events in 22 of 37 (59%) of tumors with H3K27me3 retained and in 33 of 45 (73%) of tumors with H3K27me3 loss,Results,"Whole-genome doubling (WGD) events, which were validated using image cytometry analysis, were detected in 22 of 37 (59%) of tumors with H3K27me3 retained and in 33 of 45 (73%) of tumors with H3K27me3 loss",0.95
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,consensusTME,computational_tool,Biomarker,Revealed decreased immune infiltration according to H3K27me3 status with immune score analysis,Results,Immune score analysis reveals decreased immune infiltration according to H3K27me3 status,0.9
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,BWA-MEM,computational_tool,Other,Successfully processed whole-genome sequencing data from 95 samples from 90 fresh-frozen tumors,Results,we collected and analyzed 95 samples from 90 fresh-frozen tumors (61 NF1-related; 29 sporadic) and matched blood samples from 77 individuals using whole-genome sequencing,0.85
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,Strelka2,computational_tool,Biomarker,Identified biallelic inactivation of NF1 in 56/64 (88%) tumor samples and biallelic inactivation of CDKN2A in 40/64 (63%) NF1-related MPNSTs,Results,we confirmed biallelic inactivation of NF1 in 56/64 (88%) tumor samples arising within the tumors of individuals with NF1... We detected somatic biallelic inactivation of CDKN2A in 40/64 (63%) NF1-related MPNSTs,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Percent fat mass significantly reduced and lean mass modestly increased compared to WT mice,Results,The percent fat mass is significantly reduced and lean mass is modestly increased in Nf1 +/− mice when compared with littermate WT mice,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Behavioral,Less active than WT mice despite consuming similar quantities of food and water,Results,"Interestingly, Nf1 +/− mice were less active than WT mice despite consuming similar quantities of food and water",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Heat production lower compared to WT mice,Results,"Further, heat production, a metabolic side product, was lower in Nf1 +/− mice when compared with WT mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Consumed significantly less oxygen than WT mice while CO2 production was similar,Results,Nf1 +/− mice consumed significantly less oxygen than WT mice while CO 2 production was similar between genotypes,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,"RER significantly higher than WT mice, suggesting more dependence on carbohydrates rather than fatty acids as fuel source",Results,The RER for Nf1 +/− mice is significantly higher than WT mice and suggests that Nf1 +/− mice are more dependent on carbohydrates rather than fatty acids as a fuel source,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Visceral fat mass reduced nearly 3-fold compared to WT mice,Results,"In comparison to WT mice, visceral fat mass was reduced nearly 3-fold in littermate Nf1 +/− mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Increased adipocyte density but reduced cross-sectional area in visceral fat depots compared to WT mice,Results,"Quantification of hematoxylin and eosin-stained visceral fat depots identified increased density, but reduced cross-sectional area for adipocytes isolated from Nf1 +/− mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Cell density in subcutaneous fat increased over two-fold while cross-sectional area reduced two-fold compared to WT mice,Results,the cell density in subcutaneous fat depots from Nf1 +/− mice was increased over two-fold while cross-sectional area was reduced two-fold when compared with WT mice,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,"Brown adipose mass reduced (4.1 ± 1.6 mg/g vs. 7.1 ± 1.7 mg/g, p = 0.006) compared to WT mice",Results,"Brown adipose mass was also reduced in Nf1 +/− mice when compared with WT mice (4.1 ± 1.6 mg/g vs. 7.1 ± 1.7 mg/g, p = 0.006)",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Lipid deposition significantly reduced in livers but nearly 3-fold higher in skeletal muscle compared to WT mice,Results,Lipid deposition was significantly reduced in livers isolated from Nf1 +/− mice but lipid content was nearly 3-fold higher in skeletal muscle from Nf1 +/− mice,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,"HDL concentration significantly increased, triglyceride levels increased, LDL reduced nearly 2-fold compared to WT mice",Results,"High-density lipoprotein (HDL) concentration was significantly increased as was triglyceride levels, while low-density lipoprotein (LDL) was reduced nearly 2-fold in Nf1 +/− mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Total cholesterol-to-HDL ratio reduced compared to WT mice,Results,The total cholesterol-to-HDL ratio was also reduced in Nf1 +/− mice when compared with WT mice,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Significantly lower circulating leptin levels compared to WT mice,Results,"Similar to persons with NF1, Nf1 +/− mice have significantly lower circulating leptin levels when compared with littermate WT mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,HgbA1c modestly lower (4.45% ± 0.15% vs. 4.62% ± 0.13%; p = 0.02) compared to WT mice,Results,"Initial blood glucose values after the 24 hour fast did not differ between groups, but HgbA1c was modestly lower in Nf1 +/− mice (4.62% ± 0.13% vs. 4.45% ± 0.15%; p -value = 0.02)",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Lower peak blood glucose values and recovered more quickly in glucose tolerance test compared to WT mice,Results,"In response to a glucose load, Nf1 +/− mice had lower peak blood glucose values and recovered more quickly when compared with WT mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,Dramatically lower starting blood glucose concentrations after 5-hour fast and slower recovery period from 45-90 minutes in insulin tolerance test,Results,"after a brief fast of 5 hours, Nf1 +/− mice had dramatically lower starting blood glucose concentrations when compared to WT mice...Nf1 +/− mice exhibited a much slower recovery period from 45–90 minutes",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Safety,30% increase in body weight vs. 50% increase in WT mice on high-glucose diet for 16 weeks,Results,WT mice had gained an average of 50% increase in body weight as compared to an average of 30% increase in body weight for the Nf1 +/− cohort,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Nf1+/- mice,animal_model,Biomarker,"Did not develop hyperglycemia after 16 weeks of 30% glucose drinking water, had nearly identical blood glucose values at beginning and end",Results,"Strikingly, Nf1 +/− mice did not develop hyperglycemia after 16 weeks of a 30% glucose drinking water solution and had nearly identical blood glucose values at the beginning and end of the study",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Bruker minispec LF90 TD‐NMR analyzer,clinical_assessment_tool,Biomarker,Determined altered body composition in Nf1+/- mice with significantly reduced percent fat mass and modestly increased lean mass,Results,Nf1 +/− mice display an altered body composition as determined by NMR. The percent fat mass is significantly reduced and lean mass is modestly increased,0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Comprehensive Lab Animal Monitoring System (CLAMS),clinical_assessment_tool,Behavioral,Monitored mouse activity showing Nf1+/- mice were less active than WT mice despite similar food and water consumption,Results,"Interestingly, Nf1 +/− mice were less active than WT mice despite consuming similar quantities of food and water",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Comprehensive Lab Animal Monitoring System (CLAMS),clinical_assessment_tool,Biomarker,"Measured lower heat production, significantly less oxygen consumption, and higher RER in Nf1+/- mice compared to WT",Results,"heat production, a metabolic side product, was lower in Nf1 +/− mice...Nf1 +/− mice consumed significantly less oxygen than WT mice...The RER for Nf1 +/− mice is significantly higher than WT mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,AlphaTrak 2,clinical_assessment_tool,Biomarker,"Measured blood glucose concentrations during glucose and insulin tolerance tests, showing improved glucose handling in Nf1+/- mice",Results,"In response to a glucose load, Nf1 +/− mice had lower peak blood glucose values and recovered more quickly when compared with WT mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,A1C Now Diabetes Management HbA1C test kit,clinical_assessment_tool,Biomarker,Measured modestly lower HgbA1c in Nf1+/- mice (4.45% ± 0.15%) compared to WT mice (4.62% ± 0.13%; p = 0.02),Results,HgbA1c was modestly lower in Nf1 +/− mice (4.62% ± 0.13% vs. 4.45% ± 0.15%; p -value = 0.02),0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,LDX Cholestech cartridges,clinical_assessment_tool,Biomarker,"Measured significantly increased HDL, increased triglycerides, and nearly 2-fold reduced LDL in Nf1+/- mice compared to WT",Results,"High-density lipoprotein (HDL) concentration was significantly increased as was triglyceride levels, while low-density lipoprotein (LDL) was reduced nearly 2-fold in Nf1 +/− mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Pro-diabetes multiplex assay,clinical_assessment_tool,Biomarker,"Measured significantly lower leptin levels, statistically higher glucagon concentration, and modestly elevated ghrelin in Nf1+/- mice",Results,"Nf1 +/− mice have significantly lower circulating leptin levels...the mean glucagon concentration was statistically higher in the Nf1 +/− cohort...ghrelin, a hormone that promotes growth hormone release, was modestly elevated in Nf1 +/− mice",0.9
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,Image Pro Plus,computational_tool,Biomarker,Quantified increased adipocyte density but reduced cross-sectional area in fat depots from Nf1+/- mice compared to WT,Results,"Quantification of hematoxylin and eosin-stained visceral fat depots identified increased density, but reduced cross-sectional area for adipocytes isolated from Nf1 +/− mice",0.9
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,primary cultures derived from plexiform neurofibromas,patient_derived_model,Efficacy,"Showed variable drug response patterns between tumors - tumor 1 responded well to both nilotinib and imatinib with continuous and substantial decrease in tumor cell proportion, tumor 2 responded well to nilotinib but poorly to imatinib, tumor 3 responded well to imatinib but less well to nilotinib, tumor 4 responded poorly to both drugs",Results,"A good drug response, defined as a continuous and substantial decrease in the proportion of tumor cells, was observed in the culture derived from tumor no. 1 for both nilotinib and imatinib",0.9
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,primary cultures derived from plexiform neurofibromas,patient_derived_model,Biomarker,"Demonstrated dose-dependent changes in proportions of Schwann cells and fibroblasts, with patterns varying between tumors and drugs",Results,"These proportions changed in a dose-dependent manner, but the patterns of change varied from tumor to tumor and between the two drugs",0.9
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,"rabbit anti-human S100 antibody (DAKO, Glostrup, Denmark)",antibody,Other,"Successfully stained Schwann cells specifically, enabling identification and counting of tumor cells in mixed cultures",Results,Schwann cells and fibroblasts were specifically stained with antibodies raised against S100,0.9
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,"anti-human CD90 antibody (Dianova, Hamburg, Germany)",antibody,Other,"Successfully stained fibroblasts specifically, enabling identification and counting of non-tumor cells in mixed cultures",Results,"Schwann cells and fibroblasts were specifically stained with antibodies raised against S100 ( Fig. 1A, C, and G ) and CD90 ( Fig. 1B, D, and G ), respectively",0.9
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",computational_tool,Other,Successfully used for counting stained cells in immunofluorescence images to calculate proportions of tumor and non-tumor cells,Results,Immunofluorescence images were obtained ( Fig. 1E ) and the stained cells were counted using ImageJ software ( Fig. 1F ),0.9
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,s-100b antibody (Sigma),antibody,Other,Successfully used for immunohistochemical staining to visualize Schwann cell morphology in both WT and NF cells on nanofibers,Results,Immunohistochemical staining was done 48 hours post stimulation with S100 (red) and DAPI (blue),0.9
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,"anti-rabbit IgG (Alexa Fluor 594, Invitrogen)",antibody,Other,"Used as secondary antibody for immunohistochemical staining, providing red fluorescence visualization of S100-positive Schwann cells",Results,Immunohistochemical staining was done 48 hours post stimulation with S100 (red) and DAPI (blue),0.9
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,ImageJ (v1.53a),computational_tool,Other,Used for quantitative analysis of cell morphology parameters including aspect ratio and cellular spread area measurements,Results,Cellular spread area was found to be greater in WT cells than NF cells... Elongation was measured by aspect ratio,0.8
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,NIH ImageJ (version 1.53a),computational_tool,Other,Used for quantitative analysis of fiber morphology including fiber diameter measurements and alignment analysis,Results,We analyzed at least 200 nanofibers with 10 SEM images for each fiber type... Fiber diameter for HA and HA-CNT was 160±27nm and 197±40 nm respectively,0.8
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,Taqman Gene Expression Assays,genetic_reagent,Biomarker,Successfully detected ER mRNA upregulation in 12 of 23 (52%) sporadic VS samples and PR mRNA upregulation in 16 of 23 (69.6%) sporadic VS samples,Results,"A total of 12 of 23 (52%) sporadic VS samples upregulate ER, and 16 of 23 (69.6%) sporadic VS samples upregulate PR",0.95
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,Taqman Gene Expression Assays,genetic_reagent,Biomarker,Detected ER mRNA upregulation in 4 of 16 (25%) NF2-related VS and PR mRNA upregulation in 5 of 16 (31.3%) NF2-related VS,Results,A total of 4 of 16 (25%) NF2-related VS upregulated ER and 5 of 16 (31.3%) upregulated PR,0.95
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,"ABI Prism 7,000 Sequence Detection System",computational_tool,Biomarker,Quantified sporadic VS upregulation of ER mRNA above 10-fold and PR mRNA over 100-fold,Results,"Sporadic VS upregulate ER mRNA above 10-fold, and upregulate levels of PR mRNA over 100-fold",0.92
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,"ABI Prism 7,000 Sequence Detection System",computational_tool,Biomarker,Showed control GAN samples expressed higher levels of ER and PR mRNA when compared with SN or VS,Results,Results of Q-PCR analyses indicate that the four control GAN samples expressed higher levels of ER and PR mRNA when compared with SN or VS,0.88
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,Microsoft Excel program designed for Q-PCR quantitation,computational_tool,Biomarker,Enabled statistical analysis showing most NF2-related VS did not upregulate ER mRNA and downregulated PR mRNA in a statistically significant manner,Results,"Most NF2-related VS did not upregulate ER mRNA, and downregulated PR mRNA in a statistically significant manner",0.85
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Numerical Rating Scale-11,clinical_assessment_tool,Behavioral,"At baseline, 84% (16 of 19) of patients rated having tumor pain with total sample mean of 4.95 (SD 3.44, range 0-10), with 69% (11 of 16) reporting moderate to severe levels (ratings ≥4)",Results,"At baseline, 84% (16 of 19) of patients rated having tumor pain (total sample mean, 4.95; SD, 3.44; range, 0-10) with 69% (11 of 16) reporting moderate to severe levels (ratings ≥ 4).",0.95
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Numerical Rating Scale-11,clinical_assessment_tool,Behavioral,"Mean ratings of worst tumor pain intensity decreased significantly in the total sample from baseline to course 4 (P = .0075), with both PR and no-PR groups showing similar trend toward less pain (almost two mean points lower, suggesting clinically meaningful change)",Results,"Mean ratings of worst tumor pain intensity decreased significantly in the total sample from baseline to course 4 ( P  = .0075), with both PR and no-PR groups showing a similar trend toward less pain (almost two mean points lower, suggesting clinically meaningful change ).",0.95
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Numerical Rating Scale-11,clinical_assessment_tool,Behavioral,"In the PR group, decreases in tumor pain intensity remained significantly lower at 12 months",Results,"In the PR group, decreases in tumor pain intensity remained significantly lower at 12 months (Table  14 2 ).",0.9
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Brief Pain Inventory Pain Interference subscale,clinical_assessment_tool,Behavioral,Mean total Brief Pain Inventory Pain Interference subscale scores were not significantly different from baseline to course 12 at any time point for the total sample,Results,Mean total Brief Pain Inventory Pain Interference subscale scores were not significantly different from baseline to course 12 at any time point for the total sample.,0.9
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Brief Pain Inventory Pain Interference subscale,clinical_assessment_tool,Behavioral,Only the PR group exhibited significant reduction in pain interference from baseline to course 8,Results,Only the PR group exhibited significant reduction in pain interference from baseline to course 8 (Table  2 ).,0.9
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Pediatric Quality of Life Inventory NF1 module,clinical_assessment_tool,Behavioral,The total sample showed no significant change in the Pediatric Quality of Life Inventory NF1 total mean score at any evaluation,Results,The total sample showed no significant change in the Pediatric Quality of Life Inventory NF1 total mean score at any evaluation.,0.9
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Pediatric Quality of Life Inventory NF1 module,clinical_assessment_tool,Behavioral,The PR group exhibited significant improvement in total functioning from baseline to course 8,Results,"However, the PR group exhibited significant improvement in total functioning from baseline to course 8 (Table  2 ).",0.9
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Pediatric Quality of Life Inventory NF1 module,clinical_assessment_tool,Behavioral,"Only the PR group rated significant physical changes, including improvements in Movement and Balance at courses 8 and 12 or worsening Skin Irritation at course 4",Results,"In the domains (Appendix Table A 4 , online only), only the PR group rated significant physical changes, including improvements in Movement and Balance at courses 8 and 12 or worsening Skin Irritation at course 4.",0.9
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Pediatric Quality of Life Inventory NF1 module,clinical_assessment_tool,Behavioral,"In the total sample, cognitive functioning mean scores improved significantly at course 8 (P = .042)",Results,"In the total sample, cognitive functioning mean scores improved significantly at course 8 ( P  = .042).",0.95
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Phoenix WinNonlin (Version 8.1),computational_tool,Biomarker,"Mean AUC 0-12h values (± SD) of mirdametinib and PD-0315209 (metabolite) on day 1 were 443 (± 103) and 184 (± 101) (ng * h/mL), respectively",Results,"Mean AUC 0-12h  values (± SD) of mirdametinib and PD-0315209 (metabolite) on day 1 were 443 (± 103) and 184 (± 101) (ng * h/mL), respectively.",0.95
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,Phoenix WinNonlin (Version 8.1),computational_tool,Biomarker,"The mean apparent mirdametinib clearance was 7.6 L/h (± 2.6) and showed a good correlation with both body weight and body surface area (R² of 0.80 and 0.77, respectively)",Results,"The mean apparent mirdametinib clearance was 7.6 L/h (± 2.6) and showed a good correlation with both body weight and body surface area (R 2  of 0.80 and 0.77, respectively).",0.95
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,cNF-Skindex,clinical_assessment_tool,Behavioral,Mean total cNF-Skindex score was 40.7 (SD 27.1) with median 36.0 (IQR 15.0-65.0) and score range 3-94,Results,"The mean total cNF-Skindex score was 40.7 (Table 2). Nine participants had a total cNF-Skindex score that placed them in severity stratum 1 (nonbothersome cNF, 15%), 28 were in stratum 2 (moderately bothersome cNF, 48%) and 22 patients were in stratum 3 (very bothersome cNF, 37%).",0.95
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,cNF-Skindex,clinical_assessment_tool,Other,"High internal consistency with Cronbach's alpha above 0.90 for total score (0.96) and all subdomains (Functioning: 0.93, Emotions: 0.93, Symptoms: 0.91)",Results,"The Cronbach's alpha of the total score and the subdomains were all above 0.90, indicating high internal consistency.",0.95
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,cNF-Skindex,clinical_assessment_tool,Other,"Adequate test-retest reliability with Spearman's correlation r=0.88 for total score, r=0.89 for Functioning, r=0.83 for Emotions, and r=0.85 for Symptoms (all p<0.001)",Results,"Adequate test-retest reliability was observed for both the total cNF-Skindex score (Spearman's correlation r = 0.88), the 'Functioning' subdomain (r = 0.89), 'Emotions' subdomain (r = 0.83), and 'Symptoms' subdomain (r = 0.85), with all p-values < 0.001.",0.95
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,cNF-Skindex,clinical_assessment_tool,Other,"Significant differences in scores between participants with ≤50 cNF vs >50 cNF (27.9 vs 45.4, p=0.017) and between those with vs without cNF-related intervention (30.5 vs 47.7, p=0.026)",Results,"For known-group validity, significant differences in cNF-Skindex scores were observed between participants with ≤ 50 cNF or more than 50 cNF, as well as for participants who had and who had not received a cNF-related intervention",0.95
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,EQ-5D-5L,clinical_assessment_tool,Other,"Mean Spearman correlation with cNF-Skindex total score was 0.30 (range 0.07-0.358, p-values 0.005-0.606). VAS correlation with cNF-Skindex was -0.32 (p=0.012)",Results,"Regarding convergent validity, the mean Spearman correlation between the total cNF-Skindex score and the items of the EQ-5D-5L was 0.30 (correlations ranging between 0.07 and 0.358, with p-values ranging between 0.005 and 0.606) The Spearman correlation between the total cNF-Skindex score and the EQ-5D-5L VAS was − 0.32 (p-value = 0.012).",0.95
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,SF-36,clinical_assessment_tool,Other,Total and subdomain scores of cNF-Skindex correlated significantly with several SF-36 scales,Results,The total and subdomain scores of the cNF-Skindex score also correlated significantly with several of the SF-36 scales (ANNEX 1).,0.85
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,SPSS version 28.0,computational_tool,Other,Kaiser-Meyer-Olkin test verified sampling adequacy with KMO of 0.89. Three factors explained 76.4% of total variance in exploratory factor analysis,Results,"The Kaiser–Meyer–Olkin test verified the sampling adequacy for the analysis, with a KMO of 0.89. The scree plot showed an inflexion that justified the selection of three factors. The three identified factors ('Functioning', 'Symptoms', and 'Emotions') explained 76.4% of the total variance",0.9
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),clinical_assessment_tool,Behavioral,"Baseline QOL was poor across all domains in both groups, with mean physical health scores of 57.7 (3RP-NF) and 57.5 (HEP-NF)",Results,Baseline QOL in both the 3RP-NF and HEP-NF groups was poor across all domains. Mean (SD) values on all QOL domains are presented by group in Table 2.,0.95
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),clinical_assessment_tool,Behavioral,"Physical health QOL improved significantly in both groups from baseline to post-treatment: 3RP-NF 5.1 points (95% CI, 3.2-7.0; P<.001), HEP-NF 6.4 points (95% CI, 4.6-8.3; P<.001)",Results,"Participants in both the 3RP-NF and HEP-NF groups experienced improvement in the physical health QOL score (3RP-NF, 5.1; 95% CI, 3.2-7.0; P < .001; HEP-NF, 6.4; 95% CI, 4.6-8.3; P < .001)",0.95
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),clinical_assessment_tool,Behavioral,"Psychological QOL improved significantly in both groups from baseline to post-treatment: 3RP-NF 8.5 points (95% CI, 6.4-10.7; P<.001), HEP-NF 9.2 points (95% CI, 7.1-11.2; P<.001)",Results,"psychological QOL score (3RP-NF, 8.5; 95% CI, 6.4-10.7; P < .001; HEP-NF, 9.2; 95% CI, 7.1-11.2; P < .001) from baseline to after treatment",0.95
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),clinical_assessment_tool,Behavioral,"At 12 months, 3RP-NF showed superior durability with physical health QOL improvement of 6.3 vs HEP-NF 2.8 (difference 3.6; 95% CI, 0.5-6.6; P=.02)",Results,"By 12 months after baseline, improvements in both outcomes were clinically significant only for participants receiving the 3RP-NF (physical health QOL score: 3RP-NF, 6.3; HEP-NF, 2.8; difference, 3.6)",0.95
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),clinical_assessment_tool,Behavioral,"Treatment response rates for physical health QOL at 12 months significantly favored 3RP-NF: 55% (46/84) vs HEP-NF 38% (35/92), χ²=4.94, P=.03",Results,"For physical health QOL, treatment response rates for 3RP-NF vs HEP-NF were 46% (51 of 110) vs 48% (53 of 110) after treatment, 53% (54 of 102) vs 43% (46 of 107) at 6 months, and 55% (46 of 84) vs 38% (35 of 92) at 12 months",0.95
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,Relaxation Response Resiliency Program for NF (3RP-NF),clinical_assessment_tool,Efficacy,"3RP-NF showed sustained and clinically meaningful improvement in all QOL domains, which increased through 12 months of follow-up",Discussion,"The 3RP-NF intervention showed sustained and clinically meaningful improvement in all QOL domains, which increased through 12 months of follow-up.",0.9
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,Health Enhancement Program for NF (HEP-NF),clinical_assessment_tool,Efficacy,"HEP-NF showed initial improvements in QOL but effects decreased over time, with improvements not sustained at 12 months compared to 3RP-NF",Results,"Improvements in both outcomes remained at 12 months after baseline in both groups, but the size of improvement decreased for those in the HEP-NF group and were sustained for those in the 3RP-NF group.",0.9
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,GSK2126458,genetic_reagent,Efficacy,Suppressed tumor growth by ~56% relative to vehicle-treated tumors at four months in meningioma xenograft model,Results,GSK2126458 suppressed tumor growth by an average of ~56% relative to vehicle-treated tumors at four months,0.95
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,GSK2126458,genetic_reagent,Safety,Initially administered at 3 mg/kg/day but reduced to 1.5 mg/kg/day due to significant GI toxicity; reduced dose was well tolerated,Results,"GSK2126458 was initially administered by daily oral gavage at 3 mg/kg/day, but subsequently decreased to 1.5 mg/kg/day due to significant GI toxicity. The reduced dose was well tolerated.",0.9
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,GSK2126458,genetic_reagent,Efficacy,Median tumor size was not reduced in response to treatment in schwannoma GEM model,Results,Median tumor size was not reduced in response to any of the three experimental drugs,0.9
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,GSK2126458,genetic_reagent,Mechanistic,"Led to strong increase in MIB binding of INSR and IGF1R, which has been previously described in response to mTOR inhibition",Results,"Dual inhibition of PI3K/mTOR by GSK2126458 led to a strong increase in MIB binding of INSR and IGF1R, which has been previously described in response to mTOR inhibition",0.9
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,Panobinostat,genetic_reagent,Efficacy,"Meningioma xenografts did not grow following treatment, with growth suppression becoming more significant over time versus vehicle-treated tumors which grew more than 400%",Results,"Meningioma xenografts treated with Panobinostat did not grow following treatment, and the magnitude of growth suppression became more significant over time versus vehicle-treated tumors which grew more than 400%",0.95
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,Panobinostat,genetic_reagent,Safety,Given via intraperitoneal injection at 20 mg/kg 3x/week and was well tolerated,Results,Panobinostat was given via intraperitoneal injection at a dose of 20 mg/kg 3x/week and was well tolerated.,0.9
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,Panobinostat,genetic_reagent,Efficacy,Median tumor size was not reduced in response to treatment in schwannoma GEM model,Results,Median tumor size was not reduced in response to any of the three experimental drugs,0.9
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,CUDC-907,genetic_reagent,Efficacy,Resulted in trend of suppression of tumor growth with average reduction of 55% in tumor size after 14 weeks of treatment in meningioma xenograft model,Results,CUDC-907 at 25 mg/kg/day resulted in a trend of suppression of tumor growth compared with vehicle-treated controls after ten weeks with an average reduction of 55% in tumor size after 14 weeks of treatment,0.9
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,CUDC-907,genetic_reagent,Safety,"Poorly tolerated at oral doses of 100 mg/kg/day and 50 mg/kg/day, but 25 mg/kg/day was tolerated",Results,"CUDC-907 was poorly tolerated, both at oral doses of 100 mg/kg/day and 50 mg/kg/day pointing to differences with the meningioma model. A dose of 25 mg/kg/day was tolerated.",0.9
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,CUDC-907,genetic_reagent,Efficacy,Median tumor size was not reduced in response to treatment in schwannoma GEM model,Results,Median tumor size was not reduced in response to any of the three experimental drugs,0.9
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,www.synapse.org/SynodosNF2,computational_tool,Other,"Openly accessible database for community sharing and mining of drug treatment, transcriptome and kinome data from isogenic schwannoma and meningioma cell systems",Discussion,"building an openly accessible ( www.synapse.org/SynodosNF2 ) database for community sharing and mining of drug treatment, transcriptome and kinome data from isogenic schwannoma and meningioma cell systems",0.85
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",murine NF2 −/− Schwann cell line,cell_line,Efficacy,Tumors are expected to grow and mice become moribund in 3-5 weeks following implantation,Results,Tumors are expected to grow and mice are expected to become moribund in 3–5 weeks,0.8
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",GLuc reporter gene,genetic_reagent,Biomarker,Blood GLuc levels can be monitored every 3 days to track tumor growth,Results,monitoring of tumor growth is continued by testing blood GLuc levels every 3 d,0.9
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",DPOAE,clinical_assessment_tool,Behavioral,"Surgical procedure should not cause hearing loss, but increased DPOAE thresholds indicate tumor-induced hearing loss in tumor-bearing mice",Results,The surgical procedure involving skull drilling for a craniotomy and needle injections for tumor cell implantation should not cause hearing loss...Increased DPOAE and ABR thresholds should be found in tumor-bearing mice,0.8
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",ABR,clinical_assessment_tool,Behavioral,"Surgical procedure should not cause hearing loss, but increased ABR thresholds indicate tumor-induced hearing loss in tumor-bearing mice",Results,The surgical procedure involving skull drilling for a craniotomy and needle injections for tumor cell implantation should not cause hearing loss...Increased DPOAE and ABR thresholds should be found in tumor-bearing mice,0.8
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",rotarod assay,clinical_assessment_tool,Behavioral,"Surgery and tumor implantation should not affect rotarod performance initially, but mice develop ataxia symptoms 2 weeks after tumor implantation with increasing severity as tumors progress",Results,"Surgery and tumor implantation procedures should not result in ataxia symptoms and affect rotarod performance...Mice are expected to develop symptoms of ataxia 2 weeks after tumor implantation, and the severity of ataxia will increase as tumors progress",0.8
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,mGeCKOa lentiviral library,genetic_reagent,Efficacy,"Library of 67,000 sgRNAs targeting 20,611 mouse genes (~3 sgRNAs per gene) successfully identified 267 sgRNAs enriched at least 8-fold in tumors",Results,"mGeCKOa lentiviral library of 67,000 single-guide RNA (sgRNA) targeting 20,611 mouse genes (~3 sgRNAs per gene...We identified 267 sgRNAs that were enriched at least 8-fold in tumors",0.95
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,p53−/− mouse embryonic liver progenitor cells,cell_line,Efficacy,"When combined with Myc overexpression, cells form tumors slowly in subcutaneous transplants but can be accelerated by additional tumor suppressor inactivation",Results,"p53−/−; Myc cells form tumors slowly, but inactivation of additional tumor suppressors accelerates tumor formation",0.9
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,Nu/Nu mice,animal_model,Efficacy,"100% of mice (n=8) that received sgRNA library developed subcutaneous tumors within one month, while control mice had not",Results,"Within one month, 100% (n = 8) of mice that received the sgRNA library had developed subcutaneous tumors, whereas mice that received the control cells had not",0.95
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,p53 flox/flox mice,animal_model,Efficacy,sgNf1-injected mice developed significantly more liver tumors than GFP sgRNA controls (P = .02),Results,sgNf1-injected mice developed significantly more liver tumors than mice that received the GFP sgRNA control (P = .02),0.95
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,Albumin-Cre mice,animal_model,Efficacy,"When combined with p53 flox/flox background, sgRNA multiplex with sgNf1 accelerated tumor formation within two months and all mice developed lung tumors at three months (n=3)",Results,"Within two months, the sgRNA multiplex with sgNf1 accelerated tumor formation (n = 3 per treatment)...At three months, all mice treated with the sgNf1-containing multiplex also developed lung tumors (n = 3)",0.9
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,anti-Hmga2 antibody (Biocheck),antibody,Biomarker,Successfully detected elevated Hmga2 protein in Ras-dependent mouse models of cholangiocarcinoma and in liver/lung tumors,Results,Hmga2 protein was also elevated in two Ras-dependent mouse models of cholangiocarcinoma...All liver and lung tumors were morphologically identical and positive for Hmga2,0.9
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,anti-beta-Catenin antibody (BD bioscience),antibody,Biomarker,"Successfully detected beta-catenin positivity in all liver and lung tumors, consistent with Apc loss-of-function",Results,"All liver and lung tumors were morphologically identical and positive for Hmga2 and beta-catenin, consistent with Nf1 and Apc loss-of-function",0.9
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,anti-Ck19 antibody (Abcam),antibody,Biomarker,"Successfully detected Cytokeratin 19 positivity in liver and lung tumors, indicating bile duct and cholangiocarcinoma markers",Results,liver and lung tumors were also positive for the bile duct and cholangiocarcinoma marker Cytokeratin 19 (Ck19),0.9
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,anti-pErk antibody (Cell Signaling),antibody,Biomarker,"Successfully detected increased phospho-Erk levels in sgNf1-treated cells and tumors, and upregulation by sgRNAs targeting Plxnb1, Flrt2 and B9d1",Results,"cells infected with sgNf1 or the corresponding subcutaneous tumors show increased levels of phosphor-Erk (pErk)...inactivation of Plxnb1, Flrt2 and B9d1 using two independent sgRNAs per gene also upregulated pErk",0.9
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,293fs cells,cell_line,Efficacy,Successfully used for lentivirus production in the CRISPR screening workflow,Results,We therefore stably transduced p53−/−; Myc fetal hepatocytes with a lentivirus encoding Cas9,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,WGCNA,computational_tool,Mechanistic,"Identified 26 network modules with various module sizes and preservation as Z-summary scores, with 9 modules having Z-summary scores >5 selected as preserved modules",Results,Twenty-six network modules were defined with various module sizes and preservation as Z-summary scores. The modules with Z-summary scores of more than 5 were selected as preserved modules,0.95
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,WGCNA,computational_tool,Mechanistic,"Successfully identified consensus gene regulatory network modules between PN cell lines and primary PN tumors, with preserved modules independently recapitulating PN tumor biology",Results,"The preserved modules from unsupervised analysis independently recapitulate PN tumor biology, providing validation for using this method to direct drug selection",0.9
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,Mechanism Interrogation PlatE (MIPE 4.0) library,computational_tool,Efficacy,Yielded 1831 drug candidates from 1912 oncology-focused compounds using cell viability cutoff <55% for inhibitory median response across PN cell lines,Results,This filter yielded 1831 drug candidates from 1912 oncology-focused compounds within the MIPE 4.0 library,0.95
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ConsensusClusterPlus,computational_tool,Mechanistic,Successfully performed consensus clustering analysis on drugs according to correlation coefficiency and identified six drug clusters,Results,We then performed consensus clustering analysis on those drugs according to the correlation coefficiency and identified six drug clusters,0.9
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,IDAPredict.2drug function package,computational_tool,Mechanistic,"Successfully predicted drug combination efficacy with concentration-dependent predictions representing average response across populations of cell lines, with combinations scoring >1 IDAcombo score",Results,"The predicted IDAcomboscores are shown in the heatmap. For those combinations with an IDAcombo score >1, their drug fingerprints and combination scores were demonstrated",0.9
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipNF05.5 (mixed clone),cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipNF05.5 (single clone),cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipNF95.11bC,cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipNF95.6,cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,ipnNF95.11c,cell_line,Other,Used in drug screening with transcriptome data downloaded through NF Data Portal for network module analysis,Results,The transcriptomes of cell lines used in the drug screening and the untreated surgically-resected primary PN from Jessen et al. were downloaded through the NF Data Portal,0.8
PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,Dermus SkinScanner,clinical_assessment_tool,Other,"Used in conjunction with high-frequency ultrasound to evaluate 100 neurofibromas from 14 NF1 patients, providing dermoscopy guidance for imaging",Results,"A total of 100 lesions, with a mean of 7.14 per patient, were evaluated from 14 patients with NF1...DG-HFUS revealed that 79% of lesions were cutaneous neurofibromas",0.8
PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,Dermus SkinScanner,clinical_assessment_tool,Other,"Enabled identification of eight objective imaging parameters: size, location, shape, contours, surface, echogenicity, global echogenicity, and posterior acoustic features",Discussion,"DG-HFUS is a valuable, non-invasive tool for assessing cutaneous and subcutaneous neurofibromas, providing eight objective imaging parameters",0.9
PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,SkinAid cloud software,computational_tool,Other,Used as part of the dermoscopy-guided high-frequency ultrasound system for neurofibroma assessment and analysis,Both,"DG-HFUS is a valuable, non-invasive tool for assessing cutaneous and subcutaneous neurofibromas, providing eight objective imaging parameters",0.7
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,y w Mer4,animal_model,Mechanistic,Hemizygous null allele severely truncates the Merlin protein and causes lethality that can be rescued by NF2 transgenes,Results,"Ability to rescue was tested using ubiquitous expression via the Gal4/UAS system in animals hemizygous for the Mer4 null allele, which severely truncates the Merlin protein",0.9
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,4/FM7; T80-Gal4 y w Mer4,animal_model,Efficacy,NF2 Iso1 provided 59±7% rescue at 1 dose and 72% rescue at 2 doses; NF2 Iso2 provided 8±4% rescue at 1 dose and 0% rescue at 2 doses,Results,"expression of a transgene expressing NF2Iso1 using the ubiquitously expressed T80 Gal4 driver substantially rescued the lethality of the null Mer4 allele, while NF2Iso2 provided very poor rescue",0.95
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,Mouse anti-Flag,antibody,Mechanistic,Successfully detected Flag-tagged NF2 proteins in immunostaining experiments to confirm expression of all NF2 forms,Results,immunostaining using anti-Flag antibody (Fig. 2) and immunoblot analysis (data not shown) were used to confirm expression of all NF2 forms,0.9
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,guinea-pig anti-Merlin,antibody,Mechanistic,"Specifically recognized Drosophila Merlin protein without cross-reacting with human Merlin, allowing detection of endogenous Merlin changes upon NF2 expression",Results,our anti-Drosophila Merlin antiserum (raised against the less conserved carboxyl terminal half of the protein) specifically recognized the fly protein and did not cross react with human Merlin,0.9
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,apterous-Gal4 driver,genetic_reagent,Mechanistic,"Enabled tissue-specific expression in dorsal wing compartment, revealing dominant negative effects of NF2 Iso2 including wing cupping phenotype characteristic of overproliferation",Results,we observed a marked downward 'cupping' of the wing blade when NF2Iso2 was expressed in the dorsal half of the wing. This phenotype is characteristic of overproliferation in the dorsal wing compartment,0.85
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,Zeiss LSM 410,computational_tool,Mechanistic,Used for confocal microscopy to analyze subcellular localization patterns of NF2 proteins in wing imaginal epithelia,Results,"Confocal optical sections of wing imaginal epithelia, either cutting deeply into the epithelium ('Cross section') or tangentially through the apical surface",0.8
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,Zeiss LSM 510,computational_tool,Mechanistic,Used for confocal microscopy to demonstrate temperature-sensitive mislocalization of NF2 L64P protein at 37°C versus normal localization at 25°C,Results,"the punctate apical staining that is characteristic of NF2Iso1 was disrupted when animals expressing the NF2L64P protein were maintained at 37°C for two hours, and instead the mutant protein appeared largely cytoplasmic",0.9
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,LightCycler FastStart SYBR green system,computational_tool,Mechanistic,"qPCR analysis showed no detectable effect of NF2 expression on endogenous Merlin transcription levels, indicating posttranscriptional effects",Results,quantitative PCR analysis failed to show any detectable effect on Merlin transcription in wing imaginal discs expressing either NF2 isoform under the apGal4 driver,0.85
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,S100B,antibody,Biomarker,"2.21-fold (95% CI 1.69 to 2.88, P < 0.001) expression in cNFs compared to skin, confirming successful dissection of cNF tissue from overlying skin",Results,"The successful dissection of the cNF tissue from the overlying skin was confirmed by the 2.21-fold (95% CI 1.69 to 2.88, P < 0.001) expression of the Schwann cell marker S100B in cNFs compared to skin.",0.95
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,CONFIRM anti-Ki67 (clone 30-9),antibody,Biomarker,"Few Ki67 positive cells were observed within cNFs, in contrast to numerous proliferating cells in the epidermis, confirming low rate of cell proliferation in cNFs",Results,"The low rate of cell proliferation in cNFs was confirmed by the Ki67 immunolabeling of 20 cNFs. Few Ki67 positive cells were observed within cNFs, which is in contrast to the numerous proliferating cells in the epidermis",0.9
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,"anti-collagen XV (Sigma-Aldrich, HPA017913)",antibody,Biomarker,Immunohistochemistry confirmed abundant expression of collagen XV in cNFs,Results,Immunohistochemistry confirmed the abundant expression of collagens XV and XVIII in cNFs,0.85
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,anti-collagen XVIII (DB144-N2),antibody,Biomarker,Immunohistochemistry confirmed abundant expression of collagen XVIII in cNFs,Results,Immunohistochemistry confirmed the abundant expression of collagens XV and XVIII in cNFs,0.85
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,Q Exactive HF mass spectrometer,computational_tool,Other,"Successfully performed mass spectrometry analysis of 15 cNFs and matched skin samples from four individuals with NF1, enabling protein composition comparison",Results,We performed mass spectrometry analysis of 15 cNFs and matched samples of the overlying skin from four individuals with NF1,0.9
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,Spectronaut Pulsar,computational_tool,Other,"Used for data analysis in hierarchical clustering that showed incomplete separation between cNF and skin samples, with subclusters based on tissue type rather than patient emerging when samples were pooled",Results,"When the samples from all individuals were pooled into a single analysis, subclusters based on tissue type rather than patient emerged, indicating tissue-specific patterns of protein expression shared by multiple individuals. However, the separation was incomplete.",0.8
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,K14 Cre mice,animal_model,Efficacy,No statistical difference in tumor incidence between Nf1 f/f group (14%) vs K14 Cre; Nf1 f/f group (11%) in DMBA/TPA carcinogenesis protocol,Results,there was no statistical difference (exact Fischer test value = 1) between the number of mice bearing a tumor in the Nf1 f/f group (14%) vs the K14 Cre; Nf1 f/f group (11%),0.95
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,K14 Cre mice,animal_model,Mechanistic,"Successfully achieved Nf1 knockout specifically in keratinocytes as confirmed by PCR, western blot, immunohistochemistry, and X-Gal staining",Results,"we evaluated the extent of Cre recombinase action to delete NF1 in the epidermis by four means. First, we analyzed the Nf1-deleted band from mice's skin tail by PCR",0.9
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,K14 Cre mice,animal_model,Safety,No obvious skin phenotype observed in K14 Cre; Nf1 f/f mice,Results,"Overall, we did not identify any skin phenotype in K14 Cre; Nf1 f/f mice",0.85
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,PLP CreERT2; Nf1 f/−; ROSA-LacZ mice,animal_model,Efficacy,74% of PLP CreERT2; Nf1 f/− mice developed pNF at one year vs 29% of PLP CreERT2; Nf1 f/f mice,Results,"At one year of age, the majority of PLP CreERT2; Nf1 f/− (77 out of 104, 74%) mice already developed pNF and showed the clinical signs of pNF, whereas only a minority of PLP CreERT2; Nf1 f/f (32 out of 112, 29%) mice did",0.95
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,PLP CreERT2; Nf1 f/−; ROSA-LacZ mice,animal_model,Efficacy,0% of PLP CreERT2; Nf1 f/− mice developed MPNST vs 10% of PLP CreERT2; Nf1 f/f mice (exact Fischer test value = 0.001),Results,"no MPNST developed in PLP CreERT2; Nf1 f/− mice (0 out of 104, 0%), whereas all MPNST observed arose from PLP CreERT2; Nf1 f/f mice (10%, 11 out of 112) (exact Fischer test value = 0.001)",0.95
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,"K1 antibody (BioLegend, 905601)",antibody,Biomarker,"Confirmed low K1 expression in tumor samples from both Nf1 f/f and K14 Cre; Nf1 f/f mice, while highly expressed in normal margin epidermis",Results,"immunohistochemistry using keratin 1 (K1, an epithelial cell marker that is lost upon cancer progression) antibodies confirmed the low expression of K1 in tumor samples from both Nf1 f/f and K14 Cre; Nf1 f/f mice",0.9
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,"K1 antibody (BioLegend, 905601)",antibody,Biomarker,K1 expression maintained only in tumors from Nf1 +/− mice but not in Nf1 +/+ mice tumors that progressed to SCC,Results,immunohistochemistry using the epithelial marker K1 confirmed its expression only in tumors from Nf1 +/− mice,0.9
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,NF1 antibody (Santa Cruz; sc-67),antibody,Biomarker,Successfully demonstrated NF1 knockout in epidermis of K14 Cre; Nf1 f/f mice by immunohistochemistry,Results,we performed immunohistochemistry in skin from K14 Cre; Nf1 f/f and Nf1 f/f mice using anti-NF1 antibodies,0.85
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,"S100 antibody (DAKO, Z0311)",antibody,Biomarker,MPNST showed loss of S100 Schwann cell differentiation marker compared to pNF,Results,"As opposed to pNF, MPNST often present the loss of a Schwann cell differentiation marker such as S100",0.85
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,"S100 antibody (DAKO, Z0311)",antibody,Biomarker,No obvious difference in S100 staining between pNF from PLP CreERT2; Nf1 f/f and PLP CreERT2; Nf1 f/− mice,Results,"We found no obvious difference by H&E, S100 immunohistochemistry (Schwann cells), trichrome staining (collagen), and toluidine blue (mast cells) when we compared pNF from PLP CreERT2; Nf1 f/f and PLP CreERT2; Nf1 f/− mice",0.8
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,"H3K27Me3 antibody (Cell Signaling, 9733 S)",antibody,Biomarker,MPNST showed loss of epigenetic repressive marker H3K27Me3,Results,"As opposed to pNF, MPNST often present the loss of a Schwann cell differentiation marker such as S100 as well as the epigenetic repressive marker H3K27Me3",0.85
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,LUMICAN antibody (Santa Cruz; sc-166871),antibody,Biomarker,Used as dermal marker in western blot analysis to confirm tissue separation between epidermis and dermis,Results,"Western blot of skin protein extract quantified using anti-NF1, anti-LUMICAN (dermal marker), and anti-K1 (epidermal marker)",0.8
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,pan-T-cell isolation kit (Miltenyi Biotec),genetic_reagent,Mechanistic,Successfully isolated T cells from lymph nodes for proliferation assays,Results,We isolated T cells from lymph nodes and submitted them to an in vitro T cell proliferation assay,0.8
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,anti-CD3 Ab (eBioscience; cat. no. 16-0031-86),antibody,Mechanistic,Nf1 +/− T cells showed enhanced hyperproliferation when stimulated with anti-CD3 compared to wild-type counterparts,Results,We found that Nf1 +/− T cells are more hyperproliferative when stimulated with anti-CD3 than their wild-type counterparts,0.9
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,anti-CD28 mAb (eBioscience; cat. no. 16-0281-85),antibody,Mechanistic,Used with anti-CD3 for T cell costimulation in proliferation assays,Results,Proliferation of peripheral T cells from Nf1 +/+ and Nf1 +/− mice stimulated by various concentrations of anti-CD3e antibody alone or with CD28 costimulation,0.8
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,CD8 antibody (Lifetech; cat. no. A15836),antibody,Biomarker,Higher fraction of activated cytotoxic CD8+ T cells observed in draining lymph nodes of Nf1 +/− mice compared to Nf1 +/+ mice,Results,"Detailed FACS analysis indicates again that the number of activated T cells, including the fraction of activated cytotoxic CD8+ T cells, is higher in the draining lymph nodes of Nf1 +/− mice compared to Nf1 +/+ mice",0.9
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,Nf1Prx1 mouse model,animal_model,Biomarker,More than twofold increase of Mia expression in Nf1-deficient cartilage compared to wild-type tissue,Results,qRT-PCR revealed a more than twofold increase of Mia expression in Nf1Prx1-deficient cartilage,0.95
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,Nf1Prx1 mouse model,animal_model,Biomarker,More intensive Mia expression observed in NF1-deficient cartilage compared to controls,Results,The expression of Mia was found to be more intensive in the NF1-deficient cartilage of the Nf1Prx1 mice,0.85
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,monoclonal anti-human MIA antibody,antibody,Biomarker,Successfully detected MIA in NF1-associated tumors with 50-90% of cells showing positive staining,Results,MIA was immunohistochemically detected on the paraffin sections of six cutaneous and three plexiform neurofibromas and in seven MPNSTs from NF1 patients. The proportion of MIA-positive cells varied between 50% and 90%,0.95
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,monoclonal anti-human MIA antibody,antibody,Biomarker,Most intense staining obtained in MPNSTs due to high nuclear density,Results,"The most intense staining was obtained in MPNSTs, which, however, represents the high density of nuclei in this type of tumour",0.9
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,MIA ELISA kit,clinical_assessment_tool,Biomarker,Detected significantly higher MIA serum concentration in NF1 patients versus healthy controls: 15.16 ± 1.26 pg/mL versus 4.54 ± 0.40 pg/mL (P < 0.001),Results,MIA serum concentration was significantly higher in NF1 patients than in healthy controls: 15.16 ± 1.26 pg/mL versus 4.54 ± 0.40 pg/mL (P < 0.001),0.95
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,MIA ELISA kit,clinical_assessment_tool,Biomarker,Showed positive correlation between MIA serum level and internal tumor load with R² = ~0.64,Results,linear regression analysis revealed an association between the total internal tumour load and MIA serum level (P value of 1.95E-7 for the F-test). The line that best predicts MIA level from values of logarithm of internal tumor load volume was identified by regression analysis: R² = ~0.64,0.95
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,MuLV Reverse Transcriptase,genetic_reagent,Biomarker,Successfully enabled qRT-PCR quantification showing more than twofold increase of Mia expression in Nf1-deficient cartilage,Results,We next quantified Mia expression by performing quantitative real-time polymerase chain reaction (qRT-PCR). qRT-PCR revealed a more than twofold increase of Mia expression in Nf1Prx1-deficient cartilage,0.9
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,TaqMan Universal PCR Master Mix,genetic_reagent,Biomarker,Enabled successful absolute quantification of Mia transcript levels showing more than twofold increase in Nf1-deficient tissue,Results,Absolute quantification was conducted on the RNA isolated from knee cartilage of two mutant and two control mice at P4. qRT-PCR revealed a more than twofold increase of Mia expression in Nf1Prx1-deficient cartilage,0.9
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,Affymetrix Mouse Genome 430 2.0 GeneChip,computational_tool,Biomarker,"Identified 1446 differential expressed genes (4.2% of total genes) from >39,000 transcripts representing ~34,000 mouse genes",Results,"Using Affymetrix Mouse Genome 430 2.0 GeneChip microarrays containing >39,000 transcripts and variants representing ~34,000 mouse genes, a small set of 1446 differential expressed genes (4.2% of total genes) were identified.",0.95
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,GFAP antibody (Sigma),antibody,Biomarker,"Greater than 98% of cells from CTX, CB, and BS astroglial cultures were GFAP+, while ~30% of ON cells expressed GFAP",Results,"Greater than 98% of the cells from CTX, CB, and BS astroglial cultures were GFAP+...In contrast to astroglial cells from CB, CTX, and BS, ~30% of these cells expressed GFAP",0.95
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,AQP4 antibody (Chemicon),antibody,Biomarker,">83% of cells from CTX, CB, and BS cultures expressed aquaporin-4, while ~30% of ON cells expressed AQP4",Results,"Similarly, >83% of the cells from these cultures expressed aquaporin-4 (AQP4)...In contrast to astroglial cells from CB, CTX, and BS, ~30% of these cells expressed GFAP, AQP4 or GLAST",0.9
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,GLAST antibody,antibody,Biomarker,">83% of cells from CTX, CB, and BS cultures expressed GLAST, while ~30% of ON cells expressed GLAST",Results,"Similarly, >83% of the cells from these cultures expressed aquaporin-4 (AQP4) and the astroglial glutamate transporter GLAST...In contrast to astroglial cells from CB, CTX, and BS, ~30% of these cells expressed GFAP, AQP4 or GLAST",0.9
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,NG2 antibody (Chemicon),antibody,Biomarker,~70% of ON cells expressed NG2 chondroitin sulphate proteoglycan with mutually exclusive expression of NG2 and GFAP,Results,"Interestingly, ~70% of cells expressed the NG2 chondroitin sulphate proteoglycan...It is important to note that there was mutually exclusive expression of NG2 and GFAP in these astroglial cells",0.95
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,O4 antibody (Chemicon),antibody,Biomarker,O4-positive oligodendrocyte lineage cells were rarely detected and no expression found in ON astroglial cell cultures,Results,"In contrast, O4- or APC-positive (oligodendrocyte lineage) cells were rarely detected...we examined the expression of two common OPC markers, O4 and APC, and found no expression of either O4 or APC in these ON astroglial cell cultures",0.9
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,APC antibody (Calbiochem),antibody,Biomarker,APC-positive oligodendrocyte lineage cells were rarely detected and no expression found in ON astroglial cell cultures,Results,"In contrast, O4- or APC-positive (oligodendrocyte lineage) cells were rarely detected...we examined the expression of two common OPC markers, O4 and APC, and found no expression of either O4 or APC in these ON astroglial cell cultures",0.9
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,FOXP2 antibody (Abcam),antibody,Biomarker,">90% of ON astroglial cells expressed FOXP2 compared to <10% of astroglial cells from CTX, CB and BS",Results,"In addition, FOXP2 immunocytochemistry revealed that >90% positive of ON astroglial cells expressed FOXP2 compared to <10% of the astroglial cells from CTX, CB and BS",0.95
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,NF1GRP-D antibody (Santa Cruz),antibody,Biomarker,Western blot analysis demonstrated significantly lower levels of neurofibromin expression in CTX astroglial cells than in astroglial cells from other brain regions,Results,"In addition, Western blot analysis also demonstrated significantly lower levels of neurofibromin expression in CTX astroglial cells than in astroglial cells from the other brain regions",0.9
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,Ad5-Cre adenovirus,genetic_reagent,Mechanistic,Neurofibromin levels were undetectable in astroglial cells infected with Ad5-Cre compared to Ad5-LacZ,Results,"In all cases, neurofibromin levels were undetectable in astroglial cells infected with Ad5-Cre compared to Ad5-LacZ",0.95
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,Nf1flox/flox,animal_model,Efficacy,"Nf1 inactivation resulted in ≥2-fold increase in proliferation of astroglial cells from CB, BS and ON, but no increase in CTX astroglial cells",Results,"Using [3H]-thymidine incorporation, Nf1 inactivation resulted in ≥2-fold increase in proliferation of astroglial cells from CB, BS and ON. In contrast, no increase in proliferation was observed following Nf1 inactivation in CTX astroglial cells",0.95
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,Nf1GFAP CKO,animal_model,Efficacy,"Nearly 2-fold increase in GFAP+ cells in BS and significant increase in CB, with 50% increase in NG2 staining in optic nerves, but no effect in CTX",Results,"Whereas there was no effect of Nf1 loss on the number of GFAP+ cells in the CTX, we observed nearly a 2-fold increase in the number of GFAP+ cells in the BS...we detected a 50% increase in NG2 staining in the Nf1GFAP CKO mouse optic nerves",0.95
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,Ki-67 antibody (BD Pharmingen),antibody,Biomarker,"Increased numbers of Ki-67-immunoreactive cells observed in CB, BS and ON of Nf1GFAP CKO mice, but not in CTX",Results,"Consistent with in vitro proliferation results, we observed increased numbers of Ki-67-immunoreactive cells in CB, BS and ON of Nf1GFAP CKO mice, but not in the CTX",0.9
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,Haloplex custom target enrichment system,genetic_reagent,Efficacy,Successfully identified 18 pathogenic or likely pathogenic mutations in the NGS panel out of 20 total mutations found,Results,"Of these, 18 were identified in the NGS panel and two were from RIT1 sequencing, and all were missense mutations.",0.95
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,HEK-293T cells,cell_line,Mechanistic,Successfully demonstrated that RAF1:p.R391S and RIT1:p.D87H significantly increased pELK1 expression compared with WT transcripts,Results,Both RAF1:p.R391S and RIT1:p.D87H significantly increased pELK1 expression compared with the WT transcripts,0.92
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,HEK-293T cells,cell_line,Mechanistic,A2ML1 mutations did not produce significant fold change in pELK1 levels in vitro,Results,"In contrast, the two A2ML1 mutations did not produce a significant fold change in pELK1 levels in vitro",0.9
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,Dual-Luciferase® Reporter assay system,genetic_reagent,Mechanistic,Successfully measured phosphorylation levels to evaluate RAS/MAPK pathway activation by VUSs,Results,we introduced mutant reporter plasmids into HEK-293T cells to assess phosphorylation levels using a dual luciferase reporter assay,0.88
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,zebrafish embryos,animal_model,Efficacy,"Significant portion of embryos injected with RAF1 and RIT1 mutations developed atypical craniofacial and heart structures, while A2ML1 mutations did not affect development",Results,"A significant portion of zebrafish embryos injected with human mRNA transcripts with novel mutations in RAF1 and RIT1 developed atypical craniofacial and heart structures, whereas the expression of the A2ML1 mutations did not affect zebrafish development",0.93
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,ImageJ software,computational_tool,Other,Used for morphometric analysis to compare effects of VUSs on zebrafish embryo craniofacial features,Results,A morphometric analysis was performed to compare the effect of the VUSs compared to the wild-type transcript at three dpf,0.85
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,digoxigenin-labelled cmlc1,genetic_reagent,Biomarker,Successfully used for in situ hybridization to assess cardiac marker expression and heart tube structure in zebrafish embryos,Results,in situ hybridization of the cardiac marker cmlc1...These features correspond to the typical phenotypes of Noonan syndrome,0.87
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,NextGENe software v.2.3.4.1,computational_tool,Efficacy,Successfully processed sequencing data to identify mutations in the diagnostic pipeline,Results,20 pathogenic or likely pathogenic mutations were identified in the 63 patients recruited,0.82
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,immortalized mouse Nf2 Schwann cells,cell_line,Mechanistic,Generated stable populations expressing Merlin-BirA R118G fusion proteins under doxycycline-inducible promoter control for proximity biotinylation studies,Results,We generated stable populations of immortalized murine Nf2 Schwann cells (–/– 5) expressing Merlin fused to BirA R118G at its C terminus (Merlin-BirA R118G) under the control of a doxy-cycline (Dox)–inducible promoter,0.95
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,immortalized mouse Nf2 Schwann cells,cell_line,Mechanistic,Merlin-BirA R118G fusion colocalized with biotin in transfected cells and retained Merlin function by suppressing YAP activity,Results,"The Merlin-BirA R118G fusion colocalized with biotin in transfected Schwann cells (fig. S2A), retained Merlin function by suppressing YAP activity (fig. S2B)",0.9
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,HEK 293T,cell_line,Mechanistic,Used for secondary screen with RFP-fused bait proteins cotransfected with Merlin-NanoLuc to test protein interactions,Results,We therefore designed a secondary screen in which bait proteins fused to red fluorescent protein (RFP) were cotransfected into HEK 293T cells with a probe consisting of Merlin fused to NanoLuc (NLuc),0.95
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,HEK 293T,cell_line,Mechanistic,"Cotransfection experiments confirmed complex formation with Merlin for 7 of 10 proteins tested, with Angiomotin showing highest apparent affinity (~100-fold greater than negative control)",Results,"Cotransfection experiments in HEK 293T cells confirmed complex formation with Merlin for 7 of 10 proteins tested: Angiomotin α-actinin, afadin, ASPP2, Lats1, myosin IIB, Scrib, and ZO-1. Angiomotin interacted with the highest apparent affinity (~100-fold greater than the negative control)",0.95
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,Anti-Merlin monoclonal antibody 4B5,antibody,Mechanistic,Used to detect Merlin protein expression levels in Dox-inducible cell lines expressing BirA fusion proteins in roughly equivalent amounts,Results,"The Dox-inducible cell lines expressed the BirA fusion proteins in roughly equivalent amounts (Fig. 1, B and C)",0.85
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,g:Profiler,computational_tool,Mechanistic,"Gene ontology analysis identified 34 of 52 Merlin-proximal proteins falling into three classes: 30 cell junction proteins, 16 actin-binding proteins, and 11 Hippo pathway members",Results,"Gene ontogeny (GO) analysis indicated that 34 of the 52 proteins proximal to wild-type Merlin fell into three partially overlapping classes of proteins: 30 cell junction proteins, 16 actin-binding proteins, and 11 members of the Hippo pathway",0.9
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,pcDNA3.1-ccdB-NLuc (Addgene plasmid no. 87067),genetic_reagent,Mechanistic,"Used to create Merlin-NanoLuc fusion for quantitative protein interaction assays, providing sensitive measurement of luciferase activity bound to beads",Results,We therefore designed a secondary screen in which bait proteins fused to red fluorescent protein (RFP) were cotransfected into HEK 293T cells with a probe consisting of Merlin fused to NanoLuc (NLuc),0.9
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,HEK 293T,cell_line,Mechanistic,"Used for transfection experiments to assess NF RAS GAP activity, with expression dependent on amount of NF expression construct used",Results,...the NF signal and the estimated RAS GAP activity were dependent on the amount of NF expression construct used in the transfection experiments...,0.8
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,HEK 293T,cell_line,Mechanistic,"Under standard assay conditions, WT NF expression was sufficient to increase RAS GAP activity >5-fold compared to cells not expressing any exogenous NF",Results,...the expression of WT NF was sufficient to increase RAS GAP activity >5-fold compared to cells not expressing any exogenous NF...,0.9
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,GST-RAF-RBD,genetic_reagent,Mechanistic,Used in pull-down assay to measure GTP-bound RAS levels for determining NF RAS GAP activity,Results,"...using a pull-down assay for GTP-bound RAS...We identified the NF1 c.3829G>C, p.(Gly1277Arg) and c.3651T>A, p.(Asp1217Glu) variants...",0.8
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,HA-H-RAS,genetic_reagent,Mechanistic,Used to assess RAS GAP activity by measuring levels of GTP-bound RAS in pull-down assays,Results,...as estimated from the levels of GTP-bound RAS (RAS-GTP) in the pull-down fraction...,0.8
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,FLAG-SPRED1,genetic_reagent,Mechanistic,"Used for coimmunoprecipitation experiments to assess NF-SPRED1 interaction, with coIP signal correlating with NF signal in cell lysate",Results,...We used an anti-FLAG affinity matrix to coimmunoprecipitate (coIP) the WT NF p.2069myc and p.420ins10myc proteins together with coexpressed WT FLAG-SPRED1...,0.8
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,mouse anti-FLAG,antibody,Mechanistic,Used in anti-FLAG affinity matrix for coimmunoprecipitation of NF-SPRED1 complexes to assess protein interactions,Results,...We used an anti-FLAG affinity matrix to coimmunoprecipitate (coIP) the WT NF p.2069myc and p.420ins10myc proteins together with coexpressed WT FLAG-SPRED1...,0.8
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,9B11 mouse anti-myc,antibody,Mechanistic,Used for detection of NF proteins in immunoblotting experiments to assess protein expression and stability,Results,...we compared WT and variant NF and SPRED1 signals in the cell lysates by immunoblotting...,0.7
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,mouse anti-V5,antibody,Mechanistic,Used for detection and enhanced expression of NF V5-tagged proteins in RAS GAP activity assays,Results,...We observed robust expression of the resulting WT NF V5-p.1180_1504-V5 protein and therefore derived 12 NF1 variants...,0.8
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Biomarker,20% reduction in hippocampal dopamine levels compared to control mice,Results,direct measurements of hippocampal dopamine levels ( Fig. 1B ) and DARPP32 phosphorylation ( Fig. 1D ) reveal a 20% and 61% reduction in CKO mice relative to control mice,0.95
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Biomarker,61% reduction in DARPP32 phosphorylation compared to control mice,Results,direct measurements of hippocampal dopamine levels ( Fig. 1B ) and DARPP32 phosphorylation ( Fig. 1D ) reveal a 20% and 61% reduction in CKO mice relative to control mice,0.95
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Biomarker,Reduced tyrosine hydroxylase (TH) expression in the VTA compared to littermate controls,Results,we now show that tyrosine hydroxylase (TH) expression ( 5 Fig. 1A ) is also reduced in the VTA compared to littermate controls,0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Behavioral,Diminished LTP with EPSP slope of 128.8±7.6% (n=8) compared to 165.2±6.8% (n=8) in controls,Results,"CKO slices display diminished LTP (closed circles, EPSP slope; 128.8+ 7.6%, n=8) in response to high frequency stimulation (HFS) (open circles, EPSP slope; 165.2 + 6.8%, n=8)",0.95
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Efficacy,"LTP defects rescued by 10 µM SKF38393 treatment, restoring EPSP slope to 158.5±7.7% (n=8, p<0.01 vs. untreated)",Results,"10 µM SKF38393 restored normal LTP in CKO slices ( Fig. 2C , circles, 158.5+7.7%, n=8, p<0.01 vs. untreated)",0.95
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Efficacy,"L-DOPA treatment ameliorated post-acquisition probe trial deficits, with treated mice showing control-like performance levels",Results,L-DOPA treatment ameliorated post-acquisition probe trial deficits (probe trial 2) in CKO mice...L-DOPA-treated CKO mice demonstrate control-like performance levels,0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Biomarker,Reduced cAMP levels and increased Ras/ERK activity in hippocampal tissue relative to littermate controls,Results,CKO mice exhibit reduced cAMP ( Fig. 3A ) and increased Ras/ERK activity ( Fig. 3B ) relative to littermate controls,0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Efficacy,L-DOPA treatment increased cAMP levels and DARPP32 phosphorylation in hippocampus but had no effect on Ras/ERK activity,Results,"systemic L-DOPA treatment (sufficient to rescue the behavioral and learning deficits) increased cAMP levels ( Fig. 3A ) and DARPP32 phosphorylation ( Fig. 3B ) in the hippocampus, but had no effect on Ras/ERK activity",0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Mechanistic,Hippocampal neurons have shorter processes and reduced neuronal arborization compared to littermate counterparts,Results,neurons in the hippocampus of CKO mice have shorter processes and reduced neuronal arborization compared to their littermate counterparts,0.9
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,Nf1 +/− GFAP CKO,animal_model,Efficacy,"Attention deficits rescued by treatments that elevate dopamine levels, but not by Lovastatin (to inhibit Ras hyperactivation)",Discussion,"the attention deficits in Nf1 +/− GFAP CKO mice are rescued by treatments that elevate dopamine levels, but not by Lovastatin (to inhibit Ras hyperactivation)",0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Safety,"Survival was reduced compared to WT littermates (p=0.02, logrank test) with deaths occurring after one year of age",Results,"the survival of unirradiated Nf1+/− mice was reduced compared to WT littermates (p=0.02, logrank test) with deaths occurring after one year of age",0.95
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Safety,"Cranial irradiation significantly decreased survival (p=0.05, logrank test) with median post-treatment survival of 503 days versus 596 days in WT mice",Results,"CI significantly decreased the survival of both WT (p=0.002, logrank test) and Nf1+/− (p=0.05, logrank test) mice...median post-treatment survival time was reduced in irradiated Nf1+/− mice compared to irradiated WT mice (503 versus 596 days; p =0.04)",0.95
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Efficacy,"More likely than WT mice to develop hematologic malignancies (p=0.003, log-rank test) or solid cancers (p=0.05) after irradiation",Results,"irradiated Nf1+/− mutant mice were more likely than irradiated WT mice to develop hematologic malignancies (p=0.003, log-rank test) or solid cancers (p=0.05)",0.95
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Efficacy,"Highest incidence of myeloid malignancies occurred at 15 Gy dose (0 Gy vs. 15 Gy: p=0.031, 15 Gy vs. 30 Gy: p=0.017)",Results,"highest incidence of myeloid malignancies in Nf1+/− mutant mice that received 15 Gy of CI (0 Gy vs. 15 Gy: p=0.031, 15 Gy vs. 30 Gy: p=0.017, Fisher exact tests)",0.95
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mice,animal_model,Biomarker,"Anemia was largely restricted to mice that received 15 Gy of CI, with marked splenic erythroid hyperplasia and persistent bone marrow erythropoiesis",Results,anemia was largely restricted to Nf1+/− mice that received 15 Gy of CI...marked expansion of the red pulp in the spleen...characterized by a predominance of erythroid cells,0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,"cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA)",advanced_cellular_model,Other,"Used to deliver focal, fractionated cranial irradiation with customized beam shaping to replicate clinical treatment",Results,"we developed customized beam shaping to deliver focal, fractionated, CI to mice...Similar to the whole brain irradiation technique used in patients, equally weighted, opposed lateral beams were used",0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Hemavet,clinical_assessment_tool,Biomarker,"Obtained complete blood counts from 96 of 121 (80%) mice, revealing anemia largely restricted to Nf1+/- mice receiving 15 Gy",Results,We obtained complete blood counts (CBCs) from 96 of 121 (80%) mice in the study cohort at death from disease or elective euthanasia and found that anemia was largely restricted to Nf1+/− mice that received 15 Gy of CI,0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Phosphorylated ERK Thr202/Tyr204 (catalog #4376),antibody,Biomarker,Elevated pERK levels detected less frequently in primary tumors compared to pAkt and pS6,Results,we detected elevated levels of pERK less frequently in primary tumors compared to pAkt and pS6,0.85
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,phosphorylated Akt Ser473 (#9271),antibody,Biomarker,Elevated pAkt levels observed in most tumors compared to normal tissues with considerable variability between individual tumors,Results,We observed elevated pAkt and pS6 levels in most tumors compared to normal tissues with considerable variability between individual tumors,0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,phosphorylated S6 Ser235/236 (#2211),antibody,Biomarker,pS6 was most consistently elevated in vivo relative to normal tissues in radiation-induced tumors,Results,pS6 was most consistently elevated in vivo relative to normal tissues in radiation-induced tumors,0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1-/- mouse embryo fibroblasts,cell_line,Mechanistic,"Showed similar patterns of γH2AX foci formation and resolution over time as WT cells, suggesting Nf1 inactivation does not affect DNA repair",Results,"We observed similar patterns of γH2AX foci formation and resolution over time in WT and Nf1−/− mutant mouse embryo fibroblasts, which suggests that Nf1 inactivation does not have global effects on DNA repair",0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,Nf1+/- mouse embryo fibroblasts,cell_line,Mechanistic,"Showed similar patterns of γH2AX foci formation and resolution over time as WT cells, suggesting Nf1 inactivation does not affect DNA repair",Results,"We observed similar patterns of γH2AX foci formation and resolution over time in WT and Nf1+/− mutant mouse embryo fibroblasts, which suggests that Nf1 inactivation does not have global effects on DNA repair",0.9
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,anti-γH2AX Ser139 antibody (Millipore),antibody,Mechanistic,"Used to detect γH2AX foci formation and resolution, showing similar patterns in WT and Nf1 mutant cells",Results,We observed similar patterns of γH2AX foci formation and resolution over time in WT and Nf1 mutant mouse embryo fibroblasts,0.85
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,"L5 vertebrae height significantly reduced compared to WT, Nf1+/-, and Nf1flox/flox;Col2.3Cre+ mice (p<0.05)",Results,"The average height of L5 was significantly less in flox/−;Col2.3Cre+ Nf1 mice than in WT, flox/−;Col2.3Cre+ Nf1+/−, and Nf1 mice (flox/flox;Col2.3Cre+ Figs. 1A, B, *p<0.05)",0.95
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Significant reduction in BMD in L1-L5 vertebral region compared to other genotypes (p<0.05),Results,"a significant reduction in BMD was observed in the L1–L5 region of Nf1 mice (flox/−;Col2.3Cre+ Figs. 2C–D, *p<0.05)",0.95
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Reduced cortical bone density and significantly decreased cortical bone area in L5 vertebrae,Results,reduced cortical bone density was observed in L5 of the Nf1 and flox/flox;Col2.3Cre+ Nf1 mice...cortical bone area was significantly decreased in the L5 vertebrae,0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Significant reduction in trabecular bone volumetric BMD,Results,a significant reduction in vBMD of trabecular bone was observed (Figs. 3C and D),0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,"Significant increase in spinal canal/vertebral body area ratio compared to WT, with further increase compared to Nf1+/- and Nf1flox/flox;Col2.3Cre+ mice",Results,"a significant increase in the C/V ratio was found in Nf1+/−, Nf1, and flox/flox;Col2.3Cre+ Nf1 mice...A further increase in the C/V ratio of L5 vertebrae from Nf1 mice",0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,"Significantly reduced peak load to failure and peak stress to failure in L5 vertebrae (p<0.05, p<0.01)",Results,"Peak load to failure in the L5 vertebrae of flox/−;Col2.3Cre+ Nf1+/−, Nf1, and flox/flox;Col2.3Cre+ Nf1 mice was significantly reduced (*p<0.05, **p<0.01)",0.95
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Significantly reduced osteoblast number per mm of bone surface in upper facet process compared to other genotypes,Results,significantly reduced osteoblast number per mm of bone surface was observed in the upper facet process of Nf1 mice than in the other three genotypes of mice,0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Significantly reduced CFU-OBL forming capacity in bone marrow mononuclear cells compared to controls,Results,BMMNCs cultured from Nf1 mice demonstrated significantly reduced CFU-OBL forming capacity as compared to controls,0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1(flox/-);Col2.3Cre(+) mice,animal_model,Biomarker,Reduced Alizarin staining and significant reduction in mineralized bone nodules in osteoblast cultures in gene dosage dependent fashion,Results,"reduced Alizarin staining was observed in Nf1+/−, Nf1, as well as in flox/flox;Col2.3Cre+ Nf1 cultures in a gene dosage dependent fashion...A significant reduction in the number of mineralized bone nodules",0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,Nf1 +/− mice,animal_model,Biomarker,Significantly increased osteoclast number per mm of bone surface in upper facet process compared to WT,Results,Significantly increased osteoclast number per mm of bone surface was observed in the upper facet process of Nf1+/− and Nf1 mice compared with WT mice,0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,PIXImus II,computational_tool,Biomarker,Successfully detected significant reduction in BMD in L1-L5 vertebral region of Nf1flox/-;Col2.3Cre+ mice (p<0.05),Results,DEXA was performed to assess the BMD in the spines of these mice...a significant reduction in BMD was observed in the L1–L5 region (*p<0.05),0.9
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner,computational_tool,Biomarker,"Successfully measured cortical bone density, cortical bone area, trabecular vBMD, and spinal canal/vertebral body area ratios in L5 vertebrae",Results,L5 was used to check the cortical bone density by pQCT...the ratio of spinal canal area (C)/vertebral body area (V) (C/V ratio) was measured by pQCT,0.9
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Letter‐Number Sequencing task (LNS),clinical_assessment_tool,Behavioral,"Significant differential treatment effect favoring lovastatin group (P < 0.01; f² = 0.70), with scores improving from 8.67 to 10.43 in lovastatin group vs 9.33 to 9.17 in placebo group",Results,"There was a significant differential effect of treatment over time (i.e. significant group x time interaction), favoring the lovastatin group for one primary measure, Letter‐Number Sequencing (P < 0.01; f² = 0.70)",0.95
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Hopkins Verbal Learning Test (HVLT),clinical_assessment_tool,Behavioral,"Significant differential treatment effect favoring lovastatin group (P = 0.02; f² = 0.19), with scores improving from 33.50 to 35.29 in lovastatin group vs declining from 37.67 to 23.50 in placebo group",Results,There was a significant differential effect of treatment over time...favoring the lovastatin group for...one secondary cognitive measure (HVLT; P = 0.02; f² =0.19),0.95
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,clinical_assessment_tool,Behavioral,"Differential treatment effect in favor of statin treatment for verbal category fluency (P = 0.02; f² = 0.19), with scores improving from 9.83 to 10.43 in lovastatin group vs declining from 11.33 to 8.50 in placebo group",Results,There was also a differential effect in favor of statin treatment for verbal category fluency (P = 0.02; f² = 0.19),0.95
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Young Adult Self Report (YASR),clinical_assessment_tool,Behavioral,"Significant differential treatment effect for Internalizing Problems (P = 0.03; f² = 0.26), with greater improvement in statin group (53.67 to 43.5) vs placebo group (54.08 to 53.67)",Results,"The YASR Internalizing Problems showed a differential treatment effect (P = 0.03; f² = 0.26), with greater improvement seen in the statin group",0.95
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Brief Visuospatial Memory Test – Revised (BVMT),clinical_assessment_tool,Behavioral,"No significant treatment effects for nonverbal memory (BVMT, Immediate and Delayed conditions), with F(1,33) = 1.3, P = 0.26 for immediate and F(1,30) = 0.3, P = 0.61 for delayed",Results,"However, there were no significant treatment effects for nonverbal memory (BVMT, Immediate and Delayed conditions)",0.9
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,WISC‐III Object Assembly,clinical_assessment_tool,Behavioral,"No significant treatment effects (F(1,32) = 0.2, P = 0.69), with scores improving from 7.67 to 8.14 in lovastatin group vs 8.83 to 9.83 in placebo group",Results,"However, there were no significant treatment effects for...other secondary (Object Assembly, Cancellation) or tertiary measures",0.9
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Digit Cancellation,clinical_assessment_tool,Behavioral,"No significant treatment effects (F(1,32) = 0.5, P = 0.50), with scores improving from 5.17 to 6.14 in lovastatin group vs 4.33 to 6.67 in placebo group",Results,"However, there were no significant treatment effects for...other secondary (Object Assembly, Cancellation) or tertiary measures",0.9
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Neuropsychological Assessment Battery (NAB) Mazes,clinical_assessment_tool,Behavioral,"No significant treatment effects (F(1,32) = 0.2, P = 0.66), with scores improving from 30.00 to 32.14 in lovastatin group vs 33.33 to 35.33 in placebo group",Results,"However, there were no significant treatment effects for...tertiary measures (Mazes, verbal letter fluency)",0.9
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Spatial capacity working memory (SCAP) task,clinical_assessment_tool,Behavioral,No differential treatment effects for changes in neural activity during spatial working memory (SCAP performance; all P ≥ 0.05),Results,There were no differential treatment effects for changes in neural activity during spatial working memory (SCAP performance; all P ≥ 0.05),0.9
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Achenbach Child Behavior Checklist (CBCL),clinical_assessment_tool,Behavioral,"No evidence of differential treatment effect for Internalizing or Externalizing Problems in parent-report and child self-report versions, with no significant effects on Thought, Attention, or Social Problems subscales",Results,"For the parent‐report and child self‐report versions of the CBCL, there was no evidence of a differential treatment effect for Internalizing or Externalizing Problems",0.9
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,Behavior Rating Inventory of Executive Function (BRIEF),clinical_assessment_tool,Behavioral,"No significant treatment effect observed for the BRIEF GEC score (F(1,11) = 0.0, P = 0.92)",Results,"Similarly, no significant treatment effect was observed for the BRIEF GEC score",0.9
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,hGFAP-cre+; p53floxE2–10/floxE2–10,animal_model,Efficacy,Generated malignant gliomas and GBMs with 75-80% tumor penetrance for gliomas (Grade III/IV) and 50% for GBMs (Grade IV),Results,"No significant difference was observed among the three p53 CKO models, including survival, tumor latency, histopathology, and tumor penetrance for gliomas (Grade III/IV, 75–80% of p53 CKO mice) and GBMs (Grade IV, 50%)",0.95
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,hGFAP-cre+; p53LSLR172H/floxE2–10,animal_model,Efficacy,Generated malignant gliomas and GBMs with 75-80% tumor penetrance for gliomas (Grade III/IV) and 50% for GBMs (Grade IV),Results,"No significant difference was observed among the three p53 CKO models, including survival, tumor latency, histopathology, and tumor penetrance for gliomas (Grade III/IV, 75–80% of p53 CKO mice) and GBMs (Grade IV, 50%)",0.95
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,hGFAP-cre+; p53LSLR172H/floxE2–10,animal_model,Biomarker,Tumors exhibited aberrantly high levels of Pdgfrα expression at both mRNA and protein levels in ~50% of the tumors analyzed,Results,"we observed aberrantly high levels of Pdgfrα/Pdgfrα expression at both mRNA and protein levels in ~50% of the tumors analyzed, suggesting a nongenetic mechanism of activating Pdgfrα signaling",0.9
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,hGFAP-cre+; p53LSLR172H/floxE2–10,animal_model,Mechanistic,"Exhibited clonal nonreciprocal translocations (cNRTs) in most malignant gliomas and GBMs, indicating additional oncogenic activity of p53-mutant alleles",Results,"cNRTs, the NRTs observed in >50% of metaphase cells per tumor analyzed, were specifically identified in most malignant gliomas and GBMs driven by p53 R172H and p53 ∆E5–6, but not p53 null mutations",0.9
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,rabbit anti-p53,antibody,Biomarker,Successfully detected p53 protein expression in tumor tissues for validation of p53 mutations in malignant gliomas and GBMs,Results,"We validated that malignant gliomas and GBMs in the two new p53 CKO models arose from p53 R172H/∆E2–10- mutant and p53 ∆E2–10/∆E2–10- null cells in the brain, respectively",0.85
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,mouse anti-Ki67,antibody,Biomarker,Demonstrated significantly higher proliferation index in brain parenchymal tumors compared to SVZ regions in Type 2 cases,Results,"Overall, the SVZ in these three Type 2 cases exhibited considerably lower cellularity and mitotic index than that observed in malignant gliomas and GBMs spatially segregated in the parenchyma of the same brains",0.8
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,rabbit anti-Olig2,antibody,Biomarker,"Identified Olig2+ proliferating cells in mutant SVZ that were absent in control SVZ, indicating oligodendrocyte progenitor involvement in tumor development",Results,BrdU+ proliferating cells in the mutant SVZ and in glioma precursor clusters from age-matched p53 R172H CKO and p53 ∆E5–6 CKO mice expressed Olig2,0.9
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,rabbit anti-Pten,antibody,Biomarker,Showed significantly higher Pten protein expression in SVZ-derived cells compared to autologous parenchymal tumors with Pten/chr19 loss,Results,"Consistent with intact Pten/chr19, the expression of Pten protein was significantly higher in SVZ-derived cells than those derived from autologous parenchymal tumors with Pten/chr19 loss",0.9
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,rabbit anti-p-Erk,antibody,Biomarker,"Consistently identified p-Erk+ cells in SVZ of p53 mutant mice but not in control mice, indicating Ras/MAPK pathway activation",Results,"We consistently identified p-Erk+ cells, presented as either individual cells in the SVZ or small clusters in the SVZ-associated areas, in age-matched p53 R172H CKO and p53 ∆E5–6 CKO mice, but not in the SVZ of control mice",0.95
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,C57BL/6,animal_model,Other,Used as source for oviduct and OSE tissue isolation for organoid derivation,Results,"...mouse oviduct and OSE tissues were dissected, subjected to different enzymatic treatments, embedded in basement membrane extract (BME) and cultured in appropriate media...",0.8
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,"B6J.129(B6N)-Gt(ROSA)26Sor tm1(CAG-cas9*,-EGFP)Fezh/J",animal_model,Mechanistic,Provides ubiquitous Cas9 and EGFP expression for CRISPR gene editing in organoids,Results,"We derived oviductal and OSE organoids from mice carrying a Cas9-P2A-EGFP expression cassette knocked into the ROSA26 locus, such that Cas9 and enhanced green fluorescent protein (EGFP) are expressed ubiquitously",0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,animal_model,Efficacy,"Supports tumor formation from genetically modified organoids with varying success rates: oviduct TBN (92% orthotopic, 100% subcutaneous), oviduct TBP (100% both), OSE TBN (0% orthotopic, 63% subcutaneous), OSE TBP (0% orthotopic, 50% subcutaneous)",Results,"...both TBN and TBP oviduct triple mutant organoids formed tumors (92% success rate, n = 12 and 100% success rate, n = 12, respectively)...none of the orthotopically transplanted OSE organoids gave rise to tumors...",0.95
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,PAX8 antibody,antibody,Biomarker,Successfully detects PAX8 expression in both oviductal and OSE organoids and tumors; all tumors from either origin ubiquitously stained for PAX8 except solid tumors with mesenchymal features,Results,All tumors from either origin ubiquitously stained for PAX8...with the exception of solid tumors that consisted of both glandular and mesenchymal-like tumor cells,0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,Ac-alpha-Tubulin antibody,antibody,Biomarker,Successfully identifies ciliated cells in oviductal organoids and tissues but not in OSE organoids,Results,The presence of both secretory and ciliated cell types in oviductal organoids and tissues were confirmed by positive stainings for PAX8 and cilia,0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,KI67 antibody,antibody,Biomarker,Shows higher proliferation in oviduct-derived tumors compared to OSE-derived tumors,Results,Oviduct-derived tumors were generally more proliferative as shown by bigger tumor sizes...and higher KI67 labeling index,0.85
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,Cytokeratin-8 antibody,antibody,Biomarker,"Both oviductal and OSE organoids were uniformly positive for CK8, confirming their epithelial origin",Results,"Both oviductal and OSE organoids were uniformly positive for CK8, confirming their epithelial origin",0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,GFP antibody,antibody,Biomarker,Successfully confirms tumor origin from transplanted organoid clones and reveals epithelial-to-mesenchymal transition in subset of solid tumors,Results,"To distinguish organoid-derived tumor cells from the recipient normal mouse cells, tumors were stained with an anti-GFP antibody which confirmed that the tumors originated from the transplanted clones",0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,Cleaved Caspase-3 antibody,antibody,Biomarker,Shows significantly higher number of apoptotic cells in oviductal tumors compared to OSE tumors,Results,...the oviductal tumors also displayed significantly higher number of apoptotic cells as quantified from the cleaved Caspase-3 stainings in the tumors,0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,γH2A.X antibody,antibody,Biomarker,"Heterozygous Brca1-mutants displayed significantly higher number of phosphorylated histone γH2A.X-positive cells upon Mitomycin C treatment, confirming DSB repair defect",Results,The heterozygous Brca1-mutants displayed significantly higher number of phosphorylated histone yH2A.X-positive cells upon treatment with the genotoxic agent Mitomycin C,0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,oviductal organoids,advanced_cellular_model,Efficacy,"Form tumors with high success rates: TB mutants 50% subcutaneous, TBN mutants 92% orthotopic and 100% subcutaneous, TBP mutants 100% both orthotopic and subcutaneous",Results,"...both TBN and TBP oviduct triple mutant organoids formed tumors (92% success rate, n = 12 and 100% success rate, n = 12, respectively)...When the genetically modified organoids were subcutaneously transplanted, both TBN and TBP oviduct triple mutant organoids developed into tumors (100% success rate)",0.95
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,oviductal organoids,advanced_cellular_model,Mechanistic,"WNT-independent growth, maintain normal chromosome numbers long-term (>1 year), show increased growth rate upon mutations, decreased apoptosis with mutations",Results,...oviduct organoids are not...WNT-independent...can both be expanded long-term (>1 year) while maintaining normal numbers of chromosomes...all the mutation combinations induced significantly faster growth rate...decrease in apoptosis upon introduction of mutations,0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,OSE organoids,advanced_cellular_model,Efficacy,"Lower tumor formation success: TBN mutants 0% orthotopic and 63% subcutaneous, TBP mutants 0% orthotopic and 50% subcutaneous",Results,"...none of the orthotopically transplanted OSE organoids gave rise to tumors, including the TBN and TBP triple mutants...TBN and TBP OSE-derived triple mutants...did form tumors after subcutaneous transplantions with 63% (n = 8) and 50% (n = 4) success rate",0.95
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,OSE organoids,advanced_cellular_model,Mechanistic,"WNT-dependent growth, chromosomal abnormalities evident following single Trp53 knockout, growth rate largely unaffected by mutations except TBN and TBP lines",Results,OSE organoid growth is dependent on the addition of WNT protein to the medium...chromosomal abnormalities were already evident following a single knockout of the Trp53 gene...growth rate of the OSE clones was largely unaffected upon introduction of mutations,0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,Trp53 sgRNA,genetic_reagent,Efficacy,"Achieved ≥50% targeting efficiency in organoids, confirmed by Nutlin-3a resistance and western blot analysis",Results,...all the sgRNAs exhibited ≥50% targeting efficiency in organoids as calculated by the number of targeted clones that survived in Nutlin-3a selection...Trp53 loss in single and double mutants was confirmed by western blot analysis,0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,Brca1 sgRNA,genetic_reagent,Efficacy,"Low targeting efficiency of 15%, could never obtain homozygous knockouts suggesting homozygous lethality in rapidly dividing organoid systems",Results,"Brca1 sgRNAs showed a much lower efficiency, as only 15% of screened clones had been targeted by the sgRNA...we could also never obtain clones in which both allels of Brca1 carried out-of-frame mutations",0.9
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,Nf1 sgRNA,genetic_reagent,Efficacy,Achieved ≥50% targeting efficiency and successful complete knockouts,Results,...all the sgRNAs exhibited ≥50% targeting efficiency in organoids...We were successful in targeting all remaining genes of interest and created complete knockouts of these genes,0.85
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,Pten sgRNA,genetic_reagent,Efficacy,Achieved ≥50% targeting efficiency and successful complete knockouts,Results,...all the sgRNAs exhibited ≥50% targeting efficiency in organoids...We were successful in targeting all remaining genes of interest and created complete knockouts of these genes,0.85
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,ImageJ,computational_tool,Other,Used for image analysis and quantification in the study,Results,ImageJ software was used for image analysis and quantification,0.7
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,DESeq2,computational_tool,Other,Successfully performed differential gene expression analysis between organoid lines and identified 500 most significantly differentially expressed genes,Results,Hierarchical clustering of the 500 most significantly differentially expressed genes between the oviductal and OSE organoid groups shows that oviductal organoids cluster together with the oviduct tissue,0.8
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,GSEA,computational_tool,Other,Successfully identified enrichment of motile cilium assembly genes in oviductal organoids and molecular subtype signatures in tumors,Results,Significant enrichment of motile cilium assembly genes in oviductal organoids was also confirmed by gene set enrichment analysis (GSEA)...The analysis revealed that while the tumors in cluster I had significant enrichment for the differentiated-like subtype,0.9
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,NF02.2,cell_line,Biomarker,High ABCC1 expression confirmed by quantitative real-time PCR relative to benign neurofibroma-derived cells,Results,Quantitative real-time PCR confirms the high level of expression of ABCC1 in the NF02.2 cell line relative to benign neurofibroma-derived cells,0.95
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,NF02.2,cell_line,Efficacy,Doxorubicin EC50 of 0.861 μg/ml ± 0.17 alone versus 0.248 μg/ml ± 0.07 with verapamil (p = 0.0002),Results,"Significantly lower doxorubicin EC50 values are obtained when doxorubicin dose is combined with verapamil (0.861 μg/ml ± 0.17 versus 0.248 μg/ml ± 0.07, p = 0.0002",0.98
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,NF94.3,cell_line,Efficacy,Doxorubicin EC50 of 0.81 μg/ml ± 0.42 alone versus 0.34 μg/ml ± 0.20 with verapamil (p = 0.025),Results,"A small effect of verapamil channel blockade on doxorubicin EC50 is observed in NF94.3 cells (0.81 μg/ml ± 0.42 versus 0.34 μg/ml ± 0.20, p = 0.025",0.95
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,NF96.2,cell_line,Efficacy,"Doxorubicin EC50 of 0.44 μg/ml ± 0.31 alone versus 0.22 μg/ml ± 0.25 with verapamil (p = 0.16, not significant)",Results,"no significant effect is observed in low-ABCC1 expressing NF96.2 cells (0.44 μg/ml ± 0.31 versus 0.22 μg/ml ± 0.25, p = 0.16 paired Student's t-test",0.95
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,ABCC1 antibody (Abcam ab24102),antibody,Biomarker,Successfully detected ABCC1 protein by immunofluorescent staining in NF02.2 and NF94.3 cells but not in NF96.2 cells,Results,ABCC1 protein is also detectable by immunofluorescent staining in NF02.2 cells in culture...ABCC1 is detectable by immunofluorescence in NF94.3 but not NF96.2,0.92
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,S100 antibody (Dako Z0311),antibody,Biomarker,Successfully used for immunofluorescent co-staining with ABCC1 in MPNST-derived cell lines,Results,Immunofluorescent staining for ABCC1 (green) and S100 (red) with DAPI (blue) nuclear stain as indicated,0.9
PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,FSL version 5.0.7,computational_tool,Other,"Successfully processed 93 DTI datasets from children with and without NF1, enabling measurement of FA, RD, and MD in optic radiations",Results,"A total of 93 DTI datasets were analyzed, including 40 children with NF1 and 53 children without NF1...FA, RD, and MD were measured in the optic radiations for each participant.",0.85
PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,PROBTRACKX,computational_tool,Other,"Enabled tractography analysis that could be interrupted by FASI lesions, requiring sensitivity analysis excluding participants whose optic radiations intersect with FASI",Discussion,"Because FASI may be associated with interruptions in tractography, a sensitivity analysis was performed eliminating participants whose optic radiations intersect with FASI.",0.8
PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,Tract-Based Spatial Statistics (TBSS),computational_tool,Biomarker,"Identified significant (P < .05) reductions in FA and increases in RD and MD among NF1 participants diffusely throughout the white matter skeleton, with significant NF1*ln(age) interaction in nearly all regions",Results,"This analysis identified significant (P < .05) reductions in FA and increases in RD and MD among NF1 participants diffusely throughout the white matter skeleton...the interaction term NF1*ln(age) for all DTI measures (FA, RD, and MD) was significant in nearly all regions",0.95
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,"iPlan Net software (Brainlab, Feldkirchen, Germany)",computational_tool,Other,Used for segmented volumetric analysis (SVA) which served as the gold standard for 3D tumor volume measurements in 2586 measurements across 292 vestibular schwannomas,Results,"In total, 2586 measurements (3D volumetrics: 2586; MLD measurements: 10344, including all dimensions) were performed",0.9
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,"Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)",computational_tool,Other,"Used for statistical analysis including linear regression models that showed all measurement techniques statistically significantly predict SVA, F (8,2324) = 2003.457, p < 0.0005",Results,"A linear regression model established that all measurement techniques and classification systems...statistically significantly predict SVA, F (8,2324) = 2003.457, p < 0.0005",0.9
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,Hannover classification system,clinical_assessment_tool,Other,"Showed statistically significant differences between all categories with F (15, 2329) = 210.172, p < 0.001, but reached limits in cases with large contralateral tumors causing anatomical displacement",Results,"The difference between SVA, MLD3, and OA on the combined dependent variables (Hannover categories) was statistically significant, F (15, 2329) = 210.172, p < 0.001",0.9
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,Koos classification system,clinical_assessment_tool,Other,"Demonstrated statistically significant differences between categories F (6, 4650) = 24.614, p < 0.001, with smaller tumors (K1/K2) showing low to moderate correlation with SVA (r² = 0.225–0.435) compared to larger tumors (K4) (r² = 0.540–0.758)",Results,"smaller tumors (T1/T2, K1/K2) exhibited a low to moderate positive correlation (SVA vs. OA/MLD3: r2 = 0.225–0.435) compared to medium-sized...and large tumors (T4, K4) (SVA vs. OA/MLD3: r2 = 0.540–0.758)",0.9
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,RECIST guidelines,clinical_assessment_tool,Other,"Subject to enormous scatter range and percentage deviation from segmented 3D volumetry, especially in small tumor volumes, with classification systems being insufficient for detailed monitoring of tumor volume",Discussion,"these methods are subject to an enormous scatter range and percentage deviation from segmented (3D) volumetry, especially in the case of small tumor volumes...Classification systems are sufficient for categorizing tumors...but are not suitable for detailed monitoring",0.8
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,Human Splicing Finder (HSF) Version 2.4.1,computational_tool,Efficacy,Correctly predicted splicing effects for all 5 canonical splice site variants but showed conflicting results for 7 out of 10 control variants,Results,All 5 variations involving the 5′ or 3′ GT/AG canonical splice sites of NF1 were correctly classified as splicing affecting variants by all the predicting software tools,0.85
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,Mutation taster,computational_tool,Efficacy,Correctly predicted splicing effects for canonical splice sites but showed conflicting results with other tools for non-canonical variants,Results,All 5 variations involving the 5′ or 3′ GT/AG canonical splice sites of NF1 were correctly classified as splicing affecting variants by all the predicting software tools,0.85
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,Combined Annotation Dependent Depletion (CADD) v1.6,computational_tool,Efficacy,CADD score was below 15 for c.5694G>A variant and thus considered not significant; showed score of 22.5 for c.4538_4540delGAC deletion indicating pathogenic verdict,Results,CADD score was below 15 and thus was considered not significant...showed a CADD score of 22.5 (with a pathogenic computational verdict),0.9
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,beta-globin vector,genetic_reagent,Efficacy,Successfully detected aberrant splicing patterns for pathogenic variants while maintaining normal splicing patterns for benign variants; detected residual wild-type transcript production in hypomorphic variants,Results,the expression of the mutant minigene construct did not affect transcript maturation: the same splicing pattern as that obtained with the wild-type plasmid was observed,0.9
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,HEK293 cells,cell_line,Efficacy,"Successfully expressed minigene constructs and allowed detection of aberrant splicing patterns, including multiple splicing products and residual wild-type transcript quantification",Results,"when expressed from the minigene construct, did not affect transcript maturation in HEK293 cells...expression of the minigene yielded a splicing pattern characterized by more products",0.9
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,beta-globin vector,genetic_reagent,Biomarker,"Quantified residual wild-type transcript levels: 11% for c.1722-3C>T variant, 3% for c.3496+5 variant, and 69% for c.4538_4540delGAC deletion",Results,"wild-type mRNA, which represents approximately 11% of the total transcripts...residual wild-type mRNA (approximately 3% of the total)...correctly spliced transcript (that reaches 69% of total mRNA)",0.95
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,ImageJ,computational_tool,Efficacy,Used for densitometric analysis to quantify transcript levels in minigene assays,Results,which represents approximately 11% of the total transcripts as shown by densitometric analysis,0.8
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,LLC-PK1 ATCC CL-101,cell_line,Efficacy,"Used for in vitro validation assay to design and select optimal genome editing reagents, testing two gRNA-donor pairs for HDR efficiency",Results,"First, we used an in vitro validation assay utilizing LLC-PK1 cells to design and select the optimal genome editing reagents. We tested two gRNA–donor pairs",0.8
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,CRISPOR,computational_tool,Efficacy,"Revealed that a TP53 pseudogene was also targeted by the same target sequence, allowing identification of unintended edits",Results,"When CRISPOR became available and we queried our target sites, we found that a TP53 pseudogene was also targeted by the same target sequence used in our previous experiments",0.9
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,CRISPResso,computational_tool,Efficacy,Used for quantification of DNA repair products through TAm-Seq analysis of amplicons,Results,Quantification of DNA repair products through TAm-Seq of amplicons and CRISPResso analysis,0.8
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,JMP Pro 15.0.0,computational_tool,Other,Used for logistic regression analysis showing significant association between excision allele abundance and germline transmission rate (p<0.05),Results,"There was a significant association between excision allele abundance (pixel density) and germline transmission rate (logistic regression, p <0.05)",0.9
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,Phusion polymerase (M0530S),genetic_reagent,Efficacy,Used for PCR amplification of targeted regions for molecular characterization and TAm-Seq analysis,Results,"The targeted region of exon 1 was PCR amplified for TAm-Seq, yielding the identification of four animals carrying the E19* knock-in allele",0.7
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,Q5® Hot Start High-Fidelity DNA Polymerase,genetic_reagent,Efficacy,Used for competitive PCR assays that successfully distinguished excision and non-excision alleles with different sized amplicon products,Results,Competitive PCR for excision and non-excision alleles yields amplicon products of two different sizes,0.8
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,S. pyogenes Cas9 mRNA,genetic_reagent,Efficacy,"Successfully generated genome edits in porcine embryos via microinjection, producing founders with desired mutations across multiple NF1 and TP53 models",Results,"After two rounds of embryo microinjection and surgical implantation into recipient sows, we produced 38 live piglets",0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,tp1:mCherry,genetic_reagent,Biomarker,"mCherry immunofluorescence indicates Notch signaling is activated and restricted to differentiating MG within the first 2 days post-fertilization (dpf), preceding gfap:GFP transgene induction",Results,"In developing fish, mCherry and GFP immunofluorescence indicate Notch signaling is activated and restricted to differentiating MG within the first 2 days post-fertilization (dpf), preceding gfap:GFP transgene induction",0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,tp1:mCherry,genetic_reagent,Biomarker,mCherry immunofluorescence was not detected in progenitors residing in the retinal periphery,Results,mCherry immunofluorescence was not detect in progenitors residing in the retinal periphery,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,tp1:mCherry,genetic_reagent,Biomarker,PCR analysis of retinal mCherry RNA levels indicates a gradual reduction in Notch signaling as the fish matures,Results,PCR analysis of retinal mCherry RNA levels indicates a gradual reduction in Notch signaling as the fish matures,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,tp1:mCherry,genetic_reagent,Mechanistic,"Residual Notch signaling in adult zebrafish MG is readily detected and regulated by retinal injury, γ-secretase inhibitors, and dominant-negative MAML",Results,"residual Notch signaling in adult zebrafish MG is readily detected and regulated by retinal injury, γ-secretase inhibitors, and dominant-negative MAML",0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,gfap:GFP,genetic_reagent,Biomarker,GFP+ MG were FACS purified from uninjured gfap:GFP fish for RNAseq analysis,Results,GFP+ MG were FACS purified from uninjured gfap:GFP fish treated +/−DAPT for 24 hours,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,1016 tuba1a:GFP,genetic_reagent,Biomarker,GFP+ MG were FACS purified from 1016 tuba1a:GFP fish at 2 days post injury (dpi) when most MG are in an activated state with some beginning to undergo cell division,Results,GFP+ MG that were FACS purified from the uninjured retina of gfap:GFP fish with those from 1016 tuba1a:GFP fish at 2 days post injury (dpi) when most MG are in an activated state,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,hsp70:DN-MAML-GFP,genetic_reagent,Mechanistic,"DN-MAML suppresses endogenous Notch-dependent gene activation, identifying 1,122 differentially expressed genes with only 244 showing reduced expression",Results,"DN-MAML suppresses endogenous Notch-dependent gene activation... Expression analysis identified 1,122 differentially expressed genes with only 244 showing reduced expression",0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,3kb-hey1:luciferase,genetic_reagent,Mechanistic,Mutation of either putative Rbpj binding sites in a 3kb hey1 promoter fragment resulted in a dramatic reduction in promoter activation by NICD when assayed in transfected HEK293 cells,Results,Mutation of either of these putative Rbpj binding sites in a 3kb hey1 promoter fragment driving luciferase gene expression resulted in a dramatic reduction in promoter activation by NICD,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,HEK 293T,cell_line,Mechanistic,"Used for luciferase assays to test hey1 promoter activation by NICD, showing dramatic reduction when Rbpj binding sites were mutated",Results,resulted in a dramatic reduction in promoter activation by NICD when assayed in transfected HEK293 cells,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,hsp70:GFP-P2A-hey1,genetic_reagent,Efficacy,Hey1 overexpression suppressed MG proliferation without affecting cell death and suppressed injury-dependent induction of regeneration-associated genes like ascl1a and lin28a,Results,both Hey1 and Id2b suppressed MG proliferation without affecting cell death in hsp70:GFP-P2A-hey1... Hey1 overexpression also suppressed injury-dependent induction of regeneration-associated genes,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,hsp70:id2b-P2A-GFP,genetic_reagent,Efficacy,Id2b overexpression suppressed MG proliferation without affecting cell death,Results,both Hey1 and Id2b suppressed MG proliferation without affecting cell death in hsp70:GFP-P2A-hey1 or hsp70:id2b-P2A-GFP fish,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,ubi:Cas9,genetic_reagent,Mechanistic,"Used with gRNAs to generate gene deletions confirmed using genomic DNA from fin clips, resulting in expanded zone of injury-responsive MG for hey1 editing",Results,These fish were raised to adults and gene deletions were confirmed using genomic DNA from fin clips... only editing of the hey1 gene resulted in an expanded zone of injury-responsive MG,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,u6:dll4-gRNAs,genetic_reagent,Efficacy,dll4 gene editing resulted in an expanded zone of injury-responsive proliferating MG without affecting cell death,Results,"Like Dll4 knockdown, dll4 gene editing resulted in an expanded zone of injury-responsive proliferating MG without affecting cell death",0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,u6:n3-gRNAs,genetic_reagent,Efficacy,Retinal injury in ubi:Cas9;u6:n3-gRNA fish resulted in an expanded zone of injury-responsive MG and increased MG proliferation without affecting retinal cell death,Results,Retinal injury in ubi:Cas9;u6:n3-gRNA fish resulted in an expanded zone of injury-responsive MG and increased MG proliferation without affecting retinal cell death,0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,hsp70:dll4-P2A-GFP,genetic_reagent,Efficacy,"Forced expression of Dll4 with heat shock inhibited injury-dependent proliferation of MG and MG-derived progenitors, and reduced the zone of proliferating MG without affecting retinal cell death",Results,"forced expression of Dll4 with heat shock in hsp70:dll4-P2A-GFP transgenic fish inhibited injury-dependent proliferation of MG and MG-derived progenitors, and also reduced the zone of proliferating MG",0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,hsp70:GFP-P2A-dlb,genetic_reagent,Efficacy,Dlb overexpression inhibited injury-dependent proliferation of MG-derived progenitors,Results,"Furthermore, Dlb overexpression in hsp70:GFP-p2A-dlb fish, inhibited injury-dependent proliferation of MG-derived progenitors",0.9
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,"Rabbit anti-GFP, Thermo Fisher, Cat. # A6455",antibody,Biomarker,Used for immunofluorescence detection of GFP in developing fish to indicate Notch signaling activation in differentiating MG,Results,"In developing fish, mCherry and GFP immunofluorescence indicate Notch signaling is activated and restricted to differentiating MG",0.8
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,"Mouse anti-mCherry, Abcam, Cat. # ab125096",antibody,Biomarker,Used for immunofluorescence detection of mCherry to track Notch signaling activity in developing and adult zebrafish retina,Results,"In developing fish, mCherry and GFP immunofluorescence indicate Notch signaling is activated and restricted to differentiating MG",0.8
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",MIAPaCa-2,cell_line,Biomarker,Showed elevated mRNA expression of NBCn1 and NBCe2 compared to HPDE cells,Results,MIAPaCa-2 cells predominantly showed upregulation of NBCn1 and NBCe2,0.85
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",MIAPaCa-2,cell_line,Biomarker,NBCn1 protein level was significantly increased compared to HPDE cells,Results,"western blot analysis revealed that...the NBCn1 protein level in MIAPaCa-2 and Panc-1 cells, compared to that observed in HPDE cells",0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Biomarker,Showed upregulation of both NHE2 and NBCn1 mRNA compared to HPDE cells,Results,both NHE2 and NBCn1 were upregulated in Panc-1 cells,0.85
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Biomarker,NBCn1 protein level was significantly increased compared to HPDE cells,Results,"western blot analysis revealed that...the NBCn1 protein level in MIAPaCa-2 and Panc-1 cells, compared to that observed in HPDE cells",0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Mechanistic,"TGFβ-1 treatment significantly reduced E-cadherin level and increased α-SMA and CTGF levels, consistent with EMT induction",Results,"In Panc-1 cells, TGFβ-1 treatment significantly reduced the level of E-cadherin, and increased that of α-SMA and CTGF, consistent with induction of EMT",0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Biomarker,TGFβ-1 treatment increased NHE1 protein expression by about 60% and NBCn1 by about 40%,Results,"The protein expression level of NHE1 increased by about 60%, and that of NBCn1 by about 40%, following TGFβ-1 treatment of Panc-1 cells",0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Biomarker,TGFβ-1 treatment significantly increased steady state pHi from 7.06 ± 0.105 to 7.26 ± 0.043,Results,"TGFβ-1 treatment significantly increased steady state pH i in Panc-1 cells, from an average value of 7.06 ± 0.105 in control cells to 7.26 ± 0.043 after TGFβ-1 treatment",0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Mechanistic,"TGFβ-1 treatment markedly increased the pHi recovery rate, indicating increased acid extrusion capacity",Results,TGFβ-1 treatment markedly increased the pH i recovery rate in Panc-1 cells,0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Panc-1,cell_line,Mechanistic,TGFβ-1 treatment increased invasion through Matrigel more than 4-fold,Results,Stimulation with TGFβ-1 increased invasion of Panc-1 cells through Matrigel more than 4-fold,0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",BxPC-3,cell_line,Biomarker,Showed elevated expression of NHE1 and NHE2 compared to HPDE cells,Results,BxPC-3 and AsPC-1 cells showed elevated expression of NHE1 and−2,0.85
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",BxPC-3,cell_line,Biomarker,NHE1 protein level was significantly increased compared to HPDE cells,Results,western blot analysis revealed that the NHE1 protein level was significantly increased in BxPC-3 cells,0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",BxPC-3,cell_line,Mechanistic,TGFβ-1 treatment elicited only a small yet significant decrease in E-cadherin of about 25% without detectable changes in α-SMA and CTGF,Results,"In BxPC-3 cells, TGFβ-1 treatment elicited a small yet significant decrease in E-cadherin of about 25%, which was not accompanied by detectable changes in α-SMA and CTGF expression",0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",BxPC-3,cell_line,Biomarker,"Steady state pHi was 7.01 ± 0.062 in controls and 7.09 ± 0.066 after TGFβ-1 treatment, not significantly different",Results,"the steady state pH i of BxPC-3 cells was 7.01 ± 0.062 in controls and 7.09 ± 0.066 after TGFβ-1 treatment, not significantly different",0.95
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",AsPC-1,cell_line,Biomarker,Showed elevated expression of NHE1 and NHE2 compared to HPDE cells,Results,BxPC-3 and AsPC-1 cells showed elevated expression of NHE1 and−2,0.85
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",HPDE H6c7,cell_line,Biomarker,Used as control reference for transporter expression comparisons with PDAC cell lines,Results,All PDAC cell lines studied exhibited increased mRNA levels of one or more of these transporters compared to HPDE cells,0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",mouse anti-β-actin,antibody,Other,Used as loading control in western blot analyses,Results,Data (mean with S.E.M. error bars) are normalized to the β-actin loading control,0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",rabbit anti-Merlin,antibody,Other,Used to detect Merlin protein levels in western blot analysis,Results,"Panc-1 cells were treated with siRNA against NHE1, NBCn1, and /or Merlin as indicated...followed by Western blotting to assess protein expression levels",0.85
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",mouse anti-NHE1 (clone 54),antibody,Other,Used to detect NHE1 protein levels showing significant increases in BxPC-3 cells compared to HPDE cells,Results,western blot analysis revealed that the NHE1 protein level was significantly increased in BxPC-3 cells,0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",NHE1 siRNA: ON-TARGET SMART pool,genetic_reagent,Mechanistic,Essentially abolished NHE1 protein levels and unexpectedly increased TGFβ-1-induced invasiveness,Results,Although the protein level of both transporters was essentially abolished upon siRNA treatment...siRNA-mediated knockdown of NHE1 further increased TGFβ-1-induced invasiveness,0.9
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",Merlin siRNA (SASI_Hs_01_00188862),genetic_reagent,Mechanistic,Increased basal invasion 4-fold and almost doubled TGFβ-1-induced invasiveness,Results,siRNA-mediated knockdown of Merlin...increased basal invasion 4-fold and almost doubled TGFβ-1-induced invasiveness,0.95
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,Ben-Men-1,cell_line,Biomarker,"Shows increased NRG1, HBEGF, and APLN expression compared to NF2(+) cells, with NRG1 showing 6.28 log2FC (p=1.45×10^-8)",Results,"qPCR confirmed increased expression of NRG1, HBEGF, and APLN in NF2-null(-) CRISPR-modified arachnoidal cells (AC-CRISPR) cells and MN line Ben-Men-1 compared with NF2-expressing(+) ACs",0.95
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,Ben-Men-1,cell_line,Biomarker,Secretes NRG1 ligand detectable in 48h concentrated medium,Results,"Immunoblotting revealed NRG1 secretion in 48 h-concentrated medium (48 h-CM) from NF2(−) AC cells and Ben-Men-1, whereas 48 h-CM from NF2(+) ACs or 0 h-CM from NF2(−) ACs showed no signal",0.9
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,MM-121,antibody,Efficacy,"Maximum response of 12.3% inhibition (87.7% viable cells remaining) at 10 μM in Ben-Men-1 cells, IC50 could not be determined",Results,"In Ben-Men-1 cells, MM-121 treatment only led to an MR at 10 μM of 12.3% inhibition (87.7% viable cells remaining), and calculated IC50...could not be determined",0.95
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,MM-121,antibody,Mechanistic,Blocked activated pERBB3 Y1197 in unstimulated and NRG1-stimulated cells at 2h and 24h treatment (0.5-1 μM),Results,treatment of NF2-null ACs (top panel) or Ben-Men-1 cells (bottom panel) for 2 h or 24 h with ERBB3-specific neutralizing antibody MM-121 (0.5 μM or 1 μM) blocked activated pERBB3 Y1197,0.95
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,INK128,genetic_reagent,Mechanistic,Decreased NRG1 expression and pERBB3 Y1197 activation while increasing pAkt T308 through PDK1-dependent mechanism,Results,treatment of NF2-null ACs and Ben-Men-1 with mTORC1/2 inhibitor...INK128...led to decreased expression of NRG1...showed attenuation of pERBB3 Y1197...increased pAkt T308,0.95
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,INK128,genetic_reagent,Efficacy,Shows superior efficacy compared to BMS-754807 with IC50s in nanomolar range across all NF2-null cell lines tested,Results,INK128 treatment showed superior efficacy in all cell lines tested compared with BMS-754807 with IC50s in the nanomolar range for INK128 treatment compared with micromolar IC50 range for BMS-754807,0.9
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,BMS-754807,genetic_reagent,Efficacy,IC50 of 3.2 μM (MR 77.7%) when co-treated with 400 nM INK128 vs 4.4 μM (MR 75.7%) alone in Ben-Men-1 cells,Results,"Dose–response testing in Ben-Men-1 cells for BMS-754807 in the presence of 400 nM INK128...revealed a left-shifted DRC, with a decreased IC50 of 3.2 μM (MR, 77.7%) compared with 4.4 μM (MR, 75.7%) for BMS-754807 alone",0.95
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,SynergyFinder,computational_tool,Efficacy,Demonstrated true synergistic effects (score >5.0) for INK128 and BMS-754807 combination across all four reference models in multiple NF2-null cell lines,Results,"Co-treatment of Ben-Men-1 and MN1-LF cells as well as two human primary NF2-null MN lines, MN646C and MN658, with INK128 and BMS-754807 showed true synergistic effects, defined as a score >5.0 for all four reference models",0.95
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,lapatinib,genetic_reagent,Mechanistic,"Inhibited NRG1-stimulated pERBB3, pEPHA2, and mTORC1/2 signaling but had no effect on basal activation in unstimulated cells",Results,"In NRG1-stimulated cells, lapatinib treatment led to inhibition of pERBB3, as expected, along with downregulation of pEPHA2 receptor and mTORC1/2 pathway readouts...whereas in unstimulated cells...neither lapatinib nor erlotinib treatment attenuated basally activated pEPHA2 or mTORC1/2 signaling",0.9
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,rapamycin,genetic_reagent,Mechanistic,Decreased NRG1 expression and attenuated pERBB3 Y1197 activation at 20 nM for 24h treatment,Results,qPCR analysis revealed that treatment of NF2-null ACs and Ben-Men-1 with...rapamycin led to decreased expression of NRG1...Immunoblotting also showed attenuation of pERBB3 Y1197 with...rapamycin treatment,0.9
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,AZD2014,genetic_reagent,Mechanistic,Decreased activated ERBB3 (pERBB3 Y1197) and mTORC1/2 pathway readouts at 300 nM for 24h treatment,Results,"immunoblotting of NF2-null ACs and Ben-Men-1, treated for 24 h with...mTORC1/2 inhibitor AZD2014 (300 nM), shows decrease in activated ERBB3 (pERBB3 Y1197) along with respective mTORC1/2 pathway readouts",0.9
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,Tinnitus Functional Index,clinical_assessment_tool,Behavioral,"Test-retest reliability = 0.92, internal consistency reliability = 0.99, item-total correlations 0.56–0.91",Results,Test-retest reliability = 0.92 Internal consistency reliability = 0.99 Item-total correlations 0.56–0.91; 37 correlations 0.70,0.95
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,Tinnitus Functional Index,clinical_assessment_tool,Behavioral,High correlation with the THI = 0.91; correlated with the VAS = 0.73,Results,High correlation with the THI = 0.91; correlated with the VAS = 0.73,0.95
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,Tinnitus Functional Index,clinical_assessment_tool,Behavioral,Discriminant validity 0.56 with the Beck Depression Inventory,Results,Discriminant validity 0.56 with the Beck DI,0.95
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,Tinnitus Functional Index,clinical_assessment_tool,Behavioral,Minimally clinically important difference (MCID) = 13-point reduction,Results,MCID = 13-point reduction,0.95
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,Tinnitus Functional Index,clinical_assessment_tool,Other,Validated in multicenter setting including >300 patients between 17 and 97 years of age,Results,These prototypes were (longitudinally) tested in a multicenter setting including >300 patients between 17 and 97 years of age,0.9
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),clinical_assessment_tool,Other,Overall group rating = 2.73 for Tinnitus Functional Index evaluation,Results,Overall group rating = 2.73,0.95
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,Brief Symptom Inventory 18 (BSI-18),clinical_assessment_tool,Behavioral,"Glioma survivors with NF1 showed increased risk of global distress (RR: 2.48 [1.25-4.91]), depression (1.94 [1.01-3.76]), anxiety (3.22 [1.60-6.47]) and somatization (2.07 [1.05-4.09]) compared to glioma survivors without NF1",Results,"Survivors of childhood glioma with NF1 who were adults at the time of evaluation had an increased risk of global distress (relative risk [95%CI]: 2.48 [1.25–4.91]) as well as depression (1.94 [1.01–3.76]), anxiety (3.22 [1.60–6.47]) and somatization (2.07 [1.05–4.09])",0.95
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,Brief Symptom Inventory 18 (BSI-18),clinical_assessment_tool,Behavioral,Glioma survivors with NF1 showed increased risk of emotional impairment on all BSI-18 domains compared to siblings,Results,"Compared to siblings, glioma survivors with NF1 showed an increased risk of emotional impairment on both the BSI-18 (all domains) and the BPI (peer conflict)",0.85
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,Behavior Problem Index (BPI),clinical_assessment_tool,Behavioral,Glioma survivors with NF1 showed increased risk of peer conflict on the BPI compared to siblings,Results,"Compared to siblings, glioma survivors with NF1 showed an increased risk of emotional impairment on both the BSI-18 (all domains) and the BPI (peer conflict)",0.85
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,CCSS Neurocognitive Questionnaire,clinical_assessment_tool,Behavioral,"Glioma survivors with NF1 had significantly increased risk of impairment in all neurocognitive domains compared to siblings, and increased risk of impaired task completion (1.50 [1.14-1.96]) compared to glioma survivors without NF1",Results,"Compared to siblings, glioma survivors with NF1 had significantly increased risk of impairment in all neurocognitive domains, and increased risk of impaired task completion (1.50 [1.14–1.96]) compared to glioma survivors without NF1",0.95
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",clinical_assessment_tool,Safety,"CTCAE grade 3-4 chronic health conditions diagnosed before study entry were more prevalent in glioma survivors with NF1 (46.3% [38.1%-54.4%]) vs without NF1 (30.8% [29.1%-32.6%]), p<0.001",Results,"Compared to survivors without NF1, CTCAE grade 3–4 chronic health conditions diagnosed before study entry (5 years after diagnosis) were more prevalent in glioma survivors with NF1 (46.3% [38.1%−54.4] vs. 30.8% [29.1%−32.6%], p<0.001",0.95
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",clinical_assessment_tool,Safety,Glioma survivors with NF1 developed new grade 3-5 health conditions >5 years from diagnosis at similar rate compared to glioma survivors without NF1 (rate ratio: 1.26 [0.90-1.77]),Results,Glioma survivors with NF1 developed new grade 3–5 health conditions >5 years from diagnosis at a similar rate compared to glioma survivors without NF1 (rate ratio [95%CI]: 1.26 [0.90–1.77],0.95
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",clinical_assessment_tool,Safety,New grade 3-5 health conditions arose at greater rate among all survivors with NF1 compared to survivors without NF1 (1.53 [1.13 to 2.07]),Results,although new grade 3–5 health conditions did arise at a greater rate among all survivors with NF1 compared to survivors without NF1 (1.53 [1.13 to 2.07]),0.95
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,ipNF9511bc,cell_line,Efficacy,GRDC24 construct showed most effective suppression of NF1 null cells when packaged in AAV-DJ at different MOI,Results,GRD-KRAS4B-C24 showed the most effective suppression of NF1 null cells. Three biological replicates were used.,0.85
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,ipn023λ,cell_line,Safety,"GRDC24 displayed far less cytotoxicity in non-NF1 cells, especially at lower MOI of 500 and 100",Results,"GRDC24 displayed far less cytotoxicity in non-NF1 cells, such as ipn02.3λ, especially at lower multiplicity of infection (MOI) of 500 and 100",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,ST88-14,cell_line,Mechanistic,333 AA GRD version showed highest expression and most potent inhibition of pERK1/2 in ST88-14 cells,Results,The 333 AA version (NF1 AA 1200-1532) showed the highest expression and most potent inhibition of pERK1/2.,0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,ST88-14,cell_line,Mechanistic,GRDC24 induced apoptosis in ST88-14 cells after 24h treatment with annexin V staining,Results,GRDC24 induced apoptosis in NF1 cells. ipNF9511bc cells were transfected with AAV-GRDC24 and after 24 h cells were stained with annexin V.,0.85
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,NSG mice,animal_model,Efficacy,AAV-557-2-GRDC24 significantly slowed ST88-14 tumor growth at 14 days after treatment (n=13 mice vs n=14 control),Results,AAV-557-2-GRDC24 significantly slowed down the ST88-14 tumor growth in mice. Con: n = 14 mice; 557-2: n = 13 mice.,0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,NSG mice,animal_model,Efficacy,AAV-K55-GRDC24 significantly suppressed ST88-14 tumor growth initially but showed quick rebound after 4 weeks (n=5 mice),Results,"one dose of AAV-K55-GRDC24 significantly suppressed the growth of ST88-14 tumor initially, but a quick rebound was observed after 4 weeks",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,NSG mice,animal_model,Efficacy,Two doses of AAV-K55-GRDC24 administered 7 days apart substantially enhanced therapeutic effect over extended period in ST88-14 xenografts (n=4 mice),Results,Two doses of AAV-K55-GRDC24 administered 7 days apart substantially enhanced the therapeutic effect over an extended period in ST88-14 xenografts,0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,NSG mice,animal_model,Safety,"AAV9-GRDC24 resulted in mortalities between days 15-21 of treatment, which was not observed with AAV-K55-GRDC24 at same 10^12 vg dose",Results,"AAV9-GRDC24 showed no significant therapeutic effects when administered IV at the same 10^12 vg dose and resulted in mortalities in mice between days 15 and 21 of treatment, which was not observed with AAV-K55-GRDC24",0.95
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,FiPS,cell_line,Mechanistic,"FiPS-derived neural crest cells were less affected by GRDC24 expression compared to NF1-/- cells, especially at lower MOIs",Results,"Expression of GRDC24 via AAV inhibited pERK1/2 and significantly reduced viable cell numbers in NF1−/− NC cells, while FiPS-derived NC cells were less affected, especially at lower MOIs",0.85
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",cell_line,Mechanistic,"GRDC24 rescued Schwann cell differentiation capacity when applied 3 days prior or 2 days after start of SC differentiation, enabling myelination around neurons",Results,GRDC24 packaged in AAV-DJ was applied to NF1−/− cells 3 days prior or 2 days after the start of SC differentiation and in both cases NF1−/− cells were able to acquire a SC morphology and stained positive for the SC marker S100B,0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,RHT92,cell_line,Efficacy,"AAV-K55-GRDC24 markedly slowed down RHT92 tumor growth, with more substantial response when adding a second dose (n=4-5 mice)",Results,"In RHT92 xenograft model, AAV-K55-GRDC24 also markedly slowed down the tumor growth, and adding a second dose made a more substantial response",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,RHT92,cell_line,Biomarker,AAV-K55-GFP achieved 50-60% transduction in RHT92 xenograft tumors as measured by flow cytometry,Results,"we found AAV-K55-GFP achieved 30–40% transduction in ST88-14, 50–60% in RHT92 and over 20% in JH-2-002",0.95
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,LN229,cell_line,Biomarker,NF1-deficient glioma xenograft LN229 was transduced at approximately 30% by one dose of AAV-K55-GFP,Results,"NF1-deficient glioma xenograft, LN229, also was transduced at approximately 30% by one dose of AAV-K55-GFP",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,S462,cell_line,Efficacy,S462 MPNST was resistant to AAV-K55-GFP vector transduction,Results,while S462 MPNST and JH-2-031 PDX MPNST were resistant to this vector,0.85
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,JH-2-002,patient_derived_model,Biomarker,Patient-derived xenograft MPNST JH-2-002 achieved over 20% transduction with AAV-K55-GFP,Results,"we found AAV-K55-GFP achieved 30–40% transduction in ST88-14, 50–60% in RHT92 and over 20% in JH-2-002, a patient-derived xenograft (PDX) MPSNT",0.9
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,JH-2-031,patient_derived_model,Efficacy,JH-2-031 PDX MPNST was resistant to AAV-K55-GFP vector transduction,Results,while S462 MPNST and JH-2-031 PDX MPNST were resistant to this vector,0.85
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,3PNF_SiPSsv_MM_11,advanced_cellular_model,Biomarker,"AAV-K55-GFP demonstrated substantial transduction in NF1 iPSC-derived neurofibroma xenograft, primarily transducing S100B-positive population",Results,"this vector demonstrated substantial transduction in an NF1−/− iPSC-derived neurofibroma xenograft (3MM), as shown by anti-GFP IHC. We found that AAV-K55-GFP primarily transduced the S100B-positive population",0.9
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,DINs (Deep Interactive Networks),computational_tool,Efficacy,Achieves accurate segmentation of multiple tumors with one click and iteratively improves segmentation with additional interactions,Results,DINs achieve accurate segmentation of multiple tumors with one click and iteratively improves segmentation with additional interactions.,0.8
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,DINs (Deep Interactive Networks),computational_tool,Efficacy,Can recognize neurofibromas accurately compared to other interactive methods,Results,"In comparison, DINs can recognize neurofibromas accurately. The two groups of segmentation results support the advantages of the DINs.",0.8
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,DINs (Deep Interactive Networks),computational_tool,Efficacy,Outperforms conventional interactive methods and performs significantly better than automated and interactive CNN-based methods,Discussion,Experiments on the training set and the test set show that the proposed method outperforms conventional interactive methods and performs significantly better than automated and interactive CNN-based methods.,0.9
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,DINs (Deep Interactive Networks),computational_tool,Other,May fail in some cases such as neurofibromas near the orbits due to similar intensity,Discussion,DINs may failed in some cases such as neurofibromas near the orbits due to the similar intensity.,0.8
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,Random Walk (RW),computational_tool,Efficacy,Tends to lead to undersegmentation,Results,"Random walk tends to lead to undersegmentation, while graph cut cannot distinguish neurofibromas from normal organs and tends to result in oversegmentation.",0.8
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,Graph Cut (GC),computational_tool,Efficacy,Cannot distinguish neurofibromas from normal organs and tends to result in oversegmentation,Results,"Random walk tends to lead to undersegmentation, while graph cut cannot distinguish neurofibromas from normal organs and tends to result in oversegmentation.",0.8
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,dNF1‐KO,cell_line,Mechanistic,"Showed increased rate of growth in both presence and absence of serum, indicating accelerated culture growth decoupled from upstream growth factor signaling pathways",Results,dNF1‐KO cells showed an increased rate of growth as measured using CellTiter‐Glo assays to assess total ATP levels in the population. This effect was observed in both the presence and absence of serum,0.9
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,dNF1‐KO,cell_line,Mechanistic,Showed significantly higher levels of autophagic flux under serum-free conditions compared to S2R+ controls,Results,We observed significantly higher levels of autophagic flux in dNF1‐KO cells under serum‐free conditions compared to S2R+ controls,0.9
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,"ipNF95.11b 'C' (hTERT NF1 ipNF95.11b C, RRID: CVCL_UI67)",cell_line,Mechanistic,Showed significantly higher autophagic flux relative to NF1+/- controls and increased baseline expression of LC3B protein,Results,Autophagic flux was significantly higher in NF1−/− cells (ipNF95.11b 'C' and ipNF05.5) relative to NF1+/− controls...baseline expression of LC3B...was found to be increased in NF1−/− cells,0.9
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",cell_line,Mechanistic,Showed significantly higher autophagic flux relative to NF1+/- controls,Results,Autophagic flux was significantly higher in NF1−/− cells (ipNF95.11b 'C' and ipNF05.5) relative to NF1+/− controls,0.9
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,ST88‐14 (RRID: CVCL_8916),cell_line,Efficacy,"Xenograft tumor growth was significantly reduced by chloroquine (50 mg/kg, 3x weekly) and selumetinib (25 mg/kg, 3x weekly) compared to vehicle controls, with chloroquine showing superior effect over selumetinib",Results,"treatment with CQ (50 mg·kg−1 in saline, intraperitoneally, three times per week) or selumetinib (25 mg·kg−1 in saline, oral gavage, three times per week)...resulted in a significant reduction in tumor cell growth...Furthermore, there was a significant reduction in tumor cell growth in CQ‐treated mice in comparison to selumetinib‐treated mice",0.95
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,CD‐1 nude mice (Crl:NU(NCr)‐Foxn1nu),animal_model,Safety,CQ and selumetinib treatment showed no toxicity effects during xenograft studies,Results,CQ and selumetinib treatment were found to have no toxicity effects in these mice,0.8
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,CellTiter‐Glo assay (Promega; G7570),clinical_assessment_tool,Mechanistic,Demonstrated chloroquine caused selective viability effects at 100-1000 fold lower concentrations (1-100 nM) than selumetinib (10-100 μM) in NF1-deficient cells after 48h treatment,Results,"CQ resulted in selective lethal effects at approximately 100–1000‐fold lower concentration (1–100 nm) than selumetinib (10–100 μm) after 48 h treatment in serum free media, measured using CellTiter Glo assays",0.95
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*],genetic_reagent,Mechanistic,"dNf1C1 mutant flies showed increased lethality when treated with 35 μM chloroquine compared to wild-type flies, which was rescued by re-expression of dNf1",Results,Addition of 35 μm chloroquine (CQ) to food resulted in increased lethality of dNf1C1 mutants compared to WT flies...The sensitivity of dNf1 mutant flies to CQ was rescued by re‐expression of dNf1 from a UAS‐dNF1 transgene,0.9
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,"anti‐PARP (rabbit, Cell Signaling 952)",antibody,Biomarker,"Showed significant increase in 24 kDa fragment of cleaved PARP relative to total PARP in xenografts from both CQ and selumetinib-treated mice, indicating cell apoptosis",Results,"We found a significant increase in the 24 kDa fragment of cleaved PARP relative to total PARP in xenografts from both CQ and selumetinib‐treated mice, indicating that both drugs resulted in cell apoptosis",0.9
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,Nf1Dsk9/+ mouse model,animal_model,Behavioral,"50% reduction in average litter size from Nf1+/- males (4.00 ± 1.2) compared to Nf1+/+ males (8.67 ± 0.76), p = 0.007",Results,the average number of pups per litter from Nf1+/- males was significantly reduced compared to that of Nf1+/+ control male littermates (p = 0.007),0.95
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,Nf1Dsk9/+ mouse model,animal_model,Biomarker,"Significantly higher epididymal sperm counts in Nf1+/- mice (15 ± 2.3 x10^6 spermatozoa/ml) compared to controls (8.8 ± 5.5 x10^6 spermatozoa/ml), p = 0.02",Results,Epididymal sperm counts in Nf1+/- mice were significantly higher than those of Nf1+/+ control mice (p = 0.02),0.95
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,Nf1Dsk9/+ mouse model,animal_model,Biomarker,"Significantly reduced number of Leydig cells in Nf1+/- mice (24.2 ± 1.2) compared to controls (28.2 ± 0.71), p = 0.02",Results,The number of Leydig cells present in Nf1+/- mice was significantly lower than in Nf1+/+ control littermates (p = 0.02),0.95
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,Nf1Dsk9/+ mouse model,animal_model,Biomarker,"Significantly increased number of immature spermatids in Nf1+/- mice (0.56 ± 0.008) compared to controls (0.51 ± 0.02), p = 0.03",Results,the number of immature (round or elongated) spermatids was significantly increased in Nf1+/- mice compared to Nf1+/+ control (p = 0.03),0.95
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,Nf1Dsk9/+ mouse model,animal_model,Biomarker,"Significantly increased testicular volume in Nf1+/- mice (3.11 ± 0.14) compared to controls (2.73 ± 0.09), p = 0.05",Results,Testicular volume was also significantly increased among Nf1+/- mice (p = 0.05),0.95
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,Nf1Dsk9/+ mouse model,animal_model,Mechanistic,"Demonstrated mild to moderate seminiferous tubule degeneration including detachment of germinal epithelium, vacuolation, and exfoliation of immature spermatids",Results,"We found varying amounts of mild to moderate degeneration of seminiferous tubules in all Nf1+/- males. Mild alterations include detachment of the germinal epithelium from the basal lamina, vacuolation",0.9
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2) antibody,antibody,Mechanistic,Detected increased phosphorylation and activation of ERK in Nf1+/- mice compared to controls,Results,"Nf1+/- mutation resulted in increased phosphorylation and activation of ERK, while having no effect on total ERK protein expression",0.9
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,p44/42 MAPK (ERK1/2) antibody,antibody,Mechanistic,Showed no effect on total ERK protein expression in Nf1+/- mice compared to controls,Results,"Nf1+/- mutation resulted in increased phosphorylation and activation of ERK, while having no effect on total ERK protein expression",0.9
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,phosphatidylinositol 3-kinase (PI3K) antibody,antibody,Mechanistic,Detected significant increase in total PI3K expression in Nf1+/- mice compared to controls,Results,we observed a significant increase in total PI3K expression in Nf1+/- mice when compared to Nf1+/+ control mice,0.9
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,5-point Likert-type scales,clinical_assessment_tool,Behavioral,"Measured adolescent and caregiver perspectives on cNF impact and treatment preferences, with pruritus (34%), location (34%), number (31%), and appearance (31%) selected as most bothersome cNF features by adolescents",Results,"Pruritus (34%), location (34%), number (31%), and appearance (31%) were selected as the most bothersome cNF features by adolescents",0.9
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,5-point Likert-type scales,clinical_assessment_tool,Behavioral,"Captured treatment willingness with less than 40% of adolescents and 50% of caregivers expressing willingness to remove cNFs by surgery or laser, while majority were willing to try experimental topical cream (76.9% and 66.7%) or oral medication (53.8% and 53.6%)",Results,"less than 40% of adolescents and 50% of caregivers expressed willingness to remove cNFs by surgery or laser...The majority of adolescents and caregivers were willing to try experimental treatment with topical cream (76.9% and 66.7%, respectively) or oral medication (53.8% and 53.6%, respectively)",0.9
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,5-point Likert-type scales,clinical_assessment_tool,Behavioral,Measured side effect tolerability with pain (71.9% and 77.8%) and nausea/vomiting (81.3% and 59.3%) identified as least tolerable cNF treatment side effects by adolescents and caregivers respectively,Results,"The least tolerable cNF treatment side effects by adolescents and caregivers included pain (71.9% and 77.8%, respectively) and nausea/vomiting (81.3% and 59.3%, respectively)",0.9
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,REDCap,computational_tool,Other,Successfully captured survey responses from 28 adolescents with NF1 and 32 caregivers for data collection and analysis,Results,A total of 28 adolescents with NF1 and 32 caregivers responded to the survey,0.8
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,PEERS® intervention,clinical_assessment_tool,Efficacy,"Group-level improvements in caregiver-reported social-emotional skills, social impairment, caregiver-reported number of adolescents get-togethers, and adolescent's social knowledge at post-test and at follow-up with medium to large effect sizes",Results,Caregiver-reported social-emotional skills (SSIS-SEL-P) and social impairment (SRS-2) were significantly better at post-test and follow-up compared to pre-test with medium effect sizes,0.95
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,PEERS® intervention,clinical_assessment_tool,Efficacy,SSIS-SEL-P Self-Management and Relational Skills subscales showed significant improvement at post-test with medium effect sizes,Results,"On the SSIS-SEL Parent Form, ratings on the subscales of Self-Management and Relational Skills were significantly improved at post-test with medium effect sizes",0.95
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,PEERS® intervention,clinical_assessment_tool,Efficacy,All SRS-2 subscales were significantly better at post-test with medium effect sizes,Results,All subscales on the SRS-2 were significantly better at post-test with medium effect sizes,0.95
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,PEERS® intervention,clinical_assessment_tool,Efficacy,Self-Management subscale on SSIS-SEL Student Form was significantly better at post-test with medium effect size,Results,The Self-Management subscale on the SSIS-SEL Student Form was significantly better at post-test with a medium effect size,0.95
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,PEERS® intervention,clinical_assessment_tool,Safety,Low dropout rate experienced during COVID-19 pandemic context,Discussion,"However, the relatively low drop out from the intervention experienced amidst the COVID-19 pandemic are rather remarkable",0.8
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),clinical_assessment_tool,Behavioral,"SSIS-SEL-P showed significantly lower overall social-emotional skills compared to normative mean at pre-test (t(18) = -6.23, p <.001, g = -1.37)",Results,"Adolescents with NF1 had significantly lower overall social-emotional skills...using caregiver report compared to the normative mean with large effect sizes at pre-test (SSIS-SEL-P: t (18) = -6.23, p <.001, g = -1.37",0.95
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,Social Responsiveness Scale– Second Edition (SRS-2),clinical_assessment_tool,Behavioral,"SRS-2 showed significantly more social impairment compared to normative mean at pre-test (t(18) = 7.26, p <.001, g = 1.59)",Results,"significantly more social impairment using caregiver report compared to the normative mean with large effect sizes at pre-test...SRS-2: t (18) = 7.26, p <.001, g = 1.59",0.95
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,Test of Adolescent Social Skills Knowledge (TASSK),clinical_assessment_tool,Behavioral,TASSK showed significantly better social knowledge at post-test and follow-up compared to pre-test with medium to large effect sizes,Results,social knowledge (TASSK) were also significantly better at post-test and follow-up compared to pre-test with medium to large effect sizes,0.9
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,Quality of Socialization Questionnaire (QSQ),clinical_assessment_tool,Behavioral,Caregiver-reported number of adolescent get-togethers (QSQ-Caregiver) was significantly better at post-test and follow-up compared to pre-test with medium to large effect sizes,Results,Caregiver-reported number of adolescent get-togethers (QSQ-Caregiver)...were also significantly better at post-test and follow-up compared to pre-test with medium to large effect sizes,0.9
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Pain Interference Index (PII),clinical_assessment_tool,Other,Cronbach's coefficient alpha was 0.84 (unstandardized) indicating good internal consistency reliability,Results,Cronbach's coefficient alpha was 0.84 (unstandardized) for the patient PII,0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Pain Interference Index (PII),clinical_assessment_tool,Other,Completion time of approximately 1-2 minutes demonstrating feasibility,Results,"All individuals who agreed to participate completed all the measures in about 5–10 minutes, with the PII requiring about 1–2 minutes",0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Pain Interference Index (PII),clinical_assessment_tool,Behavioral,"Patients taking prescription pain medication scored significantly higher (M = 1.92 ± 1.01) than those not taking pain medication (M = 0.90 ± 1.02; F = 10.2, P < 0.01)",Results,"patients who were taking prescription pain medication obtained significantly higher pain interference scores on the PII (N = 13; M = 1.92 ± 1.01) than those not taking pain medication (N = 47; M = 0.90 ± 1.02; F = 10.2, P < 0.01)",0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Pain Interference Index (PII),clinical_assessment_tool,Behavioral,"NF1 patients with moderate/severe disease severity scored significantly higher (M = 1.61 ± 1.0) compared to mild severity patients (M = 0.58 ± 0.75; F = 9.95, P = 0.004)",Results,"Patients rated as moderate/severe (N = 14, M = 1.61 ± 1.0) scored significantly higher on the PII compared with patients rated as mild (N = 16; M = 0.58 ± 0.75; F = 9.95, P = 0.004)",0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Pain Interference Index-Parent report (PII-P),clinical_assessment_tool,Other,Cronbach's coefficient alpha was 0.94 for mothers and 0.96 for fathers indicating excellent internal consistency reliability,Results,"Cronbach's coefficient alpha was 0.84 (unstandardized) for the patient PII, and 0.94 and 0.96 for the parent PII (mothers and fathers, respectively)",0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Pain Interference Index-Parent report (PII-P),clinical_assessment_tool,Behavioral,"Parent scores were significantly higher than patient scores (1.5 vs 1.1, t = 3.28, P = 0.002, d = 0.39) indicating parents report more pain interference",Results,"patients' scores were significantly lower, indicating less pain interference, than their parents' scores (1.1 vs 1.5, t = 3.28, P = 0.002), d = 0.39",0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Pain Interference Index-Parent report (PII-P),clinical_assessment_tool,Behavioral,"Parents of children taking prescription pain medication scored significantly higher (M = 2.63 ± 1.06) than those not taking pain medication (M = 1.29 ± 1.33; F = 11.09, P < 0.01)",Results,"Similar results were obtained on the PII-P, with mean scores higher for children who were taking pain medication (M = 2.63 ± 1.06) vs those who were not (M = 1.29 ± 1.33; F = 11.09, P < 0.01)",0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Modified Brief Pain Inventory (MBPI),clinical_assessment_tool,Other,"Highly correlated with PII scores (r = 0.81, 95% CI: 0.70–0.88; P < 0.0001) demonstrating construct validity",Results,"PII scores were highly correlated with MBPI scores (r = 0.81, 95% confidence interval [CI]: 0.70–0.88; P < 0.0001)",0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Pain Rating Scale (PRS),clinical_assessment_tool,Other,"Correlated with PII scores (r = 0.54, CI: 0.35–0.71; P < 0.0001) supporting construct validity",Results,"and with scores on the PRS (r = 0.54, CI: 0.35–0.71; P < 0.0001)",0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,Faces Pain Scale-Revised (FPS-R),clinical_assessment_tool,Other,"Could not be evaluated reliably due to lack of variance in scores; 52 patients scored '0', seven scored '2', and one scored '4'",Results,"The relationship between the PII and the FPS-R pain scale could not be evaluated reliably due to a lack of variance in FPS-R scores; 52 patients scored '0,' seven patients scored '2,' and one patient scored '4'",0.95
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,NF Disease Severity Scale,clinical_assessment_tool,Other,Ratings were available for 30 of 31 NF1 patients and successfully differentiated mild from moderate/severe disease severity groups,Results,"NF1 Disease Severity Scale ratings completed by the nurse practitioner were available for 30 of the 31 patients with NF1. Patients rated as moderate/severe (N = 14, M = 1.61 ± 1.0) scored significantly higher",0.9
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,NF1 Disease Complications Scale,clinical_assessment_tool,Other,"Showed a trend toward correlation with PII scores (r = 0.33, P = 0.07) but not statistically significant",Results,"A trend was apparent wherein higher scores on the NF1 Disease Complications Scale were related to higher PII scores but not significantly so (r = 0.33, P = 0.07)",0.85
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,P0SchΔ39-121 transgenic mice,animal_model,Biomarker,Significantly reduced myelin thickness in both uninjured and injured nerves compared to WT mice,Results,Myelin thickness was significantly reduced in uninjured and injured nerves from P0SchΔ39-121 mice compared their counterparts in WT mice,0.9
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,P0SchΔ39-121 transgenic mice,animal_model,Biomarker,Increased endoneurial space compared to WT mice,Results,there was increased endoneurial space in nerves from Nf2 mutant mice compared to WT mice,0.8
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,P0SchΔ39-121 transgenic mice,animal_model,Biomarker,Increased Schmidt-Lanterman incisures (SLIs) in uninjured nerves compared to WT mice,Results,An increase in SLIs was also found in uninjured nerves from Nf2 mutant mice compared to WT mice,0.8
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,P0SchΔ39-121 transgenic mice,animal_model,Biomarker,Misshaped and dysmorphic nerve fibers observed compared to WT mice,Results,Misshaped and dysmorphic nerve fibers were also observed in nerves from P0SchΔ39-121 compared to nerves from WT mice,0.8
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,P0SchΔ39-121 transgenic mice,animal_model,Behavioral,Delayed neural recovery following injury,Discussion,loss of merlin function in SCs delays neural recovery following injury,0.8
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,P0SchΔ39-121 transgenic mice,animal_model,Behavioral,No significant functional or electrophysiological differences in neural regeneration,Discussion,there were no significant functional or electrophysiological differences in neural regeneration attributable to Nf2 mutation in SCs,0.9
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,HEI-193,cell_line,Efficacy,99% infectability with lentivirus vector as determined by mCherry expression under fluorescence microscopy,Results,Infectability of this cell line was 99% as determined by mCherry expression under fluorescence microscopy,0.95
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,HEI-193,cell_line,Efficacy,Successful tumor establishment in 13 of 15 mice (87% success rate) with gradual increase in tumor volume over 10 weeks,Results,we observed a gradual increase in tumor volume over 10 weeks after tumor implantation in 13 of these 15 mice,0.95
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,HEI-193,cell_line,Biomarker,"Tumor doubling times were 18, 16 and 24 days for 30,000, 100,000 and 300,000 cell groups, respectively",Results,"the doubling times were quite similar between the 3 groups (18, 16 and 24 days in 30,000, 100,000 and 300,000 groups, respectively)",0.95
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,athymic mice (nu/nu),animal_model,Safety,No apparent gross neurologic deficits in hind-limb on the side of the tumor-implanted sciatic nerve,Results,There were no apparent gross neurologic deficits in hind-limb on the side of the tumor-implanted sciatic nerve,0.85
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,S100 antibody,antibody,Biomarker,Tumors were partially positive for the schwannoma cell marker S100 by immunocytochemical staining,Results,"These tumors were partially positive for the schwannoma cell marker, S100, by immunocytochemical staining of the same tumor samples",0.85
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,lentivirus expressing Fluc and mCherry,genetic_reagent,Efficacy,"Enabled monitoring of tumor growth in vivo by bioluminescence imaging with logarithmic growth rates of 8×10³±2.1×10³, 9.3×10³±1.27×10³, and 10⁴±3.6×10³ photons/minute/day",Results,"consistent logarithmic rate in average 8 × 10³ ± 2.1 × 10³, 9.3×10³ ± 1.27 × 10³, and 10⁴ ±3.6 × 10³ photons/minute/day of tumor growth",0.95
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,lentivirus expressing Fluc and mCherry,genetic_reagent,Biomarker,mCherry expression was detectable in tumor cells by fluorescent histochemical analysis,Results,"in fluorescent histochemical analysis of sections from the same tumor samples, tumor cells were found to express mCherry",0.9
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,P122-C1 NF1-area kit,genetic_reagent,Efficacy,Successfully identified breakpoint regions of 17 atypical NF1 deletions spanning between 519 kb and 5.9 Mb,Results,Custom-designed multiplex ligation-dependent probe amplification (MLPA) and targeted array comparative genomic hybridization (array CGH) were performed to identify the breakpoint regions of the 17 atypical NF1 deletions spanning between 519 kb and 5.9 Mb,0.9
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,Expand Long Template PCR system,genetic_reagent,Efficacy,Successful in 15 of 17 atypical NF1 deletions (88% success rate) for breakpoint-spanning PCRs under standard conditions,Results,"Breakpoint-spanning PCRs, using the Expand Long Template PCR system under standard conditions with primers designed on the basis of the array CGH results, were successful in the case of 15 of the 17 atypical NF1 deletions",0.95
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,BigDye Terminator v3.1 Cycle Sequencing Kit,genetic_reagent,Efficacy,Provided precise breakpoint locations of 15 deletions with simple breakpoints and readily interpretable transitions from centromeric to telomeric breakpoint-flanking sequences,Results,Sequence analysis of the corresponding PCR products provided the precise breakpoint locations of the 15 deletions that exhibited simple breakpoints with readily interpretable transitions from centromeric to telomeric breakpoint-flanking sequences,0.9
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,GenomeWalker™,genetic_reagent,Efficacy,Successfully revealed insertion of SVA retrotransposon at deletion breakpoint regions in patient DA-77,Results,"GenomeWalker analysis of the breakpoint regions in this patient then revealed the insertion of an SINE/VNTR/Alu (SVA) retrotransposon, which is absent from the human genome reference sequence (hg19), at the corresponding genomic position",0.9
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,Advantage® 2 PCR Kit,genetic_reagent,Efficacy,Successfully amplified across inserted SVA elements and deletion breakpoints using high melting-temperature primers and GC-rich sequence optimized conditions,Results,"In order to amplify across the inserted SVA element and the deletion breakpoints, we performed PCR using primers with a high melting-temperature and PCR conditions optimized to amplify GC-rich sequences",0.85
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,non-B DNA Motif Search Tool,computational_tool,Efficacy,Identified non-B DNA-forming sequences within 53% of deletion breakpoint-flanking fragments (300 bp regions),Results,Non-B DNA-forming sequences were identified within 53% of the deletion breakpoint-flanking fragments,0.9
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,MEME suite software,computational_tool,Efficacy,Detected direct and inverted repeats (≥6 bp up to 150 bp) in 77% of deletion breakpoint-flanking regions,Results,"Similarly, direct and inverted repeats in the size range of ≥ 6 bp up to 150 bp, as identified by MEME Suite sequence analysis tools, were detected in 77% of the deletion breakpoint-flanking regions",0.9
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,BLASTN,computational_tool,Efficacy,Identified repeats in size range of 244 to 316 bp in only 5 of 15 deletion breakpoint-flanking regions using 2 kb sequence screening,Results,Only 5 of the 15 deletion breakpoint-flanking regions harbored repeats in the size range of 244 to 316 bp,0.9
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,BLASTN,computational_tool,Efficacy,Successfully identified a 5.7 kb inverted repeat with 99% sequence homology harboring deletion breakpoint in patient 619,Results,A 5.7 kb inverted repeat exhibiting 99% sequence homology was identified that harbored one of the deletion breakpoints in patient 619,0.95
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,"Trp53, Nf1, Suz12 triple mutant mice",animal_model,Biomarker,"Highest L-[18F]FETrp uptake in pancreas at 5 min (15.8 ± 1.6 ID%/g), increased at 30 min (24.4 ± 15.5 ID%/g), decreased at 60 min (20.5 ± 10.1 ID%/g)",Results,"A biodistribution study in triple mutant mice showed the highest uptake in the pancreas at 5 min post-injection (15.8 ± 1.6 ID%/g). The tracer uptake in the pancreas increased at 30 min (24.4 ± 15.5 ID%/g), followed by a decreased uptake at 60 min (20.5 ± 10.1 ID%/g).",0.95
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,"Trp53, Nf1, Suz12 triple mutant mice",animal_model,Safety,"Stable bone uptake during 90 min scans (1.49 ± 0.65 ID%/g at 5 min vs. 1.44 ± 0.45 ID%/g at 90 min), indicating stability towards defluorination",Results,"The bone uptake in the triple mutant group remained stable during the 90 min scans (1.49 ± 0.65 ID%/g at 5 min vs. 1.44 ± 0.45 ID%/g at 90 min), further indicating the stability of L-[18F]FETrp towards in vivo defluorination.",0.92
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,L-[18F]FETrp,genetic_reagent,Other,"Radiosynthesized with decay-corrected radiochemical yields of 15-28%, specific activity 88-122 GBq/µmol, chemical and enantiomeric purities over 90%, synthesis time ~100 min",Results,"L-[18F]FETrp was radiosynthesized using a one-pot, two-step strategy with decay-corrected radiochemical yields of 15–28%. The specific activity was 88–122 GBq/µmol with chemical and enantiomeric purities over 90%. The entire radiolabeling procedure took approximately 100 min.",0.98
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,L-[18F]FETrp,genetic_reagent,Efficacy,"High tumor uptake (SUV 0.64 ± 0.37) with significantly higher tumor-to-brain ratio than FDG (2.0 ± 0.8 vs. 0.7 ± 0.3, p = 0.01)",Results,"Furthermore, the brain had the lowest uptake (SUV 0.31 ± 0.08) and a high tumor uptake (SUV 0.64 ± 0.37)... L-[18F]FETrp showed a significantly higher tumor-to-brain ratio than FDG (2.0 ± 0.8 vs. 0.7 ± 0.3, p = 0.01)",0.95
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,L-[18F]FETrp,genetic_reagent,Safety,Metabolically stable with low brain uptake (0.51 ± 0.10 ID%/g at 5 min vs. 1.17 ± 0.15 ID%/g at 90 min) and stable bone uptake indicating no defluorination,Results,"The bone uptake was stable during the 90-min uptake period (1.91 ± 0.52 ID%/g at 5 min post-injection vs. 1.78 ± 0.24 ID%/g at 90 min), indicating the tracer was metabolically stable towards defluorination.",0.93
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,PerkinElmer G4 microPET scanner,computational_tool,Other,"Successfully performed 60-min static scans and dynamic PET imaging in wild-type and NF1 tumor mice, enabling quantitative SUV measurements",Results,"First, we performed 60-min static scans in wild-type mice and NF1 tumor mice with L-[18F]FETrp and compared the imaging results with the most widely used PET radiotracer, FDG.",0.85
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,"indoleamine 2,3-dioxygenase rabbit monoclonal (1:100, Abcam, Cambridge, UK)",antibody,Biomarker,"High IDO expression detected in NF1 tumors, low expression in brain and muscle, correlating with L-[18F]FETrp uptake patterns",Results,"The IHC results showed that the NF1 tumors had high IDO, TDO2, and AHR expressions, which is associated with a high tumor uptake of L-[18F]FETrp in PET imaging. However, both brain and muscle showed low IDO and TDO2 expressions",0.9
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,"antibody-TDO2, rabbit/IgG polyclonal (1:100, Proteintech, Rosemont, IL, USA)",antibody,Biomarker,"High TDO2 expression in NF1 tumors, low expression in brain and muscle, associated with high tumor uptake of L-[18F]FETrp",Results,"The IHC results showed that the NF1 tumors had high IDO, TDO2, and AHR expressions, which is associated with a high tumor uptake of L-[18F]FETrp in PET imaging. However, both brain and muscle showed low IDO and TDO2 expressions",0.9
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,"AHR antibody mouse monoclonal (1:50, Santa Cruz, Dallas, TX, USA)",antibody,Biomarker,"High AHR expression in NF1 tumors and muscle, associated with tumor uptake patterns of L-[18F]FETrp",Results,"The IHC results showed that the NF1 tumors had high IDO, TDO2, and AHR expressions, which is associated with a high tumor uptake of L-[18F]FETrp in PET imaging... while the AHR expression in the muscle was high.",0.88
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,Ben-Men-1 cells,cell_line,Biomarker,PDLIM2 was found overexpressed in Ben Men-1 cells compared to normal HMC by Western blot analysis,Results,we validated PDLIM2 overexpression in Ben Men-1 cells and in six tumour-derived primary cells compared to normal HMC,0.9
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,Ben-Men-1 cells,cell_line,Biomarker,Phosphorylated PDLIM2 was statistically significantly enriched in Ben Men-1 cells (p < 0.012) compared to HMC,Results,"Phosphorylated PDLIM2 was statistically significantly enriched in Ben Men-1 cells (**,  p  < 0.012) compared to HMC",0.95
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,Ben-Men-1 cells,cell_line,Efficacy,PDLIM2 shRNA-mediated knockdown led to statistically significant reduced proliferation (p < 0.05) as measured by ki-67 proliferation assay,Results,we observed a reduction of protein expression after silencing leading to a significant decrease in cellular proliferation as measured by a ki-67 proliferation assay,0.9
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,Human meningeal cells (HMC),cell_line,Biomarker,"PDLIM2 was not expressed in HMC, serving as normal control for comparison with tumor cells",Discussion,PDLIM2 was not expressed in HMC or normal meningeal tissue and minimally expressed in the Schwann cell examined,0.9
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,PDLIM2 antibody (Cell Signaling Technology),antibody,Biomarker,Successfully detected PDLIM2 overexpression in schwannomas (4 out of 6 samples) and meningiomas compared to normal controls by Western blot,Results,The protein was found overexpressed in four out of the six schwannomas compared to the normal Schwann cell examined,0.9
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,PDLIM2 antibody (Cell Signaling Technology),antibody,Mechanistic,Detected PDLIM2 localization both in cytoplasm and nucleus of tumor cells by immunofluorescent staining,Results,We also performed immunofluorescent staining to further determine PDLIM2 localization and identified it both in the cytoplasm and the nucleus,0.9
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,λ-phosphatase (New England Biolabs),genetic_reagent,Mechanistic,"Lambda phosphatase treatment induced a shift in PDLIM2 immunoreactive band, confirming phosphorylation status of PDLIM2",Results,Lambda phosphatase treatment (λ-Ph) induced indeed a shift in PDLIM2 immunoreactive band compared to non-treated (NT) control,0.95
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,cytoplasmic and nuclear extraction assay (Thermo Scientific),genetic_reagent,Mechanistic,PDLIM2 was found to localize largely into the nucleus by subcellular fractionation,Results,PDLIM2 was found to localize largely into the nucleus suggesting a possible function as E3 ubiquitin ligase,0.9
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,pLKO.1-puro plasmid,genetic_reagent,Efficacy,PDLIM2 shRNA knockdown led to highly statistically significant reduced proliferation (p < 0.001) in schwannoma cells as measured by ki-67 staining,Results,"this led to a significant reduction in ki-67 positive cells ( p  < 0.001), reflecting a substantial reduction in proliferation",0.95
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,Orbitrap Velos Pro mass spectrometer,computational_tool,Biomarker,Successfully identified over 1559 proteins and over 2455 phospho-proteins in primary schwannoma vs Schwann cells comparison,Results,Over 1559 proteins and over 2455 phospho-proteins were identified in primary schwannoma  vs.  Schwann cells,0.9
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,MaxQuant version 1.3.05,computational_tool,Biomarker,Successfully processed mass spectrometry data to identify differentially expressed proteins with Log2 FC > 1 for upregulated and < -1 for downregulated proteins,Results,"Only 16 proteins in the proteome dataset were found to be significantly upregulated with a Log 2 FC > 1, while 93 proteins were downregulated",0.9
PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,SYNAPSE,computational_tool,Other,Recommended as collaborative data platform to harmonize datasets and annotation standards for NF1 AI research,Discussion,"Collaborative data platforms (e.g., SYNAPSE, CTF Data Portal) should be leveraged to harmonize datasets and annotation standards.",0.8
PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,CTF data portal,computational_tool,Other,Recommended as collaborative data platform to harmonize datasets and annotation standards for NF1 AI research,Discussion,"Collaborative data platforms (e.g., SYNAPSE, CTF Data Portal) should be leveraged to harmonize datasets and annotation standards.",0.8
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,Nf1Prx1-/-,animal_model,Biomarker,Quadriceps muscle showed significantly different AF spectra means (p < 0.05 between ~450 and 720 nm) and DR spectra with more pronounced absorption feature between 500-600 nm compared to controls,Results,Normalized AF spectra from B6 and NF1 quadricep muscles showed significantly different means (p < 0.05 between ~450 and 720 nm). NF1 DR spectra showed a more pronounced absorption feature between 500 and 600 nm,0.95
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,Nf1Prx1-/-,animal_model,Efficacy,Strong quadriceps separability from controls demonstrated by QDC classifier AUCs of 0.99 for AF and 0.97 for DR spectroscopy,Results,"Both AF and DR demonstrated strong quadriceps separability as indicated by distinct PC score clustering and QDC classifier AUC's of 0.99 and 0.97, respectively",0.95
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,Nf1Prx1-/-,animal_model,Biomarker,Quadriceps muscle histology showed endomysial fibrosis and intramyocellular lipid accumulation by H&E and Oil Red O staining,Results,"NF1 muscle histology showed endomysial fibrosis and intramyocellular lipid by H&E and Oil Red O staining, respectively, consistent with prior findings",0.9
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,Nf1Prx1-/-,animal_model,Biomarker,"Cardiac muscle showed no spectral differences from controls (p > 0.05) with poor QDC classification performance (ROC-AUCs of 0.67 AF, 0.63 DR)",Results,B6 and NF1 cardiac muscle showed similar spectral shapes and the same mean normalized intensity across almost all wavelengths for both AF and DR (p > 0.05). This similarity resulted in overlapping PC score clusters and poor QDC classification performance with ROC-AUCs of 0.67 and 0.63,0.95
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,mdx,animal_model,Efficacy,"Strong AF separability from controls at 3 weeks (AUC = 0.98) and 10 weeks (AUC = 0.87), with modest DR separability (AUC = 0.73 at 3 weeks, 0.77 at 10 weeks)",Results,"B10WT and B10 mdx mice were compared at 3 weeks, with strong AF separability, AUC = 0.98 and with more modest DR separability, AUC = 0.73. Finally, B10WT and B10 mdx mice were compared at 10 weeks, with similar results to that of 3 weeks, with stronger separability using AF, AUC = 0.87 and modest separability using DR, AUC = 0.77",0.95
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,mdx,animal_model,Biomarker,"10-week-old quadriceps muscle showed centralized nuclei and degenerating/regenerating muscle fibers by H&E staining, while 3-week-old muscle showed no pathological features",Results,Histology of B10 mdx mouse quadricep muscle found features of dystrophy consistent with the literature. This included centralized nuclei and degenerating/regenerating muscle fibers as seen using H&E histological staining. 3-week-old B10 mdx mouse muscle showed no pathological features,0.9
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,B10 mdx,animal_model,Efficacy,Strong temporal separability between 3 and 10 weeks using AF spectroscopy (AUC = 0.96) and modest separability using DR (AUC = 0.77),Results,"B10 mdx at 3 and 10 weeks showed differences in AF spectral features resulting in strong classifier performance, AUC = 0.96, whereas DR spectra were only modestly separable, AUC = 0.77",0.95
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,C57BL/6 mice,animal_model,Biomarker,"Cardiac muscle was well separable from all skeletal muscles in both AF and DR analyses (AUC = 1 for both), while skeletal muscles were less separable with AUCs ranging between 0.79 and 0.99",Results,"The cardiac muscle was well separable from all skeletal muscles in both AF and DR analyses (AUC = 1 for AF and DR, respectively), whereas skeletal muscles (Quad, Gastr, and TA) were less separable with AUCs ranging between 0.79 and 0.99",0.95
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,MATLAB,computational_tool,Other,Used for statistical analysis and PCA-based spectral analysis with QDC classification achieving AUCs ranging from 0.58 to 0.99 across different muscle comparisons,Results,"Statistical analysis of normalized spectra was applied to generate 95% confidence intervals. To enhance muscle group separability and resulting classification accuracy, spectra were dimensionally reduced using PCA",0.85
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,Nf1 (-/-) embryos,animal_model,Mechanistic,80% of Nf1 (-/-) fibroblast cell strains showed increased growth over wild-type cultures in 5-day growth assays,Results,This result has been replicated in 5-day growth assays of fibroblasts from over 100 Nf1 mouse embryos: 80% of Nf1 (−/−) cell strains showed increased growth over wild-type cultures.,0.95
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,Nf1 (-/-) embryos,animal_model,Mechanistic,Fibroblasts from Nf1 (-/-) embryos contained no detectable neurofibromin by Western blot analysis,Results,"Western blot analysis confirmed that fibroblasts from Nf1 (−/−) embryos contained no detectable neurofibromin, while heterozygous cells showed a reduction as compared to wild-type cells",0.95
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,Nf1 (-/-) embryos,animal_model,Mechanistic,Nf1 (-/-) cultures showed 1% as many perineurium-surrounded fascicles as wild-type sections at 30 days in vitro,Results,"At 30 days in vitro, Nf1 (−/−) cultures showed 1% as many as those from wild-type sections.",0.95
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,Nf1 (-/-) embryos,animal_model,Mechanistic,Cultures containing Nf1 (-/-) fibroblasts showed 17.7% and 23.8% as many fascicles as wild-type after 37 days in vitro,Results,Cultures containing fibroblasts without neurofibromin showed 17.7% and 23.8% as many fascicles as those with wild-type fascicles.,0.95
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,Nf1 (+/-) mice,animal_model,Mechanistic,Nf1 (+/-) fibroblasts contained 60% as many fascicles as wild-type cultures at 30 days in vitro,Results,Cultures with Nf1 (+/−) fibroblasts contained 60% as many fascicles as wild-type cultures.,0.95
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,Nf1 (+/-) mice,animal_model,Mechanistic,Heterozygous cells showed reduced neurofibromin levels compared to wild-type cells by Western blot analysis,Results,"Western blot analysis confirmed that fibroblasts from Nf1 (−/−) embryos contained no detectable neurofibromin, while heterozygous cells showed a reduction as compared to wild-type cells",0.9
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,2.5S NGF (Harlan Bio-products),genetic_reagent,Mechanistic,Lack of neurofibromin did not appear to cause changes in neuronal differentiation in response to nerve growth factor under culture conditions,Results,Lack of neurofibromin did not by itself appear to cause changes in neuron-Schwann cell adhesion or in neuronal differentiation in response to nerve growth factor under these culture conditions,0.85
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,JOEL-10 CX electron microscope,computational_tool,Other,Enabled identification of perineurial cells with caveolae and basal lamina characteristics in both Nf1 (-/-) and wild-type fibroblast cultures,Results,"Cells with these characteristics were identified in cultures containing both Nf1 (−/−) and wild-type fibroblasts, suggesting that even fibroblasts without neurofibromin are capable of responding to cues",0.8
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,Nf1flox/flox;PostnCre mice,animal_model,Efficacy,"After 12 weeks of daily cabozantinib treatment, the number of PN per mouse was reduced by approximately 60% with normalization of nerve microarchitecture",Results,"after 12 weeks of daily cabozantinib treatment, the number of PN per mouse was reduced by approximately 60% with normalization of nerve microarchitecture",0.95
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,Nf1flox/flox;PostnCre mice,animal_model,Efficacy,Cabozantinib treatment reduced the mean volume of the proximal peripheral nerve roots by 38%,Results,Cabozantinib treatment also reduced the mean volume of the proximal peripheral nerve roots by 38%,0.95
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,Nf1flox/flox;PostnCre mice,animal_model,Biomarker,Mast cell infiltration was not significantly changed despite cabozantinib treatment,Results,"despite the well-recognized modulation of c-kit by cabozantinib and the known role of c-kit in mast cell chemotaxis for PN, mast cell infiltration was not significantly changed",0.9
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,CD31 antibody (ab28364),antibody,Mechanistic,CD31 immunohistochemistry revealed a significant reduction in neoangiogenesis in cabozantinib-treated tumors versus vehicle control,Results,"we also examined blood vessels using CD31 immunohistochemistry, revealing a significant reduction in neoangiogenesis in cabozantinib-treated tumors versus vehicle control",0.9
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,AXL antibody (ab227871),antibody,Biomarker,"AXL was found to be increased in PN tissue as compared to normal nerve, as assessed by western blot",Results,"AXL was found to be increased in PN tissue as compared to normal nerve, as assessed by MIBs, western blot and immunohistochemistry",0.9
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,AXL antibody (ab227871),antibody,Mechanistic,There was a significant decline in AXL in cabozantinib treated tissues,Results,"Further, there was a significant decline in AXL in cabozantinib treated tissues",0.9
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",antibody,Biomarker,sAXL is significantly elevated in the plasma of cabozantinib treated mice as compared to the WT mice or Nf1flox/flox;PostnCre mice treated with the vehicle control,Results,we found that sAXL is significantly elevated in the plasma of cabozantinib treated mice as compared to the WT mice or Nf1flox/flox;PostnCre mice treated with the vehicle control,0.9
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,NRS-11,clinical_assessment_tool,Behavioral,"At baseline, 84% of participants reported tumor pain on the NRS-11 with total sample mean=5.0; SD=3.1; range 0–10, with 75% reporting moderate to severe pain (rating of ≥4)",Results,"At baseline, 84% of participants reported tumor pain on the NRS-11 (total sample mean=5.0; SD=3.1; range 0–10) with 75% reporting moderate to severe pain (rating of ≥4)",0.95
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,NRS-11,clinical_assessment_tool,Behavioral,"PRO assessments of pain improved from study entry in the 8 patients who achieved a PR, with a significant reduction in reported tumor pain occurring as early as cycle 4 (LSM estimate=2.7; t=4.42, p=0.0001) that persisted to cycle 12",Results,"PRO assessments of pain improved from study entry in the 8 patients who achieved a PR, with a significant reduction in reported tumor pain occurring as early as cycle 4 (LSM estimate=2.7; t=4.42, p=0.0001) that persisted to cycle 12",0.95
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,NRS-11,clinical_assessment_tool,Behavioral,"The mean decrease in worst tumor pain intensity in the responder group was 3 points from baseline to cycle 12, consistent with clinically meaningful change",Results,"the mean decrease in worst tumor pain intensity in the responder group with no attrition was 3 points from baseline to cycle 12, consistent with clinically meaningful change",0.95
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,BPI-PI Scale,clinical_assessment_tool,Behavioral,"Only the responder group exhibited significant reduction in pain interference at each evaluation timepoint from baseline to cycle 12, as assessed by the mean total BPI-PI scores (LSM estimate=1.48; t=2.74, p=0.0099)",Results,"only the responder group exhibited significant reduction in pain interference at each evaluation timepoint from baseline to cycle 12, as assessed by the mean total BPI-PI scores (LSM estimate=1.48; t=2.74, p=0.0099)",0.95
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,PedsQL NF1 Module,clinical_assessment_tool,Behavioral,"There was no significant change (p<0.01) over time in the PedsQL NF1 Total Functioning mean score at any evaluation from baseline to cycle 12 for the total sample (LSM estimate=−2.83; t=−0.85, p=0.40) or for responders versus non-responders",Results,"There was no significant change (p<0.01) over time in the PedsQL NF1 Total Functioning mean score at any evaluation from baseline to cycle 12 for the total sample (LSM estimate=−2.83; t=−0.85, p=0.40) or for responders versus non-responders",0.9
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,PedsQL NF1 Module,clinical_assessment_tool,Behavioral,"None of the domain scores changed significantly from baseline to cycle 12 except for an improvement in the general pain and hurt scale (LSM estimate= −14.98; t=−3.12, p=0.0036)",Results,"none of the domain scores changed significantly from baseline to cycle 12 except for an improvement in the general pain and hurt scale (LSM estimate= −14.98; t=−3.12, p=0.0036)",0.9
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",antibody,Biomarker,A possible but not statistically significant association was seen between an increase in sAXL and clinical response in eight participants (p=0.08),Results,A possible but not statistically significant association was seen between an increase in sAXL and clinical response in eight participants (p=0.08,0.8
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,NG2-EYFP mice,animal_model,Biomarker,"Merlin was highly concentrated in nuclei (DRAQ5-positive) of immature oligodendrocytes, which can be labeled for NG2-EYFP mice using GFP antibodies",Results,"Merlin was highly concentrated in nuclei (DRAQ5-positive) of immature oligodendrocytes, which can be labeled for NG2-EYFP mice using GFP antibodies",0.9
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,"anti-Merlin (rabbit polyclonal antibody, A-19 sc-331)",antibody,Biomarker,"Demonstrated intense immunostaining throughout gray and white matter regions of the brain, with specificity confirmed by blocking peptide and overexpression studies",Results,"Using NF2-specific antibodies, we found intense immunostaining throughout gray and white matter regions of the brain...we could also show an increase in the specific signal when overexpressing Nf2",0.9
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,"anti-Merlin (rabbit polyclonal antibody, C-18 sc-332)",antibody,Biomarker,Successfully used with comparable results to A-19 antibody for detecting Merlin expression in forebrain and cerebellar tissue,Discussion,"In this and previous studies, we successfully used NF2 (A19) and NF2 (C18) antibodies from Santa Cruz with comparable results",0.8
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,"anti-Olig2 (mouse monoclonal antibody, 1:500; Millipore AB9610)",antibody,Biomarker,Successfully co-localized with Merlin signal around Olig2-positive cell nuclei in cerebellar white matter of P9 mice,Results,We also found an evident signal for Merlin allocated around Olig2-positive cell nuclei in the cerebellar white matter of P9 mice,0.9
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,"anti-MBP (mouse monoclonal antibody, 1:500; Chemikon MAB384)",antibody,Biomarker,Successfully co-localized with NF2 in MBP-positive fibers in the inner granule cell layer of adult mouse cerebellum,Results,we detected NF2 co-localized with MBP-positive fibers in the inner granule cell layer of the cerebellum of adult mice,0.9
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,OLN93 mouse oligodendrocyte cell line,cell_line,Efficacy,NF2 overexpression reduced cell proliferation by approximately 20% in XCELLigence measurements and significantly decreased process formation (66% of cells showed no projections vs 36% in controls),Results,"Reduction in cell indices over time amounted to about 20% in rat oligodendrocytes (OLN93)...While only 36% of the control-transfected OLN93 cells showed no process, 66% of Merlin overexpressing cells had no projections",0.95
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,SC4-immortalized Nf2-/- primary Schwann cells,cell_line,Biomarker,"70 kDa Merlin band was absent, instead showing a smaller and weaker band corresponding to exon composition missing exons 2 and 3",Results,"However, the 70 kDa band of Merlin was absent in SC4 cells in which Merlin is more prominently degraded due to a deletion of exon 2 and 3",0.9
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,RT4-D6PT2 schwannoma cell line,cell_line,Efficacy,NF2 overexpression reduced cell proliferation by approximately 15% and significantly decreased process formation (53% of cells showed no projections vs 26% in controls),Results,"to 15% in schwannoma cells (RT4)...Only 26% of control RT4 cells showed no projections, but 53% of Merlin overexpressing RT4 cells failed to build processes",0.95
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,TC620 human oligodendroglioma cell line,cell_line,Efficacy,NF2 overexpression reduced cell proliferation by approximately 30% and significantly shortened process length (26.47 ± 0.81 μm vs 41.00 ± 1.18 μm in controls),Results,to 30% in human oligodendroglioma cells (TC620)...the length of these projections was significantly shorter in Merlin overexpressing (26.47 ± 0.81 μm; n > 400) as compared to the control-transfected TC620 cells (41.00 ± 1.18 μm; n > 1500; p < 0.001),0.95
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,pcNf2hflag,genetic_reagent,Efficacy,"Stable transfection resulted in prominent increase in Merlin expression and significant reduction in cell proliferation, process formation, and migration across multiple oligodendrocyte cell lines",Results,"Nf2-flag transfected oligodendroglial cells showed a prominent increase in Merlin expression, compared to cells transfected with the vector plasmid DNA pcDNA3.1",0.9
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,XCELLigence Real Time Cell Analysis System,computational_tool,Mechanistic,"Successfully measured impedance changes over 100 hours, detecting 15-30% reduction in cell index slopes in NF2-overexpressing cells across three cell lines",Results,"All three cell types showed a significant reduction in the slope of the cell indices after NF2 overexpression. Reduction in cell indices over time amounted to about 20% in rat oligodendrocytes (OLN93), to 30% in human oligodendroglioma cells (TC620) and to 15% in schwannoma cells (RT4)",0.95
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,"anti Ki67 (15580, 1:500, Abcam)",antibody,Biomarker,"Successfully detected proliferating cells, showing highly significant decrease in Ki67/Hoechst ratio for all NF2-overexpressing cell lines between 48 and 96 hours",Results,Evaluating the number of Ki67 stained pixels vs. the number of Hoechst stained pixels revealed a highly significant decrease in the Ki67/Hoechst ratio for all cell lines between 48 and 96 hours,0.9
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,"anti-phospho S518-Merlin 1:1000, Abcam",antibody,Biomarker,"Successfully detected phosphorylated Merlin, with OLN93 transfected cells exhibiting the highest level of phosphorylation despite not having the highest total Merlin protein amount",Results,OLN93 transfected cells exhibited the highest level of phosphorylation; although they did not exhibit the highest amount of the Merlin protein when compared to the other cell lines,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST 88-14 cells,cell_line,Mechanistic,NF1-GRD expression significantly reduces Ras-GTP and downstream P-MEK and P-ERK at 32h,Results,At 32h GRD expression significantly reduces Ras-GTP and downstream P-MEK and P-ERK,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST S462-TY cells,cell_line,Efficacy,MAF transduction for 48 hours significantly decreased metabolic activity as measured by MTS assay,Results,S462-TY cells transduced with MAF for 48 hours significantly decreased metabolic activity as measured by MTS assay,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST S462-TY cells,cell_line,Efficacy,MAF transduction for 48 hours revealed increased apoptotic cell death by flow cytometric analysis,Results,Flow cytometric analysis of PI and Annexin stained S462-TY cells transduced with MAF for 48 hours revealed increased apoptotic cell death,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST S462-TY cells,cell_line,Efficacy,MAF overexpression decreased anchorage independent growth in soft agar,Results,decreased anchorage independent growth in soft agar in S462-TY cells overexpressing MAF constitutively or inducibly,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MPNST S462-TY cells,cell_line,Efficacy,Combination of 10 or 30 nM RAD001 with MAF overexpression resulted in enhanced response compared to RAD001 alone,Results,the combination of treatment with 10 or 30 nM RAD001 in addition to MAF overexpression resulted in an enhanced response,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,athymic nude (nu/nu) mice,animal_model,Efficacy,Tumors overexpressing MAF were larger than vector control tumors in xenograft model,Results,Tumors overexpressing MAF were larger than vector control tumors,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,athymic nude (nu/nu) mice,animal_model,Efficacy,"S462TY cells not significantly responsive to 10mg/kg RAD001 alone, but significant decrease in tumor volume when combined with MAF overexpression",Results,"S462TY cells are also not significantly responsive to treatment with 10mg/kg RAD001, but a significant decrease in tumor volume compared to the vector control tumors was seen in combination with MAF overexpression",0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,pS6 antibody (Cell Signaling),antibody,Biomarker,Increased phosphorylation of S6 observed in S462-TY cells transduced with inducible MAF,Results,Western blot analysis of S462-TY cells transduced with inducible MAF showed increased phosphorylation of S6,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,DEPTOR antibody (Novus),antibody,Biomarker,DEPTOR decreased in MAF expressing tumors by IHC analysis,Results,P-S6 increased and DEPTOR decreased in MAF expressing tumors,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,SOX9 antibody (Santa Cruz),antibody,Biomarker,Decreased SOX9 mRNA and protein when MAF was overexpressed in MPNST cells,Results,RT-PCR and western bot analysis revealed decreased SOX9 mRNA and SOX9 protein when MAF was overexpressed,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,S100β antibody (Dako),antibody,Biomarker,Increased S100β expression verified by immunohistochemical staining in MAF transduced MPNST cells,Results,Immunohistochemical staining verified increased expression of these proteins in MAF transduced MPNST cells,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,MBP antibody (Chemicon),antibody,Biomarker,Increased MBP expression verified by immunohistochemical staining in MAF transduced MPNST cells,Results,Immunohistochemical staining verified increased expression of these proteins in MAF transduced MPNST cells,0.9
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,BLBP antibody (Millipore),antibody,Biomarker,Increased BLBP expression verified by immunohistochemical staining in MAF transduced MPNST cells,Results,Immunohistochemical staining verified increased expression of these proteins in MAF transduced MPNST cells,0.9
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,S100,antibody,Biomarker,Strong and diffuse S100 staining observed in dermal plexiform schwannoma tissue from NF2 patient,Discussion,Histological and immunohistochemical analyses showed a dermal plexiform schwannoma with swill spindle cell changes and a strong and diffuse S100 staining.,0.85
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,CD34,antibody,Biomarker,"Strong and diffuse CD34 positivity observed in cutaneous neurofibroma tissue, supporting neurofibroma diagnosis",Discussion,"The histopathology results showed wavy spindle cell changes, and immunohistochemical analysis mainly presented strong and diffuse CD34 positivity, which supported the neurofibroma changes.",0.85
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,Illumina HiSeq X Ten System,computational_tool,Other,Successfully identified NF1 and NF2 variants in all 5 probands when combined with multigene panel testing approach,Discussion,"Fortunately, all of them were diagnosed clearly using multigene panel testing combined with Sanger sequencing.",0.8
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,ABI PRISM 3730XL analyzer,computational_tool,Other,Confirmed frameshift variant c.495_498del:p.Thr165fs in cutaneous neurofibroma tissue by Sanger sequencing,Results,This result was confirmed in the cutaneous neurofibroma tissue of the proband by Sanger sequencing.,0.8
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,NOD/SCID mice,animal_model,Efficacy,MLN8237 treatment (30 mg/kg/day) resulted in stabilized disease for both sporadic and NF1-MPNST tumor explants versus linear expansion in vehicle controls (SP-MPNST p<0.0001; NF1-MPNST p=0.0011),Results,"Treatment of animals with MLN8237 resulted in stabilized disease for tumour explants from both patients, as opposed to the linear expansion of tumour volumes in the vehicle treated cohorts (SP-MPNST, p <0.0001; NF1-MPNST, p= 0.0011)",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,NOD/SCID mice,animal_model,Efficacy,MLN8237 treatment resulted in significantly lower tumor masses in both NF1-MPNST and SP-MPNST explants (p<0.01) compared to vehicle treated tumors,Results,treatment with MLN8237 resulted in tumour masses that were significantly lower in both the NF1-MPNST and SP-MPNST explants (p<0.01) compared to those of vehicle treated tumours,0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,S462 cell line,cell_line,Biomarker,"MLN8237 IC-50 was significantly lower than 2884 cells (p=0.02), showing higher sensitivity despite equivalent AURKA expression",Results,"Despite equivalent growth rates and AURKA abundance in 2884 and S462 cells, however, the cellular responses to MLN8237 were significantly different (p=0.02) with S462 being the more sensitive",0.92
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,S462 cell line,cell_line,Biomarker,2.2-9.2 fold more sensitive to pan-Aurora inhibitors VX680 (IC-50: 42±10 nM) and C1368 (IC-50: 1302±264 nM) compared to 2884 cells,Results,"S462 cells were also 2.2 – 9.2 fold more sensitive to the pan-Aurora inhibitors VX680 (IC-50- 2884, 387 ±47 nM; S462, 42 ±10 nM) and C1368 (IC-50- 2884, 2925 ±135 nM; S462, 1302 ±264 nM)",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,S462 cell line,cell_line,Mechanistic,"5.6±1.2% of S462 cells (168±25 of 3,000 seeded) capable of forming spheroids under stem cell conditions, with secondary passage forming significantly more spheres",Results,"While no spheroids were identified in 2884 cultures, 5.6 ± 1.2% of S462 cells (168 ±25 of 3,000 seeded) are capable of forming spheroids. Secondary passage formed significantly more spheres",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,2884 cell line,cell_line,Biomarker,"VX680 IC-50: 387±47 nM; C1368 IC-50: 2925±135 nM, showing lower sensitivity compared to S462 cells",Results,"S462 cells were also 2.2 – 9.2 fold more sensitive to the pan-Aurora inhibitors VX680 (IC-50- 2884, 387 ±47 nM; S462, 42 ±10 nM) and C1368 (IC-50- 2884, 2925 ±135 nM; S462, 1302 ±264 nM)",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,2884 cell line,cell_line,Mechanistic,"No spheroids identified in 2884 cultures under stem cell conditions, unlike S462 cells",Results,"While no spheroids were identified in 2884 cultures, 5.6 ± 1.2% of S462 cells (168 ±25 of 3,000 seeded) are capable of forming spheroids",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,2885 cell line,cell_line,Biomarker,"Required 400-725 fold higher MLN8237 concentrations to inhibit 50% of cellular growth (IC-50), consistent with negligible AURKA expression",Results,"The 2885 cell-line resisted MLN8237 treatment and required 400-725 fold higher concentrations to inhibit 50% of cellular growth (IC-50), which is consistent with the negligible expression of AURKA in this cell-line",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,MLN8237,genetic_reagent,Efficacy,"MLN8237 treatment at IC-50 concentrations significantly inhibited sphere formation (166 to 29 spheres, p<0.05) and reduced self-renewal capacity in S462 cells",Results,"By Day 6 (passage 0), sphere formation was significantly inhibited in cells treated with MLN8237 in comparison to the vehicle alone treated cells (166 to 29 spheres in the DMSO and MLN8237 treated cells, respectively. p<0.05)",0.95
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,MLN8237,genetic_reagent,Mechanistic,"MLN8237 treatment resulted in loss of nestin staining, strong Tuj1 expression, and neuronal morphological changes with neurite-like extensions in sphere-enriched cells",Results,"MLN8237 treatment, in relation to vehicle alone, modified the cellular fate of sphere cells and resulted in the loss of nestin staining, strong expression of the neuronal marker Tuj1, and morphological changes consistent with neurons, such as neurite-like extensions",0.92
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,shRNA against RHAMM,genetic_reagent,Biomarker,Stable RHAMM silencing (65% protein reduction) significantly reduced IC-50 for MLN8237 and VX680 by 2-fold in 2884 cells,Results,achieved stable reduction of approximately 65% of RHAMM protein after drug selection. The IC-50 for MLN8237 and VX680 were significantly reduced in sub-lines in which HMMR/RHAMM was silenced,0.92
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,shRNA against RHAMM,genetic_reagent,Mechanistic,RHAMM silencing endowed 2884 cells with capacity to both propagate and self-renew as sphere-forming cells,Results,"However, the stable silencing of HMMR/ RHAMM endowed 2884 cells with the capacity to both propagate and self-renew as sphere-forming cells",0.92
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,shRNA against TPX2,genetic_reagent,Biomarker,TPX2 silencing (40% protein reduction) did not alter IC-50 for MLN8237 or VX680 in S462 cells,Results,"reduced TPX2 protein abundance by approximately 40%. However, the reduced expression of TPX2 did not alter the IC-50 for MLN8237 or VX680",0.92
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,shRNA against TPX2,genetic_reagent,Mechanistic,TPX2 knockdown significantly reduced sphere self-renewal capacity in passage 1 but not passage 0 formation in S462 cells,Results,"Stable silencing of TPX2 did not significantly alter the propagation of sphere-forming S462 cells in the first passage, but may have impacted their self-renewal capacity, as indicated by a significant reduction in the number of spheres formed during the second passage",0.88
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,S462 spheres,advanced_cellular_model,Biomarker,Sphere-enriched S462 cells contained higher levels of auto-activated pAURKA (Thr288) indicating increased AURKA activity versus adherent cells,Results,"In comparison to adherent S462 cell lysates, sphere-enriched S462 lysates (sphere) contain higher levels of auto-activated pAURKA (Thr288) indicating increased AURKA activity in sphere versus adherent S462 cells",0.92
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,Lats1/2-mut mice,animal_model,Efficacy,"Developed MPNST-like tumors at distinct anatomical locations in dermal, paraspinal, and sciatic nerves",Results,"The genetically engineered mouse models develop MPNST-like tumors (referred as mMPNST) at distinct anatomical locations in dermal, paraspinal, and sciatic nerves",0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,NPE-mutant mice,animal_model,Safety,Life span of approximately 4 months,Results,"Similar to the mMPNST (Lats1/2-def) model, NPE-mut had a life span of approximately 4 months",0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,NPE-mutant mice,animal_model,Efficacy,SC lineage cells enriched with MES-SCP/NC–like cells were highly tumorigenic when engrafted in immunocompromised mice and able to propagate tumors resembling aggressive MPNST when serially transplanted,Results,SC lineage cells enriched with MES-SCP/NC–like cells isolated from NPE-mut sciatic nerve tumors were highly tumorigenic when engrafted in immunocompromised mice. They were able to propagate tumors that resembled aggressive MPNST when serially transplanted,0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,"ZEB1 siRNA (Sigma-Aldrich, SASI_Hs02_00330526)",genetic_reagent,Efficacy,Silencing ZEB1 expression significantly inhibited tumor cell proliferation and induced apoptosis in human MPNST cell lines,Results,we performed small interfering RNA (siRNA)–mediated knockdown in different human MPNST cell lines and found that silencing the expression of ZEB1 significantly inhibited tumor cell proliferation and induced apoptosis,0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,"ZEB1 siRNA (Sigma-Aldrich, SASI_Hs02_00330526)",genetic_reagent,Mechanistic,"ZEB1 knockdown did not affect proliferation rate of immortalized SCs or benign NF cells, showing specificity to MPNST cells",Results,ZEB1 knockdown in both immortalized SCs (ipn02.3λ) and PNF cells (ipn95.11bC and ipn95.6) did not affect the proliferation rate of SCs or benign NF cells assessed by 5-bromo-2′-deoxyuridine (BrdU) incorporation assays,0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,ZEB1 shRNA lentivirus,genetic_reagent,Efficacy,Lentivirus shRNA-mediated knockdown of ZEB1 impeded tumor growth of MPNST cell line in xenograft assays compared to control shRNA,Results,"by in vivo xenograft assays, we showed that lentivirus short hairpin RNA (shRNA)–mediated knockdown of ZEB1 impeded the tumor growth of an MPNST cell line when compared with control shRNA",0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,"ALDH1A1 siRNA (Sigma-Aldrich, SASI_Hs01_00244055)",genetic_reagent,Efficacy,Knockdown of ALDH1A1 blocked MPNST tumor cell proliferation,Results,"Similarly, knockdown of an EMT/stemness regulator ALDH1A1 also blocked MPNST tumor cell proliferation",0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,T265,cell_line,Efficacy,Used in xenograft assays where ZEB1 shRNA knockdown impeded tumor growth compared to control,Results,lentivirus short hairpin RNA (shRNA)–mediated knockdown of ZEB1 impeded the tumor growth of an MPNST cell line when compared with control shRNA,0.8
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,Drop-seq tools (version 1.12),computational_tool,Mechanistic,Successfully performed single-cell transcriptome profiling to characterize cellular diversity along malignant transformation of nerve-associated tumors,Results,we performed single-cell transcriptome profiling [single-cell RNA sequencing (scRNA-seq)] using the Drop-seq platform,0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,Seurat (version 3.1.0),computational_tool,Mechanistic,"Used for species integration platform to visualize human MPNST cells co-embedded with advanced-stage mouse MPNST cells, showing cell types overwhelmingly mapped to corresponding mouse cell phenotypes despite species difference",Results,"Using the Seurat species integration platform, we visualized human MPNST cells co-embedded with advanced-stage mouse MPNST cells. Despite the species difference, cell types in human MPNST overwhelmingly mapped to the corresponding mouse cell phenotypes",0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,CIBERSORTx,computational_tool,Mechanistic,Successfully used to infer putative cellular identities of SC-derived tumor phenotypes using reference profiles of developing neural lineages and neural crest cell types from human embryos,Results,"To infer the putative cellular identities of SC-derived tumor phenotypes, we used reference profiles of the developing neural lineages and neural crest cell types from human embryos by CIBERSORTx",0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,VECTOR,computational_tool,Mechanistic,Identified advanced tumor-specific mesenchymal neural crest–like tumor cells as the stem cell–like starting cell population following a differentiation path toward more committed SC lineage populations,Results,"we identified advanced tumor-specific mesenchymal neural crest–like tumor cells as the stem cell–like starting cell population; these cells followed a differentiation path toward tumor neural crest–like cells, mesenchymal SCPs, and subsequently to more committed SC lineage populations",0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,Slingshot,computational_tool,Mechanistic,"Determined tumorigenesis trajectory initiated in mature SCs, proceeded through neoplastic SC subpopulation, reached bifurcation point with mesenchymal traits, and ended in MES-NC–like tumor subclusters",Results,"The tumorigenesis trajectory initiated in mature SCs, proceeded through a neoplastic SC subpopulation, reached a bifurcation point enriched with tumor-like SCPs with mesenchymal traits, and ended in the MES-NC–like tumor subclusters",0.9
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,CytoTRACE version 0.3.3,computational_tool,Mechanistic,"Predicted most differentiated cell cluster as myelinating SC cluster and most stem cell–like population as tumor cell cluster with neural crest/mesenchymal phenotype, consistent with dedifferentiation path",Results,"Consistent with a dedifferentiation path, the most differentiated cell cluster is the myelinating SC cluster, whereas the most stem cell–like population is the tumor cell cluster with neural crest/mesenchymal phenotype",0.9
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,PLPCre-ERT2 transgenic mice,animal_model,Mechanistic,"Efficiently induced recombination in neonate sciatic nerves, dorsal root ganglia (DRG) and trigeminal ganglia when tamoxifen administered to lactating mothers for first five days after birth",Results,"Oral tamoxifen administration to mothers for the first five days after birth, efficiently induced recombination in neonate sciatic nerves, dorsal root ganglia (DRG) and trigeminal ganglia as assessed by X-gal staining",0.9
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,PLPCre-ERT2 transgenic mice,animal_model,Mechanistic,"Tamoxifen administration to adult (2-3 months old) mice induced recombination in sciatic nerves, DRG, and trigeminal ganglia",Results,"tamoxifen administration to adult (2- to 3-months old) mice induced recombination in sciatic nerves, DRG, and trigeminal ganglia thus demonstrating the power and specificity of the temporally- and spatially-inducible PLPCre-ERT2 transgene",0.9
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,NF1 flox/− mice,animal_model,Efficacy,100% of E12.5 tamoxifen-induced PLPCre-ERT2;NF1 flox/− mice developed plexiform neurofibromas at 5-6 months of age,Results,"The E12.5 PLPCre-ERT2;NF1 flox/− ;R26R progeny showed classic signs of illness beginning at 5 to 6-months of age and were necropsied along with control littermates. In all cases, the mice exhibited tumors along the cervical and thoracic DRG",0.95
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,NF1 flox/− mice,animal_model,Efficacy,100% of P0 tamoxifen-induced PLPCre-ERT2;NF1 flox/− mice developed plexiform neurofibromas at 5-6 months of age,Results,"the P0 tam;PLPCre-ERT2;NF1 flox/− mice began to show signs of lethargy, weight loss and paralysis at five to six-months of age requiring that they be sacrificed",0.95
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,NF1 flox/− mice,animal_model,Efficacy,Only 2 out of 19 (10.5%) adult tamoxifen-induced PLPCre-ERT2;NF1 flox/− mice developed plexiform neurofibromas in their second year of life,Results,"Two out of nineteen Atam;PLPCre-ERT2;NF1 flox/− ;R26R mice were sacrificed in their second year of life when they developed signs of sickness including lethargy, ruffled hair, weight loss, and limb paralysis",0.95
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,S100β antibody,antibody,Biomarker,All E12.5 PLPCre-ERT2;NF1 flox/− tumors exhibited Schwann cell marker (S100β) immunoreactivity,Results,Tumor sections were also evaluated immunohistochemically and all the E12.5 PLPCre-ERT2;NF1 flox/− ;R26R tumors exhibited Schwann cell marker (S100β) immunoreactivity,0.9
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,S100β antibody,antibody,Biomarker,P0 tamoxifen-induced neurofibromas expressed Schwann cell marker S100β,Results,"These neurofibromas exhibited the classic characteristics of human plexiform neurofibromas, being poorly circumscribed, composed primarily of spindle cells, and expressing the Schwann cell markers S100β and GAP43",0.9
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,GAP43 antibody,antibody,Biomarker,P0 tamoxifen-induced neurofibromas expressed Schwann cell marker GAP43,Results,"These neurofibromas exhibited the classic characteristics of human plexiform neurofibromas, being poorly circumscribed, composed primarily of spindle cells, and expressing the Schwann cell markers S100β and GAP43",0.9
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,ROSA26R,genetic_reagent,Mechanistic,Enabled verification of Cre-mediated recombination through X-gal staining in peripheral nerve plexuses at E12.5,Results,we verified the capability of PLPCre-ERT2 to ablate genes of interest in peripheral nerves by crossing into the Flox-stop-Flox ROSA26 (R26R) reporter background to generate PLPCre-ERT2;R26R mice,0.9
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,ipn97.4 immortalized human Schwann cells,cell_line,Mechanistic,NF1 knockout cells showed 1.5-fold lower NADH-linked OXPHOS and electron transfer capacity compared to wild-type cells,Results,NADH-linked OXPHOS and electron transfer capacity was ~ 1.5fold lower in NF1 -/- cells compared to NF1 +/+ (Fig. 5 C-E),0.95
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,ipn97.4 immortalized human Schwann cells,cell_line,Mechanistic,NF1 knockout cells displayed ~30% reduction in OXPHOS and electron transfer capacity with convergent substrate flow,Results,NF1 -/- cells displayed a ~ 30% reduction in OXPHOS and electron transfer capacity associated with convergent flow of NADH-linked substrates and succinate,0.95
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,ipn97.4 immortalized human Schwann cells,cell_line,Biomarker,"148 proteins significantly altered in NF1 knockout vs wild-type cells (68 increased, 76 decreased)",Results,We identified 148 proteins that were significantly altered in spectral count abundance in the WT and null ipn97.4 cells; 68 proteins are increased and 76 proteins are decreased,0.95
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,CRISPR Cas9,genetic_reagent,Efficacy,Successfully inactivated both NF1 alleles in ipn97.4 cells with no detected off-target effects by whole genome sequencing,Results,We used CRISPR Cas9 to inactivate both NF1 alleles in parental human immortalized human Schwann cell line ipn97.4 cells...To ensure no off-target CRISPR effects we utilized whole genome sequencing,0.9
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,mNf1 cDNA (GeneCopoeia NM_010897.2),genetic_reagent,Mechanistic,"Wild-type cDNA purified 104 unique protein interactions, with 98 showing no non-specific binding",Results,We purified 104 unique proteins in ipn97.4 NF1 -/- cells stably expressing the WT m Nf1 cDNA...We identified 98 protein interactions that have no non-specific binding,0.95
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,mNf1 cDNA (GeneCopoeia NM_010897.2),genetic_reagent,Mechanistic,Variant forms showed 31-67 proteins specific to wild-type compared to each of four variants tested,Results,"Of the 104 PPI's seen for the WT cDNA expressing ipn97.4 NF1 -/- cells, 31–67 proteins are seen to be specific to the WT compared to each of the four variants",0.9
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,StepTactin XT System,genetic_reagent,Efficacy,Successfully affinity purified NF1 protein-protein interactions using streptavidin tag system,Results,The streptavidin tag was used to affinity purify PPIs using StrepTactin beads. Non-specific binders were removed by identifying proteins that were affinity purified with beads,0.9
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,Thermo Q Exactive HFx mass spectrometer,computational_tool,Efficacy,"Identified 1,933 proteins in wild-type cells and 1,952 proteins in NF1 knockout cells",Results,"We observed a total of 1,933 proteins in the WT (+/+) ipn97.4 cells, and 1,952 total proteins in the NF1 null (-/-) ipn97.4 cells",0.95
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,QIAGEN Ingenuity Pathway Analysis (IPA),computational_tool,Mechanistic,"Predicted decreased oxidative phosphorylation and myelination signaling, increased mitochondrial dysfunction and glycolysis upon NF1 loss",Results,upon loss of NF1 there is a decrease in oxidative phosphorylation (OXPHOS) and Myelination Signaling Pathway. We see increases in Mitochondrial dysfunction and Glycolysis,0.9
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,O2K system (Oroboros Instruments),computational_tool,Mechanistic,Measured mitochondrial respiratory function showing NF1 stabilizes NADH-linked OXPHOS and electron transfer capacity,Results,NF1 impacts mitochondrial respiratory function by stabilizing NADH-linked OXPHOS and electron transfer capacity in Schwann cells,0.9
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,NF1 R1947/+ minipigs,animal_model,Efficacy,100% of animals displayed café au lait macules (CALMs) and a subset developed lesions resembling NF1-associated cutaneous neurofibromas,Results,"The phenotype of these NF1 minipigs was very similar to what was previously reported, with 100% of the animals displaying café au lait macules (CALMs) and a subset of NF1 minipigs developed lesions resembling NF1-associated cutaneous neurofibromas",0.95
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,NF1 R1947/+ minipigs,animal_model,Safety,"NF1 minipigs were viable, fertile, and transmitted the mutant allele to future generations with Mendelian frequencies",Results,"NF1 minipigs were viable, fertile, and transmitted the mutant allele to future generations with Mendelian frequencies",0.9
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,p75 NGFR antibody,antibody,Efficacy,Schwann cells were purified to >95% purity by flow cytometry using p75 NGFR antibody-mediated magnetic cell separation,Results,Schwann cells were purified from contaminating cells using p75 nerve growth factor receptor (NGFR) antibody-mediated magnetic cell separation and confirmed to be >95% pure by flow cytometry,0.95
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Gentamicin,genetic_reagent,Safety,"Gentamicin was well tolerated with no significant changes in renal parameters, including serum creatinine and blood urea nitrogen",Results,"Gentamicin was well tolerated with no significant changes in renal parameters, including serum creatinine and blood urea nitrogen",0.9
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Gentamicin,genetic_reagent,Biomarker,"Mean Cmax of 38 μg/mL on day 1, with no significant changes in PK parameters after 14 days",Results,"PK parameters reached a mean Cmax of 38 μg/mL on day 1, and no significant changes in PK parameters were noted after 14 days, suggesting that gentamicin did not accumulate in the plasma over time",0.95
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Gentamicin,genetic_reagent,Biomarker,"Tissue concentrations: 5.87 ± 0.97 μg/mL in optic nerve, 1.01 ± 0.2 μg/mL in cortex, 6.88 ± 1.54 μg/mL in sciatic nerve, and 3.02 ± 1.28 μg/mL in skin",Results,"Gentamicin was present in all tissues and reached a mean concentration of 5.87 ± 0.97 μg/mL in optic nerve, 1.01 ± 0.2 μg/mL in cortex, 6.88 ± 1.54 μg/mL in sciatic nerve, and 3.02 ± 1.28 μg/mL in skin",0.95
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Gentamicin,genetic_reagent,Efficacy,Significantly increased neurofibromin protein expression in optic nerve tissue (p = 0.01) but no significant change in other tissues,Results,"Neurofibromin protein expression was higher in the optic nerve tissue of animals treated with gentamicin compared with untreated controls (p = 0.01), but no significant change was observed in other tissues",0.95
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,G418,genetic_reagent,Efficacy,Caused significant and dose-dependent increase in firefly luciferase activity in dual luciferase reporter assay in both minipig and human Schwann cells,Results,"Treatment with G418, but not gentamicin or ataluren, caused a significant and dose-dependent increase in firefly luciferase activity compared with vehicle-treated cells in both minipig and human Schwann cells",0.9
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,G418,genetic_reagent,Efficacy,"In combination with siUPF1, restored detectable full-length neurofibromin protein expression in NF1 Schwann cells",Results,"However, treatment with siUPF1 in combination with G418 restored detectable full-length neurofibromin protein expression in NF1 Schwann cells",0.9
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Ataluren,genetic_reagent,Efficacy,Did not cause significant increase in firefly luciferase activity in dual luciferase reporter assay,Results,"Treatment with G418, but not gentamicin or ataluren, caused a significant and dose-dependent increase in firefly luciferase activity",0.85
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,UPF1 siRNA,genetic_reagent,Efficacy,"Resulted in 50% reduction in UPF1 transcript corresponding to 75% reduction in UPF1 protein expression, and 2- to 3-fold increase in NF1 mRNA expression",Results,"NF1 Schwann cells were treated with siRNA targeting swine UPF1, which resulted in a 50% reduction in UPF1 transcript corresponding to a 75% reduction in UPF1 protein expression and a 2- to 3-fold increase in NF1 mRNA expression",0.95
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Schwann cells,cell_line,Biomarker,"NF1 transcript levels decreased by roughly 50% in NF1 Schwann cells from sciatic nerve compared with WT, and by 90% in Schwann cells with LOH",Results,"Transcript levels of NF1 were decreased by roughly 50% in NF1 Schwann cells from NF1 minipig sciatic nerve compared with WT, and by 90% in NF1 and NF1 Schwann cells",0.9
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Schwann cells,cell_line,Biomarker,"Schwann cells derived from cutaneous neurofibromas showed altered morphology, disorganized architecture, and increased proliferation compared with WT and NF1 sciatic nerve-derived Schwann cells",Results,"Schwann cells derived from cutaneous neurofibromas showed altered morphology, disorganized architecture, and increased proliferation compared with WT and NF1 sciatic nerve-derived Schwann cells",0.85
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,alamarBlue cell viability assay,clinical_assessment_tool,Efficacy,Demonstrated increased proliferation in NF1 Schwann cells compared with WT and NF1 Schwann cells,Results,Proliferation assay showing increased proliferation in NF1 Schwann cells compared with WT and NF1 Schwann cells,0.8
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,"Ca2+ current density was ~75% higher in neurons from Nf1+/- mice: 37.7 ± 4.2 (n=9) versus 21.5 ± 3.7 (n=10) pA pF−1 (Vt=0 mV, p<0.05)",Results,"At 5–7 DIV, the Ca2+ current density was ~75% higher in neurons from Nf1+/− wild-type mice: 37.7 ± 4.2 (n=9) versus versus 21.5 ± 3.7 (n=10) pA pF−1 (Vt=0 mV, p <0.05, Student's t-test).",0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Potassium-stimulated glutamate release was ~45% higher in neurons from Nf1+/- cells: 63.0 ± 3.3% versus 43.1 ± 1.8% total glutamate content/15 min (p<0.05),Results,potassium (50 mM KCl)-stimulated glutamate release was ~45% higher in neurons from Nf1+/− cells compared with wild-type cells; 63.0 ± 3.3% total glutamate content/15 min versus 43.1 ± 1.8% total glutamate content/15,0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Evoked glutamate release was higher in Nf1+/- cells: 51.1 ± 3.4% versus 31.9 ± 1.8% total glutamate content/15 min (p<0.05),Results,The evoked glutamate release (stimulated – initial basal release) was also higher in Nf1+/− cells compared with wild-type cells; 51.1 ± 3.4% total glutamate content/15 min versus 31.9 ± 1.8% total glutamate content/15,0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Total cellular glutamate content was lower in Nf1+/- mice: 26.6 ± 3.4 nmol/well versus 47.3 ± 3.8 nmol/well in wild-type (p<0.05),Results,"we observed a significant increase in the total cellular content of glutamate in cells from wild-type versus Nf1+/− mice: 47.3 ± 3.8 nmol/well (n = 117 wells) versus 26.6 ± 3.4 (n = 48 wells), p <0.05, t-test",0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,N-type calcium currents showed hyperpolarizing shift in activation: V50% was -16.3± 1.9 mV in Nf1+/- versus -7.7 ± 1.1 mV in wild-type (p<0.05),Results,"V50% was −7.7 ± 1.1 mV (n=9) for wild-type neurons, which was significantly different from that of wild-type neurons (−16.3± 1.9 mV, n=7; p <0.05, Student's t-test)",0.95
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Dendritic complexity increased with peak of ~20 crossings at 150-250 μm from soma in Nf1+/- neurons versus ~14 crossings in wild-type,Results,This increase reached a peak of ~20 crossings at about 150–250 μm from the soma in EGFP transfected Nf1+/− neurons compared with EGFP–expressing wild-type cells which reached a peak complexity of ~14 crossings,0.9
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Nf1+/- mice,animal_model,Biomarker,Axon length was increased in Nf1+/- neurons compared with wild-type neurons,Results,Axon length was increased in Nf1+/− neurons compared with wild-type neurons,0.85
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,EPC 10 Amplifier,computational_tool,Other,Used for whole-cell patch clamp electrophysiology recordings to measure calcium currents,Results,"Using whole-cell patch clamp electrophysiology, we tested for total Ca2+ current properties in primary hippocampal neurons",0.8
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,Amplex Red glutamic acid/glutamate oxidase assay kit,computational_tool,Other,"Used to measure glutamate release from cortical neurons, showing ~45% higher potassium-stimulated release in Nf1+/- versus wild-type",Results,potassium (50 mM KCl)-stimulated glutamate release was ~45% higher in neurons from Nf1+/− cells compared with wild-type cells,0.85
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,EGFP,genetic_reagent,Other,Used for transfection to visualize hippocampal neurons for Sholl analysis of dendritic complexity at 7 DIV,Results,"Sholl analysis of hippocampal neurons, transfected at 5 DIV and analyzed at 7 DIV, revealed a significant increase in the number of processes in neurons from Nf1+/− mice",0.8
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,automated Sholl analysis plugin,computational_tool,Other,"Used to quantify dendritic branching patterns, revealing increased complexity in Nf1+/- neurons with peak ~20 crossings versus ~14 in wild-type",Results,"Sholl analysis of hippocampal neurons, transfected at 5 DIV and analyzed at 7 DIV, revealed a significant increase in the number of processes in neurons from Nf1+/− mice",0.85
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,Illumina Infinium MethylationEPIC BeadChip array,computational_tool,Biomarker,"Successfully identified two distinct MPNST subgroups (MPNST-G1 and MPNST-G2) through methylation profiling of 108 PNSTs, with MPNST-G1 showing significantly worse prognosis (median PFS 0.6 vs 1.4 years, p < 0.05)",Results,"Most notably, survival analysis revealed that prognoses of patients with MPNST-G1 were statistically significantly worse than MPNST-G2 (median PFS of 0.6 vs 1.4 years, p < 0.05, log-rank test).",0.95
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,HSC1λ,cell_line,Efficacy,"PTCH1-knockout HSC1λ cells formed tumors in 75% of mice compared to 0% with control cells, and showed statistically significant increases in cellular proliferation, anchorage independent growth and migration",Results,"In 75% of mice HSC1λ-gPTCH1 formed tumors in the flank, compared to 0% of mice injected with control parental HSC1λ-gGFP cells...PTCH1-knockout resulted in statistically significant increase in cellular proliferation, anchorage independent growth and migration",0.95
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,ipNF06.2A,cell_line,Efficacy,PTCH1-knockout in ipNF06.2A cells induced activation of the SHH pathway and significant increase in cellular proliferation and migration,Results,"Again, PTCH1-knockout in ipNF06.2A cells induced activation of the SHH pathway and a significant increase in cellular proliferation and migration",0.9
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,S462TY,cell_line,Efficacy,"Sonidegib treatment resulted in twofold lower IC50 compared to STS-26T, and xenografts treated with sonidegib survived significantly longer (median survival 78 vs 45 days, p = 0.03)",Results,"In vitro treatment of S462TY with sonidegib resulted in a twofold lower half-maximal inhibitory concentration (IC50) compared to STS-26T...S462TY xenografts treated with sonidegib survived statistically significantly longer than xenografts treated with vehicle (median survival 78 vs 45 days, log-rank test, p = 0.03)",0.95
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,STS-26T,cell_line,Efficacy,"STS-26T xenografts treated with sonidegib did not have improved survival, consistent with lack of SHH pathway activation in this cell line",Results,"In contrast, STS-26T xenografts treated with sonidegib did not have improved survival consistent with the lack of SHH pathway activation in this cell line.",0.9
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,S462,cell_line,Biomarker,"Demonstrated significantly elevated levels of GLI1, GLI2, and SMO, and clustered with MPNST-G1 tumors in methylation profiling",Results,"We identified significantly elevated levels of GLI1, GLI2, and SMO in 3 of 4 MPNST cell lines (S462, S462TY, and T265)...cell lines S462, S462TY and T265 clustered with MPSNT-G1 tumors",0.9
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,T265,cell_line,Biomarker,"Demonstrated significantly elevated levels of GLI1, GLI2, and SMO, and clustered with MPNST-G1 tumors in methylation profiling",Results,"We identified significantly elevated levels of GLI1, GLI2, and SMO in 3 of 4 MPNST cell lines (S462, S462TY, and T265)...cell lines S462, S462TY and T265 clustered with MPSNT-G1 tumors",0.9
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,NOD-SCID-Prkdc scid mice,animal_model,Efficacy,"Used for xenograft studies showing S462TY tumors treated with sonidegib (20 mg/kg/day) had significantly improved survival (78 vs 45 days median survival, p = 0.03)",Results,"To validate this finding in vivo, we injected S46TY and STS-26T cells into the flank of NOD-SCID mice and treated with sonidegib (20 mg/kg/day) until end point...S462TY xenografts treated with sonidegib survived statistically significantly longer",0.95
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,"PTCH1 antibody (Cat#MAB41051, R&D systems)",antibody,Biomarker,Successfully confirmed PTCH1 knockout in cell lines and demonstrated lower PTCH1 expression in MPNST-G1 tumors,Results,Capillary-based immunoassay (WES) confirming knockout of PTCH1...we also observed a lower expression of PTCH1 in MPNST-G1,0.85
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Nf1 +/− GFAP CKO,animal_model,Biomarker,Neurosphere formation frequency from optic nerve cultures ranged from 0.06% to 0.28% (0.15 +/− 0.11%; n=3),Results,"The frequency of this stem cell population in the murine optic gliomas ranged from 0.06% to 0.28% (0.15 +/− 0.11%; n=3), determined using a primary sphere formation assay",0.95
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Nf1 flox/flox,animal_model,Efficacy,"Cells took nearly 3 weeks to form smaller clusters, which could not be maintained by serial passaging due to loss of proliferation and self-renewal ability",Results,"cells from Nf1 flox/flox (WT) and Nf1+/− mice took nearly 3 weeks to form smaller clusters, which could not be maintained by serial passaging due to loss of proliferation and self-renewal ability",0.85
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Nf1 +/−,animal_model,Efficacy,"Cells took nearly 3 weeks to form smaller clusters, which could not be maintained by serial passaging due to loss of proliferation and self-renewal ability",Results,"cells from Nf1 flox/flox (WT) and Nf1+/− mice took nearly 3 weeks to form smaller clusters, which could not be maintained by serial passaging due to loss of proliferation and self-renewal ability",0.85
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,optic glioma neurospheres,advanced_cellular_model,Biomarker,Could be stably maintained for >30 passages without significant changes in their growth rates,Results,o-GSCs could be stably maintained for >30 passages without significant changes in their growth rates,0.9
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,optic glioma neurospheres,advanced_cellular_model,Efficacy,5-fold increased ED50 resistance to carboplatin compared to Nf1-deficient TVZ NSCs,Results,o-GSCs were more resistant to carboplatin (5-fold increased ED50,0.95
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,optic glioma neurospheres,advanced_cellular_model,Efficacy,6-fold increased ED50 resistance to rapamycin compared to Nf1-deficient TVZ NSCs,Results,rapamycin (6-fold increased ED50,0.95
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,optic glioma neurospheres,advanced_cellular_model,Efficacy,3-fold increased ED50 resistance to PD901 MEK inhibitor compared to Nf1-deficient TVZ NSCs,Results,PD901 (3-fold increased ED50,0.95
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,optic glioma neurospheres,advanced_cellular_model,Biomarker,1.5- and 1.7-fold increases in S6 Ser 240/244 and Ser 235/236 phosphorylation respectively compared to Nf1-deficient TVZ NSCs,Results,"increased mTOR activation in o-GSCs relative to Nf1 −/− TVZ NSCs (1.5- and 1.7-fold increases S6 Ser 240/244 and Ser 235/236 phosphorylation, respectively",0.95
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,optic glioma neurospheres,advanced_cellular_model,Biomarker,3-fold increase in p90-RSK-Thr 573 phosphorylation,Results,o-GSCs exhibited increased p90-RSK activation (3-fold increase in p90-RSK-Thr 573 phosphorylation,0.95
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,TVZ NSCs,advanced_cellular_model,Safety,Did not form glioma-like lesions 6 months post-injection into Nf1+/− mice,Results,Nf1 +/− mice (n=4) transplanted with Nf1 −/− TVZ NSCs did not form glioma-like lesions 6 months post-injection,0.9
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Abcg1 shRNA,genetic_reagent,Efficacy,"50-60% protein reduction, reduced o-GSC growth and self-renewal by 40-46% and 76-78% respectively",Results,"knockdown of Abcg1 expression using two different lentiviral-mediated shRNA constructs (50–60% protein reduction) reduced o-GSC growth and self-renewal by 40–46% and 76–78%, respectively",0.95
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Abcg1 shRNA,genetic_reagent,Mechanistic,Caused 2-fold increase in apoptosis without affecting proliferation,Results,This decrease in cell number was not the result of reduced proliferation but rather reflected a 2-fold increase in apoptosis,0.9
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Abcg1 shRNA,genetic_reagent,Biomarker,Increased BiP and CHOP expression by 2 to 2.5-fold and 4.5 to 7-fold respectively,Results,"Abcg1 knockdown increased BiP and CHOP expression by 2 to 2.5-fold and 4.5 to 7-fold, respectively, relative to controls",0.95
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,Affymetrix GeneChip Mouse Genome 430 2.0 Array,computational_tool,Biomarker,Revealed 59 genes with >5-fold increased expression in o-GSCs relative to Nf1-deficient TVZ NSCs and 87 genes decreased by at least 5-fold,Results,"Microarray gene expression analysis revealed 59 genes with >5-fold increased expression in o-GSCs relative to Nf1 −/− TVZ NSCs, whereas 87 genes were decreased by at least 5-fold in o-GSCs",0.9
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",iHSC1λ,cell_line,Biomarker,"Showed increased activated β-catenin when overexpressing CTNNB1 S33Y, unlike iHSC2λ",Results,"Cells overexpressing CTNNB1 S33Y showed increased levels of total β-catenin protein, but interestingly, only the iHSC1λ cells showed increased activated β-catenin",0.9
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",iHSC2λ,cell_line,Biomarker,"Did not show increased activated β-catenin when overexpressing CTNNB1 S33Y, despite increased total β-catenin",Results,"Cells overexpressing CTNNB1 S33Y showed increased levels of total β-catenin protein, but interestingly, only the iHSC1λ cells showed increased activated β-catenin",0.9
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",S462,cell_line,Biomarker,Expressed EIF3E-RSPO2 fusion transcript with 1295-fold increase in RSPO2 expression,Results,We identified a fusion transcript expressed by the S462 MPNST cell line that was not present in any of the other MPNST or immortalized human Schwann cell lines. Expression of this fusion correlated with a 1295-fold increase in RSPO2 expression,0.95
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",S462-TY,cell_line,Efficacy,IC50 values of 0.047-2.22μM for XAV-939 and 0.055-186.87μM for IWR-1,Results,the MPNST cell lines were quite sensitive with relatively low IC50s of 0.047uM to 2.22uM for XAV-939 and 0.055uM to 186.87uM for IWR-1,0.9
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",STS-26T,cell_line,Efficacy,IC50 values of 0.047-2.22μM for XAV-939 and 0.055-186.87μM for IWR-1,Results,the MPNST cell lines were quite sensitive with relatively low IC50s of 0.047uM to 2.22uM for XAV-939 and 0.055uM to 186.87uM for IWR-1,0.9
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",iHSC1λ,cell_line,Safety,Highly resistant to proliferation inhibition and cell death by XAV-939 and IWR-1 with high IC50 values,Results,We find normal Schwann cells are highly resistant to proliferation inhibition and cell death by these two compounds as demonstrated by high IC50 values,0.85
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",iHSC2λ,cell_line,Safety,Highly resistant to proliferation inhibition and cell death by XAV-939 and IWR-1 with high IC50 values,Results,We find normal Schwann cells are highly resistant to proliferation inhibition and cell death by these two compounds as demonstrated by high IC50 values,0.85
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",S462,cell_line,Efficacy,Combination treatment with IC25 doses of RAD-001 and Wnt inhibitors approached 100% TUNEL-positive cells,Results,"when the MPNST cell lines were treated with their IC25 dose of RAD-001 in combination with either IWR-1 or XAV-939 also at their IC25 dose, the percentage of TUNEL positive cells often went above 50%, and in the S462 cell line, even approached 100%",0.9
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",Foxn1 nu/nu mice,animal_model,Efficacy,CTNNB1 shRNA delayed tumor growth rate in NF1-associated cell line with fewer Ki67 positive cells,Results,Reduction in CTNNB1 by shRNA delayed the rate of tumor growth in the NF1-asociated cell line. Tumor sections derived from cells expressing the CTNNB1 shRNA showed fewer Ki67 positive cells,0.85
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",Foxn1 nu/nu mice,animal_model,Efficacy,GSK3B overexpression reduced tumor growth in sporadic MPNST cell line with fewer Ki67 positive cells,Results,Overexpression of GSK3B resulted in reduction in tumor growth in the spontaneous MPNST cell line. Tumor sections from cells overexpressing GSK3B also showed fewer Ki67 positive cells,0.85
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",CalcuSyn Version 2.1,computational_tool,Other,Used to calculate IC50 values for XAV-939 and IWR-1 in MPNST cell lines,Results,"while the MPNST cell lines were quite sensitive with relatively low IC50s of 0.047uM to 2.22uM for XAV-939 and 0.055uM to 186.87uM for IWR-1 (CalcuSyn Version 2.1, BioSoft)",0.9
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,hGFAP-cre,genetic_reagent,Mechanistic,"Onset of expression occurs in ~95% of E12/13 radial glia in the forebrain, inactivating Nf1 in both embryonic and adult neural stem cells",Results,"The onset of hGFAP-cre expression occurs in ~95% of E12/13 radial glia in the forebrain, thus inactivating Nf1 in both embryonic and adult neural stem cells as well as their differentiated progeny",0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,Nf1 hGFAP CKO,animal_model,Efficacy,Caused 10-15% increase in cerebral cortical surface area and significant increase in corpus callosum thickness at all three SVZ-associated positions,Results,Nf1 conditional bi-allelic inactivation caused a 10-15% increase in the size of cerebral cortical surface area...Nf1 inactivation caused a significant increase in the thickness of the CC,0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,Nf1 hGFAP CKO,animal_model,Biomarker,Exhibited 2- to 3-fold size increase in SVZ compared to controls and 48.3% of Ascl1+ TAP/IPCs expressed Olig2 versus 9% in controls,Results,Nf1 hGFAP CKO SVZ exhibited a 2- to 3-fold size increase compared to controls...nearly half of Ascl1+ TAP/IPCs expressed Olig2 in the Nf1 hGFAP CKO SVZ (48.3%,0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,Nf1 hGFAP CKO,animal_model,Safety,"Mice became hunched, scruffy and exhibited growth retardation within a week, weighing only half as much as control littermates by P18",Results,"Nf1 hGFAP CKO mice became hunched, scruffy and exhibited growth retardation within a week...weighed only half as much as control littermates by P18",0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,Nestin-cre ER,genetic_reagent,Mechanistic,"TM-induced recombination specifically targets neural stem and progenitor cells in the SVZ as well as neuroblasts in the RMS, but not the CC or OB",Results,"TM-induced Nestin-creER-mediated recombination specifically targets neural stem and progenitor cells in the SVZ as well as neuroblasts in the RMS, but not the CC or OB",0.9
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,Nf1 NcreER CKO,animal_model,Biomarker,"Percentage of β-gal+ cells expressing Olig2 was greatly increased after acute Nf1 inactivation, with dramatic increase in CC clustering",Results,the percentage of β-gal+ cells expressing Olig2 was greatly increased...β-gal+ cells that all expressed Olig2 were dramatically increased and often formed clusters in the CC,0.9
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,PD0325901,genetic_reagent,Efficacy,P0.5-P18 treatment completely rescued enlarged corpus callosum phenotype and significantly increased olfactory bulb size and neuronal density,Results,the enlarged CC phenotype was completely rescued in the MEKi-treated Nf1 hGFAP CKO brains...neuronal density and the size of the OB were significantly increased in mutants after MEKi treatment,0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,PD0325901,genetic_reagent,Safety,"Treatment completely rescued hunched, scruffy appearance and growth retardation, making treated mice indistinguishable from control littermates",Results,this P0.5-P18 treatment protocol completely rescued these phenotypes...the appearance of the MEKi-treated Nf1 hGFAP CKO mice was indistinguishable from control littermates at P18,0.95
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,PD0325901,genetic_reagent,Biomarker,Reduced Erk activation to control levels and rescued number of Olig2+ cells in mutant SVZ to control levels,Results,"the level of Erk activation in MEKi-treated Nf1 hGFAP CKO mice at P18 was reduced to the level of control SVZ and more importantly, the number of Olig2+ cells in the mutant SVZ was rescued",0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,HeLa cells,cell_line,Mechanistic,70-80% of HK2 localizes in MAMs and most cellular MAMs harbor HK2 proteins,Results,quantification indicate both that 70–80% of HK2 localizes in MAMs and that most cellular MAMs harbor HK2 proteins,0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,HeLa cells,cell_line,Mechanistic,cl-HK2pep induces HK2 displacement from MAMs in <2 minutes,Results,"cl‐HK2pep is indeed able to enter cells, to interact with mitochondria and to induce HK2 detachment from MAMs in < 2 min",0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,HeLa cells,cell_line,Mechanistic,"cl-HK2pep triggers mitochondrial depolarization in most tumor cells after 2-4 minutes, followed by cell death in <1 hour",Results,"Peptide administration triggers mitochondrial depolarization in most tumor cells after 2–4 min, followed by phosphatidylserine exposure on the cell surface and plasma membrane rupture in < 1 h",0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,MDA-MB-231 cells,cell_line,Mechanistic,HK2 localizes in MAMs as demonstrated by fluorescence co-staining with SPLICS probe,Results,These experiments have been extended to diverse HK2‐expressing tumor cell models,0.85
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,S462 cells,cell_line,Mechanistic,HK2 localizes in MAMs as demonstrated by fluorescence co-staining with SPLICS probe,Results,These experiments have been extended to diverse HK2‐expressing tumor cell models,0.85
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,PN 04.4 cells,cell_line,Mechanistic,HK2 localizes in MAMs as demonstrated by fluorescence co-staining with SPLICS probe,Results,These experiments have been extended to diverse HK2‐expressing tumor cell models,0.85
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,4T1 cells,cell_line,Mechanistic,cl-HK2pep does not affect HK1/HK2 specific enzymatic activities in cell extracts,Results,"cl‐HK2pep does not perturb hexokinase enzymatic activity either on the purified enzyme or on cell samples, where it is equally ineffective on HK2 and on the widespread isozyme HK1",0.9
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,CT26 cells,cell_line,Efficacy,HK2 silencing with shRNAs inhibits growth in soft agar colony formation,Results,Silencing HK2 expression hampers the ability of cancer cells to form colonies,0.9
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,CT26 cells,cell_line,Efficacy,Intratumor injections of cl-HK2pep or HK2pep significantly decrease tumor volume in allograft models,Results,intratumor injections of either cl‐HK2pep or entire HK2pep significantly decrease the volume of allograft‐injected colon cancer cells,0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,RAW 264.7 cells,cell_line,Mechanistic,"Express HK2 but it is barely located in MAMs, making cells poorly responsive to cl-HK2pep-induced death",Results,"Mouse RAW 264.7 macrophages and mouse C2C12 myoblasts express HK2, even though it is barely located in MAMs. Treatment with cl‐HK2pep is poorly effective in inducing death of these cell models",0.9
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,C2C12 cells,cell_line,Mechanistic,"Express HK2 but it is barely located in MAMs, making cells poorly responsive to cl-HK2pep-induced death",Results,"Mouse RAW 264.7 macrophages and mouse C2C12 myoblasts express HK2, even though it is barely located in MAMs. Treatment with cl‐HK2pep is poorly effective in inducing death of these cell models",0.9
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,COLO 741 cells,cell_line,Mechanistic,HK2 localizes in MAMs as demonstrated by fluorescence co-staining with SPLICS probe,Results,These experiments have been extended to diverse HK2‐expressing tumor cell models,0.85
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,MEC1 cells,cell_line,Efficacy,cl-HK2pep treatment induces calpain-dependent cell death that is blocked by PD150606,Results,the broad‐spectrum calpain inhibitor PD150606 abrogates cl‐HK2pep‐dependent induction of mitochondrial depolarization and cell death,0.9
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,Balb/c mice,animal_model,Efficacy,Intraperitoneal administration of HK2pep (5 injections of 60 nmol every 12h) reduces neoplastic growth in colon and breast cancer allografts,Results,intraperitoneal injection of entire HK2pep on both colon and breast cancer allografts,0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,Balb/c mice,animal_model,Safety,Peptide administration does not cause weight loss or tissue damage in treated animals,Results,"Peptide administration does not cause any harm in treated animals, as assessed by lack of weight loss and of tissue damage",0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,"Human HK2 recombinant protein (HXK0703, ATGEN)",genetic_reagent,Mechanistic,cl-HK2pep does not perturb hexokinase enzymatic activity on purified enzyme,Results,cl‐HK2pep does not perturb hexokinase enzymatic activity either on the purified enzyme,0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,D4ER Ca2+ probe,genetic_reagent,Biomarker,"Used to measure ER Ca2+ levels, showing cl-HK2pep prompts cycles of ER Ca2+ release and refill",Results,cl‐HK2pep prompts cycles of ER Ca2+ release and refill,0.9
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,GCAMP6f,genetic_reagent,Biomarker,"Used to record mitochondrial Ca2+ levels, showing cl-HK2pep rapidly boosts mitochondrial [Ca2+] to about 50 μM in stable, Xe-C-sensitive manner",Results,"cl‐HK2pep treatment rapidly boosts mitochondrial [Ca2+] in a stable and Xe‐C‐sensitive way, rising mitochondrial [Ca2+] to about 50 μM",0.95
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,mit-Aeqmut,genetic_reagent,Biomarker,"Used to measure mitochondrial Ca2+ levels, confirming cl-HK2pep raises mitochondrial [Ca2+] to about 50 μM",Results,rising mitochondrial [Ca2+] to about 50 μM,0.9
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,GFP-PHD,genetic_reagent,Biomarker,"Used to assess IP3 levels, showing cl-HK2pep boosts cytosolic IP3 levels in a manner prevented by Xestospongin C",Results,boosts cytosolic IP3 levels. This IP3 rise is prevented by pre‐incubation with the IP3R inhibitor Xestospongin C,0.95
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,ultra-low-pass whole genome sequencing (ULP-WGS),computational_tool,Efficacy,"Differentiated MPNST from PN with AUC of 0.83, sensitivity of 75% and specificity of 91% using 0.6× genome-wide coverage",Results,"ROC analysis further demonstrated an area under the curve (AUC) of 0.83...utilizing a Youden's index-optimized cutpoint of 0.041, pretreatment plasma tumor fraction differentiated MPNST from PN with an area under the ROC curve of 0.83, and sensitivity of 75% and specificity of 91%",0.95
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,ultra-low-pass whole genome sequencing (ULP-WGS),computational_tool,Efficacy,"Performance improved to 89% accuracy with AUC of 0.89, sensitivity of 83%, and specificity of 91% when considering highest plasma tumor fraction on serial analysis",Results,"improved to 89% with AUC of 0.89, Youden's index-optimized sensitivity of 83%, and specificity of 91% when considering the highest plasma tumor fraction measured per participant on serial time point analysis",0.95
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,ultra-low-pass whole genome sequencing (ULP-WGS),computational_tool,Efficacy,Higher performance with approximately 0.6× coverage compared to approximately 0.3× coverage,Results,which was higher with approximately 0.6× ULP-WGS than approximately 0.3×,0.85
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,ultra-low-pass whole genome sequencing (ULP-WGS),computational_tool,Efficacy,AUC decreased to 0.60 when considering all cfDNA fragment sizes versus size-selected fragments,Results,"Notably, AUC decreased to 0.60 when considering all cfDNA fragment sizes, highlighting the importance of our in silico size selection step",0.9
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,ultra-low-pass whole genome sequencing (ULP-WGS),computational_tool,Biomarker,"Detected focal somatic CNAs associated with PN tumor progression including loss of CDKN2A/B, MTAP, SMARCA2, and SUZ12 in MPNST patient plasma",Results,"focal loss of CDKN2A/B, MTAP, SMARCA2, and SUZ12, alterations shown to be associated with malignant transformation of PN, was observed in plasma from MPNST patients",0.9
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,ultra-low-pass whole genome sequencing (ULP-WGS),computational_tool,Biomarker,"Plasma tumor fraction correlated significantly with radiographic tumor burden (Pearson r = 0.387, P = 0.024)",Results,"A significantly positive correlation was observed between SLD and plasma tumor fraction (Pearson r = 0.387, P = 0.024)",0.95
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,ultra-low-pass whole genome sequencing (ULP-WGS),computational_tool,Efficacy,Detected metastatic recurrence 89 days before surveillance imaging in one patient case,Results,this preceded metastatic recurrence identified on surveillance imaging by 89 days,0.9
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,RECIST 1.1,clinical_assessment_tool,Biomarker,"Sum of longest tumor diameters (SLD) correlated significantly with plasma tumor fraction (Pearson r = 0.387, P = 0.024)",Results,"A significantly positive correlation was observed between SLD and plasma tumor fraction (Pearson r = 0.387, P = 0.024)",0.95
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,ichorCNA tool (Broad v.0.2.0),computational_tool,Biomarker,Successfully quantified tumor fractions with median levels of 0.026 in healthy/PN groups versus 0.058 in MPNST group,Results,Median tumor fraction levels in healthy (0.026) and PN (0.026) groups were lower than in MPNST (0.058),0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,sgRNA1 (5′-TAACTGCGCAACCTTCTTTA-3′),genetic_reagent,Efficacy,Global editing activity of approximately 38% in bulk transfected cells using T7 endonuclease assay,Results,"The global editing activity of Cas9 protein in the bulk of transfected cells using T7 endonuclease assay was approximately 38% and 5% for sgRNA1 and sgRNA2, respectively",0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,sgRNA1 (5′-TAACTGCGCAACCTTCTTTA-3′),genetic_reagent,Efficacy,88% of isolated clones showed editing by high-resolution melting analysis,Results,"The analysis showed that 88% and 42% of the cells were edited for sgRNA1 and sgRNA2, respectively",0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,sgRNA1 (5′-TAACTGCGCAACCTTCTTTA-3′),genetic_reagent,Mechanistic,Led to bi-allelic edition in all generated clones,Results,"Sequencing analysis indicated that sgRNA1 and sgRNA2 led to a bi-allelic and a mono-allelic edition, respectively, in all generated clones",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,sgRNA2 (5′-GTTAGCAGTTATAAATAGCC-3′),genetic_reagent,Efficacy,Global editing activity of approximately 5% in bulk transfected cells using T7 endonuclease assay,Results,"The global editing activity of Cas9 protein in the bulk of transfected cells using T7 endonuclease assay was approximately 38% and 5% for sgRNA1 and sgRNA2, respectively",0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,sgRNA2 (5′-GTTAGCAGTTATAAATAGCC-3′),genetic_reagent,Efficacy,42% of isolated clones showed editing by high-resolution melting analysis,Results,"The analysis showed that 88% and 42% of the cells were edited for sgRNA1 and sgRNA2, respectively",0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,sgRNA2 (5′-GTTAGCAGTTATAAATAGCC-3′),genetic_reagent,Mechanistic,Led to mono-allelic edition in all generated clones,Results,"Sequencing analysis indicated that sgRNA1 and sgRNA2 led to a bi-allelic and a mono-allelic edition, respectively, in all generated clones",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,"anti-neurofibromin antibody (abcam, ab17963)",antibody,Biomarker,Detected 50% reduction in full-length neurofibromin expression in NF1 (+/−) hiPSC-MSCs compared to NF1 (+/+) hiPSC-MSCs,Results,Western blotting demonstrated that the expression of full-length neurofibromin was significantly reduced by half in the NF1 (+/−) hiPSC-MSCs compared to the NF1 (+/+) hiPSC-MSCs,0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,"anti-neurofibromin antibody (abcam, ab17963)",antibody,Biomarker,No detectable expression of full-length neurofibromin in NF1 (−/−) hiPSC-MSCs,Results,No expression of full-length neurofibromin was detectable in the NF1 (−/−) hiPSC-MSCs,0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,"anti-neurofibromin antibody (abcam, ab17963)",antibody,Biomarker,Detected 50% reduction in full-length neurofibromin expression in NF1-1 and NF1-2 patient hiPSC-MSCs compared to WT-1 and WT-2 controls,Results,"According to Western blot analysis, expression of full-length neurofibromin was reduced by half in NF1-1 and NF1-2 hiPSC-MSCs compared to WT-1 and WT-2 hiPSC-MSCs",0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-1 hiPSC line,cell_line,Biomarker,Showed 50% reduction in neurofibromin expression compared to control lines,Results,"According to Western blot analysis, expression of full-length neurofibromin was reduced by half in NF1-1 and NF1-2 hiPSC-MSCs compared to WT-1 and WT-2 hiPSC-MSCs",0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-1 hiPSC line,cell_line,Efficacy,Exhibited decreased alkaline phosphatase activity after 14 days of osteogenic differentiation compared to control lines,Results,"After 14 days of differentiation, NF1-1 and NF1-2 cells harbored decreased alkaline phosphatase activity compared to WT-1 and WT-2 cells",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-1 hiPSC line,cell_line,Efficacy,Showed significant decrease in calcium deposition compared to control NF1 (+/+) cells,Results,"Furthermore, alizarin red staining solution showed a significant decrease in calcium deposition in cells derived from NF1 patients in comparison to control NF1 (+/+)",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-2 hiPSC line,cell_line,Biomarker,Showed 50% reduction in neurofibromin expression compared to control lines,Results,"According to Western blot analysis, expression of full-length neurofibromin was reduced by half in NF1-1 and NF1-2 hiPSC-MSCs compared to WT-1 and WT-2 hiPSC-MSCs",0.95
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-2 hiPSC line,cell_line,Efficacy,Exhibited decreased alkaline phosphatase activity after 14 days of osteogenic differentiation compared to control lines,Results,"After 14 days of differentiation, NF1-1 and NF1-2 cells harbored decreased alkaline phosphatase activity compared to WT-1 and WT-2 cells",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,NF1-2 hiPSC line,cell_line,Efficacy,Showed significant decrease in calcium deposition compared to control NF1 (+/+) cells,Results,"Furthermore, alizarin red staining solution showed a significant decrease in calcium deposition in cells derived from NF1 patients in comparison to control NF1 (+/+)",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,CRISPOR software,computational_tool,Other,Used to predict eight most likely off-target sites for gene editing analysis,Results,"To detect off-target activity (OFT), the eight most likely off-target sites predicted by the CRISPOR tool (https://crispor.tefor.net/) were analyzed",0.9
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,FlowJo software,computational_tool,Other,Used for flow cytometry data analysis to characterize pluripotency markers and MSC surface markers,Results,The expression of proteins related to pluripotency was evaluated through flow cytometry using surface markers TRA1-81 and SSEA3,0.8
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,GraphPad Prism 9,computational_tool,Other,"Used for statistical analysis including Mann-Whitney nonparametric tests with significance levels of p < 0.05, p < 0.01, p < 0.001, and p < 0.0001",Results,Statistical analyses are based on a Mann‒Whitney nonparametric test for side by side comparison. ** p < 0.01,0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Nf1+/- mice,animal_model,Behavioral,Exhibited increased hyperactivity in open field task measured by total distance traveled,Results,"As expected, Nf1+/- mice that were WT for Fbxw11 (NF1) showed increased hyperactivity in the OF task measured by total distance traveled",0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Nf1+/- mice,animal_model,Behavioral,Chose higher percentage of small rewards rather than waiting for large reward in delay discounting task,Results,chose a higher percentage of small rewards rather than waiting to receive the large reward,0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Nf1+/- mice,animal_model,Behavioral,Demonstrated decreased preference for novel versus familiar partner mouse on day 2 of social preference task,Results,demonstrated a decreased preference for a novel versus a familiar partner mouse on day 2 of the SP task,0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Nf1+/- mice,animal_model,Behavioral,"Had increased number of falls, over-the-edge time, and edge time in cliff avoidance reaction task",Results,"had an increase in the number of falls, over-the-edge time, and edge time while performing the CAR task",0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Fbxw11+/- mice,animal_model,Safety,Were phenotypically normal and did not exhibit neurodevelopmental abnormalities,Results,Fbxw11+/- mice (FBX) were phenotypically normal and did not exhibit neurodevelopmental abnormalities,0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Fbxw11+/- mice,animal_model,Safety,No adverse effects were appreciated in mice with germline heterozygous loss of Fbxw11,Discussion,No adverse effects were appreciated in mice with germline heterozygous loss of Fbxw11,0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Fbxw11fl/fl mice,animal_model,Behavioral,"CRE-injected mice exhibited reduced hyperactivity with decreased total distance traveled in open field task, similar to WT mice",Results,"CRE-injected Nf1+/- Fbxw11fl/fl mice (NF1/FBX) exhibited reduced hyperactivity with decreased total distance traveled, similar to WT mice",0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Fbxw11fl/fl mice,animal_model,Behavioral,CRE-injected mice exhibited large delayed choices over small impulsive choices in delay discounting task,Results,NF1/FBX mice exhibited large delayed choices over small impulsive choices after CRE injection,0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Fbxw11fl/fl mice,animal_model,Behavioral,CRE-injected mice showed restored preference for novel partner over familiar partner on day 2 of social preference task,Results,NF1/FBX mice showed restored preference for a novel partner over a familiar partner on day 2,0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Fbxw11fl/fl mice,animal_model,Behavioral,CRE-injected mice exhibited reduced edge and over-the-edge times in cliff avoidance reaction task,Results,NF1/FBX mice exhibited reduced edge and over-the-edge times,0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,HEK293T cells,cell_line,Mechanistic,Used for mass spectrometry analysis revealing endogenous phosphorylation of serine 1159 and serine 1164 in GRD1 phosphodegron,Results,we conducted mass spectrometry analysis using gel-purified GRD1 from HEK293T cells. This analysis revealed endogenous phosphorylation of serine 1159 (S1159) and serine 1164 (S1164),0.95
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,HeLa cells,cell_line,Mechanistic,FBXW11 and FBXO3 depletion by RNAi stabilized neurofibromin and suppressed constitutive phosphorylation of ERK1 and ERK2,Results,FBXW11 and FBXO3 depletion by RNAi in HeLa cells also stabilized neurofibromin and suppressed constitutive phosphorylation of the Ras effectors ERK1 and ERK2,0.95
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,HeLa cells,cell_line,Mechanistic,Neurofibromin levels were unchanged in cells transfected with FBXW11 or FBXO3 siRNA 2 hours following cycloheximide chase,Results,neurofibromin levels were unchanged in HeLa cells transfected with FBXW11 or FBXO3 siRNA 2 hours following the CHX chase,0.95
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,LUVA cells,cell_line,Mechanistic,"Used to validate siRNA sequences from library screen, showing neurofibromin accumulation with FBXW11 and FBXO3 targeting",Results,"we validated these siRNA sequences from the library in a human mast cell line (LUVA), which is amenable to transfection and screening",0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,neurofibromin/NF1 antibody (sc-67),antibody,Biomarker,Used in immunohistochemical analyses showing significantly increased neurofibromin levels in brain tissue from Nf1+/- Fbxw11+/- mice compared to Nf1+/- mice,Results,Correlative IHC analyses showed that neurofibromin levels were significantly increased in brain tissue from Nf1+/- Fbxw11+/- mice compared with that from Nf1+/- mice,0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,anti-pERK antibody (4377),antibody,Biomarker,Used in immunohistochemical analyses showing reduced phosphorylated ERK1/2 levels in brain tissue from Nf1+/- Fbxw11+/- mice,Results,phosphorylated ERK1/2 (pERK1/2) levels were reduced in brain tissue from Nf1+/- Fbxw11+/- mice compared with that from Nf1+/- mice,0.9
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,AAV5-CMV-Cre-GFP,genetic_reagent,Efficacy,"Bilateral injection into nucleus accumbens rescued all neurobehavioral deficits in Nf1+/- mice including hyperactivity, impulsivity, and social behavior",Results,targeted disruption of Fbxw11 within the NAc in adult mice rescued performance on all experimental tasks performed to assess hyperactivity/impulsivity and social behavior,0.95
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,3-chamber social preference task,clinical_assessment_tool,Behavioral,"Measured autism spectrum disorder-like social deficits, showing decreased preference for novel versus familiar partner in Nf1+/- mice",Results,The social preference (SP) task measures autism spectrum disorder–like (ASD-like) social deficits,0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Open field test,clinical_assessment_tool,Behavioral,"Assessed ADHD-like hyperactivity phenotypes, measuring total distance traveled",Results,the open field (OF)...experiments assess ADHD-like phenotypes,0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Delay discounting task,clinical_assessment_tool,Behavioral,"Assessed ADHD-like impulsivity phenotypes, measuring preference for small immediate versus large delayed rewards",Results,delay discounting task (DDT) experiments assess ADHD-like phenotypes,0.85
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,Cliff avoidance reaction test,clinical_assessment_tool,Behavioral,"Assessed ADHD-like risk-taking behavior, measuring number of falls, over-the-edge time, and edge time",Results,cliff avoidance reaction (CAR)...experiments assess ADHD-like phenotypes,0.85
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,U87 glioblastoma cells,cell_line,Mechanistic,TRAP1 ablation inhibited F-ATP synthase hydrolytic activity and sensitized cells to PTP opening following Ca2+ ionophore A23187 treatment,Results,Both ablation of TRAP1 and treatment with i5 inhibited the hydrolytic activity of F-ATP synthase in U87 cells...TRAP1 ablation sensitizes U87 cells to PTP opening following treatment with the Ca2+ ionophore A23187,0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,U87 glioblastoma cells,cell_line,Mechanistic,TRAP1 ablation accelerated mitochondrial depolarization after cl-HK2pep treatment,Results,we observed that its ablation accelerates mitochondrial depolarization after cell treatment with cl-HK2pep,0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,sMPNST cells,cell_line,Mechanistic,Used successfully for tripartite split-GFP experiments to demonstrate direct mitochondrial interactions between TRAP1-OSCP and TRAP1-CyPD,Results,"We carried out these tripartite split-GFP experiments on malignant peripheral nerve sheath tumor (sMPNST) cells, where TRAP1 is pro-tumorigenic...revealing a direct mitochondrial interaction between OSCP and TRAP1",0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,"lentiCRISPRv2 (Addgene, https://www.addgene.org/52961/)",genetic_reagent,Mechanistic,Successfully used to generate TRAP1 knockout cells for functional studies,Results,"human U87 glioblastoma cells with or without TRAP1 (infected with a vector containing a scrambled sequence, SCR, or with a knock-out one, KO, respectively)",0.8
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,anti-human TRAP1 (sc-73604),antibody,Mechanistic,Successfully detected TRAP1 binding to F-ATP synthase subunits in overlay assays and confirmed TRAP1 presence in high molecular weight fractions with F-ATP synthase,Results,binding was detected with an anti-TRAP1 antibody...Gel filtration chromatography analyses on U87 mitochondria showed colocalization between TRAP1 and F-ATP synthase subunits,0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,anti ATP50/OSCP (ab110276),antibody,Mechanistic,Successfully used to detect OSCP in immunoprecipitation experiments and BN-PAGE analyses to assess CyPD binding competition with TRAP1,Results,Immunoprecipitation of OSCP from mitochondria of U87 cells...the amount of CyPD that co-immunoprecipitated with OSCP...was higher in the absence of TRAP1,0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,anti-ATPB (ab14730),antibody,Mechanistic,"Successfully detected F-ATP synthase monomers, dimers and oligomers in BN-PAGE experiments",Results,"BN-PAGE followed by Western immunoblotting was probed with antibodies for F-ATP synthase subunit β to detect enzyme monomers, dimers and oligomers",0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,anti-Cyclophilin (ab110324),antibody,Mechanistic,"Successfully detected CyPD in various experimental conditions including gel filtration, immunoprecipitation, and BN-PAGE analyses",Results,"gel filtration chromatography experiments detected CyPD, OSCP and TRAP1 in the same high molecular weight fractions...the amount of CyPD that co-immunoprecipitated with OSCP",0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,pcDNA3 mito-GFP1-9,genetic_reagent,Mechanistic,Successfully used in tripartite split-GFP system to demonstrate mitochondrial protein interactions,Results,We co-expressed (1) a GFP portion (GFP1–9) fused with a mitochondrial import sequence...GFP reconstitution indicates a direct interaction of the three GFP portions,0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,pcDNA3-TRAP1-GFP10,genetic_reagent,Mechanistic,Successfully used to demonstrate direct mitochondrial interactions with OSCP and CyPD in split-GFP experiments,Results,"cells co-expressing Mito-GFP1-9 with either TRAP1-GFP10 and OSCP-GFP11 or TRAP1-GFP10 and CyPD-GFP11, revealing a direct mitochondrial interaction",0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,pcDNA3CyPD-GFP11,genetic_reagent,Mechanistic,Successfully demonstrated direct mitochondrial interaction with TRAP1 and enhanced binding to OSCP when TRAP1 was knocked out,Results,revealing a direct mitochondrial interaction between CyPD and TRAP1...the binding between CyPD and OSCP was enhanced by knocking-out TRAP1,0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,pcDNA3ATP50-GFP11,genetic_reagent,Mechanistic,Successfully demonstrated direct mitochondrial interaction with TRAP1 and enhanced binding to CyPD in TRAP1 knockout conditions,Results,revealing a direct mitochondrial interaction between OSCP and TRAP1...the binding between CyPD and OSCP was enhanced by knocking-out TRAP1,0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,Biacore T100 biosensor system,computational_tool,Mechanistic,Successfully measured direct binding interactions between TRAP1-CyPD and TRAP1-OSCP using surface plasmon resonance,Results,A direct interaction between TRAP1 and CyPD was also explored with surface plasmon resonance (SPR)...SPR experiments confirmed CyPD binding to OSCP and revealed a direct interaction between TRAP1 and OSCP,0.9
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,pClamp software suite,computational_tool,Mechanistic,Successfully used to analyze electrophysiological data showing TRAP1 inhibition of F-ATP synthase channel activity in concentration-dependent manner,Results,Addition of TRAP1 in 1:1 to 3:1 molar ratio with F-ATP synthase reduced channel activity in a concentration-dependent way. TRAP1 inhibition occurred in 8 out of 14 experiments,0.9
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",PedsQL™ NF1 Module,clinical_assessment_tool,Other,Final instrument has 16 subscales and 70 items (including Sexual Functioning domain) after deletion of 4 items,Results,The final instrument reported in this manuscript has 16 subscales and 70 items (including the Sexual Functioning domain),0.95
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",PedsQL™ NF1 Module,clinical_assessment_tool,Other,Feasibility measured by missing responses was 4.8% for all subscales,Results,"Feasibility, measured by the percentage of missing responses was 4.8% for all subscales on the adult version of the PedsQL™ NF1 Module",0.95
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",PedsQL™ NF1 Module,clinical_assessment_tool,Other,"Sexual Functioning subscale had highest missing responses (124, 30.8%) and was excluded from statistical analyses",Results,"The Sexual Functioning subscale had the highest number of missing responses (124, 30.8%) and was not included in any statistical analyses",0.95
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",PedsQL™ NF1 Module,clinical_assessment_tool,Other,All items exceeded 0.40 criterion for item discrimination except one Worry subscale item (correlation 0.34),Results,"all items on the adult version of the PedsQL™ NF1 Module exceeded our criterion (0.40) for item discrimination, except for one item on the Worry subscale...with a correlation of 0.34",0.95
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",PedsQL™ NF1 Module,clinical_assessment_tool,Other,Mean and median scaling success was 73% and 71.4% respectively across all subscales,Results,The mean and median of scaling success for all the subscales of the adult version of the PedsQL™ NF1 Module was 73% and 71.4% respectively,0.95
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",Cronbach's alpha,computational_tool,Other,"Subscale reliabilities ranged from 0.72 to 0.96, all exceeding minimum 0.70 criterion for group comparisons",Results,"Subscale reliabilities ranged from 0.72 to 0.96, with all subscales exceeding the minimum reliability criterion of 0.70 required for group comparisons",0.95
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",Cronbach's alpha,computational_tool,Other,"Total Score reliability was 0.97, exceeding 0.90 criterion for individual patient score analysis",Results,"Total Score was 0.97, which exceeded the reliability criterion of 0.90 recommended for analyzing individual patient scores",0.95
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",PedsQL™ NF1 Module,clinical_assessment_tool,Behavioral,"All subscale scores showed statistically significant differences among three health status groups, supporting discriminant validity",Results,"All subscale scores of the instrument were significantly different among the three groups, supporting initial discriminant validity of the PedsQL™ NF1 Module",0.95
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",PedsQL™ NF1 Module,clinical_assessment_tool,Behavioral,"Effect sizes ranged from 0.22 to 0.63, with largest for Pain and Hurt subscale and lowest for Perceived Physical Appearance",Results,"Effect sizes ranged from 0.22 to 0.63, with the largest effect sizes for the Pain and Hurt subscale, and the lowest effect sizes for the Perceived Physical Appearance subscale",0.95
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",PedsQL™ NF1 Module,clinical_assessment_tool,Other,"Demonstrates initial feasibility, reliability, and discriminant validity for understanding multidimensional NF1 impact on HRQOL",Discussion,"The instrument demonstrates initial feasibility, reliability, and discriminant validity",0.9
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,p16,antibody,Biomarker,Loss of p16 expression on immunohistochemical evaluation in NF1-associated gliomas in the molecular high-grade group compared to the molecular low-grade group,Results,"NF1-associated gliomas in the molecular high-grade group often had increased cellular density, higher Ki-67 labeling indices, and loss of p16 and/or ATRX expression on immunohistochemical evaluation compared to the molecular low-grade group.",0.85
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,ATRX,antibody,Biomarker,Loss of ATRX expression on immunohistochemical evaluation in NF1-associated gliomas in the molecular high-grade group compared to the molecular low-grade group,Results,"NF1-associated gliomas in the molecular high-grade group often had increased cellular density, higher Ki-67 labeling indices, and loss of p16 and/or ATRX expression on immunohistochemical evaluation compared to the molecular low-grade group.",0.85
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,Ki-67,antibody,Biomarker,Higher Ki-67 labeling indices in NF1-associated gliomas in the molecular high-grade group compared to the molecular low-grade group,Results,"NF1-associated gliomas in the molecular high-grade group often had increased cellular density, higher Ki-67 labeling indices, and loss of p16 and/or ATRX expression on immunohistochemical evaluation compared to the molecular low-grade group.",0.85
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,trametinib,clinical_assessment_tool,Efficacy,4 of 5 patients with molecular low-grade NF1-associated gliomas experienced stable disease and absence of tumor growth while on MEK inhibitor therapy; 1 patient experienced partial regression of optic pathway glioma,Results,"Of the five patients with NF1-associated gliomas belonging to the molecular low-grade group, four experienced stable disease and absence of tumor growth while on MEK inhibitor therapy at time of last clinical follow-up. The fifth patient (#3) experienced partial regression of an optic pathway glioma during an initial treatment course with trametinib",0.95
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,selumetinib,clinical_assessment_tool,Efficacy,Patient experienced further tumor regression during subsequent treatment course with selumetinib after initial trametinib treatment,Results,The fifth patient (#3) experienced partial regression of an optic pathway glioma during an initial treatment course with trametinib and then further regression during a subsequent treatment course with selumetinib.,0.95
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,trametinib,clinical_assessment_tool,Efficacy,3 of 4 patients with molecular high-grade NF1-associated gliomas demonstrated glioma progression during treatment with MEK inhibitor as single agent; 1 patient experienced stable disease on combination with everolimus,Results,"Of the four patients with NF1-associated gliomas belonging to the molecular high-grade group, three demonstrated glioma progression during treatment with MEK inhibitor as a single agent. The fourth patient experienced stable disease and absence of tumor growth while on the combination of trametinib and everolimus",0.95
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,trametinib,clinical_assessment_tool,Safety,"No patients experienced severe adverse events attributable to MEK inhibitor treatment, with toxicities similar to what has been previously reported",Results,"No patients experienced severe adverse events attributable to the MEK inhibitor treatment, with toxicities similar to what has been previously reported.",0.9
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,selumetinib,clinical_assessment_tool,Safety,"No patients experienced severe adverse events attributable to MEK inhibitor treatment, with toxicities similar to what has been previously reported",Results,"No patients experienced severe adverse events attributable to the MEK inhibitor treatment, with toxicities similar to what has been previously reported.",0.9
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,selumetinib,clinical_assessment_tool,Efficacy,All five NF1 patients with molecular low-grade gliomas treated with MEK inhibitors experienced stable disease or tumor regression and did not require additional therapies,Discussion,"In our cohort, all five NF1 patients with molecular low-grade gliomas that were treated with small molecule MEK inhibitors (either selumetinib or trametinib) experienced stable disease or tumor regression and did not require additional therapies",0.95
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,trametinib,clinical_assessment_tool,Efficacy,All five NF1 patients with molecular low-grade gliomas treated with MEK inhibitors experienced stable disease or tumor regression and did not require additional therapies,Discussion,"In our cohort, all five NF1 patients with molecular low-grade gliomas that were treated with small molecule MEK inhibitors (either selumetinib or trametinib) experienced stable disease or tumor regression and did not require additional therapies",0.95
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,selumetinib,clinical_assessment_tool,Efficacy,Patients with molecular high-grade gliomas did not respond to single agent MEK inhibition,Discussion,whereas patients with molecular high-grade gliomas did not respond to single agent MEK inhibition.,0.9
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,trametinib,clinical_assessment_tool,Efficacy,Patients with molecular high-grade gliomas did not respond to single agent MEK inhibition,Discussion,whereas patients with molecular high-grade gliomas did not respond to single agent MEK inhibition.,0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,sNF96.2,cell_line,Biomarker,"Low miR-29c expression, consistent with low miR-29c expression in MPNST",Results,"We chose sNF96.2 as a previous TaqMan assay showed that the sNF96.2 cell line had low miR-29c expression, a finding consistent with low miR-29c expression in MPNST.",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,sNF96.2,cell_line,Efficacy,Cell motility was significantly reduced in transwell plates and scratch/wound healing assays when transfected with miR-29c mimic,Results,"Transient transfection of the MPNST cell line, sNF96.2, using a miR-29c mimic, and scrambled oligonucleotides (control) revealed that cell motility was significantly reduced in transwell plates, and the scratch/wound healing assays",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,sNF96.2,cell_line,Efficacy,No effect on cell growth/proliferation following transfection with miR-29c mimics using multiple assays,Results,"No effect on cell growth/proliferation of the sNF96.2 cells was noted following transfection with the miR-29c mimics using a number of assays, including a live-cell imaging system IncuCyte, the MTS assay and growing the cells in 3-D culture using soft agar",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,sNF96.2,cell_line,Mechanistic,Significantly reduced proteolytic activity compared with control cultures when transfected with miR-29c mimics,Results,"We found loss of bands corresponding to MMP2, which supports the hypothesis that the cells expressing miR-29c mimics had significantly reduced proteolytic activity compared with control cultures",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,Agilent Human miRNA Microarray V2,computational_tool,Biomarker,"Successfully identified 16 miRNA significantly differentially expressed in MPNST compared with neurofibromas, with 14 downregulated including miR-29c",Results,"Sixteen miRNA were significantly differentially expressed in MPNST compared with neurofibromas and of these fourteen were downregulated in MPNST: these included miR-30e*, miR-29c*, miR-29c, miR-340*",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,TaqMan miRNA assays,computational_tool,Biomarker,"Confirmed differential expression of five miRNAs including miR-139-5p, miR-210, miR-29c, miR-30e-3p, and miR-340 on 19 index cases",Results,"The differential expression of five of these miRNA, including miR-139-5p, miR-210, miR-29c, miR-30e-3p, and miR-340 was confirmed by a TaqMan assay performed on the same source of RNA",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,miRNA mimics,genetic_reagent,Mechanistic,"miR-29c mimic significantly downregulated predicted target genes including COL1A1, COL1A2, COL5A2, COL21A1, COL4A1, COL4A2, TGFβ3, and MMP2",Results,"Analysis by RT–qPCR showed that the predicted genes including COL1A1, COL1A2, COL5A2, COL21A1, COL4A1, COL4A2, TGFβ3, and MMP2 were significantly downregulated compared with the scrambled miRNA mimic control",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,MMP2 antibody (CA-4001),antibody,Mechanistic,Showed significant reduction in MMP2 protein level in miR-29c-transfected cells,Results,"This interpretation was supported by the western blot and RT–qPCR analyses on the material from the same experiments, which showed a significant reduction in MMP2 protein level and mRNA, respectively",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,MMP9 antibody (EP1254),antibody,Mechanistic,Showed no significant effect on MMP9 protein expression level when cells were transfected with miR-29c,Results,"Western blot analysis and RT–qPCR of MMP9 showed no significant effect on the expression level of protein and mRNA, respectively. Furthermore, when the MPNST cell line sNF96.2 was transfected with miR-29c synthetic oligonucleotide (mimic), MMP9 expression was not altered",0.9
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,IncuCyte,computational_tool,Efficacy,Used to assess cell growth/proliferation and showed no effect following miR-29c mimic transfection,Results,"No effect on cell growth/proliferation of the sNF96.2 cells was noted following transfection with the miR-29c mimics using a number of assays, including a live-cell imaging system IncuCyte",0.8
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",Wisconsin Miniature SwineTM,animal_model,Biomarker,"NF1 gene shows 99.96% sequence identity match with S. scrofa, differing by single amino acid insertion (Pro771_Ala772insThr)",Results,"Local alignment of the amino acid sequences showed a sequence identity match of 99.96%, differing by a single amino acid insertion (Pro771_Ala772insThr) in the WMS TM NF1 sequence.",0.95
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",Wisconsin Miniature SwineTM,animal_model,Biomarker,NF1 amino acid sequence shows 99.12% identity match (2817/2842) and 99.47% similarity match to human homolog,Results,Comparison of the WMS TM NF1 amino acid sequence to the human homolog (ENST00000358273.9) revealed a 99.12% (2817/2842) identity match and an additional 10 positions in which they shared similar amino acids (99.47% similarity match).,0.95
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",Wisconsin Miniature SwineTM,animal_model,Biomarker,NF1 protein structural prediction shows strong similarity to human with root mean square deviation of 2.114 Å,Results,"Structural prediction and alignments show a strong similarity, reflected by a root mean square deviation of 2.114 Å",0.92
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",Wisconsin Miniature SwineTM,animal_model,Biomarker,AHR amino acid sequence shows 98.35% identity match to S. scrofa and 81.66% identity match to human AHR (699/856 positions),Results,Alignment of the S. scrofa canonical AHR CDS (ENSSSCT00000031031.4) to the WMS TM genome produced a CDS encoding an 844-long AHR amino acid that shared a 98.35% identity match to the S. scrofa AHR amino acid sequence... the WMS TM AHR amino acid sequence shared an 81.66% identity match to the human AHR (699/856 positions),0.95
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",WMSTM-WT,animal_model,Biomarker,"Shows clear genetic separation from WMS-FH herd in principal component analysis, with first 3 components explaining 65% of variance",Results,"Ordination analysis of biallelic SNPs revealed robust segregation of unique subpopulations, with the first 3 principal components explaining 65% of the variance in the dataset. Notably, a single principal component clearly distinguished between WMS TM -WT and WMS TM -FH samples",0.9
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",WMSTM-FH,animal_model,Biomarker,Shows clear genetic separation from WMS-WT herd and reveals distinct subpopulations within the herd when analyzed independently,Results,"Without the confounding effect of FH allelic discrimination, this analysis provided finer resolution and revealed distinct subpopulations within the WMS TM -FH herd.",0.88
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",Flye v2.5,computational_tool,Other,"Generated draft assembly consisting of 1,215 contigs with mean coverage of 17X from 48 Gb ONT sequencing data",Results,"Using the Flye assembler, we generated a draft WMS TM assembly consisting of 1,215 contigs exhibiting a mean coverage of 17X.",0.92
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",BUSCO v5.7.0,computational_tool,Other,"Achieved BUSCO score of 98.2% ([S:97.9%, D:0.3%], F:1.0%, M:0.8%) for WMS assembly, surpassing existing S. scrofa reference genomes",Results,"The WMS TM draft assembly achieved a BUSCO score of 98.2% ([S:97.9%, D:0.3%], F:1.0%, M:0.8%), indicating that we have a highly complete assembly... The BUSCO assessment of the assembly generated here surpasses the BUSCO scores for existing S. scrofa reference genomes (Sscrofa11.1 = 93.8% and USMARCv1.0 = 93.1%)",0.95
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",Liftoff v1.6.3,computational_tool,Other,"Resulted in 97.76% match with Sscrofa11.1 annotations with alignment coverage and sequence identity ≥50%, identifying 19,853 matches (96.4%) out of 20,306 annotations",Results,"When applied to WMS TM , the lift-over annotation resulted in a 97.76% match with Sscrofa11.1 annotations with an alignment coverage and sequence identity ≥50%. The gene features in the S. scrofa genome used in our analysis included 20,306 annotations, of which we identified 19,853 matches (96.4%).",0.95
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,Smart-seq2,computational_tool,Other,"Allowed sensitive detection of high number of genes per cell and retained 11,434 cells after stringent quality controls",Results,"We leveraged the Smart-seq2 full-length single-cell RNA-sequencing protocol and retained 11,434 cells after stringent quality controls. The Smart-Seq2 protocol was chosen as it allows for sensitive detection of a high number of genes per cell",0.9
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,scdDblFinder,computational_tool,Other,Used for doublet inference with conservative 5% cutoff - only 1 out of 90 fibroblasts and 2 out of 32 pericytes with Chr 22 deletion met doublet threshold,Results,"we performed doublet inference using two different algorithms (SCBDL and SCRAN; see Methods), setting a conservative cutoff (5%) for doublet detection. Within the fibroblasts with Chr 22 deletion, only one cell (out of 90) met the doublet threshold",0.9
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,scran,computational_tool,Other,Used for doublet inference with results consistent across algorithms - only 1 out of 90 fibroblasts and 2 out of 32 pericytes with Chr 22 deletion met doublet threshold,Results,we performed doublet inference using two different algorithms (SCBDL and SCRAN; see Methods). The results of this analysis were consistent across the two algorithms,0.9
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,"anti-HLA Class I ABC antibody, ab225636, Abcam",antibody,Biomarker,Showed lower staining intensity compared to MHC class II in schwannomas (p = 0.0086),Results,"Quantification of the relative intensity of staining demonstrated higher MHC class II staining when compared to MHC class I (p = 0.0086, Additional file 7 : Fig. S3B) in schwannoma",0.9
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,"anti-MHC Class II antibody, ab55152, Abcam",antibody,Biomarker,Showed higher staining intensity compared to MHC class I in schwannomas (p = 0.0086),Results,"Quantification of the relative intensity of staining demonstrated higher MHC class II staining when compared to MHC class I (p = 0.0086, Additional file 7 : Fig. S3B) in schwannoma",0.9
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,QuPath,computational_tool,Other,Used for quantification of relative intensity of MHC class I and II staining in immunohistochemistry analysis,Results,we performed immunohistochemistry staining for MHC class I and II proteins in schwannomas and other tumors. Quantification of the relative intensity of staining demonstrated higher MHC class II staining,0.8
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,GENIE (Genomics Evidence Neoplasia Information Exchange),computational_tool,Other,"Database analysis of 119,538 patients identified 5,767 cases harboring BRAF alterations, with specific distribution: 3,761 class 1, 529 class 2, 651 class 3, and 282 BRAF fusions",Results,"Shown by large genomic database analysis using GENIE and cancer alteration databases in cBioPortal, 5767 cases harbored BRAF alterations, 3761 of which belong to class 1, 529 class 2, 651 class 3, and 282 BRAF fusions",0.95
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,cBioPortal,computational_tool,Other,"Database analysis of 119,538 patients identified 5,767 cases harboring BRAF alterations, with specific distribution: 3,761 class 1, 529 class 2, 651 class 3, and 282 BRAF fusions",Results,"Shown by large genomic database analysis using GENIE and cancer alteration databases in cBioPortal, 5767 cases harbored BRAF alterations, 3761 of which belong to class 1, 529 class 2, 651 class 3, and 282 BRAF fusions",0.95
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,GENIE (Genomics Evidence Neoplasia Information Exchange),computational_tool,Biomarker,"Identified coexisting RAS alterations in 138 (3.6%) class 1 BRAF cases, 107 (20.2%) class 2 cases, 212 (32.6%) class 3 cases, and 8 (2.8%) BRAF fusion cases",Results,"Among them, 138 (3.6%) cases with class 1 BRAF alterations, 107 (20.2%) class 2, 212 (32.6%) class 3, and 8 (2.8%) cases with BRAF fusions harbor alterations in RAS or RAS regulatory genes",0.95
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,cBioPortal,computational_tool,Biomarker,"Identified coexisting RAS alterations in 138 (3.6%) class 1 BRAF cases, 107 (20.2%) class 2 cases, 212 (32.6%) class 3 cases, and 8 (2.8%) BRAF fusion cases",Results,"Among them, 138 (3.6%) cases with class 1 BRAF alterations, 107 (20.2%) class 2, 212 (32.6%) class 3, and 8 (2.8%) cases with BRAF fusions harbor alterations in RAS or RAS regulatory genes",0.95
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Mechanistic,"CRISPRi suppression of NF2 in HEI-193 cells promoted cell proliferation compared to control sgRNAs, suggesting NF2 retains tumor suppressor functionality",Results,CRISPRi suppression of NF2 in HEI-193 cells stably expressing dCas9-KRAB promoted cell proliferation compared to HEI-193 cells expressing non-targeted control sgRNAs (sgNTC),0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Efficacy,Radiotherapy blocked the growth of HEI-193 schwannoma cells with both fractionated (1.8 Gy x 5 fractions) and hypofractionated (12.5 Gy x 1 fraction) treatments,Results,"Radiotherapy blocked the growth of schwannoma cells (Supplementary Fig. 14a, b), and qPCR assessment of genes distinguishing molecular groups of human schwannomas",0.9
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Mechanistic,"Radiotherapy blocked HEI-193 Hedgehog target gene expression, consistent with results from human Schwann cells",Results,"Consistent with results from human Schwann cells (Supplementary Fig. 13h–j), radiotherapy blocked HEI-193 Hedgehog target gene expression",0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Mechanistic,CRISPRi suppression of APOD or SOX6 attenuated schwannoma cell proliferation compared to cells expressing control sgRNAs,Results,"APOD or SOX6 were suppressed in HEI-193 cells using CRISPRi, which each attenuated schwannoma cell proliferation compared to cells expressing sgNTC",0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,HEI-193,cell_line,Mechanistic,CRISPRi suppression of PTPRG enhanced schwannoma cell apoptosis when combined with radiotherapy,Results,CRISPRi suppression of PTPRG enhanced schwannoma cell apoptosis with radiotherapy,0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_line,Mechanistic,"Primary cilia were identified on cultured human Schwann cells, which accumulated Smoothened in cilia and activated the Hedgehog transcriptional program in response to recombinant Sonic Hedgehog",Results,"Primary cilia were also identified on cultured human Schwann cells, which accumulated Smoothened in cilia and activated the Hedgehog transcriptional program in response to recombinant Sonic Hedgehog",0.9
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_line,Efficacy,Schwann cell proliferation was blocked by the Smoothened antagonist vismodegib or radiotherapy,Results,Schwann cell proliferation was blocked by the Smoothened antagonist vismodegib or radiotherapy,0.9
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_line,Mechanistic,"Radiotherapy reduced ciliary length, attenuated Smoothened accumulation in primary cilia, and blocked Hedgehog target gene expression",Results,"radiotherapy also reduced ciliary length, attenuated Smoothened accumulation in primary cilia, and blocked Hedgehog target gene expression",0.9
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"SOX10 (API 3099, Biocare)",antibody,Biomarker,SOX10 was expressed in both molecular groups but was enriched in neural crest compared to immune-enriched tumors based on immunofluorescence on 49 schwannomas,Results,Immunofluorescence on 49 schwannomas showed the Schwann cell differentiation marker SOX10 was expressed in both molecular groups but was enriched in neural crest compared to immune-enriched tumors,0.9
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"CD3 (A0452, Agilent Technologies)",antibody,Biomarker,CD3 immunohistochemistry was greater in immune-enriched compared to neural crest schwannomas,Results,"immunohistochemistry for CD68, CD3, and PD1 was greater in immune-enriched compared to neural crest schwannomas",0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"CD68 (M0814, Agilent Technologies)",antibody,Biomarker,CD68 immunohistochemistry was greater in immune-enriched compared to neural crest schwannomas,Results,"immunohistochemistry for CD68, CD3, and PD1 was greater in immune-enriched compared to neural crest schwannomas",0.85
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,Harmony,computational_tool,Other,"Integration of 10,628 single-nuclei or single-cell transcriptomes using Harmony revealed 13 cell clusters in UMAP space",Results,"Integration of 10,628 single-nuclei or single-cell transcriptomes using Harmony revealed 13 cell clusters in uniform manifold approximation and projection (UMAP) space",0.9
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,MEMS Cap,clinical_assessment_tool,Other,MEMS caps proved a feasible method for assessing medication adherence among adults with NF1,Discussion,"MEMS TM  caps proved a feasible method, and our results can inform future clinical trials studying oral medications with an NF1 population.",0.8
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"CD90/PECy5 (5E10, BioLegend, CA, USA)",antibody,Biomarker,Showed uniform expression in both control and NF1 DPSCs at passage 3 and 4,Results,"Both control and NF1 DPSCs at passage 3 and 4 showed a uniform expression of CD90, CD105 and CD146.",0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"CD105/APC (45A5A3, BioLegend)",antibody,Biomarker,Showed uniform expression in both control and NF1 DPSCs at passage 3 and 4,Results,"Both control and NF1 DPSCs at passage 3 and 4 showed a uniform expression of CD90, CD105 and CD146.",0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"CD146/PE (P1H12, BD Biosciences)",antibody,Biomarker,Showed uniform expression in both control and NF1 DPSCs at passage 3 and 4,Results,"Both control and NF1 DPSCs at passage 3 and 4 showed a uniform expression of CD90, CD105 and CD146.",0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"CD271/APC (C401457, BD Biosciences)",antibody,Biomarker,All DPSCs cultures were negative for CD271,Results,All DPSCs cultures were negative for CD271 as well as for hematopoietic markers CD14 and CD34.,0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"CD14/PE (M5E2, BD Biosciences, CA, USA)",antibody,Biomarker,All DPSCs cultures were negative for hematopoietic marker CD14,Results,All DPSCs cultures were negative for CD271 as well as for hematopoietic markers CD14 and CD34.,0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"CD34/FITC (581, BD Biosciences)",antibody,Biomarker,All DPSCs cultures were negative for hematopoietic marker CD34,Results,All DPSCs cultures were negative for CD271 as well as for hematopoietic markers CD14 and CD34.,0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"CD45/ALexa405 (HI30, Caltag Medsystems)",antibody,Biomarker,"The percentage of CD45+ cells was less than 5%, ranging from 1.7 to 4.0%",Results,"The percentage of CD45+ cells was less than 5%, ranging from 1.7 to 4.0%",0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"anti-Ki-67 (1:80; M7240; Dako Corporation, CA, USA)",antibody,Biomarker,"None of the pellets showed Ki-67 expression at the 21st day of chondrogenic differentiation, indicating no cell proliferation",Results,"None of the pellets showed Ki-67 expression, indicating that, at the 21st day of chondrogenic differentiation, there was no cell proliferation",0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,NF37,patient_derived_model,Biomarker,Pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm during chondrogenic differentiation,Results,"CT10, CT11 and NF37 pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm.",0.8
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,NF87,patient_derived_model,Biomarker,Showed increased GAGs stained area compared to controls after chondrogenic differentiation in 2D cultures,Results,"the percentage of GAGs stained area was higher in the NF1 group compared with the control group (p = 0.004, Mann-Whitney test)",0.9
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,CT10,patient_derived_model,Biomarker,Pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm during chondrogenic differentiation,Results,"CT10, CT11 and NF37 pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm.",0.8
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,CT11,patient_derived_model,Biomarker,Pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm during chondrogenic differentiation,Results,"CT10, CT11 and NF37 pellets presented a polar area with a group of smaller cells with eosinophilic cytoplasm.",0.8
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"ImageJ software v.1.49 (NIH, USA)",computational_tool,Other,Used for quantification of GAGs stained area showing higher percentage in NF1 group compared to control group (p = 0.004),Results,"the percentage of GAGs stained area was higher in the NF1 group compared with the control group (p = 0.004, Mann-Whitney test)",0.9
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,CTL BJFF.6 hiPSCs,cell_line,Mechanistic,"Successfully differentiated into hiMGL cells expressing microglial markers AIF1, TMEM119, and P2RY12 at both mRNA and protein levels",Results,"As expected for microglia-like cells, the expression of all three genes was increased in hiMGL cells compared to that in HPCs, whereas it was undetectable or the genes were expressed at very low levels in iPSCs",0.95
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,STEMdiff hematopoietic kit,genetic_reagent,Mechanistic,"Successfully initiated hematopoiesis from hiPSCs, producing floating hematopoietic progenitor cells harvested on day 12 post induction",Results,"Briefly, hiPSCs were seeded at low density and hematopoiesis initiated using the STEMdiff hematopoietic kit. Floating hematopoietic progenitor cells (HPCs) were harvested and reseeded",0.9
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,IBA1 antibody,antibody,Biomarker,Successfully detected IBA1 protein expression in both CTL and NF1-mutant hiMGL cells by immunocytochemical staining,Results,"Immunocytochemical staining of these hiMGL cells confirmed the expression of IBA1 (encoded by AIF1), TMEM119 and P2RY12 at the protein level",0.9
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,IncuCyte Zoom live cell analysis system,computational_tool,Behavioral,Detected 30% reduced baseline motility in NF1-mutant hiMGL cells compared to CTL counterparts at 4 hours after scratch wound,Results,We next investigated the impact of NF1 mutation on hiMGL cell motility and found that NF1-mutant hiMGL cells had ∼30% reduced baseline motility relative to that of their CTL counterparts 4 h after generating the scratch,0.95
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,IncuCyte Zoom live cell analysis system,computational_tool,Mechanistic,Showed that 1000 µM ATP led to faster wound healing (RWD: 81.7±45.7%) compared to basal conditions (26.5±4.9%) in CTL hiMGL cells,Results,"In contrast, higher concentrations of ATP (1000 µM) led to faster wound healing, which was almost complete after 4 h (RWD: 81.7±45.7%), and therefore significantly faster than that observed under basal conditions without ATP (26.5±4.9%)",0.95
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,cAMP ELISA kit,clinical_assessment_tool,Biomarker,"Showed no differences in cAMP levels between NF1-mutant and CTL hiMGL cells, contrasting with mouse Nf1-mutant microglia findings",Results,"In addition, unlike Nf1+/− mouse microglia (Elmadany et al., 2020b), NF1-mutant hiMGL cells exhibited no differences in cyclic AMP (cAMP) levels relative to those of controls",0.9
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,MILLIPLEX MAP human cytokine/chemokine/growth factor panel A,clinical_assessment_tool,Biomarker,"Detected similar levels of secreted IL-6, TNF-α, and other cytokines in NF1-mutant and CTL hiMGL cells following LPS stimulation",Results,"The levels of secreted IL-6 and TNF-α (also known as TNFA) as well as G-CSF (or CSF3), IL-1β (IL1B), GRO (CXCL1), IL-10, IP-10 (CXCL10), MCP-1 (CCL2), MCP-3 (CCL7), MIP-1β (CCL4), MIP-1α (CCL3) and CCL5 (RANTES) were similar in NF1-mutant and CTL hiMGL cells",0.9
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,hiMGL cells,advanced_cellular_model,Mechanistic,"NF1-mutant hiMGL cells showed reduced P2X-dependent inward conductances: M1 (3.5±4.0 pS/pF), M2 (0.2±2.7 pS/pF), M3 (7.7±1.0 pS/pF) compared to CTL (25.7±6.2 pS/pF)",Results,"quantification of inward conductance as a measure of P2X-like currents revealed reduced conductances for M1 (3.5±4.0 pS/pF, n=9; P=0.0024), M2 (0.2±2.7 pS/pF, n=14; P<0.0001) and M3 (7.7±1.0 pS/pF, n=11; P=0.0095) NF1-mutant hiMGL cells",0.95
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,hiMGL cells,advanced_cellular_model,Behavioral,"NF1-mutant hiMGL cells showed impaired UDP-induced phagocytosis, with M2 cells showing 50% increase in baseline phagocytic index but no response to UDP treatment",Results,"Whereas M2 hiMGL cells showed a ∼50% increase in baseline phagocytic index relative to that of CTL cells, UDP treatment exclusively increased phagocytic activity in CTL hiMGL cells but not in NF1-mutant hiMGL cells",0.9
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,Illumina EPIC 850K methylation array,computational_tool,Biomarker,"Identified 31,201 significant differentially methylated probes (DMP; q < 0.05) between CNFs and PNFs",Results,"In total, we identified 31,201 significant differentially methylated probes (DMP; q < 0.05). By examining differentially methylated loci with an absolute odds ratio greater than 4",0.95
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,Illumina EPIC 850K methylation array,computational_tool,Biomarker,"Established distinct, base-pair resolution epigenetic signature for CNF and PNFs with minimal overlap between tumor types",Results,"we establish a distinct, base-pair resolution epigenetic signature for CNF and PNFs...individual CpG-based methylation events are highly consistent within CNF and PNF tumor types",0.9
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,DMRcate,computational_tool,Biomarker,"Called 6,004 significantly differentially methylated regions (DMRs; q < 0.05) with 1655 regions showing two-fold changes",Results,"we used the differentially methylated probes identified above to call 6,004 significantly differentially methylated regions (DMRs; q < 0.05) using DMRcate",0.95
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,compartmap,computational_tool,Biomarker,Revealed 3D genomic organization between CNFs and PNFs is 80-85% concordant with 15-20% of compartments inverted or discordant,Results,We show that the 3D genomic organization between CNFs and PNFs is 80–85% concordant whereas 15–20% of the compartments are inverted or discordant,0.95
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,MKK3 antibody,antibody,Biomarker,"MKK3 protein expression strongly inversely correlated with MAP2K3 DMR methylation status (ρ = -0.85, p = 0.00018)",Results,"Western blot of a representative subset of CNF and PNF tumors demonstrated that MKK3 protein expression was highly correlated to MAP2K3 DMR methylation status (DMR1:MKK3 ρ = − 0.85, p = 0.00018)",0.95
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,p38 antibody,antibody,Biomarker,"p38 protein levels negatively correlated with methylation at MAPK14 promoter region (ρ = -0.56, p = 0.038)",Results,"p38 protein levels were negatively correlated with methylation at this site (ρ = − 0.56, p = 0.038)",0.9
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,phospho-p38 antibody,antibody,Biomarker,"CNFs expressed phospho-p38 more abundantly than PNFs, indicating consistent p38 activation in CNFs",Results,"CNFs expressed both MKK3 and p38 more abundantly than PNFs, as well as phospho-p38 indicating consistent p38 activation",0.85
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,phospho-ERK1/2 antibody,antibody,Biomarker,"p38 activation strongly correlated with pERK expression regardless of tumor type (ρ = 0.70, p = 0.006)",Results,"We demonstrate that p38 activation was strongly correlated with pERK expression regardless of tumor type (ρ = 0.70, p = 0.006)",0.95
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,missMethyl,computational_tool,Mechanistic,"KEGG pathway analysis identified differential methylation in RAS, MAPK, PI3K-AKT signaling pathways and inflammatory mediator regulation of TRP channels between CNF and PNF tumor types",Results,"KEGG analysis of global DMR data identified several key cellular processes that differed significantly between tumor types...the RAS, MAPK, and PI3K–AKT signaling pathways were associated with both CNF and PNF development",0.9
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,Lats1 lox/lox Lats2 lox/lox mice,animal_model,Efficacy,"Lats1/2-deficient mice developed nerve-associated tumors with 100% penetrance, including high-grade (grade III) GEM-PNSTs resembling human MPNSTs",Results,The Lats1/2-deficient mice carrying three copies of Lats1/2 deletion alleles...developed nerve-associated tumors with 100% penetrance.,0.95
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,Lats1 lox/lox Lats2 lox/lox mice,animal_model,Safety,Maximum lifespan of Lats1/2-deficient mice was 4-5 months of age,Results,The maximum lifespan of Lats1/2-deficient mice was 4–5 months of age,0.95
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,Plp1-CreERT mice,genetic_reagent,Efficacy,Lats1/2-iDeficient adult mice developed aggressive nerve-associated tumors with full penetrance and shortened life span after tamoxifen administration,Results,Lats1/2-iDeficient adult mice developed aggressive nerve-associated tumors of Sox10+ SC origin after tamoxifen administration with full penetrance and a shortened life span,0.95
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,SNF02.2,cell_line,Efficacy,TAZ/YAP silencing resulted in robust reduction in downstream target gene expression and attenuation of proliferation,Results,We detected a robust reduction in downstream target gene expression and attenuation of proliferation in these MPNST cells,0.9
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,SNF96.2,cell_line,Efficacy,TAZ/YAP silencing resulted in robust reduction in downstream target gene expression and attenuation of proliferation,Results,We detected a robust reduction in downstream target gene expression and attenuation of proliferation in these MPNST cells,0.9
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,Taz lox/lox Yap1 lox/lox mice,genetic_reagent,Efficacy,TAZ/YAP reduction markedly extended survival of Lats1/2-deficient mice and significantly reduced numbers of visible tumor lesions,Results,reduced TAZ/YAP expression in Lats1/2-deficient SCs markedly extended the survival of Lats1/2-def-TazLo/LoYap1Lo/Lo mice...significantly reduced numbers of visible tumor lesions,0.9
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,verteporfin,advanced_cellular_model,Efficacy,"Verteporfin effectively reduced TAZ/YAP expression and activity, impeding mutant tumor cell proliferation and survival",Results,"pharmacological inhibition of TAZ/YAP by verteporfin...effectively reduced TAZ/YAP expression and activity, which impeded mutant tumor cell proliferation and survival",0.9
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,verteporfin,advanced_cellular_model,Efficacy,Single-agent verteporfin at 50 mg/kg suppressed tumor growth relative to vehicle in vivo,Results,Although the single-agent therapy suppressed tumor growth relative to vehicle,0.85
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,verteporfin,advanced_cellular_model,Efficacy,Combined verteporfin and sorafenib at reduced dosage robustly decelerated SC-derived tumor cell progression much greater than single-agent regimen,Results,concurrent targeting of TAZ/YAP and PDGFR signaling by combined verteporfin and sorafenib with the reduced dosage robustly decelerated SC-derived tumor cell progression much greater than the single-agent regimen,0.95
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,sorafenib p-Toluenesulfonate salt,advanced_cellular_model,Efficacy,Sorafenib treatment exerted dosage-dependent inhibition of proliferation in mutant tumor cells,Results,Imatinib or sorafenib treatment exerted a dosage-dependent inhibition of the proliferation in mutant tumor cells,0.9
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,imatinib mesylate,advanced_cellular_model,Efficacy,Imatinib treatment exerted dosage-dependent inhibition of proliferation in mutant tumor cells,Results,Imatinib or sorafenib treatment exerted a dosage-dependent inhibition of the proliferation in mutant tumor cells,0.9
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,imatinib mesylate,advanced_cellular_model,Efficacy,Targeting PDGFR signaling by imatinib reduced BrdU+ proliferative SNF02.2 cell number in a dose-dependent manner,Results,targeting PDGFR signaling by imatinib or sorafenib reduced BrdU+ proliferative SNF02.2 cell number in a dose-dependent manner,0.9
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,GSEA,computational_tool,Biomarker,GSEA revealed YAP conserved signature as one of the top significantly enriched oncogenic gene sets in MPNSTs compared with normal nerves or NF1-neurofibromas,Results,Gene set enrichment analysis (GSEA)...revealed a YAP conserved signature as one of the top significantly enriched oncogenic gene sets in Molecular Signatures Database (MSigDB) in MPNSTs,0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tool,Other,Final version comprised 14 items with good internal reliability (Cronbach's alpha 0.87),Results,The final version of the INF1-QOL questionnaire showed good internal reliability (Cronbach's alpha 0.87).,0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tool,Behavioral,"Mean total INF1-QOL score was 8.64 (SD 6.3), median 7.0 with a range of 0–30",Results,"The mean total INF1-QOL score was 8.64 (SD 6.3), median 7.0 with a range of 0–30",0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tool,Other,"Strong correlation with EuroQol (r = 0.82, p < 0.0001)",Results,"The correlation of total INF1-QOL score with total EuroQol was r = 0.82, p < 0.0001.",0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tool,Other,"Moderate correlation with clinical severity score (r = 0.34, p < 0.05)",Results,The mean clinical severity score was 1.95 (SD 0.65) correlated r = 0.34 with total INF1-QOL score p < 0.05,0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,EuroQol (EQ 5D),clinical_assessment_tool,Behavioral,"Mean total EuroQol score was 7.38 (SD 2.87), median 6.5, with range of 5–18; mean global EuroQol score was 76.34 (SD 16.56), median 80, range of 25–100",Results,"The mean total EuroQol score was 7.38 (SD 2.87), median 6.5, with an observed range of 5–18 and the mean global EuroQol score was 76.34 (SD 16.56), median 80, range of 25–100.",0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Riccardi NF severity grade classification,clinical_assessment_tool,Other,"Mean inter-rater reliability was 0.71 (range 0.65-0.79), intra-class correlation was 0.92",Results,"The mean inter-relater reliability for the grading of clinical severity scores was 0.71 (range 0.65-0.79), and the intra-class correlation was 0.92.",0.95
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,Riccardi NF severity grade classification,clinical_assessment_tool,Other,"Mean clinical severity score was 1.95 (SD 0.65); 34% patients had mild NF1, 32% had moderate disease, and 34% were rated as severe",Results,"The mean clinical severity score was 1.95 (SD 0.65)...17 (34%) patients had mild NF1, 16 (32%) had moderate disease and 17 (34%) were rated as severe.",0.95
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,Impact of Pediatric Illness Scale,clinical_assessment_tool,Other,Tool was used to assess study variables but no specific performance metrics or outcomes were reported,Results,"Patient age, gender, and parent education were unrelated to primary study variables.",0.6
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,Pain Management Inventory,clinical_assessment_tool,Other,Tool was used to assess pain management strategies but no specific performance metrics or outcomes were reported,Results,"Nonpharmacological techniques to address pain included yoga (n = 1), massage (n = 1), and hydrotherapy (n = 1).",0.6
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,Post-Treatment Questionnaire,clinical_assessment_tool,Behavioral,"Mean patient satisfaction rating was 3.9 out of 5 (SD = 1.3, range 1-5) and mean parent satisfaction rating was 4.6 out of 5 (SD = 0.51, range 4-5)",Results,"At the 3-month follow-up, the mean rating of how much patients liked participating in the study was 3.9 out of 5 (SD = 1.3, range 1–5). The mean parent rating was 4.6 out of 5 (SD = 0.51, range 4–5).",0.9
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,visual analogue scale,clinical_assessment_tool,Behavioral,"Used to assess pain in NF1 patients, with 8 of 20 NF1 patients (40.0%) confirmed to have NF-associated painful neuropathy",Results,"In 8 of the 20 NF1 patients (40.0%), the diagnosis of NF-associated painful neuropathy was confirmed.",0.8
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,3D Slicer,computational_tool,Other,"Used for voxel-wise DRG segmentation performed manually by two independent, blinded raters, achieving very good inter-rater intraclass correlation coefficient for DRG volume (0.94) and PD (0.98) and good correlation for T2 (0.70)",Results,"The inter-rater intraclass correlation coefficient (two-way, agreement) was 0.94 (95% confidence interval 0.87–0.97) for DRG volume, 0.70 (0.60–0.78) for DRG T2, and 0.98 (0.94–0.99) for DRG PD.",0.9
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,R,computational_tool,Other,"Used for receiver operating characteristic analysis showing DRG PD parameter achieved AUC = 0.84 for discriminating between pain and non-pain phenotype in NF1 patients, with optimal threshold of 0.918 a.u. giving sensitivity of 0.75 and specificity of 0.92",Results,"For discriminating between pain and non-pain phenotype in NF1 patients, the DRG PD parameter (AUC = 0.84; Fig. 4) was superior to DRG volume (AUC = 0.72) and DRG T2 (AUC = 0.71)",0.95
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,GraphPad Prism,computational_tool,Other,"Used for statistical analysis demonstrating significant differences in DRG measurements between NF1 patients and controls, including 176.3% increase in DRG volume (p < 0.001), 22.9% increase in T2 relaxation time (p = 0.007), and 8.4% increase in PD (p = 0.007)",Results,"DRG from patients with NF1 (n = 20) showed a significant increase in volume (+176.3%; median 1,736.5 versus 628.4 mm³, p < 0.001), T2 relaxation time (+22.9%; median 118.2 versus 96.2 ms, p = 0.007), and PD (+8.4%; median 0.903 versus 0.833 a.u., p = 0.007)",0.95
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,Nf1+/- mice,animal_model,Mechanistic,Enhanced EC outgrowth from aortic rings in response to VEGF compared to WT mice,Results,EC outgrowth was significantly higher in Nf1+/− aortic rings stimulated with VEGF when compared with WT aortic rings stimulated with VEGF,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,Nf1+/- mice,animal_model,Mechanistic,Increased CD31-positive vessel-like networks in Matrigel plugs containing VEGF compared to WT mice,Results,Matrigel plugs harvested from Nf1+/− mice were invested with more CD31-positive vessel-like networks when compared with Matrigel plugs harvested from WT mice,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,Nf1+/- mice,animal_model,Mechanistic,Increased central vessel dropout area and enhanced neovascularization in oxygen-induced retinopathy model at P17,Results,exposure to hyperoxia from P7 to P12 increased central vessel dropout area and enhanced neovascularization in Nf1+/− mice at P17 when compared with WT mice,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,Nf1+/- mice,animal_model,Mechanistic,Increased number of branching capillaries adjacent to avascular retina compared to WT mice,Results,The number of branching capillaries adjacent to the avascular retina was increased in Nf1+/− mice when compared with WT mice,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,human endothelial colony forming cells (ECFC),cell_line,Mechanistic,VEGF treatment reduced neurofibromin protein expression in both confluent and subconfluent (60%-70%) cells,Results,Incubation of human ECFC with VEGF reduced neurofibromin protein expression in confluent and subconfluent (60%–70%) ECFC,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,human endothelial colony forming cells (ECFC),cell_line,Mechanistic,"Neurofibromin expression fully restored by 30 minutes after VEGF treatment, corresponding with blunting of Erk and Akt phosphorylation",Results,"neurofibromin expression was fully restored by 30 minutes after VEGF treatment, which corresponded with blunting of Erk and Akt phosphorylation",0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,human microvascular endothelial cells (HMVEC),cell_line,Mechanistic,Similar molecular signature to ECFC with decreased neurofibromin expression and enhanced Akt/Erk phosphorylation in response to VEGF,Results,A similar molecular signature was observed in HMVEC,0.8
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,NF1 small hairpin RNA (TRCN000023878),genetic_reagent,Mechanistic,Successfully decreased neurofibromin expression in ECFC without enhancing Erk or Akt phosphorylation in absence of growth factor stimulation,Results,decreased neurofibromin expression in ECFC (NF1 KD) does not enhance Erk or Akt phosphorylation in the absence of growth factor stimulation,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,NF1 small hairpin RNA (TRCN0000039713),genetic_reagent,Mechanistic,Successfully decreased neurofibromin expression in ECFC without enhancing Erk or Akt phosphorylation in absence of growth factor stimulation,Results,"Using two shRNA constructs targeting the Nf1 gene, we show that decreased neurofibromin expression in ECFC (NF1 KD) does not enhance Erk or Akt phosphorylation",0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,Tie2cre mice,genetic_reagent,Mechanistic,Nf1flox/+;Tie2cre retinas exhibited increased neovascularization similar to Nf1+/- retinas but markedly reduced central vessel dropout,Results,"Nf1flox/+;Tie2cre retinas exhibited increased neovascularization, which was similar qualitatively and quantitatively to Nf1+/− retinas... central vessel dropout was markedly reduced",0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,VE-cadherin cre mice,genetic_reagent,Mechanistic,"Nf1flox/+;VEcre retinas exhibited increased neovascularization and vessel dropout, closely resembling Nf1+/- animals",Results,"Nf1flox/+;VEcre retinas exhibited increased neovascularization and vessel dropout, which closely resembled our observations in Nf1+/− animals",0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,anti-neurofibromin antibody (#A300),antibody,Mechanistic,Successfully detected decreased neurofibromin expression in response to VEGF treatment and in NF1 knockdown cells,Results,Representative Western blots showing neurofibromin expression in response to VEGF... Representative Western blot confirming NF1 gene silencing,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,anti-phospho-Akt XP antibody (#4060),antibody,Mechanistic,Successfully detected enhanced Akt phosphorylation in response to VEGF treatment corresponding with decreased neurofibromin expression,Results,These observations corresponded with enhanced phosphorylation of Akt and Erk kinases,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,anti-phospho-Erk XP antibody (#4370),antibody,Mechanistic,Successfully detected enhanced Erk phosphorylation in NF1 KD ECFC in response to VEGF compared to control cells,Results,"In response to VEGF, NF1KD ECFC exhibit enhanced Erk phosphorylation as compared with shCtr ECFC",0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,FITC-anti-CD31 antibody,antibody,Mechanistic,Successfully identified increased CD31-positive vessel-like networks in Matrigel plugs from Nf1+/- mice compared to WT,Results,Matrigel plugs harvested from Nf1+/− mice were invested with more CD31-positive vessel-like networks when compared with Matrigel plugs harvested from WT mice,0.9
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,ImageJ,computational_tool,Other,"Used for quantitative analysis of vessel dropout, neovascular area, and branching in retinal flat mounts",Results,Quantification of percent vessel dropout... and neovascular area... Quantification of branching,0.8
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,GraphPad Prism version 6.0h,computational_tool,Other,"Used for statistical analysis of experimental data with significance levels reported as *P < 0.01, **P < 0.001",Results,"Data represent mean ± SEM, *P < 0.01, **P < 0.001... Data represent mean ± SD",0.8
PMID:34646065,10.1155/2021/9386823,Survival and ,S100 B,antibody,Biomarker,"S100 B immunohistochemistry status was positive in 9 tumors, negative in 4, and could not be determined in 7 cases",Results,"S100 B immunohistochemistry status was reported positive in 9 tumors, negative in 4, and could not be determined in 7.",0.95
PMID:34646065,10.1155/2021/9386823,Survival and ,S100 B,antibody,Biomarker,Subjects with positive S100 B status had significantly better cumulative survival outcome (p=0.003),Results,Subjects with positive S100 B status were shown to have a significantly better cumulative survival outcome ( p =0.003),0.95
PMID:34646065,10.1155/2021/9386823,Survival and ,S100 B,antibody,Biomarker,Potential use of S100 B immunostaining in prognosis highlighted,Discussion,This work also highlighted the potential use of S100 B immunostaining in prognosis.,0.85
PMID:34646065,10.1155/2021/9386823,Survival and ,TaqMan NF1 copy-number assays,genetic_reagent,Other,"Used to analyze germline NF1 mutations in 27 NF1 cases, identifying distribution of mutation types: nonsense (9), missense (4), frameshift (5), splicing (5), deletion spanning most of gene (1), and whole-gene deletion (4)",Results,"Among banked DNAs, there were 27 NF1 cases who developed MPNSTs and/or had a positive family history of MPNSTs...germline NF1 mutations among these 27 families were distributed as follows",0.9
PMID:34646065,10.1155/2021/9386823,Survival and ,SPSS 25,computational_tool,Other,Used for statistical analysis to determine significance of survival outcomes across different patient groups,Results,the difference was not significant ( p =0.45)...the difference was not significant ( p =0.25)...significantly better cumulative survival outcome ( p =0.003),0.85
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,NeuroConn DC-STIMULATOR MR,clinical_assessment_tool,Mechanistic,"AtDCS led to 26.77% (SD 4.05%) change in GABA+ compared to 11.45% (SD 4.07%) change in sham group (F1,46 = 4.12, p = 0.05)",Results,"AtDCS led to a greater decrease in DLPFC GABA+ relative to sham (F1,46 = 4.12, p = 0.05). There was a 26.77% (SD 4.05%) change in GABA+ in atDCS group as compared to 11.45% (SD 4.07%) change in the sham group.",0.95
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,NeuroConn DC-STIMULATOR MR,clinical_assessment_tool,Mechanistic,"No significant effect on Glx (F1,46 = 0.69, p = 0.41) and no effect on occipital cortex GABA+ or Glx, showing regional specificity",Results,"There was no significant effect of atDCS on Glx (F1,46 = 0.69, p = 0.41). In the control occipital voxel, there was no significant effect of atDCS on GABA+ (F1,49 = 0.94, p = 0.34) or Glx",0.92
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,NeuroConn DC-STIMULATOR MR,clinical_assessment_tool,Behavioral,"Poorer speed-accuracy trade-off in aTDCS group on 2back task (b = -47.88, se = 24.18, t(95) = -1.98, p = 0.05) and 0back task (b = -43.06, se = 16.61, t(95) = -2.59, p = 0.01)",Results,"On the 2back IES, there was a significant main effect of the group with better speed-accuracy trade-off in the sham group (b = -47.88, se = 24.18, t(95) = -1.98, p = 0.05)",0.93
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,NeuroConn DC-STIMULATOR MR,clinical_assessment_tool,Behavioral,"Slower response times in aTDCS group on 0back task (b = -40.11, se = 14.41, t(95) = -2.78, p = 0.01)",Results,"On the 0back RT, there was a significant main effect of the group with slower response times in the aTDCS group (b = -40.11, se = 14.41, t(95) = -2.78, p = 0.01)",0.92
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,NeuroConn DC-STIMULATOR MR,clinical_assessment_tool,Mechanistic,"aTDCS group maintained task-induced regional activity in DLPFC during stimulation compared to sham (t(19) = 1.89, p = 0.05)",Results,"We found that aTDCS group maintained task-induced regional activity in the DLPFC during stimulation as compared to sham group during stimulation (t(19) = 1.89, p = 0.05)",0.91
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,NeuroConn DC-STIMULATOR MR,clinical_assessment_tool,Safety,"No significant differences in side effect profile between aTDCS and sham groups, no mood changes reported",Results,There were no significant differences in the side effect profile between the aTDCS and sham groups. There were no mood changes reported by any participants.,0.88
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,Vineland Adaptive Behaviour Scale—third edition,clinical_assessment_tool,Behavioral,"Mean composite score of 68.4 (13.0) in study sample, no relationship with DLPFC GABA+ (r(27) = 0.08, p = 0.66)",Results,"Vineland adaptive behavior composite (mean) 68.4 (13.0)... There was no relationship between parent rated measures and DLPFC GABA+ including baseline adaptive functioning (r(27) = 0.08, p = 0.66)",0.9
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,Conners 3 rating scale,clinical_assessment_tool,Behavioral,"Mean inattention T score 78.7 (13.0) and hyperactivity T score 69.1 (18.2), no relationship with DLPFC GABA+ (inattention r(27) = -0.05, p = 0.79; hyperactivity r(27) = -0.22, p = 0.23)",Results,"Inattention T score 78.7 (13.0) Hyperactivity T score 69.1 (18.2)... no relationship between parent rated measures and DLPFC GABA+ including... inattention (r(27) = -0.05, p = 0.79) or hyperactivity (r(27) = -0.22, p = 0.23)",0.91
PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,JMP,computational_tool,Other,"Used for statistical modeling and analysis of computational fracture healing model outputs, including calculation of main effects and generation of marginal model plots",Results,"The main effects, i.e. the most important factors that influence a specific outcome of the model, are summarised in Table 3. Note that the number of fibroblasts on Day 7 and Day 21 were not well predicted by the statistical model",0.8
PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,VSC (Flemish Supercomputer Center),computational_tool,Other,Provided computational infrastructure for running the multiscale computational model of bone regeneration and large sensitivity analysis using Design of Experiments,Discussion,In this study we used a well-established multiscale computational model of bone regeneration to integrate the state-of-the-art experimental knowledge on the effect of the Nf1 mutation on bone fracture healing,0.7
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,Nf1 ± mice,animal_model,Biomarker,~50% reduction in neurofibromin expression in Nf1± relative to WT microglia (male: p = 0.0006; female: p = 0.0003),Results,"Consistent with a heterozygous Nf1 mutation, there was a ~ 50% reduction in neurofibromin expression in Nf1± relative to WT microglia (male: p = 0.0006; female: p = 0.0003)",0.95
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,Nf1 ± mice,animal_model,Behavioral,Male Nf1± microglia showed reduced surveillance index (86.4 ± 5.1 µm²/min) compared to male WT microglia (153.5 ± 8.7 µm²/min; p < 0.0001),Results,"the surveillance index, which is a measure of the process retractions and extensions per unit time, was reduced in male Nf1± microglia (86.4 ± 5.1 µm²/min) compared to male WT microglia (153.5 ± 8.7 µm²/min; p < 0.0001)",0.95
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,Nf1 ± mice,animal_model,Behavioral,Male Nf1± microglia had reduced ramification index (4.8 ± 0.1) compared to male WT microglia (6.2 ± 0.2; p < 0.0001),Results,male Nf1± microglia had a ramification index (4.8 ± 0.1; n = 106 cells/4 mice) that was smaller than that observed for male WT microglia (6.2 ± 0.2; n = 53 cells/2 mice; p < 0.0001),0.95
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,Nf1 ± mice,animal_model,Behavioral,"Female WT and Nf1± microglia showed no differences in surveillance parameters (initial rates, cumulative areas, surveillance indexes)",Results,"in female mouse brains, there were no differences in the surveillance of WT and Nf1± microglia processes...neither in the initial rates of surveillance...nor in the cumulative areas surveyed after 40 min",0.9
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,MacGreen (Csf1r-eGFP),genetic_reagent,Other,Successfully enabled visualization of microglial cells by transgenic EGFP labeling for surveillance analysis in acute cortical slices,Results,The microglial cells in the slices were identified by transgenic EGFP labeling in WT and Nf1± mice intercrossed with MacGreen (Csfr1-EGFP) mice,0.9
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,CX3CR1-CreER,genetic_reagent,Other,Successfully induced Cre recombinase activity in CX3CR1+ cells when administered tamoxifen (100 mg/kg body weight) for five consecutive days between P30-P40,Results,Tamoxifen (100 mg/kg body weight) was intraperitoneally administered between P30 and P40 for five consecutive days to induce Cre recombinase activity in CX3CR1+ cells,0.9
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,R26R-EYFP mice,genetic_reagent,Other,"Clear induction of microglial YFP expression observed in mice treated with tamoxifen, but also showed weak non-specific YFP expression in non-microglial cells",Results,"We observed a clear induction of microglial YFP expression in mice treated with tamoxifen...There was also weak expression of YFP in non-microglial cells, mainly in neuronal cells independent of CreER activation",0.85
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,hGFAP-Cre,genetic_reagent,Behavioral,Male Nf1flox/wt;hGFAP-Cre microglia showed reduced branch points (32 ± 1) compared to WT (42 ± 1; p < 0.0001) and decreased process lengths (500 ± 14 μm vs 652 ± 16 μm; p < 0.0001),Results,the number of branch points per microglial cell was reduced in male Nf1flox/wt;hGFAP-Cre (32 ± 1) compared to WT microglia (42 ± 1; p < 0.0001)...there was a sexually dimorphic decrease in the cumulative process lengths,0.95
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,anti-mouse CD11b antibodies coupled to magnetic beads,antibody,Other,Successfully used for microglia isolation from whole brains by MACS for proteomic analysis,Results,Microglia were isolated from whole brains of male and female WT and Nf1± mice (12-16 weeks of age) by MACS using CD11b antibodies and subjected to proteomics analysis,0.9
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,Imaris × 64 version 9.6–9.9,computational_tool,Other,"Successfully applied for three-dimensional rendering to perform 3D Scholl analysis and quantify soma volumes, total process lengths and branch points per cell",Results,"Three-dimensional rendering was applied using Imaris software (Fig. 3A) to perform 3D Scholl analysis and quantify the average soma volumes, total process lengths and number of branch points per cell",0.9
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,Illumina HiSeq2000,computational_tool,Other,Generated on average 45 million paired-end 90 bp reads per sample with mean depth coverage of 54X and 93.4% of bases covered by at least 10X,Results,"After removing low-quality reads, we obtained on average 45 million paired-end 90 bp reads per sample. Alignment statistics showed mean depth coverage of 54X, and 93.4% of bases were covered by at least 10X.",0.95
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,wANNOVAR web server,computational_tool,Other,"Successfully identified and prioritized on average 170 novel protein-altering variants per sample from ~62,000 unique variants",Results,We applied the 'variants reduction' pipeline implemented in the wANNOVAR server and identified a small subset of candidate variants and genes...we prioritized on average 170 novel protein-altering variants per sample,0.92
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,NimbleGen targeted region arrays,computational_tool,Other,Achieved higher depth coverage with on average 455X read depth and 100% of targeted regions covered,Results,"Since the targeted region sequencing captures a smaller region compared to WGS or WES, we were able to obtain sequencing data with higher depth coverage on the targeted regions: on average, the read depth is 455X and 100% of targeted regions are covered.",0.95
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,SeqMule,computational_tool,Other,Used to implement consensus variant calling approach with GATK and SAMtools to ensure reliability of variant calls,Discussion,"we did a comparative approach by using two independent variant calling tools [GATK and SAMtools, implemented by SeqMule pipeline] and by using the consensus variants from both variant calling tools as candidate variants",0.88
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),clinical_assessment_tool,Behavioral,"No significant differences in Full Scale IQ between COMT genotype groups (Val/Val median=95, Val/Met median=94, Met/Met median=98, p=0.400)",Results,Full scale IQ 89 95 103 77 94 106 89 98 106 1.73 0.400,0.95
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),clinical_assessment_tool,Behavioral,IQ was directly associated with lower arithmetic performance (p=0.007) in backward logistic regression model,Results,IQ ( p  = 0.007) and working memory assessed by the backward digit-span task ( p  = 0.020) were directly associated with lower arithmetic performance,0.95
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,Corsi block-tapping task,clinical_assessment_tool,Behavioral,"No significant differences between COMT genotype groups for forward condition (χ²=4.29, p=0.117) or backward condition (χ²=3.27, p=0.195)",Results,"No significant differences in performance according to  1 COMT  genotype were found for the digit-span forward (χ 2  = 1.06,  p  = 0.587), Corsi block-tapping task forward (χ 2  = 4.29,  p  = 0.117) and backward (χ 2  = 3.27,  p  = 0.195)",0.95
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,Corsi block-tapping task,clinical_assessment_tool,Behavioral,"Backward Corsi block-tapping task failed to demonstrate the same level of difficulty compared to backward digit-span task, with participants reaching same performance on forward and backward versions",Discussion,"Moreover, the backward Corsi block-tapping task have failed to demonstrate the same level of difficulty compared to the backward digit-span task and participants reach the same performance on both the forward and the backward versions",0.85
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,School Achievement Test,clinical_assessment_tool,Behavioral,40% of NF1 sample had difficulties in basic arithmetic skills (performance below 25th percentile),Results,"The school performance analysis showed that 40% of our sample had difficulties in basic arithmetic skills according to the cut-offs of the School Achievement Test (i.e., performance below the 25 percentile)",0.95
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,School Achievement Test,clinical_assessment_tool,Behavioral,"No significant difference in COMT genotype distribution between low-achievement and normal-high-achievement groups (χ²=0.952, p=0.621)",Results,"However, we found no significant difference between low-achievement and normal-high-achievement groups regarding  COMT  genotypes distribution (χ 2  = 0.952,  p  = 0.621)",0.95
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,TaqMan Genotyping Master Mix,genetic_reagent,Other,"Successfully used for COMT Val158Met genotyping in NF1 participants, enabling identification of genotype groups (Val/Val N=16, Val/Met N=23, Met/Met N=11)",Results,Val/Val ( N  = 16) Val/Met ( N  = 23) Met/Met ( N  = 11),0.85
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,Stratagene Mx3005 – MxPro QPCR-Software,computational_tool,Other,"Successfully used for COMT genotyping analysis, enabling detection of genotype differences in working memory performance",Results,"In the digit-span backward condition, significant group differences were found (χ 2  = 6.65,  p  = 0.036). The Met/Met group outperformed the Val/Met group",0.8
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Biomarker,IC50 for Trametinib is 97nM,Results,The IC50s for Trametinib varied between 14 and 17nM for the mouse glioma cell lines and is 97nM for the human serum grown TM-31 line,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Biomarker,"Has full loss/inactivation of NF1, ATRX, TP53 and CDKN2A",Results,"Our human NF1-HGG line was derived from a malignant astrocytoma of a 42-year-old female Neurofibromatosis Type I patient and has full loss/inactivation of NF1, ATRX, TP53 and CDKN2A",0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Biomarker,Expresses OPC identity markers even when grown in serum conditions,Results,"Importantly, even though this line is grown in serum conditions, which induces differentiation, markers consistent with OPC identity are still expressed",0.85
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Efficacy,Shows high baseline sensitivity to compounds with LD50 values at or below 25th percentile of IC50 values from cancer cell line databases,Discussion,This is also true for most of the combinations evaluated in our human TM31 cell line (see Tables 1 and 2). Our results highlight the degree to which the NF1-HGG are sensitive to these drugs,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,TM-31,cell_line,Efficacy,None of the drug combinations worked synergistically (12 additive and 1 antagonistic combination),Discussion,None of the combinations worked synergistically in the human TM-31 line (12 additive and 1 antagonistic combination),0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,17,cell_line,Biomarker,IC50 for Trametinib varies between 14 and 17nM,Results,The IC50s for Trametinib varied between 14 and 17nM for the mouse glioma cell lines,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,17,cell_line,Biomarker,IC50 for GDC-0941 varies between 688 and 2412nM,Results,IC50s varied between 688 and 2412nM for GDC-0941,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,17,cell_line,Biomarker,Shows complete loss of wildtype allele for Nf1 and Tp53,Results,The glioma cell lines show complete loss of the wildtype allele for Nf1 and Tp53,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5653,cell_line,Biomarker,IC50 for Trametinib varies between 14 and 17nM,Results,The IC50s for Trametinib varied between 14 and 17nM for the mouse glioma cell lines,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5653,cell_line,Biomarker,Shows complete loss of wildtype allele for Nf1 and Tp53,Results,The glioma cell lines show complete loss of the wildtype allele for Nf1 and Tp53,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5746,cell_line,Biomarker,IC50 for Trametinib varies between 14 and 17nM,Results,The IC50s for Trametinib varied between 14 and 17nM for the mouse glioma cell lines,0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5746,cell_line,Biomarker,Shows complete loss of wildtype allele for Nf1 and Tp53,Results,The glioma cell lines show complete loss of the wildtype allele for Nf1 and Tp53,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,5746,cell_line,Efficacy,LD50 values consistently at or below 25th percentile of IC50 values from cancer cell line databases,Discussion,"Crucially, the observed LD50 values, i.e. the concentration that causes 50% cell death, were consistently at or below the 25th percentile of the IC50 values...in our mouse 5746 line",0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,NPcis genetically engineered mouse model,animal_model,Biomarker,About 10% of NPcis mice form high grade gliomas,Results,About 10% of these NPcis mice form high grade gliomas,0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,NPcis genetically engineered mouse model,animal_model,Biomarker,"Mice have germline mutation in both Nf1 and Tp53, in cis on mouse chromosome 11",Results,"These mice have a germline mutation in both Nf1 and Tp53, in cis on mouse chromosome 11",0.95
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,pERK antibody,antibody,Mechanistic,Shows near full inhibition of pERK at concentrations used as readout of MEK inhibition,Results,Fig 2C shows that at the concentrations used we have near full inhibition of pERK (as a readout of MEK inhibition),0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,pAKT antibody,antibody,Mechanistic,Shows near full inhibition of pAKT at concentrations used as readout for PI3K inhibition,Results,Fig 2C shows that at the concentrations used we have near full inhibition of pERK (as a readout of MEK inhibition) and pAKT (as a readout for PI3K inhibition),0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,SOX2 antibody,antibody,Biomarker,Shows expression in glioma cell lines consistent with OPC lineage markers,Results,"Finally, these glioma cell lines express the oligodendrocyte precursor cell (OPC) markers SOX2 and NG2",0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,NG2 antibody,antibody,Biomarker,Shows expression in glioma cell lines consistent with OPC lineage markers,Results,"Finally, these glioma cell lines express the oligodendrocyte precursor cell (OPC) markers SOX2 and NG2",0.9
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,spheroid culture system,advanced_cellular_model,Mechanistic,Considered more accurate models for glioma and more representative of in vivo models compared to 2D culture,Discussion,"Non-serum grown glioma cell lines are considered more accurate models for glioma, moreover, compared to 2D, a 3D organoid like growth activates different signaling pathways and is considered more representative of in vivo models",0.85
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,synergyfinder,computational_tool,Efficacy,"Used to determine synergy scores with criteria: synergistic (δ>10), additive (-10<δ<10), or antagonistic (δ<-10)",Results,"Table 1 lists if the evaluated combinations are synergistic (Synergy Score δ>10), additive (Synergy Score -10<δ<10) or antagonistic (Synergy Score δ<-10)",0.9
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,Risk-Calibrated Superspase Linear Integer Model (Risk-SLIM),computational_tool,Efficacy,Five-fold cross-validation area under the curve of 0.76,Results,The meningioma recurrence score (MRS) was then created using a machine learning algorithm. It had a five-fold cross-validation area under the curve of 0.76,0.95
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,Risk-Calibrated Superspase Linear Integer Model (Risk-SLIM),computational_tool,Efficacy,CAL error was 4.7%,Results,"It had a five-fold cross-validation area under the curve of 0.76 (Figure 1), and the CAL error was 4.7%",0.95
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,Risk-Calibrated Superspase Linear Integer Model (Risk-SLIM),computational_tool,Efficacy,Efficiently predicts recurrence risk in patients with WHO grade 1 meningioma,Discussion,"The meningioma recurrence score (MRS) efficiently predicts recurrence risk in patients with WHO grade 1 meningioma, even when surgical GTR is achieved",0.85
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,Human Schwann cells (HSCs),cell_line,Safety,"Cell viability decreased with MG-132 treatment starting at 5 μM, with dramatic reduction at continued doses",Results,The treatment with MG-132 conferred decreases in the viabilities of normal human Schwann cells (HSCs) with an initial dose of 5 μM at all time-points; cell viabilities were however dramatically reduced with continued doses,0.85
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,Human Schwann cells (HSCs),cell_line,Efficacy,EdU-positive cells increased significantly with merlin shRNA (29.2 ± 6.90% vs. 15.8 ± 3.0%; P = .021),Results,the percentage of EdU-positive cells was significantly increased in HSCs with merlin shRNA compared to the control (29.2 ± 6.90% vs. 15.8 ± 3.0%; P = .021),0.95
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,RT4-D6P2T schwannoma cells,cell_line,Efficacy,"Cell viability decreased in dose- and time-dependent manner with Nutlin-3, maximum p53 level at 10 μM for 48 h",Results,"cell viability decreased in a dose- and time-dependent manner in response to Nutlin-3, which resulted in the accumulation of p53 in these cells with a maximum level at 10 μM for 48 h",0.9
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,RT4-D6P2T schwannoma cells,cell_line,Efficacy,Combined Nutlin-3 and MG-132 treatment resulted in Nutlin-3-dose-dependent increases in apoptosis rates,Results,the combined treatment with Nutlin-3 (0–10 μM) and MG-132 (2.5 μM) resulted in a Nutlin-3-dose-dependent increases in the apoptosis rates of the cells,0.9
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,HEI-193,cell_line,Efficacy,"Combined Nutlin-3 and MG-132 fully blocked tumor growth in xenografts, with initial inhibition observed on day 6",Results,combined treatment with Nutlin-3 and MG-132 fully blocked tumour growth...The initial inhibition of tumour growth of both the RT4 and HEI-193 schwannomas in Nutlin-3 & MG-132 groups was observed on day 6,0.95
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,BALB/c nude mice,animal_model,Safety,"No significant weight differences between treatment groups (MG-132 5-10 mg/kg, Nutlin-3 40 mg/kg), no deaths, no obvious differences in activity and eating behavior",Results,"there were no significant statistical differences in the weight of non-tumour bearing mice between the MG-132 group (5–10 mg/kg), Nutlin-3 group (40 mg/kg), vehicle group and Nutlin-3 &MG-132 group. No mice died in the four groups",0.9
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,BALB/c nude mice,animal_model,Safety,Significant toxic response appeared at Nutlin-3 dosage of 80 mg/kg on day 14,Results,"the inhibitory effects of Nutlin-3 administration on the growth of RT4 schwannomas observed with an initial dosage of 40 mg/kg, and a significant toxic response appeared at a dosage of 80 mg/kg on day 14",0.9
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,Nutlin-3,advanced_cellular_model,Efficacy,Merlin-positive cells showed much lower viability (47.4% of controls) compared to merlin-null cells (70.3% of controls; P = .034) after treatment,Results,the viabilities of merlin-positive cells on day 2 following treatment (47.4% of controls; an average of 3 cases) were much lower than those of merlin-null cells (70.3% of controls; P = .034),0.95
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,Nutlin-3,advanced_cellular_model,Mechanistic,"Binds at p53 pocket on MDM2 surface, disrupts p53-MDM2 interaction, leads to p53 stabilization and merlin induction in p53-dependent manner",Results,"The research compound Nutlin-3 binds at the p53 pocket on the surface of MDM2 and disrupts the p53-MDM2 interaction, leading to p53 stabilization",0.9
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,MG-132,advanced_cellular_model,Efficacy,Amplified inhibitory effect of Nutlin-3 on schwannoma cell proliferation and narrowed differences in sensitivity between cultures with different merlin expression status,Results,"MG-132 amplified the inhibitory effect of Nutlin-3 on schwannoma cell proliferation, and MG-132 narrowed the differences in the sensitivity to Nutlin-3 between cultures with different merlin expression status",0.85
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,MG-132,advanced_cellular_model,Mechanistic,"Inhibitor of 26S proteasome, used at 2.5 μM concentration for combination therapy",Results,MG-132 (an inhibitor of the 26S proteasome)...We utilized a concentration of 2.5 μM in the following combination drug therapy,0.9
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,PubMed,computational_tool,Other,"Database provides linked reference to PubMed abstract for each variant, serving as a useful feature for accessing scientific literature supporting variant classifications",Results,"...the database provides a linked reference to the PubMed abstract for each variant. Because the classification of each variant is directly based on evidence from the scientific literature, the link to PubMed is a very useful feature of this database.",0.8
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,MySQL,computational_tool,Other,Successfully implemented as database management system for storing and managing 78 SPRED1 gene variant entries with dynamic search and sorting functionality,Results,"The database contained 78 entries as of May 2011...The database also has 'live search' functionality, so that any term entered in the search box...will dynamically filter the displayed listing.",0.8
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,PHP,computational_tool,Other,Enables dynamic web functionality including live search filtering and column sorting for gene variant database display,Results,"The database also has 'live search' functionality, so that any term entered in the search box...will dynamically filter the displayed listing. Finally, clicking any column heading will sort (ascending and descending) the gene variant entries",0.7
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,FusionCharts v3,computational_tool,Other,Generates dynamic graphical summaries of variant classification and mutation types found in the SPRED1 database,Results,SPRED1 gene variant mutation types are graphically summarized in Figure 2...Dynamic graphical summary of (A) variant classification and (B) types of mutations found in the SPRED1 database.,0.8
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,C2C12,cell_line,Mechanistic,"NF1 gene knockout in C2C12 cells resulted in significantly reduced osteogenic differentiation with decreased mRNA expression of ALP, Runx2, Osx and Col1a1 at all time points",Results,"the mRNA expression levels of ALP, Runx2, Osx and Col1a1 in the 2−7 group were significantly lower than those in the control group at different time points of osteogenic differentiation",0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,C2C12,cell_line,Biomarker,NF1 knockout C2C12 cells showed significantly decreased intracellular cAMP levels compared to control cells,Results,"after knocking out the NF1 gene, we observed the intracellular cAMP levels in 2−7 and 2−12 decreased, which was statistically significant compared with the control group",0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,C2C12,cell_line,Efficacy,"Icariin treatment at 10^-5 M concentration promoted osteogenic differentiation in NF1 knockout C2C12 cells, with increased cell viability and enhanced ALP activity especially at days 5 and 7",Results,the viability of the cells gradually increased with the time of icariin addition...The ALP activity of the 2−7 and 2−12 groups treated with icariin was higher than those of the control group,0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,CRISPR/Cas9 single-vector lentivirus,genetic_reagent,Efficacy,"Successfully knocked out NF1 gene in C2C12 cells, with gene sequencing showing nested peaks at sgRNA target sites and complete loss of neurofibromin protein expression",Results,The sequencing results showed that nested peaks appeared at the position of the corresponding sgRNA in the 2−7 and 2−12 cell lines...neurofibromin expression was undetectable in 2−7 and 2−12 cell lines,0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,neurofibromin antibody (cat. no. ab17963),antibody,Biomarker,"Successfully detected complete loss of neurofibromin protein expression in NF1 knockout cell lines by Western blot and immunofluorescence, with normal expression in control cells",Results,"the expression of neurofibromin in group C and group NC was normal. However, neurofibromin expression was undetectable in 2−7 and 2−12 cell lines",0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,phosphorylated PKA antibody (cat. no. 5661S),antibody,Mechanistic,"Detected significant activation of PKA phosphorylation after icariin treatment in NF1 knockout cells, with expression becoming more pronounced with extended treatment time up to 120 minutes",Results,PKA (p-PKA) and phosphorylation of CREB (p-CREB) were significantly activated after treatment with icariin...the expression of p-PKA and p-CREB became more pronounced,0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,phosphorylated CREB antibody (cat. no. 9198S),antibody,Mechanistic,"Detected significant activation of CREB phosphorylation after icariin treatment in NF1 knockout cells, reaching highest levels at 120 minutes",Results,PKA (p-PKA) and phosphorylation of CREB (p-CREB) were significantly activated after treatment with icariin...reached the highest level at 120 min,0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,DESeq2 (version 1.12.4),computational_tool,Mechanistic,"Identified 6404 differentially expressed genes (4732 upregulated, 1672 downregulated) between icariin-treated and untreated NF1 knockout cells, with enrichment in cAMP signaling pathway",Results,"a total of 6404 DEGs, including 4732 upregulated and 1672 downregulated genes, were obtained from the comparison between icariin-treated and untreated 2−7 group cells",0.95
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,HiSeq XTen sequencers,computational_tool,Mechanistic,Successfully performed RNA sequencing analysis that revealed cAMP pathway activation as the primary mechanism of icariin action in NF1 knockout cells,Results,KEGG analysis of DEGs in the icariin-treated 2−7 group cells compared with untreated cells suggested that the drug affected the cAMP signaling pathway,0.9
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,Slicer,computational_tool,Other,Successfully used for manual segmentation of 6 tumors when PET-signal prevented systematic segmentation,Results,The remaining 6 tumors were manually segmented using Slicer's editor module. As the PET-signal for these cases prevented systemic segmentation...,0.9
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,Law's texture energy measures,computational_tool,Biomarker,"14 2D LTEM features were statistically significant between SUV zones in MPNST subjects, with high correlation among Law's kurtosis features requiring clustering analysis",Results,"21 quantitative imaging features (4 intensity, 14 2D LTEM, 2 GLRL, 1 NGTM) extracted from the MR scans were significant between SUV zones...Further analysis showed a high correlation among the Law's kurtosis features",0.9
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,Law's texture energy measures,computational_tool,Biomarker,4 T1 kurtosis LTEM and 8 T2 skewness LTEM features were distinctive between MPNST PET-elevated zones and BPN subjects,Results,"The comparison of the PET-elevated zones in the MPNST cohort to the BPN subjects showed 20 distinctive features (4 T1 kurtosis LTEM, 8 T2 skewness LTEM, 4 GLRL, 4 NGTM)",0.9
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,neighborhood grey-tone difference matrices,computational_tool,Biomarker,1 NGTM feature was statistically significant between SUV zones in MPNST subjects,Results,"21 quantitative imaging features (4 intensity, 14 2D LTEM, 2 GLRL, 1 NGTM) extracted from the MR scans were significant between SUV zones",0.9
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,neighborhood grey-tone difference matrices,computational_tool,Biomarker,2 NGTM features from PET-signal were statistically significant between PET-hot and PET-elevated regions of MPNST patients with >90% power,Results,"From the features extracted from the PET-signal, four (2 intensity, 2 NGTM) were statistically significant between the PET-hot and PET-elevated regions...The power test on these features returned powers greater than 0.90",0.9
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,neighborhood grey-tone difference matrices,computational_tool,Biomarker,"4 NGTM features were distinctive between MPNST PET-elevated zones and BPN subjects, and 4 NGTM features from PET scan were significantly different between groups with >94% power",Results,"20 distinctive features (4 T1 kurtosis LTEM, 8 T2 skewness LTEM, 4 GLRL, 4 NGTM)...From the radiomics extracted from the PET scan, eight (4 GLRL, 4 NGTM) were significantly different...powers greater than 0.94",0.9
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,Everolimus,genetic_reagent,Efficacy,Significantly increased survival in both mouse models when used alone or in combination with PD-901,Discussion,"We show that survival is significantly increased in both mouse models when the mice are treated with Everolimus, PD-901, or the combination of both",0.85
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,Everolimus,genetic_reagent,Mechanistic,Long term treatment resulted in reactivation of the PI3K/AKT/mTOR pathway when used as single agent,Results,Because long term treatment with Everolimus or PD-901 resulted in reactivation of the PI3K/AKT/mTOR and MAPK pathways,0.9
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,Everolimus,genetic_reagent,Safety,"Treatment in combination with PD-901 at single agent doses resulted in toxicity, requiring significantly lower doses",Discussion,"We found that treatment of mice with a combination of Everolimus and PD-901 at doses given as single agents resulted in toxicity. To avoid toxicity, mice were treated with significantly lower doses",0.9
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,Everolimus,genetic_reagent,Safety,Long term treatment causes immunosuppression,Discussion,"long term treatment with Everolimus causes immunosuppresion, which could add a layer of complexity to the use of this drug in a clinical setting",0.85
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,PD-0325901,genetic_reagent,Efficacy,Significantly increased survival in both mouse models when used alone or in combination with Everolimus,Discussion,"We show that survival is significantly increased in both mouse models when the mice are treated with Everolimus, PD-901, or the combination of both",0.85
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,PD-0325901,genetic_reagent,Mechanistic,Long term treatment resulted in reactivation of the MAPK pathway when used as single agent,Results,Because long term treatment with Everolimus or PD-901 resulted in reactivation of the PI3K/AKT/mTOR and MAPK pathways,0.9
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,PD-0325901,genetic_reagent,Mechanistic,Does in fact inhibit MEK as demonstrated,Discussion,we have demonstrated that PD-0325901 does in fact inhibit MEK (Figure 6),0.9
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,PD-0325901,genetic_reagent,Other,Has been shown to have off target effects,Discussion,"Finally, it should be noted that PD-901 has been shown to have off target effects",0.85
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,p-AKT S473 antibody,antibody,Biomarker,p-AKT was inhibited at early timepoints and remained low at later time points when mice were treated with Everolimus and PD-901 in combination,Results,"when mice were treated with Everolimus and PD-901 in combination, p-AKT, p-4EBP, and p-ERK were all inhibited at early timepoints, and remained low at later time points",0.9
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,p-4EBP antibody,antibody,Biomarker,p-4EBP was inhibited at early timepoints and remained low at later time points when mice were treated with Everolimus and PD-901 in combination,Results,"when mice were treated with Everolimus and PD-901 in combination, p-AKT, p-4EBP, and p-ERK were all inhibited at early timepoints, and remained low at later time points",0.9
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,p-ERK antibody,antibody,Biomarker,p-ERK was inhibited at early timepoints and remained low at later time points when mice were treated with Everolimus and PD-901 in combination,Results,"when mice were treated with Everolimus and PD-901 in combination, p-AKT, p-4EBP, and p-ERK were all inhibited at early timepoints, and remained low at later time points",0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,NF1-null 293T cells,cell_line,Mechanistic,Successfully transduced with doxycycline-inducible HA-mScarlet-NF1 expression system showing dose-dependent expression,Results,We successfully introduced a fluorescent epitope-tagged (HA-mScarlet) WT and L847P NF1 which was expressed in a Dox dose-dependent manner,0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,NF1-null 293T cells,cell_line,Mechanistic,L847P mutant expressed considerably less than wild-type under same conditions in doxycycline-inducible system,Results,"We observed that the L847P mutant expressed considerably less than the WT under the same conditions, confirming that the previous response was not transient-transfection-specific",0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,ipNF95.11b C,cell_line,Mechanistic,Showed same phenotype as 293T cells regarding mutant protein stability after NF1 knockout and transduction,Results,we transduced a previously characterized immortalized peripheral neurofibroma-derived Schwann cell line (ipNF95.11b C) in which we had knocked out NF1. We saw the same phenotype as in the 293T,0.8
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,Anti-FLAG M2,antibody,Mechanistic,Successfully detected FLAG-tagged neurofibromin expression levels showing 844-848 mutants had reduced expression compared to wild-type,Results,Lysates from 293T NF1−/− cells expressing FLAG-tagged neurofibromin. Expression was analyzed via western blot,0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,HA antibody,antibody,Mechanistic,Detected HA-tagged proteins in coimmunoprecipitation experiments demonstrating neurofibromin dimerization and SPRED1 interactions,Results,FLAG-WT and mutant neurofibromin immunoprecipitates (IPs) from 293T NF1−/− were tested for dimerization with cotransfected HA-WT neurofibromin,0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,HSP70 antibody,antibody,Mechanistic,"Showed increased HSP70 coimmunoprecipitation with 844-848 mutants compared to wild-type, indicating protein misfolding response",Results,"844 to 848 mutants are highly ubiquitylated compared to wild-type neurofibromin and coimmunoprecipitate with increased amounts of HSP70, an indicator that the cell is responding to protein misfolding",0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,Ubiquitin antibody,antibody,Mechanistic,"Detected high ubiquitylation levels in 844-848 mutants compared to wild-type neurofibromin, and reduced ubiquitylation in suppressor mutants",Results,"844 to 848 mutants are highly ubiquitylated compared to wild-type neurofibromin... These 'suppressor' mutants, which maintain hydrophobicity, are not only less ubiquitylated than the pathogenic variants",0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,RELION,computational_tool,Mechanistic,Successfully processed cryo-EM data to determine 3.6 Å resolution structure of neurofibromin dimer,Results,"Using cryogenic electron microscopy (cryo-EM), we determined the 3.6 Å resolution structure of the 2818 amino acid isoform I",0.9
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,MotionCorr,computational_tool,Mechanistic,Used for motion correction in cryo-EM structure determination of neurofibromin,Results,"Using cryogenic electron microscopy (cryo-EM), we determined the 3.6 Å resolution structure",0.7
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,CTFFIND4,computational_tool,Mechanistic,Used for contrast transfer function estimation in cryo-EM structure determination,Results,"Using cryogenic electron microscopy (cryo-EM), we determined the 3.6 Å resolution structure",0.7
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,SureSelect,computational_tool,Other,"Used for target enrichment in NGS panel testing of NF1 and SPRED1 genes, contributing to identification of pathogenic variants in 21% of derivation cohort patients",Results,Testing of the NF1 and SPRED1 genes in 28 patients in the derivation cohort revealed six (21%) patients with likely pathogenic or pathogenic variants,0.75
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,MiSeq-M01450,computational_tool,Other,Sequencing platform used to identify disease-causing variants in 2% of validation cohort patients (11/505) and increased diagnostic yield from 23.5% to 25.7%,Results,Sequencing of all 14 RASopathy‐associated genes in the 505 patients in the validation cohort identified 11 (2%) patients with disease‐causing variants...Adding NF1 and SPRED1 to the panel increased the diagnostic yield from 23.5% (119/505) to 25.7% (130/505),0.8
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,bwa-mem v0.7.10,computational_tool,Other,Alignment tool used in bioinformatics pipeline that contributed to successful identification of pathogenic NF1 and SPRED1 variants,Results,Testing of the NF1 and SPRED1 genes in 28 patients in the derivation cohort revealed six (21%) patients with likely pathogenic or pathogenic variants,0.7
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,"GATK, version 1.0.4705",computational_tool,Other,"Variant calling tool used in analysis pipeline that enabled detection of various NF1 variant types including deletions, frameshift, missense, splice, and nonsense variants",Results,"Likely pathogenic or pathogenic variants in NF1 included one deletion of the entire NF1 gene, one splice variant, two nonsense variants, one in‐frame deletion, and three missense variants",0.75
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"GC-IPL measurements obtained in 132 eyes (88% complete scans) from 71 patients, with 95% success rate in eyes without symptomatic OPG and 69% in eyes with OPG",Results,GC-IPL data were obtained in 132 eyes (Complete scans 88%) from 71 patients...GC-IPL was obtained in 95% eyes without symptomatic OPG and in 69% eyes with OPG,0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"Mean GC-IPL thickness: 85±0.4 μm in NF1 without OPG, 70±0.7 μm in NF1-OPG, and 62±1.4 μm in sporadic OPG (p<0.001)",Results,"GC-IPL, mean ± SE (95CI) μm...85 ± 0.4 (84–85) N = 103...70 ± 0.7 (68–70) N = 22...62 ± 1.4 (60–65) N = 7 <0.001",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"GC-IPL showed significant correlation with pRNFL (r=0.662, p<0.001), VA (r=-0.661, p<0.001), and VFI (r=0.644, p<0.001)",Results,"The GC-IPL was significantly correlated to pRNFL (correlation coefficient (r) = 0.662, confidence interval (CI) = .507 to .773 p<0.001), VA (r = -0.661, CI = -7.45 to -.551, p<0.001) and VFI (r = 0.644, CI = .452 to .774, p<0.001)",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"Mean age for first reliable GC-IPL measurement was 5.6±1.5 years, significantly lower than pRNFL at 6.8±1.3 years (p<0.001)",Results,Mean age for first reliable VA measurement was significantly lower than for VFI (5.4±1.6 yrs vs 7.3±1.0 yrs; p<0.001) and for first reliable GC-IPL measurement compared to pRNFL (5.6±1.5 vs 6.8±1.3; p<0.001),0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"GC-IPL showed slight but significant decline over time in NF1-OPG group (slope -0.1207μm/trimester, p=0.004)",Results,"A slight but significant decline in GC-IPL was observed in the NF1-OPG group (slope -0.1207μm/trimester, p = 0.004) and insignificant changes were seen in the remaining groups (p>0.05)",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Efficacy,GC-IPL distinguished well between eyes with MRI-verified OPG and eyes without symptomatic OPG in children with NF1 and correlated well with visual function,Discussion,The macular GC-IPL as measured with OCT distinguished well between eyes with MRI-verifed OPG and eyes without symptomatic OPG in children with NF1 and correlated well with visual function,0.9
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Other,"Unlike VA, GC-IPL is not affected by age in young children, rendering GC-IPL measurements more reliable in follow-up of OPG",Discussion,"Unlike VA, GC-IPL is not affected by age in young children, rendering GC-IPL measurements more reliable in the follow-up of OPG",0.9
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"pRNFL measurements obtained in 73 eyes (49%) from 43 patients, with 54% success rate in eyes without symptomatic OPG and 33% in eyes with OPG",Results,pRNFL in 73 (49%) eyes from 43 patients...pRNFL in 54% eyes without symptomatic OPG and in 33% with OPG,0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"Mean pRNFL thickness: 100±0.9 μm in NF1 without OPG, 70±2.1 μm in NF1-OPG, and 77±2.6 μm in sporadic OPG (p<0.001)",Results,"pRNFL, mean ± SE (95CI) μm...100 ± 0.9 (98–101) N = 59...70 ± 2.1 (66–74) N = 11...77 ± 2.6 (72–83) N = 3 <0.001",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Cirrus HD-OCT,clinical_assessment_tool,Biomarker,"pRNFL showed significant thinning over time in NF1-OPG group (slope -0.7211μm/trimester, p<0.001)",Results,"All three groups showed a thinning in pRNFL over time, however reaching statistical significance in NF1-OPG group (slope -0.7211μm/trimester, p<0.001)",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Humphrey Field Analyzer perimetry,clinical_assessment_tool,Biomarker,"VFI measurements obtained in 55 eyes (37%) from 36 patients, with 39% success rate in eyes without symptomatic OPG and 31% in eyes with OPG",Results,VFI measurements in 55 eyes (37%) from 36 patients...VFI in 39% of eyes without symptomatic OPG and in 31% eyes with OPG,0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Humphrey Field Analyzer perimetry,clinical_assessment_tool,Biomarker,"Mean VFI: 95±0.6% in NF1 without OPG, 88±3.0% in NF1-OPG, and 47±1.8% in sporadic OPG (p<0.001)",Results,"VFI, mean ± SE (95CI) %...95 ± 0.6 (94–97) N = 42...88 ± 3.0 (83–94) N = 9...47 ± 1.8 (43–50) N = 4 <0.001",0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Humphrey Field Analyzer perimetry,clinical_assessment_tool,Other,"Mean age for first reliable VFI measurement was 7.3±1.0 years, significantly higher than VA at 5.4±1.6 years (p<0.001)",Results,Mean age for first reliable VA measurement was significantly lower than for VFI (5.4±1.6 yrs vs 7.3±1.0 yrs; p<0.001),0.95
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,Humphrey Field Analyzer perimetry,clinical_assessment_tool,Biomarker,"VFI showed improvement over time in all groups but reached statistical significance only in NF1 without OPG group (slope 0.3789%/trimester, p<0.001)",Results,"Visual field index was improving in all groups but significant results were obtained only in the NF1 noOPG group (slope 0.3789%/trimester, p<0.001)",0.95
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,Primary human Schwann cells (NHSC),cell_line,Biomarker,"RABL6A expression decreased significantly as NHSCs were passaged and underwent senescence, with concomitant p16 upregulation and reduced RB1 phosphorylation at S807/811",Results,"endogenous RABL6A expression decreased significantly as NHSCs were passaged and underwent senescence...p16INK4a (p16) was upregulated with increasing passage, while RB1 phosphorylation at S807/811...was reduced",0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,Primary human Schwann cells (NHSC),cell_line,Efficacy,Loss of RABL6A caused NHSCs to proliferate significantly slower compared to control cells expressing empty shRNA vector,Results,"Compared to control (CON) NHSCs expressing empty shRNA vector, cells lacking RABL6A proliferated significantly slower",0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,Primary human Schwann cells (NHSC),cell_line,Biomarker,"RABL6A loss led to dramatic reduction in phosphorylated RB1-S807/811 and stark upregulation of p16 expression, with significant upregulation of SA-βgal staining",Results,Loss of RABL6A led to a dramatic reduction in phosphorylated RB1-S807/811 as well as stark upregulation of p16 expression...significant upregulation of SA-βgal staining,0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,Mouse embryonic fibroblasts (MEFs),cell_line,Efficacy,Rabl6 knockout MEF cultures displayed reduced proliferation compared to wildtype culture and reduced percentage in S phase,Results,Two different Rabl6 knockout MEF cultures were generated from separate embryos and both displayed reduced proliferation compared to the wildtype culture,0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,Mouse embryonic fibroblasts (MEFs),cell_line,Biomarker,"MEFs lacking Rabl6 displayed higher p16 expression at earlier passage and decreased RB1 phosphorylation (S807/811), with premature senescence relative to wildtype MEFs",Results,MEFs lacking Rabl6 displayed higher p16 expression at an earlier passage...heightened p16 expression...strongly correlated with decreased phosphorylation of RB1 (S807/811),0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,RABL6A shRNAs in pLKO.1 lentiviral vector,genetic_reagent,Efficacy,"Two different RABL6A shRNAs (KD1 and KD2) induced cell cycle arrest in NHSCs without causing cell death, with effective knockdown confirmed by Western blot",Results,"Two different short hairpin RNAs (shRNA), named KD1 and KD2...induced a cell cycle arrest in NHSCs without causing cell death...Western blot analyses confirmed effective knockdown of RABL6A",0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,RB1 shRNAs in pLKO.1 lentiviral vector,genetic_reagent,Efficacy,"RB1 loss partially rescued anti-proliferative effects of RABL6A knockdown, restored DNA synthesis to control levels, and dramatically reduced senescence induction",Results,"RB1 loss alone had no effect on proliferation, whereas it partially rescued the anti-proliferative effects of RABL6A knockdown...loss of RB1 in RABL6A depleted cells restored DNA synthesis...dramatically reduced the induction of senescence",0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,p-RB1-S807/811 antibody (Cell Signaling #8516),antibody,Biomarker,Successfully detected reduced RB1 phosphorylation at S807/811 sites during NHSC senescence and upon RABL6A loss by Western blotting and immunofluorescence,Results,"RB1 phosphorylation at S807/811, sites of CDK4/6 phosphorylation, was reduced...Loss of RABL6A led to a dramatic reduction in phosphorylated RB1-S807/811",0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,human p16 antibody (Abcam ab108349),antibody,Biomarker,Successfully detected p16 upregulation with increasing passage and upon RABL6A loss by Western blotting and immunofluorescent staining,Results,p16INK4a (p16) was upregulated with increasing passage...stark upregulation of p16 expression. This was shown by both Western blotting...and immunofluorescent (IF) staining,0.9
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,Senescence β-Galactosidase Staining Kit (Cell Signaling #9860),clinical_assessment_tool,Biomarker,Successfully detected concomitant induction of senescence-associated β-galactosidase during NHSC passaging and significant upregulation upon RABL6A loss,Results,A concomitant induction of senescence-associated β-galactosidase (SA-βgal) was also observed...significant upregulation of SA-βgal staining,0.9
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,Numerical Rating Scale (NRS-11),clinical_assessment_tool,Behavioral,74% of patients showed clinically meaningful decrease in neurofibroma-related pain intensity,Discussion,It is notable that the decrease in neurofibroma-related pain intensity reached clinically meaningful levels in 74% of the patients.,0.95
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,Pain Interference Index,clinical_assessment_tool,Behavioral,38% of children and 50% of parents reported clinically meaningful decrease in pain interference,Discussion,"Furthermore, 38% of the children and 50% of the parents reported a clinically meaningful decrease in pain interference",0.95
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,Pain Interference Index,clinical_assessment_tool,Other,"Tool has been validated for the neurofibromatosis type 1 population, unlike other outcome measures used",Discussion,"with the exception of the Pain Interference Index and the measurements of visual acuity, the other outcome measures that were used have not yet been validated for the population with neurofibromatosis type 1",0.9
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,clinical_assessment_tool,Behavioral,48% of children and 58% of parents reported clinically meaningful increase in health-related quality of life,Discussion,"48% and 58%, respectively, reported a clinically meaningful increase in health-related quality of life",0.95
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,Global Impression of Change scale,clinical_assessment_tool,Behavioral,72% of children and 86% of parents reported improvements compared with baseline,Discussion,"The majority of the children and parents (72% and 86%, respectively) reported improvements as compared with baseline on the Global Impression of Change scale",0.95
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,Global Impression of Change scale,clinical_assessment_tool,Safety,"Few patients who reported minor worsening attributed this primarily to selumetinib-related toxic effects, all of which were reversible with treatment interruption",Discussion,"the few who reported minor worsening noted that these were primarily due to selumetinib-related toxic effects, all of which were reversible with treatment interruption",0.85
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,"NCI Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tool,Safety,"Toxic effects included asymptomatic increase in creatine phosphokinase level, gastrointestinal symptoms, paronychia, and rash with no irreversible or cumulative toxic effects",Discussion,"toxic effects of selumetinib were similar to those reported previously, including an asymptomatic increase in the creatine phosphokinase level, gastrointestinal symptoms, paronychia, and rash. No irreversible or cumulative toxic effects were noted",0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002,cell_line,Efficacy,PTPN11 genetic depletion significantly reduced MPNST cell growth as evidenced by long-term colony formation assay and short-term real-time cell confluence monitoring,Results,"PTPN11/SHP2 genetic depletion significantly reduced MPNST cell growth, as evidenced by long-term colony formation assay (Fig. 1A and fig. S1A) and short-term real-time cell confluence monitoring",0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002,cell_line,Biomarker,37 of 51 genes (73%) in the MEK-dependent set demonstrated significant down-regulation after PTPN11 depletion (P adj < 0.05),Results,Thirty-seven of the 51 genes (73%) in the MEK-dependent set demonstrated significant down-regulation after PTPN11 depletion (P adj < 0.05),0.95
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002,cell_line,Efficacy,TNO155 treatment led to fewer differentially expressed genes (740) compared to trametinib (3301) or shPTPN11 (3156),Results,"740 genes were significantly altered (P adj < 0.05 and absolute fold change > 1.5) following TNO155, while 3301 and 3156 genes were significantly altered after trametinib and shPTPN11",0.95
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002,cell_line,Efficacy,Median inhibitory concentration increase of 5-fold with WT E7 expression compared to parental cells for TNO155 resistance,Results,"We observed that WT E7–expressing cells were more resistant to TNO155, relative to parental and E7 d21-24 mutant cells, with the median inhibitory concentration increase of 5-fold in JH-2-002",0.95
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-079c,cell_line,Mechanistic,TNO155 induced caspase-3/7 activation as demonstrated by IncuCyte real-time monitoring system,Results,"Further investigation in ST8814 and JH-2-079c cell lines treated with dimethyl sulfoxide (DMSO) or 0.3 μM TNO155, using IncuCyte real-time monitoring system, demonstrated caspase-3/7 activation induced by TNO155",0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-079c,cell_line,Biomarker,Universally decreased expression of survivin/BIRC5 and claspin/CLSPN with TNO155 and ribociclib combination treatment,Results,we found universally decreased expression of two inhibitors of apoptosis proteins (IAPs) survivin/BIRC5 and claspin/CLSPN in ST8814 and JH-2-079c treated with the combination,0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-103,cell_line,Efficacy,Showed increasing trend of percent cells in G1 phase and decreasing trend in S phase when treated with TNO155 and ribociclib combination,Results,"we saw an increasing trend of percent cells in G1 phase and a decreasing trend of percent cells in S phase when comparing cells treated with DMSO, TNO155, ribociclib, and the combination",0.8
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-002 PDX,patient_derived_model,Efficacy,Classified as very sensitive (VS) PDX showing almost equal sensitivity to combination and TNO155 alone over 4 weeks,Results,We thus defined the top three PDXs that were almost equally sensitive to the combination and TNO155 alone as very sensitive (VS; Fig. 7A),0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-031 PDX,patient_derived_model,Efficacy,Classified as very sensitive (VS) PDX with activating PIK3CA Q546K mutation retaining sensitivity to TNO155,Results,The VS PDX JH-2-031 with activating PIK3CA Q546K mutation and WU-225 with TSC2 in frame deletion retained sensitivity to TNO155,0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-031 PDX,patient_derived_model,Efficacy,Showed combination benefit with TNO155 and ribociclib after drug holiday retreatment,Results,We observed combination benefit regardless of intermittent (Fig. 7H) or continuous dosing of therapy over a 10-week treatment,0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,JH-2-079c PDX,patient_derived_model,Efficacy,Classified as partially sensitive (PS) PDX displaying differential sensitivity to combination versus TNO155 alone,Results,the bottom three PDXs that displayed differential sensitivity to the combination and TNO155 as partially sensitive (PS; Fig. 7B),0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-225 PDX,patient_derived_model,Efficacy,Classified as very sensitive (VS) PDX with TSC2 in frame deletion retaining sensitivity to TNO155,Results,The VS PDX JH-2-031 with activating PIK3CA Q546K mutation and WU-225 with TSC2 in frame deletion retained sensitivity to TNO155,0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-225 PDX,patient_derived_model,Biomarker,Cleaved caspase-3 increased in tumors treated with TNO155 and ribociclib combination compared to either drug alone,Results,"Moreover, cleaved caspase-3 increased in WU-225 (fig. S7C), and the IAP survivin markedly decreased in WU-386",0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-386 PDX,patient_derived_model,Efficacy,Classified as partially sensitive (PS) PDX displaying differential sensitivity to combination versus TNO155 alone,Results,the bottom three PDXs that displayed differential sensitivity to the combination and TNO155 as partially sensitive (PS; Fig. 7B),0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-386 PDX,patient_derived_model,Biomarker,IAP survivin markedly decreased in tumors treated with TNO155 and ribociclib combination,Results,"Moreover, cleaved caspase-3 increased in WU-225 (fig. S7C), and the IAP survivin markedly decreased in WU-386",0.85
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,WU-545 PDX,patient_derived_model,Efficacy,Showed most potent antitumor effects with TNO155 and ribociclib combination relative to TNO155 alone or TNO155 and trametinib,Results,"We observed the most potent antitumor effects seen with TNO155 and ribociclib, relative to TNO155 or TNO155 and trametinib in WU-545",0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,NRG mice,animal_model,Efficacy,"TNO155 (7.5 mg/kg, twice daily) and ribociclib (75 mg/kg, once daily) combination showed potent antitumor activity across six PDX models over 4 weeks",Results,"using doses (TNO155, 7.5 mg/kg, twice daily; and ribociclib, 75 mg/kg, once daily) lower than those selected in tolerability studies",0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,shPTPN11 #5003,genetic_reagent,Efficacy,PTPN11 genetic depletion significantly reduced MPNST cell growth in colony formation and real-time confluence monitoring assays,Results,"PTPN11/SHP2 genetic depletion significantly reduced MPNST cell growth, as evidenced by long-term colony formation assay",0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,shPTPN11 #818,genetic_reagent,Efficacy,PTPN11 genetic depletion significantly reduced MPNST cell growth in colony formation and real-time confluence monitoring assays,Results,"PTPN11/SHP2 genetic depletion significantly reduced MPNST cell growth, as evidenced by long-term colony formation assay",0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,shPTPN11 #818,genetic_reagent,Biomarker,"Significant decrease in PTPN11 RNA expression (P adj = 0, log2 fold change = −4.69) confirmed by RNA-seq",Results,"RNA-seq result revealed a significant decrease in PTPN11 RNA expression [n = 3, P adj = 0, and log2 fold change (LFC) = −4.69]",0.95
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,NF1-GRD construct,genetic_reagent,Efficacy,"Reintroduction of NF1-GRD partially rescued cell viability upon TNO155 treatment, suggesting NF1 loss confers sensitivity to SHP2i",Results,Reintroduction of NF1-GRD to restore GAP function partially rescued cell viability upon TNO155 treatment,0.9
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,NF1-GRD construct,genetic_reagent,Mechanistic,"Reexpression of NF1-GRD reduced RAS-GTP levels, indicative of successful restoration of NF1 GAP function",Results,"Relative to the green fluorescent protein (GFP) control, reexpression of NF1-GRD reduced RAS-GTP levels, indicative of a successful restoration of NF1 GAP function",0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,Nf1 P1,animal_model,Biomarker,"Exhibited significantly elevated CO2 output compared to controls (p = 0.002, n = 9)",Results,"Nf1 P1 mutant flies exhibited significantly elevated CO 2 output compared to controls (Fig. 1b and Supplementary Fig. 1a), suggesting that Nf1 plays a role in metabolic regulation.",0.95
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,Nf1 P1,animal_model,Biomarker,Increased CO2 production and O2 consumption across the 24-h photoperiod relative to controls,Results,Mutant Nf1 P1 adult flies exhibited increased CO 2 production and O 2 consumption across the 24-h photoperiod relative to controls,0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,Nf1 P1,animal_model,Biomarker,"Respiratory quotient (RQ) was significantly reduced (p < 0.001, n = 14)",Results,"In both cases, the respiratory quotient (RQ), the ratio of CO 2 eliminated to O 2 consumed, was significantly reduced",0.95
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,Nf1 P1,animal_model,Biomarker,"Triglyceride stores were significantly reduced compared to controls (p = 0.002, n = 9-10)",Results,Triglyceride stores were significantly reduced in Nf1 P1 mutants compared to controls,0.95
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,Nf1 P1,animal_model,Biomarker,"48h after returning to unlabeled food, retained significantly less 14C than controls, suggesting elevated rates of lipolysis",Results,"However, 48 h after returning flies to unlabeled food, Nf1 P1 flies retained significantly less 14 C than controls. This suggests that Nf1 P1 mutants exhibited significantly elevated rates of lipolysis",0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,Nf1 P1,animal_model,Safety,"Significantly more susceptible to starvation than controls, succumbing in less than half the time (p < 0.001, n = 78-80)",Results,"Nf1 P1 mutants were significantly more susceptible to starvation than controls, succumbing in less than half the time of control flies",0.95
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,Nf1 P1,animal_model,Behavioral,"Food intake was significantly increased relative to controls (p < 0.001, n = 30 per genotype)",Results,Food intake was significantly increased in Nf1 P1 adult flies relative to controls,0.95
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,Nf1 P1,animal_model,Mechanistic,Nf1 protein was eliminated and pERK levels were increased with no detectable change in total ERK levels,Results,"We confirmed that Nf1 was eliminated in Nf1 P1 mutants and reduced with RNAi knockdown... In both Nf1 P1 mutants and Nf1 RNAi lines, there was an increase in pERK, with no detectable change in total ERK levels",0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,w CS10,animal_model,Other,"Used as control strain showing normal CO2 production, metabolic rate, triglyceride levels, starvation resistance, and feeding behavior",Results,"We first compared Nf1 P1 mutants, which harbor a large deletion in the NF1 locus, including the central catalytic GRD, with w CS10 controls",0.85
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,UAS-Nf1-eGFP,genetic_reagent,Efficacy,"Pan-neuronal rescue of full-length, wild-type Nf1 restored metabolic rate to control levels",Results,"Pan-neuronal rescue of full-length, wild-type Nf1 restored metabolic rate to control levels",0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,VDRC #109637,genetic_reagent,Biomarker,Pan-neuronal knockdown significantly elevated CO2 production relative to controls using two different Gal4 drivers,Results,"In each case, a significant elevation in CO 2 production was observed in the experimental group relative to flies harboring either the heterozygous driver (Gal4/+) or effector (UAS/+) transgenes alone",0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,UAS-rl Sem,genetic_reagent,Biomarker,"Activation of ERK in PCB-Gal4+ neurons increased CO2 production (p < 0.001, n = 10 per genotype)",Results,"Activation of ERK in PCB-Gal4+ neurons increased CO 2 production, as assayed by respirometry, partially phenocopying the effect of knocking down Nf1 in these neurons",0.95
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,nSyb (BDSC #51635),genetic_reagent,Biomarker,Pan-neuronal knockdown of Nf1 significantly elevated CO2 production and increased O2 consumption across the circadian photoperiod,Results,"when Nf1 was knocked down pan-neuronally using nSyb-Gal4, we observed increased O 2 consumption and CO 2 production across the circadian photoperiod relative to controls",0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,nSyb (BDSC #51635),genetic_reagent,Behavioral,Pan-neuronal knockdown elevated spontaneous grooming and increased feeding relative to controls,Results,Pan-neuronal knockdown of Nf1 elevated spontaneous grooming... Knocking down Nf1 pan-neuronally also increased feeding relative to controls,0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,PCB-Gal4,genetic_reagent,Biomarker,Knockdown of Nf1 produced one of the largest increases in metabolic rate among tested drivers,Results,the driver with the most restricted expression pattern that produced a large effect was the PCB-Gal4 driver... While knocking down Nf1 with this driver produced one of the largest increases in metabolic rate,0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,PCB-Gal4,genetic_reagent,Behavioral,Did not significantly elevate spontaneous grooming despite producing large metabolic effects,Results,"While knocking down Nf1 with this driver produced one of the largest increases in metabolic rate, it did not significantly elevate spontaneous grooming",0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,PCB-Gal4,genetic_reagent,Safety,Nf1 knockdown increased starvation susceptibility,Results,"Likewise, Nf1 knockdown in PCB-Gal4+ neurons increased starvation susceptibility",0.85
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,mAb21 anti-Nf1 monoclonal antibody,antibody,Mechanistic,Confirmed that Nf1 was eliminated in Nf1 P1 mutants and reduced with RNAi knockdown,Results,We confirmed that Nf1 was eliminated in Nf1 P1 mutants and reduced with RNAi knockdown,0.85
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,"anti-phospho-ERK (mouse, Sigma M8159)",antibody,Mechanistic,Detected increased pERK levels in both Nf1 P1 mutants and Nf1 RNAi lines,Results,"In both Nf1 P1 mutants and Nf1 RNAi lines, there was an increase in pERK, with no detectable change in total ERK levels",0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,"total ERK (rabbit, CST 9102)",antibody,Mechanistic,Showed no detectable change in total ERK levels in Nf1 P1 mutants and RNAi lines,Results,"In both Nf1 P1 mutants and Nf1 RNAi lines, there was an increase in pERK, with no detectable change in total ERK levels",0.9
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,"rabbit anti-GFP (Invitrogen, A11122)",antibody,Mechanistic,"Western blot analysis showed no difference between protein levels of the R1320P mutation and full-length Nf1 (p = 0.510, n = 4 per genotype)",Results,"Western blot analysis showed no significant changes in protein expression between pan-neuronal rescue of full-length, wild-type Nf1 and pan-neuronal expression of full-length Nf1 carrying the R1320P missense mutation",0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,Cnp-Cre; R26-lsl-SB11; T2/Onc15,animal_model,Efficacy,"SB mutagenesis significantly enhanced neurofibroma formation (~35%, p=0.0155) and induced grade 3 PNST formation in EGFR-overexpressing mice (p=0.0141)",Results,"SB mutagenesis significantly enhanced neurofibroma formation (~35%, p=0.0155) and induced grade 3 PNST formation in EGFR-overexpressing mice (p=0.0141)",0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,Cnp-Cre; R26-lsl-SB11; T2/Onc15,animal_model,Safety,SB mutagenesis significantly reduced grade 3 PNST free-survival compared to both pre-disposed alleles alone (p<0.0001),Results,"SB mutagenesis on both pre-disposed alleles led to neurofibroma development, significantly increased grade 3 PNST development (p=0.0005), and significantly reduced grade 3 PNST free-survival compared to both pre-disposed alleles alone (p<0.0001)",0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,Cnp-Cre,genetic_reagent,Safety,"Cnp-Cre; Nf1f/f; Ptenf/+ mice had significantly decreased median survival of 101 days compared to control Cnp-Cre; Nf1f/+ (185 days, Logrank p=0.017) and Cnp-Cre; Ptenf/+ (323 days, Logrank p<0.0001)",Results,"Cnp-Cre; Nf1f/f; Ptenf/+ mice had a significantly decreased median survival of 101 days compared to control Cnp-Cre; Nf1f/+ (185 days, Logrank p=0.017) and Cnp-Cre; Ptenf/+ (323 days, Logrank p<0.0001) mice",0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,iHSCs,advanced_cellular_model,Efficacy,FOXR2 overexpression in iHSC clone HSC1λ minimally increased in vitro proliferation and significantly increased soft-agar colony formation compared to luciferase control (two-tailed t-test p<0.0001),Results,"FOXR2 overexpression in the iHSC clone HSC1λ increased total FOXR2 protein and cytoplasmic staining, minimally increased in vitro proliferation, and significantly increased soft-agar colony formation compared to luciferase control (two-tailed t-test p<0.0001)",0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,iHSCs,advanced_cellular_model,Efficacy,"No tumor formation in control HSC1λ cells, but 3/5 mice harboring FOXR2 overexpressing cells developed a tumor in xenograft experiments",Results,"Xenograft experiments demonstrated no tumor formation in the control HSC1λ cells, but 3/5 mice harboring FOXR2 overexpressing cells developed a tumor",0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,STS26T,cell_line,Efficacy,FOXR2 knockout and mutation detected cell lines had reduced proliferation and significant reductions in colony formation ability compared to HPRT knockout control cells (t-test p<0.0001),Results,FOXR2 knockout and mutation detected cell lines had reduced proliferation and significant reductions in colony formation ability compared to HPRT knockout control cells (t-test p<0.0001),0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,STS26T,cell_line,Efficacy,FOXR2 loss inhibited the ability of STS26T cells to form tumors in xenograft experiments compared to HRPT knockout controls,Results,"Additionally, FOXR2 loss inhibited the ability of STS26T cells to form tumors in xenograft experiments compared to HRPT knockout controls",0.9
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,S462-TY,cell_line,Efficacy,FOXR2 knockout and mutation detected cell lines had reduced proliferation and significant reductions in colony formation ability compared to HPRT knockout control cells (t-test p<0.0001),Results,FOXR2 knockout and mutation detected cell lines had reduced proliferation and significant reductions in colony formation ability compared to HPRT knockout control cells (t-test p<0.0001),0.95
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,FOXR2 TALENs,genetic_reagent,Efficacy,TALENs that generated knockout or heterogeneous mutations of FOXR2 caused loss of protein by western blot analysis,Results,TALENs that generated knockout or heterogeneous mutations (called mutation detected) of FOXR2 caused loss of protein by western blot analysis,0.9
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,TAPDANCE,computational_tool,Efficacy,td-CIS analysis identified 511 neurofibroma and 34 grade 3 PNST driver-mutations with 21 genes overlapping,Results,td-CIS analysis identified 511 neurofibroma and 34 grade 3 PNST driver-mutations with 21 genes overlapping,0.95
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,RealSeqS,computational_tool,Biomarker,"Amplifies approximately 750,000 loci across 39 chromosome arms to calculate genome wide aneuploidy score (GAS)",Results,"RealSeqS, which amplifies approximately 750,000 loci across 39 chromosome arms, was used to calculate a genome wide aneuploidy score (GAS)",0.95
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,RealSeqS,computational_tool,Efficacy,Achieved 33% sensitivity for detecting MPNST at 97% specificity,Results,"the sensitivity for detecting MPNST was 33% (4/12, p < 0.001 compared to healthy controls)",0.95
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,RealSeqS,computational_tool,Efficacy,False positive rate among benign/plexiform neurofibromas was 6.3% (1/16),Results,"the false positive rate among benign/plexiform neurofibromas was 6.3% (1/16, p = 0.42 compared to healthy controls)",0.95
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,RealSeqS,computational_tool,Biomarker,"Can detect focal amplifications and deletions across 39 chromosome arms, identifying 50% of MPNST patients with losses on 17q at SUZ12",Results,50% (6/12) had losses on 17q at SUZ12,0.95
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,RealSeqS,computational_tool,Efficacy,Combination of GAS and detection of sub-chromosomal changes may lead to sensitivity of ~50% at 97% specificity,Discussion,"the combination of GAS and detection of sub-chromosomal changes in genes such as TERT, TP53, and SUZ12 or mutations in ctDNA may lead to a sensitivity of ~50% at a high specificity of 97%",0.9
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,RealSeqS,computational_tool,Other,Requires relatively low sequencing coverage of ~10 M reads per sample to identify relevant CNAs,Discussion,each sample only requires ~10 M reads to identify relevant CNAs,0.95
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,BioRad QX200 droplet digital PCR system,computational_tool,Biomarker,"Successfully detected ctDNA mutations in 3 of 6 patients tested, including mutations at MAF of 0.04% to 2.55%",Results,"Three patients had positive ctDNA results, including one patient...that had a GOLGA2 splice site acceptor mutation at a mutant allele frequency (MAF) of 0.19%, and two MPNST patients...at 2.55% and...at 0.04%",0.95
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,sNF96.2,cell_line,Biomarker,"Expressed HER1 antigen, confirmed by flow cytometry analysis",Results,"After confirming the expression of HER1 on sNF96.2 (Fig. 2 A), we assessed the tumor-lysing capabilities of 806, E2 and NEC.",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,sNF96.2,cell_line,Biomarker,Released nearly 2000 pg/ml of TGFβ1 in culture medium,Results,The concentration of TGFβ1 in the sNF96.2 culture medium reached nearly 2000 pg/ml (Fig. 3 C).,0.95
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,sNF96.2,cell_line,Biomarker,Approximately 95% of cells were PDL1-positive,Results,"Additionally, approximately 95% of sNF96.2, T20210108 and T20210618, around 85% of T20210304, T20210401 and T20211105 cells, and nearly 60% of T20210106 cells were PDL1-positive",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,anti-HER1 CAR (806),genetic_reagent,Efficacy,"Completely eliminated sNF96.2-luci cells at E:T ratio of 1:1, and lysed 75% of tumor cells at E:T ratio of 0.25:1",Results,"sNF96.2-luci was completely eliminated by all three types of CAR-T cells at an effector to target (E:T) ratio of 1: 1. Notably, 806 exhibited superior performance even at lower E:T ratios. At an E:T ratio of 0.25: 1, E2 and NEC lost their tumor-lysing activity, whereas 806 was still able to lyse 75% of the tumor cells",0.95
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,anti-HER1 CAR (E2),genetic_reagent,Efficacy,"Completely eliminated sNF96.2-luci cells at E:T ratio of 1:1, but lost tumor-lysing activity at E:T ratio of 0.25:1",Results,"sNF96.2-luci was completely eliminated by all three types of CAR-T cells at an effector to target (E:T) ratio of 1: 1. At an E:T ratio of 0.25: 1, E2 and NEC lost their tumor-lysing activity",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,anti-HER1 CAR (NEC),genetic_reagent,Efficacy,"Completely eliminated sNF96.2-luci cells at E:T ratio of 1:1, but lost tumor-lysing activity at E:T ratio of 0.25:1",Results,"sNF96.2-luci was completely eliminated by all three types of CAR-T cells at an effector to target (E:T) ratio of 1: 1. At an E:T ratio of 0.25: 1, E2 and NEC lost their tumor-lysing activity",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,anti-HER1 CAR (806),genetic_reagent,Efficacy,Demonstrated superior efficacy against primary tumor cells at E:T ratio of 0.5:1 compared to E2 and NEC,Results,"Our results showed that three types of CAR-T cells induced varying degree of tumor clearance at an E:T ratio of 0.5:1, with 806 demonstrating superior efficacy",0.85
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,anti-HER1 CAR (806),genetic_reagent,Safety,Did not exhibit any cytolytic effect on HFFs normal cells despite their HER1 positivity,Results,"Although HFFs are HER1-positive, 806 did not exhibit any cytolytic effect on these normal cells.",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,anti-HER1 CAR (806),genetic_reagent,Efficacy,Completely eliminated NCI-H266 cells at E:T ratio of 0.2:1,Results,"NCI-H266 was completely eliminated at an E:T of 0.2:1, with the lysis decreasing as the E:T ratio was reduced.",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,anti-HER1 CAR (806),genetic_reagent,Safety,"Did not lyse K562 cells which had no HER1 expression, demonstrating specificity",Results,"As expected, K562 cells were not lysed by 806.",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,anti-HER1 CAR (806),genetic_reagent,Efficacy,TGFBR2-edited version (806-TKO) showed 94% vs 60% efficacy compared to control at E:T ratio of 0.25:1,Results,"TGFBR2-edited 806 (referred to as 806-TKO) demonstrated a significant advantage at an E:T ratio of 0.25:1 compared to control 806 electroporated without ribonucleoproteins (referred to as 806-EP), showing 94% versus 60% efficacy, respectively.",0.95
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,anti-HER1 CAR (806),genetic_reagent,Efficacy,TGFBR2-edited version showed enhanced efficacy at E:T ratios of 0.125:1 (76% vs 45%) and 0.0625:1 (24.5% vs 2.7%),Results,This advantage became more pronounced at lower E:T ratios of 0.125:1 (806-TKO vs. 806-EP: 76% vs.45%) and 0.0625:1 (806-TKO vs. 806-EP: 24.5% vs. 2.7%).,0.95
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,HFFs,cell_line,Biomarker,Showed 98.6% HER1 positivity with low expression intensity,Results,While HFFs showed 98.6% HER1 positivity with low expression intensity.,0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,NCI-H266,cell_line,Biomarker,Was nearly 100% HER1 positive with high expression intensity,Results,NCI-H266 was nearly 100% HER1 positive with high expression intensity.,0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,K562,cell_line,Biomarker,Had no HER1 expression,Results,K562 had no HER1 expression.,0.95
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,3D tumor spheroid model,advanced_cellular_model,Efficacy,"Tumor cells in spheroids were more sensitive to 806 CAR-T cells than those cultured in 2D, with complete tumor elimination at E:T ratio of 0.25:1",Results,"Interestingly, tumor cells in spheroids were more sensitive to 806 CAR-T cells than those cultured in 2D. As shown in Figure S4E, 806-EP along with other groups achieved complete tumor elimination at a E:T ratio of 0.25:1.",0.9
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,3D tumor spheroid model,advanced_cellular_model,Mechanistic,Showed substantial infiltration of CD3-positive T cells in spheroids treated with 806 CAR-T cells,Results,"Notably, substantial infiltration of CD3-positive T cells was observed in the spheroids treated with 806 CAR-T cells.",0.85
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,3D tumor spheroid model,advanced_cellular_model,Mechanistic,"Displayed compact morphology, high expression of HER1 and TGFβ1, and relatively low expression of PDL1",Results,"The spheroids displayed a compact morphology, high expression of HER1 and TGFβ1, and relatively low expression of PDL1, with nearly absent S100 expression",0.85
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,Neurofibromatosis 1 fibroblasts,patient_derived_model,Biomarker,"NFFs showed significantly downregulated NF1 protein expression compared to HEFs, while NF1 mRNA expression was comparable between groups",Results,"Although the mRNA expression of NF1 was comparable between HEFs and NFFs (Fig. 2a), the protein expression of NF1 was significantly downregulated in NFFs compared with that in HEFs",0.95
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,Neurofibromatosis 1 fibroblasts,patient_derived_model,Biomarker,"NFFs showed significantly decreased MMP1 protein expression compared to HEFs, with no detectable MMP1 release in supernatants",Results,"the expression of MMP1 protein was significantly decreased in NFFs compared with that in HEFs...significant amounts of MMP1 protein were detected in the supernatants of HEFs, while NFFs did not release detectable amounts",0.95
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,Neurofibromatosis 1 fibroblasts,patient_derived_model,Biomarker,COL1A1 protein expression was comparable between NFFs and HEFs,Results,The protein expression of COL1A1 was comparable between HEFs and NFFs,0.9
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,Neurofibromatosis 1 fibroblasts,patient_derived_model,Efficacy,"HCQ treatment at 50 μM significantly increased MMP1 mRNA and protein levels in NFFs, with restored MMP1 release in culture supernatants",Results,CQ and HCQ significantly increased the mRNA (Fig. 3b) and protein (Fig. 3c and Supplementary Fig. S4) levels of MMP1...The MMP1 proteins upregulated by CQ and HCQ were actually released in the culture supernatants,0.95
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,MMP1 antibody (#E9S9N),antibody,Biomarker,Successfully detected significantly decreased MMP1 protein expression in NFFs compared to HEFs by western blot analysis,Results,"the expression of MMP1 protein was significantly decreased in NFFs compared with that in HEFs, as revealed by western blot analysis",0.9
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,NF1 antibody (#D7R7D),antibody,Biomarker,Successfully detected significantly downregulated NF1 protein expression in NFFs compared to HEFs,Results,the protein expression of NF1 was significantly downregulated in NFFs compared with that in HEFs,0.9
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,Aryl hydrocarbon receptor antibody (#H-211),antibody,Mechanistic,Successfully detected HCQ-induced cytoplasmic-to-nuclear translocation of AHR compared to predominantly cytoplasmic staining in untreated controls,Results,"Compared with the predominantly cytoplasmic staining of AHR in the untreated control NFFs, HCQ appeared to induce the cytoplasmic-to-nuclear translocation of AHR",0.9
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,siRNA targeting NF1 (s221793),genetic_reagent,Mechanistic,"Successfully lowered NF1 mRNA and protein levels in both HEFs and NFFs, but unexpectedly augmented MMP1 expression rather than reducing it",Results,"The transfection of NF1 siRNA successfully lowered the mRNA (Fig. 4c) and protein (Fig. 4d) levels of NF1 in both HEFs and NFFs. Unexpectedly, NF1 knockdown rather augmented the MMP1 expression",0.95
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,siRNA targeting AHR (s1200),genetic_reagent,Mechanistic,"Successfully decreased AHR mRNA and protein expression, and notably reduced HCQ-induced MMP1 upregulation in both HEFs and NFFs",Results,The mRNA and protein expression of AHR was successfully decreased by transfection with AHR siRNA...the HCQ-induced MMP1 upregulation was reduced in both HEFs and NFFs transfected with AHR siRNA,0.95
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,anti-S100 protein antibody,antibody,Biomarker,"Successfully identified S100+ Schwann-like cells in neurofibroma lesional skin, stained brown in immunohistochemical analysis",Results,"The lesional skin of the neurofibromas contained S100 + cells (Fig. 7, 16 1 b, j, stained brown)",0.9
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,Postn-Cre; Nf2flox/flox,animal_model,Safety,"High mortality and frailty of transgenic line, with significant animal losses during treatment (5 out of 9 animals died during human bevacizumab + FUS treatment)",Both,Establishing the colony was challenging due to the frailty of this specific transgenic line...out of 9 animals 5 died during treatment,0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,Postn-Cre; Nf2flox/flox,animal_model,Efficacy,"Consistently developed DRG schwannomas detectable by MRI at 2 months, but no vestibular schwannomas up to 13 months of age",Both,Schwannomas of the DRGs were readily detectable on initial MRI at 2 months...we could not detect vestibular schwannomas on the vestibulocochlear nerve up to 13 months,0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,Postn-Cre; Nf2flox/flox,animal_model,Biomarker,"Tumor growth progression measured by MRI voxel counts: age 4-5 months (87.2 ± 30.1), age 7-8 months (109.4 ± 35.5), age 9-11 months (112.4 ± 40.6)",Results,"pooled lumbar DRG voxel counts across the cohort...age 4–5 months: n = 120, 87.2 ± 30.1; age 7–8 months: n = 68, 109.4 ± 35.5; age 9–11 months: n = 60, 112.4 ± 40.6",0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,Avastin,clinical_assessment_tool,Efficacy,"3.8-fold higher bevacizumab concentrations in FUS-treated DRGs (51.84 ± 41.37 ng/mg tissue) compared to non-FUS-treated DRGs (13.65 ± 9.57 ng/mg tissue, p = 0.025)",Results,human bevacizumab concentrations were 3.8-fold higher in FUS-treated DRGs (n = 9 tumors; 51.84 ± 41.37 ng/mg tissue) compared to non-FUS-treated DRGs...p = 0.025,0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,Avastin,clinical_assessment_tool,Efficacy,"Human bevacizumab + FUS treatment showed trend toward smaller DRG schwannomas (98.2 ± 43.7 voxels, 0.86 ± 0.14 mm diameter) compared to bevacizumab alone (144.8 ± 72.1 voxels, 1.02 ± 0.17 mm diameter, p = 0.035)",Results,DRGs treated with human bevacizumab + FUS...98.2 ± 43.7; diameter: 0.86 ± 0.14 mm) showed a trend to being smaller (p = 0.035) than those receiving human bevacizumab alone,0.9
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,LP-100 FUS system,clinical_assessment_tool,Safety,Two animals died during FUS treatment in the acute model (2 out of 5 animals),Results,"Tissue for ELISA analysis was acquired from 3 animals, since two died during the FUS-treatment",0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,LP-100 FUS system,clinical_assessment_tool,Efficacy,FUS treatment enabled 3.8-fold increase in bevacizumab delivery to DRG schwannomas compared to non-FUS treated tumors,Results,human bevacizumab concentrations were 3.8-fold higher in FUS-treated DRGs...compared to non-FUS-treated DRGs from the same animals,0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,BioSpec 70/30 USR,clinical_assessment_tool,Safety,Repeated general anesthesia procedures for MRI scans (up to 120 min) contributed to significant reduction in colony size due to possible hypothermia,Discussion,"repeated general anesthesia procedures contributed to a significant reduction in colony size...animals had to be under anesthesia up to 120 min, which further altered colony survival due to possible hypothermia",0.9
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,BioSpec 70/30 USR,clinical_assessment_tool,Biomarker,Successfully monitored tumor growth progression via MRI voxel counts showing significant increases from 4-5 months to 7-8 months (p = 0.021) and 9-11 months (p = 0.002),Results,"Tumor growth of DRG schwannomas was monitored by MRI...confirmed by pooled lumbar DRG voxel counts...p = 0.021, p = 0.002",0.95
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,Gadovist,clinical_assessment_tool,Biomarker,"Gadolinium contrast enabled detection and monitoring of DRG schwannomas on MRI, with tumors readily detectable at 2 months of age",Results,Representative MRI images with gadolinium contrast...Schwannomas of the DRGs were readily detectable on initial MRI at 2 months,0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,iHSCs,cell_line,Mechanistic,NF1-deficient iHSCs showed increased basal RAS-GTP levels compared to NF1-proficient sister clones,Results,"NF1-deficient clones also show increased basal RAS–GTP levels, as expected, when compared with the isogenic-matched NF1-proficient sister clones",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,iHSCs,cell_line,Efficacy,"NF1-deficient iHSCs exhibited robust colony formation in low-serum soft agar conditions, while NF1-proficient cells formed limited numbers of colonies",Results,"All NF1-deficient lines tested exhibited robust colony formation in these conditions, similar to the phenotype of an HSC1λ cell line in which the tumor-suppressor PTEN has been knocked out",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,iHSCs,cell_line,Efficacy,"NF1-deficient iHSCs formed tumors with 50% penetrance in athymic nude mice, while NF1-proficient lines never formed tumors",Results,"Tumor formation was never observed for the NF1-proficient cell lines. In contrast, all NF1-deficient lines showed the ability to form tumors upon xenograft, with 50% penetrance",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,S462-TY,cell_line,Efficacy,"Digoxin showed >1 log shift in IC50 concentration against S462-TY compared to NF1-proficient iHSCs, with near doubling of potency",Results,"When digoxin was used against NF1-deficient iHSCs, a shift of more than 1 log was seen in the IC50 concentration when comparing the MPNST cell line S462-TY with NF1-proficient iHSCs, with a near doubling of potency",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,S462-TY,cell_line,Efficacy,Rigosertib showed IC50 concentration in nmol/L range for S462-TY cells but was ineffective against NF1-proficient iHSCs,Results,Rigosertib showed an IC50 concentration in the nmol/L range for S462-TY cells but was ineffective against NF1-proficient iHSCs,0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,S462-TY,cell_line,Mechanistic,"S462-TY cells showed limited sensitivity to MEK inhibition, with 125 μmol/L selumetinib resulting in ~65% cells in S-phase at 24 hours",Results,"S462-TY MPNST cells show limited sensitivity to MEK inhibition. At 24 hours, 125 µmol/L selumetinib alone results in ∼65% of the cells showing an accumulation in the S-phase",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,S462-TY,cell_line,Mechanistic,Treatment with selumetinib alone for 24 hours resulted in significant feedback activation of RAS pathway as detected by RAS-GTP levels,Results,Treatment of S462-TY cells with selumetinib alone for 24 hours resulted in significant (P < 0.0001) feedback activation of the RAS pathway as detected by RAS–GTP levels,0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,athymic nude mice (RRID: JAX:002019),animal_model,Efficacy,"NF1-deficient iHSCs formed tumors with 50% penetrance in athymic nude mice over 16 weeks, while NF1-proficient lines never formed tumors",Results,"Each line was injected into the flanks of four mice and monitored for signs of tumor formation for 16 weeks. Tumor formation was never observed for the NF1-proficient cell lines. In contrast, all NF1-deficient lines showed the ability to form tumors upon xenograft, with 50% penetrance",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"NOD-Rag1 null IL2rg null, NOD rag gamma, NOD-RG (NRG) mice (RRID: JAX:007799)",animal_model,Efficacy,NF1-deficient iHSCs developed tumors with 100% penetrance in NRG mice,Results,"When the same lines were tested in the less stringent NRG mouse strain, the NF1-deficient lines developed tumors with 100% penetrance",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"NOD-Rag1 null IL2rg null, NOD rag gamma, NOD-RG (NRG) mice (RRID: JAX:007799)",animal_model,Efficacy,"S462-TY xenograft tumors progressed rapidly from ~200 mm³ to 2,000 mm³ endpoint in about a week in vehicle-treated mice",Results,"Tumors in vehicle-treated mice progressed rapidly after reaching the study size enrollment of ∼200 mm3, with tumors reaching endpoint size criteria of 2,000 mm3 in about a week",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"NOD-Rag1 null IL2rg null, NOD rag gamma, NOD-RG (NRG) mice (RRID: JAX:007799)",animal_model,Efficacy,Digoxin + selumetinib combination showed dramatic survival improvement with long-term survivors and some animals having no detectable tumors at study conclusion,Results,"Not only did the combination significantly outperform either of the single agents, but we also observed long-term survivors at the conclusion of the study. Some animals had no detectable tumors at the conclusion of the study",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"Dhh::Cre, Nf1fl/fl, Pten",animal_model,Efficacy,"Vehicle-treated animals had median survival of 18 days, while single-agent treatments extended survival: rigosertib (22 days), LB100 (24 days), digoxin (27 days), DMAPT (27.5 days), selumetinib (24 days)",Results,"Vehicle-treated animals had a median survival of 18 days, whereas the cohorts treated with rigosertib (22 days), LB100 (24 days), digoxin (27 days), DMAPT (27.5 days), and selumetinib (24 days) showed increased survival",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"Dhh::Cre, Nf1fl/fl, Pten",animal_model,Efficacy,"Combination therapies showed dramatic increases in median survival: rigosertib + selumetinib (22 to 47 days) and digoxin + selumetinib (27 to 47.5 days), P < 0.001",Results,"The rigosertib + selumetinib and digoxin + selumetinib combinations each showed dramatic increases in median survival when compared with their single-agent results (22 to 47 days and 27 to 47.5 days, respectively, P < 0.001)",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"Dhh::Cre, Nf1fl/fl, Pten",animal_model,Safety,All single agents and combinations were well tolerated with no signs of toxicity including therapy-related lethargy or gastrointestinal issues,Results,"These compounds were well tolerated, with none of the single agents or combinations tested in this model eliciting signs of toxicity in the mice, including therapy-related lethargy or gastrointestinal issues",0.9
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,Patient-derived xenograft (PDX) MPNST model,patient_derived_model,Efficacy,"Selumetinib + digoxin combination showed increase in survival and reduction in tumor growth, though not as robust as in GEMM or cell line xenograft",Results,"We also tested the selumetinib + digoxin combination in an MPNST PDX grown in NRG mice. In the PDX, an increase in survival and reduction in tumor growth was also observed, although it was not as robust as the response seen in the GEMM or MPNST cell line xenograft",0.8
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,Patient-derived xenograft (PDX) MPNST model,patient_derived_model,Efficacy,"Selumetinib + rigosertib combination showed superior tumor growth control compared to monotherapy with corresponding increase in overall survival, and significantly better response than selumetinib + digoxin combination",Results,"when the selumetinib + rigosertib combination was tested in the MPNST PDX mentioned, control of tumor growth was superior to either monotherapy, and there was a corresponding increase in overall survival. The response of this combination in the PDX model was significantly better than the selumetinib + digoxin combination",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Mut3,animal_model,Safety,Symptomatic Mut3 mice usually survived up to 8 weeks beyond initial appearance of symptoms,Results,"In contrast, symptomatic Mut3 or Mut5 mice (containing wt Pten alleles) usually survived up to 8 weeks beyond initial appearance of symptoms.",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Mut3,animal_model,Efficacy,Astrocytomas from asymptomatic Mut3 mice were primarily classified as grade 2 astrocytomas,Results,"Consistent with the previous report, gliomas from asymptomatic Mut3 mice were primarily classified as grade 2 astrocytomas",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Mut3,animal_model,Efficacy,Tumor incidence in asymptomatic Mut3 mice was 4 of 13,Results,"In age-matched asymptomatic Mut4 mice, tumor incidence was higher (11 of 18) than the Mut3 counterparts (4 of 13).",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Mut4,animal_model,Safety,Most symptomatic Mut4 mice died as early as 10 weeks of age and usually within a week after showing signs of morbidity,Results,"Interestingly, most symptomatic Mut4 and Mut6 mice died as early as 10 weeks of age and usually within a week after showing signs of morbidity.",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Mut4,animal_model,Efficacy,Tumor incidence in asymptomatic Mut4 mice was higher (11 of 18) than Mut3 counterparts (4 of 13),Results,"In age-matched asymptomatic Mut4 mice, tumor incidence was higher (11 of 18) than the Mut3 counterparts (4 of 13).",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Mut4,animal_model,Efficacy,All astrocytomas from asymptomatic Mut4 mice were classified as grade 3 tumors,Results,"In contrast to Mut3 counterparts, all astrocytomas from asymptomatic Mut4 mice were classified as grade 3 tumors.",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Mut4,animal_model,Efficacy,5-fold higher growth rate of Mut4 astrocytomas compared with Mut3 tumors,Results,We found a 5-fold higher growth rate of Mut4 astrocytomas compared with Mut3 tumors,0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Ki67 antigen antibody (Novocastra),antibody,Biomarker,"High expression of Ki67 antigen in all abnormal brain regions, suggesting gliomas",Results,"All abnormal regions had high expression of the astrocytic and neural precursor marker Gfap and also of the proliferation marker Ki67 antigen, suggesting that the tumors are gliomas",0.8
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Ki67 antigen antibody (Novocastra),antibody,Biomarker,Increased density of Ki67-positive cells in Mut4 over Mut3 tumors,Results,The accelerated growth rate of Mut4 tumors correlated with increased mitotic index and density of Ki67-positive cells in Mut4 over Mut3 tumors,0.8
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,glial fibrillary acidic protein antibody (Gfap; Sigma),antibody,Biomarker,"High expression of Gfap in all abnormal brain regions, suggesting gliomas",Results,"All abnormal regions had high expression of the astrocytic and neural precursor marker Gfap and also of the proliferation marker Ki67 antigen, suggesting that the tumors are gliomas",0.8
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,Pten antibody (NeoMarkers),antibody,Biomarker,Normal brains exhibit high Pten expression while Pten expression was low or absent in all astrocytomas examined,Results,"Consistent with previous reports, normal brains exhibit high Pten expression and no evidence of p-Akt. In contrast, Pten expression was low or absent in all astrocytomas examined.",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,phosphorylated Akt antibody (p-Akt; Cell Signaling),antibody,Biomarker,Normal brains show no evidence of p-Akt while all grade 4 and a subset of grade 3 gliomas harbored elevated p-Akt,Results,"normal brains exhibit high Pten expression and no evidence of p-Akt. In contrast, Pten expression was low or absent in all astrocytomas examined. All grade 4 and a subset of grade 3 gliomas harbored elevated p-Akt",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,BrdUrd antibody (DAKO),antibody,Biomarker,"One week after injection, Pten-deficient Mut4 (one of three) or Mut6 (three of three) mice exhibited ectopic localization of BrdUrd-containing cells",Results,"However, 1 week after injection, Pten-deficient Mut4 (one of three) or Mut6 (three of three) mice exhibited ectopic localization of BrdUrd-containing cells in the vicinity of the SVZ/RMS/OB",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,neurosphere cultures,advanced_cellular_model,Mechanistic,"All neurospheres derived from Mut3, Mut4, and Mut6 astrocytomas exhibit LOH at both Nf1 and p53 loci",Results,"Similarly, all neurospheres derived from Mut3, Mut4, and Mut6 astrocytomas exhibit LOH at both Nf1 and p53 loci",0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,neurosphere cultures,advanced_cellular_model,Mechanistic,Pten LOH was obvious in one of three Mut3 and all Mut4 and Mut6 neurospheres derived from astrocytomas,Results,Pten LOH was obvious in one of three Mut3 and all Mut4 and Mut6 neurospheres derived from astrocytomas.,0.9
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,neurosphere cultures,advanced_cellular_model,Biomarker,"All Mut3 tumor-derived neurospheres showed reduction or absence of Pten expression, compared with controls",Results,"Interestingly, all Mut3 tumor-derived neurospheres showed reduction or absence of Pten expression, compared with controls",0.9
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,Human Genome U133 Plus 2.0 Array,computational_tool,Biomarker,Successfully identified 21 significantly differentially expressed genes between early-onset and late-onset vestibular schwannomas with fold change >1.5 and p value <0.01,Results,"Twenty one significantly differentially expressed genes are identified by fold change >1.5 and p value <0.01: ANLN, NAV3, ZNF718, PSCD3, C180rf54, C10rf79, XPO1, GMNN, WHSC1, EPHA2, SNF1LK2, NGFRAP1L1, ELL2, SYTL3, KCNK17, IGLV1-44, PID1, RGN, PTPN1, ZNF331, and RNF19A",0.95
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,DNA Engine Opticon 2 Continuous Fluorescence Detection System,computational_tool,Biomarker,"Validated differential expression of 4 key genes with high statistical significance: SNF1LK2 (p=2×10⁻⁷), NGFRAP1L1/BEX5 (p=0.0002), GMNN (p=0.0009), and EPHA2 (p=9×10⁻⁶), all p<0.005",Results,"RT-PCR confirmed the results for these genes and t test for all genes were significant at p value <0.005 (SNF1LK2 p value 2 × 10⁻⁷, NGFRAP1L1 (BEX5) p value 0.0002, GMNN p value 0.0009, and EPHA2 p value 9 × 10⁻⁶)",0.95
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,Bioconductor limma package,computational_tool,Biomarker,Generated volcano scatter plot analysis showing statistically significant differential gene expression between early and late onset vestibular schwannomas using fold change and t-test criteria,Results,The results were summarized in a volcano scatter plot that summarizes both fold change and t test criteria. The negative log 10-transformed p values from the gene-specific t test was plotted against the log 2 fold change between early and late onset,0.85
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01,cell_line,Efficacy,480 active compounds identified from MIPE library screening with CRC scores of -1.1,Results,"480 active compounds at MPNST-SP-01 cell line, 507 at S462 and 410 at sNF96.2) ( 24 , 32 ). The CRC score is a measure of both potency (AC 50 ) and maximum response (MAXR)",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,S462,cell_line,Efficacy,507 active compounds identified from MIPE library screening with CRC scores of -1.2,Results,"480 active compounds at MPNST-SP-01 cell line, 507 at S462 and 410 at sNF96.2) ( 24 , 32 ). The CRC score is a measure of both potency (AC 50 ) and maximum response (MAXR)",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,sNF96.2,cell_line,Efficacy,410 active compounds identified from MIPE library screening with CRC scores of -2.1,Results,"480 active compounds at MPNST-SP-01 cell line, 507 at S462 and 410 at sNF96.2) ( 24 , 32 ). The CRC score is a measure of both potency (AC 50 ) and maximum response (MAXR)",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01,cell_line,Efficacy,Showed stronger synergies at 48h treatment compared to S462 and sNF96.2 cell lines,Results,"synergies are stronger for the MPNST-SP-01 cell line at 48h, while they are weaker and similar between the S462 and sNF96.2 cell lines",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01,cell_line,Efficacy,"18 combinations met DBSumNeg values lower than -7, with 7 including Panobinostat",Results,"from the eighteen combinations that met this criterion for the MPNST-SP-01 cell line, seven included Panobinostat (histone deacetylase inhibitor) combined with compounds targeting many different targets",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,S462,cell_line,Efficacy,"11 combinations met DBSumNeg values lower than -7, with 4 including Doxorubicin",Results,"from the eleven combinations that met the criterion for S462, four included Doxorubicin with NVP-BGT226, Englerin A, Neratinib, and Torin 2",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,sNF96.2,cell_line,Efficacy,"16 combinations met DBSumNeg values lower than -7, with 4 combining Sirolimus",Results,"from sixteen combinations for sNF96.2, four combined Sirolimus (mTOR inhibitor) with AT-9283, Cabozantinib, Crizotinib, and CUDC-101",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,S462,cell_line,Biomarker,"Showed greater apoptotic response to treatments compared to MPNST-SP-01, proving higher sensitivity",Results,"the combined treatment and the single compounds caused a greater apoptotic response in the S462 cell line, proving that this cell line is more sensitive to the treatments",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,Human Foreskin Fibroblast (HFF),cell_line,Safety,"Synergism observed in Panobinostat combinations but at higher concentrations than MPNST cell lines, indicating tumor cell selectivity",Results,"Synergism was observed in all the combinations containing Panobinostat, but at higher concentrations than in the MPNST cell lines, indicating that tumor cells are more sensitive to the treatment",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,Human Foreskin Fibroblast (HFF),cell_line,Safety,"MK-1775 with Doxorubicin did not show synergism, indicating selectivity for tumor cells",Results,MK-1775 with Doxorubicin did not show synergism in the HFF cell line,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01 PDOX,patient_derived_model,Efficacy,MK-1775 with Doxorubicin reduced final tumor volume 7 times lower than vehicle after 18 days treatment,Results,The treatment caused the final tumor volume in mice to be seven times lower than the vehicle in the sporadic model after eighteen days of treatment,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-NF1-09 PDOX,patient_derived_model,Efficacy,MK-1775 with Doxorubicin reduced final tumor volume almost 4 times lower than vehicle,Results,almost four times lower in the NF1-PDOX model,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01 PDOX,patient_derived_model,Efficacy,Tumor weight was almost 2 times lower than control with MK-1775 and Doxorubicin treatment,Results,"In the sporadic model, tumor weight was almost two times lower than control",0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-NF1-09 PDOX,patient_derived_model,Efficacy,Tumor weight was 3 times lower than control with MK-1775 and Doxorubicin treatment,Results,three times lower in the case of the NF1-related PDOX-MPNST,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-NF1-09 PDOX,patient_derived_model,Safety,Treatment minimally reduced mice body weight by approximately 10%,Results,treatment minimally reduced mice's body weight: approximately 10% in the NF1-related PDOX,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01 PDOX,patient_derived_model,Safety,No detectable weight loss observed with MK-1775 and Doxorubicin treatment,Results,no detectable weight loss in the sporadic model,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,MPNST-SP-01 PDOX,patient_derived_model,Efficacy,Panobinostat combinations did not reduce tumor volume or weight after 25 days treatment,Results,the three combinations selected with Panobinostat neither reduced the tumor volume nor the final tumor weight in the sporadic PDOX model (MPNST-SP-01) after 25 days of treatment,0.95
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,phospho-Cdk1 Tyr15 antibody (9111T),antibody,Biomarker,Showed reduction of phosphorylation in some tumors treated with MK-1775 and Doxorubicin due to Wee1 kinase inactivation,Results,We observed a reduction of phosphorylation of Cdk1 (P-Cdk1) in some tumors treated with the combination MK-1775 with Doxorubicin due to the inactivation of Wee1 kinase activity,0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,Cleaved Caspase-3 antibody (9661S),antibody,Biomarker,"Showed higher levels in tumors treated with MK-1775 and Doxorubicin, suggesting apoptosis pathway activation",Results,"this combination caused higher levels of cleaved Caspase-3, which suggests activation of the apoptosis pathway due to DNA damage caused by Doxorubicin",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,Acetyl-Histone H3 Lys18 antibody (9675S),antibody,Biomarker,Some tumors treated with Panobinostat combinations showed higher acetylation levels than controls due to HDAC inhibition,Results,"Some tumors treated using Panobinostat with Torin 2 and Panobinostat with NVP-BGT226 presented higher levels of acetylation of Histone 3 than controls, due to Panobinostat working as a histone deacetylase (HDAC) inhibitor",0.85
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,phospho-p70 Thr389 S6 Kinase antibody (9234S),antibody,Biomarker,Phosphorylation was reduced in treated tumors due to mTOR kinase activity inhibition by Torin 2 and NVP-BGT226,Results,"phosphorylation of p70S6 kinase was reduced in treated tumors, as both Torin 2 and NVP-BGT226 inhibit mTOR kinase activity",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,athymic nude mice,animal_model,Safety,"Did not tolerate 10 mg/kg daily Panobinostat dosage, requiring dose reduction to 5 mg/kg",Discussion,"engrafted mice did not tolerate that dosage of Panobinostat. We then reduced the dose of Panobinostat to 5mg/kg for testing in the MPNST-SP-01 PDOX model, which was well tolerated",0.9
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,NCATS Mechanism Interrogation PlatE (MIPE) library,genetic_reagent,Efficacy,"Screening of 1,912 oncology-focused molecules identified several hundred active compounds across three MPNST cell lines",Results,We screened the MIPE library using a quantitative high-throughput screen (qHTS) approach against three different MPNST cell lines... several hundred compounds were judged to be active,0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Efficacy,Selumetinib was associated with decreases from baseline in neurofibroma volume in 12 of 18 mice (67%),Results,Selumetinib was associated with decreases from baseline in neurofibroma volume in 12 of 18 mice (67%) in the animal model of neurofibromatosis type 1– related neurofibroma,0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Efficacy,Vehicle-treated control animals showed neurofibroma volume increase from baseline in 14 of 15 animals,Results,"in contrast, neurofibroma volume increase from baseline was observed in 14 of the 15 vehicle-treated control animals",0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Mechanistic,Mouse tumor samples showed a transient decrease in phosphorylated extracellular signal-regulated kinase (ERK),Results,Mouse tumor samples showed a transient decrease in phosphorylated extracellular signal-regulated kinase (ERK),0.9
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Efficacy,MEK inhibitors showed the greatest activity among targeted agents tested in the neurofibroma animal model,Discussion,MEK inhibitors also showed the greatest activity among the targeted agents that have been tested in the neurofibroma animal model,0.85
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,DhhCre;Nf1fl/fl,animal_model,Mechanistic,Intermittent dosing was efficacious despite modest and transient target inhibition of MEK in tumor tissue,Discussion,"It is of interest that in the mouse model, intermittent dosing was efficacious, even though target inhibition of MEK in tumor tissue was modest and transient",0.85
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,volumetric magnetic resonance imaging analysis,clinical_assessment_tool,Efficacy,"Decrease from baseline in plexiform neurofibroma volume was observed in all patients (median change, −31%; range, −5.8 to −47)",Results,"A decrease from baseline in plexiform neurofibroma volume was observed in all patients (median change, −31%; range, −5.8 to −47)",0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,volumetric magnetic resonance imaging analysis,clinical_assessment_tool,Efficacy,17 of 24 patients (71%) met criteria for confirmed partial response using volumetric analysis,Results,A total of 17 of the 24 patients (71%) met the criteria for confirmed partial response,0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,volumetric magnetic resonance imaging analysis,clinical_assessment_tool,Efficacy,"Maximum response to selumetinib was reached after a median of 20 cycles (range, 5 to 42)",Results,"The maximum response to selumetinib was reached after a median of 20 cycles (range, 5 to 42)",0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,volumetric magnetic resonance imaging analysis,clinical_assessment_tool,Efficacy,"Partial responses were durable, sustained for a median of 23 cycles (range, 6 to 42)",Results,"Partial responses were durable, in that they were sustained for a median of 23 cycles (range, 6 to 42)",0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,volumetric magnetic resonance imaging analysis,clinical_assessment_tool,Efficacy,Slow regrowth of tumors observed after dose reductions or interruptions of selumetinib dosing,Results,"Slow regrowth of tumors has been observed in some cases, most notably after dose reductions or interruptions of selumetinib dosing as a result of toxic effects",0.9
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tool,Safety,"Dose-limiting toxic effects included grade 3 cellulitis, grade 3 urticaria, grade 3 creatine kinase elevation, and grade 3 asymptomatic decreased left ventricular ejection fraction",Results,"Dose-limiting toxic effects that were counted toward the determination of the maximum tolerated dose were grade 3 cellulitis (1 patient), grade 3 urticaria (1 patient), and grade 3 creatine kinase elevation (1 patient)",0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tool,Safety,Most selumetinib-related adverse events were mild (grade 1),Results,Most selumetinib-related adverse events were mild (grade 1),0.9
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",clinical_assessment_tool,Safety,Grade 1 asymptomatic cataract observed at cycle 16 in 1 patient,Results,"Serial ophthalmologic examinations revealed no abnormalities, with the exception of a grade 1 asymptomatic cataract at cycle 16 in 1 patient",0.95
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,Responsibility for Medication Questionnaire,clinical_assessment_tool,Other,"Mean percentage of patients with adherence to dosing schedule was 99% (range, 91 to 100) based on patient diaries during cycles 1-3",Results,"During cycles 1 through 3, the mean percentage of patients who were considered to have adhered to the dosing schedule was 99% (range, 91 to 100) on the basis of patient diaries",0.95
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,R,computational_tool,Other,"Used for statistical analysis of voxel size effects on segmentation accuracy, including correlation analysis showing R-squared values of 0.548 for manual and 0.469 for AI segmentation",Discussion,"Scatter plot showing the relationship between manual Dice similarity scores and original volume in cubic millimeters... The correlation coefficient is 0.74, and R-squared is 0.548",0.9
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,ggplot2,computational_tool,Other,Used for generating visualization plots including bar charts and scatter plots showing segmentation performance metrics across different voxel sizes,Results,"Bar graph titled ""Average Manual Percentage Change by Voxel Size"" depicting four bars with varying heights... Bar chart titled ""Average Dice Score by Voxel Size with AI Comparison""",0.8
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",ABI Prism 7700 Sequence Detection System,computational_tool,Biomarker,"Successfully quantified mRNA expression of 489 genes with mean TBP gene Ct values of 26.18 ± 0.39 for MPNST pool, 26.23 ± 1.45 for plexiform neurofibroma pool, and 26.30 ± 0.47 for dermal neurofibroma pool",Results,"The mean TBP gene Ct (threshold cycle) values for the four tumor samples were 26.18 ± 0.39 (MPNST pool), 26.23 ± 1.45 (plexiform neurofibroma pool) and 26.30 ± 0.47 (dermal neurofibroma pool).",0.95
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",SYBR Green PCR Core Reagents kit,genetic_reagent,Biomarker,Detected very low levels of target gene mRNA that were only detectable but not reliably quantifiable (Ct >32) for 50 genes (10.2%) of the 489 genes tested,Results,"Very low levels of target gene mRNA, that were only detectable but not reliably quantifiable by means of real-time quantitative RT-PCR assays, mainly based on fluorescence SYBR Green methodology (Ct >32), were observed for 50 (10.2%) of the 489 genes",0.92
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",TaqMan PCR Core REAGENTS Kit,genetic_reagent,Biomarker,"Successfully identified 40 genes (9.1%) expressed at different levels (>10-fold) in MPNST pool compared to both neurofibroma pools, with 27 genes upregulated and 13 genes downregulated",Results,Forty (9.1%) of the 439 remaining genes were expressed at a different level (> 10-fold) in the MPNST pool compared to both the dermal neurofibroma and plexiform neurofibroma pools; 27 (6.1%) genes were upregulated and 13 (3.0%) were down-regulated.,0.93
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",S100 antibody,antibody,Biomarker,S100B gene showed significant downregulation in MPNSTs (0.01 [0.00-0.17]) compared to plexiform neurofibromas (0.77 [0.14-3.03]) with P<0.01 and ROC-AUC of 0.992,Results,"S100B S100 calcium binding protein, beta Schwann cell-specific marker 0.77 [0.14–3.03] 0.01 [0.00–0.17] <0.01 0.992",0.94
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Rex Gauge durometer,clinical_assessment_tool,Other,Demonstrated substantial agreement between visits with Lin's concordance correlation coefficient of 0.771 (95% CI = 0.681–0.844),Results,"For the REX (Figure 4 b), the data points were evenly distributed along the diagonal line, with a Lin's CCC of 0.771 (95% CI = 0.681–0.844), also indicating substantial agreement of the values between the 2 visits.",0.95
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Rex Gauge durometer,clinical_assessment_tool,Other,Showed excellent within-visit agreement with ICC = 0.937 (95% CI = 0.913–0.953) when accounting for clustering,Results,"visit-within tumor-within patient-level ICC (briefly, within-visit correlation) that quantifies the correlation between measurements taken at the same visit in the same cNF nested in the same patient was 0.937 (95% CI = 0.913–0.953)",0.95
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Rex Gauge durometer,clinical_assessment_tool,Other,Demonstrated moderate within-tumor agreement with ICC = 0.740 (95% CI = 0.631–0.816),Results,"tumor-within patient-level ICC (briefly, within-tumor correlation) that quantifies the correlation between measurements in the same cNF in the same patient was 0.740 (95% CI = 0.631–0.816)",0.95
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Rex Gauge durometer,clinical_assessment_tool,Other,94.5% of measurement points fell within limits of agreement in Bland-Altman analysis,Results,"The Bland–Altman plot for the 3 REX measurements, with all pairwise comparisons, is shown in Figure 3 b, where the mean difference between the 2 measurements was also close to zero, and 94.5% of the points fell within the LOAs",0.95
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Delfin SkinFibroMeter,clinical_assessment_tool,Other,Demonstrated substantial agreement between visits with Lin's concordance correlation coefficient of 0.744 (95% CI = 0.644–0.811),Results,"For the DEFLIN (Figure 4 a), most points were close to the diagonal line, except for 3 larger values in visit 1. Lin's concordance correlation coefficient (CCC) was 0.744 (95% confidence interval [CI] = 0.644–0.811)",0.95
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Delfin SkinFibroMeter,clinical_assessment_tool,Other,Showed moderate within-visit agreement with ICC = 0.732 (95% CI = 0.665–0.786) when accounting for clustering,Results,"visit-within tumor-within patient-level ICC (briefly, within-visit correlation) that quantifies the correlation between measurements taken at the same visit in the same cNF nested in the same patient was 0.732 (95% CI = 0.665–0.786)",0.95
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Delfin SkinFibroMeter,clinical_assessment_tool,Other,Demonstrated moderate within-tumor agreement with ICC = 0.607 (95% CI = 0.512–0.691),Results,"tumor-within patient-level ICC (briefly, within-tumor correlation) that quantifies the correlation between measurements in the same cNF in the same patient was 0.607 (95% CI = 0.512–0.691)",0.95
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Delfin SkinFibroMeter,clinical_assessment_tool,Other,98.5% of measurement points fell within limits of agreement in Bland-Altman analysis,Results,"The mean difference between measurements was close to zero, and 98.5% of the points fell within the limits of agreement (LOAs). Outliers were more likely at larger values.",0.95
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Delfin SkinFibroMeter,clinical_assessment_tool,Other,Limited accuracy for smaller tumors <0.5 cm due to 1.25 mm diameter indenter requiring precise placement,Discussion,"A limitation of the device was shown for smaller tumors <0.5 cm. To accurately measure cNF stiffness, the DELFIN indenter, roughly 1.25 mm in diameter, would need to precisely land on the tumor",0.9
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,Rex Gauge durometer,clinical_assessment_tool,Other,"Potential limitation of user-dependent force application affecting readings, with no inherent user checking system",Discussion,"The REX was similarly easy to use, but a potential limitation depended considerably on the user-applied force between the device and tumor. The device did not inherently have a user checking system",0.85
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,U87-MG,cell_line,Biomarker,"Used as NF1-low control with similar or less NF1 signal than 8 GBM samples (H5M, LNA, YXL, VVN, R7K, TRM, UNY, W31)",Results,"Eight other samples had similar or less NF1 signal than the U87-MG NF1-low control (H5M, LNA, YXL, VVN, R7K, TRM, UNY, W31)",0.9
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,U87-MG,cell_line,Biomarker,"With proteasome inhibitors served as positive control with equal or greater NF1 than two samples (PBH, RIW)",Results,"Two samples (PBH, RIW) had equal or greater NF1 than the positive control, U87-MG + proteasome inhibitors (preventing NF1 degradation)",0.9
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,anti-NF1 D7R7D #14624,antibody,Biomarker,"Successfully detected variable NF1 protein concentrations across 12 GBM samples, with two samples showing no apparent NF1 protein (CB2, 3HQ)",Results,"We characterized NF1 protein concentrations as well as other molecules involved in RAS signaling in the 12 GBM samples...Two samples (CB2, 3HQ) had no apparent NF1 protein",0.9
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,anti-EGFR D38B1 #4267,antibody,Biomarker,"Detected variable EGFR content in GBM samples ranging from non-existent to low levels (3HQ, YXL, R7K) to medium to large EGFR signal in other samples",Results,"We also observed variable EGFR content in these samples, with non-existent to low levels (3HQ, YXL, R7K), or medium to large EGFR signal (CB2, H5M, PBH, LNA, YXL, VVN, RIW, TRM, UNY, W31)",0.9
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,p-ERK ½ (p44/42 MAPK) #9101,antibody,Biomarker,All GBM samples showed high concentrations of phospho-ERK1/2 signal relative to cell line controls,Results,All GBM samples had high concentrations of phospho-ERK1/2 signal relative to cell line controls,0.9
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,Sci-kit Learn,computational_tool,Efficacy,Machine learning classifier achieved mean test AUROC of 0.77 (95% Quantiles: 0.53-0.95) and mean train AUROC of 0.997 (95% Quantiles: 0.98-1.00) using 5-fold cross validation,Results,These models had mean test area under the receiver operating characteristic curve (AUROC) of 0.77 (95% Quantiles: 0.53 – 0.95) and a mean train AUROC of 0.997,0.95
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,Sci-kit Learn,computational_tool,Efficacy,"Classifier consistently separated NF1 wildtype and NF1 inactivated GBM samples with high effect sizes (Training: mean Cohen's D = 3.07, 95% CI = 2.24-4.16; Testing: mean Cohen's D = 1.27, 95% CI = 0.19-2.67)",Results,"The classifier consistently and robustly separated NF1 wildtype and NF1 inactivated GBM samples with high effect sizes (Training: mean Cohen's D = 3.07, 95% CI = 2.24 – 4.16; Testing: mean Cohen's D = 1.27)",0.95
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,GeneChip Human Transcriptome Array 2.0,computational_tool,Other,"Validation set was measured by microarray, requiring use of TDM transformed classifier data for ensemble classifier construction",Results,"Because the validation set was measured by microarray, we used the classifier trained on TDM transformed data to construct our ensemble classifier",0.85
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,Meso-33,cell_line,Efficacy,Complete proliferation arrest in response to re-expression of Merlin,Results,Meso-33 mesothelioma cells undergo a complete proliferation arrest in response to re-expression of Merlin,0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,Meso-33,cell_line,Mechanistic,Re-expression of Merlin induced robust phosphorylation of YAP at Ser 127,Results,"re-expression of Merlin induced robust phosphorylation of YAP at its major negative regulatory site, Ser 127",0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,Meso-33,cell_line,Mechanistic,Depletion of DCAF1 induced phosphorylation of YAP and suppressed expression of YAP target genes CTGF,Results,depletion of DCAF1 induced phosphorylation of YAP and suppressed expression of the YAP target genes CTGF,0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,FC-1801,cell_line,Efficacy,Undergo proliferation arrest and are no longer tumorigenic in response to re-expression of Merlin,Results,"In response to re-expression of Merlin, these cells undergo proliferation arrest and are no longer tumorigenic",0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,FC-1801,cell_line,Mechanistic,Silencing of DCAF1 provoked almost complete YAP/TAZ extrusion to the cytoplasm in most cells,Results,silencing of DCAF1 provoked almost complete YAP/TAZ extrusion to the cytoplasm in most cells,0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,293T,cell_line,Mechanistic,Flag-HA-DCAF1 associates efficiently with endogenous Lats1 and 2 but not with MST1 or 2,Results,Flag-HA-DCAF1 associates efficiently with endogenous Lats1 and 2 but not with MST1 or 2 in HEK 293T cells,0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,nude mice,animal_model,Efficacy,YAP-5SA enabled DCAF1-silenced FC-1801 cells to form tumors upon subcutaneous injection,Results,YAP-5SA enabled the DCAF1-silenced FC-1801 cells to grow in soft agar and to form tumors upon subcutaneous injection in nude mice,0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,nude mice,animal_model,Efficacy,Silencing of Lats1/2 rescued the ability of DCAF1-depleted Schwannoma cells to form tumors to a very large extent,Results,silencing of Lats1/2 rescued the ability of DCAF1-depleted Schwannoma cells to form tumors to a very large extent,0.95
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,NE-PER Nuclear and Cytoplasmic Extraction Reagents,genetic_reagent,Mechanistic,Enabled detection of endogenous LATS1 and 2 accumulation in nuclear fraction while MST1 and Sav1 partition preferentially in non-nuclear fraction,Results,"Subcellular fractionation experiments indicated that endogenous LATS1 and 2 accumulate in the nuclear fraction, whereas MST1 and Sav1 partition preferentially in the non-nuclear fraction",0.9
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,NIH-3T3,cell_line,Efficacy,ΔBB cells showed almost twice the invasiveness of control NIH-3T3 cells in Matrigel invasion assay,Results,the invasiveness of ΔBB cells was almost twice that of control NIH-3T3 cells,0.9
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,NIH-3T3,cell_line,Efficacy,PID expression reduced invasiveness by about 10% in control NIH-3T3 cells,Results,"In control NIH-3T3 cells, PID expression had a slight effect on morphology, and reduced invasiveness by about 10%",0.9
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,GST-PID,genetic_reagent,Efficacy,PID expression substantially restored normal morphology in ΔBB cells and significantly inhibited invasive capacity,Results,"Expression of the PID, but not the control PID LF, showed substantial restoration of normal morphology...significantly inhibited the invasive capacity of Merlin ΔBB cells",0.9
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,GST-PID,genetic_reagent,Efficacy,ΔBB/PID cells developed much smaller tumors with average volume of 38 mm³ compared to >200 mm³ for ΔBB cells at 6 weeks,Results,"ΔBB cells developed substantial tumors by 6 weeks post-injection (average volume >200 mm³)...Tumors derived from ΔBB/PID cells were much smaller in size, with an average volume of 38 mm³",0.95
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,GST-PID,genetic_reagent,Mechanistic,"Pak activity was inhibited in ΔBB/PID cells in vivo, indicating the suppressor remained effective",Results,"Pak activity was inhibited in ΔBB/PID cells, indicating that this suppressor remained effective in vivo",0.9
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,GST-PID,genetic_reagent,Mechanistic,"PID expression decreased Pak activity, Mek phosphorylation at S298, Mek activity, and ERK activity in NIH-3T3 xenografts",Results,"PID expression decreased Pak activity, as well as the Mek phosphorylation at S298, Mek activity, and ERK activity",0.9
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,Gst-PID L107F,genetic_reagent,Efficacy,ΔBB/PID LF cells developed even larger tumors (average volume ~450 mm³) than ΔBB cells alone,Results,mice injected with ΔBB/PID LF cells developed tumors even larger (average volume ∼450 mm³) than those injected with ΔBB cells,0.9
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,Gst-PID L107F,genetic_reagent,Other,"PID LF appears to have gain-of-function effects in various cell types, raising caution about its use as a negative control",Discussion,"One note of caution raised by our studies is that the putative negative control for the PID, PID LF, appears to have gain-of-function effects in a variety of cell types",0.8
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,BALB/c nu/nu,animal_model,Efficacy,Used for xenograft studies showing PID strongly inhibited tumor formation in NF2 model over 6 weeks,Results,"we injected nude mice only with ΔBB, ΔBB/PID, or ΔBB/PID LF cells...PID expression strongly inhibited tumor formation in the NF2 xenograft model",0.9
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,phospho-Pak1–3 (Ser141) antibody,antibody,Biomarker,Successfully detected inhibited Pak activity in ΔBB/PID cells in vivo,Results,"Pak activity was inhibited in ΔBB/PID cells, indicating that this suppressor remained effective in vivo",0.85
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,GST antibody,antibody,Biomarker,Successfully detected readily detectable GST-PID and GST-PID LF signals in infected cells,Results,The ΔBB cells infected with the PID or PID LF retrovirus displayed readily detectable signals in anti-GST immunoblots,0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,H1838,cell_line,Efficacy,NF1-null NSCLC cell line showed comparable sensitivity to RMC-4550 as other NF1-deficient cancer cell lines,Results,"These results were comparable to other NF1-deficient cancer cell lines (WM3918 and M308, NF1-null melanoma; H1838, NF1-null NSCLC, Figure 3E)",0.8
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,WM3918,cell_line,Efficacy,NF1-null melanoma cell line showed comparable sensitivity to RMC-4550 as other NF1-deficient cancer cell lines,Results,"These results were comparable to other NF1-deficient cancer cell lines (WM3918 and M308, NF1-null melanoma; H1838, NF1-null NSCLC, Figure 3E)",0.8
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,M308,cell_line,Efficacy,NF1-null melanoma cell line harboring BRAF V600E mutation showed resistance to SHP2 inhibition,Results,"Of note, the sporadic MPNST cell line STS26T and the melanoma cell line M308 harbor the BRAF V600E mutation, which confers resistance to SHP2 inhibition",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,STS26T,cell_line,Efficacy,Sporadic MPNST cell line harboring BRAF V600E mutation showed resistance to SHP2 inhibition,Results,"Of note, the sporadic MPNST cell line STS26T and the melanoma cell line M308 harbor the BRAF V600E mutation, which confers resistance to SHP2 inhibition",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,ST8814,cell_line,Efficacy,Demonstrated >50% inhibition of proliferation at 10 μM SHP099 and intermediate sensitivity to RMC-4550 with GI50 within 3 μM,Results,"only two cell lines (ST8814 and JH-2–009) demonstrated > 50% inhibition of proliferation at the maximum dose of SHP099 tested of 10 μM...Three cell lines (ST8814, NF11.1 and JH-2–009) demonstrated intermediate sensitivity to RMC-4550",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,ST8814,cell_line,Biomarker,"Showed increases in phospho-AKT, phospho-S6-kinase and phospho-ribosomal protein S6 in response to MEK inhibition",Results,"In ST8814, we observed increases in phospho-AKT (pAKT), phospho-S6-kinase (pS6K) and phospho-ribosomal protein S6 (pS6) in response to MEK inhibition",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,NF11.1,cell_line,Efficacy,Demonstrated intermediate sensitivity to RMC-4550 with GI50 within 3 μM,Results,"Three cell lines (ST8814, NF11.1 and JH-2–009) demonstrated intermediate sensitivity to RMC-4550, with the concentration for 50% of maximal inhibition of cell proliferation (GI50) within 3 μM",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,JH-2–009,cell_line,Efficacy,Demonstrated >50% inhibition of proliferation at 10 μM SHP099 and intermediate sensitivity to RMC-4550 with GI50 within 3 μM,Results,"only two cell lines (ST8814 and JH-2–009) demonstrated > 50% inhibition of proliferation at the maximum dose of SHP099 tested of 10 μM...Three cell lines (ST8814, NF11.1 and JH-2–009) demonstrated intermediate sensitivity to RMC-4550",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,JH-2–031,cell_line,Efficacy,"Did not demonstrate additive effect of combined MEK and SHP2 inhibition, harbors oncogenic PIK3CA Q546K mutation",Results,"Indeed, the one cell line (JH-2–031) that did not demonstrate an additive effect of combined MEK and SHP2 inhibition harbors an oncogenic mutation (PIK3CA Q546K)",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,DUSP6 antibody (ab76310),antibody,Biomarker,Used to measure downregulation of ERK-dependent transcriptional output marker in xenograft models treated with combination therapy,Results,"The combination was associated with a more profound reduction in Ki-67 staining, pMEK and pERK inhibition, and downregulation of the ERK-dependent transcriptional output marker DUSP6",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,Ki-67 antibody (Ab16667),antibody,Biomarker,Showed more profound reduction in staining with combination therapy compared to single agents in xenograft models,Results,"The combination was associated with a more profound reduction in Ki-67 staining, pMEK and pERK inhibition, and downregulation of the ERK-dependent transcriptional output marker DUSP6",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,PamChip peptide arrays,computational_tool,Mechanistic,Identified 41 PTK peptides and 28 STK peptides with significantly altered phosphorylation in response to MEKi across five MPNST cell lines,Results,"Using a differential analysis of all five MPNST lines in aggregate, we identified a total of 41 PTK peptides and 28 STK peptides that showed significantly altered phosphorylation in response to MEKi",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,athymic nude mice (#002019),animal_model,Efficacy,Used for subcutaneous xenograft studies showing greater growth inhibition with combination therapy sustained for up to 28 days,Results,"Again, greater growth inhibition was observed, and this effect was sustained for up to 28 days of treatment in the two MPNST xenograft models tested",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,athymic nude mice (#002019),animal_model,Safety,No adverse effects of drug treatment on body weight were observed,Results,No adverse effects of drug treatment on body weight were observed,0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,SMARTPool ON-TARGETplus Human PTPN11 siRNA (#L-003947–00-0005),genetic_reagent,Mechanistic,PTPN11 knockdown prevented feedback-induced SHP2 phosphorylation by trametinib and attenuated reactivation of ERK signaling,Results,"our data demonstrated that PTPN11 knockdown prevented feedback-induced SHP2 phosphorylation by trametinib, attenuated reactivation of ERK signaling, and synergistically inhibited cyclin D1 expression",0.9
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,SMARTPool ON-TARGETplus Human PTPN11 siRNA (#L-003947–00-0005),genetic_reagent,Efficacy,Sensitized NF1-MPNST cells to MEKi treatment,Results,Further evidence showed that siPTPN11 also sensitized the NF1-MPNST cells to MEKi,0.9
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,Vectra H1,clinical_assessment_tool,Other,Software was only able to render 3D models of 49 out of 58 cNFs (84.5%) due to technical failure,Results,"Vectra H1 software was only able to render 3D models of 49 cNFs for measurement analysis, due to a technical failure.",0.95
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,Vectra H1,clinical_assessment_tool,Other,"Demonstrated excellent reliability with intra-rater and inter-rater ICC of 0.99 for all measurements (length, width, surface area, volume)",Results,All three imaging systems demonstrated 'excellent' reliability (ICC ≥0.9)... Vectra H1 Length 0.99 0.99 Width 0.99 0.99 Surface Area 0.99 0.99 Volume 0.99 0.99,0.95
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,Vectra H1,clinical_assessment_tool,Other,Required longest analysis time (5.0-9.5 min) with total acquisition and analysis time of ~7.5 min,Results,Vectra H1 software required the longest time for analysis (5.0–9.5 min)... LifeViz Micro had the shortest total image acquisition and analysis time (∼4.5 min) compared to Vectra H1 (∼7.5 min),0.9
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,Vectra H1,clinical_assessment_tool,Other,"Least expensive system at ~$17,000",Results,"Cherry Imaging was the most expensive system (∼$34 000), followed by LifeViz Micro (∼$28 000) and Vectra H1 (∼$17 000).",0.9
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,LifeViz Micro,clinical_assessment_tool,Other,Demonstrated excellent reliability with intra-rater ICC of 0.97-0.99 and inter-rater ICC of 0.99 for all measurements,Results,All three imaging systems demonstrated 'excellent' reliability (ICC ≥0.9)... LifeViz Micro Length 0.99 0.99 Width 0.99 0.99 Height 0.97 0.99 Surface Area 0.99 0.99 Volume 0.97 0.99,0.95
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,LifeViz Micro,clinical_assessment_tool,Other,Measured significantly higher cNF heights than Cherry Imaging with median height 1.43 mm vs 1.33 mm (p < 0.001),Results,"cNF height measurements were significantly higher by LifeViz Micro than Cherry Imaging (Z = −5.579, p < 0.001)... median (IQR) height was 1.43 (0.77–2.37) mm measured by LifeViz Micro and 1.33 (0.77–1.66) mm measured by Cherry Imaging",0.95
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,LifeViz Micro,clinical_assessment_tool,Other,Had shortest total image acquisition and analysis time (~4.5 min) and demonstrated least measurement variability for surface area,Results,"LifeViz Micro had the shortest total image acquisition and analysis time (∼4.5 min)... For surface area, the LifeViz Micro demonstrated the least measurement variability compared to the other two imaging systems",0.9
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,LifeViz Micro,clinical_assessment_tool,Other,"Mid-range cost at ~$28,000",Results,"Cherry Imaging was the most expensive system (∼$34 000), followed by LifeViz Micro (∼$28 000) and Vectra H1 (∼$17 000).",0.9
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,Cherry Imaging,clinical_assessment_tool,Other,Demonstrated excellent reliability with intra-rater and inter-rater ICC of 0.99 for all measurements,Results,All three imaging systems demonstrated 'excellent' reliability (ICC ≥0.9)... Cherry Imaging Length 0.99 0.99 Width 0.99 0.99 Height 0.99 0.99 Surface Area 0.99 0.99 Volume 0.99 0.99,0.95
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,Cherry Imaging,clinical_assessment_tool,Other,Required longest time for image acquisition (0.5-2 min) and 3D model generation (1.0-6.5 min) with total time ~6.5 min,Results,Cherry Imaging required the longest time for image acquisition (0.5–2 min) and 3D model generation (1.0–6.5 min)... compared to Vectra H1 (∼7.5 min) and Cherry Imaging (∼6.5 min),0.9
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,Cherry Imaging,clinical_assessment_tool,Other,"Most expensive system at ~$34,000",Results,"Cherry Imaging was the most expensive system (∼$34 000), followed by LifeViz Micro (∼$28 000) and Vectra H1 (∼$17 000).",0.9
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,PERADIGM,computational_tool,Efficacy,"Identified 3 significant genes (PKD1, PKD2, IFT140) for ADPKD after p-value adjustment, compared to SKAT-O which identified only PKD1 and PKD2",Results,"genome-wide scanning with PERADIGM identified three significant genes associated with ADPKD-related phenotypes after p-value adjustment. In comparison, SKAT-O identified only PKD1 and PKD2",0.95
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,PERADIGM,computational_tool,Efficacy,"Identified 2 significant genes (FBN1, COL5A1) for Marfan syndrome after p-value adjustment, while SKAT-O identified only FBN1",Results,"the whole-genome scan identified 2 significant genes after p-value adjustment, whereas SKAT-O identified only FBN1",0.95
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,PERADIGM,computational_tool,Efficacy,"With preselected phenotypes, identified 6 genes for Marfan syndrome including TGFBR2, compared to 2 genes without phenotype preselection",Results,"six genes were significantly associated with Marfan syndrome-specific phenotypes. These include the two previously identified genes, indicating that refining phenotype representation can help uncover additional relevant genes",0.9
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,PERADIGM,computational_tool,Efficacy,"For NF1, identified only NF1 gene as statistically significant after p-value adjustment, consistent with SKAT-O results",Results,"after p-value adjustment, PERADIGM identified only NF1 as a statistically significant gene associated with NF1-specific phenotypes, consistent with SKAT-O results",0.9
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,PERADIGM,computational_tool,Efficacy,"Showed 6, 7, and 27 overlapping genes with SKAT-O among top 100, 200, and 500 genes respectively, suggesting different prioritization approaches",Results,"we examined overlapping genes among the top 100, 200, and 500 genes ranked by raw p-values. The results showed 6, 7, and 27 overlapping genes, respectively",0.9
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,UK Biobank 200K dataset,patient_derived_model,Other,"Contained 142 ADPKD patients coded as Q61.2 or Q61.3, 39 Marfan syndrome patients (Q87.4), and 62 NF1 patients (Q85.0)",Results,only 142 patients were coded as either Q61.2 or Q61.3... 39 individuals were diagnosed with Marfan syndrome (ICD-10 code: Q87.4)... 62 individuals diagnosed with NF1 (ICD-10 code: Q85.0),0.95
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,Word2Vec,computational_tool,Mechanistic,Used continuous bag-of-words (CBOW) model to create embedding representations for each phenotype from individual-level ICD-10 codes,Results,we utilize individual-level ICD-10 codes from EHR data to create embedding representations for each phenotype using a continuous bag-of-words (CBOW) Word2Vec model,0.9
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,CBOW,computational_tool,Mechanistic,Implemented as part of Word2Vec model to generate phenotype embeddings from ICD-10 codes in the first stage of PERADIGM framework,Results,we utilize individual-level ICD-10 codes from EHR data to create embedding representations for each phenotype using a continuous bag-of-words (CBOW) Word2Vec model,0.9
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",I2HCP panel,computational_tool,Efficacy,Analytical sensitivity of 98.4% (96.4-99.4%) and analytical specificity of 100% (99-100%) for detecting known variants in training and validation sets,Results,"Therefore, considering the 358 known variants in the training and validation sets, the analytical sensitivity of the panel was 98.4% (96.4–99.4%) and the analytical specificity was of 100% (99–100%).",0.95
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",I2HCP panel,computational_tool,Efficacy,Within-run precision (repeatability) of 98% (97-98.7%) and between-run precision (reproducibility) of 95.7% (94.6-96.6%),Results,"within-run precision (repeatability) was 98% (97–98.7%) and between-run precision (reproducibility) was 95.7% (94.6–96.6%), both within the optimal range for diagnostic purposes",0.95
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",I2HCP panel,computational_tool,Efficacy,98.9% ± 0.7% SD of targeted bases covered ≥ 30× with mean depth of coverage 495 ± 170 SD,Results,More than 98.9% ± 0.7% SD of the targeted bases was covered ≥ 30× (Supplementary Fig S2). Detailed sequencing statistics are given in Supplementary Table S3.,0.95
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",I2HCP panel,computational_tool,Efficacy,"Correctly identified all 36 pathogenic variants in validation set including substitutions, small insertions/deletions (up to 19 bp), and deletions of single exon and whole gene",Results,"This new approach correctly identified all 36 pathogenic variants in the validation set, including substitutions, small insertions/deletions (up to 19 bp), and deletions of a single exon and a whole gene.",0.95
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",SureSelect bait library V1,computational_tool,Efficacy,"Sensitivity of 90.4% (84.2-94.8%) detecting 123 out of 136 pathogenic and non-pathogenic variants, failed to identify 7 out of 23 pathogenic variants mostly in homopolymers",Results,"123 out of 136 pathogenic and non-pathogenic variants previously identified in the training set were correctly detected, providing a sensitivity of 90.4% (84.2–94.8%). However, this first approach failed to identify 7 out of 23 pathogenic variants",0.95
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",SureSelect bait library V1,computational_tool,Efficacy,Mean depth of coverage 490.7 ± 221.5 SD with more than 86% ± 4% SD of targeted ROI bases covered ≥ 30x,Results,"the mean depth of coverage was 490.7 ± 221.5 SD, and more than 86% ± 4% SD of the targeted ROI bases was covered ≥ 30x.",0.95
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",SureSelect bait library V2,computational_tool,Efficacy,"Sensitivity of 100% (97.3-100%) for all pathogenic and non-pathogenic variants, correctly identified 22 of 23 pathogenic variants and all 113 non-pathogenic SNVs and indels",Results,"Taking into account all pathogenic and non-pathogenic variants previously identified in the training set, NGS data provided a sensitivity of 100% (97.3–100%).",0.95
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",SureSelect bait library V2,computational_tool,Efficacy,Specificity of 100% (98.3-100%) with no false positives identified in training set,Results,"Overall, no false positive was identified, resulting in a specificity of 100% (98.3–100%) for the training set.",0.95
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",CLC Genomics Workbench v6,computational_tool,Efficacy,Used for initial data analysis approach but was replaced by custom NGS pipeline for improved variant calling quality,Results,"Data were analyzed using both CLC Genomics Workbench (Qiagen) and our custom NGS pipeline... we analyzed all data using only our custom NGS pipeline, to ensure greater control over variant calling algorithms",0.85
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,D22S193,genetic_reagent,Biomarker,"Used as microsatellite marker to detect NF2 LOH, which was found in 52.1% of meningioma cohort",Results,"LOH of the NF2 locus was seen with an incidence of 52.1% in the cohort, similar to previously reported values.",0.8
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,D22S929,genetic_reagent,Biomarker,"Used as microsatellite marker to detect NF2 LOH, contributing to the 52.1% incidence finding",Results,"LOH of the NF2 locus was seen with an incidence of 52.1% in the cohort, similar to previously reported values.",0.8
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,D22S268,genetic_reagent,Biomarker,"Used as microsatellite marker to detect NF2 LOH, contributing to the 52.1% incidence finding",Results,"LOH of the NF2 locus was seen with an incidence of 52.1% in the cohort, similar to previously reported values.",0.8
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,D22S430,genetic_reagent,Biomarker,"Used as microsatellite marker to detect NF2 LOH, contributing to the 52.1% incidence finding",Results,"LOH of the NF2 locus was seen with an incidence of 52.1% in the cohort, similar to previously reported values.",0.8
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,BstUI,genetic_reagent,Biomarker,"Used for restriction enzyme digestion to analyze p53 codon 72 polymorphism, enabling detection of Arg72/Arg72 (45.6%), Arg72/Pro72 (44.6%), and Pro72/Pro72 (9.8%) genotype frequencies",Results,"Distribution of the p53 codon 72 polymorphism among meningioma cases was found to be consistent with Hardy–Weinberg equilibrium, with allelic frequencies of 45.6% (Arg72/Arg72), 44.6% (Arg72/Pro72), and 9.8% (Pro72/Pro72)",0.9
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,"Taq polymerase (Qiagen, Valencia, CA)",genetic_reagent,Biomarker,"Used for PCR amplification to analyze microsatellite markers and p53 polymorphism, enabling detection of NF2 LOH in 52.1% of cases and p53 genotype distribution",Results,LOH of the NF2 locus was seen with an incidence of 52.1% in the cohort... Distribution of the p53 codon 72 polymorphism among meningioma cases was found to be consistent with Hardy–Weinberg equilibrium,0.8
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,Research Patient Database Registry,clinical_assessment_tool,Other,Enabled collection of cohort data showing 2.4:1 female to male ratio and 29.3% high grade tumor incidence in 92 meningioma patients,Results,"Similar to previous findings, a 2.4:1 female to male ratio was found. Meanwhile, a higher typical incidence of high grade tumors is present (29.3%; 27/92)",0.9
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;Nes-TK,animal_model,Efficacy,"GCV treatment significantly inhibited tumor development compared to saline-treated controls, with significant reduction of GFP+ tumor population",Results,"GCV treatment significantly inhibited tumor development compared to saline-treated controls, and the GFP+ tumor population was significantly reduced",0.85
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;Nes-TK,animal_model,Safety,Nes-TK;cisNP cohort exhibited significantly extended survival compared to control cisNP cohort (p=0.0061),Results,the Nes-TK;cisNP cohort exhibited significantly extended survival compared to the control cisNP cohort (p=0.0061,0.95
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;Nes-TK,animal_model,Biomarker,"GFP+ tumor cells incorporated BrdU at significantly slower rate, reaching near saturating levels only on day 20 of pulse period",Results,GFP+ tumor cells incorporated BrdU at a significantly slower rate and only reached near saturating levels of GFP and BrdU coexpression on day 20 of the pulse period,0.9
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;CGD,animal_model,Efficacy,DT treatment impeded tumor initiation resulting in significant survival benefit compared to saline cohort (p=0.034),Results,DT treatment impeded tumor initiation resulting in a significant survival benefit compared to the saline cohort (p=0.034,0.95
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;CGD,animal_model,Efficacy,Four DT doses (50 µg/kg) given on alternate days essentially eliminated CGD-expressing GFP+ cells,Results,Four DT doses (50 µg/kg) given on alternate days essentially eliminated CGD-expressing GFP+ cells without significantly altering the proportion of KI67+ cells,0.9
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Nf1f/f;Trp53f/f;CGD,animal_model,Efficacy,Doxo+DT group exhibited the greatest tumor volume inhibition compared to other treatment groups,Results,"All drug-treated mice exhibited varying degrees of tumor inhibition as compared to the saline group. However, the Doxo+DT group exhibited the greatest tumor volume inhibition",0.85
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,cisNP,animal_model,Biomarker,Spontaneous Nes-TK;cisNP MPNST contained approximately 3% GFP+ cells with low cycling frequency,Results,"Spontaneous Nes-TK;cisNP MPNST were found to contain approximately 3% GFP+ cells and as for the Nes-TK;SKP model, KI67+ or BrdU incorporating tumor cells were seldom GFP positive",0.9
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,S3e sorter,computational_tool,Efficacy,Enabled efficient isolation of GFP+ MPNST cells with stringent gating to effectively segregate GFP+ and GFP- tumor populations,Results,Stringent gating for GFP was applied to effectively segregate GFP+ and GFP- tumor populations and to reduce cross-contamination,0.8
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,DeSeq2,computational_tool,Biomarker,Identified 127 upregulated DEGs in GFP+ cells versus 34 genes in GFP- cells (fold change >1.5 & adjusted p <0.05),Results,"We observed a greater number of upregulated DEGs in GFP+ cells compared to GFP- cells (127 genes versus 34 genes, fold change >1.5 & adjusted p <0.05",0.95
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,Seurat V3.0,computational_tool,Biomarker,Successfully resolved single cell data into multiple aggregated cell clusters including three specific neural crest/Schwann cell lineage clusters (CL1-CL3),Results,the data resolved into multiple aggregated cell clusters of tumor and non-tumor cells that by gene expression included diverse immune and inflammatory cell types as well as tumor associated fibroblasts,0.85
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Safety,Germline Nf1-/- embryos die from cardiac defect by embryonic day E14.5,Results,Germline Nf1−/− embryos die from a cardiac defect by embryonic day (E)14.5,0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Biomarker,"3-6 fold higher frequency of cells forming multipotent neurospheres in sympathetic chain, DRG, and sciatic nerve compared to controls (p<0.05)",Results,"The sympathetic chain, DRG, and sciatic nerve from Nf1−/− embryos contained a significantly higher percentage of cells (3−6 fold higher; p<0.05) that formed multipotent neurospheres",0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Mechanistic,"Increased phosphorylated Erk (pErk) in Nf1-/- colonies, consistent with increased Ras signaling",Results,"Western blot demonstrated increased phosphorylated Erk (pErk) in the Nf1−/− colonies, consistent with increased Ras signaling in these cells",0.9
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Biomarker,"Significantly larger multipotent neurospheres formed by NCSCs from DRG, sciatic nerve, and sympathetic chain",Results,"Multipotent neurospheres formed by NCSCs from DRG, sciatic nerve, and sympathetic chain were significantly larger in the absence of Nf1",0.9
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1-/- mice,animal_model,Biomarker,"4 to 10 times as many multipotent daughter neurospheres compared to control neurospheres from DRG, nerve, or sympathetic chain",Results,"When cultured from the DRG, nerve, or sympathetic chain, Nf1−/− neurospheres gave rise to 4 to 10 times as many multipotent daughter neurospheres as compared to control neurospheres",0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Wnt-1-Cre+ mice,genetic_reagent,Safety,Wnt1-Cre+ Nf1fl/- mice die at birth,Results,Wnt1-Cre+ Nf1fl/− mice die at birth,0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,3.9Periostin-Cre+ mice,genetic_reagent,Safety,"Most 3.9Periostin-Cre+ Nf1fl/- mice died by 4 weeks after birth. Of 32 expected mice, only 6 survived more than four weeks",Results,"Most 3.9Periostin-Cre+ Nf1fl/− mice died by 4 weeks after birth. Of 32 expected 3.9Periostin-Cre+ Nf1fl/− mice, only 6 survived more than four weeks after birth",0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,P0a-Cre+ mice,genetic_reagent,Efficacy,All 6 P0a-Cre+ Nf1fl/- mice but none of the littermate controls exhibited neurofibromas between 15-20 months of age,Results,All 6 of the P0a-Cre+ Nf1fl/− mice but none of the littermate controls exhibited neurofibromas,0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Nf1/p53-/- cis mutant mice,animal_model,Efficacy,Formed MPNSTs by 6 months of age,Results,Nf1+/−/p53+/− mice formed MPNSTs by 6 months of age,0.9
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Ink4aArf-/- mice,animal_model,Safety,"Virtually all Nf1+/- Ink4a/Arf-/- mice died by 10 months of age, more quickly than littermates with other genotypes",Results,"Virtually all Nf1+/− Ink4a/Arf−/− mice died by 10 months of age, more quickly than littermates with other genotypes",0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,Ink4aArf-/- mice,animal_model,Efficacy,"26% of Nf1+/- Ink4a/Arf-/- mice had to be euthanized due to formation of MPNSTs, with most tumors becoming evident at 4-6 months of age",Results,26% of Nf1+/− Ink4a/Arf−/− mice had to be euthanized due to the formation of MPNSTs. Most of the MPNSTs developed by Nf1+/− Ink4a/Arf−/− mice became grossly evident at 4 to 6 months of age,0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,p75 antibody (Ab 1554; Chemicon),antibody,Biomarker,Significant increase (4.0-6.4 fold; p<0.01) in frequency of p75+ cells within plexiform neurofibromas compared to normal nerves,Results,We observed a significant increase (4.0−6.4 fold; p<0.01) in the frequency of p75+ cells within the plexiform neurofibromas in sciatic nerves and DRGs as compared to normal nerves,0.95
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,FACSVantage SE-dual laser flow-cytometer,computational_tool,Biomarker,"Successfully detected significantly higher frequencies of p75+ α4+ cells in freshly dissociated Nf1-/- DRG, sciatic nerve, and sympathetic chain (p<0.05)",Results,"Freshly dissociated Nf1−/− DRG, sciatic nerve, and sympathetic chain all had significantly (p<0.05) higher frequencies of p75+ α4+ cells",0.9
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.","Mx1-Cre, Nf1 flox/flox mice (129SV × C57BL/6 J)",animal_model,Biomarker,Higher recovery of Lin- BM cells from Nf1−/− mice (0.7%) compared to WT littermates (0.3%),Results,There was a higher recovery of Lin- BM cells from the Nf1−/− mice (0.7%) than the WT littermates (0.3%). The greater recovery of Lin- BM cells in the Nf1−/− mice is likely indicative of chronic polyclonal hyperproliferation,0.95
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.","Mx1-Cre, Nf1 flox/flox mice (129SV × C57BL/6 J)",animal_model,Biomarker,Significantly greater induction of micronuclei in Nf1−/− cultures than WT cultures at 50 μM (p < 0.01) and 100 μM (p < 0.05) HQ treatment,Results,there was a significantly greater induction of MN in the Nf1−/− cultures than the WT cultures at both 50 μM (p < 0.01) and 100 μM (p < 0.05),0.95
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.","Mx1-Cre, Nf1 flox/flox mice (129SV × C57BL/6 J)",animal_model,Efficacy,Nf1−/− progenitors demonstrated significantly increased survival to HQ exposure compared to WT at 10 μM (p-value 0.0010),Results,Nf1−/− progenitors demonstrated significantly increased survival to HQ exposure in comparison to WT (Figure 3) at 10 μM [p-value 0.0010],0.95
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",BY4743 background diploid yeast deletion strains,cell_line,Efficacy,"ira2Δ strain showed sensitivity to HQ treatment, ras1Δ showed increased tolerance to HQ, ras2Δ showed no effect compared to wild type",Results,"IRA2 was previously identified in a genome-wide screen for genes required for HQ tolerance and sensitivity to HQ was confirmed by analysis of the individual deletion strain. Deletion of RAS1 results in increased tolerance to HQ treatment, whereas deletion of RAS2 has no effect",0.9
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",Y258 background haploid yeast MORF strain,cell_line,Efficacy,RAS1 overexpression strain exhibited increased sensitivity to HQ,Results,"we examined a RAS1 overexpression strain, and this strain also exhibits increased sensitivity to HQ",0.9
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",biotin-conjugated α-Lin Abs,antibody,Other,Successfully used to isolate lineage-marker-negative (Lin-) BM cells for in vitro erythropoietic MN experiments,Results,"Lineage-marker-negative (Lin-) BM was used as a starting population for in vitro erythropoietic MN experiments, and terminal erythropoiesis progressed normally",0.85
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",MethoCult® M3434,genetic_reagent,Other,Successfully supported CFU-GM colony growth for 12 days in both WT and Nf1−/− bone marrow cultures with HQ treatment,Results,Bone marrow cells from each genotype were treated with HQ in MethoCult® capable of inducing growth of CFU-GM colonies and then cultured for 12 days,0.85
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",Axioplan 2 microscope,computational_tool,Other,Used at 100x magnification to visualize and identify micronucleated PCEs in erythropoietic cultures,Results,"Representative micrograph of Day 2 harvested cultures at 100x magnification. The arrows indicate normally enucleated PCEs, and the arrowhead indicates a micronucleated PCE",0.8
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,AMBER16,computational_tool,Mechanistic,"Used for molecular dynamics simulations to generate training sets with 9 inhibitor-free and 9 inhibitor-bound complexes, enabling machine learning classification of TRAP1 allosteric states",Results,ML models were built to ensure learning of inhibitor-bound patterns from the allosteric ligands expected to have the biggest detectable impact on TRAP1 local unperturbed dynamics.,0.85
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,VMD (version 1.9.3),computational_tool,Mechanistic,"Used for analysis of MD trajectories to extract local features including residue-level solvation, contacts, and distances from flexible regions of TRAP1 monomers",Results,"We focused on residue-level solvation, contacts, and distances obtained from four inherently flexible regions of the buckled and straight monomers",0.8
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,MATLAB version 2019b,computational_tool,Efficacy,"Machine learning models achieved 66.7-94.9% average accuracy in cross-validation, with GDF-SVM showing highest performance (94.9% accuracy, 0.95 TPR, 0.95 TNR)",Results,"The average accuracy in each validation fold varies between 66.7 and 94.9%, with the discriminative models outperforming the generative ones",0.95
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,Classification Learner app,computational_tool,Efficacy,External validation showed 68-69% specificity for SVM models and up to 77% specificity for GNB models in recognizing unperturbed TRAP1 states,Results,"68–69% of inhibitor-free trajectories can be genuinely recovered as TN. For NB models, the loss in specificity is lower, in the range of 2–23%",0.9
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,MATLAB version 2019b,computational_tool,Efficacy,"Linear regression models achieved r² values up to 0.71 for correlating ML predictions with experimental TRAP1 inhibition data, outperforming docking-based approaches",Results,showing a significant r² value of 0.71 for the KNB model... ML-based classification of inhibitors from MD simulations outperform docking-based models,0.92
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,gromacs (version 4.6),computational_tool,Mechanistic,"Used for molecular dynamics simulations that revealed ligand-induced perturbations in TRAP1 local dynamics, particularly affecting ATP lid SASA and cross-monomer contacts",Results,Such an effect was sought in changes in the ATP lid SASA and cross-monomer contacts involving the strap motifs and their partner NTDs,0.8
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,PredictSNP2,computational_tool,Mechanistic,"Analyzed 204 mutations and categorized them into deleterious or neutral categories, with 123 mutations designated as deleterious",Results,"Using PredictSNP, the 204 mutations were analyzed and categorized primarily into deleterious or neutral categories. Among the other computational tools, PredictSNP...designated 123...as deleterious",0.95
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,iStable,computational_tool,Mechanistic,"Predicted a decrease in protein stability for a significant number of mutations using iMutant, MUpro, and its own assessments",Results,"The iStable server, utilizing iMutant, MUpro, and its own assessments, predicted a decrease in protein stability for a significant number of mutations",0.85
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,Align GVGD,computational_tool,Mechanistic,Assigned GV scores and classified all mutations into classes indicating high likelihood of deleterious impact through multiple sequence alignment,Results,"The biophysical impact of mutations was assessed through multiple sequence alignment using the align GVGD tools, which assigned a GV score and classified all mutations into a class, indicating a high likelihood of deleterious impact",0.9
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,AlphaFold3,computational_tool,Mechanistic,"Generated structural predictions showing RMSD of 1.737 for C379R mutant, 3.626 for R1000C mutant, and 1.832 for C1016Y mutant compared to wild-type NF1",Results,Structural alignment of the protein models was performed using PyMOL...yielding a root mean square deviation (RMSD) of 1.737...RMSD of 3.626...RMSD of 1.832,0.95
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,SNPeffect 4.0,computational_tool,Mechanistic,"Identified that R1000C mutation increases protein aggregation tendency, while C379R and C1016Y mutations do not affect aggregation, amyloid formation, or chaperone binding",Results,"The findings from the SNPeffect database indicated that the R1000C mutation increases the aggregation tendency of the protein. In contrast, the other two mutations, C379R and C1016Y, do not influence the protein's tendency to aggregate",0.92
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,iMutant 2.0,computational_tool,Mechanistic,Used within iStable server to predict decrease in protein stability for mutations,Results,"The iStable server, utilizing iMutant, MUpro, and its own assessments, predicted a decrease in protein stability for a significant number of mutations",0.8
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,MUpro,computational_tool,Mechanistic,Used within iStable server to predict decrease in protein stability for mutations,Results,"The iStable server, utilizing iMutant, MUpro, and its own assessments, predicted a decrease in protein stability for a significant number of mutations",0.8
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,Nf1 GFAP CKO mice (Nf1 flox/flox; GFAP-Cre),animal_model,Biomarker,Brain rapamycin levels were exponentially correlated with blood rapamycin levels (R² = 0.8 and P<0.0001),Results,brain rapamycin levels were exponentially correlated with blood rapamycin levels ( Fig. 1C ) (R 2 = 0.8 and P<0.0001),0.95
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,Nf1 GFAP CKO mice (Nf1 flox/flox; GFAP-Cre),animal_model,Mechanistic,"4-fold increase in AKT activation at 5mg/kg/day rapamycin, but not at 2 or 20mg/kg/day",Results,"we found a 4-fold increase in AKT activation at 5mg/kg/day, but not at 2 or 20mg/kg/day",0.95
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,K4622 grade II glioma cell line,cell_line,Mechanistic,5-fold increase in AKT activation with 0.75nM rapamycin compared to vehicle control,Results,we found that 0.75nM rapamycin resulted in a 5-fold increase in AKT activation compared to vehicle control,0.95
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,K4622 grade II glioma cell line,cell_line,Efficacy,Maximum inhibitory effect on cell growth with 10nM rapamycin treatment,Results,we observed a maximum inhibitory effect on cell growth and histone-H3 phosphorylation following 10nM rapamycin treatment,0.9
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,K4622 grade II glioma cell line,cell_line,Efficacy,Combined 0.750nM rapamycin and 30 μM LY294002 treatment resulted in 81% reduction in cell proliferation,Results,combined 0.750nM rapamycin and 30 μM LY294002 treatment resulted in an 81% reduction in cell proliferation,0.95
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,Ki67 antibody (BD PharMingen),antibody,Biomarker,Significant decrease in Ki67-immunoreactive cells at 2mg/kg/day rapamycin despite no mTOR signaling inhibition,Results,"we observed a significant decrease in the number of Ki67-immunoreactive (proliferating) cells ( Fig. 3A ) at 2mg/kg/day rapamycin. As shown above, 2mg/kg/day rapamycin did not inhibit mTOR signaling",0.9
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,Ki67 antibody (BD PharMingen),antibody,Other,May not be the ideal marker to measure glial cell proliferation in preclinical Nf1 GEM low-grade glioma rapamycin drug studies,Results,This finding suggests that Ki67 may not be the ideal marker to measure glial cell proliferation in preclinical Nf1 GEM low-grade glioma rapamycin drug studies,0.85
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,phospho-histone-H3 (Ser 10) antibody (Abcam),antibody,Biomarker,Reduced phospho-HH3 only with 20mg/kg/day rapamycin treatment,Results,we observed reduced phospho-HH3 only with 20mg/kg/day rapamycin,0.9
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,phospho-histone-H3 (Ser 10) antibody (Abcam),antibody,Biomarker,More accurate indicator of mTOR-mediated glial growth inhibition in the brain compared to Ki67,Results,these results demonstrate that phospho-HH3 and cyclin D1 may be more accurate indicators of mTOR-mediated glial growth inhibition in the brain,0.85
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,Cell Signaling Technology antibodies,antibody,Biomarker,Phospho-S6 suppression at 5 and 20mg/kg/day rapamycin doses but not at 2mg/kg/day,Results,Rapamycin treatment at 5 and 20mg/kg/day doses resulted in suppression of S6 activation using both phospho-S6-Ser 235/236 ( Fig. 2A ) and phospho-S6-Ser 240/244 (data not shown) antibodies,0.9
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,Cell Signaling Technology antibodies,antibody,Biomarker,"4EBP1 phosphorylation unchanged at 2mg/kg/day dose, significant reductions at 5 and 20mg/kg/day rapamycin doses",Results,"4EBP1 phosphorylation was unchanged at the 2mg/kg/day dose, whereas significant reductions were observed both at 5 and 20mg/kg/day rapamycin doses",0.9
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,Cell Signaling Technology antibodies,antibody,Biomarker,STAT3 inhibition only observed at 5 and 20 mg/kg/day rapamycin doses,Results,STAT3 inhibition was only observed in the brain at the 5 and 20 mg/kg/day doses,0.9
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,Nf1 9a−/9a− mice,animal_model,Behavioral,"Showed impaired spatial learning in Morris water maze, utilizing exclusively non-spatial search strategy with no preference for target quadrant",Results,Nf1 9a−/9a− mice utilized an exclusively non-spatial search strategy and showed no preference for the target quadrant,0.95
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,Nf1 9a−/9a− mice,animal_model,Biomarker,36 ± 7% reduction in total Nf1 mRNA and 39 ± 2% reduction in total neurofibromin protein in hippocampus,Results,"total Nf1 mRNA was reduced by 36 ± 7% (n = 9), with concomitant reduction of total neurofibromin protein (a reduction of 39 ± 2% in the hippocampus, n = 11)",0.95
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,Nf1 9a−/9a− mice,animal_model,Mechanistic,"Showed significant deficit in theta burst stimulation-induced LTP, but normal LTP when induced using high-frequency stimulation protocol",Results,"Nf1 9a−/9a− mice showed a significant deficit in TBS-induced LTP. Consistent with the sensitivity of TBS-induced LTP to changes in GABAergic inhibition, LTP was normal when induced using a high-frequency stimulation (HFS) protocol",0.95
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,Nf1 9a−/9a− mice,animal_model,Mechanistic,"Showed increased inhibitory postsynaptic potential amplitude at higher stimulus levels and reduced paired-pulse ratio, suggesting enhanced GABA release",Results,"inhibitory postsynaptic potential amplitude was bigger at higher stimulus levels in Nf1 9a−/9a− mice, whereas paired-pulse ratio was reduced, suggesting a change in presynaptic GABA release",0.9
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,Nf1 9a−/9a− mice,animal_model,Mechanistic,PV neurons showed 7 mV hyperpolarizing shift in I_h half-activation potential (-88.4 ± 1.9 mV vs -81.2 ± 2.0 mV in WT),Results,"Fits of the activation curve with a Boltzmann function yielded a hyperpolarizing shift of 7 mV in the half-activation potential (V1/2) in Nf1 9a−/9a− mice (-88.4 ± 1.9 mV, n = 10) compared with their WT littermates (-81.2 ± 2.0 mV, n = 7, P < 0.01)",0.95
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,Nf1 9a−/9a− mice,animal_model,Mechanistic,PV neurons had hyperpolarized resting membrane potential (-64.1 ± 0.7 mV vs -60.6 ± 0.7 mV) and higher input resistance (279 ± 19 MΩ vs 235 ± 14 MΩ),Results,"PV neurons of Nf1 9a−/9a− mice had a significantly hyperpolarized resting membrane potential (-64.1 ± 0.7 mV, n = 17 vs -60.6 ± 0.7 mV, n = 12; P < 0.005) and a higher input resistance (279 ± 19 MΩ, n = 15 vs 235 ± 14 MΩ, n = 16, P < 0.05)",0.95
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,lamotrigine,genetic_reagent,Mechanistic,"At 50 μM, increased I_h magnitude and caused significant depolarizing shift in activation, fully normalizing V1/2 to -80.9 ± 2.0 mV in Nf1 PV neurons",Results,"LTG increased the magnitude of Ih in Nf1 9a−/9a− mice and caused a significant depolarizing shift in Ih activation in Nf1 9a−/9a− PV neurons, which was fully normalized compared with recordings from WT mice. The V1/2 in the presence of LTG was −80.9 ± 2.0 mV (n = 9)",0.95
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,lamotrigine,genetic_reagent,Mechanistic,"Caused reduction of action potential firing rates in Nf1 PV neurons, with effect blocked by prior HCN antagonist ZD7288 application",Results,"bath application of LTG caused a reduction of action potential firing rates in response to depolarizing current injections in Nf1 9a−/9a− mice. To determine whether the effect of LTG on membrane excitability was directly mediated via Ih, the HCN antagonist ZD7288 was applied before application of LTG. In this condition, the effect of LTG on membrane excitability was fully blocked",0.9
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,lamotrigine,genetic_reagent,Efficacy,Restored LTP in Nf1 mice to the level of WT mice at Schaffer collateral-CA1 synapses,Results,"LTG restored LTP in Nf1 9a−/9a− mice to the level of WT mice, whereas the LTP deficit remained evident in vehicle-treated slices from Nf1 9a−/9a− mice",0.95
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,lamotrigine,genetic_reagent,Behavioral,"At 25 mg/kg i.p., restored spatial learning capacity in Nf1 9a−/9a− mice, showing clear preference for target quadrant in Morris water maze",Results,"LTG treatment restored the learning capacity of Nf1 9a−/9a− mice, without altering the performance of their WT littermates. Furthermore, and consistent with a prominent influence of HCN channel function in the pathophysiology of the Nf1+/− mouse model, Nf1+/− mice treated with LTG also showed a clear preference for the target quadrant",0.95
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,Morris water maze,clinical_assessment_tool,Behavioral,"Successfully detected spatial learning impairments in both Nf1 9a−/9a− and Nf1+/− mice, with deficits rescued by lamotrigine treatment",Results,"Nf1 9a−/9a− mice were tested in the Morris water maze task previously demonstrated to be impaired in Nf1+/− mice. Indeed, Nf1 9a−/9a− mice utilized an exclusively non-spatial search strategy and showed no preference for the target quadrant",0.9
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,Rotarod,clinical_assessment_tool,Behavioral,Detected motor coordination deficits in Nf1+/− mice that were completely rescued by lamotrigine treatment,Results,"Nf1+/− mice showed impaired learning on the accelerating rotarod, a motor learning paradigm that does not depend on hippocampal function. Indeed, LTG treatment completely rescued the motor coordination deficit in Nf1+/− mice",0.9
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,G12V H-Ras mice,animal_model,Biomarker,Showed dramatic increase in Ras-ERK pathway with phosphorylated ERK1 at 212% of WT and ERK2 at 246% of WT in hippocampus,Results,"H-RasG12V mice showed a dramatic increase of the Ras-ERK pathway, as measured by the relative level of phosphorylated ERK1 (212% of WT, P < 0.01) and ERK2 (246% of WT, P < 0.001) in the hippocampus",0.95
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,G12V H-Ras mice,animal_model,Mechanistic,"Despite marked ERK activation, showed no alterations in I_h current-voltage relationship, voltage dependence, or PV neuron excitability compared to WT",Results,"in contrast to Nf1 mutant mice, the current–voltage relationship and voltage dependence of Ih in PV neurons were similar between H-RasG12V and WT littermates. Furthermore, the slope of activation and the Ih kinetics remained intact. Consistent with the absence of any detectable changes in Ih, neither the resting membrane potential nor the input resistance was altered in H-RasG12V PV neurons",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,HSR-GBM1,cell_line,Biomarker,"Identified as NF1 intact with lack of MGMT expression, conveying sensitivity to TMZ",Results,"We identified two lines as NF1 intact (HSR-GBM1, JHU-0879)...lack of MGMT expression (HSR-GBM1, JHH-520, JHU-1016B) conveyed sensitivity to TMZ",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,JHH-520,cell_line,Efficacy,Exhibited decreased growth in response to combined MEKi and radiation therapy in heterotopic xenografts,Results,NF1-deficient heterotopic xenografts (JHH-520 and JHH-136) exhibited decreased growth in response to combined treatment as compared to monotherapy,0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,JHU-0879,cell_line,Biomarker,Identified as NF1 intact with intact MGMT expression associated with TMZ resistance,Results,"We identified two lines as NF1 intact (HSR-GBM1, JHU-0879)...intact MGMT expression was associated with resistance (JHU-0879 and JHH-136)",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,JHU-1016B,cell_line,Biomarker,"Identified as NF1 deficient with lack of MGMT expression, conveying sensitivity to TMZ",Results,"three as NF1 deficient (JHH-136, JHH-520, JHH-1016B)...lack of MGMT expression (HSR-GBM1, JHH-520, JHU-1016B) conveyed sensitivity to TMZ",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,JHH-136,cell_line,Efficacy,Exhibited decreased growth in response to combined MEKi and radiation therapy in heterotopic xenografts,Results,NF1-deficient heterotopic xenografts (JHH-520 and JHH-136) exhibited decreased growth in response to combined treatment as compared to monotherapy,0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,B76,cell_line,Biomarker,Identified as having BRAF V600E with intact NF1,Results,"three having BRAF V600E with intact NF1 (B76, DBTRG, NMCG1)",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,NGT-41,cell_line,Biomarker,Identified as having BRAF V600E and deficient NF1,Results,one having BRAF V600E and deficient NF1 (NGT41),0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,NMCG-1,cell_line,Biomarker,Identified as having BRAF V600E with intact NF1,Results,"three having BRAF V600E with intact NF1 (B76, DBTRG, NMCG1)",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,DBTRG,cell_line,Biomarker,Identified as having BRAF V600E with intact NF1,Results,"three having BRAF V600E with intact NF1 (B76, DBTRG, NMCG1)",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,NSG mice,animal_model,Efficacy,Combination of radiation therapy with MEKi resulted in significantly improved survival in two different orthotopic models,Results,"When evaluated in an intracranial model of glioblastoma, similar results were observed. The combination of radiation therapy with MEKi resulted in significantly improved survival",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,mirdametinib,genetic_reagent,Efficacy,"Showed highest sensitivity in glioblastoma models with loss of NF1 or BRAF V600E alterations, with synergistic effects when combined with radiation",Results,"Glioblastoma models exhibited varied sensitivity to MEKi, with highest sensitivity in those with loss of NF1 or BRAF V600E alterations",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,mirdametinib,genetic_reagent,Mechanistic,Decreased transcription of BRCA2 and RAD51 mRNA following 24 hours of treatment in neurosphere lines with NF1 deficiency,Results,"We observed decreased transcription of both genes following 24 hours of treatment with MEKi in neurosphere lines with NF1 deficiency, though not in those with intact NF1",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,mirdametinib,genetic_reagent,Efficacy,Did not demonstrate any synergistic effect on cell growth inhibition or cell death when combined with TMZ in any neurosphere lines,Results,We evaluated the combination of TMZ with MEKi but did not observe any synergistic effect on cell growth inhibition or cell death in any neurosphere lines,0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,phospho-ERKthr202/tyr204 antibody,antibody,Biomarker,Showed adequate inhibition of ERK activity in all cell lines treated with MEKi,Results,"despite adequate inhibition of ERK activity (phospho-ERK) in all cell lines, as previously reported",0.8
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,BRCA2 antibody,antibody,Biomarker,Showed decreased BRCA2 protein expression following MEKi therapy compared with vehicle in NF1-deficient adherent glioblastoma line,Results,"We observed decreased BRCA2 protein expression, and fewer RAD51 nuclear foci following MEKi therapy as compared with vehicle in an NF1-deficient adherent glioblastoma line",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,RAD51 antibody,antibody,Biomarker,Showed fewer RAD51 nuclear foci following MEKi therapy and decreased RAD51 foci with MEKi treatment in NF1-deficient cells,Results,"fewer RAD51 nuclear foci following MEKi therapy...The number of RAD51 foci decreased with MEKi treatment in NF1-deficient cells, irrespective of whether radiation had occurred",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,yH2AX antibody,antibody,Biomarker,Showed increased DNA double-strand damage in both NF1-intact and deficient lines following radiation,Results,"In both NF1-intact and deficient lines, radiation resulted in increased DNA double-strand damage as quantified by γH2AX",0.9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,cleaved PARP antibody,antibody,Biomarker,Demonstrated more induction for the combination of radiation with MEKi over any other combination in NF1 cell lines,Results,"apoptotic markers such as cleaved PARP demonstrated more induction for the combination of radiation with MEKi over any other combination, including the addition of TMZ or TMZ with radiation alone",0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,M059J,cell_line,Biomarker,Used as normal control cell line for comparison of WT1-AS and miR-494-3p expression levels in glioma cell lines,Results,"As compared to M059J, WT1-AS expression was decreased in these glioma cell lines",0.8
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U87,cell_line,Biomarker,WT1-AS expression was markedly increased at 48-hour posttransfection compared to control cells,Results,Quantitative real time polymerase chain reaction assays showed that WT1-AS expression was markedly increased in both the U87 and U118 cells at 48-hour posttransfection,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U87,cell_line,Efficacy,WT1-AS overexpression significantly suppressed cell proliferation as measured by CCK-8 assay,Results,The CCK-8 assay demonstrated that overexpression of WT1-AS significantly suppressed the proliferation of U87 and U373 cells,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U87,cell_line,Efficacy,EdU incorporation ratios were significantly lower in WT1-AS plasmid transfected cells compared to control cells,Results,"the EdU incorporation ratios were significantly lower in WT1-AS plasmid transfected U87 and U118 cells, as compared with the corresponding control cells",0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U87,cell_line,Efficacy,WT1-AS overexpression significantly inhibited cell migration and invasion,Results,overexpression of WT1-AS significantly inhibited glioma cell migration and invasion,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U87,cell_line,Efficacy,WT1-AS overexpression significantly reduced IC50 value for TMZ treatment and decreased viable cell proportion at various TMZ doses (0-400 μM),Results,The proportion of viable cells transfected with WT1-AS was significantly lower in both U87 and U118 cells than in control cells,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U118,cell_line,Biomarker,WT1-AS expression was markedly increased at 48-hour posttransfection compared to control cells,Results,Quantitative real time polymerase chain reaction assays showed that WT1-AS expression was markedly increased in both the U87 and U118 cells at 48-hour posttransfection,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U118,cell_line,Efficacy,WT1-AS overexpression significantly suppressed cell proliferation as measured by CCK-8 assay,Results,The CCK-8 assay demonstrated that overexpression of WT1-AS significantly suppressed the proliferation of U87 and U373 cells,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U118,cell_line,Efficacy,EdU incorporation ratios were significantly lower in WT1-AS plasmid transfected cells compared to control cells,Results,"the EdU incorporation ratios were significantly lower in WT1-AS plasmid transfected U87 and U118 cells, as compared with the corresponding control cells",0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U118,cell_line,Efficacy,WT1-AS overexpression significantly inhibited cell migration and invasion,Results,overexpression of WT1-AS significantly inhibited glioma cell migration and invasion,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,U118,cell_line,Efficacy,WT1-AS overexpression significantly reduced IC50 value for TMZ treatment and decreased viable cell proportion at various TMZ doses (0-400 μM),Results,The proportion of viable cells transfected with WT1-AS was significantly lower in both U87 and U118 cells than in control cells,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,Ago2 antibody,antibody,Mechanistic,RIP assay validated that WT1-AS and miR-494-3p were both enriched in Ago2 complex,Results,RIP assay validated that WT1-AS and miR-494-3p were both enriched in Ago2 complex,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,p-AKT antibody,antibody,Mechanistic,p-Akt levels reduced by WT1-AS were rescued by miR-494-3p as detected by Western blot,Results,p-Akt levels reduced by WT1-AS were rescued by miR-494-3p,0.9
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,total AKT antibody,antibody,Mechanistic,Used to detect total AKT levels in Western blot analysis alongside p-AKT measurements,Results,"phospho-Akt (p-AKT) and AKT levels in (A, B) were analyzed by Western blot",0.8
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,U87,cell_line,Biomarker,TRAP1 protein levels increased rapidly following exposure to hypoxic conditions,Results,"We also observed a fast induction of TRAP1 following exposure to hypoxic conditions in several human tumor cell types, encompassing MIA PaCa-2 pancreatic cancer cells (Fig. 3d), U87 and U251 glioblastoma cells",0.8
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,U251,cell_line,Biomarker,TRAP1 protein levels increased rapidly following exposure to hypoxic conditions,Results,"We also observed a fast induction of TRAP1 following exposure to hypoxic conditions in several human tumor cell types, encompassing MIA PaCa-2 pancreatic cancer cells (Fig. 3d), U87 and U251 glioblastoma cells",0.8
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,MiaPaCa-2,cell_line,Biomarker,TRAP1 protein levels increased following 2-6 hours of hypoxia (0.5% O2) or treatment with CoCl2 (0.5 mM for 6 h),Results,Western blot analysis and quantification of TRAP1 expression in MIA PaCa-2 human pancreatic adenocarcinoma cells following 2–6 h of hypoxia (0.5% O2) or treatment with CoCl2 (0.5 mM for 6 h),0.9
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,MiaPaCa-2,cell_line,Biomarker,TRAP1 mRNA expression levels increased when exposed to hypoxia,Results,"we exposed to hypoxia both Zebrafish embryos and human pancreatic adenocarcinoma MIA PaCa-2 cells, finding an increase of TRAP1 mRNA levels (Fig. 4d, e)",0.8
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,BxPc3,cell_line,Biomarker,TRAP1 protein levels increased rapidly following exposure to hypoxic conditions,Results,"We also observed a fast induction of TRAP1 following exposure to hypoxic conditions in several human tumor cell types, encompassing MIA PaCa-2 pancreatic cancer cells (Fig. 3d), U87 and U251 glioblastoma cells, BxPC3 pancreatic carcinoma cells",0.8
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,ipNF95.6,cell_line,Biomarker,TRAP1 protein levels increased rapidly following exposure to hypoxic conditions,Results,"We also observed a fast induction of TRAP1 following exposure to hypoxic conditions in several human tumor cell types, encompassing MIA PaCa-2 pancreatic cancer cells (Fig. 3d), U87 and U251 glioblastoma cells, BxPC3 pancreatic carcinoma cells, and ipNF95.6 plexiform neurofibroma cells",0.8
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,Tg(4xhre-tata:eGFP)ia,animal_model,Biomarker,"High transcriptional activity of HIF1α in early stages of embryonic development, which strongly decreased at 4-5 dpf",Results,"By using a Zebrafish GFP reporter line, we measured a high transcriptional activity of HIF1α in the early stages of embryonic development, which strongly decreased at 4–5 dpf",0.9
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D,animal_model,Biomarker,TRAP1 expression strongly increased both at protein and mRNA levels in K-RasG12D-driven pancreatic adenocarcinomas,Results,"TRAP1 expression, which was very low in fish pancreas under physiological conditions (Supplementary Fig. 5c), was strongly increased both at protein and mRNA levels in K-RasG12D-driven pancreatic adenocarcinomas",0.9
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D,animal_model,Mechanistic,"SDH activity was strongly reduced in tumor masses compared to normal pancreas, and TRAP1 inhibitor compound 5 restored SDH enzymatic activity in pancreatic tumor samples",Results,"Histochemical investigations of SDH activity on tissue slices showed that SDH activity was strongly reduced in tumor masses compared to the normal pancreas, and incubation with the specific TRAP1 inhibitor compound 5 restored the SDH enzymatic activity",0.9
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,anti-rodent TRAP1,antibody,Biomarker,"Successfully detected TRAP1 protein levels in zebrafish embryos, showing absence in knock-out animals at 96 hpf",Results,Western blot analysis of TRAP1 protein level in wild-type and knock-out animals at 96 hpf. The mitochondrial protein citrate synthase was used as a loading control,0.9
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,anti-human TRAP1,antibody,Biomarker,Successfully detected TRAP1 protein expression changes in human cancer cell lines following hypoxia treatment,Results,Western blot analysis and quantification of TRAP1 expression in MIA PaCa-2 human pancreatic adenocarcinoma cells following 2–6 h of hypoxia (0.5% O2) or treatment with CoCl2,0.9
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,anti-citrate synthetase,antibody,Other,Used as loading control for mitochondrial protein normalization in zebrafish samples,Results,The mitochondrial protein citrate synthase was used as a loading control,0.9
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,anti-HIF1α (Novus),antibody,Biomarker,Successfully detected HIF1α protein levels that increased parallel to TRAP1 following hypoxia exposure in zebrafish embryos,Results,finding an increase in TRAP1 protein levels that was paralleled by the expected raise in HIF1α expression,0.8
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,"athymic nude mice (female, nu/nu Balb/c)",animal_model,Safety,All animals tolerated xenografting and treatments well without visible signs of toxicity and gross abnormalities,Results,All animals tolerated xenografting and treatments well without visible signs of toxicity and gross abnormalities. General conditions of mice were also compatible among the untreated and the two treated groups.,0.9
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,"athymic nude mice (female, nu/nu Balb/c)",animal_model,Safety,"Body weights increased 10% in control group (23.9±1.0 to 26.4±1.6 g), 7% in nilotinib group (23.4±1.8 to 25.1±1.8 g), and 2% in imatinib group (23.3±1.2 to 23.7±1.7 g) over 28 days",Results,The body weights of mice increased 10% (23.9 ±1.0 to 26.4 ±1.6 g) in the control group and 7% (23.4 ±1.8 to 25.1 ±1.8 g) in the nilotinib group but not in the imatinib group (2% = 23.3 ±1.2 to 23.7 ±1.7 g),0.95
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,"athymic nude mice (female, nu/nu Balb/c)",animal_model,Efficacy,Xenograft size reduction was 68±7% with nilotinib vs 33±8% in untreated controls (P<0.05) and 47±15% with imatinib (P<0.05),Results,"The decrease in xenograft size was significantly more profound in the nilotinib group than in the untreated group (68 ±7 % vs. 33 ±8 %, P<0.05) and than in the imatinib group (47 ±15 %, P<0.05)",0.95
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,PNF-derived Schwann cells,cell_line,Efficacy,"Nilotinib IC50 values were 4.0 µM (proliferation) and 4.7 µM (viability), much lower than imatinib's 12.4 µM and 14.6 µM respectively",Results,"However, the IC 50 values of nilotinib were 4.0 and 4.7 µM, much lower than the 12.4 and 14.6 µM of imatinib.",0.95
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,CytoTox 96 Non-Radioactive Cytotoxicity assay,clinical_assessment_tool,Biomarker,Imatinib elevated cytotoxicity of mouse spleen cells to 21.1±7.2% vs 12.5±7.1% in untreated mice; nilotinib elevated to 17.6±6.2%,Results,"Imatinib and nilotinib elevated cytotoxicity of mouse spleen cells on cultured PNF Schwann cells significantly, 21.1 ±7.2 % and 17.6 ±6.2 %, respectively vs. 12.5 ±7.1 % in spleen cells of untreated mice",0.9
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,Nf1flox/flox,animal_model,Biomarker,"Used as normal control group (N) equivalent to wild-type mice, showed no Etv5 expression by qPCR",Results,Etv5 expression was detected in in one representative murine Nf1 optic glioma model (OPG-1) but was not detected (n.d.) in the normal murine optic nerve (N) by qPCR,0.9
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,Nf1flox/null; GFAP-Cre (OPG-1),animal_model,Biomarker,Showed 2.74-fold increased Etv5 expression and differential expression of 31 Etv5 target genes compared to normal controls,Results,"Etv5 expression was detected in the tumor-bearing optic nerves, but not in their non-neoplastic counterparts",0.9
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,Nf1flox/R681*; GFAP-Cre (OPG-2),animal_model,Biomarker,"Showed 3.54-fold increased Etv5 expression, the highest among all OPG models tested",Results,"In each of the murine Nf1 OPG models, we observed increased Etv5 RNA expression",0.9
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3),animal_model,Biomarker,Showed 2.40-fold increased Etv5 expression and differential expression of most validated Etv5 target genes,Results,"In each of the murine Nf1 OPG models, we observed increased Etv5 RNA expression",0.9
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,Nf1flox/null; Olig2-Cre (OPG-4),animal_model,Biomarker,"Showed 2.07-fold increased Etv5 expression, representing tumors arising from Olig2+ cells",Results,"In each of the murine Nf1 OPG models, we observed increased Etv5 RNA expression",0.9
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,Rabbit anti-Etv5 antibody (Novus Biologicals),antibody,Biomarker,Successfully detected Etv5 protein expression in optic glioma tissue but not in normal healthy optic nerves by immunohistochemistry,Results,"Etv5 protein expression was also observed in optic glioma tissue, but not in normal healthy optic nerves, by immunohistochemistry with an Etv5-specific antibody",0.9
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,ARACNe-AP algorithm,computational_tool,Mechanistic,Successfully created regulatory network from 427 human glioma gene expression profiles using mutual information and bootstrapping to measure gene similarities,Results,"Four hundred twenty-seven human glioma gene expression profiles were obtained from the Rembrandt data repository, and these were combined to create a network using the ARACNe-AP",0.9
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,DESeq2 version 1.18.1,computational_tool,Biomarker,Identified Etv5 as most significantly differentially expressed central gene with p-value 1.34E-09 and log2 fold change 1.4474,Results,the gene that was mostly clearly differentially expressed was Etv5,0.9
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,Wild-type and Nf1-/- primary astrocytes,cell_line,Biomarker,"Did not show differential Etv5 expression when analyzed in isolation, confirming Etv5 expression reflects whole tumor property rather than single cell type",Results,These particular findings were confirmed by the analysis of Nf1-deficient neoplastic cells (astrocytes) by qPCR,0.8
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,"NFC antibody (Sigma-Aldrich, MABE1820)",antibody,Biomarker,86% sensitivity for detecting tumors with confirmed NF1 genomic loss,Results,"Of the 14 scorable tumors assessed to be NF1-deficient by NGS, 12 (86%) also demonstrated minimal to absent NF1 immunostaining with NFC antibody.",0.95
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,"NFC antibody (Sigma-Aldrich, MABE1820)",antibody,Biomarker,"Immunoreactive in 26 tumors (41%) of total cohort, with 34 (54%) showing minimal or absent staining",Results,"The NFC immunostain was immunoreactive in 26 tumors (41%), whereas 34 (54%) had minimal or absent staining, one had equivocal staining",0.95
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,"NFC antibody (Sigma-Aldrich, MABE1820)",antibody,Safety,"Loss of NF1 immunostaining associated with decreased overall survival (8.5 vs 16.4 months, p=0.011)",Results,"patients with NF1 loss by NFC immunostaining had decreased survival compared with NF1 intact tumors (8.5 (4.5–12.6) vs. 16.4 (13.2–25.4) months, p = 0.011",0.95
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,"NFC antibody (Sigma-Aldrich, MABE1820)",antibody,Safety,"Minimal or absent NFC immunostaining remained significantly associated with decreased overall survival (HR 3.23, 95% CI 1.29–8.06, p=0.01) in multivariate analysis",Results,"Minimal or absent NFC immunostaining remained significantly associated with decreased overall survival (HR 3.23, 95% CI 1.29–8.06, p = 0.01)",0.95
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,iNF-07E antibody (iNFixion Bioscience),antibody,Biomarker,57% sensitivity for detecting tumors with confirmed NF1 genomic loss,Results,"Of the 14 scorable tumors considered NF1-deficient by NGS, eight (57%) also demonstrated minimal or absent immunostaining with iNF-07E.",0.95
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,iNF-07E antibody (iNFixion Bioscience),antibody,Biomarker,Immunoreactive in 46 tumors (76%) with 14 (23%) showing minimal or absent immunostaining,Results,The iNF-07E antibody was immunoreactive in 46 tumors (76%). Fourteen (23%) demonstrated minimal or absent immunostaining,0.95
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,iNF-07E antibody (iNFixion Bioscience),antibody,Safety,"No significant association with survival (9.8 vs 11.4 months, p=0.63)",Results,"This difference was not observed with the iNF-07E antibody (9.8 (6.5—18.0) vs. 11.4 (4.5—NR) months, p = 0.63)",0.95
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,"phospho-ERK antibody (#9101, Cell Signaling)",antibody,Biomarker,Positive phospho-ERK immunostaining associated with NF1 genomic loss (p=0.045),Results,We next asked whether IHC would be associated with NF1 genomic status and found positive phospho-ERK immunostaining to be associated with NF1 genomic loss (p = 0.045,0.9
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,QuPath (v0.4.3),computational_tool,Other,Used for digital pathology analysis of immunohistochemistry staining,Results,QuPath (v0.4.3) was used for digital pathology analysis,0.8
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,R (version 4.3.1),computational_tool,Other,Used for statistical analysis including survival analysis and correlation studies,Results,Statistical analyses were performed using R (version 4.3.1),0.8
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",National COVID Cohort Collaborative (N3C),computational_tool,Other,"Contains 6.4 million patients in v3.3 (July 2021), with NF1 cohort of 2501 patients, NF2 cohort of 665 patients, and SWN cohort of 762 patients",Results,"From the 6.4 million patients present in N3C Data Enclave (v3.3, July 2021), we selected cohorts of rare (NF1: 2501, NF2: 665, SWN: 762...",0.95
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",N3C Data Enclave,computational_tool,Other,"Successfully identified higher than expected population prevalence for NF diseases (NF1: 0.0004 vs expected 0.0002, NF2: 0.0001 vs expected 0.00002, SWN: 0.0001 vs expected 0.000008)",Results,"The occurrence of NF1, NF2, and SWN cases in the N3C data (NF1: 0.0004 of total N3C patients, NF2: 0.0001 of total N3C patients, SWN: 0.0001 of total N3C patients) was higher than the expected population prevalence",0.92
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",Wilcoxon rank-sum test,computational_tool,Other,Successfully detected that NF1 cohort proportion of positive cases was not higher than non-NF1 cohort (bootstrap Wilcoxon P = 0.5),Results,This suggests that the proportion of positive cases in the NF1 N3C cohort was not higher than the non-NF1 N3C cohort...bootstrap Wilcoxon P = .5,0.9
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",Benjamini-Hochberg (BH) method,computational_tool,Other,"Applied for multiple comparison correction, showing NF1 vs all comparison with z-test P = 0.0028, BH-adjusted P = 0.008",Results,"The proportion of positive cases in the NF1 cohort was significantly different from other cohorts...z-test P = .0028, BH-adjusted P = .008",0.88
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",R v3.6.3,computational_tool,Other,"Used for statistical analyses including bootstrap analysis with 10,000 iterations to validate P values",Results,"The gray bars show a histogram of all possible P values obtained through 10,000 iterations of bootstrap analysis",0.85
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",N3C Data Enclave,computational_tool,Other,"Enabled detection of well-established DM1-COVID-19 severity association, validating analytical methods (DM1 severe outcomes: Wilcoxon P = 0.003, BH-adjusted P = 0.009)",Discussion,"we recapitulated well-established associations between COVID-19 and DM1 (one of our control cohorts), suggesting that our methods can identify underlying patterns",0.87
PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,NFTI-QOL,clinical_assessment_tool,Behavioral,"Mean NFTI-QOL score was 8.7 (SD 5.4) for 288 patients at first visit, 9.3 (SD 5.2) for 117 patients at second visit, and 9.2 (SD 5.4) for all visits",Results,"The mean NFTI-QOL score for 288 patients for the first clinic visit was 8.7 (SD 5.4), for the 117 patients who attended on a second visit it was 9.3 (SD 5.2), and for all visits the mean NFTI-QOL was 9.2 (SD 5.4)",0.95
PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,NFTI-QOL,clinical_assessment_tool,Other,Internal reliability was very good with Cronbach's alpha score of 0.85 and re-test reliability r = 0.84,Results,"The internal reliability of NFTI-QOL was found to be very good, with a Cronbach's alpha score of 0.85 and re-test reliability r = 0.84",0.95
PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,NFTI-QOL,clinical_assessment_tool,Behavioral,NFTI-QOL score changes greater than 5 points up or down would be statistically significant for an individual patient,Results,Examination of longitudinal changes indicated that any NFTI-QOL score change up or down of greater than five points would be statistically significant for an individual,0.92
PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,NFTI-QOL,clinical_assessment_tool,Behavioral,"NFTI-QOL correlated with clinical severity (r = 0.41, p < 0.001; r = 0.46 for all visits) but only weakly with genetic severity (r = 0.16, p < 0.05; r = 0.15 for all visits)",Results,"The NFTI-QOL was related to ClinSev (r = 0.41, p < 0.001; r = 0.46 for all visits), but was only related weakly to GenSev (r = 0.16, p < 0.05; r = 0.15 for all visits)",0.95
PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,NFTI-QOL,clinical_assessment_tool,Other,NFTI-QOL is quick and easy to administer and has the ability to detect significant changes over time in quality of life of individual patients,Discussion,NFTI-QOL is a disease-specific questionnaire that is quick and easy to administer. It shows good reliability and has the ability to detect significant changes over time in QOL of individual patients,0.88
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,Nf1fl/fl;DhhCre,animal_model,Biomarker,Content of F4/80+;CD11b+ macrophages was 2.6 fold higher (P < 0.01) in 7-month-old Nf1fl/fl;DhhCre (0.77 ± 0.09%) than in 1-month-old Nf1fl/fl;DhhCre mice (0.27 ± 0.03%),Results,Content of F4/80+;CD11b+ macrophages was 2.6 fold (P < 0.01) higher in 7-month-old Nf1fl/fl;DhhCre (0.77 ± 0.09%) than in 1-month-old Nf1fl/fl;DhhCre mice (0.27 ± 0.03%),0.95
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,Nf1fl/fl;DhhCre,animal_model,Mechanistic,"51.5% of p75+ cells are p75+/EGFP+, and 42.9% are p75+/EGFP−, confirming Cre-mediated recombination pattern",Results,"We found that 51.5% of p75+ cells are p75+/EGFP+, and 42.9% are p75+/EGFP−, confirming prior descriptions of this model",0.92
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,"anti-mouse monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson)",antibody,Mechanistic,Successfully used for FACS sorting of F4/80+;CD11b+ macrophages in three independent experiments,Results,We sorted F4/80+;CD11b+ macrophages in three independent experiments,0.85
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,"anti-p75/NGFR (C40-1457, Becton–Dickinson)",antibody,Mechanistic,"Successfully used for FACS sorting of p75+ Schwann cells, with sorted cells expressing SC lineage markers Sox10, Fabp7, Erbb3, Mbp, and Mag",Results,"We used p75+ cells to sort SCs, and confirmed that the sorted cells express the SC lineage marker Sox10, the immature SC/satellite cell marker Fabp7",0.88
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,Anti-CSF1 (R&D Systems MAB4161),antibody,Efficacy,Function-blocking antibody significantly decreased macrophage migration stimulated by neurofibroma SC conditioned medium (p < 0.036) in 3 experiments,Results,"we tested if an anti-CSF1 function-blocking antibody might reduce macrophage migration stimulated by neurofibroma SC conditioned medium. Indeed, in 3 experiments a significant decrease was observed (p < 0.036)",0.93
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,FACSCanto (Becton–Dickinson),advanced_cellular_model,Mechanistic,Successfully used for cell sorting and analysis of p75+ Schwann cells and F4/80+;CD11b+ macrophages from neurofibroma tissues,Results,We FACS-sorted p75+ SCs from mice expressing a green fluorescent protein (GFP) reporter allele,0.85
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,RNeasy mini kit (QIAGEN),genetic_reagent,Mechanistic,Successfully used for RNA extraction from FACS-sorted cells for microarray analysis,Results,We used the sorted cells to perform microarray experiments and analyze the data according to the analysis pipeline,0.82
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,Affymetrix Mouse Gene 2.0 ST array,genetic_reagent,Mechanistic,Successfully identified differentially expressed genes (DEGs) using fold change >2x and false discovery rate (FDR) q < 0.05 as criteria,Results,"using fold change >2x and false discovery rate (FDR) q < 0.05 as criteria, no significant DEGs were detected in comparisons of SCs and macrophages from 1-month-old",0.88
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,PEGylated interferon alpha-2b,clinical_assessment_tool,Efficacy,"Does not shrink tumors significantly, unlike MEK inhibition which shrinks 75% of neurofibromas",Results,"MEK inhibition shrinks 75% of neurofibromas, while PEGylated IFN-α2b does not shrink tumors significantly (not shown)",0.9
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,PEGylated interferon alpha-2b,clinical_assessment_tool,Biomarker,"Treatment at 10,000 IU weekly for 8 weeks reduced levels of IFN-γ, IL1B, and CSF1 to, or close to, levels present in wild-type nerve",Results,"IFN-α2b was administered at 10,000 IU weekly, by subcutaneous injection. This treatment reduced levels of IFN-γ, IL1B, and CSF1 to, or close to, levels present in wild-type nerve",0.95
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,"mouse cytokine array (panel A, R&D system)",clinical_assessment_tool,Biomarker,"Successfully detected eight pro-inflammatory cytokine proteins (IFN-γ, CSF1, IL1B, CASP1) over-expressed in mouse neurofibroma tumors compared to WT sciatic nerve lysates",Results,"Eight pro-inflammatory cytokine mRNAs over-expressed in 7-month-old SCs or macrophages were evaluated for protein expression in mouse neurofibroma tumors, as compared to WT sciatic nerve lysates",0.9
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,MATLAB,computational_tool,Other,Used for heterogeneity analysis calculations and statistical processing of PET imaging parameters,Results,Good inter-observer agreement was found for measurement of all parameters with ICC varying from 0.86 (NGTDM contrast and GLCM contrast) to 1.0 (SUVmax and SUVpeak) on 1.5-h and 4-h scans,0.75
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,SPSS,computational_tool,Other,Performed statistical analysis showing significant differences between benign and malignant tumours for SUV and heterogeneity parameters with p-values ranging from <0.0001 to 0.047,Results,"On 1.5-h scans, there was a significant difference between benign and malignant tumours for all SUV and other first-order parameters, for none of the second-order parameters and for all four high-order parameters",0.85
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,MedCalc,computational_tool,Other,Generated ROC analysis showing SUVmax achieved highest AUROC of 0.992 at 1.5h and SUVpeak achieved 0.997 at 4h for discriminating benign from malignant tumours,Results,"SUVmax showed the highest AUROC at 1.5 h (0.992) and SUVpeak at 4 h (0.997), closely followed by SUVmax (0.996)",0.9
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,ichorCNA,computational_tool,Biomarker,Tumor fractions in plasma measured by ichorCNA correlated strongly with the NMF-inferred malignant signature weight (r = 0.6; P = 0.002),Results,"In MPNST samples, tumor fractions in plasma measured by ichorCNA correlated strongly with the NMF-inferred malignant signature weight ( r  = 0.6;  P  = 0.002)",0.95
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,ichorCNA,computational_tool,Efficacy,26 of 35 (74.3%) MPNST plasma samples detectable using ichorCNA tumor fraction compared to 32 of 35 (91.4%) using NMF deconvolution approach,Results,"with 32 of 35 (91.4%) MPNST plasma samples detectable by the NMF deconvolution approach, compared with 26 of 35 (74.3%) using ichorCNA tumor fraction",0.95
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,ichorCNA,computational_tool,Efficacy,MPNST–healthy threshold 0.0305 for tumor fraction detection,Results,six MPNST plasma samples that fell below the tumor fraction detection threshold (MPNST–healthy threshold 0.0305),0.9
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,QIAamp Circulating Nucleic Acid kit,genetic_reagent,Other,Used for cfDNA extraction from plasma samples under standardized conditions,Results,cfDNA from these participants was prepared and sequenced under standardized conditions to allow for fragment length and end-motif analysis,0.8
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,KAPA HyperPrep kit,genetic_reagent,Other,Used for library preparation with eight PCR cycles at 6× depth for fragment analysis,Results,"cfDNA from these participants was prepared and sequenced under standardized conditions to allow for fragment length and end-motif analysis (eight PCR cycles, 6× depth",0.8
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,BoN (Burden of NF1) questionnaire,clinical_assessment_tool,Behavioral,"Cronbach's alpha coefficient was 0.91 for the entire questionnaire, reflecting excellent internal coherence",Results,"Cronbach's alpha coefficient was 0.91 for the entire questionnaire, reflecting its excellent internal coherence, while intradimensional coherences exhibiting good reliability.",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,BoN (Burden of NF1) questionnaire,clinical_assessment_tool,Behavioral,Test-retest reliability demonstrated good reproducibility with intraclass correlation >0.85 for each domain,Results,"The test-retest reliability was obtained on 23 evaluable subjects (Day 1 and Day 10), demonstrating good reproducibility. The intraclass correlation of each dimension was > 0.85 for each domain.",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,BoN (Burden of NF1) questionnaire,clinical_assessment_tool,Behavioral,"Mean BoN score was 28.42 (±16.87), with men scoring 22.48 (±16.47) versus women 31.67 (±16.38) (p<0.001)",Results,"In our patient cohort, the mean BoN score obtained was 28.42 (±16.87), the mean score for men being 22.48 (±16.47) versus 31.67 (±16.38) for women ( p  < 0.001).",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,BoN (Burden of NF1) questionnaire,clinical_assessment_tool,Behavioral,"BoN scores varied significantly by disease severity: low severity 17.6 (±11.9), moderate 29.3 (±14.4), high 45.5 (±18.2)",Results,"The BoN score of the low severity group was 17.6 (±11.9), while that of the moderate severity group was 29.3 (±14.4), and that of the high severity group 45.5 (±18.2), the BoN score differences statistically significant.",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,Dermatology Life Quality Index (DLQI),clinical_assessment_tool,Behavioral,"DLQI highly correlated with BoN questionnaire (r=0.69930, p<0.0001)",Results,"The BoN questionnaire highly correlated with the Dermatology Life Quality Index (DLQI), Perceived Stress Scale (PSS), and SF12 mental scores",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,Perceived Stress Scale (PSS),clinical_assessment_tool,Behavioral,"PSS highly correlated with BoN questionnaire (r=0.72643, p<0.0001)",Results,"The BoN questionnaire highly correlated with the Dermatology Life Quality Index (DLQI), Perceived Stress Scale (PSS), and SF12 mental scores",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,SF12,clinical_assessment_tool,Behavioral,"SF12 mental composite score correlated with BoN (r=-0.57650, p<0.0001), while physical score showed weaker correlation (r=-0.26242, p=0.0347)",Results,"The correlation coefficients between BoN and validated questionnaires were relatively high, confirming BoN's external validity; the correlation with the SF12 physical score proved the weakest.",0.95
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,SAS software Version 9.4,computational_tool,Other,Used for statistical analysis including Shapiro test of normality for BoN score (p=0.15),Results,"The Shapiro test of normality for the BoN score provided a  p -value of 0.15, meaning that the hypothesis that the data are normally distributed can-not be rejected.",0.9
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,PROC CALIS procedure,computational_tool,Other,Confirmatory analysis showed Bentler comparative fit index of 0.9521 and Bentler-Bonett non-normed fit index of 0.9355,Results,"The practical goodness-of-fit indices were acceptable, with a Bentler comparative fit index of 0.9521 and a Bentler-Bonett non-normed fit index of 0.9355.",0.95
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,Autism Diagnostic Observation Schedule-2 (ADOS-2),clinical_assessment_tool,Behavioral,"Mean ADOS-SA CSS was 7.3 (95% CI: 7.2-7.4) in NF1+ASD, 6.4 (95% CI: 6.1-6.7) in NS+ASD, and 5.3 (95% CI: 4.5-5.9) in CFC+ASD (p=0.078)",Results,Mean ADOS-SA CSS (95% CI) 7.3 (7.2–7.4) 6.4(6.1–6.7) 5.3 (4.5–5.9) 0.078,0.95
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,Autism Diagnostic Observation Schedule-2 (ADOS-2),clinical_assessment_tool,Behavioral,"Mean ADOS-RRB CSS was 5.0 (95% CI: 4.9-5.1) in NF1+ASD, 6.5 (95% CI: 6.2-6.8) in NS+ASD, and 8.3 (95% CI: 8.0-8.5) in CFC+ASD (p=0.009)",Results,Mean ADOS-RRB CSS (95% CI) 5.0 (4.9–5.1) 6.5(6.2–6.8) 8.3 (8.0–8.5) 0.009,0.95
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,Autism Diagnostic Observation Schedule-2 (ADOS-2),clinical_assessment_tool,Behavioral,"Mean ADOS-composite CSS was 6.8 (95% CI: 6.7-6.9) in NF1+ASD, 6.4 (95% CI: 6.2-6.6) in NS+ASD, and 6.4 (95% CI: 5.9-6.9) in CFC+ASD (p=0.652)",Results,Mean ADOS-composite CSS (95% CI) 6.8 (6.7–6.9) 6.4(6.2–6.6) 6.4 (5.9–6.9) 0.652,0.95
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,Autism Diagnostic Interview Revised (ADI-R),clinical_assessment_tool,Behavioral,"Mean Qualitative Abnormalities in Reciprocal Social Interaction was 18.9 (95% CI: 18.7-19.1) in NF1+ASD, 17.4 (95% CI: 16.4-18.4) in NS+ASD, and 18.4 (95% CI: 17.2-19.6) in CFC+ASD (p=0.743)",Results,Domain A: Mean Qualitative Abnormalities in Reciprocal Social Interaction (95% CI) 18.9 (18.7–19.1) 17.4(16.4–18.4) 18.4 (17.2–19.6) 0.743,0.95
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,Autism Diagnostic Interview Revised (ADI-R),clinical_assessment_tool,Behavioral,"Mean Qualitative Abnormalities in Communication was 13.7 (95% CI: 13.5-13.9) in NF1+ASD, 14.8 (95% CI: 14.2-15.4) in NS+ASD, and 14.7 (95% CI: 14.1-15.2) in CFC+ASD (p=0.895)",Results,Domain B: Mean Qualitative Abnormalities in Communication (95% CI) 13.7 (13.5–13.9) 14.8(14.2–15.4) 14.7 (14.1–15.2) 0.895,0.95
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,Autism Diagnostic Interview Revised (ADI-R),clinical_assessment_tool,Behavioral,"Mean Restricted, Repetitive, and Stereotyped Patterns of Behavior was 5.8 (95% CI: 5.7-5.9) in NF1+ASD, 4.7 (95% CI: 4.1-5.3) in NS+ASD, and 5.6 (95% CI: 5.5-5.7) in CFC+ASD (p=0.649)",Results,"Domain C: Mean Restricted, Repetitive, and Stereotyped Patterns of Behavior (95% CI) 5.8 (5.7–5.9) 4.7(4.1–5.3) 5.6 (5.5–5.7) 0.649",0.95
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,"Conners Parent Rating Scale (3rd edition, short form)",clinical_assessment_tool,Behavioral,"Mean inattention score was 75.7 (95% CI: 75.2-76.2) in NF1+ASD, 73.1 (95% CI: 71.2-75.0) in NS+ASD, and 80.7 (95% CI: 78.5-82.9) in CFC+ASD (p=0.460)",Results,Mean inattention (SD) (95% CI) 75.7 (75.2–76.2) 73.1(71.2–75.0) 80.7 (78.5–82.9) 0.460,0.95
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,"Conners Parent Rating Scale (3rd edition, short form)",clinical_assessment_tool,Behavioral,"Mean hyperactivity score was 74.1 (95% CI: 73.5-74.7) in NF1+ASD, 71.8 (95% CI: 69.2-74.3) in NS+ASD, and 74.3 (95% CI: 71.4-77.2) in CFC+ASD (p=0.923)",Results,Mean hyperactivity (SD) (95% CI) 74.1 (73.5–74.7) 71.8(69.2–74.3) 74.3 (71.4–77.2) 0.923,0.95
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,Wechsler Abbreviated Scale of Intelligence-II (WASI-II),clinical_assessment_tool,Behavioral,"Mean verbal IQ was 88.7 (95% CI: 88.1-89.3) in NF1+ASD, 89.1 (95% CI: 87.5-90.7) in NS+ASD, and 79.8 (95% CI: 73.6-85.9) in CFC+ASD (p=0.853)",Results,Mean VIQ (95% CI) 88.7 (88.1–89.3) 89.1(87.5–90.7) 79.8 (73.6–85.9) 0.853,0.95
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,multispectral neural network (MSNN),computational_tool,Efficacy,Achieved Sørensen–Dice coefficient of 0.77 ± 0.016 (range 0.54–0.96) when compared with manual segmentation,Results,"The Sørensen–Dice coefficient was 0.77 ± 0.016 (± SEM, range 0.54–0.96).",0.95
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,multispectral neural network (MSNN),computational_tool,Efficacy,"Showed significant correlation with manual segmentation (r = 0.51, p = 0.002)",Results,"Linear regression (Fig. 5) showed significant correlation (r = 0.51, p = 0.002).",0.95
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,multispectral neural network (MSNN),computational_tool,Efficacy,Processing time averaged 6 minutes per case compared to 18 minutes for manual measurement,Results,"On average, a neural network case including manual definition of tumor classes with removal of obvious normal anatomy took 6 min, while manually measuring the PNs took an average of 18 min.",0.95
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,multispectral neural network (MSNN),computational_tool,Other,"Performance limited by susceptibility artifacts in head, neck and chest anatomy",Discussion,"However, PNs in anatomy typically affected by susceptibility artifact within the head, neck and chest limit greater concordance and further work is needed to develop this technology into a routine clinical tool.",0.85
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,ST88-14,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,STS26T,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,S520,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,S462,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,88-3,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,90-8,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,YST1,cell_line,Mechanistic,MPNST cell line used in DNA microarray gene expression profiling to identify gene programmes normally expressed at neural crest stage,Results,"DNA microarrays to profile the gene expression in normal Schwann cells, Schwann cells cultured from primary benign neurofibromas (dermal and plexiform subtypes), MPNST cell lines and solid tumours",0.8
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,shRNAs targeting SOX9 (Open Biosystems; TRC library),genetic_reagent,Efficacy,Reduction of SOX9 expression in MPNST cell lines causes cell death,Results,Reduction of SOX9 expression in MPNST cell lines causes cell death,0.9
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,shRNAs targeting SOX9 (Open Biosystems; TRC library),genetic_reagent,Mechanistic,Reducing SOX9 expression kills MPNST cells but has minimal effect on NF cell survival in vitro,Discussion,reducing SOX9 expression kills MPNST cells but has a minimal effect on NF cell survival in vitro,0.9
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,Affymetrix GeneChip HU133 Plus 2.0,computational_tool,Mechanistic,"Used for DNA microarray gene expression profiling that identified 1,108 unique gene signature distinguishing NF1 tumour samples from normal Schwann cells",Discussion,"Comparing gene expression profiles of NF1 tumour samples to cultured primary Schwann cells resulted in a 1,108 unique gene signature distinguishing NF1 tumour samples from normal Schwann cells",0.8
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,hTERT,genetic_reagent,Mechanistic,"Co-transduction with mCdk4 enabled creation of cell lines that passage well beyond primary cultures, with 14 out of 15 attempted co-transductions successful",Results,Co-transduction of 14 primary cNF SC cultures with lentiviral vectors containing wild type hTERT and mCdk4 cDNA transgenes led to creation of cell lines that passage well beyond the primary cultures,0.95
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,mCdk4,genetic_reagent,Mechanistic,"Co-transduction with hTERT enabled creation of cell lines that passage well beyond primary cultures, with 14 out of 15 attempted co-transductions successful",Results,Co-transduction of 14 primary cNF SC cultures with lentiviral vectors containing wild type hTERT and mCdk4 cDNA transgenes led to creation of cell lines that passage well beyond the primary cultures,0.95
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,hTERT,genetic_reagent,Mechanistic,Presence and expression confirmed via WGS and transcript mapping in immortalized lines,Results,Presence and expression of transgenes in the immortalized lines was confirmed via WGS and transcript mapping,0.9
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,mCdk4,genetic_reagent,Mechanistic,Presence and expression confirmed via WGS and transcript mapping in immortalized lines,Results,Presence and expression of transgenes in the immortalized lines was confirmed via WGS and transcript mapping,0.9
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,icNF97.2a,cell_line,Other,Already published in a study for testing exon skipping approach due to specific mutation repertoire,Discussion,"One cell line (icNF97.2a) has already been published in a study by our group, chosen for its specific mutation repertoire to test an exon skipping approach",0.85
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,icNF97.2b,cell_line,Other,Published to evaluate transcriptomic effects of selumetinib,Discussion,This cell line as well as 2 others (icNF97.2b and icNF98.4d) have also been published by our group to evaluate the transcriptomic effects of selumetinib,0.85
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,icNF98.4d,cell_line,Other,Published to evaluate transcriptomic effects of selumetinib,Discussion,This cell line as well as 2 others (icNF97.2b and icNF98.4d) have also been published by our group to evaluate the transcriptomic effects of selumetinib,0.85
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,icNF98.4c,cell_line,Biomarker,Showed lowest pERK:ERK ratio despite predicted high pERK from germline and somatic mutations,Results,"icNF98.4c has the lowest pERK:ERK ratio, which is difficult to interpret given that the germline pathogenic variant results in out-of-frame skipping of exon 43, and the somatic mutation is deletion of the gene",0.8
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,N-Terminal NF1 antibody (Cell Signaling cat# D7R7D),antibody,Biomarker,"Used to detect neurofibromin protein levels in Western blot analysis, showing variable results between cell lines consistent with different NF1 genotypes",Results,"Western blots of protein from the tumor-derived immortal cell lines were used to detect neurofibromin and determine the phosphorylated ERK (pERK, active form) to total ERK ratio",0.9
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,p-ERK antibody (Cell Signaling cat# 9101),antibody,Biomarker,"Used to measure phosphorylated ERK as downstream measure of RAS activity, showing all cNF cell lines had elevated pERK:ERK ratios compared to wild type control",Results,"As expected, all cNF cell lines show pERK:ERK ratios elevated compared to the wild type control ipn97.4 cells, which have very low pERK levels",0.9
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,total ERK antibody (Cell Signaling cat# 9102),antibody,Biomarker,Used to measure total ERK protein for calculating pERK:ERK ratios as measure of RAS pathway activation,Results,"Western blots of protein from the tumor-derived immortal cell lines were used to detect neurofibromin and determine the phosphorylated ERK (pERK, active form) to total ERK ratio",0.9
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,DeepVariant,computational_tool,Other,Used to calculate Jaccard indices showing immortalized cell lines had higher similarity to matched primary cultures than unrelated cultures (0.679 to 0.722),Results,"The Jaccard index, a measure of similarity, was calculated for all cell lines in a pairwise manner using the variants called with DeepVariant",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,Nf1−/− MEFs,cell_line,Biomarker,Lower expression and activity of OXPHOS complex I compared to wild type counterparts,Results,we have found that Nf1 −/−  MEFs have a lower expression and activity of OXPHOS complex I ( aka  NADH dehydrogenase or NADH-ubiquinone oxidoreductase) than their wild type counterparts,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,Nf1−/− MEFs,cell_line,Biomarker,OCR is down-regulated compared to Nf1+/+ cells,Results,OCR is down-regulated in cells lacking neurofibromin,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,Nf1−/− MEFs,cell_line,Biomarker,Display lower level of mitochondrial ROS than Nf1+/+ MEFs,Results,Nf1 +/+  MEF cells display a higher level of mitochondrial ROS than Nf1 −/−  MEFs,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,Nf1−/− MEFs,cell_line,Efficacy,NDI1 expression increases OCR to reach the level of Nf1+/+ cells,Results,"When expressing NDI1, Nf1 −/−  MEFs increase their OCR and reach the level of Nf1 +/+  cells",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,Nf1−/− MEFs,cell_line,Efficacy,NDI1 expression raises intracellular NAD+/NADH ratio and NAD+ levels,Results,"In Nf1 −/−  cells, but not in the wild type ones, NDI1 expression raises intracellular NAD + /NADH ratio and NAD +  levels",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,Nf1−/− MEFs,cell_line,Efficacy,Tumorigenicity decreased by NDI1 in soft agar assay,Results,tumorigenicity of neurofibromin-deficient cells is decreased by NDI1 in a soft agar assay,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,Nf1−/− MEFs,cell_line,Efficacy,NAD+ precursors nicotinic acid (NIC) and nicotinamide (NAM) decrease tumorigenicity to levels comparable to NDI1-expressing counterparts,Results,"the NAD +  precursors nicotinic acid (NIC) and nicotinamide (NAM), which augment NAD +  levels through the Preiss-Handler and the salvage pathway, respectively [ 15 ], decrease tumorigenicity of Nf1 −/−  cells to levels comparable to their NDI1-expressing counterparts",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,sMPNST cells,cell_line,Efficacy,NDI1 expression increases OCR and reduces tumorigenicity,Results,"NDI1 expression increases OCR (Fig.  5A, B ) and reduces tumorigenicity (Fig.  5C ) in MPNST cells too",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,sMPNST cells,cell_line,Efficacy,SIRT3 overexpression has antineoplastic effect similar to NDI1,Results,a similar antineoplastic effect is obtained by SIRT3 overexpression,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,sMPNST cells,cell_line,Efficacy,TRAP1 knock-out reduces tumorigenicity,Results,knocking-out TRAP1 expression reduces tumorigenicity of MPNST cells,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,sMPNST cells,cell_line,Efficacy,NIC administration reduces colony growth and further inhibits growth in TRAP1 knock-out cells,Results,"A similar antineoplastic effect is obtained upon NIC administration to TRAP1-expressing cells, and NIC further inhibits colony growth in TRAP1 knock-out cells",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,cisMPNST cells,cell_line,Efficacy,NDI1 expression increases OCR and reduces tumorigenicity,Results,"NDI1 expression increases OCR (Fig.  5A, B ) and reduces tumorigenicity (Fig.  5C ) in MPNST cells too",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,ipNF 04.4 cells,cell_line,Biomarker,MEK inhibition correlates with increase in complex I expression,Results,MEK inhibition correlates with an increase in complex I expression also in human U87 glioblastoma cells (Supplementary Fig.  1C ) and ipNF 04.4 plexiform neurofibroma cells,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,nude female mice,animal_model,Efficacy,"Neoplastic growth of MPNST cells inhibited by SIRT3 overexpression, NIC treatment, and TRAP1 knock-out",Results,"In vivo, neoplastic growth of MPNST cells is inhibited by SIRT3 overexpression or treatment of mice with NIC, as well as by TRAP1 knock-out",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,nude female mice,animal_model,Efficacy,NIC treatment almost abrogates tumor growth in TRAP1-null background,Results,NIC treatment almost abrogates it,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,nude female mice,animal_model,Biomarker,"Both NAD+/NADH ratio and NAD+ increased following NIC administration and TRAP1 ablation, dramatically raised when NIC provided to TRAP1 knock-out cells",Results,"In tumor samples both NAD + /NADH ratio and NAD +  are increased following NIC administration and when TRAP1 is ablated, and are dramatically raised when NIC is provided to animals harboring TRAP1 knock-out cells",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,XF24 Extracellular Flux Analyzer,computational_tool,Biomarker,Successfully measured OCR changes in various cell lines including rescue by NDI1 expression,Results,"OCR is down-regulated in cells lacking neurofibromin...When expressing NDI1, Nf1 −/−  MEFs increase their OCR and reach the level of Nf1 +/+  cells",0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,NAD+/NADH colorimetric assay kit,computational_tool,Biomarker,Successfully detected increased NAD+/NADH ratio and NAD+ levels following NDI1 expression in Nf1−/− cells,Results,NDI1 expression raises intracellular NAD + /NADH ratio and NAD +  levels,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,MitoSOX,computational_tool,Biomarker,Successfully measured mitochondrial ROS levels showing Nf1+/+ MEFs display higher levels than Nf1−/− MEFs,Results,Nf1 +/+  MEF cells display a higher level of mitochondrial ROS than Nf1 −/−  MEFs,0.9
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,anti HIF1α antibody,antibody,Biomarker,"Detected marked nuclear localization of HIF1α in xenografted sMPNST cells, which was abrogated by TRAP1 knock-out, SIRT3 induction and NIC supplementation",Results,"We observe a marked nuclear localization of the transcription factor HIF1α in xenografted sMPNST cells...Not only TRAP1 knock-out, but also SIRT3 induction and NIC supplementation abrogate the nuclear localization of HIF1α",0.9
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,U-Net convolutional neural network,computational_tool,Efficacy,"Successfully refined Raman spectra by removing background interferences, enabling clear molecular signature identification",Results,"After application of U-Net for the refinement from background interferences, the mean purified Raman spectra of cutaneous neurofibroma and physiological mucosa, bone, nerve, skin, and fat are shown",0.85
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,Shifted-Excitation Raman Spectroscopy,computational_tool,Efficacy,Successfully isolated Raman spectra of various tissues when used in conjunction with U-Net convolutional neural network,Discussion,"Herein, Raman spectra of various tissues were isolated with the SERDS technique in conjunction with U-Net convolutional neural network",0.8
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,SERDS,computational_tool,Efficacy,Successfully isolated Raman spectra of various tissues when used in conjunction with U-Net convolutional neural network,Discussion,"Herein, Raman spectra of various tissues were isolated with the SERDS technique in conjunction with U-Net convolutional neural network",0.8
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,Ventana-785-Raman spectrometer,computational_tool,Biomarker,"Successfully acquired raw Raman spectra from 82 distinct measurement loci in 34 surgical specimens, enabling molecular analysis of cutaneous neurofibroma",Results,"For this study, raw Raman spectra were acquired from 82 distinct measurement loci in 34 surgical specimens of cutaneous neurofibroma and physiological tissues",0.85
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,Hematoxylin & Eosin,clinical_assessment_tool,Other,"Successfully confirmed cutaneous neurofibroma diagnosis by showing uniform density of spindle shaped tumor cells with wavy contour and slender nuclei, with no mitosis or necrosis observed",Results,"Here, cutaneous neurofibroma was confirmed by uniform density of spindle shaped tumor cells with wavy contour and slender nuclei. No mitosis or necrosis was seen",0.9
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,Spatial capacity working memory (SCAP) task,clinical_assessment_tool,Behavioral,Task performance showed hypoactivation in right IPS and left DLPFC in NF1 patients relative to healthy controls during task performance,Discussion,"we found significant hypoactivation of key components of working memory circuitry, the right IPS and left DLPFC in patients with NF1 relative to healthy controls during task performance",0.85
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,Spatial capacity working memory (SCAP) task,clinical_assessment_tool,Behavioral,Controls showed greater right lateral occipital activation than NF1 patients when investigating regions activated in high memory loads relative to low loads,Discussion,"when investigating regions activated in high memory loads relative to low loads, controls showed greater right lateral occipital activation than NF1 patients",0.85
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,Spatial capacity working memory (SCAP) task,clinical_assessment_tool,Behavioral,"NF1 patients exhibited more diffuse activation during high loads than low loads in posterior cingulate, right angular gyrus, right orbitofrontal cortex, right temporal pole, right middle frontal gyrus, left parietal cortex, and left inferior temporal gyrus",Discussion,"NF1 patients exhibited more diffuse activation during high loads than low loads, specifically in the posterior cingulate, right angular gyrus, right orbitofrontal cortex, right temporal pole, right middle frontal gyrus, left parietal cortex, and left inferior temporal gyrus",0.85
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,generalized psychophysiological interaction (gPPI) method,computational_tool,Mechanistic,"Revealed differential patterns of connectivity between NF1 patients and healthy controls, with NF1 patients showing greater connectivity between bilateral parietal regions and visual cortices",Discussion,"The PPI analyses indicated differential patterns of connectivity between patients with NF1 and healthy controls. Specifically, NF1 patients exhibited greater connectivity than healthy controls between bilateral parietal ('task-positive') regions and visual cortices",0.85
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,generalized psychophysiological interaction (gPPI) method,computational_tool,Mechanistic,Task-related long-range connectivity between PCC and frontal/parietal lobes was associated with better performance on behavioral measures of visuospatial and working memory ability in NF1 patients but not controls,Discussion,"task-related long-range connectivity between the PCC and frontal/parietal lobes was associated with better performance on behavioral measures of visuospatial and working memory ability (respectively) in patients with NF1, although this relationship was not observed in controls",0.85
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,FMRIB software library (FSL),computational_tool,Other,"Successfully identified regions of differential connectivity at cluster thresholds of z=2.3 and z=3.1, with specific activation patterns documented in multiple brain regions",Results,"At a cluster threshold of 3.1 there were no regions of differential connectivity with the left parietal seed... At a cluster threshold of 3.1, NF1 patients still showed greater connectivity between the PCC and cerebellum than healthy controls",0.8
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",Spectramax M5,computational_tool,Other,Used as microplate reader for absorption measurements at 440 nm with capability to process 2400 samples/hr (5 plates × 96 wells × 5 rounds/h),Results,The absorption values were recorded with a plate redear at 440 nm (λmax of SEL-DDQ CTC)...2400 samples can be processed/hr (5 plates × 96 wells × 5 rounds/h),0.9
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",SoftMax Pro Enterprise software,computational_tool,Other,Used for data acquisition and analysis in the microwell spectrophotometric assay with high precision (RSD 1.25-1.81%) and accuracy (99.5-101.3% recovery),Results,"The RSD values for intra– and inter-assay precision were 1.25–1.72% and 1.25–1.81%, respectively...recovery values...ranged from 99.5 to 101.3%",0.9
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",GAMESS software,computational_tool,Mechanistic,Used for DFT calculations with B3LYP/6-31G basis set to determine ground state structures and bond length changes in SEL-DDQ complex formation,Results,The B3LYP/6-31G basis set which is a hybrid functional employed in density functional theory (DFT) calculations was employed...bond length of LB1 (from 1.21378 Å to 1.21681 Å),0.9
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",Mutiwfn 3.7,computational_tool,Mechanistic,"Used for molecular orbital calculations, HOMO-LUMO analysis, and non-covalent interaction analysis showing van der Waals and hydrogen bonding stabilization of SEL-DDQ complex",Results,"The NCI-graph...depicts weak van der Waals interactions with green disks...blue and red disks depict strong, attracting H-bonds and repulsive steric effects",0.9
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",VMD,computational_tool,Other,Used for visualization of molecular structures and non-covalent interactions in the SEL-DDQ charge transfer complex,Results,The NCI-graph (Fig. 7) depicts a three-dimensional depiction of all interactions within the analyzed complex,0.8
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,DynaPro NanoStar,computational_tool,Biomarker,Static light scattering measurements indicated that Merlin(wt) and Merlin(S518D) are monomers in solution,Results,Molecular mass measurements by static light scattering indicates that Merlin(wt) and Merlin(S518D) are monomers in solution,0.9
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,DichroWeb,computational_tool,Biomarker,CD spectra deconvolution yielded comparable helical and beta sheet structure around 40-50% and 20% respectively for full-length Merlin(wt) and Merlin(S518D),Results,"Deconvolution of the CD spectra yields the fractions of secondary structures. For the full-length Merlin(wt) and Merlin(S518D), the CD spectra suggest a comparable helical and beta sheet structure around 40-50 % and 20% respectively",0.9
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,Biacore X100,computational_tool,Biomarker,SPR showed NHERF1 binds to full-length Merlin(wt) with Kd=956±70 nM and to Merlin(S518D) with Kd=1240±220 nM,Results,"SPR shows that NHERF1 binds to the full-length Merlin(wt) with K d =956±70 nM, and to Merlin(S518D) with K d =1240±220 nM",0.9
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,MicroCal™ Auto-iTC 200,computational_tool,Biomarker,ITC experiments showed less than 40% of full-length Merlin(wt) or Merlin(S518D) are active in binding to NHERF1 based on N values,Results,"However, for the full-length Merlin(wt) and Merlin(S518D), the N value indicate that less than 40% of Merlin or Merlin(S518D) are active or competent in binding to NHERF1",0.9
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,MicroCal™ Auto-iTC 200,computational_tool,Biomarker,"ITC determined that ezFERM, mFERM, Merlin(wt), and Merlin(S518D) have similar magnitude binding affinities for PIP2, with full-length proteins having slightly higher affinity",Results,"The results show that ezFERM, mFERM, Merlin(wt), and Merlin(S518D) have similar magnitude binding affinities for PIP2, with the full-length Merlin(wt) and Merlin(S518D) having slightly higher affinity for PIP2",0.8
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,GNOM,computational_tool,Biomarker,"SANS analysis showed Rg and Dmax values of d Merlin(wt) are very similar to d Merlin(S518D), indicating similar conformation",Results,"The length distribution function P(r), R g , and D max of d Merlin(wt) are very similar to that of d Merlin(S518D), indicating that these d Merlin(wt) and d Merlin(S518D) have similar conformation",0.9
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,DAMMIN,computational_tool,Biomarker,"3-D shape reconstruction showed overall shapes of d Ezrin, d Merlin(wt), and d Merlin(S518D) are quite similar, with crystal structure of Moesin fitting better in d Ezrin envelope",Results,"The overall 3-D shapes of d Ezrin, d Merlin(wt), and d Merlin(S518D) are quite similar. However, Figure 3D shows that the crystal structure of Moesin fits better in the map of d Ezrin envelope than in that of d Merlin or d Merlin(S518D)",0.8
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 mice,animal_model,Efficacy,13% meningioma development rate (9 of 72 histologically examined mice) when injected with adCre,Results,adCre;Nf2 flox2/flox2 (9 of 72 histologically examined mice; 13%) mice,0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 mice,animal_model,Biomarker,46% meningothelial proliferation rate (33/72 mice) when injected with adCre,Results,adCre;Nf2 flox2/flox2 (33/72; 46%) mice,0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 ;p16 Ink4a*/* mice,animal_model,Efficacy,"37% meningioma development rate (10 of 27 histologically examined mice), significantly higher than Nf2 flox2/flox2 alone (P < 0.01)",Results,"adCre;Nf2 flox2/flox2 ;Ink4a*/* (10 of 27 histologically examined mice; 37%) compared with adCre;Nf2 flox2/flox2 (9 of 72 histologically examined mice; 13%) mice (χ2, P < 0.01)",0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 ;p16 Ink4a*/* mice,animal_model,Biomarker,"77% meningothelial proliferation rate (21/27 mice), significantly higher than Nf2 flox2/flox2 alone (P < 0.01)",Results,"adCre;Nf2 flox2/flox2 ;Ink4a*/* (21/27; 77%) than in adCre;Nf2 flox2/flox2 (33/72; 46%) mice (χ2, P < 0.01)",0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Nf2 flox2/flox2 ;p16 Ink4a*/* mice,animal_model,Safety,Survival was not reduced compared with Nf2 flox2/flox2 mice,Results,The survival of adCre;Nf2 flox2/flox2 ;Ink4a*/* mice was not reduced compared with that of adCre;Nf2 flox2/flox2,0.9
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,PGDS antibody (Santa Cruz sc-14825),antibody,Biomarker,"Almost all mouse meningiomas showed some positive staining, with different pattern from normal arachnoid cells (fewer, fine granules dispersed in cytoplasm vs perinuclear distribution)",Results,Almost all mouse meningiomas showed some positive staining...PGDS staining of tumor cells was different from that seen in the adjacent normal arachnoid cells,0.85
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Biospec 4.7 Tesla microimaging system,computational_tool,Biomarker,75% of intracranial mouse meningiomas showed pathological gadolinium enhancement,Results,Pathological gadolinium enhancement was observed in 75% of the intracranial mouse meningiomas,0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,Biospec 4.7 Tesla microimaging system,computational_tool,Efficacy,70% sensitivity and 78% specificity for diagnosing meningothelial proliferation,Results,MRI allowed the diagnosis of meningothelial proliferation with a sensitivity of 70% and a specificity of 78%,0.95
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,adCre,genetic_reagent,Mechanistic,Induces biallelic Nf2 inactivation in arachnoid cells leading to meningioma development,Results,adCre-injected Nf2 flox2/flox2...meningioma development,0.85
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,"ActiveTwo system (BioSemi, Amsterdam, Netherlands)",computational_tool,Biomarker,"Successfully recorded EEG data showing NF1 group had significantly higher delta power (F(1,28) = 7.135, p = 0.012, ηp² = 0.203) and theta power (F(1,28) = 9.145, p = 0.005, ηp² = 0.246) compared to controls during resting state",Results,"The difference in power between groups was significant for delta (F(1,28) = 7.135, p = 0.012, ηp² = 0.203) and theta (F(1,28) = 9.145, p = 0.005, ηp² = 0.246)",0.95
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,"ActiveTwo system (BioSemi, Amsterdam, Netherlands)",computational_tool,Biomarker,"Detected significantly lower peak alpha frequency (PAF) in NF1 group compared to controls (F(1,28) = 12.276, p = 0.002, ηp² = 0.305)",Results,"There was a significant difference in PAF between groups (F(1,28) = 12.276, p = 0.002, ηp² = 0.305), whereby compared to CON, NF1 showed a lower PAF",0.95
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,Vineland Adaptive Behaviour Scale (VABS-III),clinical_assessment_tool,Behavioral,"NF1 group performed significantly worse than controls on parent-rated Vineland ABC (t(29) = 3.573, p < 0.001)",Results,"NF1 performed significantly worse than CON on the parent-rated Vineland ABC (t(29) = 3.573, p < 0.001)",0.95
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,adaptive auditory n-back task,clinical_assessment_tool,Behavioral,"NF1 group performed significantly worse than controls on adaptive auditory n-back task (mean n-back; t(30) = 5.412, p < 0.001)",Results,"NF1 performed significantly worse than CON on the parent-rated Vineland ABC (t(29) = 3.573, p < 0.001) and adaptive auditory n-back task (mean n-back; t(30) = 5.412, p < 0.001)",0.95
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,non-adaptive visual n-back task,clinical_assessment_tool,Behavioral,"No significant impairment detected in NF1 group performance on EEG n-back task (hits − false alarms (%); F(1,30) = 0.094, p = 0.762, ηp² = 0.003)",Results,"Moreover, the NF1 group did not demonstrate any impairment in EEG n-back task performance (hits − false alarms (%); F(1,30) = 0.094, p = 0.762, ηp² = 0.003)",0.95
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,EEGLAB (version 13.6.5b),computational_tool,Biomarker,"Successfully processed EEG data to reveal oscillatory reactivity patterns in NF1 group, showing significant power increases during eyes closed vs eyes open for delta (t(13) = 5.004, p < 0.001, d = 1.34), theta (t(13) = 4.296, p = 0.001, d = 1.15), and alpha (t(13) = 5.291, p < 0.001, d = 1.41)",Results,"Planned paired t-tests to examine oscillatory reactivity in the NF1 group showed that power was significantly higher during eyes closed relative to eyes open for delta (t(13) = 5.004, p < 0.001, d = 1.34), theta (t(13) = 4.296, p = 0.001, d = 1.15), and alpha (t(13) = 5.291, p < 0.001, d = 1.41)",0.92
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,FieldTrip,computational_tool,Biomarker,"Enabled detection of significantly higher unadjusted frontoparietal theta phase coherence in NF1 group compared to controls (F(1,29) = 4.852, p = 0.036, ηp² = 0.143), though this difference disappeared when adjusted for resting state",Results,"This group difference in unadjusted theta phase coherence was significantly different (F(1,29) = 4.852, p = 0.036, ηp² = 0.143). However, the 2 (CON/NF1) × 3 (ML/MM/MR) × 2 (1-/2-back) ANOVA using task-specific (adjusted) theta phase coherence showed no significant main effects or interactions involving the factor 'group'",0.9
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,Brief Pain Inventory Short Form (BPI-SF),clinical_assessment_tool,Behavioral,"Mean pain scores: 4.8 (SD 1.8) for past 2 weeks, 3.7 (SD 2.9) at time of interview in NF1 patients",Results,BPI-SF Past 2 weeks 4.8 (1.8) At the time of the interview 3.7 (2.9),0.95
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,Patient Health Questionnaire (PHQ),clinical_assessment_tool,Behavioral,"Mean depression score of 12.1 (SD 2.3, range 0-14) in NF1 patients with moderate to severe depression excluded",Results,"The mean score for depression on the PHQ was 12.1 (SD, 2.3; range, 0 - 14)",0.95
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,Generalized Anxiety Disorder 7 Item version (GAD-7),clinical_assessment_tool,Behavioral,"Mean anxiety score of 10.7 (SD 1.1, range 0-14) in NF1 patients with severe anxiety excluded",Results,"the mean score for anxiety on the GAD-7 was 10.7 (SD, 1.1; range, 0 - 14)",0.95
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,Qualtrics,computational_tool,Other,Used for data collection in focus group discussions and individual interviews,Results,six FGDs (n = 37) involving NF1 patients were conducted between September 2022 and June 2023,0.8
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,ATLAS.ti (Version 9),computational_tool,Other,Used for thematic analysis identifying three main themes across patient and provider data,Results,"We identified three themes across the data from both participant groups: (1) Describing the Physical CP Experience, (2) Treating and Dealing With CP, and (3) Attitudes About Current Pain Measures",0.85
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,Weighted Gene Co-expression Network Analysis (WGCNA),computational_tool,Mechanistic,"Identified a co-expression module highly correlated with tumor malignancy, with hub genes markedly enriched in microtubule-related pathways",Discussion,"This study has evidenced that meningioma gene expression contains a co-expression module highly correlated with tumor malignancy, whose hub genes are markedly enriched in microtubule-related pathways",0.85
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,Weighted Gene Co-expression Network Analysis (WGCNA),computational_tool,Mechanistic,"Determined genetic loci linked to cytoskeleton, cell-cell adhesion, angiogenesis, calcium-channels, glutamate receptors, and ERAD pathways as potential regulators of the co-expression network",Discussion,"Genetic loci linked to cytoskeleton, cell–cell adhesion, angiogenesis, calcium-channels, glutamate receptors, and ERAD pathways were determined as potential regulators of the whole co-expression network",0.85
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,n-back task,clinical_assessment_tool,Behavioral,"Working memory variables from n-back task loaded onto 3 independent factors accounting for 54% of total variance, with high working memory load (factor 1), low working memory load (factor 2), and auditory working memory (factor 3)",Results,"The working memory variables were subjected to a varimax rotated PCA, which produced 3 independent factors with eigenvalue > 1, which accounted for 54% of total variance",0.95
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,n-back task,clinical_assessment_tool,Behavioral,Poorer performance on high working memory load tasks (verbal and visuospatial 2-back and 3-back) was significantly associated with increased volumes in inferior lateral parietal lobe (22 voxels),Results,Poorer performance on high working memory load tasks was significantly associated with increased volumes in a small region of inferior lateral parietal lobe (22 voxels),0.92
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,n-back task,clinical_assessment_tool,Behavioral,Poorer performance on low working memory load tasks (verbal and visuospatial 0-back and 1-back) was significantly associated with increased volumes in posterior cingulate cortex and other regions,Results,Poorer performance on low working memory load was significantly associated with increased volumes in a larger region of medial gray matter centered on the posterior cingulate cortex,0.92
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,Corsi block task,clinical_assessment_tool,Behavioral,Corsi block memory span loaded onto factor 1 (high working memory load) with factor loading of 0.488,Results,Corsi block memory span 0.488 0.195 0.370,0.88
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),clinical_assessment_tool,Behavioral,Digit span forward and backwards tasks loaded onto factor 3 (auditory working memory) with loadings of 0.676 and 0.670 respectively,Results,Digit span forward 0.116 −0.063 0.676 Digit span backwards 0.212 0.071 0.670,0.88
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),clinical_assessment_tool,Behavioral,"Auditory working memory performance (including digit span tasks) was associated with gray matter volumes in middle frontal gyrus (132 voxels, Z-score 4.18)",Results,Auditory working memory performance was associated with gray matter volumes in a single smaller region centered on the middle frontal gyrus,0.9
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,Vineland Adaptive Behavior Scale—third edition,clinical_assessment_tool,Behavioral,"Overall Vineland adaptive functioning score was 68 (SD 13.0), well below the normative mean of 100 in NF1 participants",Results,"The overall Vineland adaptive functioning score was 68, well below the normative mean of 100",0.95
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,Conners 3 rating scale,clinical_assessment_tool,Behavioral,Parent-rated Conners-3 indicated significant impairments with T-scores of 78.7 (SD 13.0) on inattention and 69.1 (SD 18.2) on hyperactivity subscales,Results,Parent-rated Conners-3 rating scale indicated significant impairments with T-scores of 78 and 69 on the inattention and hyperactivity subscales respectively,0.95
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,SPM12 v7771,computational_tool,Other,"SPM12 identified significantly larger gray matter volumes in NF1 group in 3 clusters including subcortical structures (thalamus, globus pallidus, caudate, putamen, dorsal midbrain, cerebellum) with global maxima in left cerebellar lobules IV–V (P < 0.05 FWE corrected)",Results,"The NF1 group showed significantly larger volumes in 3 clusters—the first large cluster included a large portion of medial subcortical structures including the thalamus, globus pallidus, caudate, putamen",0.93
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Behavioral,Mean completion time of 4 minutes (range 2-8 minutes) in Dutch NF1 patients with plexiform neurofibromas,Results,The mean time to complete the PlexiQoL questionnaire was 4 min (range 2–8 min).,0.95
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,High internal consistency with Cronbach's α of 0.825 at first administration and 0.844 at second administration,Results,The PlexiQoL showed high internal consistency at both administrations (Table 2).,0.95
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,Excellent test-retest reliability with correlation coefficient of 0.928 between first and second administration (p<0.001),Results,"We found a correlation coefficient of 0.928 between the first and second administration, indicating excellent test-retest reliability (p-value < 0.001).",0.95
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,No floor effects observed and no significant ceiling effects,Results,"For the PlexiQoL there were no floor effects, and the observed ceiling effects were not significant.",0.9
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,"Strong correlation with NHP Emotional Reactions (0.793) and Social Isolation (0.831) subsections, moderate correlation with Energy Scale (0.584) and Physical Mobility (0.567)",Results,The PlexiQoL score showed strong correlation with the NHP 'Emotional Reactions' and 'Social Isolation' subsections...There was a moderate correlation between the 'Energy Scale' and the 'Physical Mobility' subsections.,0.95
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",PlexiQoL,clinical_assessment_tool,Other,"Significant differences in scores between participants with different self-reported general health (effect size 0.48, p=0.002) and plexiform neurofibroma severity (effect size 0.42, p=0.009)",Results,"Significant differences in PlexiQoL scores were observed between participants regarding their self-reported general health and plexiform neurofibroma severity (with effect sizes of 0.48 and 0.42, respectively)",0.95
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",Nottingham Health Profile (NHP),clinical_assessment_tool,Other,"Significant floor effects observed on all six NHP subsections, with one ceiling effect on the Energy Scale subsection",Results,"Significant floor effects were observed on all six NHP subsections, as well as one ceiling effect on the 'Energy Scale' subsection.",0.9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,Nf1^flox/mut;GFAP-Cre,animal_model,Efficacy,"8 of 13 OPG mice developed induced cortical gliomas following PDE4A1 injection (statistically significant, P=0.02)",Results,"Eight of the 13 OPG mice with increased BLI following PDE4A1 injection were considered to have induced cortical gliomas (Table 1). This was a statistically significant rate of induced tumor formation, as determined by Fisher's Exact Test (P=0.02).",0.95
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,Nf1^flox/mut;GFAP-Cre,animal_model,Efficacy,Four weeks of Rolipram treatment resulted in tumor regression with restoration of optic nerve volumes to near normal values,Results,"Using this preclinical paradigm, four weeks of Rolipram resulted in tumor regression as measured by a restoration of optic nerve volumes to near normal values (Figure 5B, C).",0.9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,Nf1^flox/flox;GFAP-Cre,animal_model,Efficacy,Only 1 of 7 Tumor Progenitor mice had evidence of induced glioma following PDE4A1 injection,Results,"In contrast, only 1 of 7 Tumor Progenitor mice and 1 of 6 wild-type mice had evidence of induced glioma.",0.9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,Daoy,cell_line,Mechanistic,"Only catalytically-active PDE4A1 decreased intracellular cAMP levels, while both active and inactive forms were equally expressed",Results,"While both forms of PDE4A1 were equally expressed (Supplemental Figure 2A) and localized to the Golgi apparatus (Supplemental Figure 2B), only catalytically-active PDE4A1 decreased intracellular cAMP levels",0.9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,GFAP antibody,antibody,Biomarker,Successfully identified bipolar GFAP-positive astrocytoma cells in induced cortical gliomas with characteristic piloid morphology,Results,The diagnosis of an induced glioma was made when hypercellular lesions expressing mCherry fluorescent protein and PDE4 also contained GFAP-positive cells with the bipolar morphology characteristic of tumor cells (piloid cells),0.9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,Olig2 antibody (DF-308),antibody,Biomarker,Induced tumors demonstrated significantly increased Olig2 expression compared to uninvolved contralateral cortex,Results,"As a group, the induced tumors demonstrated significantly increased Olig2 expression compared to the uninvolved contralateral cortex (Figure 3B).",0.9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,phosphorylated protein kinase A substrate antibody,antibody,Biomarker,"Tumor sites exhibited decreased labeling with phosphoPKA substrate antibody, indicating decreased PKA activity and suggestive of decreased cAMP levels",Results,"Tumor sites exhibited decreased labeling with phosphoPKA (pPKA) substrate antibody, indicating decreased PKA activity (Figure 3C,D) and suggestive of decreased levels of cAMP.",0.85
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,PDE4A1-mCherry lentiviral construct,genetic_reagent,Efficacy,12 of 13 OPG mice injected with catalytically-active PDE4A1 lentivirus demonstrated increased BLI and mCherry expression at injection site,Results,Twelve of 13 OPG mice injected with catalytically-active PDE4A1 lentivirus demonstrated increased BLI and expression of mCherry fluorescent protein/PDE4A at the injection site,0.9
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,PDE4A1-H229Q-mCherry lentiviral construct,genetic_reagent,Efficacy,None of the 15 control injections of catalytically-inactive PDE4A1-H229Q resulted in tumor formation,Results,None of the 15 control injections of PDE4A1-H229Q resulted in a tumor.,0.95
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,mCherry antibody,antibody,Biomarker,"Successfully detected mCherry-positive cells at injection sites in both tumor-bearing and non-tumor mice, allowing differentiation based on morphology",Results,"While PDE4A (not shown) and mCherry positive cells (Figure 4A) were observed at injection sites in mice without tumors, these differed from induced tumors by the absence of abnormal astrocyte morphologies",0.85
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,GL261,cell_line,Efficacy,"In subcutaneous model, C. novyi-NT treatment alone resulted in 1/11 mice cured, 8/11 partial response, 2/11 died from toxicity",Results,"Of the surviving animals, 8 mice with initial tumor reduction were found later to have tumor regrowth (partial), and 1 mouse was cured as determined by absence of tumor after 3 weeks",0.95
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,GL261,cell_line,Efficacy,"Tumor size of 400-500 mm³ was required for consistent C. novyi-NT germination, as smaller tumors showed inconsistent germination",Results,This tumor size was selected to ensure consistent C. novyi-NT germination as we observed inconsistent germination in smaller tumor in this model,0.9
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,GL261,cell_line,Mechanistic,"Showed distribution of small hypoxic pockets throughout tumor body and rim areas, validated by pimonidazole staining and C. novyi-NT colonization",Results,showed a distribution of small hypoxic pockets in the tumor body and rim areas adjacent to surrounding tissues,0.9
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,GL261-luc,cell_line,Efficacy,Bioluminescence imaging demonstrated therapeutic outcomes with quantified bioluminescence counts showing treatment effects,Results,Bioluminescence imaging of the luciferase-labeled tumor illustrated these therapeutic outcomes,0.85
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,anti-Ly6G antibody,antibody,Efficacy,"Pretreatment with anti-Ly6G antibody resulted in 11/15 mice cured, 2/15 partial response, 2/15 died from toxicity when combined with C. novyi-NT",Results,"in the cohorts treated with anti-Ly6G 1A8 antibody or HU, 11/15 or 9/12 mice respectively were cured of tumor, 2/15 or 1/12 were partial, and 2/15 or 2/12 died from immediate toxicities",0.95
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,anti-Ly6G antibody,antibody,Mechanistic,"Successfully depleted neutrophils when administered IP 24 hours before spore injection, preventing neutrophil barrier formation around germinating bacteria",Results,Those immune cells could be depleted by treating the mice with 1A8 antibody intraperitoneally (IP) 24 hours before the spore injection,0.9
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,anti-Ly6G antibody,antibody,Safety,Anti-Ly6G antibody alone showed no noticeable therapeutic effects and no apparent toxicity,Results,HU or 1A8 antibody alone did not show any noticeable therapeutic effects,0.8
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,"NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, strain #:005557)",animal_model,Efficacy,"Notable benefit of LXH254 plus trametinib combination in reducing tumor growth observed in three xenograft models (JH-2-002, ST8814 and MA1334), and additive anti-tumor activity in JH-2-079c",Results,"A notable benefit of the combination in reducing tumor growth was observed in three models, JH-2–002, ST8814 and MA1334, and additive anti-tumor activity was seen in JH-2-079c",0.85
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,"NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, strain #:005557)",animal_model,Biomarker,Combination significantly repressed tumor mitotic activity and proliferation as indicated by mitotic counts and Ki-67 decrease in PDX JH-2-002,Results,the combination significantly repressed tumor mitotic activity and proliferation as indicated by mitotic counts and Ki-67 decrease,0.9
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,"NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, strain #:005557)",animal_model,Mechanistic,"Combination markedly inhibited p-ERK, DUSP6 and several downstream effectors (p-RSK, p-S6, p-RB, Cyclin D1) in xenograft models",Results,"markedly inhibited p-ERK, DUSP6 and several other downstream effectors (p-RSK, p-S6, p-RB, Cyclin D1)",0.9
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,patient-derived xenograft models,patient_derived_model,Efficacy,"Three patient-derived xenograft models (JH-2-002, JH-2-079c and MA1334) tested with LXH254 plus trametinib combination showing notable benefit in tumor growth reduction in JH-2-002 and MA1334, additive activity in JH-2-079c",Results,"We thus tested the effects of combined LXH254 and trametinib in four xenograft models of NF1-MPNST, including three patient-derived (JH-2–002, JH-2-079c and MA1334)",0.85
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,CRISPR-CAS9,genetic_reagent,Mechanistic,"CRISPR-Cas9 knockout of NF1 in STS26T cells resulted in increased activity of CRAF (elevated p-CRAF Ser338), p-MEK, p-ERK, and to lesser extent p-AKT and p-S6",Results,"We observed an increase in the activity of CRAF, as evidenced by elevation in p-CRAF Ser338, as well as other RAS effectors, in particular p-MEK and p-ERK, and to a lesser extent p-AKT and p-S6, upon NF1 depletion",0.9
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,shRNA,genetic_reagent,Efficacy,"CRAF knockdown most potently inhibited cell growth, BRAF knockdown had moderate effect, ARAF knockdown had only subtle impact on cell growth in MPNST cells",Results,"CRAF knockdown most potently inhibited cell growth, while BRAF knockdown had a moderate effect, and ARAF knockdown had only a subtle impact on cell growth",0.9
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,shRNA,genetic_reagent,Efficacy,"CRAF shRNA decreased trametinib GI50 by 54% on average, BRAF shRNA by 36%, and ARAF shRNA by 10% compared to control in three NF1-MPNST cell lines",Results,"sh CRAF decreased trametinib GI50 by 54% on average, sh BRAF by 36% and sh ARAF by 10%, compared to sh GFP",0.95
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,shRNA,genetic_reagent,Mechanistic,"BRAF expression was significantly downregulated by CRAF knockdown in all three NF1-MPNST cell lines, suggesting enhanced effects of CRAF knockdown stem from downregulation of both BRAF and CRAF",Results,"BRAF expression was significantly downregulated by CRAF knockdown, relative to sh GFP controls and ARAF knockdown cells. Therefore, the enhanced effects of CRAF knockdown may stem from the downregulation of both BRAF and CRAF",0.85
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,neurofibromasphere model,advanced_cellular_model,Efficacy,Selumetinib-ogerin cotreatment enhanced disaggregation index compared with single agents and controls,Results,Selumetinib-ogerin cotreatments exhibited a significantly enhanced disaggregation index compared with single agents and controls,0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,neurofibromasphere model,advanced_cellular_model,Efficacy,Selumetinib-ogerin cotreatment showed significant increase in cell death compared with single treatments alone,Results,"we observed a significant increase in cell death in selumetinib-ogerin cotreatments, compared with single treatments alone, especially at high concentrations of selumetinib",0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"p75 antibody (Ab3125, Abcam)",antibody,Biomarker,Successfully used to quantify percentage of Schwann cells through flow cytometry analysis in cocultures,Results,We used some of the harvested cells to quantify the percentage of both cell types through flow cytometry analysis using the SC maker p75 (NGFR),0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"S100B antibody (Z0311, Dako)",antibody,Biomarker,Used in combination with Click-iT EdU to measure proliferation status of SC and FB populations in cocultures,Results,Using S100B staining in combination with Click-iT EdU we measured the proliferation status of SC and FB populations in cocultures,0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"MPZ antibody (Ab183868, Abcam)",antibody,Biomarker,"Cotreated cells were highly MPZ positive, indicating a promyelinization-differentiating SC phenotype",Results,"While cells treated with single agents alone did not stain for MPZ protein, cotreated cells were highly MPZ positive, indicating a promyelinization-differentiating SC phenotype",0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"selumetinib (Tocris, catalog 6815)",genetic_reagent,Efficacy,Strongly reduced cell viability in SC cultures and SC-FB cocultures with slight effect on FB cultures,Results,Selumetinib treatment strongly reduced cell viability in SC cultures and SC-FB cocultures with a slight effect on FB cultures,0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"selumetinib (Tocris, catalog 6815)",genetic_reagent,Efficacy,Elicited potent arrest of SCs in single cultures after 48 hours and strong arrest of both SCs and FBs in cocultures,Results,"selumetinib elicited a potent arrest of SCs in single cultures after 48 hours...Again, selumetinib elicited a strong arrest of both SCs and FBs in cocultures",0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"ogerin (Tocris, catalog 5722)",genetic_reagent,Efficacy,Reduced viability and proliferation of cNF-derived primary SCs in both single cultures and SC-FB cocultures,Results,"ogerin-treated SC cultures, alone or in cocultures, with no effect on FBs viability...Ogerin produced a slight arrest on SCs, in both single and cocultures",0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"ogerin (Tocris, catalog 5722)",genetic_reagent,Mechanistic,Treatment elevated cAMP levels in cNF SCs,Results,we confirmed that ogerin treatment was elevating cAMP levels in cNF SCs,0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"PAM71 (MedChemExpress, catalog HY-134494)",genetic_reagent,Efficacy,Selumetinib-PAM71 cotreatment triggered the same loss of SC viability as selumetinib-ogerin,Results,Selumetinib-PAM71 cotreatment triggered the same loss of SC viability as selumetinib-ogerin,0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"PAM71 (MedChemExpress, catalog HY-134494)",genetic_reagent,Efficacy,Selumetinib-PAM71 significantly reduced neurofibromasphere viability compared with selumetinib alone,Results,selumetinib-PAM71 cotreatment also elicited a significant decrease in cell viability when compared with selumetinib treatment alone,0.9
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"8CPT cAMP (Abcam, catalog ab120424)",genetic_reagent,Efficacy,Low concentrations in combination with selumetinib produced similar physiological changes to cNF-derived primary SCs as ogerin combinations,Results,"low concentrations of 8CPT cAMP and forskolin alone elicited no change in MPZ expression or morphological change, all combinations with selumetinib induced a clear promyelinization state in SCs",0.8
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"Forskolin (MilliporeSigma, catalog F6886)",genetic_reagent,Efficacy,Forskolin-selumetinib combination exhibited similar decrease in SC viability as other cAMP elevators with selumetinib,Results,The combinations composed of 8CPT cAMP–selumetinib and forskolin-selumetinib exhibited a similar decrease in SC viability,0.8
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"GANT61 (Tocris, catalog 3191)",genetic_reagent,Efficacy,Exhibited certain effect on SC viability but response was not as clear as ogerin or showed inconsistencies among different cNF-derived cells,Results,"For GANT61 and LGK974, although they exhibited a certain effect on SC viability, the response was either not as clear as that from ogerin (GANT61) or exhibited inconsistencies",0.7
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"LGK-974 (Selleckchem, catalog S7143)",genetic_reagent,Efficacy,Exhibited inconsistencies among different cNF-derived cells and showed no effect on proliferation,Results,"For GANT61 and LGK974...exhibited inconsistencies among different cNF-derived cells (LGK974)...For GANT61 and LGK974, responses were either with no effect (LGK974)",0.7
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,DhhCre mice,animal_model,Biomarker,"Cenpf expression was significantly increased in GEM-PNST compared to PST (p=0.0035), but was not significant compared to NF (p=0.1126)",Results,"In the DhhCre model, Cenpf expression was significantly increased in GEM-PNST compared to PST (p=0.0035), but was not significant compared to NF (p=0.1126)",0.95
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,Nf1flox/flox;PostnCre+ mice,animal_model,Biomarker,Cenpf expression demonstrated upregulation in MPNST compared to both PNF (p=0.0647) and ANNUBP (p=0.0783) but not achieving significance,Results,"Cenpf expression demonstrated upregulation in MPNST compared to both PNF (p=0.0647) and ANNUBP (p=0.0783) in the PostnCre model, though not achieving significance",0.9
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,Nf1flox/flox;Arf flox/flox;PostnCre+ mice,animal_model,Biomarker,Robust expression of Birc5 observed in GEM-PNST/MPNST arising in this model,Results,We observed robust expression of Birc5 in GEM-PNST/MPNST arising in both models,0.85
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,"CD31 antibody (3528S, Cell Signaling)",antibody,Biomarker,Immunohistochemical staining demonstrated a significant increase in tumor vascularity in MPNST,Results,"Immunohistochemical staining for CD31 positive blood vessels across PNF, ANNUBP, and MPNST in our dataset was consistent with these findings, demonstrating a significant increase in tumor vascularity in MPNST",0.9
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,"Survivin antibody (MA5-15077, Invitrogen)",antibody,Biomarker,IHC analysis confirmed an increase in the percentage of BIRC5 positive cells in MPNST relative to PNF,Results,IHC analysis independently confirmed an increase in the percentage of BIRC5 positive cells in MPNST relative to PNF,0.9
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,"CENPF antibody (PA5-84637, Invitrogen)",antibody,Biomarker,Immunohistochemical staining confirmed elevated CENPF protein expression in ANNUBP and a marked increase in CENPF in MPNST as compared to both PNF and ANNUBP,Results,Immunohistochemical staining confirmed elevated CENPF protein expression in ANNUBP and a marked increase in CENPF in MPNST as compared to both PNF and ANNUBP,0.95
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,"H3K27me3 antibody (9733S, Cell Signaling)",antibody,Biomarker,4 out of 6 MPNSTs were negative for H3K27Me3 staining by immunohistochemistry,Results,4 out of 6 MPNSTs were negative for H3K27Me3 staining by immunohistochemistry,0.95
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,ST-8814 cell line,cell_line,Efficacy,"Significant reduction in cell viability with BIRC5 inhibitors YM155 and LQZ-7I, with minimal effect on wild-type and NF1 mutant Schwann cells",Results,"observed a significant reduction in cell viability with both drugs in human MPNST and murine MPNST precursor ecell lines, with minimal effect on the viability of human wild-type and NF1 mutant Schwann cells",0.9
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,JH-2-002 cell line,cell_line,Efficacy,"Significant reduction in cell viability with BIRC5 inhibitors YM155 and LQZ-7I, and siRNA-mediated depletion of CENPF or BIRC5 impaired viability",Results,siRNA-mediated depletion of CENPF or BIRC5 impaired viability of human MPNST cell lines,0.9
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,hTERT ipn02.3 2λ cell line,cell_line,Efficacy,Minimal effect on cell viability with BIRC5 inhibitors YM155 and LQZ-7I compared to MPNST cell lines,Results,with minimal effect on the viability of human wild-type and NF1 mutant Schwann cells,0.85
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,hTERT NF1 ipNF95.6 cell line,cell_line,Efficacy,Minimal effect on cell viability with BIRC5 inhibitors YM155 and LQZ-7I compared to MPNST cell lines,Results,with minimal effect on the viability of human wild-type and NF1 mutant Schwann cells,0.85
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,nCounter Sprint Profiler,computational_tool,Other,"Used for spatially restricted, multiplexed quantification of gene expression across 770 genes from tumors across the neurofibroma to MPNST continuum",Results,"subjected to RNA expression profiling across a high-content panel of 770 genes involved in tumor progression, microenvironment, and immune response (PanCancer IO360™ Panel, NanoString Technologies, Inc.)",0.9
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",Illumina Infinium HumanMethylationEPIC (EPIC) array,computational_tool,Biomarker,Demonstrated robust separation between SWNs and neurofibromas in DNA methylome profiling,Results,Our DNA methylome profiling demonstrated a robust separation between SWNs and neurofibromas,0.85
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",Illumina Infinium HumanMethylationEPIC (EPIC) array,computational_tool,Biomarker,"No clear separation between SWNTS-SWNs and NS-SWNs, suggesting same cell of origin",Results,"there was no clear separation between SWNTS-SWNs and NS-SWNs, suggesting that they arise from the same cell of origin",0.85
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",Illumina Infinium HumanMethylationEPIC (EPIC) array,computational_tool,Biomarker,SWNTS-SWNs from extremities separated from other anatomic locations,Results,SWNTS-SWNs from extremities (arms and legs) were separated from other anatomic locations,0.85
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",ConsensusClusterPlus,computational_tool,Biomarker,Generated four stable clusters of SWNTS-SWNs specifically associated with anatomic location of tumors,Results,"Consensus clustering...of SWNTS-SWNs alone generated four stable clusters, which were specifically associated with the anatomic location of tumors",0.9
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",MuTect1,computational_tool,Biomarker,"Detected low tumor mutation burden: SWNTS-SWNs (WES = 0.17/Mb or 5.92/sample, WGS = 0.23/Mb or 8.81/sample)",Results,"SWNTS-SWNs displayed a similar TMB: SWNTS-SWNs (WES = 0.17/Mb or 5.92/sample, WGS = 0.23/Mb or 8.81/sample)",0.95
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",Strelka,computational_tool,Biomarker,Identified NF2 gene as only recurrent driver somatic mutation with 83% of SWNTS-SWNs harboring mutations and copy number loss,Results,NF2 gene was the only recurrent driver somatic mutation in all SWNs with interestingly a statistically significant higher proportion of SWNTS-SWNs harboring mutations and copy number loss in NF2 compared to NS-SWNs (83% vs. 58%),0.95
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",Sequenza,computational_tool,Biomarker,"Detected higher fraction of genome altered (CNV) in SWNTS-SWNs (WES = 5.97%, WGS = 2.40%) compared with NS-SWNs (WES = 0.86%)",Results,"overall higher fraction of genome altered (CNV) in SWNTS-SWNs (WES = 5.97%, WGS = 2.40%) compared with NS-SWNs (WES = 0.86%, Student's t test, p = 0.005)",0.95
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",FusionCatcher,computational_tool,Biomarker,"Detected SH3PXD2A-HTRA1 gene fusion in 14% of SWNTS-SWNs with male predominance (14/22, 63%)",Results,"Using RT-PCR we detected this fusion in SWNTS-SWNs (14%), consistently with a male predominance (14/22, 63%)",0.9
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",DESeq2,computational_tool,Biomarker,"Identified upregulated pathways in SWNTS-SWNs including PIGF, VEGF, MEK, ERBB2, and SHH, while RB was highest scoring downregulated pathway",Results,"majority of upregulated pathways in SWNTS-SWNs relative to NS-SWNs included PIGF, VEGF, MEK, ERBB2, and SHH, while RB was the highest scoring downregulated pathway",0.9
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",CIBERSORT,computational_tool,Biomarker,"SWNTS-SWNs displayed statistically higher proportion of naïve B cells, plasma cells, and activated NK cells, but lower number of total macrophages and CD8+ T cells compared to NS-SWNs",Results,"SWNTS-SWNs displayed a statistically higher proportion of naïve B cells, plasma cells, and activated natural killer (NK) cells, but lower number of total macrophages and CD8+ T cells compared to NS-SWNs",0.9
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",CIBERSORT,computational_tool,Biomarker,Painful SWNTS-SWNs consisted of statistically higher proportion of total mast cells,Results,"painful SWNTS-SWNs consisted of a statistically higher proportion of total mast cells (Student's t test, p < 0.01)",0.9
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,Nf1flox/mut; GFAP-Cre (FMC) mice,animal_model,Efficacy,~90% of FMC mice form low-grade gliomas within the prechiasmatic optic nerves and chiasms by 3 months of age,Results,"By 3 months of age, ~90% of FMC mice form low-grade gliomas within the prechiasmatic optic nerves and chiasms, characterized by increased proliferation, microglia infiltration, nuclear atypia, cellular pleiomorphism, axonal damage, and retinal ganglion cell death",0.95
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,Nf1flox/mut; Olig2-Cre (FMOC) mice,animal_model,Efficacy,FMOC mice had larger optic nerve volumes relative to control littermates at 3 months of age but no evidence for glioma formation,Results,"While Nf1flox/mut; Olig2-Cre (FMOC) mice had larger optic nerve volumes relative to control littermates at 3 months of age, in striking contrast to FMC optic nerves, there was no evidence for glioma",0.9
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,Nf1flox/mut; Olig2-Cre (FMOC) mice,animal_model,Efficacy,"At 6 months of age, FMOC mice showed 1.8-fold increase in Iba1+ microglia and 5.7-fold increase in Ki67+ cells, indicating glioma formation",Results,"there was now a 1.8-fold increase in the percent of Iba1+ microglia and a 5.7-fold increase in the percent of Ki67+ cells relative to controls, indicating glioma",0.95
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,Nf1flox/mut; Prom1-CreER (FMPrC) mice,animal_model,Efficacy,"At 3 months of age, FMPrC mice had increased optic nerve volumes, percentages of Iba1+ cells, and percentages of Ki67+ cells, similar to FMC mice",Results,"At 3 months of age, FMPrC mice had increased optic nerve volumes, percentages of Iba1+ cells, and percentages of Ki67+ cells, similar to that observed with FMC mice",0.9
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,tamoxifen,genetic_reagent,Mechanistic,"Tamoxifen injection at E15 in Prom1-CreER mice enabled Nf1 loss in CD133+ neural progenitor/stem cells, resulting in glioma formation by 3 months",Results,"we generated Nf1flox/mut; Prom1-CreER (FMPrC) mice for tamoxifen and progesterone injection at E15. At 3 months of age, FMPrC mice had increased optic nerve volumes, percentages of Iba1+ cells, and percentages of Ki67+ cells",0.9
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,progesterone,genetic_reagent,Mechanistic,"Progesterone injection at E15 with tamoxifen in Prom1-CreER mice enabled Nf1 loss in CD133+ neural progenitor/stem cells, resulting in glioma formation by 3 months",Results,"we generated Nf1flox/mut; Prom1-CreER (FMPrC) mice for tamoxifen and progesterone injection at E15. At 3 months of age, FMPrC mice had increased optic nerve volumes, percentages of Iba1+ cells, and percentages of Ki67+ cells",0.9
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,GFAP-Cre mice,animal_model,Mechanistic,GFAP-Cre mice give rise to S100β+ glia and GFAP+ astrocytes but do not generate Olig2+ cells,Results,"Similar to the GFAP-Cre mice used to generate FMC optic gliomas, Olig2-Cre mice also give rise to S100β+ glia and GFAP+ astrocytes. The fact that the GFAP-Cre transgene does not generate Olig2+ cells suggests that the cells of origin for FMOC optic gliomas are distinct",0.9
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,"B6-Olig2tm2(TVA,cre)Rth/J",animal_model,Mechanistic,Olig2-Cre transgene was expressed by E12 and gives rise to S100β+ glia and GFAP+ astrocytes,Results,"the Olig2-Cre transgene was expressed by E12, similar to previously-employed Nf1 optic glioma GEM models, labeling cells along the lateral and third ventricles where Sox2+ progenitors reside",0.9
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Nf1flox/flox;PostnCre+ mice,animal_model,Efficacy,Begin to acquire Schwann cell hyperplasia at approximately 4-6 weeks of age prior to pNF formation,Results,Nf1 flox/flox ;PostnCre+ mice begin to acquire Schwann cell hyperplasia at approximately 4–6 weeks of age prior to the formation of multiple pNFs.,0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Nf1flox/flox;PostnCre+ mice,animal_model,Efficacy,Uniformly acquire multiple pNFs by four months of age,Results,Nf1 flox/flox ;PostnCre+ mice uniformly acquire multiple pNFs by four months of age.,0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Nf1flox/flox;PostnCre+ mice,animal_model,Efficacy,Tumor number ranged from 0-22 in water/vehicle-treated mice and 0-20 in ketotifen-treated mice at seven months,Results,Tumor number ranged from 0–22 in water/vehicle-treated Nf1 flox/flox ;PostnCre+ mice and 0–20 in the ketotifen-treated Nf1 flox/flox ;PostnCre + mice at seven months.,0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Ketotifen fumarate,genetic_reagent,Efficacy,10 mg/kg treatment from 5-6 weeks to 4 months showed no difference in nerve hyperplasia compared to vehicle,Results,Nf1 flox/flox ;PostnCre+ mice (n = 6) were treated with 10 mg/kg of ketotifen from 5–6 weeks post-natal...there was no difference in nerve hyperplasia between the treatment and water/vehicle-treated,0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Ketotifen fumarate,genetic_reagent,Efficacy,Did not reduce the number of mast cells infiltrating nerve tissue,Results,"ketotifen treatment did not reduce the number of mast cells infiltrating nerve tissue ( Figure 1C and 1D , ns)",0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Ketotifen fumarate,genetic_reagent,Efficacy,Did not reduce the percentage of degranulating mast cells,Results,"nor did it reduce the percentage of degranulating mast cells ( Figure 1C and 1E , ns).",0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Ketotifen fumarate,genetic_reagent,Efficacy,No statistical difference in proximal nerve root volume or tumor number between ketotifen (n=14) and vehicle-treated (n=14) groups,Results,"There was no statistical difference in proximal nerve root volume ( Figure 2B , ns) or tumor number ( Figure 2C , ns) between ketotifen (n = 14) and water/vehicle-treated (n = 14)",0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Ketotifen fumarate,genetic_reagent,Biomarker,"Maximum plasma concentration was 40 ng/mL, AUC 0-∞ 119 ng/mL·h, and t½ 29.9 hours after single 10 mg/kg dose",Results,"After a single dose of ketotifen at 10 mg/kg...the maximum plasma concentration was 40 ng/mL, AUC 0−∞ 119 ng/mL·h, and t ½ 29.9 hours",0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Ketotifen fumarate,genetic_reagent,Biomarker,"Mean concentration in nerve tissue was 14.56 ng/g at 4 hours, below quantification level at 24 hours",Results,"At four hours, the mean concentration of ketotifen in all nerves measured was 14.56 ng/g of nerve tissue...while at 24 hours the concentration of ketotifen in all nerve tissue samples was below the level of quantification",0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Ketotifen fumarate,genetic_reagent,Safety,No significant difference in weight between vehicle-treated (n=15) versus ketotifen-treated (n=14) cohorts during 12-week treatment,Results,There was no significant difference between the vehicle-treated (n = 15) versus ketotifen-treated (n = 14) cohorts in weight.,0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Ketotifen fumarate,genetic_reagent,Mechanistic,Decreased number of infiltrating mast cells in mice receiving Kit ligand infusion (P < 0.0001) but failed to decrease percentage of degranulating mast cells,Results,"In mice receiving Kit ligand infusion, ketotifen treatment decreased the number of infiltrating mast cells when compared with water treatment ( Figure 3D , P < 0.0001). However, ketotifen treatment failed to induce a significant decrease in the percentage of degranulating mast cells",0.95
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",Kit Ligand,genetic_reagent,Mechanistic,Infusion revealed statistically significant increase in mast cell infiltrate (P < 0.0001) but had no impact on percentage of degranulating mast cells,Results,"Kit ligand infusion revealed a statistically significant increase in mast cell infiltrate ( Figure 3C and 3D , P < 0.0001). Kit ligand infusion had no impact on the percentage of degranulating mast cells relative to PBS infusion",0.95
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,"M14 (ST88-14, RRID:CVCL_8916)",cell_line,Efficacy,DAC treatment markedly suppressed MPNST tumor growth in orthotopic xenografts,Results,We observed that DAC exhibits selective antitumor activity against PRC2-loss tumors,0.85
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,"M14 (ST88-14, RRID:CVCL_8916)",cell_line,Efficacy,GSK3685032 potently inhibited orthotopic tumor growth of PRC2-loss MPNST xenograft,Results,we observed that GSK3685032 potently inhibited orthotopic tumor growth of a PRC2-loss human MPNST cell line–derived xenograft,0.9
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,M3,cell_line,Efficacy,DAC treatment showed selective antitumor activity against PRC2-WT tumors in orthotopic xenografts,Results,Growth curves over time of orthotopically transplanted human PRC2-WT (M3) and PRC2-loss (M14) cell line–derived xenografts,0.85
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,M3,cell_line,Biomarker,Enhanced sensitivity to DNMT1 knockdown in PRC2-loss setting via shRNA-linked GFP FACS-based growth competition assay,Results,Validation of increased sensitivity to DNMT1 knockdown in PRC2-loss setting via shRNA-linked GFP FACS-based growth competition assay in PRC2-isogenic MPNST cells,0.9
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,MPNST PDX-1,patient_derived_model,Efficacy,5 mg/kg DAC treatment showed fold change tumor volume reduction in subcutaneous PRC2-loss MPNST patient-derived xenograft,Results,Fold change tumor volume of subcutaneous PRC2-loss human MPNST patient-derived xenograft (PDX-1) treated with 5 mg/kg DAC or vehicle control,0.9
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,Eed f/f mice,animal_model,Efficacy,Enhanced sensitivity to DNMTi in PRC2-loss (Eed−/−) compared with PRC2-intact (Eedf/−) murine MPNST cells,Results,we observed enhanced sensitivity to DNMTi in PRC2-loss (Eed−/−) compared with PRC2-intact (Eedf/−) murine MPNST cells,0.9
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,"CB-17 SCID mice (Taconic, RRID:IMSR_TAC:cb17sc)",animal_model,Efficacy,DAC treatment showed selective antitumor activity in orthotopically transplanted human MPNST xenografts,Results,Growth curves over time of orthotopically transplanted human PRC2-WT (M3) and PRC2-loss (M14) cell line–derived xenografts (CDX) in CB-17 SCID mice treated with DAC,0.9
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,HiTSelect,computational_tool,Other,"Used to rank each set of five shRNAs per gene in the library across all cell lines for depletion analysis, identifying DNMT1-specific shRNAs among top 10 statistically significant candidates",Results,we used HiTSelect to rank each set of five shRNAs per gene in the library across all cell lines in the screen for depletion,0.95
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,MSK-IMPACT,clinical_assessment_tool,Biomarker,Used to authenticate complete PRC2 inactivation in five of seven (~71%) MPNST cell lines,Results,five of seven (∼71%) cell lines had complete PRC2 inactivation by Memorial Sloan Kettering-Integrated Mutation Profiling of Actional Cancer Targets (MSK-IMPACT),0.95
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,MSK-IMPACT,clinical_assessment_tool,Other,"Can be used for biomarker-driven clinical investigation of pan-DNMT– and DNMT1-targeted therapeutics in solid tumors, as PRC2 loss can be readily identified",Discussion,"PRC2 loss can be readily identified by IHC staining of H3K27me3 and FDA-approved molecular biomarker testing assays, such as Foundation One (Foundation Medicine, Inc.) or MSK-IMPACT",0.85
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipNF05.5-MX,cell_line,Efficacy,"Particularly sensitive to PD-0325901 (mirdametinib) and trametinib, and to a lesser extent, selumetinib",Results,"we show that these cells are particularly sensitive to PD-0325901 (mirdametinib) and trametinib, and to a lesser extent, selumetinib",0.85
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipNF05.5-MX,cell_line,Efficacy,Showed resistance to a panel of TOP2A inhibitors compared to control cell line,Results,"ipNF05.5-MX cells showed resistance to a panel of TOP2A inhibitors, compared to the response of the control ipnNF95.11C cell line",0.85
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipNF05.5-MX,cell_line,Efficacy,Drug resistance found for 6/7 anthracyclines,Results,"Furthermore, drug resistance was found for 6/7 anthracyclines in ipNF05.5-MX cells",0.9
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipNF05.5-MX,cell_line,Other,Individual low-concentration responses higher than 100% of DMSO control were indicative of drug-stimulated growth when treated with MEK inhibitors and doxorubicin,Results,"Individual low-concentration responses higher than 100% of the DMSO control were indicative of drug-stimulated growth, as found for ipNF05.5-MX treated with MEK inhibitors and doxorubicin",0.8
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,ipnNF95.11C,cell_line,Other,Used as reference control cell line (NF1 +/−) for drug sensitivity comparisons,Results,We assessed the drug sensitivity of ipNF05.5-MX cells (ΔS NF1 −/−) using ipnNF95.11C (NF1 +/−) as the reference cell line,0.9
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,DREA web tool,computational_tool,Other,Can be used to explore analyses of compounds and assess candidate compounds individually by cell line,Results,can be explored via the DREA web tool...DREA can be used to assess candidate compounds individually by the cell line,0.85
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,DREA web tool,computational_tool,Other,Available at https://nf.mocomakers.com and can be applied to any cancer model with high-throughput data,Discussion,"Drug Response Evaluation and Assessment (DREA) web tool (available at: https://nf.mocomakers.com)...Given high-throughput data, the algorithm can be applied to any cancer model as needed",0.9
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,SigmaPlot,computational_tool,Other,"Used for statistical analysis with Pearson product-moment correlation to compare outcomes from ΔS, ΔpAC50, and ΔpAUC",Results,"the Pearson product-moment correlation was used to compare outcomes from ΔS, ΔpAC50, and ΔpAUC",0.8
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Plp-Cre,genetic_reagent,Mechanistic,Successfully induced oligodendrocyte-specific Nf1 deletion when crossed with Nf1 fl/+ mice following tamoxifen treatment,Results,Oligodendrocyte-specific Nf1 deletion was achieved by crossing of Plp-Cre and Nf1 fl/+ mice. Plp-Nf1 fl/+ and littermate animals received a 3-d tamoxifen treatment (twice daily) to induce the deletion,0.95
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Nf1 fl/+,genetic_reagent,Behavioral,"Plp-Nf1 fl/+ mice showed impaired initial motor coordination (U = 42, P = 0.006) but normal learning rate (U = 73, P = 0.17) on rotarod test",Results,"Plp-Nf1 fl/+ mice showed reduced initial motor coordination (U = 42, P = 0.006) but a normal learning rate (U = 73, P = 0.17)",0.95
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Nf1 fl/+,genetic_reagent,Biomarker,"Plp-Nf1 fl/+ mice showed widespread reduction in fractional anisotropy (FA) across the brain, with recovery to control levels in 6 out of 7 regions after L-NAME treatment",Results,"We observed a reliable recovery of FA to control levels in six out of seven regions including the brachium of superior colliculus (Z = 2.31, P = 0.01), fasciculus reticulata (Z = 2.03, P = 0.02)",0.95
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Nf1 fl/+,genetic_reagent,Biomarker,"Plp-Nf1 fl/+ mice showed reduced interhemispheric connectivity (U = 15, P = 0.037) that was rescued by L-NAME administration (Z = 2.134, P = 0.033)",Results,"Plp-Nf1 fl/+ mice showed reduced interhemispheric connectivity (Mann–Whitney U test: U = 15, P = 0.037). This reduced connectivity was rescued by L-NAME administration (Wilcoxon signed-rank test: Z = 2.134, P = 0.033)",0.95
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Rotarod,clinical_assessment_tool,Behavioral,"Detected significant genotype differences with main effects of genotype (F 1,27 = 6.3, P = 0.018), time (F 1,27 = 38.4, P < 0.001), and interaction (F 1,27 = 4.65, P = 0.04)",Results,"Repeated-measures ANOVA showed main effects of genotype (F 1,27 = 6.3, P = 0.018), time (F 1,27 = 38.4, P < 0.001), and interaction (F 1,27 = 4.65, P = 0.04)",0.95
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,BioSpec 94/20 USR MRI,computational_tool,Biomarker,"Successfully detected widespread FA reductions and functional connectivity changes in Plp-Nf1 fl/+ mice, with rescue effects measurable after L-NAME treatment",Results,We scanned controls and Plp-Nf1 fl/+ mice using DTI. We calculated and coregistered FA maps of each animal onto a common atlas and then compared the genotypes with a whole-brain voxel-based two-sample Student's t test,0.9
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,ExplorDTI,computational_tool,Biomarker,Enabled quantification of fractional anisotropy changes and detection of recovery in white matter integrity following treatment,Results,We calculated and coregistered FA maps of each animal onto a common atlas and then compared the genotypes with a whole-brain voxel-based two-sample Student's t test,0.85
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Advanced Normalization Tools (ANTs),computational_tool,Other,Successfully performed image registration and normalization for brain-wide analysis of structural and functional connectivity data,Results,We calculated and coregistered FA maps of each animal onto a common atlas,0.8
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,Allen Brain Atlas,computational_tool,Other,"Provided anatomical reference framework for identifying and quantifying changes in specific white matter regions including corpus callosum, internal capsule, and other structures",Results,We focused on selected white matter tracts as regions of interest (ROIs) to quantify effects,0.8
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,NF Research Tools Database,computational_tool,Other,Database enables interactive exploration and filtering of NF1-relevant research tools through clickable charts and free-text search functionality,Results,"From the home page, users can type in a search term of interest (e.g. 'plexiform neurofibroma'; Figure 2A) to identify NF1-relevant animal models and cell lines. From there, users can use interactive, clickable charts to further filter and refine their results",0.9
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,NF Research Tools Database,computational_tool,Other,"Tool detail pages provide comprehensive metadata including mutation information for selected genes, vendor links, and community-contributed observations",Results,"The tools listed in the database have an associated 'tool detail page' (Figure 2B) that shows additional in-depth metadata, community-contributed observations and tool-related data",0.9
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,NF Research Tools Database,computational_tool,Other,"Database successfully integrates with NF Data Portal to highlight data generated using specific research tools, enabling users to find sequencing and drug screening data",Results,"This tab highlights data in the NF Data Portal that were generated using that tool, enabling, for example, users to find sequencing data or drug screening data for a cell line listed in the database",0.9
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,schematic Python library,computational_tool,Other,Library successfully enables standardized metadata validation and data model implementation for the database,Results,"We developed documentation for the database, which is available at help.nf.synapse.org",0.7
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,Synapse collaborative science platform,computational_tool,Other,Platform successfully hosts and provides infrastructure for the NF Research Tools Database with community contribution capabilities,Results,"A core goal of this resource is to enable the community to contribute new tools and observations. We welcome any contributions for NF1, NF2 or schwannomatosis-relevant tools",0.8
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,S100 antibody,antibody,Biomarker,"Successfully identified Schwann cells in cNF organoids with extensive S100 positivity, maintaining similar staining pattern between original cNF and derived organoids",Results,"Expression of these markers is typical of the histopathology of cNF tumors. For instance, we observed extensive S100 positivity, indicative of Schwann cells",0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,CD34 antibody,antibody,Biomarker,"Identified fibroblasts showing lattice-like CD34+ fibroblastic network in cNF organoids, with 18-35% of cells being CD34+ in parental cNFs",Results,a lattice-like CD34+ fibroblastic network; and mast cells...There were variable proportions of cells in the parental cNFs...followed by CD34+ fibroblasts (18%–35%),0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,CD117/c-kit antibody,antibody,Biomarker,"Detected mast cells comprising 3-9% of cells in parental cNFs, with c-Kit+ cells hyperproliferating in DMEM conditions for most cNFs",Results,and a smaller population of c-Kit+ cells (3%–9%)...c-Kit+ cells hyperproliferated in DMEM conditions for all cNFs with the exclusion of NF0008,0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,CD56 antibody,antibody,Biomarker,"Showed CD56- staining pattern in cNF organoids, consistent with the neuronal marker expression typical of cNF histopathology",Results,"Immunohistopathology of the cNF organoids showed that the cell populations within the organoids closely matched the cells in the cNFs of origin (S100+, CD56−, CD34+, SOX2+, toluidine blue+",0.8
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,SOX2 antibody,antibody,Biomarker,"Demonstrated SOX2+ staining for dedifferentiated Schwann cells in cNF organoids, maintaining similar expression pattern to original tumors",Results,"SOX2 (dedifferentiated Schwann cells)...Immunohistopathology of the cNF organoids showed that the cell populations within the organoids closely matched the cells in the cNFs of origin (S100+, CD56−, CD34+, SOX2+, toluidine blue+",0.8
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,cNF organoids,advanced_cellular_model,Efficacy,"Successfully established from 100+ cNFs with 66% success rate from 12 patients, yielding 0.3-7.5 million cells per cNF and demonstrating exponential growth over time",Results,We processed over 100 cNFs in total; those with sizes greater than 0.5 cm were processed individually and yielded between 0.3 and 7.5 million cells/cNF,0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,cNF organoids,advanced_cellular_model,Biomarker,"Maintained high transcriptional correlation with parental tumors (Spearman's rank correlations >0.8 for all culture conditions, with StemPro showing median 0.91)",Results,"Our results showed that cNF organoids correlate strongly with the parental tumors, with calculated Spearman's rank correlations >0.8 for all culture conditions",0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,cNF organoids,advanced_cellular_model,Efficacy,"Demonstrated drug screening capability with 43 targeted kinase inhibitors, identifying 4 compounds (copanlisib, onalespib, linsitinib, digoxin) that induced ≤50% residual viability across all samples",Results,"These include copanlisib, a PI3K inhibitor; onalespib, an Hsp90 inhibitor; linsitinib, an IGF-1R inhibitor; and digoxin, an Na+/K+ ATPase inhibitor, which induced an average residual viability of ≤50% across all samples",0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,Cutaneous neurofibroma samples,patient_derived_model,Biomarker,"Showed variable cell proportions with dominant S100+ Schwann cells (19-48%), CD34+ fibroblasts (18-35%), and c-Kit+ mast cells (3-9%)",Results,"There were variable proportions of cells in the parental cNFs, with a dominant population of S100+ Schwann cells (19%–48% across samples) followed by CD34+ fibroblasts (18%–35%) and a smaller population of c-Kit+ cells (3%–9%)",0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,CellTiter-Glo 3D Reagent,clinical_assessment_tool,Biomarker,"Successfully measured organoid viability and proliferation in ATP-release assays, showing significant differences between culture conditions with StemPro demonstrating superior growth support",Results,"we seeded cells to develop organoids in a 96-well mini-ring format, incubated them for 6 days, and measured the aggregate viability as the endpoint assay via ATP release",0.9
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,MCP-Counter,computational_tool,Biomarker,"Successfully identified stromal cell subtypes including abundant fibroblasts and myeloid lineage cells in bulk transcriptome data, with proportions maintained in most cNF organoids",Results,"the method could identify the presence of abundant fibroblasts as well as cells from the myeloid lineage, in all parental cNFs and most corresponding organoids",0.8
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Efficacy,CRISPRi suppression of SUZ12 or EED attenuated selumetinib responses compared to non-targeted control sgRNAs but did not render cells insensitive to selumetinib,Results,"CRISPRi suppression of the PRC2 components SUZ12 or EED inhibited Schwann cell differentiation marker expression and attenuated selumetinib responses compared to non-targeted control sgRNAs (sgNTC), but did not render NF95.11b cells insensitive to selumetinib",0.85
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Mechanistic,"Cells showed initial repression of ERK phosphorylation and early induction of apoptosis after selumetinib treatment, followed by recovery of pERK in cells that persisted despite continued treatment",Results,"Immunoblotting of neurofibroma cell lysates after selumetinib treatment showed initial repression of ERK phosphorylation (pERK) and early induction of apoptosis (cleaved Caspase-3, cleaved Caspase-7), followed by recovery of pERK",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Efficacy,"Cells with combined loss of NF1 and NF2 were resistant to selumetinib compared to NF1-mutant, NF2-intact cells",Results,"Moreover, NF95.11b cells with combined loss of NF1 and NF2 were resistant to selumetinib compared to NF1-mutant, NF2-intact NF95.11b cells",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Mechanistic,"CRISPRi suppression of NF2 induced PAK1 phosphorylation without significantly affecting pMEK, pERK, or pAKT",Results,"CRISPRi suppression of NF2 in NF1-mutant NF95.11b neurofibroma cells induced PAK1 phosphorylation (pPAK1) without significantly affecting pMEK, pERK, or pAKT compared to sgNTC",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Mechanistic,"NF1-mutant, NF2-mutant cells maintained pERK in response to selumetinib monotherapy compared to NF1-mutant, NF2-intact cells",Results,"NF1-mutant, NF2-mutant NF95.11b cells maintained pERK in response to selumetinib monotherapy compared to NF1-mutant, NF2-intact NF95.11b cells",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,NF95.11b,cell_line,Mechanistic,Combination treatment with selumetinib and NVS-PAK1-1 showed greater initial repression of pERK and sustained repression of pPAK1,Results,"Moreover, combination treatment with selumetinib and NVS-PAK1-1 showed greater initial repression of pERK and sustained repression of pPAK1 after compared to control NF95.11b cells",0.85
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,ST88-14,cell_line,Efficacy,PRC2-mutant ST88-14 MPNST cells demonstrated resistance to selumetinib compared to PRC2-intact cells,Results,PRC2-mutant ST88-14 MPNST cells demonstrated resistance to selumetinib compared to PRC2-intact cells,0.85
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,ST88-14,cell_line,Biomarker,"High pPAK1 was observed in NF1-mutant, SUZ12-mutant ST88-14 MPNST cells independent of CRISPRi suppression of NF2",Results,"High pPAK1 was observed in NF1-mutant, SUZ12-mutant ST88-14 MPNST cells independent of CRISPRi suppression of NF2",0.85
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,JW23.3,animal_model,Efficacy,Combination molecular therapy with selumetinib and NVS-PAK1-1 additively inhibited allograft growth compared to vehicle or monotherapy,Results,combination molecular therapy additively inhibited JW23.3 and JW18.2 allograft growth compared to vehicle or selumetinib or NVS-PAK1-1 monotherapy,0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,JW18.2,animal_model,Efficacy,Combination molecular therapy with selumetinib and NVS-PAK1-1 additively inhibited allograft growth compared to vehicle or monotherapy,Results,combination molecular therapy additively inhibited JW23.3 and JW18.2 allograft growth compared to vehicle or selumetinib or NVS-PAK1-1 monotherapy,0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,JW23.3,animal_model,Biomarker,Proliferating tumor cells and Nf2 expression were reduced in MPNST allografts after selumetinib compared to vehicle control treatment,Results,"Moreover, proliferating tumor cells (Fig. 2e) and Nf2 (Fig. 2f) were reduced in JW23.3 MPNST allografts after selumetinib compared to vehicle control treatment",0.9
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,CellTiter 96 Non-Radioactive Cell Proliferation Assay,clinical_assessment_tool,Other,"Used to assess cell viability after 48 h of 1 μM selumetinib treatment, normalized to vehicle control treatments",Results,Cell viability after 48 h of 1 μM selumetinib treatment was assessed using MTT assays and normalized to vehicle control treatments for each cell line,0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,Periostin-CRE;NF2 fl/fl,animal_model,Efficacy,73% and 52% decrease in tumor cell proliferation in VG with VT1 and VT2 treatment respectively,Results,"Both VT1 and VT2 showed significant decreases in tumour cell proliferation (73% and 52%, respectively) within the VG",0.95
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,Periostin-CRE;NF2 fl/fl,animal_model,Efficacy,Significant reductions in tumor volume in VG and DRG with VT1 or VT2 treatment in 9-month-old animals,Results,We observed significant reductions in tumour volume in VT1- or VT2-treated animals,0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,Periostin-CRE;NF2 fl/fl,animal_model,Safety,No apparent side effects or weight loss in animals treated with VT1 and VT2,Results,"There were no apparent side effects or weight loss in animals, as in their previous use",0.85
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,NF2 fl/fl YAP fl/fl -CRE+,animal_model,Efficacy,Significant reduction in cell proliferation in both DRG and VG tumor sites compared to NF2 single null,Results,loss of either YAP or TAZ significantly reduced cell proliferation; although loss of either YAP or TAZ seemingly had a greater effect on proliferation in the VG than the DRG,0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,NF2 fl/fl TAZ fl/fl -CRE+,animal_model,Efficacy,Significant reduction in cell proliferation in both DRG and VG tumor sites compared to NF2 single null,Results,loss of either YAP or TAZ significantly reduced cell proliferation; although loss of either YAP or TAZ seemingly had a greater effect on proliferation in the VG than the DRG,0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,BenMen-1,cell_line,Efficacy,Proliferation reduced by ALDH1A1-specific inhibitor in dose-dependent manner,Results,use of an ALDH1A1-specific inhibitor slowed the proliferation of BenMen-1 meningioma cells,0.85
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,BenMen-1,cell_line,Efficacy,Strong synergistic effects of cisplatin and ALDH1A1 inhibitor combination on proliferation reduction,Results,"Either reagent alone reduced BenMen-1 cell proliferation, but the combination was strongly synergistic in reducing cell proliferation",0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,ALDH1A1 shRNA (TRCN0000026415),genetic_reagent,Efficacy,Significantly reduced cell proliferation in BenMen-1 meningioma cells,Results,"Loss of either ALDH1A1 or TAZ both significantly reduced cell proliferation, but knockdown of TAZ was more effective",0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,TAZ shRNA (TRCN0000307197),genetic_reagent,Efficacy,Significantly reduced schwannoma cell proliferation and was more effective than ALDH1A1 knockdown in meningioma cells,Results,Knockdown of either YAP or TAZ significantly reduced schwannoma cell proliferation,0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,YAP shRNA (TRCN0000107266),genetic_reagent,Efficacy,Significantly reduced schwannoma cell proliferation,Results,Knockdown of either YAP or TAZ significantly reduced schwannoma cell proliferation,0.9
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,YAP shRNA (TRCN0000107266),genetic_reagent,Mechanistic,Knockdown of YAP reduced TAZ expression in primary schwannoma cells,Results,"while knockdown of TAZ did not affect YAP expression, knockdown of YAP did reduce TAZ in primary schwannoma cells",0.9
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,WAIS-III,clinical_assessment_tool,Behavioral,"NF1 group showed significantly inferior performance compared to controls in full scale IQ (91.19 ± 15.28 vs 107.81 ± 5.64, p=0.003, d=1.38)",Results,"The NF1 group had a significantly inferior performance compared to controls in intelligence (full scale IQ) and verbal short-term memory (i.e., Digit Span forward) tests.",0.95
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,WISC-III,clinical_assessment_tool,Behavioral,"NF1 group showed significantly inferior performance compared to controls in full scale IQ (91.19 ± 15.28 vs 107.81 ± 5.64, p=0.003, d=1.38)",Results,"The NF1 group had a significantly inferior performance compared to controls in intelligence (full scale IQ) and verbal short-term memory (i.e., Digit Span forward) tests.",0.95
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,Nine-Hole Peg Test,clinical_assessment_tool,Behavioral,"Medium effect size differences observed in dexterity measures (dominant hand: 0.89 ± 0.30 vs 0.79 ± 0.23, d=-0.38)",Results,"Group differences with medium effects were observed in measures of dexterity (9HPT dominant hand), visuoconstructive abilities (ROCF copy)",0.85
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,Rey-Osterrieth Complex Figure Test,clinical_assessment_tool,Behavioral,"Medium effect differences in visuoconstructive abilities (copy: 26.81 ± 8.36 vs 30.38 ± 6.21, d=0.50) and immediate recall (12.94 ± 9.14 vs 17.94 ± 6.83, d=0.64)",Results,"Group differences with medium effects were observed in measures of dexterity (9HPT dominant hand), visuoconstructive abilities (ROCF copy), short-term verbal and visual episodic memory",0.85
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,Rey Auditory-Verbal Learning Test (RAVLT),clinical_assessment_tool,Behavioral,"Medium effect differences in immediate recall (A6: 8.31 ± 2.57 vs 10.06 ± 3.60, d=0.58) and small differences in delayed recall (A7: 8.63 ± 2.50 vs 9.06 ± 3.00, d=0.16)",Results,Group differences with medium effects were observed in measures of...short-term verbal and visual episodic memory (immediate recalls of RAVLT and ROCF),0.85
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,Five Digits Test (FDT),clinical_assessment_tool,Behavioral,"Small differences between groups in automatic (Part 1-Decoding: 26.81 ± 7.09 vs 25.44 ± 8.73, d=-0.18) and controlled attention processes (Part 3-Inhibiting: 52.19 ± 14.53 vs 53.19 ± 23.93, d=0.00)",Results,Small differences between NF1 patients and the control group were noticed in...automatic (FDT-Decoding) and controlled (FDT-Inhibiting) attention processes,0.85
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,Corsi block-tapping task,clinical_assessment_tool,Behavioral,"Medium effect differences in visual working-memory (forward: 38.13 ± 21.28 vs 45.75 ± 16.72, d=0.41; backward: 20.38 ± 21.36 vs 36.81 ± 32.44, d=0.62)",Results,Group differences with medium effects were observed in measures of...visual working-memory (Corsi Block-Tapping Test forward and backward),0.85
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,Tower of London Test,clinical_assessment_tool,Behavioral,"Small differences in planning abilities (28.69 ± 3.91 vs 29.56 ± 3.16, d=0.25)",Results,Small differences between NF1 patients and the control group were noticed in...planning (Tower of London),0.85
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,Statistical Parametric Mapping toolbox (SPM8),computational_tool,Other,Used for processing brain metabolism images to reduce age effects on metabolism measured at each voxel,Discussion,We started by processing images in order to reduce the effect of age on the metabolism measured at each voxel. This step is important because the impact of age must be taken into account,0.8
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,kernlab R library,computational_tool,Other,Achieved significant correlation of r=0.926 (p<0.001) between observed and predicted values for PC1 using Gaussian Process Regression,Results,"Only the first component (PC1) showed a significant correlation between observed and predicted values (r = 0.926, p<0.001)",0.95
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,GE Discovery 690,clinical_assessment_tool,Other,Used for 18F-FDG PET/CT imaging during resting state to measure metabolic activity of the brain in relationship to cognitive abilities,Discussion,"we aimed to investigate the relationship between the metabolic activity of the brain, as measured by 18F-FDG PET/CT imaging during resting state, and cognitive abilities in NF1 patients",0.9
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,MultiPLIER,computational_tool,Mechanistic,Quantified expression of 962 latent variables (LVs) in all 77 samples using gene expression data and reduced batch effects with significantly reduced within-cluster distances (p-value = 2.1 × 10^-182),Results,"This analysis quantified the expression of 962 latent variables (LVs) in all 77 samples using their gene expression data... within-cluster distances were significantly reduced (p-value = 2.1 × 10^-182, Wilcoxon test)",0.95
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,randomforest,computational_tool,Efficacy,"Achieved median accuracy scores of cNF = 0.97, MPNST = 0.67, NF = 0.67, pNF = 0.57 with full feature set, improved to cNF = 1.00, MPNST = 0.86, NF = 0.86, pNF = 0.75 with top 98 LVs",Results,"median accuracy scores: cNF = 0.97, MPNST = 0.67, NF = 0.67, pNF = 0.57... Using the top 40 set of LVs... median accuracy scores: cNF = 1.00, MPNST = 0.86, NF = 0.86, pNF = 0.75",0.95
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,CIBERSORT,computational_tool,Biomarker,"Deconvolution indicated presence of activated mast cells and M2 macrophages in all tumor types, and population of resting CD4+ memory T cells across all tumors",Results,CIBERSORT deconvolution indicated the presence of activated mast cells and M2 macrophages in all tumor types... all of the tumors have a population of resting CD4+ memory T cells,0.9
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,MCP-counter,computational_tool,Biomarker,Identified presence of cancer-associated fibroblasts across all tumors that were not captured in CIBERSORT analysis,Results,we found the presence of cancer-associated fibroblasts across all tumors that were not captured in CIBERSORT,0.9
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,metaVIPER,computational_tool,Mechanistic,Assigned numerical scores of activity across 6168 proteins for each of the 77 samples to identify protein activity measurements correlated with latent variable expression,Results,to assign numerical scores of activity across 6168 proteins for each of the 77 samples... We then measured the correlation of these scores and latent variable scores,0.9
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,Drug Target Explorer database,computational_tool,Mechanistic,"Enabled identification of drugs and drug-like compounds significantly enriched for targets in protein activity clusters, including clinically approved drugs like dovitinib and cell cycle compounds like dinaciclib and abemaciclib",Results,"This enabled the identification of drugs and drug-like compounds that are significantly enriched for targets in each cluster... has correlated VIPER proteins that are enriched for both clinically approved drugs (dovitinib)... cluster 3 was enriched for compounds that affect cell cycle progression (e.g., dinaciclib, abemaciclib)",0.85
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,U251,cell_line,Efficacy,"U251-S subpopulation was highly tumorigenic compared to U251-R cells (p<0.01), which were not able to generate tumors. Tumors were significantly larger in U251-S than U251p (p<0.05)",Results,"Consistent with our in vitro studies, the U251-S subpopulation was highly tumorigenic compared to U251-R cells (p<0.01), which were not able to generate tumors. Of note, tumors were significantly larger in U251-S than U251p",0.95
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,U251,cell_line,Mechanistic,"U251-S cells showed 70% Ki67-positive cells at high confluence (p<0.01) compared to U251-R (33%) and astrocytes (41%), indicating defective cell-contact inhibition",Results,"the percentage of Ki67-positive cells was higher in U251-S cells at high confluence (70%, p<0.01) compared to U251-R and astrocytes (33% and 41%, respectively",0.92
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,siRNA SMARTpool (Thermo Scientific),genetic_reagent,Mechanistic,Achieved 93% decrease in Merlin mRNA (p<0.001) and 100% decrease in protein levels,Results,"After achieving 93% decrease in mRNA (Figure 7c, p<0.001) and 100% decrease in protein (Figure 7d)",0.95
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,S518A pXJ40-HA-Merlin,genetic_reagent,Efficacy,"Tumor growth was abrogated in cells transfected with Merlin-S518A, while cells treated with Merlin-S518wt generated tumors (p<0.05)",Results,"However, tumor growth was abrogated in cells transfected with Merlin-S518A. Conversely, cells treated with Merlin-S518wt generated tumors (Figure 9, p<0.05)",0.95
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,S518A pXJ40-HA-Merlin,genetic_reagent,Mechanistic,"Caused significant decrease in Notch1 and EGFR proteins, and decrease in Hes1 (p<0.001) with slight increase in Ccnd1 mRNA (p<0.05)",Results,"we detected a significant decrease in Notch1 and EGFR proteins...found a decrease in Hes1 and a slight increase in Ccnd1 mRNA content (Figure 7f, p<0.001 and p<0.05 respectively)",0.92
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,rabbit anti S518-Merlin (Abcam),antibody,Mechanistic,"Detected S518-Merlin particularly enriched in the nucleus, with cell cycle-dependent nuclear enrichment in early G1 phase and nuclear punctuated localization in S and late G2 phases",Results,S518-Merlin was particularly enriched in the nucleus...S518-Merlin mainly localized in the nucleus in early G1 phase...S518-Merlin had a nuclear punctuated localization in S and late G2 phases,0.88
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,IPA-3 (Sigma-Aldrich),genetic_reagent,Efficacy,Treatment resulted in 47% decrease in cell proliferation and marked decrease in S518 phosphorylation without affecting overall Merlin levels,Results,"MTT assays were performed in U251-S cells exposed to IPA-3, resulting in a significant decrease (47%) in cell proliferation...a marked decrease in S518 phosphorylation was observed, without however affecting overall Merlin levels",0.92
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,IPA-3 (Sigma-Aldrich),genetic_reagent,Mechanistic,"Caused significant decrease in S518-Merlin, Notch1 and EGFR signal intensity (p<0.05) and significant decrease of Hes1 and cyclin D1 mRNA levels (p<0.05)",Results,"The quantification of fluorescence intensity confirmed results significance (Figure 6b, p<0.05)...We detected a significant decrease of both genes when S518-Merlin was dephosphorylated in cells treated with PAK inhibitor (Figure 7b, P<0.05)",0.92
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,Co-IP kit (Thermo Scientific),genetic_reagent,Mechanistic,Demonstrated that EGFR and S518-Merlin directly associated while no interaction was found with Notch1,Results,EGFR and S518-Merlin directly associated while no interaction was found in the presence of Notch1 (Figure 8e),0.9
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,Vybrant® MTT cell proliferation assay kit (Life Technologies),genetic_reagent,Efficacy,Showed 47% decrease in cell proliferation in U251-S cells exposed to IPA-3,Results,"MTT assays were performed in U251-S cells exposed to IPA-3, resulting in a significant decrease (47%) in cell proliferation",0.92
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,PredictProtein,computational_tool,Mechanistic,"Predicted features for theoretical effect of skipping each exon on resulting Merlin protein, with 7 candidate exons showing high conservation score >6.5, 3 predicted to induce high change of surface area, and 5 showing several phosphorylation sites",Results,"Next, we annotated Merlin protein post-translational modifications and the theoretical effect of skipping for each exon (or consecutive exons) in the resulting Merlin protein by PredictProtein",0.8
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,25-mer-specific PMOs,genetic_reagent,Efficacy,"Full skipping of exons 4 and 8 achieved at 20 μM at 24h, 48h, and 72h timepoints",Results,"Dose-response and time-course studies confirmed the efficiency of the PMO treatment at RNA level, showing full skipping of exons 4 and 8 at 20 μM at 24 h, 48 h, and 72 h",0.9
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,25-mer-specific PMOs,genetic_reagent,Efficacy,"For exon 11, maximum skipping effect observed at highest tested dose (40 μM), achieving more than 50% of the exon-less form after 72h of treatment",Results,"for the second design (PMO_ES11_v2), the maximum skipping effect observed was at the highest tested dose (40 μM), achieving more than 50% of the exon-less form after 72 h of treatment",0.9
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,25-mer-specific PMOs,genetic_reagent,Mechanistic,"Merlin-e4 and Merlin-e8 showed little or no expression, indicating these forms could not be synthesized or were degraded shortly after synthesis",Results,"Flag-Merlin western Blot showed that there was little or no expression of Merlin-e4 or Merlin-e8, indicating that these Merlin forms could not be synthesized or were degraded shortly after synthesis",0.9
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,25-mer-specific PMOs,genetic_reagent,Biomarker,Skipping of exon 11 generated shorter isoform Merlin-e11 and quantification showed slight increase in total levels of Merlin (WT Merlin and Merlin-e11),Results,"the skipping of exon 11 generated a shorter isoform of Merlin (Merlin-e11), and quantification of these results determine a slight increase in the total levels of Merlin",0.8
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,Phalloidin,antibody,Mechanistic,Revealed altered phenotype in primary fibroblast samples with prominent membrane ruffles in one patient and cytoskeletal abnormalities with tendency to growth as aggregates in another patient,Results,"Phalloidin staining revealed an altered phenotype in both primary fibroblast samples, but it was slightly different in each patient tested: patient_ES11_1 showed prominent membrane ruffles",0.8
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,Phalloidin,antibody,Efficacy,"After PMO treatment, showed improvement in organizational capacity of cytoskeleton with decreased membrane ruffles in one patient and improved cell-cell contact organization in another",Results,"After PMO treatment, an improvement in the organizational capacity of the cytoskeleton was observed, membrane ruffles were decreased in patient_ES11_1, and in patient_ES11_2 we observed an improvement",0.8
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit,clinical_assessment_tool,Efficacy,"Patient_ES11_1 showed statistically significant depletion of proliferation when treated with PMOs (65.6%; p < 0.05), while patient_ES11_2 showed less pronounced decrease (25.1%)",Results,"Patient_ES11_1 showed a statistically significant depletion of proliferation when treated with PMOs (65.6%; p < 0.05), while patient_ES11_2 showed a less pronounced decrease (25.1%)",0.9
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit,clinical_assessment_tool,Efficacy,Primary fibroblasts expressing Merlin-e11 by PMO treatment showed 51% decrease in proliferation compared with vehicle (p < 0.01) and 39.7% compared with treatment control (p < 0.01) on average,Results,primary fibroblasts with a truncating variant in exon 11 and expressing Merlin-e11 by PMO treatment showed a 51% decrease in proliferation when compared with the vehicle (Endo-Porter) (p < 0.01),0.9
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,RealTime-Glo MT Cell Viability Assay,clinical_assessment_tool,Safety,PMO treatment did not induce significant differences in cell viability,Results,"To determine absence of potential toxic effects, a viability test was performed, revealing that PMO treatment did not induce significant differences in cell viability",0.8
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,HeLa cells,cell_line,Mechanistic,Used to verify that induced skipping of exons 4 or 8 caused decrease in Merlin levels rather than lack of immunoreactivity by transfecting exon-less NF2 cDNAs with N-terminal FLAG tag,Results,"To verify that the induced skipping of exons 4 or 8 caused a decrease in Merlin levels rather than a lack of immunoreactivity, the exon-less NF2 cDNAs were cloned to an N-terminal FLAG tag expression vector and transfected to HeLa cells",0.8
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,NF2 primary fibroblasts,patient_derived_model,Mechanistic,"Showed actin cytoskeleton abnormalities and loss of contact inhibition consistent with Merlin loss, with recovery of cell-cell contact inhibition and capacity for monolayer growth after Merlin-e11 induction",Results,pediatric-derived NF2 (+/−) fibroblasts recovered part of the cell-cell contact inhibition and recovered the capacity of growth as a monolayer after the induction of Merlin-e11,0.8
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,AdCMVNeuroD1,genetic_reagent,Efficacy,"Transduction efficiency of ~85% in human VS cells, with statistically significant and dose-dependent reduction in EdU uptake (proliferation) compared to empty vector control",Results,Transduction efficiency of VS cells with adenoviral vectors is ~85%. The data show statistically significant and dose dependent reduction in EdU uptake in VS cells that express Neurod1 relative to those treated with EV.,0.95
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,AdCMVempty vector,genetic_reagent,Efficacy,Served as control vector showing higher EdU uptake (proliferation) compared to Neurod1-expressing vector in human VS cells,Results,The data show statistically significant and dose dependent reduction in EdU uptake in VS cells that express Neurod1 relative to those treated with EV.,0.9
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,Rosa26 LSL-Neurod1 (R26ND1),genetic_reagent,Efficacy,Completely suppressed MB formation in anterior lobes of cerebellum and reduced formation in posterior lobes when combined with Neurod1-cre,Results,MB formation was completely suppressed by R26ND1 in the anterior lobes of the cerebellum and is at least reduced in the posterior lobes,0.95
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,Rosa26 LSL-Neurod1 (R26ND1),genetic_reagent,Efficacy,Significantly reduced SC proliferation (p<0.05) following sciatic nerve axotomy in Nf2cKO+ND1 group compared to controls,Results,"the percentage of EdU positive cells in Nf2cKO+ND1 group was significantly reduced (p<0.05). Thus, expression of Neurod1 decreased SC proliferation following axotomy",0.95
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,Postn-cre,genetic_reagent,Mechanistic,"Drives cre expression specifically and exclusively in Schwann cells, effectively recombines floxed stop codon in Rosa26 locus",Results,a newly generated Postn-cre line drives cre expression specifically and exclusively in SCs. We first verified that this cre line effectively recombines the floxed stop codon in the Rosa26 locus,0.9
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,Postn-cre;Nf2f/f,animal_model,Biomarker,Showed significant increase in EdU-positive proliferating cells in vestibular ganglia compared to control animals,Results,Quantifying the EdU positive profiles showed significant increase in proliferation of Nf2 cKOs compared to control animals,0.9
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,Postn-cre;Nf2f/f,animal_model,Behavioral,"Showed statistically significant reduction in VsEP amplitudes and significantly longer response latencies (p1: p=0.015, n1: p=0.002, p2: p=0.001) when combined with ND1",Results,"there is a statistically significant reduction in VsEP amplitudes in Nf2 cKO mice. mean latencies of p1, n1 and p2 were significantly longer only for Nf2 cKO+ND1 compared to controls",0.95
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,R26LacZ,genetic_reagent,Mechanistic,Expression detected in all SCs of peripheral nerves in embryos using X-gal reaction when recombined by Postn-cre,Results,Removing the LoxP stop codon using the Postn-cre line results in expression of the blue X-gal reaction product in all SCs of peripheral nerves already in embryos,0.9
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,Primary human vestibular schwannoma (VS) cell cultures,patient_derived_model,Efficacy,Showed statistically significant and dose-dependent reduction in proliferation (EdU uptake) when transduced with Neurod1-expressing vectors,Results,"statistically significant and dose dependent reduction in EdU uptake in VS cells that express Neurod1 relative to those treated with EV. Thus, gene transfer with Neurod1 expressing viral vectors reduces human VS proliferation in vitro",0.95
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,tg(Neurod1-cre)29,genetic_reagent,Efficacy,"When used to induce R26smo expression, developed MB of variable size with complete suppression in anterior lobes and reduction in posterior lobes when combined with R26ND1",Results,"These mice developed MB of variable size, increasing in the anterior and posterior direction, reflecting the variable Neurod1 effects in mutants along the vermis",0.85
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,NF90-8,cell_line,Mechanistic,"Reduction of Ras prenylation observed following combination treatment of 1 μM FTI compounds with 1 μM lovastatin, with near complete inhibition achieved",Results,"However, a reduction of Ras prenylation was observed in the NF90-8 cells following combination treatment of 1 μM 1 or 2 with 1 μM lovastatin",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,NF90-8,cell_line,Efficacy,Combination treatments of 500 nM FTI plus 500 nM lovastatin were cytostatic after 24 hours and reduced total cell number below initial plating after 72 hours,Results,"However, combination treatments of 500 nM 1 plus 500 nM lovastatin were cytostatic after 24 hours of treatment, and reduced total cell number below initial plating after 72 hours",0.95
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,NF90-8,cell_line,Mechanistic,Combination treatment resulted in increased percentage of cells in G1 and significant percentage of cells undergoing apoptosis compared to controls,Results,"The combination treatment results in an increased percentage of cells in G1, and a significant percentage of cells undergoing apoptosis, compared to the control cultures",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,NF90-8,cell_line,Mechanistic,High amounts of active DEVDase (caspases-3 and -7) were observed following treatment with 500 nM FTI compounds and 500 nM lovastatin,Results,"However, high amounts of active DEVDase were observed in NF90-8 cells (Fig. 7C-D), and moderate amounts in ST88-14 (Fig. 7A-B) cells, following treatment with 500 nM 1 or 2 and 500 nM lovastatin",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,ST88-14,cell_line,Mechanistic,Moderate reduction of Ras prenylation observed in FTI/lovastatin combination treated cells compared to single treatments,Results,"Ras prenylation was also reduced in ST88-14 FTI/lovastatin combination treated cells compared to the single treatments of 1, 2, or lovastatin. The observed reduction of Ras prenylation in ST88-14 cells was moderate",0.85
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,ST88-14,cell_line,Efficacy,Reduction of proliferation observed when 500 nM FTI compounds were used in combination with 500 nM lovastatin,Results,"However, when 500 nM 1 or 2 were used in combination with 500 nM lovastatin, we observed a reduction of ST88-14 proliferation",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,ST88-14,cell_line,Mechanistic,"Moderate G1 cell cycle arrest at 24 hours maintained at 48 hours following FTI/lovastatin combination treatment, with modest increase in apoptotic cells",Results,"We observed a moderate G1 cell cycle arrest at 24 hours that was maintained at 48 hours following FTI/lovastatin combination treatment. Although we observed an increased percentage of apoptotic cells at 48 hours, the effect was more modest",0.85
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,Primary normal rat Schwann cells,cell_line,Safety,Combination treatments of 500 nM FTI compounds with 500 nM lovastatin had no observable toxicity on normal primary Schwann cells,Results,"However, in a stark contrast to the effect on MPNST cells, combination treatments of 500 nM 1 or 2 with 500 nM lovastatin had no observable toxicity on normal primary Schwann cells",0.95
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,iSC,cell_line,Safety,Combination treatments of 500 nM FTI compounds with 500 nM lovastatin did not significantly reduce proliferation of immortalized Schwann cells,Results,Combination treatments of 500 nM 1 or 2 with 500 nM lovastatin also did not significantly reduce proliferation of iSC cells,0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,anti-pan Ras monoclonal antibody,antibody,Mechanistic,"Successfully detected Ras prenylation status, with inhibition indicated by slower mobility band or upshift in western analysis",Results,Inhibition of prenylation is indicated by the slower mobility band or upshift by western analysis,0.85
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,anti-Phospho-Rb Ser 780 polyclonal antibody,antibody,Mechanistic,"Detected significant reduction in phosphorylated pRb signal when combining 1 μM FTI compounds with 1 μM lovastatin, with total pRb expression also reduced",Results,"However, combining 1 μM 1 or 2 with 1 μM lovastatin significantly reduced the phosphorylated pRb signal. Total pRb expression was also reduced in 1 or 2 plus lovastatin treated cultures",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,anti-Caspase-3 polycolonal antibody,antibody,Mechanistic,Exhibited time-dependent increase of cleaved pro-caspase-3 in NF90-8 cells treated with 500 nM FTI plus 500 nM lovastatin,Results,NF90-8 cells treated with 500 nM 1 plus 500 nM lovastatin also exhibited a time-dependent increase of cleaved pro-caspase-3,0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,FACScalibur instrument,computational_tool,Mechanistic,"Successfully quantified mitochondrial membrane potential changes, showing progressive loss of membrane potential from 24 to 72 hours following FTI/lovastatin combination treatment",Results,"However, following FTI/lovastatin combination treatment, a progressive loss of Δψm occurred from 24 to 72 hours",0.9
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,Axiovert 200M fluorescence microscope,computational_tool,Mechanistic,"Successfully visualized mitochondrial membrane potential changes using Mitotracker Orange, showing dramatic reductions in red fluorescence within 48 hours of combination treatment",Results,"Within 48 hours of treatment, both the cells and nuclei had shrunken, and there were dramatic reductions in red fluorescence (i.e., reduced Δψm)",0.85
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,64-channel Neuroscan system,clinical_assessment_tool,Biomarker,"Successfully recorded visual evoked potentials and EEG oscillations, detecting significant differences in alpha amplitude between NF1 and control groups across all stimulation types",Results,"The non-phase-locked oscillations presented a significant effect of group (F (1,33) = 11.0, P <0.01) and a significant interaction between frequency band and group (F (1.9,64) = 11.0, P <0.001)",0.95
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,"STIM 2 (Neuroscan, Charlotte, NC, USA)",clinical_assessment_tool,Behavioral,"Enabled visual detection task performance measurement showing NF1 group had significantly reduced correct hits (F(1,33) = 11.3, P = 0.002) and increased incorrect responses",Results,"Repeated measures ANOVA showed a significant effect of group regarding the number of events responded correctly (correct hits: reduced in the NF1 group; F (1,33) = 11.3, P = 0.002)",0.92
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,Scan 4.5 (Neuroscan),computational_tool,Biomarker,"Successfully processed EEG data to identify abnormal late visual responses (LC component) at 300ms showing significant group differences (F(1,34) = 6.4, P <0.05) for red-green stimulation",Results,"The mean amplitude within a time window around 300 ms showed a significant effect of group (F (1,34) = 6.4, P <0.05) with the control group presenting more negative values",0.93
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,Wechsler Intelligence Scale for Children (WISC-III),clinical_assessment_tool,Behavioral,"IQ scores showed no significant correlation with neurophysiological measures that differed between groups, indicating group IQ differences were not a major factor in EEG results",Results,"However, none of these measures of brain activity correlated significantly with IQ. Notably, this finding also indicates that group IQ differences are not a major factor in our results",0.88
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,"IBM SPSS Statistics, version 19",computational_tool,Other,Successfully performed statistical analyses revealing significant group differences in alpha oscillations and visual evoked potentials with multiple F-statistics and p-values reported,Results,"Repeated measures ANOVA showed a significant effect of group regarding the number of events responded correctly (correct hits: reduced in the NF1 group; F (1,33) = 11.3, P = 0.002)",0.9
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,"MATLAB (R2008a, MathWorks, Natick, MA, USA)",computational_tool,Biomarker,"Enabled frequency domain analysis revealing significantly higher non-phase-locked alpha amplitude in NF1 group during all visual stimulation conditions with effect sizes F(1,33) = 11.0 to F(1,34) = 11.1",Results,Post-hoc t-tests confirmed that the amplitude of the non-phase-locked alpha was significantly higher in the NF1 group when compared with control levels (red-green and blue-yellow: P <0.01),0.94
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,WGCNA package v1.69,computational_tool,Mechanistic,"Identified conserved gene regulation networks in pNF cell lines and primary tumor tissues, with magenta network reflecting stem-like signatures",Results,Our previous characterization of conserved gene regulation networks in pNF cell lines and primary tumor tissues revealed a series of essential networks. These conserve networks were defined by the WGCNA algorithms,0.85
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,IDACombo package,computational_tool,Efficacy,Calculated IDAcombo Score to predict combination benefit between HSP90i and selumetinib based on individual drug effects,Results,"To evaluate the drug combination potential between HSP90i and selumetinib, we use the IDAcombo R package to calculate the IDAcombo Score, which predicts the combination benefit",0.9
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,ipNF05.5 Mixed Clones,cell_line,Efficacy,"Showed modest dose-dependent responses to selumetinib alone, with significantly improved inhibition when combined with lowest concentrations of HSP90i",Results,treatment with selumetinib alone (the left column) resulted in modest dose-dependent responses in pNF cell lines. The administration of the lowest concentrations of HSP90i...yielded significantly improved inhibition,0.9
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,ipNF05.5 Single Clone,cell_line,Efficacy,Demonstrated synergistic effects with mean synergy scores above cutoff (>10) for HSP90i and selumetinib combinations,Results,"the means of synergy scores for the ipNF05.5 Mixed Clones, ipNF05.5 Single Clone, and ipNF95.11bC are all above the cutoff for the combinations",0.95
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,ipNF95.11bC,cell_line,Efficacy,"Achieved synergy scores above cutoff (>10) with HSP90i and selumetinib combinations, with highest synergy scores at low concentrations of both agents",Results,"the means of synergy scores for the ipNF05.5 Mixed Clones, ipNF05.5 Single Clone, and ipNF95.11bC are all above the cutoff...highest synergy scores were commonly observed within the combination therapy",0.95
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,ipnNF95.11c,cell_line,Safety,Non-tumor Schwann cell line showed only mild inhibitory effects when treated with selumetinib and HSP90i combinations,Results,"Meanwhile, the combinations exhibited mild inhibitory effects on non-tumor Schwann cell lines, ipnNF95.11c",0.9
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,DhhCre;Nf1f/f;Luciferase,animal_model,Efficacy,Combination treatment (selumetinib 40 mg/kg + SNX-2112 30 mg/kg) showed much stronger tumor growth inhibition compared to selumetinib alone (50 mg/kg) and vehicle control,Results,The growth rate of tumors demonstrated a much stronger inhibitory effect of the combination compared to both selumetinib alone and vehicle control,0.95
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,DhhCre;Nf1f/f;Luciferase,animal_model,Safety,No significant toxicity reflected by body weight loss in any treatment cohort,Results,with no significant toxicity reflected by body weight loss,0.9
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,CellTiter-Glo Luminescent Cell Viability Assay,clinical_assessment_tool,Efficacy,ATP-based assay demonstrated that combination of selumetinib with HSP90i (SNX-2112 or retaspimycin) yielded significantly improved inhibition compared to selumetinib alone,Results,We employed the ATP-based cell viability assay to assess the efficacy of the combination...yielded significantly improved inhibition compared to selumentinib alone,0.95
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,SynergyFinder,computational_tool,Efficacy,"Calculated Bliss synergy scores with cutoff >10, confirming synergistic effects in NF1-deficient cell models for HSP90i and selumetinib combinations",Results,"Utilizing the SynergyPlus web tool, we calculated the Bliss synergy score...The synergistic effect score cutoff defined by the SynergyPlus algorithm is that the mean synergy score should be more than 10",0.95
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,Nestin-Cre (#003771),genetic_reagent,Efficacy,Mice lacking 3 alleles of Lats1;2 with Nestin-Cre all developed tumors at 4-6 months of age with 100% penetrance,Results,"we found that mice lacking 3 alleles of Lats1;2, Lats fl/fl ;Lats2 fl/+ ;Nestin-Cre and Lats1 fl/+ ;Lats2 fl/fl ;Nestin-Cre (referred to as Lats-Nes mice), all developed tumors at 4–6 months of age",0.95
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,Nestin-Cre (#003771),genetic_reagent,Safety,"Mice had to be euthanized 2-4 months after tumor appearance, usually due to tumor ulceration and occasionally limb paralysis",Results,"the mice had to be euthanized 2–4 months after tumor appearance, usually because of tumor ulceration and occasionally because of limb paralysis",0.9
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,Plp-CreER (#005975),genetic_reagent,Efficacy,"Tamoxifen administration to Lats1 fl/+ ;Lats2 fl/fl ;Plp-CreER mice resulted in dozens of firm, slow-growing dermal tumors with 100% penetrance",Results,"Tamoxifen administration to 1- to 2-month-old Lats1 fl/+ ;Lats2 fl/fl ;Plp-CreER (Lats-Plp) mice resulted in dozens of firm, slow-growing dermal tumors in each mouse and occasional internal tumors with 100% penetrance",0.95
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,Plp-CreER (#005975),genetic_reagent,Biomarker,All Lats-Plp tumors were grade II GEM-MPNST,Results,All Lats-Plp tumors were grade II GEM-MPNST,0.9
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,Direct-zol RNA Miniprep Kit (Zymo),genetic_reagent,Other,Used for RNA extraction in RNA-seq analysis of tumor samples,Results,mRNA counts obtained from RNA-seq analysis of tumor samples and fold changes (FC) in NP (NP-Plp and NPcis) versus Lats (Lats-Nes and Lats-Plp) tumors,0.8
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,TruSeq Stranded Total RNA Library Prep Kit (Illumina),genetic_reagent,Other,Used for library preparation in RNA-seq analysis comparing NP versus Lats tumors,Results,mRNA counts obtained from RNA-seq analysis of tumor samples and fold changes (FC) in NP (NP-Plp and NPcis) versus Lats (Lats-Nes and Lats-Plp) tumors,0.8
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,STAR aligner,computational_tool,Other,Used for RNA-seq data alignment in transcriptome analysis of tumor samples,Results,mRNA counts obtained from RNA-seq analysis of tumor samples and fold changes (FC) in NP (NP-Plp and NPcis) versus Lats (Lats-Nes and Lats-Plp) tumors,0.8
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,RSEM,computational_tool,Other,Used for quantification in RNA-seq analysis comparing tumor samples,Results,mRNA counts obtained from RNA-seq analysis of tumor samples and fold changes (FC) in NP (NP-Plp and NPcis) versus Lats (Lats-Nes and Lats-Plp) tumors,0.8
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,MaxEntScan,computational_tool,Other,Failed to predict splicing effects for variant c.1532A>G that was confirmed by RNA analysis to cause aberrant splicing,Results,"one variant, c.1532A>G, predicted to produce the missense change, p.(Asp511Gly), and not predicted to affect splicing by the MaxEntScan and SpliceSiteFinder-Like tools, was shown to affect splicing by RNA analysis",0.9
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,SpliceSiteFinder-like tool,computational_tool,Other,Failed to predict splicing effects for variant c.1532A>G that was confirmed by RNA analysis to cause aberrant splicing,Results,"one variant, c.1532A>G, predicted to produce the missense change, p.(Asp511Gly), and not predicted to affect splicing by the MaxEntScan and SpliceSiteFinder-Like tools, was shown to affect splicing by RNA analysis",0.9
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,REVEL (Rare Exome Variant Ensemble Learner),computational_tool,Other,17 NF2 missense variants had computational evidence of pathogenicity applied by splicing prediction tools in the absence of a pathogenic REVEL metascore,Results,"Seventeen NF2 missense variants had in silico computational evidence of pathogenicity (PP3) applied by splicing prediction tool scores, MaxEntScan and SpliceSiteFinder-Like, in the absence of a pathogenic REVEL metascore",0.8
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,gnomAD v2.1.1,computational_tool,Other,"Showed highly consistent rate of missense variants across the NF2 transcript, serving as control dataset for variant rate analysis",Results,Missense variants recorded within gnomAD occurred at a highly consistent rate across the NF2 transcript,0.9
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,ClinVar NCBI,computational_tool,Other,"17 variants showed conflicting classifications compared to existing ClinVar interpretations, with vast majority being downgraded in pathogenicity class",Results,"When all variant classifications were compared to existing ClinVar interpretations, 17 variants were in conflict with current submissions. The vast majority of these variants were downgraded in pathogenicity class",0.9
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,DECIPHER database,computational_tool,Other,"No specific structural domains of NF2 display missense constraint in DECIPHER, preventing application of mutational hotspot evidence",Discussion,"Evidence of mutational hotspots and functional domains (PM1), was not applied to any of the variants in this study as no specific structural domains of NF2 display missense constraint in DECIPHER",0.8
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,Manchester Criteria,clinical_assessment_tool,Other,"Used to identify individuals with confirmed NF2-associated phenotypic features, with all likely pathogenic and pathogenic variants identified in association with NF2 disease presentation meeting these criteria",Results,All variants classified as likely pathogenic and pathogenic were identified in association with NF2 disease presentation,0.8
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,SCID mice,animal_model,Safety,No increased mortality or signs of drug toxicity was observed in animals treated with pirfenidone,Results,No increased mortality or signs of drug toxicity was observed in animals treated with pirfenidone.,0.9
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Efficacy,Survival rates ranged from 84.6% to 100% across various implantation locations without treatment over 6 weeks,Results,The survival of the neurofibroma xenografts in the various locations ranged from 84.6% to 100% ( Table 1 ).,0.95
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Efficacy,"Subcutaneous implants had 77/91 survival rate, epineurium implants had 13/15 survival rate",Results,Subcutaneously implanted tumors had similar survival rates (77/91) as tumors implanted into epineurium of the sciatic nerve (13/15),0.95
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Efficacy,Xenotransplants in ear remained stable in appearance and size for 12 months post-implantation (P = .41),Results,Neurofibroma xenotransplants in the ear were stable in appearance and size for twelve months postimplantation ( P = .41 Figure 1b ).,0.9
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Efficacy,"Survival of neurofibromas was lower in pirfenidone-treated animals compared to controls, irrespective of implantation location",Results,"Survival of neurofibromas in animals treated with pirfenidone was lower than in control animals, irrespective of the location of implanted tumor",0.85
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,human neurofibroma xenografts,patient_derived_model,Biomarker,"Retained histologic characteristics of original tumors over 6 weeks, with no significant change in cellularity or collagen content except appearing more dense in 6-week-old implants",Results,"Over the 6 weeks of monitoring, human neurofibroma implants retained the histologic characteristics of the original tumors...No significant change in cellularity or collagen content was observed, except that tumors appeared more dense in 6-week-old implants",0.9
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,rabbit anti-S-100 antibodies,antibody,Biomarker,Immunohistochemical reaction remained as strong as in original tumor over 6 weeks,Results,The immunohistochemical reaction with anti-S-100 remained as strong as in the original tumor ( Figure 3 ).,0.9
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,Fluorescein-conjugated IB4,antibody,Biomarker,Confirmed blood vessels were of host origin by binding to Gal α 1-3Gal on nonprimate cells,Results,"The blood vessels were of host origin since they bound GS IB4, a lectin recognizing Gal α 1-3Gal on cells of nonprimates",0.9
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,Nf1+/− GFAP CKO mice,animal_model,Biomarker,10% reduction in number of tyrosine hydroxylase (TH)-positive neurons innervating the striatum in vivo,Results,Our previous experiments using Nf1 CKO mice revealed a 10% reduction in the number of Nf1 +/− tyrosine hydroxylase (TH)-positive neurons innervating the striatum in vivo,0.95
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,Nf1+/− GFAP CKO mice,animal_model,Biomarker,50% decrease in neurite length in vitro,Results,"as well as a cell-autonomous 50% decrease in neurite length in vitro, suggesting a presynaptic defect",0.95
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,Nf1+/− GFAP CKO mice,animal_model,Biomarker,"10% reduction in expression of presynaptic VMAT2 and DAT transporters (p=.03, p=.0004; N=6)",Results,"we demonstrate a 10% reduction in the expression of presynaptic (VMAT2 and DAT) DA transporters, but normal expression of postsynaptic D1, D2, and D3 receptors",0.95
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,Nf1+/− GFAP CKO mice,animal_model,Biomarker,"Normal expression of postsynaptic D1, D2, and D3 receptors",Results,"but normal expression of postsynaptic D1, D2, and D3 receptors ( Fig. 1C–D ) (p=.03, p=.0004; N=6)",0.9
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,[11C]-raclopride,genetic_reagent,Biomarker,Confirmed 40% reduction in striatal DA levels in CKO mice relative to WT littermate controls,Results,"Using [11C]-raclopride PET imaging, we confirmed the 40% reduction in striatal DA levels originally measured by HPLC ( Brown et al., 2010a ) in CKO mice relative to their WT littermate controls",0.95
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,[11C]-raclopride,genetic_reagent,Efficacy,MPH treatment reduced [11C]-raclopride binding in CKO mice to WT levels,Results,"Using MPH doses which we have been previously shown to increase exploratory activity and rearing ( Brown et al., 2010a ), [11C]-raclopride binding in CKO mice was reduced to WT levels",0.9
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,[11C]-raclopride,genetic_reagent,Efficacy,L-Deprenyl treatment restored [11C]-raclopride levels to WT levels,Results,"Similar to MPH and L-Dopa ( Brown et al., 2010a ), L-Deprenyl treatment restored the [11C]-raclopride levels to WT levels",0.9
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,[11C]-raclopride,genetic_reagent,Efficacy,Neither Rolipram nor Lovastatin normalized striatal [11C]-raclopride binding,Results,"Despite good target inhibition, neither therapy normalized striatal [11C]-raclopride binding",0.9
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,DARPP32 antibody,antibody,Biomarker,Reduced DARPP32 phosphorylation found in striatum of CKO mice using IHC,Results,"Using IHC ( Fig. 1A ) and Western blotting ( Fig. 1B ), we found reduced DARPP32 phosphorylation, a key protein activated by DA release, in the striatum of CKO mice",0.9
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,p-DARPP32 antibody,antibody,Biomarker,Reduced DARPP32 phosphorylation found in striatum of CKO mice using Western blotting,Results,"Using IHC ( Fig. 1A ) and Western blotting ( Fig. 1B ), we found reduced DARPP32 phosphorylation, a key protein activated by DA release, in the striatum of CKO mice",0.9
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,p-MAPK antibody,antibody,Biomarker,"MAPK activation used as surrogate marker for RAS activity, attenuated after Lovastatin treatment",Results,"which is attenuated after treatment with the HMG-CoA reductase inhibitor, Lovastatin ( Li et al., 2005 ), using MAPK activation as a surrogate marker for RAS activity",0.85
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,MC-780MA Tanita Tokyo body composition analyzer,clinical_assessment_tool,Biomarker,"Mean reduction in fat mass by 0.8% (SD 4.5, p = 0.76) and mean reduction in fat amount by 2.8% (SD 4.4, p = 0.21), neither statistically significant",Results,"Bioelectrical impedance analysis was performed to assess the effect of L‐carnitine supplementation on body fat mass (kg) or amount (% body weight), due to its primary role in fat metabolism. There was a mean reduction in fat mass by 0.8% (SD 4.5, p = 0.76), and mean reduction in fat amount by 2.8% (SD 4.4, p = 0.21)",0.95
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,Citec hand-held dynamometer,clinical_assessment_tool,Efficacy,No significant improvement in grip strength (95% CI −2.49 to 10.15; p = 0.18); mean 53% increase in dorsiflexion strength (95% CI 8.89–60.75; p = 0.02) and mean 66% increase in plantarflexion strength (95% CI 12.99–134.1; p = 0.03),Results,"Following 12 weeks of L‐carnitine supplementation, there was no significant improvement in grip strength (95% CI −2.49 to 10.15; p = 0.18); however, there was a mean 53% increase in dorsiflexion strength (95% CI 8.89–60.75; p = 0.02) and a mean 66% increase in plantarflexion strength",0.95
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,Citec hand-held dynamometer,clinical_assessment_tool,Efficacy,Z-score improvement of dorsiflexion strength from −1.57 to −0.32 (95% CI 0.17–2.33; p = 0.03) and plantarflexion strength from −1.98 to −0.15 (95% CI 0.08–3.59; p = 0.04),Results,"After 12 weeks of L‐carnitine supplementation, there was an average Z‐score improvement of dorsiflexion strength from −1.57 to −0.32 (95% CI 0.17–2.33; p = 0.03) and plantarflexion strength from −1.98 to −0.15 (95% CI 0.08–3.59; p = 0.04)",0.95
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,Handwriting Speed Test,clinical_assessment_tool,Efficacy,"Handwriting speed increased by 15% on average; however, due to considerable variability in participant performance, this failed to reach statistical significance (95% CI −7.38 to 20.24; p = 0.28)",Results,"Furthermore, handwriting speed was increased by 15% on average; however, due to the considerable variability in participant performance, this failed to reach statistical significance (95% CI −7.38 to 20.24; p = 0.28)",0.9
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,6-minute-walk test,clinical_assessment_tool,Efficacy,Mean 10% improvement observed for the 6MWT after 12-weeks of L‐carnitine supplementation (95% CI 5.88–75.45; p = 0.03),Results,"A mean 10% improvement was also observed for the 6MWT after 12‐weeks of L‐carnitine supplementation (95% CI 5.88–75.45; p = 0.03). To note, the 6MWT of participant two was excluded due to cramping during testing time",0.95
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,6-minute-walk test,clinical_assessment_tool,Efficacy,6MWT Z-score improved from −3.2 to −2.38 (95% CI 0.34–1.3; p = 0.01),Results,"Long jump Z‐score improved from −2.05 to −1.5 (95% CI 0.15–0.95; p = 0.02), and 6MWT from −3.2 to −2.38 (95% CI 0.34–1.3; p = 0.01)",0.95
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,PedsQL Generic 4.0,clinical_assessment_tool,Behavioral,"Trend toward improvement on the physical health summary domain (median 46.9, IQR 42.2–60.9 to median 71.9, IQR 51.6–87.5); other domains showed no significant differences",Results,"Comparison of PedsQL™ scores between baseline and 12‐weeks posttreatment showed a trend toward improvement on the physical health summary domain of the generic module (median 46.9, interquartile range [IQR] 42.2–60.9 to median 71.9, IQR 51.6–87.5)",0.85
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,PedsQL Neuromuscular 3.0,clinical_assessment_tool,Behavioral,"Neuromuscular disease summary, communication summary, and family resources summary scores showed no significant differences",Results,"Other domains, including psychosocial health summary, neuromuscular disease summary, communication summary, and family resources summary scores showed no significant differences suggesting that L‐carnitine supplementation does not interfere with participant's quality of life",0.85
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,CBCL/6-18,clinical_assessment_tool,Behavioral,"Majority of children (4/6) fell within clinical range of >2 syndrome scales at baseline, reduced to 2/6 children following 12-weeks posttreatment; however, no statistically significant differences detected due to sample size and interparticipant variability",Results,"Majority of the children (4/6) fell within the clinical range of >2 syndrome scales at baseline. This was reduced to 2/6 children following 12‐weeks posttreatment. However, no statistically significant differences could be detected due to sample size and interparticipant variability",0.85
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,Wechsler Intelligence Scale,clinical_assessment_tool,Behavioral,NS group demonstrated lower full-scale IQ compared to TD group,Results,The NS group demonstrated lower full-scale IQ and lower scores for most NEPSY-II subtests,0.8
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,A Developmental NEuroPSYchological Assessment (NEPSY-II),clinical_assessment_tool,Behavioral,NS group showed lower scores for most NEPSY-II subtests compared to TD group,Results,The NS group demonstrated lower full-scale IQ and lower scores for most NEPSY-II subtests,0.8
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,A Developmental NEuroPSYchological Assessment (NEPSY-II),clinical_assessment_tool,Other,"PCA reduced NEPSY-II data into 3 components accounting for 49.5% of variance, with first component (30.1% variance) strongly correlated with IQ (r(57) = −0.790, p<0.0001)",Results,"PCA reduced NEPSY-II data into 3 components while accounting for 49.5% of the variance...The first component (accounting for 30.1% of the variance)...was strongly correlated with IQ (r(57) = −0.790, p<0.0001)",0.95
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,A Developmental NEuroPSYchological Assessment (NEPSY-II),clinical_assessment_tool,Behavioral,"Within NS group, inhibition/motor component was significantly related to connectivity within left frontoparietal and limbic clusters (p<0.05), relationships not significant in TD group (p>0.10)",Results,Within the NS group the inhibition/motor component was significantly related to connectivity within with left frontoparietal and limbic clusters (p<0.05)...These relationships were not significant within the TD group (p>0.10),0.9
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,melodic v3.15,computational_tool,Other,"ICA demonstrated significant hyperconnectivity for NS group relative to TD group for four of eight canonical RSNs: visual, ventral attention, left frontoparietal and limbic (p<0.05 FEW)",Results,"ICA demonstrated significant hyperconnectivity for the NS group relative to the TD group for four of eight canonical RSNs: visual, ventral attention, left frontoparietal and limbic (p<0.05 FEW",0.9
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,Tanner staging,clinical_assessment_tool,Other,NS and TD groups did not differ in Tanner stage (p>0.09),Results,"NS and TD groups did not differ in age, sex or Tanner stage (all p's >0.09",0.9
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,SeqCap EZ Human Exome Library,genetic_reagent,Mechanistic,Successfully identified constitutional NF1 mutations in 15 of 16 individuals with tibial pseudoarthrosis,Results,"WES identified the constitutional NF1 mutation in 15 of 16 individuals, which predicted missense (n=3), nonsense (n=4), frameshift (n=3) and splice-site (n=5) changes",0.95
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,TruSeq Exome kit,genetic_reagent,Mechanistic,Successfully identified constitutional NF1 mutations in 15 of 16 individuals with tibial pseudoarthrosis,Results,"WES identified the constitutional NF1 mutation in 15 of 16 individuals, which predicted missense (n=3), nonsense (n=4), frameshift (n=3) and splice-site (n=5) changes",0.95
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,Burrow-Wheeler aligner,computational_tool,Mechanistic,Successfully processed sequencing data to enable identification of NF1 mutations and somatic variants in pseudoarthrosis samples,Results,"WES identified the constitutional NF1 mutation in 15 of 16 individuals...Additional somatic sequence mutations, including three nonsense, two frameshift and one splice-site changes, were confirmed in six additional individuals",0.85
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,Genome Analysis Toolkit,computational_tool,Mechanistic,Successfully processed sequencing data to enable identification of NF1 mutations and somatic variants in pseudoarthrosis samples,Results,"WES identified the constitutional NF1 mutation in 15 of 16 individuals...Additional somatic sequence mutations, including three nonsense, two frameshift and one splice-site changes, were confirmed in six additional individuals",0.85
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,TopHat,computational_tool,Mechanistic,"Successfully processed RNA-seq data to identify differential gene expression, detecting 258 genes with altered expression associated with neurofibromin deficiency",Results,Differentially expressed genes with greater than 2-fold expression difference in pseudoarthrosis samples compared to control samples were identified...This analysis identified 258 genes with differential expression associated with bi-allelic NF1 inactivation,0.9
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,EdgeR software,computational_tool,Mechanistic,Successfully identified 258 differentially expressed genes with greater than 2-fold expression difference and FDR-adjusted p<0.05 in pseudoarthrosis samples,Results,Differentially expressed genes with greater than 2-fold expression difference in pseudoarthrosis samples compared to control samples were identified with false discovery rate (FDR)-adjusted FDRp<0.05...This analysis identified 258 genes,0.95
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,Alexa Fluor 647-conjugated anti-phospho-ERK1/2 primary antibody,antibody,Mechanistic,Detected no quantitative increase in ERK activation (phosphorylation) in pseudoarthrosis cells compared to individual-matched iliac crest cells,Results,"Using fluorescent-activated flow cytometry, we detected no quantitative increase in ERK activation (phosphorylation) in pseudoarthrosis cells compared to individual-matched iliac crest cells",0.95
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,INFLUX cell sorter,advanced_cellular_model,Mechanistic,"Successfully analyzed ERK phosphorylation levels in pseudoarthrosis cells versus control cells, showing no quantitative increase in ERK activation",Results,"Using fluorescent-activated flow cytometry, we detected no quantitative increase in ERK activation (phosphorylation) in pseudoarthrosis cells compared to individual-matched iliac crest cells",0.9
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,NVivo software,computational_tool,Other,Used for qualitative data analysis in developing patient reported outcome measures,Discussion,"Using qualitative data from patients and expert input, two PRO measures were developed that assess pNF-related pain intensity and pain interference in individuals with NF1 ages 8 years and older.",0.75
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),clinical_assessment_tool,Other,"Developed PRO measure to assess pNF-related pain intensity in individuals with NF1 ages 8 years and older, designed for electronic completion from home prior to clinical trial evaluations",Discussion,two PRO measures were developed that assess pNF-related pain intensity and pain interference in individuals with NF1 ages 8 years and older. These measures are to be completed electronically from home prior to clinical trial endpoint evaluations.,0.85
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,Pain Interference Index for plexiform neurofibromas (PII-pNF),clinical_assessment_tool,Other,"Developed PRO measure to assess pain interference in individuals with NF1 ages 8 years and older, designed for electronic completion from home prior to clinical trial evaluations",Discussion,two PRO measures were developed that assess pNF-related pain intensity and pain interference in individuals with NF1 ages 8 years and older. These measures are to be completed electronically from home prior to clinical trial endpoint evaluations.,0.85
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,Pain Interference Index for plexiform neurofibromas (PII-pNF),clinical_assessment_tool,Other,"Content validity established through qualitative data from patients and expert input, validation underway with tools to be available after publication of quantitative results",Discussion,It is critically important to have PROs with excellent content validity to assess clinical benefit in trials targeting the reduction of pNFs and pain in NF1 across the lifespan. Validation of these tools is underway,0.8
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),clinical_assessment_tool,Other,"Content validity established through qualitative data from patients and expert input, validation underway with tools to be available after publication of quantitative results",Discussion,It is critically important to have PROs with excellent content validity to assess clinical benefit in trials targeting the reduction of pNFs and pain in NF1 across the lifespan. Validation of these tools is underway,0.8
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,PedsQL 4.0 Generic Core Scales,clinical_assessment_tool,Behavioral,"Parent ratings showed declines of 9, 17, and 27 points in PedsQL Total scale scores in 3 of 4 patients, indicating worse quality of life",Results,"Parent ratings indicated that three of these four patients had declines of 9, 17, and 27 points in the PedsQL Total scale score indicating worse QOL.",0.95
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,PedsQL 4.0 Generic Core Scales,clinical_assessment_tool,Behavioral,"QOL decreases corresponded to toxicities including rash, itching, pain, and irritability, with one patient decreasing on all four subscales",Results,"These decreases appeared to correspond to toxicities experienced by these patients between the baseline and pre-cycle 4 evaluations, including rash, itching, pain, and irritability.",0.9
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,PedsQL 4.0 Generic Core Scales,clinical_assessment_tool,Behavioral,"Decreases in parent-reported QOL had substantial impact on patients' physical, emotional, social, and school functioning",Discussion,"Decreases in parent-reported QOL appeared to correspond to reported toxicities and suggested that the side effects had a substantial impact on patients' physical, emotional, social, and school functioning.",0.85
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,Quantikine™ human VEGF immunoassay kit,antibody,Biomarker,"No statistically significant changes in plasma VEGF from baseline to steady-state (P = 0.7, n = 5 paired samples)",Results,"Among paired samples for plasma VEGF and sVEGFR2 (n = 5), there were no statistically significant changes from baseline to steady-state (Wilcoxon signed-rank test P = 0.7 and 0.2).",0.95
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,Quantikine™ human sVEGFR2 immunoassay kit,antibody,Biomarker,"No statistically significant changes in sVEGFR2 from baseline to steady-state (P = 0.2, n = 5 paired samples)",Results,"Among paired samples for plasma VEGF and sVEGFR2 (n = 5), there were no statistically significant changes from baseline to steady-state (Wilcoxon signed-rank test P = 0.7 and 0.2).",0.95
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,CADvue software,computational_tool,Biomarker,Baseline DCE MRI measurements showed mean Ktrans of 0.043 (0.017) minutes⁻¹ and iAUGC(90 seconds) of 5.50 (1.25) mMseconds in 6 patients,Results,The mean (SD) baseline K trans and iAUGC(90 seconds) was 0.043 (0.017) minutes −1 and 5.50 (1.25) mMseconds.,0.95
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,CADvue software,computational_tool,Biomarker,Patients with baseline and follow-up scans (n = 3) demonstrated slight increases in both Ktrans and iAUGC values,Results,Patients with both baseline and follow up scan (n = 3) demonstrated a slight increase in both K trans and iAUGC.,0.85
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,Tg(HOTCre:Cas9),genetic_reagent,Mechanistic,"Heat shock induced Cas9 expression in presence of nf2a/b-targeting gRNAs, enabling conditional knockout strategy",Results,heat shock induced the expression of Cas9 in the presence of the nf2a/b-targeting gRNAs,0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,Tg(-7.2kb-sox10:mRFP),genetic_reagent,Biomarker,~40% of sox10-positive cells were nf2b positive in cranial region at 1 dpf,Results,Quantification of nf2b and Tg(−7.2 sox10:mRFP) populations at 1 dpf indicated that ∼40% of the sox10-positive cells are nf2b positive in the cranial region,0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,Tg(-7.2kb-sox10:mRFP),genetic_reagent,Biomarker,~45% of sox10-positive posterior lateral line Schwann cells were nf2b positive at 3 dpf,Results,quantification of nf2b and Tg(sox10:mRFP) populations revealed that ∼45% of the sox10-positive posterior lateral line Schwann cells (pLLn SCs) was nf2b positive,0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,Tg(-7.2kb-sox10:mRFP),genetic_reagent,Efficacy,"No difference in Schwann cell number at 3 dpf between nf2a/b knockouts and controls, but striking increase in numbers and thickness of Schwann cell clusters at 5 dpf",Results,we did not see any difference in the Schwann cell number at 3 dpf between nf2a/b knockouts and Cas9-only controls...we observed a striking increase in the numbers and thickness of Schwann cell clusters along the posterior lateral line in nf2a/b knockout larvae,0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,Tg(U6x:nf2a/b-4sgRNA),genetic_reagent,Efficacy,All four gRNAs elicited mutations in vivo at 80-95% efficiency using T7 endonuclease assay,Results,we observed that all four gRNAs could elicit mutations in vivo at almost 80-95% efficiency,0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,Tg(U6x:nf2a/b-4sgRNA),genetic_reagent,Efficacy,CRISPR-Cas9-induced modifications observed in 70-95% of sequencing reads for nf2a and nf2b target regions,Results,We performed PCR sequencing for the nf2a and nf2b target regions and observed CRISPR-Cas9-induced modifications in 70-95% of the reads,0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,anti-pH3 antibody,antibody,Biomarker,Significant increase in meningeal pH3 staining after loss of nf2 compared to controls,Results,Quantitation of this effect demonstrated a significant increase in meningeal phospho-histone 3 (pH3) staining after the loss of nf2,0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,anti-merlin antibody,antibody,Biomarker,Concomitant loss of Nf2 protein observed in CRISPR-Cas9-induced animals by western blot analysis,Results,"Using western blot analysis, we observed concomitant loss of the Nf2 protein in the CRISPR-Cas9-induced animals",0.9
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,CRISPResso2,computational_tool,Efficacy,Used to analyze CRISPR-Cas9-induced modifications showing 70-95% mutation rates in target regions,Results,We performed PCR sequencing for the nf2a and nf2b target regions and observed CRISPR-Cas9-induced modifications in 70-95% of the reads,0.8
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,ImageJ,computational_tool,Other,Used for quantification of normalized proliferation showing significant increase in nf2a/b knockouts (P=0.0197),Results,Bar plot showing quantification of normalized proliferation (* P=0.0197; each dot represents data from one larva),0.8
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,NOD-Rag1 null IL2rg (NRG) mice,animal_model,Efficacy,Successfully established 13 MPNST PDX lines through serial passage in NRG mice,Results,MPNST PDX lines were established from biopsy-proven NF1-MPNST between 2014 and 2021 at three institutions...established by engrafting minced tumor or single cell suspension into immunodeficient NRG mice followed by serial passage,0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,NOD-Rag1 null IL2rg (NRG) mice,animal_model,Efficacy,"MN-2 tumor growth was slowed after trabectedin treatment (P < 0.0001), with greater effect from mirdametinib-alone treatment (P < 0.05)",Results,"MN-2 tumor growth was slowed after trabectedin treatment (P < 0.0001), and the effect was greater with mirdametinib-alone treatment (P < 0.05)",0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,NOD-Rag1 null IL2rg (NRG) mice,animal_model,Efficacy,"WU-225 showed dramatic growth inhibition with trabectedin single agent, enhanced slightly with addition of mirdametinib",Results,"With WU-225, a dramatic growth inhibition was observed with trabectedin single agent. This effect was enhanced slightly with the addition of mirdametinib",0.9
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,NOD-Rag1 null IL2rg (NRG) mice,animal_model,Efficacy,JH-2-079-c combination therapy with trabectedin plus olaparib (P < 0.05) and trabectedin plus mirdametinib (P < 0.05) significantly impeded tumor growth,Results,"In JH-2-079-c mice, combination therapy with trabectedin plus olaparib (Figure 5C, P < 0.05), and trabectedin plus mirdametinib (Figure 5B, P < 0.05) significantly impeded tumor growth in vivo",0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,NOD-Rag1 null IL2rg (NRG) mice,animal_model,Safety,Trabectedin plus olaparib combination elicited unacceptable toxicity in WU-225 mice and treatment lasted only 14 days,Results,While the trabectedin plus olaparib combination elicited unacceptable toxicity in WU-225 mice and treatment lasted only 14 days,0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,anti-mouse H-2 (125505),antibody,Biomarker,Cell populations were effectively depleted of mouse cells (<1.5% mouse) as verified via flow cytometry,Results,We verified via flow cytometry that the cell populations were highly viable (>94% alive) and were effectively depleted of mouse cells (<1.5% mouse),0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,"human nuclei (ab254080, Abcam)",antibody,Biomarker,Successfully verified assembled 3D microtissues were of MPNST origin through immunofluorescence staining,Results,"We also verified the assembled 3D microtissues were still of MPNST origin by performing immunofluorescence staining for human nuclear antigen, Ki67, and MPNST-associated markers S100b, H3K27me3",0.9
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,"Ki-67 (RM9106S1, Fisher Scientific)",antibody,Biomarker,Successfully verified assembled 3D microtissues were of MPNST origin through immunofluorescence staining,Results,"We also verified the assembled 3D microtissues were still of MPNST origin by performing immunofluorescence staining for human nuclear antigen, Ki67, and MPNST-associated markers S100b, H3K27me3",0.9
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,"S-100 b (sc-393919, Santa Cruz Biotechnology)",antibody,Biomarker,Successfully verified assembled 3D microtissues were of MPNST origin through immunofluorescence staining,Results,"We also verified the assembled 3D microtissues were still of MPNST origin by performing immunofluorescence staining for human nuclear antigen, Ki67, and MPNST-associated markers S100b, H3K27me3",0.9
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,"H3K27me3 (9733, Cell Signaling Technologies)",antibody,Biomarker,Successfully verified assembled 3D microtissues were of MPNST origin through immunofluorescence staining,Results,"We also verified the assembled 3D microtissues were still of MPNST origin by performing immunofluorescence staining for human nuclear antigen, Ki67, and MPNST-associated markers S100b, H3K27me3",0.9
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,"pERK (4370, Cell Signaling Technologies)",antibody,Mechanistic,"Microtissues respond to MEK inhibition by suppressing ERK phosphorylation, with mirdametinib (10 µM) and selumetinib (10 µM) showing significant reduction (P < 0.001 and P < 0.0001)",Results,"Finally, we were able to show that our microtissues respond to MEK inhibition by suppressing ERK phosphorylation...WU-225 microtissues were exposed to mirdametinib (10 µM), selumetinib (10 µM) or DMSO for 0, 2 or 8 h and phospho-ERK levels were assessed",0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,3D microtissues,advanced_cellular_model,Efficacy,"Successfully created from dissociated PDX as 200-300 µm structures with 12-32 total cells per microtissue, each having at least 10 viable cells after 48-hour treatment",Results,Dissociated PDX were depleted of mouse and dead cells and assembled into 200–300 µm 3D microtissues with the addition of collagen and Matrigel...our experimental 3D microtissues were composed of between 12 and 32 total cells per microtissue with each having at least 10 viable cells,0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,3D microtissues,advanced_cellular_model,Biomarker,Cell populations were highly viable (>94% alive) as verified via flow cytometry,Results,We verified via flow cytometry that the cell populations were highly viable (>94% alive) and were effectively depleted of mouse cells (<1.5% mouse),0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,3D microtissues,advanced_cellular_model,Efficacy,"Four out of nine (44%) PDX-microtissues tested met quality criteria for drug studies: MN-2, JH-2-002, JH-2-079-c, and WU-225",Results,"Four out of nine (44%) PDX-microtissues tested met these criteria: MN-2, JH-2-002, JH-2-079-c, and WU-225",0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,3D microtissues,advanced_cellular_model,Efficacy,"At highest concentration, mirdametinib had strongest effect on cell viability for each of the four microtissues, while olaparib and trabectedin had varied effects",Results,"At the highest concentration attempted, mirdametinib had the strongest effect on cell viability for each of the four microtissues, while olaparib and trabectedin had varied effects",0.9
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,3D microtissues,advanced_cellular_model,Efficacy,"JH-2-079-c exhibited dramatic reduction in cell viability after five days in culture, even at lowest concentrations of trabectedin plus olaparib or plus mirdametinib",Results,"Additionally, JH-2-079-c exhibited a dramatic reduction in cell viability after five days in culture, even at the lowest concentrations of trabectedin plus olaparib or plus mirdametinib",0.9
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,NF1-associated MPNST-PDX,patient_derived_model,Biomarker,"Successfully reflect genomic diversity of MPNST with somatic NF1 mutations in 8 of 13 pairs, germline NF1 variants in 10 of 13 pairs (77%), and somatic NF1 variants in 12 of 13 pairs (92%)",Results,"We identified common genetic alterations in the 13 PDX-MPNST pairs, including somatic NF1 mutations in 8 of 13 pairs...Germline NF1 variants were identified in 10 out of 13 PDX-tumor pairs (77%) and somatic NF1 variants were identified in in 12 out of 13 pairs (92%)",0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,NF1-associated MPNST-PDX,patient_derived_model,Biomarker,"About half, six of thirteen (46%), PDX tested could be established as cell lines",Results,"About half, six of thirteen (46%), PDX tested could be established as cell lines, but most PDX could not form spheroids in a collagen-free environment",0.95
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,NF1-associated MPNST-PDX,patient_derived_model,Efficacy,Success rate of PDX that could be assembled as viable microtissues (46%) was similar to those that could be grown as 2D cell lines (44%),Discussion,The success rate of PDX in our study that could be assembled as viable microtissues (46%) was similar to those that could be grown as 2D cell lines (44%),0.95
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,ab207178,antibody,Biomarker,"MPNSTs showed moderate to strong FAP expression on most tumor cells and partly also in surrounding stromal cells, with significantly higher FAP expression in tumor and stroma compartments than neurofibromas (both p < 0.001)",Results,"MPNSTs showed moderate to strong FAP expression on most tumor cells and partly also in surrounding stromal cells...MPNSTs displayed significantly higher FAP expression in the tumor as well as stroma compartment than neurofibromas (Fig. 4 b, both p < 0.001)",0.95
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,ab207178,antibody,Biomarker,"Plexiform neurofibromas exhibited higher FAP expression than conventional neurofibromas both in perilesional stroma (p = 0.001) and tumor cells (p < 0.001), while MPNSTs displayed higher FAP expression in tumor cells than plexiform neurofibromas (p = 0.015)",Results,"plexiform neurofibromas exhibited higher FAP expression than conventional neurofibromas both in the perilesional stroma (p = 0.001) and tumor cells (p < 0.001). Nevertheless, MPNSTs displayed higher FAP expression in tumor cells than plexiform neurofibromas (p = 0.015)",0.95
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,ab207178,antibody,Biomarker,"Confirmed inter- and intra-tumoral heterogeneity of FAP expression in MPNST tumor cells, consistent with spatial and scRNA data findings",Results,"IHC confirmed the inter- and intra-tumoral heterogeneity of FAP expression in MPNST tumor cells, which we also observed in spatial and scRNA data",0.85
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,ab207178,antibody,Other,"Low-level cross-reactivity observed in eccrine sweat glands, likely due to structural similarity between FAP and DPP4 (51.9% sequence identity)",Results,"We observed almost no relevant immunoreactivity in neurofibromas and uninvolved healthy tissue...except of eccrine sweat glands, which are known to express dipeptidyl peptidase IV (DPP4)...BLAST alignment revealed 51.9% sequence identify",0.8
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,[68Ga]Ga-LNTH-1363S,clinical_assessment_tool,Biomarker,"MPNST on left forearm showed high FAP expression uptake (SUVmax 14.7) while adjacent neurofibroma showed lower uptake (SUVmax 3.5), with histopathological confirmation of strong FAP expression in MPNST and no FAP expression in neurofibroma",Results,the MPNST on the left forearm shows high [18F]FDG uptake (a) and high FAP expression (b) (SUVmax 10.7 vs. 14.7)...whereas the MPNST lesion on the left forearm consisted of a hyper-cellular tumor...with strong cytoplasmic and membranous FAP expression,0.95
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,[68Ga]Ga-LNTH-1363S,clinical_assessment_tool,Biomarker,"One neurofibroma at sciatic nerve showed moderate, patchy tracer uptake (SUVmax FAP: 9.5) but lacked detectable FAP protein expression on immunohistochemistry, suggesting possible stromal remodeling or sampling limitations",Discussion,"one neurofibroma located at the sciatic nerve, that exhibited moderate, patchy tracer uptake, lacked any detectable FAP protein expression in immunohistochemistry. This discrepancy and the patchy tracer accumulation in PET imaging may reflect localized stromal remodeling",0.85
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,H-score,clinical_assessment_tool,Biomarker,"Used to quantify FAP expression differences between tumor types, showing MPNSTs had significantly higher H-scores than neurofibromas in both tumor and stromal compartments (both p < 0.001)",Results,"H scores for immuno-histochemical FAP expression in MPNSTs (n = 12), conventional neurofibromas (n = 12)...MPNSTs exhibited significantly higher FAP expression compared to neurofibromas in stromal as well as tumor cells (both p < 0.001)",0.9
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,SF-36,clinical_assessment_tool,Behavioral,NF1 and NF2 patients had significantly lower scores in all domains compared to Canadian normative population (P < 0.005),Results,Patients with NF1 and NF2 had significantly lower scores in all the domains in the SF-36 compared to the Canadian normative population at this age range (t test P < .005),0.95
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,SF-36,clinical_assessment_tool,Behavioral,"NF2 patients had significantly lower Social Functioning and General Health scores than NF1 patients (P-values 0.02 and 0.016, respectively)",Results,"NF2 patients had lower scores than patients with NF1, although this difference was only significant for Social Functioning and General Health (P-values .02 and .016, respectively)",0.95
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,EQ-5D-5L,clinical_assessment_tool,Behavioral,"High proportion of patients reported pain/discomfort (66% NF1, 73% NF2) and anxiety/depression (61% NF1, 68% NF2)",Results,"we found that a high proportion of patients reported some degree of pain/discomfort (66% for NF1 and 73% NF2, respectively) and anxiety/depression (61% and 68% for NF1 and NF2, respectively)",0.95
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,EQ-5D-5L,clinical_assessment_tool,Behavioral,Mean VAS score was 74.5 ± 23 for NF1 and 64.2 ± 21 for NF2 (P = 0.05); mean health utility score was 0.73 ± 0.24 for NF1 and 0.65 ± 0.25 for NF2 (P = 0.16),Results,The mean EQ-5D-5L VAS score was 74.5 ± 23 for NF1 patients and 64.2 ± 21 for NF2 (P-value .05). The mean EQ-5D-5L health utility score was 0.73 ± 0.24 for NF1 and 0.65 ± 0.25 for NF2 patients (P-value .16),0.95
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,PedsQL NF1 adult module,clinical_assessment_tool,Behavioral,"Cronbach's alpha was 0.96; domains with lowest scores (worse QoL) were perceived physical appearance, worry, cognitive, emotion, fatigue, and pain",Results,"Cronbach's alpha for the PedsQL NF1 was 0.96. The PedsQL NF1 domains with the lowest scores (worse QoL) were perceived physical appearance, worry, cognitive, emotion, fatigue, and pain",0.95
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,NFTI-QOL,clinical_assessment_tool,Behavioral,"Cronbach's alpha was 0.87; items with highest (worse) scores were hearing (median 2, range 1-3) and outlook on life (median 2, range 0-3)",Results,"Cronbach's alpha was 0.87. The items with highest (worse) scores were hearing (median 2, range 1–3) and outlook on life (median 2, range 0–3)",0.95
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,NFTI-QOL,clinical_assessment_tool,Behavioral,"High correlations with EQ-5D-5L utility score (r: -0.76, P < 0.001), EQ-5D-5L VAS score (r: -0.52, P = 0.01), SF-36 PCS (r: -0.65, P = 0.003), and SF-36 MCS (r: -0.63, P = 0.004)",Results,"The total NFTI-QoL had moderate to high correlations with the EQ-5D-5L utility score (r: −0.76, CI: −0.89, −0.49, P < .001), the EQ-5D-5L VAS score (r: −0.52, CI: −0.77, −0.11, P = .01), SF-36 PCS (r: −0.65, CI: −0.86, −0.26, P = .003), and the SF-36 MCS (r: −0.63, CI: −0.85, −0.23, P = .004)",0.95
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,PROMIS pain interference short form 8a,clinical_assessment_tool,Behavioral,High correlations with health utilities: -0.70 for NF1 (P < 0.001) and -0.90 for NF2 (P < 0.001),Results,"the correlation between pain interference and health utilities was −0.70 (CI: −0.77, −0.61, P < .001) for NF1 and −0.90 (CI: −0.96, −0.78, P < .001) for NF2",0.95
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,PROMIS pain interference short form 8a,clinical_assessment_tool,Behavioral,"Pain interference was significantly associated with worse SF-36 PCS (estimate -0.68, P < 0.0001) and was main driver of QoL for both NF1 and NF2",Results,"Worse pain interference scores and older age were significantly associated with worse SF-36 PCS... pain interference was the main driver of QoL both for NF1 and NF2, demonstrated by the high correlations between pain interference and QoL scales",0.95
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,Ablon visibility index,clinical_assessment_tool,Behavioral,"No correlation found with mental health when rated by examiner, unlike self-reported physical appearance measures",Discussion,"when we looked at the Ablon index—rated by an examiner—we did not find a correlation with mental health; however, when we used self-reported physical appearance, it became a major driver of mental health related QoL",0.85
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,House and Brackmann facial nerve scale,clinical_assessment_tool,Behavioral,"Grade 1: 14 patients (63%), Grades 2-3: 5 patients (23%), Grades 5-6: 3 patients (14%) in NF2 cohort",Results,Facial nerve scale Grade 1 NA 14 (63%) Grades 2 and 3 NA 5 (23%) Grades 5 and 6 NA 3 (14%),0.95
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,NF1 R1947X minipig model,animal_model,Biomarker,Optic nerve from untreated NF1 minipigs showed significantly elevated p-ERK compared to WT controls,Results,"However, optic nerve from untreated NF1 minipigs showed significantly elevated p-ERK compared to WT controls",0.9
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,NF1 R1947X minipig model,animal_model,Mechanistic,Selumetinib concentrations were higher in cerebral cortex (P = .03) and optic nerve (P = .03) from NF1 minipigs compared to WT minipigs,Results,"Interestingly, the mean selumetinib concentration was higher in cerebral cortex (P = .03) and optic nerve (P = .03) from NF1 minipigs compared to WT minipigs",0.95
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,NF1 R1947X minipig model,animal_model,Mechanistic,"Selumetinib treatment resulted in inhibition of p-ERK in optic nerve from NF1 minipigs (mean 60% inhibition), effectively reducing p-ERK to WT levels",Results,"Selumetinib treatment resulted in inhibition of p-ERK in optic nerve from NF1 minipigs (mean 60% inhibition), effectively reducing p-ERK to WT levels",0.95
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,NF1 R1947X minipig model,animal_model,Mechanistic,"Inhibition of p-ERK was detected in cerebral cortex from NF1 minipigs (mean 71% inhibition), but the change was not significant",Results,"Similarly, inhibition of p-ERK was detected in cerebral cortex from NF1 minipigs (mean 71% inhibition), but the change was not significant",0.85
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,Phospho-p44/42 ERK1/2 antibody (Cell Signaling Technologies #4370S),antibody,Biomarker,Up to 90% inhibition of p-ERK (mean 60%) was observed from 2 to 5 h in PBMCs and did not differ between genotypes,Results,Up to 90% inhibition of p-ERK (mean 60%) was observed from 2 to 5 h and did not differ between genotypes,0.95
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,Phospho-p44/42 ERK1/2 antibody (Cell Signaling Technologies #4370S),antibody,Biomarker,Inhibition of p-ERK was pronounced in the skin (mean 94% inhibition) and sciatic nerve (mean 64% inhibition) of all minipigs after selumetinib treatment,Results,Inhibition of p-ERK was pronounced in the skin (mean 94% inhibition) and sciatic nerve (mean 64% inhibition) of all minipigs after selumetinib treatment,0.95
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,Phospho-p44/42 ERK1/2 antibody (Cell Signaling Technologies #4370S),antibody,Biomarker,The magnitude of p-ERK inhibition positively correlated with selumetinib plasma concentration at 2 h and 5 h,Results,The magnitude of p-ERK inhibition positively correlated with selumetinib plasma concentration at 2 h and 5 h,0.9
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,DUSP6 TaqMan primer (Ss06941845_m1),genetic_reagent,Biomarker,"DUSP6 was downregulated in skin, sciatic nerve, optic nerve, and cerebral cortex of all treated minipigs, illustrating target engagement",Results,"Key MAPK pathway genes DUSP6 and FOS were downregulated in skin, sciatic nerve, optic nerve, and cerebral cortex of all treated minipigs, illustrating target engagement",0.9
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,FOS TaqMan primer (Ss03390402_m1),genetic_reagent,Biomarker,"FOS was downregulated in skin, sciatic nerve, optic nerve, and cerebral cortex of all treated minipigs, illustrating target engagement",Results,"Key MAPK pathway genes DUSP6 and FOS were downregulated in skin, sciatic nerve, optic nerve, and cerebral cortex of all treated minipigs, illustrating target engagement",0.9
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,Wes system (ProteinSimple 004–600),advanced_cellular_model,Biomarker,"System successfully detected p-ERK inhibition in tissues, with skin and sciatic nerve showing the most drastic decrease in target gene expression",Results,"Consistent with pharmacodynamic analysis of p-ERK, skin and sciatic nerve showed the most drastic decrease in target gene expression",0.85
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,"Nf1+/- GFAP CKO (Nf1flox/mut;GFAP-Cre, Nf1-CKO)",animal_model,Behavioral,Only female Nf1-CKO mice exhibited reduced visual acuity on VOS testing,Results,only female Nf1-CKO mice exhibited reduced visual acuity on VOS testing,0.95
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,"Nf1+/- GFAP CKO (Nf1flox/mut;GFAP-Cre, Nf1-CKO)",animal_model,Biomarker,Female Nf1-CKO mice had ~2-fold more retinal ganglion cell death (RGC apoptosis) relative to their male counterparts,Results,female Nf1-CKO mice had ~2-fold more retinal ganglion cell death (RGC apoptosis) relative to their male counterparts,0.95
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,"Nf1+/- GFAP CKO (Nf1flox/mut;GFAP-Cre, Nf1-CKO)",animal_model,Behavioral,Only Nf1-CKO male mice showed no spatial preference and spent equal time in all quadrants during memory acquisition and retention trials,Results,only Nf1-CKO male mice showed no spatial preference and spent equal time in all quadrants during both the memory acquisition (probe trial 1) and retention (probe trial 2) trials,0.95
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,"Nf1+/- GFAP CKO (Nf1flox/mut;GFAP-Cre, Nf1-CKO)",animal_model,Behavioral,Male Nf1-CKO mice exhibited a 25% reduction in time spent and number of entries into the target quadrant relative to littermate controls,Results,male Nf1-CKO mice exhibited a 25% reduction in time spent and number of entries into the target quadrant relative to littermate controls,0.95
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,"Nf1+/- GFAP CKO (Nf1flox/mut;GFAP-Cre, Nf1-CKO)",animal_model,Biomarker,Only female Nf1-CKO mice had lower retinal cAMP levels relative to controls,Results,only female Nf1-CKO mice had lower retinal cAMP levels relative to controls,0.95
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,"Nf1+/- GFAP CKO (Nf1flox/mut;GFAP-Cre, Nf1-CKO)",animal_model,Biomarker,Only Nf1-CKO male mice had reduced hippocampal dopamine levels and DARPP32 phosphorylation compared to controls,Results,only Nf1-CKO male mice had reduced hippocampal dopamine levels and DARPP32 phosphorylation compared to controls,0.95
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,"Nf1+/- GFAP CKO (Nf1flox/mut;GFAP-Cre, Nf1-CKO)",animal_model,Biomarker,Only male Nf1-CKO mice exhibited increased hippocampal Ras activation and ERK1/2 phosphorylation (activation) relative to controls,Results,only male Nf1-CKO mice exhibited increased hippocampal Ras activation and ERK1/2 phosphorylation (activation) relative to controls,0.95
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,virtual optokinetic system (VOS),clinical_assessment_tool,Behavioral,Successfully detected reduced visual acuity specifically in female Nf1-CKO mice but not males,Results,only female Nf1-CKO mice exhibited reduced visual acuity on VOS testing,0.9
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,Morris Water Maze,clinical_assessment_tool,Behavioral,"Successfully detected spatial learning impairments specifically in male Nf1-CKO mice during probe trials, showing no spatial preference",Results,only Nf1-CKO male mice showed no spatial preference and spent equal time in all quadrants during both the memory acquisition (probe trial 1) and retention (probe trial 2) trials,0.9
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,TUNEL assay (Roche Diagnostics),genetic_reagent,Biomarker,Detected ~2-fold more retinal ganglion cell death in female Nf1-CKO mice relative to males,Results,female Nf1-CKO mice had ~2-fold more retinal ganglion cell death (RGC apoptosis) relative to their male counterparts,0.9
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,cAMP assay (New East Biosciences),genetic_reagent,Biomarker,Detected lower retinal cAMP levels specifically in female Nf1-CKO mice compared to controls,Results,only female Nf1-CKO mice had lower retinal cAMP levels relative to controls,0.9
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,dopamine assay (Rocky Mountain Diagnostics),genetic_reagent,Biomarker,Detected reduced hippocampal dopamine levels specifically in male Nf1-CKO mice compared to controls,Results,only Nf1-CKO male mice had reduced hippocampal dopamine levels and DARPP32 phosphorylation compared to controls,0.9
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,Ras activation assay (Millipore),genetic_reagent,Biomarker,Detected increased hippocampal Ras activation specifically in male Nf1-CKO mice relative to controls,Results,only male Nf1-CKO mice exhibited increased hippocampal Ras activation and ERK1/2 phosphorylation (activation) relative to controls,0.9
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,pDARPP32 antibody,antibody,Biomarker,Detected reduced DARPP32 phosphorylation specifically in male Nf1-CKO mice compared to controls,Results,only Nf1-CKO male mice had reduced hippocampal dopamine levels and DARPP32 phosphorylation compared to controls,0.9
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,pERK1/2 antibody,antibody,Biomarker,Detected increased ERK1/2 phosphorylation (activation) specifically in male Nf1-CKO mice relative to controls,Results,only male Nf1-CKO mice exhibited increased hippocampal Ras activation and ERK1/2 phosphorylation (activation) relative to controls,0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Nf1Osx-/- mice,animal_model,Biomarker,BMSCs formed significantly less CFU-Ap and CFU-Ob colonies than WT littermates,Results,BMSCs from Nf1 mice formed significantly less CFU-Ap and CFU-Ob colonies than BMSCs from WT littermates,0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Nf1Osx-/- mice,animal_model,Biomarker,"Significant decrease in expression of osteoblast marker genes including Alpl, Runx2, Osx, Col1a1 and Ocn compared to WT BMSCs",Results,"characterized by a significant decrease in the expression of major osteoblast marker genes, including Alpl, Runx2, Osx, Col1a1 and Ocn compared to WT BMSCs",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Nf1Osx-/- mice,animal_model,Biomarker,Higher level of P-ERK detected in BMSCs compared to WT mice,Results,higher level of P-ERK was detected in BMSCs prepared from Nf1 osx −/− mice compared to WT mice,0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Nf1Osx-/- mice,animal_model,Efficacy,Callus formation severely impaired with atrophic callus 21 days post-fracture,Results,"callus formation was severely impaired in Nf1 osx −/− mice compared to WT mice, as visualized by the formation of an atrophic callus 21 days post-fracture",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Nf1Osx-/- mice,animal_model,Biomarker,"Significantly smaller calcified callus 21 day post-fracture, lower callus tissue mineral density and callus BV/TV compared to WT mice",Results,"significantly smaller calcified callus 21 day post-fracture...as well as a lower callus tissue mineral density (TMD, Fig. 4f ) and callus BV/TV ( Fig. 4g ) in Nf1 osx −/− mice compared to WT mice",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Nf1Osx-/- mice,animal_model,Efficacy,Calluses were less stiff and mechanically weaker than WT mice as measured by flexural testing,Results,"calluses from Nf1 osx −/− mice were less stiff and mechanically weaker than the ones from WT mice, as measured by flexural testing",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Nf1flox/flox bone marrow stromal cells,cell_line,Biomarker,Ex vivo Nf1 ablation induced significant reduction in CFU-Ap and CFU-Ob colonies following 14 days of differentiation,Results,ex vivoNf1 ablation in Nf1 flox/flox BMSCs induces a significant reduction in the number of CFU-Ap and CFU-Ob colonies following 14 days of differentiation,0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Ad5-CMV-cre,genetic_reagent,Efficacy,Led to approximately 70% recombination efficiency as shown by genomic PCR,Results,"This approach led to an approximate 70% recombination efficiency, as shown by genomic PCR",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Trametinib,genetic_reagent,Mechanistic,"Potently abolished ERK1/2 phosphorylation at 0.1μM, with or without BMP2 treatment",Results,"Trametinib potently abolished ERK1/2 phosphorylation, with or without BMP2 treatment",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Trametinib,genetic_reagent,Efficacy,Had no effect on differentiation of Nf1-deficient BMSCs when used alone,Results,"MEK inhibition enhanced differentiation of WT BMSCs, but had no effect on the differentiation of Nf1 -deficient BMSCs either",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Trametinib,genetic_reagent,Efficacy,"Combination treatment with rBMP2 significantly increased CFU-Ob colonies in Nf1-deficient BMSC cultures and increased osteoblast marker gene expression including Alpl, Runx2 and Ocn",Results,"combination treatment with Trametinib and rBMP2significantly increased the number of CFU-Ob colonies in Nf1 -deficient BMSC cultures...resulted in an increase in osteoblast marker gene expression, including Alpl, Runx2 and Ocn",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Trametinib,genetic_reagent,Efficacy,Local administration alone did not improve bone healing parameters in Nf1 osx −/− mice,Results,rBMP2 and Trametinib treatment alone did not improve bone healing parameters in Nf1 osx −/− mice,0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Trametinib,genetic_reagent,Efficacy,"Combined with rBMP2, significantly increased callus TV, BV, BV/TV and TMD in Nf1 osx −/− mice compared to vehicle or single drug controls",Results,"callus TV, BV, BV/TV and TMD were significantly higher in Nf1 osx −/− mice treated with the rBMP2+Trametinib combination, compared to vehicle or single drug controls",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,Trametinib,genetic_reagent,Efficacy,"Combined with BMP2, produced callus with higher strength as indicated by increased stiffness and peak force measured by 3-point bending",Results,"mice treated with BMP2+Trametinib had a callus with higher strength compared to mice treated with BMP2 or Trametinib alone, as indicated by their increased stiffness and peak force measured by 3-point bending",0.9
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,anti-Phospho-ERK1/2 antibody,antibody,Biomarker,Detected higher level of P-ERK in BMSCs from Nf1 osx −/− mice compared to WT mice,Results,higher level of P-ERK was detected in BMSCs prepared from Nf1 osx −/− mice compared to WT mice,0.9
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,BRIEF,clinical_assessment_tool,Behavioral,"Small but significant improvements in BRIEF scores from pretreatment to 24-week follow-up (Metacognition Index: F(1,58) = 5.79, p = 0.02, d = 0.18; Behavioral Regulation Index: F(1,59) = 9.19, p = 0.004, d = 0.24)",Results,"ANOVAs indicated small but significant improvements in BRIEF scores from pretreatment to 24-week follow-up (Metacognition Index [MCI]: F (1,58) = 5.79, p = 0.02, d = 0.18; Behavioral Regulation Index [BRI]: F (1,59) = 9.19, p = 0.004, d = 0.24)",0.95
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,BRIEF,clinical_assessment_tool,Behavioral,"Significant improvements at 48-week follow-up (Metacognition Index: F(1,39) = 7.29, p = 0.01, d = 0.27; Behavioral Regulation Index: F(1,39) = 5.63, p = 0.02, d = 0.26)",Results,"48-week follow-up (MCI: F (1,39) = 7.29, p = 0.01, d = 0.27; BRI: F (1,39) = 5.63, p = 0.02, d = 0.26)",0.95
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,Behavior Rating Inventory of Executive Function,clinical_assessment_tool,Behavioral,"At 48 weeks, participants with impaired scores at pretreatment were significantly more likely to show meaningful improvement on Metacognition Index (71%) than those whose initial scores were not impaired (16%; χ² = 9.45, p = 0.009, OR = 13.5)",Results,"at the 48-week follow-up, participants with impaired scores at pretreatment were significantly more likely to show meaningful improvement on MCI (71%) than those whose initial scores were not impaired (16%; χ 2 = 9.45, p = 0.009, OR = 13.5)",0.95
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,Cogstate,clinical_assessment_tool,Behavioral,Analysis of changes in Cogstate working memory (one-back task speed) and visual learning/memory (one-card learning task) did not reveal significant change from pretreatment to 24- or 48-week follow-up,Results,Analysis of changes in Cogstate working memory (one-back task [ONB] speed) and visual learning/memory (one-card learning task [OCL]) did not reveal a significant change in performance from pretreatment to 24- or 48-week follow-up,0.9
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,Cogstate,clinical_assessment_tool,Behavioral,"Distributions of RCI classifications for ONB speed were significantly different from normative population at 24-week (14/66/20%; χ² = 13.74, p = 0.001, OR = 4.6) and 48-week assessment (12/66/22%; χ² = 12.58, p = 0.002, OR = 5.3)",Results,"the distributions of RCI classifications for ONB speed were significantly different from those of the normative population (5/90/5%) at the 24-week assessment (14/66/20%; χ 2 = 13.74, p = 0.001, OR = 4.6) and the 48-week assessment (12/66/22%; χ 2 = 12.58, p = 0.002, OR = 5.3)",0.95
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,Reliable Change Index,clinical_assessment_tool,Behavioral,"RCI analyses indicated proportions for Metacognition Index were significantly different at 48 weeks (5/70/25%; χ² = 12.02, p = 0.002, OR = 6.3), with proportion classified as improved larger than expected",Results,"The proportions for MCI but not BRI were significantly different at 48 weeks (MCI: 5/70/25%; χ 2 = 12.02, p = 0.002, OR = 6.3; Figure 1 ), such that the proportion classified as improved was larger than expected",0.95
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,Reliable Change Index,clinical_assessment_tool,Safety,Overall decreases in executive function ratings were seen in only 5% of the sample on the Metacognition Index and 2.5% on the Behavioral Regulation Index by 48 weeks,Results,overall decreases in executive function ratings were seen in only 5% of the sample on the MCI and 2.5% on the BRI by 48 weeks,0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,"p16/p19+/− Cdkn2a mice (01XB2, FVB/N.129-Cdkn2atm1Rdp)",animal_model,Efficacy,Nf2+/−;p16/p19+/− mice developed MM at greatly accelerated rate (median 24 weeks) compared to Nf2+/− (38 weeks) and WT (45 weeks) mice,Results,"Nf2+/−;p16/p19+/− mice developed MM at a greatly accelerated rate (median, 24 weeks) compared to Nf2+/− (38 weeks) and WT (45 weeks) mice",0.95
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,"p16/p19+/− Cdkn2a mice (01XB2, FVB/N.129-Cdkn2atm1Rdp)",animal_model,Biomarker,Spheroids found in 22% of Nf2+/−;p16/p19+/− mice compared to 4% of Nf2+/− mice and 0% of WT mice,Results,"Overall, spheroids were found in 22% of Nf2+/−;p16/p19+/− mice compared to 4% of Nf2+/− mice and 0% of WT mice",0.95
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,SCID mice,animal_model,Efficacy,"All 9 SCID mice injected with MM cells from Nf2+/−;p16/p19+/− mice showed multiple lung tumors, whereas only 3/9 mice from Nf2+/− mice and 0/9 from WT mice developed tumors",Results,"All 9 SCID mice injected with MM cells from Nf2+/−;p16/p19+/− mice showed multiple tumors in the lungs, whereas only 3/9 mice (embolisms) from Nf2+/− mice and 0/9 from WT mice developed tumors",0.95
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,SCID mice,animal_model,Efficacy,"6/9 lines from p16/p19+/− mice formed tumors in the lung, whereas none of the MM cell lines from WT mice seeded the lungs",Results,"6/9 lines from p16/p19+/− mice formed tumors in the lung, whereas none of the MM cell lines from WT mice seeded the lungs",0.95
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,Ki67 rat monoclonal antibody (Dako),antibody,Biomarker,Nf2+/−;p16/p19+/− mice had tumors with high percentage of Ki67-positive cells,Results,"Nf2+/−;p16/p19+/− mice had an increased incidence of advanced disease compared to Nf2+/− and WT mice, with most tumors being sarcomatous and having a high percentage of Ki67-positive cells",0.85
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,anti-CD24 FITC-labeled antibody (BD Biosciences),antibody,Biomarker,Adherent MM cells from Nf2+/−;p16/p19+/− mice stained more intensely for CD24 than MM cells from WT mice,Results,adherent MM cells from Nf2+/−;p16/p19+/− mice stained more intensely for the MM-specific CSC marker CD24 than did MM cells from WT mice,0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,c-met rabbit polyclonal antibody (Santa Cruz),antibody,Biomarker,Total c-Met protein expression was elevated in MM cells from Nf2+/−;p16/p19+/− mice and in primary tumors from these mice vs. WT animals,Results,both total c-Met protein expression and phosphorylation/activation were elevated in MM cells from Nf2+/−;p16/p19+/− mice and in primary tumors from Nf2+/−;p16/p19+/− mice vs. from WT animals,0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,phosphorylated c-met rabbit polyclonal antibody (Invitrogen),antibody,Biomarker,c-Met phosphorylation/activation was elevated in MM cells from Nf2+/−;p16/p19+/− mice and in primary tumors from these mice vs. WT animals,Results,both total c-Met protein expression and phosphorylation/activation were elevated in MM cells from Nf2+/−;p16/p19+/− mice and in primary tumors from Nf2+/−;p16/p19+/− mice vs. from WT animals,0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,SU-11274,genetic_reagent,Efficacy,SU11274 treatment for 24 h inhibited wound closure/migration of MM cells from Nf2+/−;p16/p19+/− mice,Results,SU11274 treatment for 24 h inhibited wound closure/migration of MM cells from these mice,0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,SU-11274,genetic_reagent,Mechanistic,SU11274 treatment blocks phosphorylation of c-Met and ERK1/2 in MM cell lines tested,Results,SU11274 treatment blocks phosphorylation of c-Met and ERK1/2 in both MM cell lines tested,0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,SU-11274,genetic_reagent,Efficacy,Treatment with SU11274 significantly reduced the invasiveness of all three MM cell lines from Nf2+/−;p16/p19+/− mice,Results,treatment with SU11274 significantly reduced the invasiveness of all three MM cell lines from Nf2+/−;p16/p19+/− mice,0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,SU-11274,genetic_reagent,Efficacy,SU11274 significantly reduced the size of spheroids formed without affecting cell viability,Results,"MM cells grown in a spheroid assay were treated with SU11274 and SGX-523, and both inhibitors significantly reduced the size of spheroids formed without affecting cell viability",0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,SGX2943 (Calbiochem),genetic_reagent,Efficacy,SGX-523 significantly reduced the size of spheroids formed without affecting cell viability,Results,"MM cells grown in a spheroid assay were treated with SU11274 and SGX-523, and both inhibitors significantly reduced the size of spheroids formed without affecting cell viability",0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,SGX2943 (Calbiochem),genetic_reagent,Efficacy,SGX-523 decreased the percentage of aldefluor-positive MM cells from Nf2+/−;p16/p19+/− mice in a concentration-dependent manner,Results,"inhibition of c-Met with the less promiscuous small molecule inhibitor SGX-523, decreased the percentage of aldefluor-positive MM cells from Nf2+/−;p16/p19+/− mice in a concentration-dependent manner",0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,siRNA against Tp53 (Dharmacon),genetic_reagent,Mechanistic,miR34a levels were significantly downregulated when Tp53 was knocked down,Results,miR34a levels were significantly downregulated when Tp53 was knocked down,0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,siRNA against Tp53 (Dharmacon),genetic_reagent,Mechanistic,Knockdown of p53 with siRNA caused a modest upregulation of c-Met protein levels,Results,knockdown of p53 with siRNA caused a modest upregulation of c-Met protein levels,0.85
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,siRNA against miR34a (Dharmacon),genetic_reagent,Mechanistic,Re-expression of miR34a in Nf2+/−;p16/p19+/− cells was sufficient to downregulate c-Met protein levels,Results,re-expression of miR34a in Nf2+/−;p16/p19+/− cells was sufficient to downregulate c-Met protein levels,0.9
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,BioCoat Matrigel invasion chambers (Becton Dickinson),advanced_cellular_model,Efficacy,All three MM cell lines derived from Nf2+/−;p16/p19+/− mice were more invasive than MM cells from WT mice,Results,"All three MM cell lines derived from Nf2+/−;p16/p19+/− mice were more invasive than MM cells from WT mice, consistent with c-Met activation correlating with invasiveness",0.9
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,NuGEN SPET for RNA,genetic_reagent,Efficacy,Successfully detected all expected pathogenic splicing events in validation samples with high enrichment scores (ERS ranging from 6.1 to 44.9),Results,For the nine samples with a known pathogenic splice-variant all expected (major) pathogenic splicing events were detected using QURNAs. The highest ERS per sample and concomitant major drop in ERS of the normal exon-exon splice-junctions due to alternative splicing are listed,0.95
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,Agilent SureSelect RNA Target Enrichment,genetic_reagent,Efficacy,"Comparable results to NuGEN SPET with some variations in ERS and reads, successfully detected all splicing events",Results,Comparable results were obtained with QURNAs using the different enrichment protocols. All splicing events were present using both methods with some variations in ERS and reads,0.9
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,QURNAs,computational_tool,Efficacy,"Detected 24 out of 25 previously reported normal splicing events, with median ERS ~1 and >5000 reads per splice junction for normal events",Results,"From the 25 previously reported normal (rare) events, 24 were detected. Approximately half of these previously reported events are major splicing events, detected by QURNAs in almost all of the patient derived cells (median ERS~1 & reads >1000)",0.95
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,QURNAs,computational_tool,Efficacy,Successfully identified pathogenic splicing events in 5 out of 11 undiagnosed patients (45% detection rate),Results,(Likely) pathogenic NF1 splicing events could be detected in five out of these 11 patients using RNAseq (45%). For three of them this was a confirmation of a (likely) pathogenic splicing event caused by a DNA variant suspected to have an effect on splicing,0.95
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,QURNAs,computational_tool,Efficacy,Detected 2 deep intronic variants in 8 patients without prior molecular diagnosis (25% detection rate),Results,"For two patients (of eight without a prior molecular diagnosis) the pathogenic splicing event was caused by a deep-intronic DNA variant (25%), that was previously not detected using standard DNA diagnostics",0.9
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,STAR mapper (Version 2.4.1d),computational_tool,Efficacy,Successfully mapped RNA sequencing reads for splice junction analysis,Results,RNA was enriched for NF1 using PCR based (NuGEN SPET) approach or for NF1 and SPRED1 using hybridization based enrichment (Agilent SureSelect) as indicated,0.8
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,puromycin (Sigma-Aldrich),genetic_reagent,Mechanistic,Used as NMD inhibitor in cell culture to prevent nonsense-mediated mRNA decay for better detection of aberrant transcripts,Results,short term cultured blood lymphocytes + puromycin,0.85
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,Genome Analysis Toolkit (GATK),computational_tool,Other,Used as part of the ngVES pipeline for variant calling in exome sequencing data analysis,Results,"Based on best-match phenotype-genotype associations of genes known to be linked to skin diseases, 88 (66%) of patients had a positive gene finding",0.7
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,Burrows-Wheeler Aligner (bwa-0.7.15),computational_tool,Other,Used as part of the ngVES pipeline for sequence alignment in the diagnostic workflow,Results,"Overall, the diagnostic rate of ES analysis (SNVs/INDELs) improved from 58% to 66% with ngVES analysis (SNVs/INDELs plus CNVs)",0.7
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,Sambamba (v0.6.6),computational_tool,Other,Used as part of the ngVES pipeline contributing to the improved diagnostic yield from 58% to 66%,Results,"This was considered a small, but clinically significant, increased diagnostic yield",0.7
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,exome hidden Markov model (XHMM),computational_tool,Efficacy,"Successfully identified 9 pathogenic CNVs as part of the ngVES pipeline, with all CNVs independently confirmed by other molecular methods",Results,"The 9 pathogenic CNVs identified by the ngVES pipeline were independently assessed by other molecular methods... In all 5 cases, independent MLPA confirmed the CNVs called by ngVES",0.9
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,Leiden Open Variation Database (LOVD),computational_tool,Other,"Used as source for known pathogenicity status of NF1 variants in training dataset, containing 22,323 variants total with 751 (3.36%) pathogenic and 21,572 (96.6%) benign variants",Results,"Initially we composed a comprehensive list of all the variants with known pathogenicity status across the NF1 gene. The final list of variants included 22,323 variants, 21,572 (96.6%) of which were benign and 751 (3.36%) pathogenic.",0.95
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,1000 Genomes Project,computational_tool,Other,"Used as annotation source for population-based allele frequencies in the final variant dataset of 19,145 nonsynonymous and splice site variants",Discussion,"The final variant list includes 19,145 variants with various genetic annotations including variant type, genetic region, population based allele frequencies, functional prediction scores and our own model's final score.",0.85
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,Exome Aggregation Consortium (ExAC),computational_tool,Other,"Used as annotation source for population-based allele frequencies in the final variant dataset of 19,145 nonsynonymous and splice site variants",Discussion,"The final variant list includes 19,145 variants with various genetic annotations including variant type, genetic region, population based allele frequencies, functional prediction scores and our own model's final score.",0.85
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,Genome Aggregation Database (gnomAD),computational_tool,Other,"Used as annotation source for population-based allele frequencies in the final variant dataset of 19,145 nonsynonymous and splice site variants",Discussion,"The final variant list includes 19,145 variants with various genetic annotations including variant type, genetic region, population based allele frequencies, functional prediction scores and our own model's final score.",0.85
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,SnpEff,computational_tool,Other,"Used for variant annotation including genetic effect prediction and variant type classification in the analysis of 22,323 NF1 variants",Results,"Variants were annotated with their predicted genetic effect, the rate of pathogenic variants was calculated for each genetic effect and an odds ratio was calculated in order to rank them according to their association with pathogenicity.",0.85
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,dbNSFP,computational_tool,Efficacy,"Provided functional prediction scores used as input features for the NF1-specific machine learning model, which achieved AUC of 0.946 for nonsynonymous variants and 0.962 including splice variants",Results,"In order to train our own prediction model, we used as input the scores provided by each prediction tool, together with various other annotations... The model demonstrated a significantly higher AUC value than the tool with the highest AUC (0.946; P < 0.05).",0.9
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,H2O R package,computational_tool,Efficacy,"Used to implement stacked ensemble machine learning algorithms that achieved superior performance with AUC of 0.946 for nonsynonymous variants, significantly outperforming existing tools",Results,The final model was based on a stacked ensemble of four different machine learning algorithms... The model demonstrated a significantly higher AUC value than the tool with the highest AUC (0.946; P < 0.05).,0.92
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,shiny web application framework,computational_tool,Other,"Used to create publicly accessible webserver containing 19,145 annotated NF1 variants with prediction scores for researchers and clinicians to evaluate variants of interest",Results,"In order to allow researchers and clinicians to evaluate NF1 variants of interest, we generated a webserver that includes the entire set of NF1 nonsynonymous and splice site variants with various annotations, including our model's final score",0.9
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,Illumina Infinium HumanOmni-1Quad bead-chips,computational_tool,Other,"Generated 608,561 SNPs from 112 samples in the CALM1 cohort for GWAS analysis",Results,"Figure 1 presents the ‐log 10 ( p ‐value) of tests of association using EMMAX on 608,561 SNPs from 112 samples in the CALM1 cohort",0.95
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,Illumina Infinium Omni2.5 bead-chips,computational_tool,Other,"Generated 623,562 SNPs from 59 samples from the CALM2 cohort for GWAS analysis",Results,"623,562 SNPs from 59 samples from the CALM2 cohort (middle panel)",0.95
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,EMMAX,computational_tool,Other,Identified two SNPs (rs12190451 and rs3799603) with borderline genome-wide significant association (p = 7.4 × 10^-8) with CALM number in CALM1 cohort,Results,"two SNPs in LD ( r 2 = 1, D' = 1) on chromosome 6, rs12190451 and rs3799603, in the intronic region of RPS6KA2 , had a borderline genome‐wide significant association ( p = 7.4 × 10 −8 )",0.95
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,EMMAX,computational_tool,Other,Identified 15 RPS6KA2 SNPs with suggestive genome-wide significance (p < 1.0 × 10^-5) using simple linear regression in CALM1 cohort,Results,There were 15 RPS6KA2 SNPs with suggestive genome‐wide significance ( p < 1.0 × 10 −5 ) using simple linear regression (SLR) in the CALM1 cohort,0.95
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,ComPaSS-GWAS,computational_tool,Other,"Identified SNPs with corroboration scores >0.6: rs3799603 and rs12190451 in RPS6KA2 (score 0.72) in CALM1, and rs11742602 (score 0.75) and rs1025291 (score 0.67) in ADCY2 in CALM2",Results,the two most significant SNPs identified by EMMAX in RPS6KA2 intron on chromosome 6 (rs3799603 and rs12190451) also had the highest ComPaSS‐GWAS corroboration score (0.72),0.95
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,ComPaSS-GWAS,computational_tool,Other,Confirmed EMMAX findings within each cohort and suggested findings may be replicated in larger more homogeneous samples,Results,The ComPaSS‐GWAS analyses confirmed the findings by EMMAX within each cohort of CALM1 and CALM2 and suggest that these findings may be replicated if larger more homogeneous samples can be obtained,0.85
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,AmpliSeq/IonTorrent platform,computational_tool,Other,"Successfully sequenced ~24 Kb of intron 1 of RPS6KA2 (chr6:166,995,059–167,018,915) for targeted sequencing analysis",Results,"~24 Kb (chr6:166,995,059–167,018,915) of intron 1 of RPS6KA2 was sequenced (transcript variant 1, NM_021135.6 )",0.9
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,GTEx,computational_tool,Biomarker,"None of the RPS6KA2 or ADCY2 associated SNPs were identified as eQTLs for respective genes or any genes in-cis in sun-exposed, non-exposed skin tissues, whole blood, and transformed cultured fibroblasts",Results,"none of the RPS6KA2 or ADCY2 associated SNP (and with ComPaSS‐GWAS scores >0.6) were identified as eQTLs for the respective genes or any genes in‐cis in sun‐exposed, non‐exposed skin tissues, whole blood, and transformed cultured fibroblasts from GTEx",0.9
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,Metabolomics GWAS,computational_tool,Biomarker,"RPS6KA2 SNPs rs4710070 and rs10946177 were significant mQTLs for glutamine (beta = 0.01, p = 9.8 × 10^-4) and prolyl-4-hydroxyproline (beta = 0.02, p = 6.1 × 10^-4) respectively after multiple comparison correction",Results,"RPS6KA2 SNPs rs4710070 and rs10946177 ( r 2 = 0.83) were significant mQTLs for glutamine (beta = 0.01, p ‐value = 9.8 × 10 −4 ) and prolyl‐4‐hydroxyproline (beta = 0.02, p ‐value = 6.1 × 10 −4 )",0.95
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,Wood's lamp,clinical_assessment_tool,Other,"Used for CALM1 cohort to find fainter CALM in older people, but not used for CALM2 cohort, contributing to phenotyping differences between cohorts",Discussion,"The Wood's lamp method (UV light in a dark room) method was used to find CALM for CALM1; this is helpful to find fainter CALM in older people. However, counting of CALM by Wood's lamp was not used for CALM2",0.85
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Safety,"High dose abdominal irradiation (15 and 30 Gy) reduced overall survival in a dose-dependent manner (log-rank test p<0.0001), with median survivals of 469 and 410 days respectively compared to 583 days for unirradiated controls",Results,"radiation-exposure reduced the overall survival of Nf1+/− mice in a dose-dependent manner (log-rank test p<0.0001, Figure 1B) at higher dose levels (15 and 30 Gy). The median survivals of Nf1+/− mice receiving 0, 3, 15, and 30 Gy were 583, 652, 469 and 410 days, respectively.",0.95
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Efficacy,"Tumor incidence increased with increasing radiation dose (p < 0.0001 by χ2 analysis), demonstrating enhanced radiation-induced tumorigenesis compared to wildtype mice",Results,"Tumors were more common in Nf1+/− mice than WT mice, and for Nf1+/− mice tumor incidence increased with increasing radiation dose (p < 0.0001 by χ2 analysis, Figure 2)",0.95
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Efficacy,"Sarcomas were significantly more common in irradiated Nf1+/- mice than irradiated wildtype mice (p = 0.0175, log-rank)",Results,"sarcomas are well recognized SMNs after high-dose radiation therapy (21–23), and were significantly more common in irradiated Nf1+/− mice than irradiated WT mice (p = 0.0175, log-rank)",0.95
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Safety,"Solid tumor free survival and hematologic disease free survival were both reduced in a dose-dependent manner (log rank test, p<0.0001 for solid tumor free survival and p=0.0001 for hematologic disease free survival)",Results,"solid tumor free survival and hematologic disease free survival were both reduced in a dose-dependent manner in Nf1+/− mice but not WT mice (Figure 3, log rank test, p<0.0001 for solid tumor free survival in Nf1+/− mice and p=0.0001 for hematologic disease free survival in Nf1+/− mice)",0.95
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Biomarker,Significantly increased mean terminal splenic weight compared to wildtype mice in unirradiated controls,Results,found significantly increased mean terminal splenic weight in unirradiated Nf1+/− mice as compared to WT mice (Supplementary Figure 2A),0.9
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Nf1+/- mice,animal_model,Mechanistic,"Loss of heterozygosity was a common event in tumors, with LOH of Nf1 accompanied by LOH of at least one microsatellite in 87% of all tumors",Results,"Microsatellite and SNP sequencing analysis revealed that loss of heterozygosity was a common event in tumors isolated from Nf1+/− mutant mice (Figure 5), and the frequency of LOH at rs13481119 was similar across the three major classes of solid malignancies... LOH of Nf1 was accompanied by LOH of at least one of the microsatellites in 87% percent of all tumors",0.95
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,"cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA) animal irradiator",advanced_cellular_model,Efficacy,"Successfully delivered fractionated abdominal irradiation at doses of 3, 15, and 30 Gy to generate radiation-induced tumors modeling second malignant neoplasms",Results,"Between 5 – 8 weeks of age, mice were assigned to one of four AI treatment regimens: 0 Gy, 3 Gy (single dose), 15 Gy (5 daily doses of 3 Gy), or 30 Gy (10 daily doses of 3 Gy)",0.9
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,Peak Scanner software from Applied Biosystems,computational_tool,Mechanistic,Successfully analyzed microsatellite markers to determine loss of heterozygosity patterns in radiation-induced tumors,Results,Microsatellite and SNP sequencing analysis revealed that loss of heterozygosity was a common event in tumors isolated from Nf1+/− mutant mice,0.8
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,"7900 HT Fast Real-Time PCR system (Applied Biosystems, USA)",advanced_cellular_model,Mechanistic,Successfully performed Taqman-based SNP genotyping to detect NF1 loss of heterozygosity in human radiation-induced breast cancers,Results,"Radiation-induced breast cancers and matched normal tissue from patients (8 total patients, none known to have the NF1 syndrome) were analyzed using Taqman-based SNP genotyping at multiple loci across the NF1 gene",0.85
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,COSMIC Database,computational_tool,Mechanistic,"Confirmed that identified Trp53 mutations occur in diverse human cancers, validating the clinical relevance of the mouse model findings",Results,"Examination of these mutations in the Catalogue of Somatic Mutations in Cancer (COSMIC, Wellcome Trust Sanger Institute, United Kingdom) revealed that each of these mutations occur in diverse human cancers",0.9
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,Wechsler Intelligence Scales,clinical_assessment_tool,Behavioral,"RASopathies group demonstrated significantly lower full-scale IQ score compared to TD (p=2.35e-13), NS vs TD (p=3.86e-12), NF1 vs TD (p=4.0e-6)",Results,"Our RASopathies group, along with NS and NF1, demonstrated a lower full-scale IQ score compared to TD (RASopathies vs. TD: p= 2.35e −13 , NS vs. TD: p =3.86e −12 , NF1 vs. TD: p =4.0e −6 )",0.95
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,Wechsler Intelligence Scales,clinical_assessment_tool,Behavioral,RASopathies group and specific syndromes (NS and NF1) had significantly lower verbal and performance components of IQ compared to TD,Results,"Additionally, the RASopathies group, as well as the specific syndromes (NS and NF1), compared to TD had significantly lower verbal and performance components of IQ",0.9
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,FreeSurfer,computational_tool,Biomarker,"Detected decreased surface area in temporal pole, lateral occipital, and precuneus regions, with increased surface area in precentral gyrus in RASopathies vs TD (cluster-based fwe p<0.05 corrected)",Results,"Compared to TD, we found that RASopathies had decreased SA in the temporal pole, lateral occipital, and precuneus regions, with increased SA in the precentral gyrus ( Figure 1a , Table 2 )",0.95
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,FreeSurfer,computational_tool,Biomarker,"Identified large effect sizes (d>0.79) in lateralorbitofrontal (d=1.15), lingual (d=1.01), temporal pole (d=1.06), perialcarine (d=1.1), superior frontal (d=0.98), superior temporal (d=0.90), superior parietal (d=0.82), and insula (d=0.79) regions",Results,"specifically the regions with large effect sizes (d>0.79) were the lateralorbitofrontal (d=1.15), lingual (d=1.01), temporal pole (d=1.06), perial carine (d=1.1), superior frontal (d=0.98), superior temporal (d=0.90)",0.95
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,FreeSurfer,computational_tool,Biomarker,Detected overall thinner cortical thickness in precentral gyrus for RASopathies vs TD (cluster-based fwe p<0.05 corrected),Results,"When directly comparing the effect of RASopathies versus TD, we found overall thinner CT in the precentral gyrus ( cluster-based fwe p < 0.05 corrected , Figure 3a )",0.95
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,FreeSurfer,computational_tool,Biomarker,"Identified significant subcortical volume differences in left and right putamen (p=0.003, p=0.002), left and right accumbens (p=0.003, p=1.3e-4), left and right caudate (p=0.004, p=0.005), and left pallidum (p=0.022) for RASopathies vs TD",Results,"we found significant group differences after FDR correction in the left and right putamen ( p =0.003, p =0.002), left and right accumbens ( p =0.003, p= 1.3e −4 ), left and right caudate ( p =0.004, p =0.005), and left pallidum ( p= 0.022)",0.95
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,ComBat harmonization,computational_tool,Other,"Used harmonization methods to preserve biological variability across scanners, accounting for differences in data acquisition",Discussion,"We used harmonization methods to preserve biological variability across scanners, accounting for differences in data acquisition",0.85
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,mri_glmfit,computational_tool,Other,"Used vertex-based analyses to achieve higher spatial resolution, avoid parcellation bias, and detect regional variability",Discussion,"we used vertex-based analyses to have a higher spatial resolution, avoid parcellation bias, and detect regional variability",0.8
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,Desikan ROI parcellation,computational_tool,Biomarker,Used in ROI analysis of subcortical volumes to identify significant group differences between RASopathies and TD groups,Results,"In our ROI analysis of subcortical volumes, we compared RASopathies versus TD and found significant group differences after FDR correction",0.85
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,Nf1+/- mice,animal_model,Efficacy,TGF-β and Nf1+/- MCCM mediated increased recruitment of Nf1+/- fibroblasts into matrigel plugs compared to WT mice,Results,"Consistent with in vitro studies, TGF-β and Nf1+/− MCCM mediates an increase in the recruitment of Nf1+/− fibroblasts into the matrigel plug.",0.85
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,Nf1+/- mice,animal_model,Efficacy,Treatment with 6 μM imatinib mesylate daily for 1 week reduced fibroblast recruitment into matrigel plugs,Results,"Further, treatment of Nf1+/− mice with imatinib mesylate reduces this process.",0.8
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,FITC-conjugated anti-ColIA monoclonal antibody,antibody,Other,Used for verification of fibroblast purity from human neurofibromas by fluorescence cytometry,Results,Verification of the purity of the fibroblasts was established using fluorescence cytometry using a ColIA antibody that specifically recognizes human fibroblasts,0.9
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,"TGF-β neutralizing antibodies (Cat. no. AF-101-NA, R&D Systems)",antibody,Mechanistic,Reduced Nf1+/- fibroblast collagen synthesis to basal levels when added to cultures stimulated with Nf1+/- MCCM,Results,"In five independent experiments, the Nf1+/− fibroblast collagen synthesis was reduced to a basal level by the addition of TGF-β neutralizing antibodies.",0.95
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,MSCV-NF1 GRD-pac,genetic_reagent,Mechanistic,Corrected elevated Ras activity in Nf1+/- fibroblasts to WT levels following TGF-β stimulation,Results,"However, expression of the GRD domains in Nf1+/− fibroblasts corrects the elevated Ras activity of Nf1+/− fibroblasts to WT levels.",0.95
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,MSCV-NF1 GRD-pac,genetic_reagent,Efficacy,Reduced collagen synthesis in Nf1+/- fibroblasts to levels comparable to WT control fibroblasts,Results,"However, the proline incorporation of Nf1+/− fibroblasts transduced with the GRD construct was comparable to WT control fibroblasts",0.9
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,MSCV-NF1 GRD-pac,genetic_reagent,Efficacy,Restored collagen synthesis to control fibroblast levels in human neurofibroma fibroblasts in response to TGF-β,Results,"Importantly, transduction of the GRD transgene into fibroblasts generated from human neurofibromas restored collagen synthesis to control fibroblast levels in response to TGF-β.",0.95
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,MSCV-NF1 GRD-pac,genetic_reagent,Mechanistic,Restored c-abl activity to WT levels in Nf1+/- fibroblasts,Results,"However, this increased activity was corrected to WT levels in cells that contained the GRD sequences, indicating that hyperactivation of c-abl was mediated through p21 ras signalling.",0.9
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,MSCV-1276P NF1 GRD-pac,genetic_reagent,Mechanistic,"Did not alter migration, proliferation or collagen synthesis of Nf1+/- fibroblasts, confirming requirement for functional GAP activity",Discussion,"Importantly, transduction of GRD sequences harboring a known patient mutation that inactivates GTPase function does not alter the migration, proliferation or collagen synthesis of Nf1+/− fibroblasts.",0.9
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,"c-abl siRNA oligonucleotides (Cat. no. sc-29844, Santa Cruz Biotechnology)",genetic_reagent,Mechanistic,Diminished endogenous c-abl transcripts by at least 90%,Results,c-abl siRNA diminished endogenous c-abl transcripts by at least 90%,0.95
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,"c-abl siRNA oligonucleotides (Cat. no. sc-29844, Santa Cruz Biotechnology)",genetic_reagent,Efficacy,Inhibited collagen synthesis in Nf1+/- fibroblasts,Results,Nf1+/− fibroblasts transfected with siRNA sequences to c-abl inhibited collagen synthesis,0.9
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,p21 ras activation pulldown assay kit (Upstate Biotechnology),computational_tool,Biomarker,Detected approximately 3-fold increase in Ras activity in Nf1+/- fibroblasts compared to WT cells following TGF-β stimulation,Results,"Following stimulation, Nf1+/− fibroblasts transduced with the reporter transgene or the construct containing the 1276 Arg mutation have approximately a 3-fold increase in Ras activity when compared with WT cells.",0.95
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,p21 ras activation pulldown assay kit (Upstate Biotechnology),computational_tool,Biomarker,Showed significant increase in TGF-β-stimulated Ras activity in human neurofibroma fibroblasts compared to control fibroblasts,Results,"Similar to murine Nf1+/− fibroblasts, there is a significant increase in TGFβ-stimulated Ras activity in fibroblasts from neurofibromas when compared with Ras activity in fibroblasts from unaffected control individuals",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Sprague‒Dawley rats,animal_model,Behavioral,Rats transplanted with LV-NF-1-treated NSCs achieved notably better BBB scores than other injured groups from 2nd week through 8th week,Results,the rats transplanted with the LV-NF-1-treated NSCs achieved notably better BBB scores than those in the other injured groups in each evaluation from the 2nd week,0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Sprague‒Dawley rats,animal_model,Behavioral,"Rats in SCI+LV-NF-1 NSC group could stand up and walk slowly using hindlimbs, while LV-vector NSC-treated rats could hardly stand up",Results,"The rats in the SCI+LV-NF-1 NSC group could stand up and walk slowly using their hindlimbs, while the rats in the LV-vector NSC-treated group could hardly stand up",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Sprague‒Dawley rats,animal_model,Biomarker,SCEP of LV-NF-1 NSC-treated rats showed shorter latency and higher amplitude compared to control groups,Results,"the SCEP of the LV-NF-1 NSC-treated rats with SCI was stronger than that of the SCI+LV-vector NSC and control groups, expressed as shorter latency and higher amplitude",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,LV-NF-1 sgRNA-CAS9 lentivirus,genetic_reagent,Efficacy,Significantly decreased TUNEL-positive cells in NF-1 knockout NSCs compared to control and LV-vector groups,Results,the number of TUNEL-positive cells significantly decreased in the NF-1 knockout NSCs but increased overwhelmingly in the Rictor knockout NSCs,0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,LV-NF-1 sgRNA-CAS9 lentivirus,genetic_reagent,Mechanistic,"Enhanced mTORC2 pathway with upregulated P-mTOR, Rictor, MAP2, and β3-Tubulin expression after NF-1 knockout",Results,"after the knockout of NF-1, the expression of phosphorylated mTOR (P-mTOR), Rictor, MAP2, and β3-Tubulin was upregulated",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,LV-NF-1 sgRNA-CAS9 lentivirus,genetic_reagent,Efficacy,Proportions of MAP2-positive and β3-Tubulin-positive cells increased significantly in LV-NF-1-treated NSCs,Results,the proportions of MAP2-positive and β3-Tubulin-positive cells in the LV-NF-1-treated NSCs increased significantly,0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,LV-Rictor sgRNA-CAS9 lentivirus,genetic_reagent,Efficacy,Increased TUNEL-positive cells overwhelmingly in Rictor knockout NSCs,Results,the number of TUNEL-positive cells significantly decreased in the NF-1 knockout NSCs but increased overwhelmingly in the Rictor knockout NSCs,0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,LV-Rictor sgRNA-CAS9 lentivirus,genetic_reagent,Mechanistic,"Blocked mTORC2 pathway with significantly decreased P-mTOR, Rictor, MAP2, and β3-Tubulin expression",Results,"after Rictor knockout, the mTORC2 pathway was blocked, and the expression levels of P-mTOR, Rictor, MAP2, and β3-Tubulin decreased significantly",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Neural stem cells,cell_line,Efficacy,"NF-1 knockout NSCs showed 1.8-fold greater NF-200-positive cells, 2.1-fold greater MAP2-positive cells, and 2.2-fold greater β3-Tubulin-positive cells compared to vector control",Results,"the counts of NF-200-, MAP2- and β3-Tubulin-positive cells in the SCI+LV-NF-1 NSC group were 1.8-, 2.1-, and 2.2-fold greater, respectively",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Neural stem cells,cell_line,Efficacy,GFAP-positive cells reduced to 28.3% in NF-1 knockout NSCs compared to vector control,Results,while the count of GFAP-positive cells was reduced to 28.3%,0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,BBB open-field locomotor test,clinical_assessment_tool,Behavioral,"All rats subjected to SCI had score of zero on first day, with LV-NF-1 NSC group achieving notably better scores from 2nd week onwards",Results,"All rats subjected to SCI had a score of zero on the first day after the injury, which indicates the success of SCI. All injured rats achieved higher BBB scores from the 1st week to the 8th week",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Anti-MAP2 antibody,antibody,Biomarker,MAP2 expression upregulated after NF-1 knockout and downregulated after Rictor knockout in NSCs,Results,"after the knockout of NF-1, the expression of phosphorylated mTOR (P-mTOR), Rictor, MAP2, and β3-Tubulin was upregulated",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Anti-β3-Tubulin antibody,antibody,Biomarker,β3-Tubulin expression upregulated after NF-1 knockout and downregulated after Rictor knockout in NSCs,Results,"after the knockout of NF-1, the expression of phosphorylated mTOR (P-mTOR), Rictor, MAP2, and β3-Tubulin was upregulated",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Anti-GFAP antibody,antibody,Biomarker,GFAP expression significantly downregulated in LV-NF-1-treated NSCs and upregulated in LV-Rictor-treated NSCs,Results,GFAP expression was significantly downregulated in both the LV-NF-1-treated NSCs and the LV-NF-1+Rictor-treated NSCs but significantly upregulated in the LV-Rictor-treated NSCs,0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Anti-cleaved caspase-3 antibody,antibody,Biomarker,"Cleaved caspase-3 expression decreased in NF-1 knockout NSCs, showing strongest alleviation of cell apoptosis",Results,"The LV-NF-1-treated NSCs showed the strongest alleviation of cell apoptosis, followed by the NSCs treated with LV-NF-1+LV-Rictor, LV-vector, and LV-Rictor",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Anti-P-mTOR antibody,antibody,Biomarker,P-mTOR expression upregulated after NF-1 knockout and decreased after Rictor knockout,Results,"after the knockout of NF-1, the expression of phosphorylated mTOR (P-mTOR), Rictor, MAP2, and β3-Tubulin was upregulated",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Anti-Rictor antibody,antibody,Biomarker,Rictor expression upregulated after NF-1 knockout and decreased significantly after Rictor knockout,Results,"after the knockout of NF-1, the expression of phosphorylated mTOR (P-mTOR), Rictor, MAP2, and β3-Tubulin was upregulated",0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Anti-CNPase antibody,antibody,Biomarker,CNPase levels markedly higher in rats treated with LV-NF-1 NSCs compared to LV-vector NSC-treated rats,Results,the rats treated with LV-NF-1 NSCs expressed markedly higher CNPase and MBP levels than the LV-vector NSC-treated rats,0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,Anti-myelin basic protein (MBP) antibody,antibody,Biomarker,MBP levels markedly higher in rats treated with LV-NF-1 NSCs compared to LV-vector NSC-treated rats,Results,the rats treated with LV-NF-1 NSCs expressed markedly higher CNPase and MBP levels than the LV-vector NSC-treated rats,0.9
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,TUNEL kit,genetic_reagent,Biomarker,TUNEL staining showed significantly decreased apoptotic cells in NF-1 knockout NSCs compared to control groups,Results,"TUNEL staining showed that compared with that of the control and LV-vector-treated NSCs, the number of TUNEL-positive cells significantly decreased in the NF-1 knockout NSCs",0.9
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,Nf2flox/flox mice,animal_model,Mechanistic,Primary embryonic spinal cord NPCs from Nf2flox/flox mice used for conditional Nf2 inactivation via adenoviral Cre delivery,Results,we chose to employ primary embryonic spinal cord (SC) NPC cultures from Nf2 floxed mice (Nf2flox/flox; [13]) in which merlin expression could be eliminated following adenoviral delivery of Cre recombinase,0.95
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,cleaved caspase-3 antibody,antibody,Biomarker,Detected 2-fold decrease in apoptosis following Nf2 inactivation in SC NPCs,Results,"Following Nf2 inactivation, there was a 2-fold decrease in apoptosis as measured by cleaved caspase-3 immunocytochemistry and Western blotting",0.95
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,NSC23766,genetic_reagent,Efficacy,Pharmacologic Rac1 inhibition decreased Nf2-deficient NPC neurosphere diameters and glial differentiation to WT levels,Results,pharmacologic Rac1 inhibition (NSC23766) decreased Nf2-deficient NPC neurosphere diameters (Fig. 7B) and glial differentiation (Fig. 7C) to WT levels,0.95
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,NSC23766,genetic_reagent,Mechanistic,Decreased ErbB2 activity and plasma membrane ErbB2 expression to WT levels in Nf2-deficient NPCs,Results,pharmacologic Rac1 inhibition decreased ErbB2 activity...Pharmacologic Rac1 inhibition (NSC23766) decreased plasma membrane ErbB2 expression to WT levels,0.95
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,AG825,genetic_reagent,Efficacy,"10 μM AG825 reduced Nf2-deficient SC NPC neurosphere diameters, increased cell death, and reduced glial differentiation to WT levels",Results,"pharmacologic ErbB2 inhibition (tyrphostin; AG825) decreased Nf2−/− NPC neurosphere diameters (Fig. 4A), cell survival (Fig. 4B), and glial differentiation (Fig. 4C) to WT levels",0.95
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,MSCV,genetic_reagent,Mechanistic,Used as retroviral vector for merlin re-expression and constitutively-activated ErbB2 expression experiments,Results,merlin was re-expressed in Nf2-deficient NPCs by retroviral infection...Expression of ErbB2-V659E in WT SC NPCs resulted in a 1.4-fold increase in cell growth,0.9
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,Rac1 N17,genetic_reagent,Efficacy,Dominant-negative Rac1 expression reduced Nf2-deficient NPC neurosphere diameters toward WT levels,Results,Genetic Rac1 inhibition (Rac1N17 expression) reduces Nf2−/− NPC neurosphere diameters to WT levels,0.9
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,PLKO virus,genetic_reagent,Mechanistic,Used as control vector for shRNA-mediated ErbB2 silencing experiments,Results,"shRNA-mediated ErbB2 silencing (B) decreases Nf2−/− SC NPC neurosphere diameters (PLKO: WT vs. Nf2−/−, p<0.001",0.85
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,Rac1 activation Assay Kit,genetic_reagent,Biomarker,Detected 2.6-fold increase in Rac1 activation in Nf2-deficient SC NPCs relative to WT,Results,Rac1 activation was increased 2.6-fold in Nf2−/− SC NPCs relative to their WT counterparts,0.95
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,pErbB2 antibody,antibody,Biomarker,Detected 2-fold increase in ErbB2 activation (Y877 phosphorylation) in Nf2-deficient SC NPCs and robust expression in human NF2-patient ependymomas,Results,found a 2-fold increase in ErbB2 activation relative to WT SC NPCs using Y877 phospho-specific antibodies...the two human NF2-patient ependymoma samples exhibited robust phospho-ErbB2 expression,0.95
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,Nf2-deficient spinal cord neural progenitor cells,advanced_cellular_model,Mechanistic,"Showed 1.8-fold increase in neurosphere diameter, 3.6-fold increase in cell number, 1.7-fold increase in clonogenic expansion, and altered differentiation patterns",Results,Nf2 inactivation results in increased NPC growth (1.8-fold increase in neurosphere diameter...3.6-fold increase in cell number at day 8...1.7-fold increase in clonogenic expansion,0.95
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,H929,cell_line,Mechanistic,"Established sensitivity to MCL-1 targeting BH3-mimetics, used to validate PRIMAB detection of MCL-1:BIM complexes",Results,"...measured BCL-2 family PPIs in cell lines with established sensitivities to BH3-mimetics specific for BCL-2 (U2932), BCL-XL (U266B1), and MCL-1 (H929)...",0.8
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,U266B1,cell_line,Mechanistic,"Established sensitivity to BCL-XL targeting BH3-mimetics, used to validate PRIMAB detection of BCL-XL:BIM complexes",Results,"...measured BCL-2 family PPIs in cell lines with established sensitivities to BH3-mimetics specific for BCL-2 (U2932), BCL-XL (U266B1), and MCL-1 (H929)...",0.8
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,U2932,cell_line,Mechanistic,"Established sensitivity to BCL-2 targeting BH3-mimetics, used to validate PRIMAB detection of BCL-2:BIM complexes",Results,"...measured BCL-2 family PPIs in cell lines with established sensitivities to BH3-mimetics specific for BCL-2 (U2932), BCL-XL (U266B1), and MCL-1 (H929)...",0.8
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,MCF7,cell_line,Mechanistic,"Used for PRIMAB validation in FFPE IHC format, showed disruption of pro-survival protein-BIM complexes when treated with specific BH3-mimetics",Results,"...untreated MCF-7 cells or those treated with BCL-2-targeting ABT-199/Venetoclax, BCL-XL-targeting A1155463, or MCL-1-targeting AZD5991 were prepared as FFPE slides, and the pro-survival protein–BIM complexes were stained using PRIMABs...",0.9
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,MCF7,cell_line,Mechanistic,"BIM knockout resulted in fourfold reduction in HSMCB signal by flow cytometry, confirming BIM requirement for PRIMAB binding",Results,"...we fixed, permeabilized, and stained MCF7 wild type (WT) and BIM KO clone 2E9 cells with HSMCB and found a fourfold reduction in signal in the KO cell by flow cytometry...",0.95
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,HCC1937,cell_line,Mechanistic,Treatment with BCL-XL:BIM-disrupting BH3-mimetic A1155463 caused HSBXB PRIMAB signal to dissipate while total BCL-XL signal remained unaffected,Results,"...the complex detected with HSBXB by IF clearly dissipated in the treated cells compared with the untreated cells, while the total BCL-XL signal was unaffected...",0.9
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,H929,cell_line,Biomarker,Treatment with CDK9 inhibitor Enitociclib resulted in time- and dose-dependent reductions in both MCL-1 and MCL-1:BIM complex as measured by HSMCB,Results,...treatment with Enitociclib resulted in reductions in both MCL-1 and the MCL-1:BIM complex as measured by HSMCB in a time- and dose-dependent manner...,0.9
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,anti-human C-terminal BIM,antibody,Mechanistic,Used to confirm BIM knockdown in siRNA experiments and validate PRIMAB specificity requirements,Results,...we knocked down BIM in MCF-7 cells using siRNA and measured the HSMCB signal...,0.8
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,anti-human N-terminal BIM (C34C5),antibody,Mechanistic,Used to measure BIM levels in patient samples and validate PRIMAB specificity in clinical applications,Results,...Samples were then analyzed with the PRIMABs and with antibodies to each of the constituent anti-apoptotic proteins and BIM...,0.8
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,FlowJo software v10.0.8,computational_tool,Other,Used for flow cytometry data analysis in PRIMAB validation experiments and clinical sample analysis,Results,"...Performance metrics for intra- and interuser accuracy and precision were achieved and provide supporting data for CLIA validation of the PRIMABs-DX, AML-Flow test...",0.8
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,GraphPad Prism v8.3,computational_tool,Other,Used for statistical analysis showing significant correlations between PRIMAB readouts and event-free survival (p = 0.026 and 0.037 for BCL-2:BIM and MCL-1:BIM respectively),Results,"...significantly higher MFIs were observed for both the BCL-2:BIM and MCL-1:BIM complex-binding PRIMABs (p = 0.026 and 0.037, respectively)...",0.95
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",Fmr1 KO,animal_model,Mechanistic,Changes in morphology were not reflected in obvious changes in baseline synaptic transmission or short-term plasticity at the calyx of Held synapse,Discussion,Changes in morphology in the mouse models for TSC and FXS were not reflected in obvious changes in baseline synaptic transmission or short-term plasticity.,0.8
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",Nf1 (+/-),animal_model,Mechanistic,Some evidence that EPSP-AP coupling was stronger in the NF1 mice,Discussion,"We found some evidence that EPSP-AP coupling was stronger in the NF1 mice, but this was not observed in the CS mouse",0.7
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",H-ras G12V,animal_model,Mechanistic,"No changes in EPSP-AP coupling observed, unlike in NF1 mice despite both being RASopathies",Discussion,"but this was not observed in the CS mouse, which is like NF1 a RASopathy",0.7
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",Tsc1 (+/-),animal_model,Mechanistic,Changes in morphology were not reflected in obvious changes in baseline synaptic transmission or short-term plasticity at the calyx of Held synapse,Discussion,Changes in morphology in the mouse models for TSC and FXS were not reflected in obvious changes in baseline synaptic transmission or short-term plasticity.,0.8
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,NSG mice,animal_model,Efficacy,50% engraftment success rate for MPNST PDX establishment,Results,Eight MPNST PDX lines were established from 8 biopsy-proven NF1-MPNST between 2014 and 2019 at 2 different institutions: Washington University and John Hopkins University. The engraftment success rate was 50%.,0.95
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,NF1-MPNST patient-derived xenografts,patient_derived_model,Biomarker,PDX showed overall similarity to parental tumors with median correlation coefficient of 0.79 (range 0.66-0.92) for gene expression levels,Results,"scatter plots comparing the gene expression levels in the parental tumor versus the PDX showed an overall similarity, with a median correlation coefficient of 0.79 (range, 0.66–0.92)",0.95
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,NF1-MPNST patient-derived xenografts,patient_derived_model,Biomarker,"PDX demonstrated selective advantage for cells with Chr8 gain during engraftment process, with 7 of 8 PDX showing Chr8 gain in >50% of cells compared to 5 of 8 parental tumors",Results,"All but 1 PDX showed Chr8 gain, defined as 3 or more copies, in > 50% of cells (7 of 8 PDX). Of the corresponding parental tumors, Chr8 gain was observed in 5 cases.",0.92
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,S100 antibody,antibody,Biomarker,Successfully confirmed histological comparability between PDX and parental tumors,Results,"All PDX are histologically comparable with the parental tumors based on morphology on H&E stains and S100, COL4A, and KI-67 staining",0.85
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,KI-67 antibody,antibody,Biomarker,Successfully confirmed histological comparability between PDX and parental tumors,Results,"All PDX are histologically comparable with the parental tumors based on morphology on H&E stains and S100, COL4A, and KI-67 staining",0.85
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,COL4A antibody,antibody,Biomarker,Successfully confirmed histological comparability between PDX and parental tumors,Results,"All PDX are histologically comparable with the parental tumors based on morphology on H&E stains and S100, COL4A, and KI-67 staining",0.85
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,anti-histone H3 (tri methyl K27) antibody,antibody,Biomarker,"Immunostaining revealed H3K27me3 was absent, consistent with SUZ12 mutations observed in 62.5% (5 of 8 pairs) of samples",Results,"Immunostaining revealed that H3K27me3 was absent, consistent with SUZ12 mutations that we observed in these samples",0.9
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,Vysis CEP 8 (D8Z2) SpectrumGreen,genetic_reagent,Biomarker,Successfully detected Chr8 gain in 7 of 8 PDX models and 8 of 10 validation cohort NF1-MPNST cases with >50% of cells showing 3 or more copies,Results,"All but 1 PDX showed Chr8 gain, defined as 3 or more copies, in > 50% of cells (7 of 8 PDX)... in the validation cohort, 8 of 10 NF1-MPNST had Chr8 gains in > 50% of cells",0.95
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,Cell Ranger,computational_tool,Other,"Successfully processed 24,055 cells from each of the 8 MPNST PDX for single-cell RNA sequencing analysis",Results,"To characterize the intratumoral heterogeneity at single-cell resolution, we performed droplet-based scRNA-seq on 24,055 cells from each of the 8 MPNST PDX",0.88
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,Seurat,computational_tool,Other,"Successfully clustered scRNA-seq data into 14 distinct clusters, with cells from different PDX sharing transcriptional similarities regardless of cell cycle stages",Results,"Clustering of the scRNA-seq data revealed that cells from different PDX shared transcriptional similarities, regardless of their cell cycle stages, separating the cells into 14 distinct clusters",0.9
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,inferCNV,computational_tool,Biomarker,"Successfully detected Chr8q gain in >90% of cells across all PDX, confirming it as the most prevalent CNV event among 74 events detected",Results,"A summary of each possible CNV event and the percentage of cells exhibiting these CNV events confirmed that Chr8q gain was the most prevalent and dominant CNV, present in > 90% of cells",0.95
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Biomarker,Significant increase in ROS levels after 24h treatment with 10 μM FT895,Results,"Further analysis to determine the mean fluorescent intensity revealed a significant increase in ROS levels in S462TY, STS26T, and T265 cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Biomarker,Significant reduction in mtDNA-CN levels based on both ND2 and ND4L genes after 24h exposure to 10 μM FT895,Results,"Following a 24 h exposure to 10 μM FT895, the levels of mtDNA-CN based on both ND2 and ND4L genes exhibited a significant reduction in all four different MPNST cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,"Reduced activities of mitochondrial respiration and no reaction to ATP synthase inhibitor, oxidative phosphorylation uncoupler, and complex I/III inhibitors after 24h FT895 treatment",Results,"kinetic measurements showed the reduced activities of mitochondrial respiration when FT895 was administered to S462TY, T265, and ST8814 cell lines...Furthermore, S462TY and T265 displayed no reaction to the treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,"Significant decrease in basal respiration, maximal respiration, and ATP-production-coupled respiration compared to DMSO group",Results,"the FT895 group exhibited a significant decrease in basal respiration, maximal respiration, and ATP-production-coupled respiration in four cell lines",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,6-hour exposure to 10 and 20 μM FT895 suppressed mitochondrial respiration in dose-dependent manner with significant reductions in basal and maximal respiration,Results,"A six-hour exposure to 10 and 20 μM FT895 suppressed mitochondrial respiration in a dose-dependent manner, resulting in significant reductions in both basal and maximal respiration",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,Upward shift in side scatter (SSC) indicating increase in cellular granularity after FT895 treatment,Results,"we observed an upward shift in side scatter (SSC), particularly in S462TY cells, indicating an increase in cellular granularity",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,Decrease in PINK1 and Parkin protein levels following FT895 treatment,Results,"Our experiment revealed a decrease in PINK1 and Parkin protein levels in S462TY, STS26T, T265, and STS8814 cells following FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,Decrease in XBP1s level after FT895 treatment while XBP1u level remained constant,Results,"The results revealed a constant XBP1u level in MPNST cells and a decrease in the XBP1s level in S462TY, T265, and ST8814 cells after FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Mechanistic,"XBP1s-mediated transcriptional activities for MPV17L2, POLG, TFAM, PINK1, and Parkin notably decreased after FT895 treatment",Results,"the XBP1s-mediated transcriptional activities for MPV17L2, POLG, TFAM, PINK1, and Parkin notably decreased in S462TY, STS26T, and T265 cells after FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Biomarker,"Significantly decreased mRNA expression levels of Parkin, PINK1, POLG, MPV17L2, and PGC1α after FT895 treatment",Results,"The levels of Parkin, PINK1, POLG, and MPV17L2 were significantly decreased in all four MPNST cell lines...albeit a significant decrease in the levels in S462TY and STS26T cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,S462TY,cell_line,Biomarker,Increased GLUT1 mRNA and protein expression after FT895 treatment,Results,"Further investigation of the mRNA expression of GLUT1 in MPNST cells showed increased expression in S462TY, T265, and ST8814...The changes in GLUT1 protein levels in MPNST cells were consistent with the mRNA expression",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,STS26T,cell_line,Biomarker,Significant increase in ROS levels after 24h treatment with 10 μM FT895,Results,"Further analysis to determine the mean fluorescent intensity revealed a significant increase in ROS levels in S462TY, STS26T, and T265 cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,STS26T,cell_line,Biomarker,Significant reduction in mtDNA-CN levels based on both ND2 and ND4L genes after 24h exposure to 10 μM FT895,Results,"Following a 24 h exposure to 10 μM FT895, the levels of mtDNA-CN based on both ND2 and ND4L genes exhibited a significant reduction in all four different MPNST cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,STS26T,cell_line,Mechanistic,"Modest alteration in mitochondrial respiration activities and partial response to ATP synthase inhibitor, oxidative phosphorylation uncoupler, and complex I/III inhibitors",Results,while STS26T showed a modest alteration...whereas STS26T and ST8814 exhibited only a partial response,0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,STS26T,cell_line,Mechanistic,Became more energetically active based on extracellular acidification (ECAR) measurements after FT895 treatment,Results,"we noted that FT895 induced a relatively less active state in S462TY and T265 cells, whereas STS26T cells became more energetically active",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,T265,cell_line,Biomarker,Significant increase in ROS levels after 24h treatment with 10 μM FT895,Results,"Further analysis to determine the mean fluorescent intensity revealed a significant increase in ROS levels in S462TY, STS26T, and T265 cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,T265,cell_line,Biomarker,Significant reduction in mtDNA-CN levels based on both ND2 and ND4L genes after 24h exposure to 10 μM FT895,Results,"Following a 24 h exposure to 10 μM FT895, the levels of mtDNA-CN based on both ND2 and ND4L genes exhibited a significant reduction in all four different MPNST cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,T265,cell_line,Mechanistic,"Reduced activities of mitochondrial respiration and no reaction to ATP synthase inhibitor, oxidative phosphorylation uncoupler, and complex I/III inhibitors after 24h FT895 treatment",Results,"kinetic measurements showed the reduced activities of mitochondrial respiration when FT895 was administered to S462TY, T265, and ST8814 cell lines...Furthermore, S462TY and T265 displayed no reaction to the treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,T265,cell_line,Biomarker,Increased GLUT1 mRNA and protein expression after FT895 treatment,Results,"Further investigation of the mRNA expression of GLUT1 in MPNST cells showed increased expression in S462TY, T265, and ST8814",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,ST8814,cell_line,Biomarker,Modest elevation of ROS after 24h treatment with 10 μM FT895,Results,while a modest elevation of ROS in ST8814 cells after treatment,0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,ST8814,cell_line,Biomarker,Significant reduction in mtDNA-CN levels based on both ND2 and ND4L genes after 24h exposure to 10 μM FT895,Results,"Following a 24 h exposure to 10 μM FT895, the levels of mtDNA-CN based on both ND2 and ND4L genes exhibited a significant reduction in all four different MPNST cells",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,ST8814,cell_line,Mechanistic,Showed preference for glycolytic pathway as energy source following FT895 treatment,Results,"Furthermore, STS8814 cells appeared to show a preference for the glycolytic pathway as their energy source following FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,ST8814,cell_line,Biomarker,Increased GLUT1 mRNA and protein expression after FT895 treatment,Results,"Further investigation of the mRNA expression of GLUT1 in MPNST cells showed increased expression in S462TY, T265, and ST8814",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,anti-LC3B,antibody,Mechanistic,"No noticeable co-localization of LC3B with mitochondria following FT895 treatment, indicating abnormal mitophagy was not the cause of defective mitochondria",Results,"There was no noticeable co-localization of LC3B with mitochondria following FT895 treatment, indicating that abnormal mitophagy was not the cause of the defective mitochondria",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,anti-ATP5H,antibody,Mechanistic,"Used to label mitochondrial ATP synthase and track mitochondrial localization, showing aggregated mitochondria positioned around nucleus periphery after FT895 treatment",Results,we labeled mitochondrial ATP synthase ATP5H...we observed aggregated mitochondria positioned around the nucleus periphery after FT895 treatment,0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,anti-PINK1,antibody,Mechanistic,Detected decrease in PINK1 protein levels in all four MPNST cell lines following FT895 treatment,Results,"Our experiment revealed a decrease in PINK1 and Parkin protein levels in S462TY, STS26T, T265, and STS8814 cells following FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,anti-Parkin,antibody,Mechanistic,Detected decrease in Parkin protein levels in all four MPNST cell lines following FT895 treatment,Results,"Our experiment revealed a decrease in PINK1 and Parkin protein levels in S462TY, STS26T, T265, and STS8814 cells following FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,anti-XBP1u,antibody,Mechanistic,Detected constant XBP1u protein levels in MPNST cells after FT895 treatment,Results,"The results revealed a constant XBP1u level in MPNST cells and a decrease in the XBP1s level in S462TY, T265, and ST8814 cells after FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,anti-XBP1s,antibody,Mechanistic,"Detected decrease in XBP1s protein levels in S462TY, T265, and ST8814 cells after FT895 treatment",Results,"The results revealed a constant XBP1u level in MPNST cells and a decrease in the XBP1s level in S462TY, T265, and ST8814 cells after FT895 treatment",0.9
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,anti-GLUT1,antibody,Biomarker,Detected increased GLUT1 protein levels consistent with mRNA expression changes in MPNST cells after FT895 treatment,Results,The changes in GLUT1 protein levels in MPNST cells were consistent with the mRNA expression with FT895 treatment,0.9
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,Varsome Clinical Software v.12.3.2,computational_tool,Other,Successfully performed Tumor-Normal matching analysis on FASTQ files from whole exome sequencing data,Results,The FASTQ files were loaded into the Varsome Clinical software v.12.3.2 to perform Tumor–Normal matching.,0.9
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,Varsome Clinical Software v.12.3.2,computational_tool,Other,"Identified 67 CNVs in primary tumor, 233 CNVs in lung metastasis, and 243 CNVs in skin metastasis",Results,"Finally, we used Varsome Clinical software (v12.3.2) to identify CNVs. The primary tumor exhibits a total of 67 CNVs, dissimilar metastases, which show 233 and 243 CNVs, respectively.",0.95
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,CNVKit version 0.9.11,computational_tool,Other,Successfully performed CNV calling and revealed greater genomic instability in metastases with log2 ratio values of about 3 and -3,Results,"Finally, we performed the calling of CNVs using the CNVkit...the metastases show a more pronounced presence of amplifications and deletions, suggesting greater genomic instability...with log2 ratio values of about 3 and −3",0.9
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,GEPIA,computational_tool,Biomarker,"Kaplan-Meier analysis identified 6 genes (RBMX, PNPLA6, C1S, LAMB3, SMC1A, PLOD2) associated with lower and significant patient survival in sarcoma samples",Results,"Using The Cancer Genome Atlas (TCGA) database related to sarcoma samples (SARC), accessible via the GEPIA portal...we observed that a change in expression of RBMX, PNPLA6, C1S, LAMB3, SMC1A and PLOD2 was associated with lower and significant patient survival",0.9
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,GEPIA,computational_tool,Biomarker,"Analysis of metastatic samples identified 4 genes (AGAP2, VSIG8, RBMX, PRSS2) associated with reduced overall survival in lung and skin cancer datasets",Results,"For the metastatic samples, we chose to perform Kaplan–Meier analysis on common genes...Out of 14 common genes, only expression changes in AGAP2, VSIG8, RBMX and PRSS2 were associated with reduced overall survival",0.9
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,Cluster Profiler v.4.0,computational_tool,Mechanistic,"Successfully performed pathway analysis identifying statistically significant GO terms, KEGG pathways, and Reactome pathways associated with cell motility, division, signaling and metabolism for primary tumor",Results,"To define a biological significance of the candidate genes, we performed a pathway analysis using the information available in the Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Reactome databases, obtaining statistically significant results only for the primary tumor gene list.",0.85
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Distress Thermometer (DT),clinical_assessment_tool,Behavioral,"Overall patient-reported distress rating was 3.4 (SD = 3.5, range = 0–10), below the validated clinical cutoff of 4",Results,"The overall patient-reported distress rating was 3.4 (SD = 3.5, range = 0–10). The overall mean distress ratings for each of the age groups was reported below the validated clinical cutoff of 4.",0.95
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Distress Thermometer (DT),clinical_assessment_tool,Behavioral,"Poor caregiver/patient concordance with only 13-17 year olds showing significant but modest correlation (r = 0.41, p < 0.05)",Results,"Caregiver/patient and provider/patient concordance were both quite poor. Only one age group (13–17 year olds) exhibited a significant, but modest, correlation in reported distress levels between the caregivers and their child (r = 0.41, p < 0.05).",0.92
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Distress Thermometer (DT),clinical_assessment_tool,Behavioral,44% of caregivers designated a different distress category than was reported by their child,Results,"When classified as 'low distress' (DT rating of 0–3), 'moderate distress' (DT Rating of 4–6), and 'high distress' (DT rating of 7–10), 44% of caregivers designated a different distress category than was reported by their child.",0.95
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Distress Thermometer Acceptability and Feasibility Scales,clinical_assessment_tool,Other,"65.8% of patients, 79% of caregivers, and 87.5% of medical providers reported the DT was very easy to complete",Results,"Nearly 80% of caregivers, 87.5% of medical providers and 65.8% of patients reported that the DT was very easy to complete, with another 12.8%, 11.3% and 30.4%, respectively, reporting that it was somewhat easy.",0.95
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Distress Thermometer Acceptability and Feasibility Scales,clinical_assessment_tool,Other,"92.4% of patients, 97.4% of caregivers, and 96.3% of medical providers reported completion didn't bother them at all",Results,"When asked if they were bothered by having to complete it, 97.4% of caregivers, 96.3% of medical providers and 92.4% of patients reported that it 'didn't bother me at all'",0.95
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Children's Depression Inventory (CDI-S),clinical_assessment_tool,Safety,1.3% of children endorsed wanting to kill themselves and 6.3% reported thoughts about killing themselves; one child with highest CDI score required safety evaluation,Results,"Among the children (ages 7–17), one child (1.3%) endorsed wanting to kill him/herself, and another 6.3% reported that they had thoughts about killing themselves... The one person who wanted to kill him/herself had the highest CDI score and had a safety evaluation",0.92
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Lansky Score,clinical_assessment_tool,Behavioral,"Average performance status score was 92.5 for children under 18, significantly correlated to DT scores (r = −.27, p < .05 for patient rating)",Results,"The average performance status score was 92.5 for children under 18... Performance status scores were significantly correlated to DT scores for medical provider ratings and patient ratings, for patients under 18 (r = −.27, p < .05 for patient rating)",0.92
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Karnofsky Score,clinical_assessment_tool,Behavioral,"Average performance status score was 85.9 for those 18 and over, with no significant correlation to DT scores for this age group",Results,The average performance status score was... 85.9 for those 18 and over... Ratings for patients over 18 were not significantly related to performance status,0.9
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Brief Symptom Inventory 18 (BSI-18),clinical_assessment_tool,Behavioral,"12.5% of caregivers met criteria for somatization case, 11.3% for anxiety, 3.8% for depression, and 8.8% for Global Severity Index",Results,"Caregiver distress was identified on the BSI with 12.5% meeting criteria for a 'case' (t-score greater or equal to 63) on somatization, 11.3% for anxiety, and 3.8% for depression and 8.8% for the Global Severity Index.",0.95
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,Distress Thermometer (DT),clinical_assessment_tool,Other,May be a useful screening tool for clinicians to implement within the NF1 setting for psychosocial assessment,Discussion,Our findings suggest that the DT and problem checklist may be a useful screening tool for clinicians to implement within the NF1 setting.,0.85
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,S462,cell_line,Efficacy,Most responsive MPNST cell line to 3-BrPA treatment with significant viability reduction at 20-120 μM (p ≤ 0.031),Results,S462 cells were most responsive... viability decreases of S462 cells were significant in an agent concentration range of 20 to 120 μM (p ≤ 0.031),0.95
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,S462,cell_line,Biomarker,Showed highest Ki67 expression (nearly 100%) and p53 expression (about 80%) among MPNST cell lines,Results,MPNST showed a moderate to high labelling for Ki67 (highest in S462 with nearly 100%) and for p53 (highest in S462 with about 80%),0.95
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,S462,cell_line,Efficacy,"Under starvation conditions, showed significant viability reduction with 3-BrPA at 0-20 μM range (p = 0.029)",Results,significant differences in a range of 20 to 80 μM: 0 to 20 μM in S462 cells (p = 0.029),0.92
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,NSF1,cell_line,Efficacy,Showed significant viability reduction at 40-120 μM 3-BrPA concentration range (p ≤ 0.017),Results,The corresponding concentration range for the NSF1 cells was 40 to 120 μM (p ≤ 0.017),0.95
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,NSF1,cell_line,Efficacy,"Under starvation, showed enhanced dose response with significant differences at 0-40 μM range (p ≤ 0.015) and slope change from -40.3%/10 μM to -12.6%/10 μM",Results,0 to 40 μM in NSF1 cells (p ≤ 0.015)... slopes of the regression lines for the cell line NSF1 without and NSF1* with starvation were quite different: − 40.3%/10 μM versus − 12.6%/10 μM,0.93
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,T265,cell_line,Efficacy,Showed no significant decreases in viability with 3-BrPA treatment (p ≥ 0.605),Results,We found no significant decreases in the viability of T265 cells (p ≥ 0.605),0.95
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,T265,cell_line,Efficacy,"Under starvation conditions, showed significant viability reduction with 3-BrPA at 0-80 μM range (p ≤ 0.029)",Results,significant differences in a range of 20 to 80 μM... 0 to 80 μM in T265 cells (p ≤ 0.029),0.92
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,B8 fibroblasts,cell_line,Efficacy,"PA28γ overexpressing B8γ cells showed partial resistance to 3-BrPA treatment, with viability reduction only at concentrations >80 μM",Results,B8γ cells treated with 3-BrPA displayed a reduction of viability only at higher concentrations > 80 μM... PA28y overexpressing cells are partially resistant to 3-BrPA treatment,0.93
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,B8 fibroblasts,cell_line,Mechanistic,PA28γ overexpressing cells showed higher NADH dehydrogenase activity and less sensitivity to 3-BrPA treatment compared to controls,Results,NADH dehydrogenase activity in untreated B8y cells was higher compared to controls... differences indicating that PA28 overexpression is associated with a higher enzyme activity and less sensitivity to treatment,0.88
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,B8 fibroblasts,cell_line,Mechanistic,Control B8vc cells showed significant viability reduction at 100-120 μM 3-BrPA (p = 0.003) and much higher ROS reduction at 80-120 μM (p ≤ 0.036),Results,Viability of control B8vc cells was reduced significantly and pronounced at 100 and 120 μM of 3-BrPA probably indicating higher cytotoxicity (p = 0.003)... p values were ≤ 0.036 in the concentration range of 80 to 120 μM,0.94
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,CellTiter-Blue® assay,clinical_assessment_tool,Other,Successfully measured dose-dependent viability changes in MPNST cell lines with significant correlations (p ≤ 0.005) across all tested concentrations,Results,Results of the correlation analyses are summarised in Additional file 1; all correlations were significant (p ≤ 0.005),0.9
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,"Ki67 antibody (clone MIB1, M7240, DAKO)",antibody,Biomarker,"Successfully detected moderate to high Ki67 labelling in MPNST cells, with highest expression in S462 (nearly 100%)",Results,MPNST showed a moderate to high labelling for Ki67 (highest in S462 with nearly 100%),0.92
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,"p53 antibody (M7001, DAKO)",antibody,Biomarker,"Successfully detected moderate to high p53 expression in MPNST cells, with highest expression in S462 (about 80%)",Results,MPNST showed a moderate to high labelling for... p53 (highest in S462 with about 80%),0.92
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,"bcl6 antibody (M7211, DAKO)",antibody,Biomarker,"Successfully detected Bcl6 expression only in NSF1 and T265 cell lines, but not in S462",Results,Bcl6 was only expressed in NSF1 and T265,0.9
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,"bcl2 antibody (M887, DAKO)",antibody,Biomarker,Successfully detected bcl2 expression only weakly in S462 cells,Results,bcl2 only weakly in S462,0.88
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,"p21 antibody (M7202, DAKO)",antibody,Biomarker,Successfully detected P21 expression in NSF1 and T265 at low levels,Results,P21 was expressed in NSF1 and T265 at low levels,0.9
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,"cyclin D1 antibody (M3642, DAKO)",antibody,Biomarker,"Successfully detected cyclin D1 expression in all cell lines, but only very mild in S462 and T265",Results,"cyclin D1 was expressed in all cell lines, but only very mild in S462 and T265",0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",STS26T,cell_line,Efficacy,Relatively resistant to MEK inhibition with high IC50s and treatment failing to achieve maximal efficacy,Results,both 26T and S462 cells were relatively resistant to MEK inhibition with high IC50s and treatment failing to achieve maximal efficacy,0.85
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",STS26T,cell_line,Efficacy,Low dose combination of mirdametinib with palbociclib yielded highly synergistic anti-proliferative activity,Results,low dose combination of mirdametinib with palbociclib yielded highly synergistic anti-proliferative activity,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",STS26T,cell_line,Efficacy,Combination therapy significantly increased cell death and senescence relative to vehicle or either monotherapy,Results,Combination therapy significantly increased MPNST cell death and senescence in both 26T and S462 cells relative to vehicle or either monotherapy,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",STS26T,cell_line,Efficacy,Combination therapy greatly reduced clonogenic survival compared to each drug alone,Results,combination therapy greatly reduced MPNST cell clonogenic survival compared to each drug alone,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",S462,cell_line,Efficacy,Relatively resistant to MEK inhibition with high IC50s and treatment failing to achieve maximal efficacy,Results,both 26T and S462 cells were relatively resistant to MEK inhibition with high IC50s and treatment failing to achieve maximal efficacy,0.85
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",S462,cell_line,Efficacy,Low dose combination of mirdametinib with palbociclib yielded highly synergistic anti-proliferative activity,Results,low dose combination of mirdametinib with palbociclib yielded highly synergistic anti-proliferative activity,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",S462,cell_line,Efficacy,Combination therapy significantly increased cell death and senescence relative to vehicle or either monotherapy,Results,Combination therapy significantly increased MPNST cell death and senescence in both 26T and S462 cells relative to vehicle or either monotherapy,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",S462,cell_line,Efficacy,Daily oral therapy with palbociclib plus mirdametinib significantly slowed tumor growth in orthotopic xenografts compared to vehicle or either monotherapy,Results,Daily oral therapy with palbociclib plus mirdametinib significantly slowed tumor growth compared to vehicle or either monotherapy,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",C57BL/6N mice,animal_model,Efficacy,Dual therapy caused tumors to shrink early in treatment with negative fold change in tumor volume at day 10 of therapy,Results,"Dual therapy with palbociclib plus mirdametinib caused tumors to shrink early in treatment, as illustrated by the negative fold change in tumor volume at day 10 of therapy",0.95
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",C57BL/6N mice,animal_model,Efficacy,Dual CDK4/6-MEK inhibition prolonged the time for tumors to triple in size compared to vehicle or single agents,Results,dual CDK4/6-MEK inhibition prolonged the time for tumors to triple in size compared to vehicle or single agents,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",C57BL/6N mice,animal_model,Efficacy,"Median survival ranged from 13.6 days for vehicle control, 20 to 22.7 days for monotherapies, to 38.1 days for the two-drug combination",Results,"Median survival ranged from 13.6 days for vehicle control, 20 to 22.7 days for palbociclib or mirdametinib alone, respectively, to 38.1 days for the two-drug combination",0.95
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",C57BL/6N mice,animal_model,Efficacy,"82% of tumors treated with CDK4/6-MEK inhibitors plus anti-PD-L1 antibodies had shrunk by day 10, with 64% becoming too small to measure",Results,"most tumors treated with CDK4/6-MEK inhibitors plus anti-PD-L1 antibodies (14 of 17; 82%) had shrunk from their original size, with most of those (9 of 14; 64%) becoming too small to be measured",0.95
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",C57BL/6N mice,animal_model,Efficacy,12% of mice from triple treatment group showed complete tumor eradication by histopathologic analyses,Results,"two mice (12%) from the triple treatment group showed complete tumor eradication by histopathologic analyses of excised, CRISPR edited sciatic nerves",0.95
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",C57BL/6N mice,animal_model,Safety,Therapies had no detrimental effect on mouse weights or health during therapy,Results,the therapies had no detrimental effect on mouse weights or health during therapy,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",NOD scid gamma mice,animal_model,Efficacy,Drug-responsive tumors showed delayed growth but not regression in immune deficient mice,Results,"Importantly, drug-responsive tumors showed delayed growth but not regression",0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",adenovirus containing Cas9 and sgRNAs targeting Nf1+Cdkn2a,genetic_reagent,Efficacy,"Successfully inactivated endogenous Nf1 and Cdkn2a in sciatic nerve of C57BL/6 mice, generating tumors that reached ~250 mm3 in size at ~3-4 months",Results,Endogenous Nf1 and Cdkn2a were inactivated via Adenovirus-mediated CRISPR-Cas9 editing in the sciatic nerve of C57BL/6 wild-type mice. Drug therapy began once tumors reached ~250 mm3 in size (~3-4 months after Adenovirus delivery),0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",phospho-RB1 S807/811 antibody,antibody,Biomarker,Served as readout of cyclin D-CDK4/6 inhibition; palbociclib reduced RB1 phosphorylation with no effects on ERK1/2 phosphorylation,Results,Phospho-RB1 (p-RB1) S807/811 was a readout of cyclin D-CDK4/6 inhibition. Palbociclib reduced RB1 phosphorylation yet had no effects on ERK1/2 phosphorylation,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",phospho-RB1 S807/811 antibody,antibody,Biomarker,Mean expression significantly reduced in combination therapy resistant tumors and trended similarly in drug sensitive tumors versus vehicle controls,Results,The mean expression of p-RB1-S807/811 was significantly reduced in combination therapy resistant tumors and trended similarly in drug sensitive tumors versus vehicle controls,0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",kappa light chain antibody,antibody,Biomarker,Plasma cell marker with superior specificity compared to CD138; plasma cells were significantly increased in drug-sensitive tumors,Results,"This was verified at the cellular level by IHC staining for kappa light chain, a plasma cell marker with superior specificity compared to CD138. Plasma cells were significantly increased in drug-sensitive tumors",0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",CD3 antibody,antibody,Biomarker,"CD3+ T cell clusters were increased in plasma cell-positive, drug-sensitive tumors compared to vehicle and drug-resistant tumors",Results,"CD3+ T cell clusters were increased in plasma cell-positive, drug-sensitive tumors compared to vehicle and drug-resistant tumors",0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",SIAH antibody,antibody,Biomarker,Marker of Ras/MEK/MAPK pathway activation; substantial increase in SIAH expression occurred in MPNSTs coincident with RABL6A upregulation,Results,"a substantial increase in SIAH expression, a marker of Ras/MEK/MAPK pathway activation, occurred in MPNSTs coincident with RABL6A upregulation",0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",RABL6A antibody,antibody,Biomarker,"Significant positive correlations between RABL6A gene and protein upregulation in MPNSTs with increased MYC, EGFR, and SIAH expression",Results,"Significant positive correlations between RABL6A gene and protein upregulation in MPNSTs were found with increased MYC, EGFR, and SIAH expression",0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",anti-PDL1 antibody,antibody,Efficacy,PD-L1 antibody alone caused little tumor regression although it did delay tumor growth,Results,PD-L1 antibody alone caused little tumor regression although it did delay tumor growth,0.85
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",anti-PDL1 antibody,antibody,Efficacy,Mean time for tumor regression was 4-fold longer with CDK4/6-MEK inhibitor plus anti-PD-L1 treatment (42 days) compared to CDK4/6-MEK inhibitor alone (10 days),Results,The mean time for tumor regression was 4-fold longer with CDK4/6-MEK inhibitor plus anti-PD-L1 treatment (42 days) compared to CDK4/6-MEK inhibitor alone (10 days),0.95
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",CIBERSORT,computational_tool,Biomarker,Revealed ~50% myeloid cells in human MPNSTs and identified plasma cell gene signature in drug-sensitive tumors compared to vehicle and drug-resistant tumors,Results,A similarly high fraction of myeloid cells (~50%) was revealed by CIBERSORT analyses. The only significant difference observed was a plasma cell gene signature in drug-sensitive tumors compared to vehicle (p=0.04) and drug-resistant tumors (p=0.018),0.9
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",Patient-derived xenografts,patient_derived_model,Efficacy,"One PDX was unresponsive to all drugs tested, while two PDXs responded but showed no synergy or partial synergy, and two other PDXs displayed robust synergistic antitumor activity",Results,"One PDX was unresponsive to all drugs tested, while two PDXs responded to the drugs but either exhibited no synergy or partial synergy. Two other PDXs displayed robust synergistic antitumor activity with the combination",0.9
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,ST88-14,cell_line,Efficacy,APX3330 treatment resulted in 40-50% decrease in cell migration in wound closure assay,Results,Wound closure assay indicated a 40–50% decrease in migration in ST88-14 and S462 cells after treatment with APX3330,0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,S462,cell_line,Efficacy,APX3330 treatment resulted in 40-50% decrease in cell migration in wound closure assay,Results,Wound closure assay indicated a 40–50% decrease in migration in ST88-14 and S462 cells after treatment with APX3330,0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,APX2009,genetic_reagent,Efficacy,3-7-fold decrease in IC50 compared to APX3330 in MPNST cell lines,Results,"Increased potency was observed with analogues, APX2009 and APX2014 in the panel of MPNST cell lines compared to APX3330 (3–7-fold decrease in IC50)",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,APX2014,genetic_reagent,Efficacy,3-7-fold decrease in IC50 compared to APX3330 in MPNST cell lines,Results,"Increased potency was observed with analogues, APX2009 and APX2014 in the panel of MPNST cell lines compared to APX3330 (3–7-fold decrease in IC50)",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,APX2009,genetic_reagent,Efficacy,Significantly reduced both colony number and size at fivefold reduction in dosage compared to APX3330 in ST88-14 spheroid assays,Results,APX2009 was more potent and significantly reduced both colony number and size at fivefold reduction in dosage compared to APX3330,0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,Napabucasin,genetic_reagent,Efficacy,IC50s in the nanomolar range for MPNST cell proliferation inhibition,Results,"There was a dose-dependent decrease in cell proliferation with both drugs, with Napa showing IC50s in the nanomolar range",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,Ruxolitinib,genetic_reagent,Biomarker,At least 2-fold reduction in phosphorylated STAT3 (Y705) in NF90-8 cells,Results,A reduction of at least 2-fold in phosphorylated STAT3 (Y705) was observed with both Rux and Napa in NF90-8 cells,0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,Napabucasin,genetic_reagent,Biomarker,At least 2-fold reduction in phosphorylated STAT3 (Y705) in NF90-8 cells,Results,A reduction of at least 2-fold in phosphorylated STAT3 (Y705) was observed with both Rux and Napa in NF90-8 cells,0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,Ref-1 siRNA #1,genetic_reagent,Efficacy,"Reduction in protein expression by >85% and reduced proliferation of MPNST cells, with more pronounced effects compared to STAT3 siRNA",Results,resulting in a reduction in the amount of protein by >85% versus scrambled siRNA controls...Knockdown of STAT3 and Ref-1 reduced proliferation of these cells and the effects on cell growth were more pronounced with Ref-1 siRNA,0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,"STAT3 siRNA (sc-44275, sc-29493)",genetic_reagent,Efficacy,Reduction in protein expression by >85% and reduced proliferation of MPNST cells,Results,resulting in a reduction in the amount of protein by >85% versus scrambled siRNA controls on day 3 post transfection...Knockdown of STAT3 and Ref-1 reduced proliferation of these cells,0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,APX2009,genetic_reagent,Efficacy,35 mg/kg treatment decreased tumor volume and tumor weight in ST88-14 xenografts (P < 0.05),Results,"Both APX2009 (35 mg/kg) and Napa (75 mg/kg) decreased the tumour volume (Fig. 6a, P < 0.05) with a corresponding decrease in tumour weight at the end of study",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,Napabucasin,genetic_reagent,Efficacy,"75 mg/kg treatment decreased tumor volume and tumor weight in ST88-14 xenografts (P < 0.05), though effect was not as robust as APX2009",Results,"Both APX2009 (35 mg/kg) and Napa (75 mg/kg) decreased the tumour volume...Although statistically significant, the effect on tumour growth following Napa treatment was not as robust as treatment with APX2009",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,APX2009,genetic_reagent,Safety,35 mg/kg dosing was not overly toxic as body weights were maintained throughout three weeks of treatment,Results,Both dosing regimens were not overly toxic to the mice as body weights were maintained throughout the three weeks of dosing,0.9
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,Napabucasin,genetic_reagent,Safety,75 mg/kg dosing was not overly toxic as body weights were maintained throughout three weeks of treatment,Results,Both dosing regimens were not overly toxic to the mice as body weights were maintained throughout the three weeks of dosing,0.9
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,APX2009,genetic_reagent,Biomarker,28% decrease in pH3 positivity and ~30% decrease in Ki67 positivity in treated tumors,Results,"IHC staining of tumours with proliferative markers, pH3 and Ki67 revealed expected decreases in proliferation in the APX2009-treated tumours with a 28% decrease in pH3 positivity...Ki67 positivity also decreased by ~30%",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,Napabucasin,genetic_reagent,Biomarker,41% decrease in Ki67 positivity but significant increase in pH3 positivity in treated tumors,Results,"In the Napa-treated tumours, the positivity of Ki67 was significantly decreased by 41%...however, the pH3 positivity actually increased significantly",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,NF90-8,cell_line,Biomarker,17-300-fold increase in Y705 phosphorylation in response to IL-6 stimulation,Results,"NF90-8, ST88-14 and RHT-92 all responded to IL-6 stimulation as seen by the 17–300-fold increase in Y705 phosphorylation",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,ST88-14,cell_line,Biomarker,17-300-fold increase in Y705 phosphorylation in response to IL-6 stimulation,Results,"NF90-8, ST88-14 and RHT-92 all responded to IL-6 stimulation as seen by the 17–300-fold increase in Y705 phosphorylation",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,RHT-92,cell_line,Biomarker,17-300-fold increase in Y705 phosphorylation in response to IL-6 stimulation,Results,"NF90-8, ST88-14 and RHT-92 all responded to IL-6 stimulation as seen by the 17–300-fold increase in Y705 phosphorylation",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,S462,cell_line,Biomarker,Did not activate STAT3 in response to IL-6 and had lower levels of total STAT3 compared to ST88-14 and NF90-8 cells,Results,"However, S462 cells did not activate STAT3 in response to IL-6 and had lower levels of total STAT3 in comparison to ST88-14 and NF90-8 cells",0.95
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,Nf1-Arf flox/flox ;Postn-Cre,animal_model,Biomarker,"Malignant transformation was associated with significant upregulation of p-STAT3 and Ref-1, with p-STAT3 increase correlating with disease progression",Results,malignant transformation of plexiform neurofibroma and ANNUBP precursor tumours to MPNST was associated with significant upregulation of p-STAT3 and Ref-1...The increase in expression of p-STAT3 appeared to correlate with disease progression,0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Behavioral,"Completion time ranged from 2 to 7 minutes (mean = 4.4, SD = 1.3)",Results,"The time taken to complete the PlexiQoL ranged from 2 to 7 (mean =4.4, SD =1.3) minutes.",0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Other,Internal reliability was good with Person-Separation Index (PSI) = 0.84,Results,All items fit the Rasch model and internal reliability was good (PSI = 0.84).,0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Other,Cronbach's α coefficients were 0.90 at both time points,Results,"Cronbach's α coefficients for the PlexiQoL were 0.90 at both time points, confirming that the items had a good level of association.",0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Other,"Test-retest reliability was 0.90, demonstrating excellent reproducibility",Results,"Test‐retest reliability was 0.90, demonstrating excellent reproducibility, indicating that the PlexiQoL produces low levels of measurement error.",0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Behavioral,97.4% of respondents obtained valid scores on the measure,Discussion,The PlexiQoL has a wide measurement range with 97.4% of respondents obtaining valid scores on the measure.,0.95
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,PlexiQoL,clinical_assessment_tool,Other,"Minimal floor and ceiling effects found (7.3% scoring minimum, 2.1% scoring maximum at Time 1)",Results,"In contrast, minimal floor and ceiling effects were found for the PlexiQoL.",0.9
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,Nottingham Health Profile,clinical_assessment_tool,Behavioral,"Large end effects observed for several NHP sections, indicating poor targeting to this sample",Results,Large end effects were observed for several NHP and SF‐36 sections. This indicates that the subscales are not well targeted to this sample.,0.85
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,Short Form-36,clinical_assessment_tool,Behavioral,"Large end effects observed for several SF-36 sections, indicating poor targeting to this sample",Results,Large end effects were observed for several NHP and SF‐36 sections. This indicates that the subscales are not well targeted to this sample.,0.85
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,RUMM2030,computational_tool,Other,Used to identify 7 participants who did not respond logically and 24 participants with extreme scores for exclusion from analysis,Results,"Seven participants were removed from the analysis as they did not respond to the items in a logical manner, as would be expected to occur with all questionnaires. This can only be determined by the application of RMT.",0.9
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,clinical_assessment_tool,Safety,"Most frequent pirfenidone related toxicities were nausea, vomiting, and diarrhea; only three patients required dose reduction for toxicities including recurrent grade 2 neutropenia, grade 3 nausea, and grade 3 neutropenia",Results,"The most frequent pirfenidone related toxicities were nausea, vomiting, and diarrhea (Table II). Only three patients required a dose reduction for pirfenidone related toxicities consisting of: (1) recurrent grade 2 neutropenia in cycle 39, (2) grade 3 nausea in cycle 1, and (3) grade 3 neutropenia in cycle 1.",0.95
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,Impact of Pediatric Illness (IPI) Scale,clinical_assessment_tool,Behavioral,Parents rated children's cognitive functioning (59.8) as significantly lower than all other domains; adaptive behavior (68.4) was significantly poorer than medical/physical status (76.3),Results,"Furthermore, parents rated their children's cognitive functioning (59.8) as significantly lower than all the other three domains (adaptive behavior [68.4], P=0.0092; emotional functioning [71.4], P=0.0237; medical/ physical status [76.3], P=0.0002).",0.95
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,Impact of Pediatric Illness (IPI) Scale,clinical_assessment_tool,Behavioral,"No significant differences found in mean total scores from baseline to pre-cycle 4, 7, or 10 follow-up evaluations as rated by either parents or children (all Ps>0.05)",Results,"No significant differences were found in the mean total scores from baseline to either the pre-cycle 4, 7, or 10 follow-up evaluations as rated by either the parents or children (all Ps>0.05).",0.95
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,Impact of Pediatric Illness (IPI) Scale,clinical_assessment_tool,Behavioral,Children's scores were significantly lower than parents' ratings on emotional functioning (63.7 vs. 72.4; P=0.0186) and medical/physical status (67.1 vs. 77.6; P=0.0032),Results,"In contrast, the children's scores were significantly lower than the parents' ratings on the domains of emotional functioning (63.7 vs. 72.4; F=6.56, P=0.0186) and medical/physical status (67.1 vs. 77.6; F=11.23, P=0.0032).",0.95
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,STIR MRI,clinical_assessment_tool,Efficacy,Progressive disease by volumetric analysis occurred in 31 patients; median time to progression was 13.2 months; no partial responses were observed,Results,Reasons for removal from treatment with pirfenidone were: Progressive disease by volumetric analysis (n = 31)... The median TTP on treatment with pirfenidone was 13.2 months... No partial responses were observed.,0.95
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,STIR MRI,clinical_assessment_tool,Efficacy,"In 11 patients with any degree of PN volume decrease, the median % decrease was −4% (range −1 to −12%)",Results,"In 11 patients with any degree of PN volume decrease, the median % decrease was −4% (range −1 to −12%).",0.95
